Both B-Claim
the I-Claim
III I-Claim
+ I-Claim
ISG I-Claim
and I-Claim
III-only I-Claim
demonstrated I-Claim
pre-post I-Claim
reductions I-Claim
in I-Claim
depressive I-Claim
symptoms I-Claim
and I-Claim
high I-Claim
rates I-Claim
of I-Claim
utilization I-Claim
compared I-Claim
with I-Claim
other I-Claim
web-based I-Claim
treatments I-Claim
for I-Claim
depression I-Claim
. I-Claim

A B-Claim
carboplatin I-Claim
containing I-Claim
regimen I-Claim
with I-Claim
better I-Claim
toxicity I-Claim
profile I-Claim
and I-Claim
a I-Claim
similar I-Claim
potentiality I-Claim
for I-Claim
symptoms I-Claim
control I-Claim
offers I-Claim
an I-Claim
option I-Claim
in I-Claim
comparison I-Claim
to I-Claim
similar I-Claim
cisplatin I-Claim
containing I-Claim
combinations I-Claim
in I-Claim
the I-Claim
palliative I-Claim
treatment I-Claim
of I-Claim
advanced I-Claim
NSCLC I-Claim
. I-Claim

The B-Claim
maximum I-Claim
IPSS I-Claim
after I-Claim
the I-Claim
implant I-Claim
was I-Claim
the I-Claim
best I-Claim
predictor I-Claim
of I-Claim
the I-Claim
resolution I-Claim
of I-Claim
dysuria I-Claim
. I-Claim

At B-Claim
the I-Claim
end I-Claim
of I-Claim
primary I-Claim
treatment I-Claim
for I-Claim
breast I-Claim
cancer I-Claim
, I-Claim
women I-Claim
in I-Claim
all I-Claim
treatment I-Claim
groups I-Claim
report I-Claim
good I-Claim
emotional I-Claim
functioning I-Claim
but I-Claim
report I-Claim
decreased I-Claim
physical I-Claim
functioning I-Claim
, I-Claim
particularly I-Claim
among I-Claim
women I-Claim
who I-Claim
have I-Claim
a I-Claim
mastectomy I-Claim
or I-Claim
receive I-Claim
chemotherapy I-Claim
. I-Claim

Patient B-Claim
preference I-Claim
, I-Claim
demographic I-Claim
variables I-Claim
, I-Claim
and I-Claim
medical I-Claim
variables I-Claim
moderated I-Claim
the I-Claim
effects I-Claim
of I-Claim
exercise I-Claim
training I-Claim
in I-Claim
breast I-Claim
cancer I-Claim
patients I-Claim
who I-Claim
were I-Claim
receiving I-Claim
chemotherapy I-Claim
. I-Claim

No B-Claim
difference I-Claim
in I-Claim
QOL I-Claim
was I-Claim
observed I-Claim
. I-Claim

Further B-Claim
research I-Claim
on I-Claim
dose I-Claim
and I-Claim
mode I-Claim
of I-Claim
treatment I-Claim
is I-Claim
mandatory I-Claim
. I-Claim

However B-Claim
, I-Claim
further I-Claim
research I-Claim
is I-Claim
needed I-Claim
to I-Claim
identify I-Claim
ways I-Claim
to I-Claim
improve I-Claim
the I-Claim
potency I-Claim
and I-Claim
sustainability I-Claim
of I-Claim
psychoeducational I-Claim
interventions I-Claim
for I-Claim
managing I-Claim
cancer-related I-Claim
fatigue I-Claim
. I-Claim

There B-Claim
was I-Claim
no I-Claim
differences I-Claim
in I-Claim
acute I-Claim
toxicities I-Claim
between I-Claim
the I-Claim
2 I-Claim
groups I-Claim
. I-Claim

This B-Claim
effect I-Claim
is I-Claim
an I-Claim
important I-Claim
clinically I-Claim
meaningful I-Claim
reduction I-Claim
from I-Claim
baseline I-Claim
in I-Claim
the I-Claim
cisplatin/raltitrexed I-Claim
arm I-Claim
. I-Claim

The B-Claim
combined I-Claim
treatment I-Claim
improved I-Claim
both I-Claim
immunometabolic I-Claim
alterations I-Claim
and I-Claim
patient I-Claim
QoL I-Claim
. I-Claim

Comparing B-Claim
the I-Claim
results I-Claim
2 I-Claim
and I-Claim
3 I-Claim
years I-Claim
after I-Claim
radiotherapy I-Claim
, I-Claim
the I-Claim
symptoms I-Claim
of I-Claim
rectal I-Claim
bleeding I-Claim
had I-Claim
improved I-Claim
, I-Claim
erectile I-Claim
function I-Claim
had I-Claim
decreased I-Claim
, I-Claim
and I-Claim
urinary I-Claim
urge I-Claim
incontinence I-Claim
had I-Claim
increased I-Claim
. I-Claim

A B-Claim
three-times-per-week I-Claim
dosing I-Claim
schedule I-Claim
was I-Claim
noted I-Claim
to I-Claim
be I-Claim
more I-Claim
effective I-Claim
compared I-Claim
with I-Claim
a I-Claim
once-a-week I-Claim
schedule I-Claim
without I-Claim
any I-Claim
significant I-Claim
difference I-Claim
in I-Claim
toxicity I-Claim
reported I-Claim
. I-Claim

Our B-Claim
findings I-Claim
suggest I-Claim
that I-Claim
switching I-Claim
patients I-Claim
to I-Claim
adjuvant I-Claim
exemestane I-Claim
treatment I-Claim
after I-Claim
at I-Claim
least I-Claim
2 I-Claim
years I-Claim
of I-Claim
tamoxifen I-Claim
therapy I-Claim
may I-Claim
be I-Claim
associated I-Claim
with I-Claim
an I-Claim
advantage I-Claim
over I-Claim
continuing I-Claim
adjuvant I-Claim
tamoxifen I-Claim
treatment I-Claim
in I-Claim
terms I-Claim
of I-Claim
body I-Claim
composition I-Claim
. I-Claim

Patients B-Claim
with I-Claim
bone-cancer I-Claim
pain I-Claim
, I-Claim
already I-Claim
on I-Claim
opioids I-Claim
, I-Claim
obtain I-Claim
clinically I-Claim
important I-Claim
, I-Claim
additional I-Claim
pain-control I-Claim
, I-Claim
with I-Claim
regular I-Claim
oxycodone/paracetamol I-Claim
dosing I-Claim
. I-Claim

Metastatic B-Claim
prostate I-Claim
cancer I-Claim
patients I-Claim
with I-Claim
high I-Claim
baseline I-Claim
PSA I-Claim
, I-Claim
pain I-Claim
, I-Claim
and I-Claim
high I-Claim
PSA I-Claim
nadir I-Claim
have I-Claim
a I-Claim
poor I-Claim
prognosis I-Claim
with I-Claim
ADT I-Claim
. I-Claim

Although B-Claim
there I-Claim
are I-Claim
no I-Claim
significant I-Claim
differences I-Claim
between I-Claim
treatment I-Claim
changes I-Claim
, I-Claim
the B-Claim
observed I-Claim
trend I-Claim
towards I-Claim
a I-Claim
better I-Claim
health-related I-Claim
quality I-Claim
of I-Claim
life I-Claim
is I-Claim
remarkable I-Claim
in I-Claim
low-frequency I-Claim
low-intensity I-Claim
electrotherapy I-Claim
. I-Claim

Despite B-Claim
considerable I-Claim
improvement I-Claim
in I-Claim
the I-Claim
treatment I-Claim
of I-Claim
advanced I-Claim
ovarian I-Claim
cancer I-Claim
, I-Claim
the I-Claim
optimization I-Claim
of I-Claim
efficacy I-Claim
and I-Claim
tolerability I-Claim
remains I-Claim
an I-Claim
important I-Claim
issue I-Claim
. I-Claim

This B-Claim
procedure I-Claim
has I-Claim
been I-Claim
performed I-Claim
with I-Claim
the I-Claim
patient I-Claim
in I-Claim
the I-Claim
hypothyroid I-Claim
state I-Claim
to I-Claim
promote I-Claim
endogenous I-Claim
TSH I-Claim
stimulation I-Claim
and I-Claim
is I-Claim
often I-Claim
associated I-Claim
with I-Claim
hypothyroid I-Claim
symptoms I-Claim
and I-Claim
impaired I-Claim
quality I-Claim
of I-Claim
life I-Claim
. I-Claim

The B-Claim
addition I-Claim
of I-Claim
RT I-Claim
did I-Claim
not I-Claim
negatively I-Claim
impact I-Claim
ED I-Claim
. I-Claim

At B-Claim
higher I-Claim
doses I-Claim
, I-Claim
however I-Claim
, I-Claim
TMX I-Claim
inhibits I-Claim
HCC I-Claim
through I-Claim
ER-independent I-Claim
mechanisms I-Claim
. I-Claim

The B-Claim
previously I-Claim
reported I-Claim
survival I-Claim
advantage I-Claim
supporting I-Claim
the I-Claim
use I-Claim
of I-Claim
adjuvant I-Claim
chemotherapy I-Claim
is I-Claim
maintained I-Claim
when I-Claim
adjusted I-Claim
using I-Claim
quality I-Claim
adjusted I-Claim
survival I-Claim
methodology I-Claim
. I-Claim

Anemia B-Claim
, I-Claim
highly I-Claim
common I-Claim
among I-Claim
cancer I-Claim
patients I-Claim
, I-Claim
is I-Claim
often I-Claim
an I-Claim
underlying I-Claim
cause I-Claim
of I-Claim
cancer-related I-Claim
fatigue I-Claim
and I-Claim
other I-Claim
quality-of-life I-Claim
( I-Claim
QOL I-Claim
) I-Claim
deficits I-Claim
. I-Claim

However B-Claim
, I-Claim
combination I-Claim
modalities I-Claim
including I-Claim
IPC I-Claim
and I-Claim
SLD I-Claim
may I-Claim
be I-Claim
the I-Claim
preferred I-Claim
choices I-Claim
for I-Claim
their I-Claim
applicability I-Claim
at I-Claim
home I-Claim
. I-Claim

Treatment B-Claim
with I-Claim
cisplatin-based I-Claim
chemotherapy I-Claim
provides I-Claim
a I-Claim
modest I-Claim
survival I-Claim
advantage I-Claim
over I-Claim
supportive I-Claim
care I-Claim
alone I-Claim
in I-Claim
advanced I-Claim
non-small-cell I-Claim
lung I-Claim
cancer I-Claim
( I-Claim
NSCLC I-Claim
) I-Claim
. I-Claim

Patients B-Claim
treated I-Claim
with I-Claim
single-agent I-Claim
E I-Claim
followed I-Claim
by I-Claim
single-agent I-Claim
M I-Claim
had I-Claim
similar I-Claim
survival I-Claim
, I-Claim
but I-Claim
less I-Claim
treatment-related I-Claim
toxicity I-Claim
and I-Claim
better I-Claim
QOL I-Claim
as I-Claim
compared I-Claim
with I-Claim
those I-Claim
treated I-Claim
with I-Claim
CEF I-Claim
followed I-Claim
by I-Claim
MV I-Claim
. I-Claim

Compared B-Claim
with I-Claim
the I-Claim
EP I-Claim
regimen I-Claim
, I-Claim
the I-Claim
PCDE I-Claim
regimen I-Claim
yielded I-Claim
higher I-Claim
response I-Claim
rates I-Claim
and I-Claim
better I-Claim
survival I-Claim
rates I-Claim
in I-Claim
patients I-Claim
with I-Claim
extensive I-Claim
SCLC I-Claim
without I-Claim
affecting I-Claim
the I-Claim
quality I-Claim
of I-Claim
life I-Claim
of I-Claim
the I-Claim
patients I-Claim
during I-Claim
chemotherapy I-Claim
. I-Claim

The B-Claim
magnitude I-Claim
of I-Claim
improvement I-Claim
obtained I-Claim
was I-Claim
similar I-Claim
whether I-Claim
on I-Claim
a I-Claim
self-declared-healer- I-Claim
or I-Claim
an I-Claim
actor-provided I-Claim
" I-Claim
treatment I-Claim
" I-Claim
. I-Claim

The B-Claim
addition I-Claim
of I-Claim
isotretinoin I-Claim
to I-Claim
an I-Claim
adjuvant I-Claim
treatment I-Claim
of I-Claim
low-dose I-Claim
IFNalpha I-Claim
in I-Claim
patients I-Claim
with I-Claim
stage I-Claim
IIA I-Claim
and I-Claim
IIB I-Claim
melanoma I-Claim
had I-Claim
no I-Claim
significant I-Claim
effect I-Claim
on I-Claim
disease-free I-Claim
or I-Claim
overall I-Claim
survival I-Claim
and I-Claim
is I-Claim
therefore I-Claim
not I-Claim
recommended I-Claim
. I-Claim

However B-Claim
, I-Claim
patient I-Claim
self-assessments I-Claim
suggested I-Claim
a I-Claim
possible I-Claim
advantage I-Claim
to I-Claim
AM I-Claim
that I-Claim
is I-Claim
being I-Claim
explored I-Claim
with I-Claim
modified I-Claim
dosing I-Claim
route I-Claim
strategies I-Claim
. I-Claim

The B-Claim
addition I-Claim
of I-Claim
gemcitabine I-Claim
to I-Claim
PB I-Claim
was I-Claim
not I-Claim
associated I-Claim
with I-Claim
a I-Claim
statistically I-Claim
significant I-Claim
improvement I-Claim
in I-Claim
ORR I-Claim
. I-Claim

Amenorrhea B-Claim
rates I-Claim
differed I-Claim
significantly I-Claim
by I-Claim
treatment I-Claim
arm I-Claim
, I-Claim
with I-Claim
the I-Claim
AT I-Claim
arm I-Claim
having I-Claim
the I-Claim
lowest I-Claim
rate I-Claim
. I-Claim

Interestingly B-Claim
, I-Claim
the I-Claim
QOL I-Claim
response I-Claim
analysis I-Claim
also I-Claim
showed I-Claim
that I-Claim
aggressive I-Claim
premedication I-Claim
regimens I-Claim
appear I-Claim
to I-Claim
ameliorate I-Claim
potential I-Claim
negative I-Claim
effects I-Claim
of I-Claim
DPPE I-Claim
on I-Claim
emesis I-Claim
and I-Claim
nausea I-Claim
as I-Claim
measured I-Claim
by I-Claim
patient I-Claim
assessed I-Claim
QOL I-Claim
. I-Claim

The B-Claim
results I-Claim
are I-Claim
consistent I-Claim
with I-Claim
the I-Claim
findings I-Claim
of I-Claim
the I-Claim
women I-Claim
's I-Claim
health I-Claim
initiative I-Claim
study I-Claim
and I-Claim
secondary I-Claim
prevention I-Claim
studies I-Claim
. I-Claim

Vandetanib B-Claim
failed I-Claim
to I-Claim
demonstrate I-Claim
efficacy I-Claim
as I-Claim
maintenance I-Claim
therapy I-Claim
for I-Claim
small-cell I-Claim
lung I-Claim
cancer I-Claim
. I-Claim

In B-Claim
summary I-Claim
, I-Claim
this I-Claim
six-week I-Claim
supervised I-Claim
multimodal I-Claim
exercise I-Claim
intervention I-Claim
can I-Claim
lead I-Claim
to I-Claim
significant I-Claim
reduction I-Claim
in I-Claim
self-reported I-Claim
CRF I-Claim
in I-Claim
cancer I-Claim
patients I-Claim
undergoing I-Claim
chemotherapy I-Claim
. I-Claim

We B-Claim
recommend I-Claim
implementation I-Claim
alongside I-Claim
evaluation I-Claim
in I-Claim
wider I-Claim
clinical I-Claim
settings I-Claim
and I-Claim
patient I-Claim
populations I-Claim
. I-Claim

Efficacy B-Claim
is I-Claim
low I-Claim
but I-Claim
similar I-Claim
to I-Claim
that I-Claim
of I-Claim
other I-Claim
treatments I-Claim
used I-Claim
in I-Claim
this I-Claim
setting I-Claim
. I-Claim

Gemcitabine-carboplatin B-Claim
treatment I-Claim
significantly I-Claim
improves I-Claim
the I-Claim
PFS I-Claim
of I-Claim
patients I-Claim
with I-Claim
platinum-sensitive I-Claim
recurrent I-Claim
ovarian I-Claim
cancer I-Claim
. I-Claim

Tumor B-Claim
characteristics I-Claim
and I-Claim
wound I-Claim
complications I-Claim
have I-Claim
a I-Claim
detrimental I-Claim
effect I-Claim
on I-Claim
patient I-Claim
function I-Claim
. I-Claim

The B-Claim
study I-Claim
results I-Claim
suggest I-Claim
that I-Claim
K-tape I-Claim
could I-Claim
replace I-Claim
the I-Claim
bandage I-Claim
in I-Claim
DLT I-Claim
, I-Claim
and I-Claim
it I-Claim
could I-Claim
be I-Claim
an I-Claim
alternative I-Claim
choice I-Claim
for I-Claim
the I-Claim
breast-cancer-related I-Claim
lymphedema I-Claim
patient I-Claim
with I-Claim
poor I-Claim
short-stretch I-Claim
bandage I-Claim
compliance I-Claim
after I-Claim
1-month I-Claim
intervention I-Claim
. I-Claim

Using B-Claim
video I-Claim
and I-Claim
print I-Claim
materials I-Claim
, I-Claim
with I-Claim
brief I-Claim
individualized I-Claim
training I-Claim
, I-Claim
effectively I-Claim
improved I-Claim
pain I-Claim
management I-Claim
over I-Claim
time I-Claim
for I-Claim
cancer I-Claim
patients I-Claim
of I-Claim
varying I-Claim
diagnostic I-Claim
and I-Claim
demographic I-Claim
groups I-Claim
. I-Claim

Our B-Claim
findings I-Claim
suggest I-Claim
that I-Claim
an I-Claim
oncologist I-Claim
recommendation I-Claim
may I-Claim
increase I-Claim
exercise I-Claim
behavior I-Claim
in I-Claim
newly I-Claim
diagnosed I-Claim
breast I-Claim
cancer I-Claim
survivors I-Claim
, I-Claim
particularly I-Claim
if I-Claim
it I-Claim
is I-Claim
recalled I-Claim
1 I-Claim
week I-Claim
after I-Claim
the I-Claim
recommendation I-Claim
. I-Claim

Short-term B-Claim
administration I-Claim
of I-Claim
exogenous I-Claim
ghrelin I-Claim
at I-Claim
the I-Claim
start I-Claim
of I-Claim
cisplatin-based I-Claim
chemotherapy I-Claim
stimulated I-Claim
food I-Claim
intake I-Claim
and I-Claim
minimized I-Claim
adverse I-Claim
events I-Claim
. I-Claim

rhTSH B-Claim
preserves I-Claim
QoL I-Claim
of I-Claim
patients I-Claim
undergoing I-Claim
RRA I-Claim
with I-Claim
similar I-Claim
rates I-Claim
of I-Claim
ablation I-Claim
success I-Claim
compared I-Claim
to I-Claim
hypothyrodism I-Claim
. I-Claim

Systematic B-Claim
assessment I-Claim
of I-Claim
depression I-Claim
is I-Claim
needed I-Claim
in I-Claim
hospice I-Claim
patients I-Claim
. I-Claim

Patient B-Claim
QOL I-Claim
favours I-Claim
delivering I-Claim
cancer I-Claim
treatment I-Claim
in I-Claim
the I-Claim
home I-Claim
rather I-Claim
than I-Claim
GP I-Claim
surgeries I-Claim
. I-Claim

Sentinel B-Claim
lymph I-Claim
node I-Claim
biopsy I-Claim
is I-Claim
associated I-Claim
with I-Claim
reduced I-Claim
arm I-Claim
morbidity I-Claim
and I-Claim
better I-Claim
quality I-Claim
of I-Claim
life I-Claim
than I-Claim
standard I-Claim
axillary I-Claim
treatment I-Claim
and I-Claim
should I-Claim
be I-Claim
the I-Claim
treatment I-Claim
of I-Claim
choice I-Claim
for I-Claim
patients I-Claim
who I-Claim
have I-Claim
early-stage I-Claim
breast I-Claim
cancer I-Claim
with I-Claim
clinically I-Claim
negative I-Claim
nodes I-Claim
. I-Claim

Trials B-Claim
with I-Claim
late I-Claim
intensification I-Claim
HDCT I-Claim
have I-Claim
failed I-Claim
to I-Claim
show I-Claim
an I-Claim
advantage I-Claim
in I-Claim
overall I-Claim
survival I-Claim
. I-Claim

However B-Claim
, I-Claim
the I-Claim
intervention I-Claim
was I-Claim
not I-Claim
found I-Claim
to I-Claim
reduce I-Claim
the I-Claim
risk I-Claim
of I-Claim
cancer I-Claim
recurrence I-Claim
and I-Claim
death I-Claim
. I-Claim

Although B-Claim
the I-Claim
ability I-Claim
of I-Claim
dignity I-Claim
therapy I-Claim
to I-Claim
mitigate I-Claim
outright I-Claim
distress I-Claim
, I-Claim
such I-Claim
as I-Claim
depression I-Claim
, I-Claim
desire I-Claim
for I-Claim
death I-Claim
or I-Claim
suicidality I-Claim
, I-Claim
has I-Claim
yet I-Claim
to I-Claim
be I-Claim
proven I-Claim
, I-Claim
its B-Claim
benefits I-Claim
in I-Claim
terms I-Claim
of I-Claim
self-reported I-Claim
end-of-life I-Claim
experiences I-Claim
support I-Claim
its I-Claim
clinical I-Claim
application I-Claim
for I-Claim
patients I-Claim
nearing I-Claim
death I-Claim
. I-Claim

The B-Claim
advantages I-Claim
of I-Claim
a I-Claim
long-lasting I-Claim
improved I-Claim
body I-Claim
image I-Claim
and I-Claim
cosmesis I-Claim
for I-Claim
this I-Claim
relatively I-Claim
young I-Claim
patient I-Claim
population I-Claim
may I-Claim
compensate I-Claim
for I-Claim
the I-Claim
longer I-Claim
operating I-Claim
times I-Claim
and I-Claim
higher I-Claim
costs I-Claim
, I-Claim
particularly I-Claim
for I-Claim
women I-Claim
. I-Claim

For B-Claim
patients I-Claim
with I-Claim
metastatic I-Claim
prostate I-Claim
cancer I-Claim
, I-Claim
treatment I-Claim
is I-Claim
primarily I-Claim
palliative I-Claim
, I-Claim
relying I-Claim
mainly I-Claim
on I-Claim
the I-Claim
suppression I-Claim
of I-Claim
systemic I-Claim
androgen I-Claim
hormone I-Claim
levels I-Claim
. I-Claim

These B-Claim
results I-Claim
support I-Claim
the I-Claim
efficacy I-Claim
and I-Claim
safety I-Claim
of I-Claim
an I-Claim
every-2-weeks I-Claim
treatment I-Claim
with I-Claim
gemcitabine I-Claim
plus I-Claim
cisplatin I-Claim
. I-Claim

Patient-caregiver B-Claim
dyads I-Claim
benefit I-Claim
when I-Claim
viewed I-Claim
as I-Claim
the I-Claim
'unit I-Claim
of I-Claim
care I-Claim
' I-Claim
. I-Claim

Compared B-Claim
with I-Claim
IFN5 I-Claim
, I-Claim
IFN1 I-Claim
is I-Claim
neither I-Claim
more I-Claim
nor I-Claim
less I-Claim
effective I-Claim
but I-Claim
is I-Claim
less I-Claim
toxic I-Claim
, I-Claim
with I-Claim
a I-Claim
better I-Claim
reported I-Claim
QOL I-Claim
. I-Claim

Whether B-Claim
such I-Claim
a I-Claim
lozenge I-Claim
would I-Claim
be I-Claim
beneficial I-Claim
in I-Claim
treatment I-Claim
situations I-Claim
where I-Claim
rate I-Claim
of I-Claim
severe I-Claim
mucositis I-Claim
is I-Claim
higher I-Claim
( I-Claim
ie I-Claim
, I-Claim
in I-Claim
patients I-Claim
treated I-Claim
with I-Claim
unconventional I-Claim
fractionation I-Claim
or I-Claim
with I-Claim
concomitant I-Claim
chemotherapy I-Claim
) I-Claim
is I-Claim
unknown I-Claim
. I-Claim

AET B-Claim
significantly I-Claim
improved I-Claim
important I-Claim
patient-rated I-Claim
outcomes I-Claim
and I-Claim
objective I-Claim
physical I-Claim
functioning I-Claim
in I-Claim
lymphoma I-Claim
patients I-Claim
without I-Claim
interfering I-Claim
with I-Claim
medical I-Claim
treatments I-Claim
or I-Claim
response I-Claim
. I-Claim

These B-Claim
data I-Claim
suggest I-Claim
the I-Claim
utility I-Claim
of I-Claim
strong I-Claim
opioids I-Claim
for I-Claim
first-line I-Claim
treatment I-Claim
of I-Claim
pain I-Claim
in I-Claim
patients I-Claim
with I-Claim
terminal I-Claim
cancer I-Claim
. I-Claim

In B-Claim
V325 I-Claim
, I-Claim
advanced I-Claim
gastric I-Claim
or I-Claim
gastroesophageal I-Claim
junction I-Claim
cancer I-Claim
patients I-Claim
receiving I-Claim
DCF I-Claim
not I-Claim
only I-Claim
had I-Claim
statistically I-Claim
improved I-Claim
overall I-Claim
survival I-Claim
and I-Claim
time I-Claim
to I-Claim
tumor-progression I-Claim
, I-Claim
but I-Claim
they I-Claim
also I-Claim
had I-Claim
better I-Claim
preservation I-Claim
of I-Claim
QOL I-Claim
compared I-Claim
with I-Claim
patients I-Claim
receiving I-Claim
CF I-Claim
. I-Claim

Results B-Claim
showed I-Claim
a I-Claim
significant I-Claim
increase I-Claim
in I-Claim
pain I-Claim
knowledge I-Claim
in I-Claim
patients I-Claim
who I-Claim
received I-Claim
the I-Claim
Pain I-Claim
Education I-Claim
Program I-Claim
and I-Claim
a I-Claim
significant I-Claim
decrease I-Claim
in I-Claim
pain I-Claim
intensity I-Claim
. I-Claim

There B-Claim
were I-Claim
no I-Claim
unexpected I-Claim
hematological I-Claim
or I-Claim
non-hematological I-Claim
toxicities I-Claim
. I-Claim

CRO B-Claim
is I-Claim
effective I-Claim
, I-Claim
safe I-Claim
, I-Claim
and I-Claim
cost-effective I-Claim
in I-Claim
the I-Claim
control I-Claim
of I-Claim
postoperative I-Claim
pain I-Claim
after I-Claim
transarterial I-Claim
chemoembolization I-Claim
for I-Claim
patients I-Claim
with I-Claim
inoperable I-Claim
liver I-Claim
cancer I-Claim
. I-Claim

Genotypes B-Claim
of I-Claim
glutathione-related I-Claim
enzymes I-Claim
, I-Claim
especially I-Claim
GCLC I-Claim
, I-Claim
may I-Claim
be I-Claim
used I-Claim
as I-Claim
host I-Claim
factors I-Claim
in I-Claim
predicting I-Claim
patients I-Claim
' I-Claim
survival I-Claim
after I-Claim
platinum-based I-Claim
chemotherapy I-Claim
. I-Claim

The B-Claim
addition I-Claim
of I-Claim
ASA404 I-Claim
to I-Claim
carboplatin I-Claim
and I-Claim
paclitaxel I-Claim
, I-Claim
although I-Claim
generally I-Claim
well I-Claim
tolerated I-Claim
, I-Claim
failed I-Claim
to I-Claim
improve I-Claim
frontline I-Claim
efficacy I-Claim
in I-Claim
advanced I-Claim
NSCLC I-Claim
. I-Claim

Neither B-Claim
FU24h I-Claim
+ I-Claim
LV I-Claim
nor I-Claim
FU24h I-Claim
prolong I-Claim
survival I-Claim
, I-Claim
relative I-Claim
to I-Claim
bolus I-Claim
FU I-Claim
+ I-Claim
LV I-Claim
. I-Claim

In B-Claim
cachectic I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
cancer I-Claim
, I-Claim
oral I-Claim
melatonin I-Claim
20 I-Claim
mg I-Claim
at I-Claim
night I-Claim
did I-Claim
not I-Claim
improve I-Claim
appetite I-Claim
, I-Claim
weight I-Claim
, I-Claim
or I-Claim
quality I-Claim
of I-Claim
life I-Claim
compared I-Claim
with I-Claim
placebo I-Claim
. I-Claim

Anemia B-Claim
is I-Claim
an I-Claim
expected I-Claim
consequence I-Claim
of I-Claim
intensive I-Claim
chemotherapy I-Claim
regimens I-Claim
administered I-Claim
to I-Claim
patients I-Claim
with I-Claim
acute I-Claim
leukemia I-Claim
. I-Claim

Treatment B-Claim
with I-Claim
MEV I-Claim
was I-Claim
well I-Claim
tolerated I-Claim
and I-Claim
demonstrated I-Claim
clinical I-Claim
activity I-Claim
in I-Claim
patients I-Claim
with I-Claim
CRPC I-Claim
. I-Claim

It B-Claim
is I-Claim
a I-Claim
safe I-Claim
, I-Claim
effective I-Claim
and I-Claim
durable I-Claim
treatment I-Claim
for I-Claim
vasomotor I-Claim
symptoms I-Claim
secondary I-Claim
to I-Claim
long-term I-Claim
antiestrogen I-Claim
hormone I-Claim
use I-Claim
in I-Claim
patients I-Claim
with I-Claim
breast I-Claim
cancer I-Claim
. I-Claim

The B-Claim
global I-Claim
health I-Claim
status I-Claim
showed I-Claim
similar I-Claim
improvement I-Claim
in I-Claim
both I-Claim
arms I-Claim
during I-Claim
treatment I-Claim
. I-Claim

Epoetin B-Claim
alfa I-Claim
administered I-Claim
at I-Claim
40,000 I-Claim
U I-Claim
qw I-Claim
is I-Claim
effective I-Claim
in I-Claim
improving I-Claim
QOL I-Claim
, I-Claim
maintaining I-Claim
hemoglobin I-Claim
level I-Claim
, I-Claim
and I-Claim
reducing I-Claim
transfusion I-Claim
requirements I-Claim
in I-Claim
breast I-Claim
cancer I-Claim
patients I-Claim
. I-Claim

Irinotecan B-Claim
schedules I-Claim
of I-Claim
weekly I-Claim
and I-Claim
of I-Claim
once I-Claim
every I-Claim
3 I-Claim
weeks I-Claim
demonstrated I-Claim
similar I-Claim
efficacy I-Claim
and I-Claim
quality I-Claim
of I-Claim
life I-Claim
in I-Claim
patients I-Claim
with I-Claim
FU-refractory I-Claim
, I-Claim
metastatic I-Claim
colorectal I-Claim
cancer I-Claim
. I-Claim

More B-Claim
efficient I-Claim
treatment I-Claim
protocol I-Claim
is I-Claim
needed I-Claim
for I-Claim
clinical I-Claim
practice I-Claim
. I-Claim

The B-Claim
results I-Claim
of I-Claim
this I-Claim
randomized I-Claim
clinical I-Claim
trial I-Claim
indicate I-Claim
that I-Claim
daunomycin-cytosine I-Claim
arabinoside I-Claim
plus I-Claim
GM-CSF I-Claim
is I-Claim
not I-Claim
a I-Claim
cost-effective I-Claim
treatment I-Claim
strategy I-Claim
when I-Claim
compared I-Claim
with I-Claim
daunomycin-cytosine I-Claim
arabinoside I-Claim
alone I-Claim
. I-Claim

Behavioral B-Claim
change I-Claim
, I-Claim
rather I-Claim
than I-Claim
immunity I-Claim
change I-Claim
, I-Claim
was I-Claim
influential I-Claim
in I-Claim
achieving I-Claim
lower I-Claim
levels I-Claim
of I-Claim
symptomatology I-Claim
and I-Claim
higher I-Claim
functional I-Claim
status I-Claim
. I-Claim

We B-Claim
conclude I-Claim
that I-Claim
TEC I-Claim
, I-Claim
compared I-Claim
with I-Claim
EUC I-Claim
, I-Claim
resulted I-Claim
in I-Claim
improved I-Claim
pain I-Claim
communication I-Claim
self-efficacy I-Claim
and I-Claim
temporary I-Claim
improvement I-Claim
in I-Claim
pain-related I-Claim
impairment I-Claim
, I-Claim
but I-Claim
no I-Claim
improvement I-Claim
in I-Claim
pain I-Claim
severity I-Claim
. I-Claim

Breast B-Claim
and I-Claim
colorectal I-Claim
cancer I-Claim
survivors I-Claim
enrolled I-Claim
in I-Claim
a I-Claim
multicenter I-Claim
, I-Claim
telephone-based I-Claim
physical I-Claim
activity I-Claim
intervention I-Claim
increased I-Claim
physical I-Claim
activity I-Claim
and I-Claim
experienced I-Claim
significant I-Claim
improvements I-Claim
in I-Claim
fitness I-Claim
and I-Claim
physical I-Claim
functioning I-Claim
. I-Claim

The B-Claim
combination I-Claim
of I-Claim
interferon I-Claim
alfa I-Claim
( I-Claim
IFNalpha I-Claim
) I-Claim
and I-Claim
isotretinoin I-Claim
has I-Claim
shown I-Claim
a I-Claim
direct I-Claim
antiproliferative I-Claim
effect I-Claim
on I-Claim
human I-Claim
melanoma I-Claim
cell I-Claim
lines I-Claim
, I-Claim
but B-Claim
it I-Claim
remained I-Claim
unclear I-Claim
whether I-Claim
this I-Claim
combination I-Claim
is I-Claim
more I-Claim
effective I-Claim
than I-Claim
IFNalpha I-Claim
alone I-Claim
in I-Claim
patients I-Claim
with I-Claim
metastatic I-Claim
melanoma I-Claim
. I-Claim

AET B-Claim
did I-Claim
not I-Claim
significantly I-Claim
improve I-Claim
sleep I-Claim
quality I-Claim
in I-Claim
this I-Claim
heterogeneous I-Claim
sample I-Claim
of I-Claim
patients I-Claim
with I-Claim
lymphoma I-Claim
";" I-Claim
however B-Claim
, I-Claim
clinically I-Claim
identifiable I-Claim
subgroups I-Claim
appeared I-Claim
to I-Claim
benefit I-Claim
. I-Claim

Patients B-Claim
receiving I-Claim
concomitant I-Claim
and I-Claim
maintenance I-Claim
temozolomide I-Claim
+ I-Claim
radiotherapy I-Claim
had I-Claim
significantly I-Claim
improved I-Claim
overall I-Claim
survival I-Claim
. I-Claim

Treatment B-Claim
with I-Claim
marimastat I-Claim
after I-Claim
induction I-Claim
therapy I-Claim
for I-Claim
SCLC I-Claim
did I-Claim
not I-Claim
result I-Claim
in I-Claim
improved I-Claim
survival I-Claim
and I-Claim
had I-Claim
a I-Claim
negative I-Claim
impact I-Claim
on I-Claim
quality I-Claim
of I-Claim
life I-Claim
. I-Claim

Rigorous B-Claim
standard I-Claim
operating I-Claim
procedures I-Claim
for I-Claim
data I-Claim
collection I-Claim
are I-Claim
required I-Claim
. I-Claim

Exercise B-Claim
training I-Claim
to I-Claim
improve I-Claim
cardiovascular I-Claim
fitness I-Claim
should I-Claim
be I-Claim
considered I-Claim
in I-Claim
the I-Claim
management I-Claim
of I-Claim
lymphoma I-Claim
patients I-Claim
. I-Claim

In B-Claim
fatigued I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
cancer I-Claim
, I-Claim
nurse-led I-Claim
monitoring I-Claim
and I-Claim
protocolized I-Claim
treatment I-Claim
of I-Claim
physical I-Claim
symptoms I-Claim
is I-Claim
effective I-Claim
in I-Claim
alleviating I-Claim
fatigue I-Claim
. I-Claim

Induction B-Claim
chemotherapy I-Claim
with I-Claim
TPF I-Claim
before I-Claim
RT I-Claim
not I-Claim
only I-Claim
improves I-Claim
survival I-Claim
and I-Claim
reduces I-Claim
toxicity I-Claim
compared I-Claim
with I-Claim
PF I-Claim
but I-Claim
also I-Claim
seems I-Claim
to I-Claim
improve I-Claim
global I-Claim
HRQOL I-Claim
in I-Claim
a I-Claim
more I-Claim
sustainable I-Claim
manner I-Claim
. I-Claim

The B-Claim
oral I-Claim
regimen I-Claim
also I-Claim
can I-Claim
be I-Claim
safely I-Claim
given I-Claim
with I-Claim
appropriate I-Claim
toxicity I-Claim
and I-Claim
tolerability I-Claim
. I-Claim

Flavonoid-rich B-Claim
fruits I-Claim
and I-Claim
vegetables I-Claim
may I-Claim
provide I-Claim
additional I-Claim
protection I-Claim
against I-Claim
CINV I-Claim
. I-Claim

Quality B-Claim
of I-Claim
life I-Claim
is I-Claim
an I-Claim
important I-Claim
issue I-Claim
in I-Claim
pancreatic I-Claim
cancer I-Claim
patients I-Claim
. I-Claim

This B-Claim
translational I-Claim
intervention I-Claim
trial I-Claim
, I-Claim
delivered I-Claim
either I-Claim
FtF I-Claim
or I-Claim
Tel I-Claim
, I-Claim
supports I-Claim
exercise I-Claim
as I-Claim
a I-Claim
form I-Claim
of I-Claim
adjuvant I-Claim
breast I-Claim
cancer I-Claim
therapy I-Claim
that I-Claim
can I-Claim
prevent I-Claim
declines I-Claim
in I-Claim
fitness I-Claim
and I-Claim
function I-Claim
during I-Claim
treatment I-Claim
and I-Claim
optimise I-Claim
recovery I-Claim
post-treatment I-Claim
. I-Claim

Of B-Claim
the I-Claim
three I-Claim
regimens I-Claim
tested I-Claim
, I-Claim
the I-Claim
combination I-Claim
of I-Claim
LV5FU2-irinotecan I-Claim
is I-Claim
the I-Claim
most I-Claim
promising I-Claim
and I-Claim
will I-Claim
be I-Claim
assessed I-Claim
in I-Claim
a I-Claim
phase I-Claim
III I-Claim
trial I-Claim
. I-Claim

In B-Claim
the I-Claim
clinical I-Claim
trial I-Claim
, I-Claim
treatment I-Claim
with I-Claim
epoetin I-Claim
alfa I-Claim
overcame I-Claim
much I-Claim
of I-Claim
the I-Claim
QOL I-Claim
deficit I-Claim
seen I-Claim
in I-Claim
anemic I-Claim
cancer I-Claim
patients I-Claim
compared I-Claim
with I-Claim
the I-Claim
norm I-Claim
population I-Claim
sample I-Claim
. I-Claim

The B-Claim
combination I-Claim
of I-Claim
radiotherapy I-Claim
plus I-Claim
6 I-Claim
months I-Claim
of I-Claim
androgen I-Claim
suppression I-Claim
provides I-Claim
inferior I-Claim
survival I-Claim
as I-Claim
compared I-Claim
with I-Claim
radiotherapy I-Claim
plus I-Claim
3 I-Claim
years I-Claim
of I-Claim
androgen I-Claim
suppression I-Claim
in I-Claim
the I-Claim
treatment I-Claim
of I-Claim
locally I-Claim
advanced I-Claim
prostate I-Claim
cancer I-Claim
. I-Claim

The B-Claim
effect I-Claim
of I-Claim
grape I-Claim
juice I-Claim
flavonoids I-Claim
on I-Claim
CINV I-Claim
should I-Claim
be I-Claim
investigated I-Claim
further I-Claim
with I-Claim
a I-Claim
larger I-Claim
sample I-Claim
to I-Claim
determine I-Claim
whether I-Claim
preliminary I-Claim
findings I-Claim
are I-Claim
supported I-Claim
. I-Claim

There B-Claim
is I-Claim
a I-Claim
paucity I-Claim
of I-Claim
high-level I-Claim
evidence I-Claim
on I-Claim
potentially I-Claim
useful I-Claim
interventions I-Claim
and I-Claim
a I-Claim
continued I-Claim
need I-Claim
for I-Claim
new I-Claim
and I-Claim
innovative I-Claim
research I-Claim
, I-Claim
incorporating I-Claim
quality-of-life I-Claim
measurements I-Claim
, I-Claim
in I-Claim
patients I-Claim
experiencing I-Claim
radiation-induced I-Claim
mucositis I-Claim
. I-Claim

On B-Claim
the I-Claim
basis I-Claim
of I-Claim
these I-Claim
findings I-Claim
, I-Claim
the I-Claim
policy I-Claim
of I-Claim
EOF I-Claim
should I-Claim
be I-Claim
used I-Claim
after I-Claim
a I-Claim
complex I-Claim
gynecologic I-Claim
oncologic I-Claim
laparotomy I-Claim
. I-Claim

This B-Claim
investigation I-Claim
supports I-Claim
the I-Claim
clinical I-Claim
relevance I-Claim
of I-Claim
linear I-Claim
analogue I-Claim
self-assessment I-Claim
scales I-Claim
as I-Claim
indicators I-Claim
of I-Claim
components I-Claim
of I-Claim
quality I-Claim
of I-Claim
life I-Claim
in I-Claim
cancer I-Claim
clinical I-Claim
trials I-Claim
. I-Claim

Hormonal B-Claim
breast I-Claim
cancer I-Claim
treatment I-Claim
increases I-Claim
menopausal I-Claim
symptoms I-Claim
in I-Claim
women I-Claim
. I-Claim

The B-Claim
effect I-Claim
appeared I-Claim
to I-Claim
be I-Claim
dose-dependent I-Claim
. I-Claim

No B-Claim
substantive I-Claim
differences I-Claim
were I-Claim
detected I-Claim
between I-Claim
outcomes I-Claim
of I-Claim
embolization I-Claim
with I-Claim
PVA I-Claim
particles I-Claim
or I-Claim
tris-acryl I-Claim
gelatin I-Claim
microspheres I-Claim
. I-Claim

Safe B-Claim
and I-Claim
effective I-Claim
interventions I-Claim
are I-Claim
needed I-Claim
to I-Claim
alleviate I-Claim
sexual I-Claim
dysfunction I-Claim
. I-Claim

The B-Claim
two I-Claim
schedules I-Claim
are I-Claim
equivalent I-Claim
in I-Claim
terms I-Claim
of I-Claim
overall I-Claim
response I-Claim
rate I-Claim
, I-Claim
median I-Claim
time-to-progression I-Claim
and I-Claim
overall I-Claim
survival I-Claim
. I-Claim

The B-Claim
use I-Claim
of I-Claim
home-based I-Claim
assessments I-Claim
by I-Claim
a I-Claim
research I-Claim
nurse I-Claim
proved I-Claim
to I-Claim
be I-Claim
an I-Claim
effective I-Claim
way I-Claim
of I-Claim
obtaining I-Claim
high-quality I-Claim
data I-Claim
. I-Claim

Low-dose B-Claim
CDDP I-Claim
improved I-Claim
the I-Claim
response I-Claim
rate I-Claim
while I-Claim
keeping I-Claim
toxicities I-Claim
within I-Claim
clinically I-Claim
acceptable I-Claim
limits I-Claim
. I-Claim

The B-Claim
observation I-Claim
that I-Claim
longer I-Claim
infusion I-Claim
produces I-Claim
more I-Claim
myelosuppression I-Claim
but I-Claim
does I-Claim
not I-Claim
yield I-Claim
higher I-Claim
response I-Claim
rates I-Claim
should I-Claim
lead I-Claim
to I-Claim
further I-Claim
studies I-Claim
to I-Claim
determine I-Claim
the I-Claim
optimal I-Claim
dose I-Claim
and I-Claim
schedule I-Claim
of I-Claim
this I-Claim
interesting I-Claim
new I-Claim
agent I-Claim
. I-Claim

After B-Claim
major I-Claim
surgery I-Claim
, I-Claim
specialized I-Claim
supportive I-Claim
enteral I-Claim
and I-Claim
parenteral I-Claim
nutrition I-Claim
are I-Claim
not I-Claim
superior I-Claim
to I-Claim
oral I-Claim
nutrition I-Claim
only I-Claim
when I-Claim
guided I-Claim
by I-Claim
a I-Claim
dietitian I-Claim
. I-Claim

Nocturnal B-Claim
administration I-Claim
of I-Claim
BCAA I-Claim
granules I-Claim
in I-Claim
patients I-Claim
with I-Claim
cirrhosis I-Claim
reduced I-Claim
the I-Claim
occurrence I-Claim
of I-Claim
muscle I-Claim
cramps I-Claim
in I-Claim
the I-Claim
leg I-Claim
but I-Claim
did I-Claim
not I-Claim
improve I-Claim
the I-Claim
patients I-Claim
' I-Claim
QOL I-Claim
. I-Claim

The B-Claim
TAX I-Claim
326 I-Claim
study I-Claim
shows I-Claim
that I-Claim
docetaxel-platinum I-Claim
regimens I-Claim
relieve I-Claim
symptoms I-Claim
and I-Claim
improve I-Claim
QoL I-Claim
in I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
NSCLC I-Claim
. I-Claim

Further B-Claim
research I-Claim
is I-Claim
needed I-Claim
into I-Claim
a I-Claim
number I-Claim
of I-Claim
areas I-Claim
including I-Claim
the I-Claim
long-term I-Claim
aspects I-Claim
of I-Claim
quality I-Claim
of I-Claim
life I-Claim
, I-Claim
clinical I-Claim
outcomes I-Claim
, I-Claim
costs I-Claim
and I-Claim
consequences I-Claim
of I-Claim
omitting I-Claim
radiotherapy I-Claim
. I-Claim

Overall B-Claim
survival I-Claim
was I-Claim
not I-Claim
statistically I-Claim
significantly I-Claim
improved I-Claim
at I-Claim
this I-Claim
time I-Claim
. I-Claim

Abatacept B-Claim
demonstrated I-Claim
acceptable I-Claim
safety I-Claim
and I-Claim
tolerability I-Claim
and I-Claim
clinically I-Claim
meaningful I-Claim
efficacy I-Claim
over I-Claim
6 I-Claim
months I-Claim
in I-Claim
patients I-Claim
with I-Claim
inadequate I-Claim
response I-Claim
to I-Claim
anti-TNF I-Claim
therapy I-Claim
. I-Claim

Although B-Claim
TMZ I-Claim
( I-Claim
both I-Claim
arms I-Claim
combined I-Claim
) I-Claim
did I-Claim
not I-Claim
show I-Claim
a I-Claim
clear I-Claim
benefit I-Claim
compared I-Claim
with I-Claim
PCV I-Claim
, I-Claim
comparison I-Claim
of I-Claim
the I-Claim
TMZ I-Claim
schedules I-Claim
demonstrated I-Claim
that I-Claim
the I-Claim
21-day I-Claim
schedule I-Claim
was I-Claim
inferior I-Claim
to I-Claim
the I-Claim
5-day I-Claim
schedule I-Claim
in I-Claim
this I-Claim
setting I-Claim
. I-Claim

The B-Claim
clinical I-Claim
efficacy I-Claim
of I-Claim
pemetrexed I-Claim
and I-Claim
gemcitabine I-Claim
combined I-Claim
with I-Claim
cisplatin I-Claim
for I-Claim
the I-Claim
treatment I-Claim
of I-Claim
previously I-Claim
untreated I-Claim
advanced I-Claim
NSCLC I-Claim
was I-Claim
roughly I-Claim
the I-Claim
same I-Claim
, I-Claim
but B-Claim
the I-Claim
adverse I-Claim
reactions I-Claim
decreased I-Claim
significantly I-Claim
in I-Claim
the I-Claim
PP I-Claim
group I-Claim
compared I-Claim
with I-Claim
those I-Claim
in I-Claim
the I-Claim
GP I-Claim
group I-Claim
. I-Claim

These B-Claim
results I-Claim
provide I-Claim
further I-Claim
support I-Claim
for I-Claim
the I-Claim
efficacy I-Claim
of I-Claim
abiraterone I-Claim
in I-Claim
this I-Claim
population I-Claim
. I-Claim

The B-Claim
addition I-Claim
of I-Claim
paclitaxel I-Claim
to I-Claim
best I-Claim
supportive I-Claim
care I-Claim
significantly I-Claim
improved I-Claim
survival I-Claim
and I-Claim
time I-Claim
to I-Claim
disease I-Claim
progression I-Claim
compared I-Claim
with I-Claim
best I-Claim
supportive I-Claim
care I-Claim
in I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
NSCLC I-Claim
and I-Claim
may I-Claim
improve I-Claim
some I-Claim
aspects I-Claim
of I-Claim
QOL I-Claim
. I-Claim

Acupuncture B-Claim
is I-Claim
an I-Claim
effective I-Claim
intervention I-Claim
for I-Claim
managing I-Claim
the I-Claim
symptom I-Claim
of I-Claim
CRF I-Claim
and I-Claim
improving I-Claim
patients I-Claim
' I-Claim
quality I-Claim
of I-Claim
life I-Claim
. I-Claim

Impaired B-Claim
cognition I-Claim
, I-Claim
fatigue I-Claim
, I-Claim
and I-Claim
diminished I-Claim
quality I-Claim
of I-Claim
life I-Claim
( I-Claim
QOL I-Claim
) I-Claim
are I-Claim
commonly I-Claim
associated I-Claim
with I-Claim
breast I-Claim
cancer I-Claim
chemotherapy I-Claim
. I-Claim

Thalidomide B-Claim
was I-Claim
well I-Claim
tolerated I-Claim
and I-Claim
effective I-Claim
at I-Claim
attenuating I-Claim
loss I-Claim
of I-Claim
weight I-Claim
and I-Claim
lean I-Claim
body I-Claim
mass I-Claim
in I-Claim
patients I-Claim
with I-Claim
cachexia I-Claim
due I-Claim
to I-Claim
advanced I-Claim
pancreatic I-Claim
cancer I-Claim
. I-Claim

MA.17 B-Claim
showed I-Claim
that I-Claim
letrozole I-Claim
is I-Claim
extremely I-Claim
well-tolerated I-Claim
relative I-Claim
to I-Claim
placebo I-Claim
. I-Claim

The B-Claim
TOM I-Claim
+ I-Claim
LFA I-Claim
5-FU I-Claim
regimen I-Claim
showed I-Claim
a I-Claim
RR I-Claim
and I-Claim
a I-Claim
toxicity I-Claim
profile I-Claim
very I-Claim
close I-Claim
to I-Claim
the I-Claim
MTX I-Claim
+ I-Claim
LFA I-Claim
5-FU I-Claim
combination I-Claim
, I-Claim
and I-Claim
does I-Claim
not I-Claim
deserve I-Claim
further I-Claim
evaluation I-Claim
in I-Claim
advanced I-Claim
colorectal I-Claim
cancer I-Claim
patients I-Claim
. I-Claim

It B-Claim
is I-Claim
not I-Claim
known I-Claim
whether I-Claim
imatinib I-Claim
may I-Claim
be I-Claim
stopped I-Claim
in I-Claim
patients I-Claim
in I-Claim
whom I-Claim
disease I-Claim
is I-Claim
controlled I-Claim
. I-Claim

No B-Claim
differences I-Claim
were I-Claim
observed I-Claim
between I-Claim
groups I-Claim
regarding I-Claim
HRQOL I-Claim
at I-Claim
24-month I-Claim
follow-up I-Claim
. I-Claim

DPPE B-Claim
( I-Claim
tesmilifene I-Claim
) I-Claim
plus I-Claim
doxorubicin I-Claim
( I-Claim
DOX I-Claim
) I-Claim
demonstrated I-Claim
a I-Claim
significant I-Claim
improvement I-Claim
in I-Claim
survival I-Claim
versus I-Claim
DOX I-Claim
in I-Claim
a I-Claim
phase I-Claim
III I-Claim
clinical I-Claim
trial I-Claim
in I-Claim
advanced I-Claim
breast I-Claim
cancer I-Claim
. I-Claim

Medical B-Claim
castration I-Claim
reduces I-Claim
TPV I-Claim
and I-Claim
could I-Claim
also I-Claim
improve I-Claim
LUTS I-Claim
in I-Claim
patients I-Claim
with I-Claim
PCa I-Claim
. I-Claim

In B-Claim
conclusion I-Claim
, I-Claim
palliative I-Claim
chemotherapy I-Claim
with I-Claim
carboplatin I-Claim
and I-Claim
vinorelbine I-Claim
beyond I-Claim
three I-Claim
courses I-Claim
conveys I-Claim
no I-Claim
survival I-Claim
or I-Claim
consistent I-Claim
QoL I-Claim
benefits I-Claim
in I-Claim
advanced I-Claim
NSCLC I-Claim
. I-Claim

Our B-Claim
data I-Claim
indicate I-Claim
that I-Claim
protracted I-Claim
palliative I-Claim
TRT I-Claim
renders I-Claim
no I-Claim
improvement I-Claim
in I-Claim
symptom I-Claim
relief I-Claim
, I-Claim
HRQOL I-Claim
, I-Claim
or I-Claim
survival I-Claim
when I-Claim
compared I-Claim
with I-Claim
short-term I-Claim
hypofractionated I-Claim
treatment I-Claim
in I-Claim
advanced I-Claim
NSCLC I-Claim
. I-Claim

This B-Claim
supports I-Claim
the I-Claim
need I-Claim
for I-Claim
an I-Claim
individualized I-Claim
approach I-Claim
to I-Claim
therapy I-Claim
recommendations I-Claim
. I-Claim

DC/CIK B-Claim
treatment I-Claim
had I-Claim
potential I-Claim
benefit I-Claim
for I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
non-small I-Claim
cell I-Claim
lung I-Claim
cancer I-Claim
compared I-Claim
with I-Claim
the I-Claim
control I-Claim
group I-Claim
and I-Claim
had I-Claim
no I-Claim
obvious I-Claim
side I-Claim
effects I-Claim
. I-Claim

However B-Claim
, I-Claim
its I-Claim
safety I-Claim
should I-Claim
be I-Claim
confirmed I-Claim
by I-Claim
the I-Claim
results I-Claim
of I-Claim
larger I-Claim
randomized I-Claim
trials I-Claim
and I-Claim
meta-analyses I-Claim
. I-Claim

Qualitative B-Claim
interviews I-Claim
suggested I-Claim
that I-Claim
patients I-Claim
found I-Claim
participation I-Claim
in I-Claim
the I-Claim
trial I-Claim
acceptable I-Claim
and I-Claim
that I-Claim
they I-Claim
would I-Claim
consider I-Claim
participating I-Claim
in I-Claim
a I-Claim
future I-Claim
trial I-Claim
. I-Claim

Global B-Claim
quality I-Claim
of I-Claim
life I-Claim
did I-Claim
not I-Claim
differ I-Claim
within I-Claim
the I-Claim
three I-Claim
arms I-Claim
. I-Claim

Adding B-Claim
E I-Claim
to I-Claim
G I-Claim
did I-Claim
not I-Claim
increase I-Claim
hematologic I-Claim
toxicities I-Claim
. I-Claim

Distress B-Claim
reduction I-Claim
is I-Claim
highlighted I-Claim
as I-Claim
an I-Claim
important I-Claim
mechanism I-Claim
by I-Claim
which I-Claim
health I-Claim
can I-Claim
be I-Claim
improved I-Claim
. I-Claim

Although B-Claim
it I-Claim
is I-Claim
premature I-Claim
to I-Claim
make I-Claim
any I-Claim
determination I-Claim
as I-Claim
to I-Claim
the I-Claim
efficacy I-Claim
of I-Claim
the I-Claim
interventions I-Claim
tested I-Claim
in I-Claim
this I-Claim
feasibility I-Claim
study I-Claim
, I-Claim
these B-Claim
results I-Claim
indicate I-Claim
that I-Claim
pursuing I-Claim
the I-Claim
III I-Claim
+ I-Claim
ISG I-Claim
model I-Claim
, I-Claim
as I-Claim
well I-Claim
as I-Claim
standard I-Claim
IIIs I-Claim
, I-Claim
may I-Claim
be I-Claim
fruitful I-Claim
areas I-Claim
of I-Claim
future I-Claim
research I-Claim
. I-Claim

This B-Claim
is I-Claim
the I-Claim
first I-Claim
prospective I-Claim
, I-Claim
randomized I-Claim
controlled I-Claim
trial I-Claim
to I-Claim
report I-Claim
that I-Claim
participation I-Claim
in I-Claim
a I-Claim
home I-Claim
walking I-Claim
program I-Claim
confers I-Claim
a I-Claim
significant I-Claim
benefit I-Claim
in I-Claim
resected I-Claim
PPC I-Claim
patients I-Claim
with I-Claim
regard I-Claim
to I-Claim
fatigue I-Claim
levels I-Claim
, I-Claim
physical I-Claim
functioning I-Claim
, I-Claim
and I-Claim
health-related I-Claim
quality I-Claim
of I-Claim
life I-Claim
. I-Claim

ALT B-Claim
was I-Claim
found I-Claim
to I-Claim
be I-Claim
a I-Claim
safe I-Claim
method I-Claim
, I-Claim
with I-Claim
high I-Claim
adherence I-Claim
, I-Claim
in I-Claim
treating I-Claim
women I-Claim
who I-Claim
suffer I-Claim
from I-Claim
mild I-Claim
to I-Claim
moderate I-Claim
lymphedema I-Claim
. I-Claim

These B-Claim
results I-Claim
may I-Claim
have I-Claim
implications I-Claim
for I-Claim
the I-Claim
design I-Claim
of I-Claim
combination I-Claim
regimens I-Claim
incorporating I-Claim
IFN I-Claim
with I-Claim
targeted I-Claim
agents I-Claim
. I-Claim

Psychosocial B-Claim
intervention I-Claim
is I-Claim
a I-Claim
cost-effective I-Claim
approach I-Claim
that I-Claim
can I-Claim
improve I-Claim
a I-Claim
patient I-Claim
's I-Claim
mood I-Claim
and I-Claim
QOL I-Claim
both I-Claim
during I-Claim
and I-Claim
after I-Claim
RT I-Claim
. I-Claim

In B-Claim
patients I-Claim
with I-Claim
advanced I-Claim
NSCLC I-Claim
, I-Claim
GCa I-Claim
chemotherapy I-Claim
was I-Claim
shown I-Claim
to I-Claim
be I-Claim
a I-Claim
better-tolerated I-Claim
treatment I-Claim
that I-Claim
conferred I-Claim
a I-Claim
survival I-Claim
advantage I-Claim
over I-Claim
MIC I-Claim
. I-Claim

However B-Claim
, I-Claim
the I-Claim
trend I-Claim
in I-Claim
RR I-Claim
, I-Claim
PFS I-Claim
, I-Claim
and I-Claim
OS I-Claim
favors I-Claim
PC I-Claim
. I-Claim

Abiraterone B-Claim
acetate I-Claim
plus I-Claim
prednisone I-Claim
significantly I-Claim
improves I-Claim
radiographic I-Claim
progression-free I-Claim
survival I-Claim
in I-Claim
asymptomatic I-Claim
or I-Claim
mildly I-Claim
symptomatic I-Claim
, I-Claim
chemotherapy-naive I-Claim
patients I-Claim
with I-Claim
metastatic I-Claim
castration-resistant I-Claim
prostate I-Claim
cancer I-Claim
compared I-Claim
with I-Claim
prednisone I-Claim
alone I-Claim
. I-Claim

Its B-Claim
leakage I-Claim
rate I-Claim
was I-Claim
lower I-Claim
and I-Claim
quality I-Claim
of I-Claim
life I-Claim
was I-Claim
better I-Claim
. I-Claim

Treatment B-Claim
, I-Claim
particularly I-Claim
the I-Claim
combination I-Claim
therapy I-Claim
, I-Claim
was I-Claim
associated I-Claim
with I-Claim
a I-Claim
decrease I-Claim
in I-Claim
QOL I-Claim
. I-Claim

Radiation B-Claim
therapy I-Claim
for I-Claim
prostate I-Claim
carcinoma I-Claim
causes I-Claim
persistent I-Claim
GI I-Claim
toxicity I-Claim
that I-Claim
is I-Claim
largely I-Claim
independent I-Claim
of I-Claim
the I-Claim
two I-Claim
dose I-Claim
schedules I-Claim
. I-Claim

Addition B-Claim
of I-Claim
bevacizumab I-Claim
to I-Claim
FU/LV I-Claim
as I-Claim
first-line I-Claim
therapy I-Claim
in I-Claim
CRC I-Claim
patients I-Claim
who I-Claim
were I-Claim
not I-Claim
considered I-Claim
optimal I-Claim
candidates I-Claim
for I-Claim
first-line I-Claim
irinotecan I-Claim
treatment I-Claim
provided I-Claim
clinically I-Claim
significant I-Claim
patient I-Claim
benefit I-Claim
, I-Claim
including I-Claim
statistically I-Claim
significant I-Claim
improvement I-Claim
in I-Claim
progression-free I-Claim
survival I-Claim
. I-Claim

After B-Claim
1 I-Claim
month I-Claim
of I-Claim
r-HuEPO I-Claim
, I-Claim
there I-Claim
is I-Claim
also I-Claim
a I-Claim
reduction I-Claim
in I-Claim
transfusion I-Claim
requirement I-Claim
. I-Claim

This B-Claim
trial I-Claim
failed I-Claim
to I-Claim
show I-Claim
a I-Claim
benefit I-Claim
for I-Claim
up-front I-Claim
tandem I-Claim
HDCT I-Claim
compared I-Claim
with I-Claim
standard I-Claim
combination I-Claim
therapy I-Claim
. I-Claim

Letrozole B-Claim
should I-Claim
be I-Claim
considered I-Claim
for I-Claim
all I-Claim
women I-Claim
completing I-Claim
tamoxifen I-Claim
";" I-Claim
new B-Claim
results I-Claim
from I-Claim
the I-Claim
post-unblinding I-Claim
analysis I-Claim
suggest I-Claim
that I-Claim
letrozole I-Claim
treatment I-Claim
should I-Claim
also I-Claim
be I-Claim
considered I-Claim
for I-Claim
all I-Claim
disease-free I-Claim
women I-Claim
for I-Claim
periods I-Claim
up I-Claim
to I-Claim
5 I-Claim
years I-Claim
following I-Claim
completion I-Claim
of I-Claim
adjuvant I-Claim
tamoxifen I-Claim
. I-Claim

Bevacizumab B-Claim
, I-Claim
a I-Claim
monoclonal I-Claim
antibody I-Claim
against I-Claim
vascular I-Claim
endothelial I-Claim
growth I-Claim
factor I-Claim
, I-Claim
increases I-Claim
survival I-Claim
when I-Claim
combined I-Claim
with I-Claim
irinotecan-based I-Claim
chemotherapy I-Claim
in I-Claim
first-line I-Claim
treatment I-Claim
of I-Claim
metastatic I-Claim
colorectal I-Claim
cancer I-Claim
( I-Claim
CRC I-Claim
) I-Claim
. I-Claim

The B-Claim
survival I-Claim
with I-Claim
DOX I-Claim
and I-Claim
VNB I-Claim
is I-Claim
not I-Claim
superior I-Claim
to I-Claim
DOX I-Claim
alone I-Claim
in I-Claim
MBC I-Claim
. I-Claim

The B-Claim
16-week I-Claim
regimen I-Claim
should I-Claim
not I-Claim
be I-Claim
used I-Claim
instead I-Claim
of I-Claim
a I-Claim
standard-dose I-Claim
regimen I-Claim
without I-Claim
careful I-Claim
consideration I-Claim
of I-Claim
the I-Claim
16-week I-Claim
regimen I-Claim
's I-Claim
pros I-Claim
and I-Claim
cons I-Claim
, I-Claim
which I-Claim
include I-Claim
its I-Claim
complicated I-Claim
schedule I-Claim
. I-Claim

A B-Claim
significant I-Claim
immediate I-Claim
and I-Claim
insignificant I-Claim
long-term I-Claim
effect I-Claim
on I-Claim
limb I-Claim
volume I-Claim
was I-Claim
noted I-Claim
. I-Claim

Radiotherapy B-Claim
was I-Claim
then I-Claim
associated I-Claim
with I-Claim
increased I-Claim
breast I-Claim
symptoms I-Claim
and I-Claim
with I-Claim
greater I-Claim
fatigue I-Claim
but I-Claim
with I-Claim
less I-Claim
insomnia I-Claim
and I-Claim
endocrine I-Claim
side-effects I-Claim
. I-Claim

Coloplasty B-Claim
pouches I-Claim
resulted I-Claim
in I-Claim
more I-Claim
anastomotic I-Claim
leaks I-Claim
and I-Claim
minimal I-Claim
differences I-Claim
in I-Claim
bowel I-Claim
function I-Claim
. I-Claim

Erlotinib B-Claim
maintenance I-Claim
therapy I-Claim
significantly I-Claim
extends I-Claim
progression-free I-Claim
survival I-Claim
without I-Claim
compromising I-Claim
patient I-Claim
HRQoL I-Claim
in I-Claim
comparison I-Claim
with I-Claim
placebo I-Claim
, I-Claim
with I-Claim
some I-Claim
improvement I-Claim
in I-Claim
symptoms I-Claim
. I-Claim

These B-Claim
results I-Claim
support I-Claim
the I-Claim
use I-Claim
of I-Claim
weekly I-Claim
epoetin I-Claim
alfa I-Claim
as I-Claim
an I-Claim
ameliorative I-Claim
agent I-Claim
for I-Claim
cancer-related I-Claim
anemia I-Claim
. I-Claim

Functional B-Claim
outcome I-Claim
, I-Claim
QOL I-Claim
, I-Claim
and I-Claim
morbidity I-Claim
are I-Claim
similar I-Claim
for I-Claim
the I-Claim
two I-Claim
approaches I-Claim
. I-Claim

There B-Claim
was I-Claim
no I-Claim
statistically I-Claim
significant I-Claim
difference I-Claim
in I-Claim
effect I-Claim
on I-Claim
quality I-Claim
of I-Claim
life I-Claim
as I-Claim
assessed I-Claim
using I-Claim
the I-Claim
DLQI I-Claim
. I-Claim

In B-Claim
conclusion I-Claim
, I-Claim
MBAT I-Claim
is I-Claim
associated I-Claim
with I-Claim
significant I-Claim
, I-Claim
sustained I-Claim
benefits I-Claim
across I-Claim
a I-Claim
diverse I-Claim
range I-Claim
of I-Claim
breast I-Claim
cancer I-Claim
patients I-Claim
, I-Claim
particularly I-Claim
those I-Claim
with I-Claim
high I-Claim
stress I-Claim
levels I-Claim
. I-Claim

Methadone B-Claim
was I-Claim
significantly I-Claim
less I-Claim
expensive I-Claim
, I-Claim
but I-Claim
required I-Claim
more I-Claim
changes I-Claim
, I-Claim
up I-Claim
and I-Claim
down I-Claim
, I-Claim
of I-Claim
the I-Claim
doses I-Claim
, I-Claim
suggesting I-Claim
that I-Claim
dose I-Claim
titration I-Claim
of I-Claim
this I-Claim
drug I-Claim
requires I-Claim
major I-Claim
clinical I-Claim
expertise I-Claim
. I-Claim

Findings B-Claim
suggest I-Claim
that I-Claim
self-efficacy I-Claim
may I-Claim
influence I-Claim
long-term I-Claim
maintenance I-Claim
of I-Claim
healthy I-Claim
lifestyle I-Claim
practices I-Claim
among I-Claim
cancer I-Claim
survivors I-Claim
. I-Claim

SLN B-Claim
biopsy I-Claim
is I-Claim
an I-Claim
effective I-Claim
and I-Claim
well-tolerated I-Claim
procedure I-Claim
. I-Claim

Combined B-Claim
cardiorespiratory I-Claim
and I-Claim
resistance I-Claim
training I-Claim
, I-Claim
even I-Claim
of I-Claim
very I-Claim
brief I-Claim
duration I-Claim
, I-Claim
improves I-Claim
the I-Claim
QOL I-Claim
and I-Claim
the I-Claim
overall I-Claim
physical I-Claim
fitness I-Claim
of I-Claim
women I-Claim
breast I-Claim
cancer I-Claim
survivors I-Claim
. I-Claim

An B-Claim
antidepressant I-Claim
should I-Claim
be I-Claim
considered I-Claim
for I-Claim
early I-Claim
stage I-Claim
breast I-Claim
cancer I-Claim
patients I-Claim
with I-Claim
depressive I-Claim
symptoms I-Claim
who I-Claim
are I-Claim
receiving I-Claim
adjuvant I-Claim
treatment I-Claim
. I-Claim

For B-Claim
patients I-Claim
with I-Claim
anthracycline-pretreated I-Claim
metastatic I-Claim
breast I-Claim
carcinoma I-Claim
, I-Claim
capecitabine I-Claim
plus I-Claim
docetaxel I-Claim
significantly I-Claim
increased I-Claim
overall I-Claim
survival I-Claim
compared I-Claim
with I-Claim
docetaxel I-Claim
alone I-Claim
. I-Claim

The B-Claim
TC I-Claim
regimen I-Claim
achieved I-Claim
comparable I-Claim
efficacy I-Claim
to I-Claim
the I-Claim
PT I-Claim
regimen I-Claim
but I-Claim
was I-Claim
associated I-Claim
with I-Claim
better I-Claim
tolerability I-Claim
and I-Claim
quality I-Claim
of I-Claim
life I-Claim
, I-Claim
and I-Claim
should I-Claim
, I-Claim
therefore I-Claim
, I-Claim
be I-Claim
considered I-Claim
as I-Claim
an I-Claim
important I-Claim
alternative I-Claim
for I-Claim
standard I-Claim
first-line I-Claim
chemotherapy I-Claim
in I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
ovarian I-Claim
cancer I-Claim
. I-Claim

A B-Claim
multidimensional I-Claim
rehabilitation I-Claim
program I-Claim
has I-Claim
statistically I-Claim
and I-Claim
clinically I-Claim
relevant I-Claim
beneficial I-Claim
effects I-Claim
on I-Claim
health-related I-Claim
quality I-Claim
of I-Claim
life I-Claim
, I-Claim
exercise I-Claim
capacity I-Claim
, I-Claim
and I-Claim
muscle I-Claim
force I-Claim
in I-Claim
cancer I-Claim
patients I-Claim
with I-Claim
different I-Claim
diagnoses I-Claim
. I-Claim

Erlotinib B-Claim
was I-Claim
superior I-Claim
to I-Claim
placebo I-Claim
for I-Claim
survival I-Claim
, I-Claim
progression-free I-Claim
survival I-Claim
, I-Claim
and I-Claim
tumor I-Claim
response I-Claim
rate I-Claim
. I-Claim

Response B-Claim
proportion I-Claim
and I-Claim
survival I-Claim
did I-Claim
not I-Claim
improve I-Claim
significantly I-Claim
with I-Claim
the I-Claim
addition I-Claim
of I-Claim
13-CRA I-Claim
to I-Claim
IFNalpha2a I-Claim
therapy I-Claim
in I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
RCC I-Claim
. I-Claim

Although B-Claim
these I-Claim
findings I-Claim
are I-Claim
promising I-Claim
, I-Claim
a I-Claim
larger I-Claim
study I-Claim
is I-Claim
needed I-Claim
to I-Claim
determine I-Claim
more I-Claim
specifically I-Claim
what I-Claim
short- I-Claim
and I-Claim
long-term I-Claim
effects I-Claim
are I-Claim
possible I-Claim
. I-Claim

The B-Claim
IMPACT I-Claim
collaborative I-Claim
care I-Claim
program I-Claim
appears I-Claim
to I-Claim
be I-Claim
feasible I-Claim
and I-Claim
effective I-Claim
for I-Claim
depression I-Claim
among I-Claim
older I-Claim
cancer I-Claim
patients I-Claim
in I-Claim
diverse I-Claim
primary I-Claim
care I-Claim
settings I-Claim
. I-Claim

EW B-Claim
was I-Claim
associated I-Claim
with I-Claim
a I-Claim
higher I-Claim
level I-Claim
of I-Claim
satisfaction I-Claim
with I-Claim
emotional I-Claim
support I-Claim
compared I-Claim
with I-Claim
controls I-Claim
. I-Claim

Additional B-Claim
studies I-Claim
are I-Claim
warranted I-Claim
. I-Claim

The B-Claim
results I-Claim
of I-Claim
this I-Claim
brief I-Claim
pilot I-Claim
counseling I-Claim
intervention I-Claim
demonstrated I-Claim
significant I-Claim
gains I-Claim
in I-Claim
sexual I-Claim
function I-Claim
and I-Claim
satisfaction I-Claim
and I-Claim
increased I-Claim
utilization I-Claim
of I-Claim
treatments I-Claim
for I-Claim
ED I-Claim
. I-Claim

The B-Claim
combination I-Claim
of I-Claim
self-directed I-Claim
movement I-Claim
and I-Claim
mindfulness I-Claim
, I-Claim
as I-Claim
tested I-Claim
here I-Claim
, I-Claim
may I-Claim
be I-Claim
a I-Claim
valuable I-Claim
tool I-Claim
for I-Claim
promoting I-Claim
health I-Claim
and I-Claim
well-being I-Claim
in I-Claim
older I-Claim
long-term I-Claim
survivors I-Claim
of I-Claim
breast I-Claim
cancer I-Claim
. I-Claim

Breast B-Claim
IMRT I-Claim
significantly I-Claim
reduced I-Claim
the I-Claim
occurrence I-Claim
of I-Claim
moist I-Claim
desquamation I-Claim
compared I-Claim
with I-Claim
a I-Claim
standard I-Claim
wedged I-Claim
technique I-Claim
. I-Claim

Compared B-Claim
with I-Claim
participants I-Claim
receiving I-Claim
usual I-Claim
oncology I-Claim
care I-Claim
, I-Claim
those I-Claim
receiving I-Claim
a I-Claim
nurse-led I-Claim
, I-Claim
palliative I-Claim
care-focused I-Claim
intervention I-Claim
addressing I-Claim
physical I-Claim
, I-Claim
psychosocial I-Claim
, I-Claim
and I-Claim
care I-Claim
coordination I-Claim
provided I-Claim
concurrently I-Claim
with I-Claim
oncology I-Claim
care I-Claim
had I-Claim
higher I-Claim
scores I-Claim
for I-Claim
quality I-Claim
of I-Claim
life I-Claim
and I-Claim
mood I-Claim
, I-Claim
but B-Claim
did I-Claim
not I-Claim
have I-Claim
improvements I-Claim
in I-Claim
symptom I-Claim
intensity I-Claim
scores I-Claim
or I-Claim
reduced I-Claim
days I-Claim
in I-Claim
the I-Claim
hospital I-Claim
or I-Claim
ICU I-Claim
or I-Claim
emergency I-Claim
department I-Claim
visits I-Claim
. I-Claim

Only B-Claim
the I-Claim
combined I-Claim
intervention I-Claim
yielded I-Claim
effects I-Claim
on I-Claim
quality I-Claim
of I-Claim
life I-Claim
outcomes I-Claim
, I-Claim
and I-Claim
these I-Claim
were I-Claim
limited I-Claim
to I-Claim
anxiety I-Claim
and I-Claim
depression I-Claim
. I-Claim

On B-Claim
the I-Claim
basis I-Claim
of I-Claim
our I-Claim
trial I-Claim
and I-Claim
the I-Claim
meta-analysis I-Claim
, I-Claim
GEM-CAP I-Claim
should I-Claim
be I-Claim
considered I-Claim
as I-Claim
one I-Claim
of I-Claim
the I-Claim
standard I-Claim
first-line I-Claim
options I-Claim
in I-Claim
locally I-Claim
advanced I-Claim
and I-Claim
metastatic I-Claim
pancreatic I-Claim
cancer I-Claim
. I-Claim

The B-Claim
randomized I-Claim
controlled I-Claim
double-blind I-Claim
HECTOR I-Claim
trial I-Claim
showed I-Claim
no I-Claim
survival I-Claim
benefit I-Claim
for I-Claim
HCC I-Claim
patients I-Claim
treated I-Claim
with I-Claim
long-acting I-Claim
octreotide I-Claim
compared I-Claim
with I-Claim
placebo I-Claim
. I-Claim

Docetaxel B-Claim
monotherapy I-Claim
may I-Claim
be I-Claim
considered I-Claim
as I-Claim
an I-Claim
option I-Claim
in I-Claim
the I-Claim
standard I-Claim
treatment I-Claim
of I-Claim
elderly I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
NSCLC I-Claim
. I-Claim

Strong B-Claim
opioids I-Claim
were I-Claim
safe I-Claim
and I-Claim
well-tolerated I-Claim
, I-Claim
with I-Claim
no I-Claim
development I-Claim
of I-Claim
tolerance I-Claim
or I-Claim
serious I-Claim
adverse I-Claim
events I-Claim
. I-Claim

Increased B-Claim
expression I-Claim
of I-Claim
metalloproteinases I-Claim
is I-Claim
associated I-Claim
with I-Claim
poor I-Claim
prognosis I-Claim
in I-Claim
small-cell I-Claim
lung I-Claim
cancer I-Claim
( I-Claim
SCLC I-Claim
) I-Claim
. I-Claim

To B-Claim
our I-Claim
knowledge I-Claim
, I-Claim
this I-Claim
study I-Claim
provided I-Claim
novel I-Claim
evidence I-Claim
that I-Claim
MBSR I-Claim
can I-Claim
help I-Claim
alleviate I-Claim
long-term I-Claim
emotional I-Claim
and I-Claim
physical I-Claim
adverse I-Claim
effects I-Claim
of I-Claim
medical I-Claim
treatments I-Claim
, I-Claim
including I-Claim
endocrine I-Claim
treatments I-Claim
. I-Claim

Prophylactic B-Claim
alpha-blockers I-Claim
gave I-Claim
significantly I-Claim
lower I-Claim
maximum I-Claim
dysuria I-Claim
scores I-Claim
but B-Claim
did I-Claim
not I-Claim
affect I-Claim
the I-Claim
time I-Claim
to I-Claim
the I-Claim
resolution I-Claim
of I-Claim
dysuria I-Claim
. I-Claim

This B-Claim
study I-Claim
represents I-Claim
, I-Claim
to I-Claim
our I-Claim
knowledge I-Claim
, I-Claim
the I-Claim
largest I-Claim
analysis I-Claim
of I-Claim
HRQOL I-Claim
as I-Claim
a I-Claim
prognostic I-Claim
factor I-Claim
in I-Claim
locally I-Claim
advanced I-Claim
head I-Claim
and I-Claim
neck I-Claim
cancer I-Claim
patients I-Claim
. I-Claim

This B-Claim
research I-Claim
study I-Claim
indicates I-Claim
that I-Claim
live I-Claim
music I-Claim
therapy I-Claim
using I-Claim
patient-preferred I-Claim
music I-Claim
can I-Claim
be I-Claim
beneficial I-Claim
in I-Claim
improving I-Claim
quality I-Claim
of I-Claim
life I-Claim
indicators I-Claim
such I-Claim
as I-Claim
anxiety I-Claim
, I-Claim
perception I-Claim
of I-Claim
the I-Claim
hospitalization I-Claim
or I-Claim
procedure I-Claim
, I-Claim
relaxation I-Claim
, I-Claim
and I-Claim
stress I-Claim
in I-Claim
patients I-Claim
undergoing I-Claim
surgical I-Claim
procedures I-Claim
of I-Claim
the I-Claim
brain I-Claim
. I-Claim

Preliminary B-Claim
results I-Claim
suggested I-Claim
a I-Claim
positive I-Claim
impact I-Claim
on I-Claim
survival I-Claim
. I-Claim

Laparoscopic B-Claim
resection I-Claim
reduced I-Claim
length I-Claim
of I-Claim
hospital I-Claim
stay I-Claim
, I-Claim
improved I-Claim
first-year I-Claim
quality I-Claim
of I-Claim
life I-Claim
, I-Claim
and I-Claim
slightly I-Claim
increased I-Claim
hospital I-Claim
costs I-Claim
. I-Claim

Psychological B-Claim
interventions I-Claim
are I-Claim
efficacious I-Claim
in I-Claim
reducing I-Claim
emotional I-Claim
distress I-Claim
for I-Claim
cancer I-Claim
patients I-Claim
. I-Claim

A B-Claim
peer-modeling I-Claim
videotape I-Claim
can I-Claim
accelerate I-Claim
the I-Claim
recovery I-Claim
of I-Claim
energy I-Claim
during I-Claim
the I-Claim
re-entry I-Claim
phase I-Claim
in I-Claim
women I-Claim
treated I-Claim
for I-Claim
breast I-Claim
cancer I-Claim
, I-Claim
particularly I-Claim
among I-Claim
those I-Claim
who I-Claim
feel I-Claim
less I-Claim
prepared I-Claim
for I-Claim
re-entry I-Claim
. I-Claim

Cisplatin B-Claim
reduces I-Claim
plasma I-Claim
ghrelin I-Claim
levels I-Claim
through I-Claim
the I-Claim
5-hydroxytryptamine I-Claim
( I-Claim
5-HT I-Claim
) I-Claim
receptor I-Claim
. I-Claim

Postmenopausal B-Claim
patients I-Claim
with I-Claim
lymph I-Claim
node-negative I-Claim
breast I-Claim
cancer I-Claim
benefited I-Claim
substantially I-Claim
from I-Claim
adjuvant I-Claim
chemotherapy I-Claim
if I-Claim
their I-Claim
cancer I-Claim
was I-Claim
ER-negative I-Claim
( I-Claim
i.e. I-Claim
, I-Claim
endocrine-nonresponsive I-Claim
) I-Claim
. I-Claim

Capecitabine/docetaxel B-Claim
was I-Claim
a I-Claim
cost-effective I-Claim
treatment I-Claim
in I-Claim
patients I-Claim
with I-Claim
anthracycline-pretreated I-Claim
advanced I-Claim
breast I-Claim
carcinoma I-Claim
, I-Claim
and I-Claim
had I-Claim
an I-Claim
incremental I-Claim
cost-effectiveness I-Claim
ratio I-Claim
that I-Claim
compares I-Claim
very I-Claim
favorably I-Claim
with I-Claim
that I-Claim
of I-Claim
many I-Claim
other I-Claim
oncology I-Claim
therapies I-Claim
. I-Claim

CBT-I B-Claim
delivered I-Claim
through I-Claim
an I-Claim
interactive I-Claim
, I-Claim
individually I-Claim
tailored I-Claim
Internet I-Claim
intervention I-Claim
may I-Claim
be I-Claim
a I-Claim
viable I-Claim
treatment I-Claim
option I-Claim
for I-Claim
cancer I-Claim
survivors I-Claim
experiencing I-Claim
insomnia I-Claim
. I-Claim

The B-Claim
available I-Claim
data I-Claim
suggest I-Claim
a I-Claim
high I-Claim
probability I-Claim
of I-Claim
favourable I-Claim
cost-utility I-Claim
outcomes I-Claim
with I-Claim
epoetin-alfa I-Claim
treatment I-Claim
for I-Claim
anaemia I-Claim
in I-Claim
patients I-Claim
with I-Claim
stage I-Claim
IV I-Claim
breast I-Claim
cancer I-Claim
receiving I-Claim
nonplatinum-containing I-Claim
chemotherapy I-Claim
. I-Claim

The B-Claim
data I-Claim
suggest I-Claim
that I-Claim
combination I-Claim
therapy I-Claim
might I-Claim
provide I-Claim
another I-Claim
treatment I-Claim
option I-Claim
for I-Claim
SUI I-Claim
in I-Claim
men I-Claim
that I-Claim
might I-Claim
increase I-Claim
the I-Claim
percentage I-Claim
of I-Claim
early I-Claim
postsurgery I-Claim
continence I-Claim
. I-Claim

However B-Claim
, I-Claim
identification I-Claim
of I-Claim
prognostic I-Claim
factors I-Claim
from I-Claim
responses I-Claim
to I-Claim
questionnaires I-Claim
may I-Claim
be I-Claim
unstable I-Claim
, I-Claim
and I-Claim
their I-Claim
reliability I-Claim
and I-Claim
clinical I-Claim
utility I-Claim
should I-Claim
be I-Claim
tested I-Claim
prospectively I-Claim
. I-Claim

In B-Claim
vivo I-Claim
data I-Claim
have I-Claim
shown I-Claim
a I-Claim
more I-Claim
potent I-Claim
antiangiogenic I-Claim
effect I-Claim
and I-Claim
a I-Claim
higher I-Claim
antitumor I-Claim
activity I-Claim
of I-Claim
low-dose I-Claim
interferon I-Claim
( I-Claim
IFN I-Claim
) I-Claim
given I-Claim
twice I-Claim
daily I-Claim
. I-Claim

However B-Claim
, I-Claim
presuming I-Claim
these I-Claim
improvements I-Claim
were I-Claim
caused I-Claim
by I-Claim
the I-Claim
individualized I-Claim
homeopathic I-Claim
approach I-Claim
, I-Claim
the I-Claim
study I-Claim
failed I-Claim
to I-Claim
show I-Claim
clearly I-Claim
that I-Claim
the I-Claim
specific I-Claim
effect I-Claim
of I-Claim
the I-Claim
remedy I-Claim
added I-Claim
further I-Claim
to I-Claim
the I-Claim
nonspecific I-Claim
effects I-Claim
of I-Claim
the I-Claim
consultation I-Claim
. I-Claim

Unless B-Claim
additional I-Claim
follow-up I-Claim
data I-Claim
demonstrate I-Claim
a I-Claim
survival I-Claim
advantage I-Claim
at I-Claim
higher I-Claim
doses I-Claim
, I-Claim
the I-Claim
160-mg/d I-Claim
dose I-Claim
is I-Claim
optimal I-Claim
, I-Claim
achieving I-Claim
maximal I-Claim
treatment I-Claim
effect I-Claim
with I-Claim
the I-Claim
fewest I-Claim
side I-Claim
effects I-Claim
and I-Claim
better I-Claim
quality I-Claim
of I-Claim
life I-Claim
. I-Claim

Clinically B-Claim
, I-Claim
HBO I-Claim
appears I-Claim
to I-Claim
be I-Claim
a I-Claim
useful I-Claim
adjunct I-Claim
to I-Claim
ONJ I-Claim
treatment I-Claim
, I-Claim
particularly I-Claim
for I-Claim
more I-Claim
severe I-Claim
cases I-Claim
, I-Claim
although I-Claim
this I-Claim
study I-Claim
was I-Claim
underpowered I-Claim
to I-Claim
fully I-Claim
support I-Claim
this I-Claim
claim I-Claim
. I-Claim

Participation B-Claim
in I-Claim
an I-Claim
upper-body I-Claim
exercise I-Claim
program I-Claim
caused I-Claim
no I-Claim
changes I-Claim
in I-Claim
arm I-Claim
circumference I-Claim
or I-Claim
arm I-Claim
volume I-Claim
in I-Claim
women I-Claim
with I-Claim
lymphedema I-Claim
after I-Claim
breast I-Claim
cancer I-Claim
, I-Claim
and I-Claim
they I-Claim
may I-Claim
have I-Claim
experienced I-Claim
an I-Claim
increase I-Claim
in I-Claim
quality I-Claim
of I-Claim
life I-Claim
. I-Claim

ADAPt-C B-Claim
collaborative I-Claim
care I-Claim
is I-Claim
feasible I-Claim
and I-Claim
results I-Claim
in I-Claim
significant I-Claim
reduction I-Claim
in I-Claim
depressive I-Claim
symptoms I-Claim
, I-Claim
improvement I-Claim
in I-Claim
quality I-Claim
of I-Claim
life I-Claim
, I-Claim
and I-Claim
lower I-Claim
pain I-Claim
levels I-Claim
compared I-Claim
with I-Claim
EUC I-Claim
for I-Claim
patients I-Claim
with I-Claim
depressive I-Claim
disorders I-Claim
in I-Claim
a I-Claim
low-income I-Claim
, I-Claim
predominantly I-Claim
Hispanic I-Claim
population I-Claim
in I-Claim
public I-Claim
sector I-Claim
oncology I-Claim
clinics I-Claim
. I-Claim

Those B-Claim
who I-Claim
respond I-Claim
to I-Claim
gemcitabine I-Claim
may I-Claim
experience I-Claim
a I-Claim
slight I-Claim
slowing I-Claim
of I-Claim
functional I-Claim
deterioration I-Claim
. I-Claim

GPX1 B-Claim
may I-Claim
be I-Claim
an I-Claim
inherited I-Claim
factor I-Claim
in I-Claim
predicting I-Claim
patients I-Claim
' I-Claim
QOL I-Claim
. I-Claim

EXE B-Claim
prolongs I-Claim
survival I-Claim
time I-Claim
, I-Claim
time I-Claim
to I-Claim
tumor I-Claim
progression I-Claim
, I-Claim
and I-Claim
time I-Claim
to I-Claim
treatment I-Claim
failure I-Claim
compared I-Claim
with I-Claim
MA I-Claim
and I-Claim
offers I-Claim
a I-Claim
well-tolerated I-Claim
treatment I-Claim
option I-Claim
for I-Claim
postmenopausal I-Claim
women I-Claim
with I-Claim
progressive I-Claim
advanced I-Claim
breast I-Claim
cancer I-Claim
who I-Claim
experienced I-Claim
failure I-Claim
of I-Claim
tamoxifen I-Claim
. I-Claim

The B-Claim
efficacy I-Claim
and I-Claim
safety I-Claim
of I-Claim
uterine-artery I-Claim
embolization I-Claim
, I-Claim
as I-Claim
compared I-Claim
with I-Claim
standard I-Claim
surgical I-Claim
methods I-Claim
, I-Claim
for I-Claim
the I-Claim
treatment I-Claim
of I-Claim
symptomatic I-Claim
uterine I-Claim
fibroids I-Claim
remain I-Claim
uncertain I-Claim
. I-Claim

HRQOL B-Claim
was I-Claim
better I-Claim
in I-Claim
Japanese I-Claim
postmenopausal I-Claim
women I-Claim
treated I-Claim
with I-Claim
tamoxifen I-Claim
than I-Claim
those I-Claim
treated I-Claim
with I-Claim
exemestane I-Claim
or I-Claim
anastrozole I-Claim
. I-Claim

The B-Claim
use I-Claim
of I-Claim
recombinant I-Claim
human I-Claim
thyrotropin I-Claim
and I-Claim
low-dose I-Claim
( I-Claim
1.1 I-Claim
GBq I-Claim
) I-Claim
postoperative I-Claim
radioiodine I-Claim
ablation I-Claim
may I-Claim
be I-Claim
sufficient I-Claim
for I-Claim
the I-Claim
management I-Claim
of I-Claim
low-risk I-Claim
thyroid I-Claim
cancer I-Claim
. I-Claim

The B-Claim
treatment I-Claim
choice I-Claim
for I-Claim
patients I-Claim
with I-Claim
inoperable I-Claim
esophageal I-Claim
cancer I-Claim
should I-Claim
be I-Claim
between I-Claim
a I-Claim
SEMS I-Claim
or I-Claim
a I-Claim
non-stent I-Claim
treatment I-Claim
after I-Claim
consideration I-Claim
has I-Claim
been I-Claim
given I-Claim
to I-Claim
both I-Claim
patient I-Claim
and I-Claim
tumor I-Claim
characteristics I-Claim
and I-Claim
clinician I-Claim
and I-Claim
patient I-Claim
preferences I-Claim
. I-Claim

IMRT B-Claim
results I-Claim
in I-Claim
clinically I-Claim
meaningful I-Claim
and I-Claim
statistically I-Claim
better I-Claim
QOL I-Claim
scores I-Claim
for I-Claim
some I-Claim
domains I-Claim
compared I-Claim
to I-Claim
3D-CRT I-Claim
at I-Claim
several I-Claim
time I-Claim
points I-Claim
with I-Claim
comparable I-Claim
disease I-Claim
outcomes I-Claim
that I-Claim
could I-Claim
support I-Claim
its I-Claim
widespread I-Claim
adoption I-Claim
in I-Claim
routine I-Claim
clinical I-Claim
practice I-Claim
. I-Claim

Four B-Claim
cycles I-Claim
of I-Claim
PE I-Claim
induction I-Claim
therapy I-Claim
followed I-Claim
by I-Claim
four I-Claim
cycles I-Claim
of I-Claim
topotecan I-Claim
improved I-Claim
PFS I-Claim
but I-Claim
failed I-Claim
to I-Claim
improve I-Claim
overall I-Claim
survival I-Claim
or I-Claim
quality I-Claim
of I-Claim
life I-Claim
in I-Claim
extensive-stage I-Claim
SCLC I-Claim
. I-Claim

In B-Claim
women I-Claim
with I-Claim
symptomatic I-Claim
fibroids I-Claim
, I-Claim
the I-Claim
faster I-Claim
recovery I-Claim
after I-Claim
embolization I-Claim
must I-Claim
be I-Claim
weighed I-Claim
against I-Claim
the I-Claim
need I-Claim
for I-Claim
further I-Claim
treatment I-Claim
in I-Claim
a I-Claim
minority I-Claim
of I-Claim
patients I-Claim
. I-Claim

Further B-Claim
investigation I-Claim
to I-Claim
define I-Claim
and I-Claim
measure I-Claim
the I-Claim
effects I-Claim
of I-Claim
these I-Claim
genes I-Claim
in I-Claim
chemotherapeutic I-Claim
regimens I-Claim
, I-Claim
drug I-Claim
toxicities I-Claim
, I-Claim
disease I-Claim
progression I-Claim
, I-Claim
and I-Claim
QOL I-Claim
are I-Claim
critical I-Claim
. I-Claim

For B-Claim
treatment I-Claim
of I-Claim
advanced I-Claim
breast I-Claim
cancer I-Claim
, I-Claim
SFI I-Claim
can I-Claim
alleviate I-Claim
the I-Claim
bone I-Claim
marrow I-Claim
inhibition I-Claim
caused I-Claim
by I-Claim
chemotherapy I-Claim
, I-Claim
improve I-Claim
clinical I-Claim
symptoms I-Claim
and I-Claim
quality I-Claim
of I-Claim
life I-Claim
and I-Claim
prolong I-Claim
the I-Claim
survival I-Claim
period I-Claim
by I-Claim
regulating I-Claim
cellular I-Claim
immune I-Claim
function I-Claim
of I-Claim
patients I-Claim
, I-Claim
so I-Claim
as I-Claim
to I-Claim
enhance I-Claim
the I-Claim
therapeutic I-Claim
effect I-Claim
of I-Claim
chemotherapy I-Claim
. I-Claim

Monthly B-Claim
infusion I-Claim
of I-Claim
pamidronate I-Claim
30 I-Claim
mg I-Claim
should I-Claim
be I-Claim
the I-Claim
recommended I-Claim
dose I-Claim
for I-Claim
prevention I-Claim
of I-Claim
bone I-Claim
disease I-Claim
in I-Claim
patients I-Claim
with I-Claim
multiple I-Claim
myeloma I-Claim
. I-Claim

Intensive B-Claim
nutrition I-Claim
intervention I-Claim
following I-Claim
the I-Claim
ADA I-Claim
MNT I-Claim
protocol I-Claim
results I-Claim
in I-Claim
improved I-Claim
dietary I-Claim
intake I-Claim
compared I-Claim
with I-Claim
standard I-Claim
practice I-Claim
and I-Claim
seems I-Claim
to I-Claim
beneficially I-Claim
impact I-Claim
nutrition-related I-Claim
outcomes I-Claim
previously I-Claim
observed I-Claim
in I-Claim
oncology I-Claim
outpatients I-Claim
receiving I-Claim
radiotherapy I-Claim
. I-Claim

QOL B-Claim
was I-Claim
similar I-Claim
for I-Claim
both I-Claim
arms I-Claim
. I-Claim

The B-Claim
addition I-Claim
of I-Claim
bevacizumab I-Claim
to I-Claim
paclitaxel I-Claim
improved I-Claim
progression-free I-Claim
survival I-Claim
( I-Claim
PFS I-Claim
) I-Claim
of I-Claim
patients I-Claim
with I-Claim
metastatic I-Claim
breast I-Claim
cancer I-Claim
( I-Claim
MBC I-Claim
) I-Claim
. I-Claim

Intraperitoneal B-Claim
administration I-Claim
limits I-Claim
cardiotoxicity I-Claim
of I-Claim
verapamil I-Claim
. I-Claim

Since B-Claim
the I-Claim
cost I-Claim
difference I-Claim
between I-Claim
the I-Claim
two I-Claim
treatments I-Claim
was I-Claim
only I-Claim
small I-Claim
, I-Claim
cost B-Claim
should I-Claim
not I-Claim
play I-Claim
a I-Claim
predominant I-Claim
role I-Claim
when I-Claim
deciding I-Claim
on I-Claim
the I-Claim
type I-Claim
of I-Claim
treatment I-Claim
assigned I-Claim
to I-Claim
patients I-Claim
with I-Claim
malignant I-Claim
GOO I-Claim
. I-Claim

Chemotherapy B-Claim
prolongs I-Claim
survival I-Claim
and I-Claim
improves I-Claim
quality I-Claim
of I-Claim
life I-Claim
( I-Claim
QOL I-Claim
) I-Claim
for I-Claim
good I-Claim
performance I-Claim
status I-Claim
( I-Claim
PS I-Claim
) I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
non-small I-Claim
cell I-Claim
lung I-Claim
cancer I-Claim
( I-Claim
NSCLC I-Claim
) I-Claim
. I-Claim

Surgery B-Claim
was I-Claim
associated I-Claim
with I-Claim
a I-Claim
short-term I-Claim
negative I-Claim
impact I-Claim
in I-Claim
some I-Claim
aspects I-Claim
of I-Claim
health I-Claim
related I-Claim
quality I-Claim
of I-Claim
life I-Claim
assessments I-Claim
but B-Claim
these I-Claim
changes I-Claim
became I-Claim
insignificant I-Claim
2 I-Claim
years I-Claim
after I-Claim
treatment I-Claim
. I-Claim

Erlotinib B-Claim
not I-Claim
only I-Claim
improves I-Claim
survival I-Claim
in I-Claim
previously I-Claim
treated I-Claim
patients I-Claim
with I-Claim
NSCLC I-Claim
, I-Claim
but I-Claim
also I-Claim
improves I-Claim
tumor-related I-Claim
symptoms I-Claim
and I-Claim
important I-Claim
aspects I-Claim
of I-Claim
QOL I-Claim
. I-Claim

No B-Claim
differences I-Claim
in I-Claim
patients I-Claim
' I-Claim
appetite I-Claim
or I-Claim
QOL I-Claim
were I-Claim
found I-Claim
either I-Claim
between I-Claim
CE I-Claim
, I-Claim
THC I-Claim
, I-Claim
and I-Claim
PL I-Claim
or I-Claim
between I-Claim
CE I-Claim
and I-Claim
THC I-Claim
at I-Claim
the I-Claim
dosages I-Claim
investigated I-Claim
. I-Claim

The B-Claim
LV5FU2-oxaliplatin I-Claim
combination I-Claim
seems I-Claim
beneficial I-Claim
as I-Claim
first-line I-Claim
therapy I-Claim
in I-Claim
advanced I-Claim
colorectal I-Claim
cancer I-Claim
, I-Claim
demonstrating I-Claim
a I-Claim
prolonged I-Claim
progression-free I-Claim
survival I-Claim
with I-Claim
acceptable I-Claim
tolerability I-Claim
and I-Claim
maintenance I-Claim
of I-Claim
QoL I-Claim
. I-Claim

A B-Claim
combination I-Claim
regimen I-Claim
of I-Claim
MA I-Claim
and I-Claim
thalidomide I-Claim
is I-Claim
more I-Claim
effective I-Claim
than I-Claim
MA I-Claim
alone I-Claim
in I-Claim
the I-Claim
treatment I-Claim
of I-Claim
CACS I-Claim
. I-Claim

The B-Claim
combination I-Claim
of I-Claim
etoposide I-Claim
plus I-Claim
cisplatin I-Claim
( I-Claim
EP I-Claim
) I-Claim
is I-Claim
considered I-Claim
to I-Claim
be I-Claim
standard I-Claim
therapy I-Claim
for I-Claim
small-cell I-Claim
lung I-Claim
cancer I-Claim
( I-Claim
SCLC I-Claim
) I-Claim
. I-Claim

A B-Claim
more I-Claim
effective I-Claim
, I-Claim
better I-Claim
tolerated I-Claim
version I-Claim
of I-Claim
this I-Claim
FUP I-Claim
combination I-Claim
is I-Claim
needed I-Claim
. I-Claim

Results B-Claim
of I-Claim
previous I-Claim
phase I-Claim
3 I-Claim
trials I-Claim
in I-Claim
inoperable I-Claim
HCC I-Claim
have I-Claim
been I-Claim
conflicting I-Claim
and I-Claim
inconclusive I-Claim
. I-Claim

The B-Claim
sequential I-Claim
addition I-Claim
of I-Claim
topotecan I-Claim
to I-Claim
carboplatin-paclitaxel I-Claim
did I-Claim
not I-Claim
result I-Claim
in I-Claim
superior I-Claim
overall I-Claim
response I-Claim
or I-Claim
progression-free I-Claim
or I-Claim
overall I-Claim
survival I-Claim
. I-Claim

Vinorelbine B-Claim
prolongs I-Claim
survival I-Claim
and I-Claim
improves I-Claim
quality I-Claim
of I-Claim
life I-Claim
in I-Claim
elderly I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
non-small-cell I-Claim
lung I-Claim
cancer I-Claim
( I-Claim
NSCLC I-Claim
) I-Claim
. I-Claim

Our B-Claim
present I-Claim
study I-Claim
shows I-Claim
that I-Claim
glutamine-enriched I-Claim
TPN I-Claim
may I-Claim
be I-Claim
beneficial I-Claim
in I-Claim
improving I-Claim
the I-Claim
inflammatory I-Claim
status I-Claim
and I-Claim
decreasing I-Claim
the I-Claim
infectious I-Claim
morbidity I-Claim
in I-Claim
postoperative I-Claim
GI I-Claim
cancer I-Claim
patients I-Claim
. I-Claim

IMRT B-Claim
was I-Claim
significantly I-Claim
better I-Claim
than I-Claim
CRT I-Claim
in I-Claim
terms I-Claim
of I-Claim
parotid I-Claim
sparing I-Claim
and I-Claim
improved I-Claim
QoL I-Claim
for I-Claim
early-stage I-Claim
disease I-Claim
. I-Claim

Four B-Claim
cycles I-Claim
of I-Claim
standard I-Claim
PE I-Claim
remains I-Claim
an I-Claim
appropriate I-Claim
first-line I-Claim
treatment I-Claim
for I-Claim
extensive-stage I-Claim
SCLC I-Claim
patients I-Claim
with I-Claim
good I-Claim
performance I-Claim
status I-Claim
. I-Claim

Our B-Claim
preliminary I-Claim
data I-Claim
suggest I-Claim
that I-Claim
rhDNase I-Claim
did I-Claim
not I-Claim
significantly I-Claim
improve I-Claim
study I-Claim
primary I-Claim
endpoints I-Claim
of I-Claim
QOL I-Claim
measures I-Claim
compared I-Claim
with I-Claim
the I-Claim
placebo I-Claim
group I-Claim
. I-Claim

These B-Claim
findings I-Claim
provide I-Claim
evidence I-Claim
for I-Claim
the I-Claim
short-term I-Claim
benefits I-Claim
of I-Claim
minimally I-Claim
invasive I-Claim
oesophagectomy I-Claim
for I-Claim
patients I-Claim
with I-Claim
resectable I-Claim
oesophageal I-Claim
cancer I-Claim
. I-Claim

Therefore B-Claim
, I-Claim
pemetrexed I-Claim
combined I-Claim
with I-Claim
cisplatin I-Claim
can I-Claim
be I-Claim
used I-Claim
as I-Claim
a I-Claim
safe I-Claim
and I-Claim
effective I-Claim
drug I-Claim
for I-Claim
clinical I-Claim
first-line I-Claim
treatment I-Claim
for I-Claim
previously I-Claim
untreated I-Claim
NSCLC I-Claim
. I-Claim

Hypnosis B-Claim
appears I-Claim
to I-Claim
reduce I-Claim
perceived I-Claim
hot I-Claim
flashes I-Claim
in I-Claim
breast I-Claim
cancer I-Claim
survivors I-Claim
and I-Claim
may I-Claim
have I-Claim
additional I-Claim
benefits I-Claim
such I-Claim
as I-Claim
reduced I-Claim
anxiety I-Claim
and I-Claim
depression I-Claim
, I-Claim
and I-Claim
improved I-Claim
sleep I-Claim
. I-Claim

The B-Claim
role I-Claim
of I-Claim
high-dose I-Claim
chemotherapy I-Claim
( I-Claim
HDCT I-Claim
) I-Claim
in I-Claim
metastatic I-Claim
breast I-Claim
cancer I-Claim
remains I-Claim
controversial I-Claim
. I-Claim

The B-Claim
BT I-Claim
group I-Claim
, I-Claim
on I-Claim
average I-Claim
, I-Claim
experienced I-Claim
significant I-Claim
improvement I-Claim
on I-Claim
global I-Claim
sleep I-Claim
quality I-Claim
compared I-Claim
with I-Claim
the I-Claim
HEC I-Claim
group I-Claim
, I-Claim
but B-Claim
not I-Claim
on I-Claim
objective I-Claim
sleep I-Claim
or I-Claim
fatigue I-Claim
outcomes I-Claim
. I-Claim

Adding B-Claim
docetaxel I-Claim
to I-Claim
CF I-Claim
significantly I-Claim
improved I-Claim
TTP I-Claim
, I-Claim
survival I-Claim
, I-Claim
and I-Claim
response I-Claim
rate I-Claim
in I-Claim
gastric I-Claim
cancer I-Claim
patients I-Claim
, I-Claim
but I-Claim
resulted I-Claim
in I-Claim
some I-Claim
increase I-Claim
in I-Claim
toxicity I-Claim
. I-Claim

Small B-Claim
effects I-Claim
were I-Claim
seen I-Claim
in I-Claim
some I-Claim
domains I-Claim
consistent I-Claim
with I-Claim
a I-Claim
minority I-Claim
of I-Claim
patients I-Claim
experiencing I-Claim
changes I-Claim
in I-Claim
QOL I-Claim
compatible I-Claim
with I-Claim
a I-Claim
reduction I-Claim
in I-Claim
estrogen I-Claim
synthesis I-Claim
. I-Claim

Hot B-Claim
flashes I-Claim
are I-Claim
a I-Claim
significant I-Claim
problem I-Claim
for I-Claim
many I-Claim
breast I-Claim
cancer I-Claim
survivors I-Claim
. I-Claim

The B-Claim
efficacy I-Claim
of I-Claim
5-FU I-Claim
, I-Claim
modulated I-Claim
with I-Claim
6S-LV I-Claim
, I-Claim
is I-Claim
moderate I-Claim
in I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
gastric I-Claim
carcinoma I-Claim
, I-Claim
similar I-Claim
to I-Claim
cisplatin-containing I-Claim
regimens I-Claim
. I-Claim

TCM B-Claim
therapy I-Claim
for I-Claim
removing I-Claim
toxic I-Claim
substance I-Claim
and I-Claim
unblocking I-Claim
meridians I-Claim
can I-Claim
improve I-Claim
the I-Claim
post-radiation I-Claim
QOL I-Claim
of I-Claim
patients I-Claim
with I-Claim
lung I-Claim
cancer I-Claim
to I-Claim
some I-Claim
extent I-Claim
. I-Claim

Subgroup B-Claim
analyses I-Claim
suggested I-Claim
a I-Claim
dose-dependent I-Claim
treatment I-Claim
effect I-Claim
. I-Claim

However B-Claim
, I-Claim
it I-Claim
is I-Claim
not I-Claim
clear I-Claim
whether I-Claim
psychological I-Claim
improvements I-Claim
are I-Claim
, I-Claim
in I-Claim
turn I-Claim
, I-Claim
related I-Claim
to I-Claim
improved I-Claim
health I-Claim
. I-Claim

During B-Claim
radiotherapy I-Claim
, I-Claim
both I-Claim
interventions I-Claim
positively I-Claim
influenced I-Claim
outcomes I-Claim
";" I-Claim
dietary B-Claim
counseling I-Claim
was I-Claim
of I-Claim
similar I-Claim
or I-Claim
higher I-Claim
benefit I-Claim
, I-Claim
whereas I-Claim
even I-Claim
3 I-Claim
months I-Claim
after I-Claim
RT I-Claim
, I-Claim
it I-Claim
was I-Claim
the I-Claim
only I-Claim
method I-Claim
to I-Claim
sustain I-Claim
a I-Claim
significant I-Claim
impact I-Claim
on I-Claim
patient I-Claim
outcomes I-Claim
. I-Claim

Standard B-Claim
chemotherapy I-Claim
regimens I-Claim
are I-Claim
generally I-Claim
considered I-Claim
too I-Claim
toxic I-Claim
for I-Claim
elderly I-Claim
patients I-Claim
. I-Claim

The B-Claim
combination I-Claim
of I-Claim
day I-Claim
1-8 I-Claim
VNR I-Claim
plus I-Claim
CDDP I-Claim
every I-Claim
3 I-Claim
weeks I-Claim
is I-Claim
less I-Claim
toxic I-Claim
and I-Claim
better I-Claim
tolerated I-Claim
than I-Claim
the I-Claim
regimen I-Claim
of I-Claim
weekly I-Claim
VNR I-Claim
plus I-Claim
CDDP I-Claim
every I-Claim
4 I-Claim
weeks I-Claim
. I-Claim

Somatostatin B-Claim
has I-Claim
been I-Claim
shown I-Claim
to I-Claim
have I-Claim
antimitotic I-Claim
activity I-Claim
in I-Claim
endocrine I-Claim
as I-Claim
well I-Claim
as I-Claim
in I-Claim
a I-Claim
variety I-Claim
of I-Claim
nonendocrine I-Claim
tumors I-Claim
. I-Claim

We B-Claim
propose I-Claim
that I-Claim
VEGF I-Claim
expression I-Claim
levels I-Claim
in I-Claim
MPE I-Claim
could I-Claim
serve I-Claim
as I-Claim
a I-Claim
prognostic I-Claim
marker I-Claim
for I-Claim
bevacizumab I-Claim
therapy I-Claim
. I-Claim

The B-Claim
study I-Claim
fails I-Claim
to I-Claim
demonstrate I-Claim
efficacy I-Claim
of I-Claim
dl-alpha I-Claim
tocopheryl I-Claim
acetate I-Claim
plus I-Claim
pentoxifylline I-Claim
in I-Claim
patients I-Claim
with I-Claim
arm I-Claim
lymphoedema I-Claim
following I-Claim
axillary I-Claim
surgery I-Claim
and I-Claim
lymphatic I-Claim
radiotherapy I-Claim
, I-Claim
nor I-Claim
does I-Claim
it I-Claim
suggest I-Claim
any I-Claim
benefits I-Claim
of I-Claim
these I-Claim
drugs I-Claim
in I-Claim
radiation-induced I-Claim
induration I-Claim
( I-Claim
fibrosis I-Claim
) I-Claim
in I-Claim
the I-Claim
breast I-Claim
, I-Claim
chest I-Claim
wall I-Claim
, I-Claim
pectoral I-Claim
fold I-Claim
, I-Claim
axilla I-Claim
or I-Claim
supraclavicular I-Claim
fossa I-Claim
. I-Claim

The B-Claim
mood I-Claim
linear I-Claim
analogue I-Claim
self-assessment I-Claim
scale I-Claim
is I-Claim
a I-Claim
valid I-Claim
indicator I-Claim
of I-Claim
emotional I-Claim
well-being I-Claim
in I-Claim
patients I-Claim
with I-Claim
breast I-Claim
cancer I-Claim
in I-Claim
large I-Claim
multicenter I-Claim
, I-Claim
multicultural I-Claim
trials I-Claim
in I-Claim
which I-Claim
comprehensive I-Claim
scales I-Claim
are I-Claim
less I-Claim
feasible I-Claim
. I-Claim

Exercise B-Claim
training I-Claim
during I-Claim
breast I-Claim
cancer I-Claim
chemotherapy I-Claim
may I-Claim
result I-Claim
in I-Claim
some I-Claim
longer-term I-Claim
and I-Claim
late I-Claim
effects I-Claim
for I-Claim
selected I-Claim
patient-rated I-Claim
outcomes I-Claim
. I-Claim

Relapse B-Claim
after I-Claim
completing I-Claim
adjuvant I-Claim
tamoxifen I-Claim
therapy I-Claim
is I-Claim
a I-Claim
persistent I-Claim
threat I-Claim
for I-Claim
women I-Claim
with I-Claim
hormone-responsive I-Claim
breast I-Claim
cancer I-Claim
. I-Claim

Facial B-Claim
hirsutism I-Claim
is I-Claim
one I-Claim
of I-Claim
the I-Claim
characteristic I-Claim
features I-Claim
of I-Claim
polycystic I-Claim
ovary I-Claim
syndrome I-Claim
( I-Claim
PCOS I-Claim
) I-Claim
, I-Claim
and I-Claim
this I-Claim
can I-Claim
lead I-Claim
to I-Claim
high I-Claim
levels I-Claim
of I-Claim
depression I-Claim
and I-Claim
anxiety I-Claim
. I-Claim

Exploratory B-Claim
analyses I-Claim
indicate I-Claim
that I-Claim
epidermal I-Claim
growth I-Claim
factor I-Claim
receptor I-Claim
status I-Claim
may I-Claim
be I-Claim
an I-Claim
important I-Claim
predictor I-Claim
of I-Claim
the I-Claim
erlotinib I-Claim
survival I-Claim
effect I-Claim
. I-Claim

These B-Claim
interim I-Claim
data I-Claim
indicate I-Claim
no I-Claim
early I-Claim
evidence I-Claim
of I-Claim
detriment I-Claim
to I-Claim
quality I-Claim
of I-Claim
life I-Claim
, I-Claim
overall I-Claim
survival I-Claim
or I-Claim
QALYs I-Claim
for I-Claim
patients I-Claim
allocated I-Claim
to I-Claim
OSC I-Claim
alone I-Claim
. I-Claim

CBT B-Claim
and I-Claim
PE I-Claim
can I-Claim
have I-Claim
salutary I-Claim
effects I-Claim
on I-Claim
endocrine I-Claim
symptoms I-Claim
and I-Claim
, I-Claim
to I-Claim
a I-Claim
lesser I-Claim
degree I-Claim
, I-Claim
on I-Claim
sexuality I-Claim
and I-Claim
physical I-Claim
functioning I-Claim
of I-Claim
patients I-Claim
with I-Claim
breast I-Claim
cancer I-Claim
experiencing I-Claim
treatment-induced I-Claim
menopause I-Claim
. I-Claim

Equivalence B-Claim
for I-Claim
three I-Claim
versus I-Claim
four I-Claim
cycles I-Claim
is I-Claim
claimed I-Claim
because I-Claim
both I-Claim
the I-Claim
upper I-Claim
and I-Claim
lower I-Claim
bounds I-Claim
of I-Claim
the I-Claim
80 I-Claim
% I-Claim
CL I-Claim
are I-Claim
less I-Claim
than I-Claim
5 I-Claim
% I-Claim
. I-Claim

Le B-Claim
( I-Claim
y I-Claim
) I-Claim
is I-Claim
an I-Claim
attractive I-Claim
target I-Claim
since I-Claim
it I-Claim
is I-Claim
expressed I-Claim
by I-Claim
most I-Claim
NSCLC I-Claim
. I-Claim

Sunitinib B-Claim
37.5 I-Claim
mg I-Claim
, I-Claim
administered I-Claim
on I-Claim
a I-Claim
continuous I-Claim
once-daily I-Claim
dosing I-Claim
regimen I-Claim
, I-Claim
has I-Claim
a I-Claim
manageable I-Claim
safety I-Claim
profile I-Claim
as I-Claim
second-line I-Claim
mRCC I-Claim
therapy I-Claim
, I-Claim
providing I-Claim
flexible I-Claim
dosing I-Claim
, I-Claim
which I-Claim
can I-Claim
be I-Claim
explored I-Claim
in I-Claim
combination I-Claim
studies I-Claim
. I-Claim

DCb B-Claim
and I-Claim
DC I-Claim
were I-Claim
superior I-Claim
to I-Claim
VC I-Claim
in I-Claim
all I-Claim
QoL I-Claim
outcomes I-Claim
assessed I-Claim
except I-Claim
for I-Claim
the I-Claim
difference I-Claim
between I-Claim
DC I-Claim
and I-Claim
VC I-Claim
in I-Claim
LCSS I-Claim
" I-Claim
QoL I-Claim
today I-Claim
" I-Claim
, I-Claim
which I-Claim
was I-Claim
not I-Claim
significant I-Claim
. I-Claim

Despite B-Claim
the I-Claim
early I-Claim
closure I-Claim
of I-Claim
the I-Claim
study I-Claim
and I-Claim
the I-Claim
lack I-Claim
of I-Claim
power I-Claim
of I-Claim
the I-Claim
comparison I-Claim
, I-Claim
it I-Claim
seems I-Claim
that I-Claim
ldLV5FU2 I-Claim
could I-Claim
be I-Claim
considered I-Claim
as I-Claim
an I-Claim
active I-Claim
, I-Claim
easier I-Claim
and I-Claim
less I-Claim
expensive I-Claim
option I-Claim
for I-Claim
the I-Claim
treatment I-Claim
of I-Claim
metastatic I-Claim
colorectal I-Claim
cancer I-Claim
compared I-Claim
to I-Claim
classic I-Claim
LV5FU2 I-Claim
or I-Claim
weekly I-Claim
HD-FU I-Claim
. I-Claim

Therefore B-Claim
, I-Claim
this I-Claim
regimen I-Claim
is I-Claim
not I-Claim
recommended I-Claim
as I-Claim
standard I-Claim
of I-Claim
care I-Claim
treatment I-Claim
for I-Claim
ovarian I-Claim
cancer I-Claim
. I-Claim

The B-Claim
small I-Claim
sample I-Claim
size I-Claim
may I-Claim
have I-Claim
limited I-Claim
our I-Claim
ability I-Claim
to I-Claim
detect I-Claim
significant I-Claim
differences I-Claim
beyond I-Claim
6 I-Claim
months I-Claim
of I-Claim
observation I-Claim
as I-Claim
well I-Claim
as I-Claim
additional I-Claim
significant I-Claim
differences I-Claim
in I-Claim
our I-Claim
study I-Claim
. I-Claim

ONJ B-Claim
is I-Claim
multifactorial I-Claim
and I-Claim
no I-Claim
single I-Claim
treatment I-Claim
modality I-Claim
is I-Claim
likely I-Claim
to I-Claim
reverse I-Claim
it I-Claim
";" I-Claim
however B-Claim
, I-Claim
it I-Claim
is I-Claim
treatable I-Claim
and I-Claim
even I-Claim
advanced I-Claim
presentations I-Claim
can I-Claim
improve I-Claim
with I-Claim
intensive I-Claim
multimodal I-Claim
therapy I-Claim
. I-Claim

Hot B-Claim
flashes I-Claim
can I-Claim
cause I-Claim
discomfort I-Claim
, I-Claim
disrupted I-Claim
sleep I-Claim
, I-Claim
anxiety I-Claim
, I-Claim
and I-Claim
decreased I-Claim
quality I-Claim
of I-Claim
life I-Claim
. I-Claim

Patients B-Claim
with I-Claim
low I-Claim
PSA I-Claim
nadir I-Claim
do I-Claim
significantly I-Claim
worse I-Claim
with I-Claim
IAD I-Claim
compared I-Claim
with I-Claim
CAD I-Claim
. I-Claim

Tamoxifen B-Claim
decreases I-Claim
the I-Claim
incidence I-Claim
of I-Claim
invasive I-Claim
and I-Claim
noninvasive I-Claim
breast I-Claim
cancer I-Claim
. I-Claim

This B-Claim
initial I-Claim
evidence I-Claim
involving I-Claim
a I-Claim
small I-Claim
sample I-Claim
size I-Claim
suggests I-Claim
that I-Claim
appropriately I-Claim
designed I-Claim
and I-Claim
supervised I-Claim
resistance I-Claim
exercise I-Claim
may I-Claim
be I-Claim
safe I-Claim
and I-Claim
well I-Claim
tolerated I-Claim
by I-Claim
prostate I-Claim
cancer I-Claim
patients I-Claim
with I-Claim
bone I-Claim
metastatic I-Claim
disease I-Claim
and I-Claim
can I-Claim
lead I-Claim
to I-Claim
improvements I-Claim
in I-Claim
physical I-Claim
function I-Claim
, I-Claim
physical I-Claim
activity I-Claim
levels I-Claim
and I-Claim
lean I-Claim
mass I-Claim
. I-Claim

Data B-Claim
suggest I-Claim
that I-Claim
the I-Claim
GE I-Claim
combination I-Claim
may I-Claim
improve I-Claim
clinical I-Claim
outcomes I-Claim
. I-Claim

GC B-Claim
is I-Claim
as I-Claim
effective I-Claim
as I-Claim
PE I-Claim
in I-Claim
terms I-Claim
of I-Claim
overall I-Claim
survival I-Claim
and I-Claim
progression-free I-Claim
survival I-Claim
and I-Claim
has I-Claim
a I-Claim
toxicity I-Claim
profile I-Claim
more I-Claim
acceptable I-Claim
to I-Claim
patients I-Claim
. I-Claim

HRQOL B-Claim
evaluated I-Claim
3.2 I-Claim
to I-Claim
6.5 I-Claim
years I-Claim
after I-Claim
treatment I-Claim
showed I-Claim
an I-Claim
advantage I-Claim
for I-Claim
BT I-Claim
in I-Claim
urinary I-Claim
and I-Claim
sexual I-Claim
domains I-Claim
and I-Claim
in I-Claim
patient I-Claim
satisfaction I-Claim
. I-Claim

Pilates B-Claim
exercises I-Claim
are I-Claim
effective I-Claim
and I-Claim
safe I-Claim
in I-Claim
female I-Claim
breast I-Claim
cancer I-Claim
patients I-Claim
. I-Claim

Analyses B-Claim
by I-Claim
bortezomib I-Claim
dose I-Claim
intensity I-Claim
indicated I-Claim
better I-Claim
HRQoL I-Claim
in I-Claim
patients I-Claim
receiving I-Claim
lower I-Claim
dose I-Claim
intensity I-Claim
. I-Claim

Leucovorin B-Claim
increases I-Claim
PFS I-Claim
if I-Claim
added I-Claim
to I-Claim
FU24h I-Claim
, I-Claim
but I-Claim
increases I-Claim
toxicity I-Claim
. I-Claim

In B-Claim
advanced I-Claim
not I-Claim
selected I-Claim
NSCLC I-Claim
chemotherapy I-Claim
achieved I-Claim
an I-Claim
advantage I-Claim
of I-Claim
approximately I-Claim
1-2 I-Claim
months I-Claim
on I-Claim
median I-Claim
survival I-Claim
versus I-Claim
best I-Claim
supportive I-Claim
care I-Claim
. I-Claim

Additional B-Claim
studies I-Claim
of I-Claim
DPPE I-Claim
are I-Claim
warranted I-Claim
. I-Claim

Improvements B-Claim
were I-Claim
seen I-Claim
for I-Claim
symptom I-Claim
scores I-Claim
over I-Claim
the I-Claim
study I-Claim
period I-Claim
. I-Claim

Dermatitis B-Claim
is I-Claim
a I-Claim
frequent I-Claim
adverse I-Claim
effect I-Claim
of I-Claim
adjuvant I-Claim
breast I-Claim
radiotherapy I-Claim
. I-Claim

No B-Claim
significant I-Claim
differences I-Claim
in I-Claim
terms I-Claim
of I-Claim
response I-Claim
rate I-Claim
, I-Claim
time I-Claim
to I-Claim
progression I-Claim
and I-Claim
overall I-Claim
survival I-Claim
were I-Claim
observed I-Claim
between I-Claim
the I-Claim
two I-Claim
regimen I-Claim
. I-Claim

Future B-Claim
trials I-Claim
involving I-Claim
larger I-Claim
sample I-Claim
sizes I-Claim
are I-Claim
required I-Claim
to I-Claim
expand I-Claim
these I-Claim
preliminary I-Claim
findings I-Claim
. I-Claim

It B-Claim
should I-Claim
probably I-Claim
not I-Claim
be I-Claim
tested I-Claim
further I-Claim
, I-Claim
but B-Claim
its I-Claim
antimetabolite I-Claim
schedules I-Claim
and I-Claim
frequent I-Claim
drug I-Claim
administration I-Claim
( I-Claim
ie I-Claim
, I-Claim
dose I-Claim
density I-Claim
) I-Claim
should I-Claim
be I-Claim
considered I-Claim
in I-Claim
the I-Claim
development I-Claim
of I-Claim
new I-Claim
regimens I-Claim
. I-Claim

Small B-Claim
sample I-Claim
size I-Claim
precludes I-Claim
definitive I-Claim
answers I-Claim
, I-Claim
but B-Claim
results I-Claim
from I-Claim
this I-Claim
preliminary I-Claim
trial I-Claim
suggest I-Claim
that I-Claim
homeopathy I-Claim
may I-Claim
be I-Claim
of I-Claim
value I-Claim
in I-Claim
the I-Claim
treatment I-Claim
of I-Claim
menopausal I-Claim
symptoms I-Claim
and I-Claim
improving I-Claim
quality I-Claim
of I-Claim
life I-Claim
, I-Claim
especially I-Claim
in I-Claim
those I-Claim
women I-Claim
not I-Claim
on I-Claim
tamoxifen I-Claim
. I-Claim

This B-Claim
study I-Claim
demonstrated I-Claim
no I-Claim
advantage I-Claim
in I-Claim
RR I-Claim
, I-Claim
RD I-Claim
, I-Claim
or I-Claim
PFS I-Claim
but I-Claim
significantly I-Claim
superior I-Claim
OS I-Claim
for I-Claim
DPPE I-Claim
plus I-Claim
DOX I-Claim
. I-Claim

Quality B-Claim
of I-Claim
life I-Claim
during I-Claim
maintenance I-Claim
therapy I-Claim
with I-Claim
pemetrexed I-Claim
is I-Claim
similar I-Claim
to I-Claim
placebo I-Claim
, I-Claim
except B-Claim
for I-Claim
a I-Claim
small I-Claim
increase I-Claim
in I-Claim
loss I-Claim
of I-Claim
appetite I-Claim
, I-Claim
and I-Claim
significantly I-Claim
delayed I-Claim
worsening I-Claim
of I-Claim
pain I-Claim
and I-Claim
haemoptysis I-Claim
. I-Claim

Research B-Claim
is I-Claim
needed I-Claim
to I-Claim
assess I-Claim
the I-Claim
long I-Claim
term I-Claim
risks I-Claim
and I-Claim
benefits I-Claim
of I-Claim
starting I-Claim
hormone I-Claim
replacement I-Claim
therapy I-Claim
near I-Claim
the I-Claim
menopause I-Claim
, I-Claim
when I-Claim
the I-Claim
effect I-Claim
may I-Claim
be I-Claim
different I-Claim
. I-Claim

The B-Claim
impact I-Claim
of I-Claim
treatment I-Claim
on I-Claim
health-related I-Claim
quality I-Claim
of I-Claim
life I-Claim
( I-Claim
HRQoL I-Claim
) I-Claim
is I-Claim
an I-Claim
important I-Claim
consideration I-Claim
in I-Claim
the I-Claim
adjuvant I-Claim
treatment I-Claim
of I-Claim
operable I-Claim
breast I-Claim
cancer I-Claim
. I-Claim

GEM B-Claim
does I-Claim
not I-Claim
provide I-Claim
an I-Claim
advantage I-Claim
compared I-Claim
with I-Claim
PLD I-Claim
in I-Claim
terms I-Claim
of I-Claim
TTP I-Claim
in I-Claim
ovarian I-Claim
cancer I-Claim
patients I-Claim
who I-Claim
experience I-Claim
recurrence I-Claim
within I-Claim
12 I-Claim
months I-Claim
after I-Claim
primary I-Claim
treatment I-Claim
but I-Claim
should I-Claim
be I-Claim
considered I-Claim
in I-Claim
the I-Claim
spectrum I-Claim
of I-Claim
drugs I-Claim
to I-Claim
be I-Claim
possibly I-Claim
used I-Claim
in I-Claim
the I-Claim
salvage I-Claim
setting I-Claim
. I-Claim

Grade B-Claim
2 I-Claim
or I-Claim
higher I-Claim
acute I-Claim
toxicity I-Claim
was I-Claim
more I-Claim
common I-Claim
in I-Claim
the I-Claim
4 I-Claim
day I-Claim
group I-Claim
, I-Claim
approaching I-Claim
statistical I-Claim
significance I-Claim
. I-Claim

Treatment B-Claim
with I-Claim
radiotherapy I-Claim
and I-Claim
5-fluorouracil I-Claim
changed I-Claim
only I-Claim
some I-Claim
aspects I-Claim
of I-Claim
quality I-Claim
of I-Claim
life I-Claim
and I-Claim
did I-Claim
not I-Claim
have I-Claim
a I-Claim
significant I-Claim
impact I-Claim
on I-Claim
quality I-Claim
of I-Claim
life I-Claim
. I-Claim

In B-Claim
patients I-Claim
with I-Claim
cancer I-Claim
, I-Claim
a I-Claim
high-fat I-Claim
diet I-Claim
may I-Claim
possibly I-Claim
support I-Claim
the I-Claim
maintenance I-Claim
of I-Claim
both I-Claim
body I-Claim
weight I-Claim
and I-Claim
body I-Claim
cell I-Claim
mass I-Claim
. I-Claim

Adverse B-Claim
events I-Claim
during I-Claim
temozolomide I-Claim
treatment I-Claim
included I-Claim
thrombocytopenia I-Claim
, I-Claim
nausea I-Claim
, I-Claim
vomiting I-Claim
, I-Claim
anorexia I-Claim
, I-Claim
constipation I-Claim
, I-Claim
alopecia I-Claim
, I-Claim
headache I-Claim
, I-Claim
fatigue I-Claim
, I-Claim
and I-Claim
convulsions I-Claim
. I-Claim

Epoetin B-Claim
alfa I-Claim
significantly I-Claim
improved I-Claim
HgB I-Claim
and I-Claim
reduced I-Claim
transfusions I-Claim
in I-Claim
this I-Claim
patient I-Claim
population I-Claim
. I-Claim

Thalidomide B-Claim
, I-Claim
which I-Claim
is I-Claim
an I-Claim
inhibitor I-Claim
of I-Claim
TNF-alpha I-Claim
synthesis I-Claim
, I-Claim
may I-Claim
represent I-Claim
a I-Claim
novel I-Claim
and I-Claim
rational I-Claim
approach I-Claim
to I-Claim
the I-Claim
treatment I-Claim
of I-Claim
cancer I-Claim
cachexia I-Claim
. I-Claim

The B-Claim
incidence I-Claim
and I-Claim
development I-Claim
of I-Claim
cancer I-Claim
are I-Claim
closely I-Claim
related I-Claim
to I-Claim
dysfunction I-Claim
of I-Claim
immune I-Claim
function I-Claim
. I-Claim

Although B-Claim
this I-Claim
trial I-Claim
met I-Claim
the I-Claim
pre-determined I-Claim
criteria I-Claim
for I-Claim
equivalence I-Claim
between I-Claim
the I-Claim
two I-Claim
palliative I-Claim
regimens I-Claim
, I-Claim
significantly B-Claim
more I-Claim
patients I-Claim
achieved I-Claim
complete I-Claim
resolution I-Claim
of I-Claim
symptoms I-Claim
and I-Claim
palliation I-Claim
of I-Claim
chest I-Claim
pain I-Claim
and I-Claim
dyspnoea I-Claim
with I-Claim
the I-Claim
fractionated I-Claim
regimen I-Claim
. I-Claim

After B-Premise
the I-Premise
first I-Premise
year I-Premise
of I-Premise
follow-up I-Premise
, I-Premise
14 I-Premise
women I-Premise
in I-Premise
the I-Premise
embolization I-Premise
group I-Premise
( I-Premise
13 I-Premise
% I-Premise
) I-Premise
required I-Premise
hospitalization I-Premise
, I-Premise
3 I-Premise
of I-Premise
them I-Premise
for I-Premise
major I-Premise
adverse I-Premise
events I-Premise
and I-Premise
11 I-Premise
for I-Premise
reintervention I-Premise
for I-Premise
treatment I-Premise
failure I-Premise
. I-Premise

Grade B-Premise
3 I-Premise
or I-Premise
4 I-Premise
weight I-Premise
changes I-Premise
were I-Premise
more I-Premise
common I-Premise
with I-Premise
MA I-Premise
( I-Premise
17.1 I-Premise
% I-Premise
v I-Premise
7.6 I-Premise
% I-Premise
";" I-Premise
P I-Premise
=.001 I-Premise
) I-Premise
. I-Premise

Patients B-Premise
in I-Premise
the I-Premise
PCDE I-Premise
arm I-Premise
survived I-Premise
longer I-Premise
than I-Premise
those I-Premise
in I-Premise
the I-Premise
EP I-Premise
arm I-Premise
( I-Premise
1-year I-Premise
survival I-Premise
rate I-Premise
: I-Premise
40 I-Premise
% I-Premise
and I-Premise
29 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
median I-Premise
survival I-Premise
: I-Premise
10.5 I-Premise
and I-Premise
9.3 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
log-rank I-Premise
P I-Premise
=.0067 I-Premise
) I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
significant I-Premise
differences I-Premise
between I-Premise
randomised I-Premise
groups I-Premise
in I-Premise
terms I-Premise
of I-Premise
secondary I-Premise
endpoints I-Premise
, I-Premise
including I-Premise
tissue I-Premise
induration I-Premise
( I-Premise
fibrosis I-Premise
) I-Premise
in I-Premise
the I-Premise
irradiated I-Premise
breast I-Premise
or I-Premise
chest I-Premise
wall I-Premise
, I-Premise
pectoral I-Premise
fold I-Premise
or I-Premise
supraclavicular I-Premise
fossa I-Premise
, I-Premise
change I-Premise
in I-Premise
photographic I-Premise
breast/chest I-Premise
wall I-Premise
appearance I-Premise
or I-Premise
patient I-Premise
self-assessment I-Premise
of I-Premise
function I-Premise
and I-Premise
Quality I-Premise
of I-Premise
Life I-Premise
at I-Premise
either I-Premise
6 I-Premise
or I-Premise
12 I-Premise
months I-Premise
. I-Premise

The B-Premise
median I-Premise
survival I-Premise
in I-Premise
the I-Premise
patients I-Premise
receiving I-Premise
induction I-Premise
chemotherapy I-Premise
only I-Premise
was I-Premise
8.9 I-Premise
months I-Premise
. I-Premise

Median B-Premise
and I-Premise
1-year I-Premise
survival I-Premise
rates I-Premise
were I-Premise
10.0 I-Premise
months I-Premise
and I-Premise
38.4 I-Premise
% I-Premise
for I-Premise
NP I-Premise
, I-Premise
and I-Premise
8.2 I-Premise
months I-Premise
and I-Premise
33.7 I-Premise
% I-Premise
for I-Premise
NIP I-Premise
, I-Premise
respectively I-Premise
. I-Premise

The B-Premise
analysis I-Premise
of I-Premise
quality I-Premise
of I-Premise
live I-Premise
assessment I-Premise
showed I-Premise
a I-Premise
statistically I-Premise
significant I-Premise
decrease I-Premise
in I-Premise
quality I-Premise
of I-Premise
life I-Premise
after I-Premise
treatment I-Premise
in I-Premise
patients I-Premise
with I-Premise
resectable I-Premise
pancreatic I-Premise
cancer I-Premise
and I-Premise
treated I-Premise
with I-Premise
radiotherapy I-Premise
and I-Premise
gemcitabine I-Premise
. I-Premise

With B-Premise
a I-Premise
median I-Premise
follow-up I-Premise
of I-Premise
8 I-Premise
years I-Premise
, I-Premise
the I-Premise
5-year I-Premise
overall I-Premise
survival I-Premise
was I-Premise
68 I-Premise
% I-Premise
( I-Premise
+/- I-Premise
3 I-Premise
% I-Premise
standard I-Premise
error I-Premise
of I-Premise
the I-Premise
mean I-Premise
( I-Premise
SEM I-Premise
) I-Premise
and I-Premise
the I-Premise
5-year I-Premise
event-free I-Premise
survival I-Premise
53 I-Premise
% I-Premise
( I-Premise
+/- I-Premise
4 I-Premise
% I-Premise
SEM I-Premise
) I-Premise
. I-Premise

Among B-Premise
the I-Premise
patients I-Premise
receiving I-Premise
treatment I-Premise
3 I-Premise
times I-Premise
weekly I-Premise
, I-Premise
16 I-Premise
of I-Premise
49 I-Premise
patients I-Premise
( I-Premise
32.7 I-Premise
% I-Premise
) I-Premise
achieved I-Premise
a I-Premise
clinical I-Premise
response I-Premise
at I-Premise
the I-Premise
end I-Premise
of I-Premise
the I-Premise
third I-Premise
treatment I-Premise
cycle I-Premise
( I-Premise
no I-Premise
CRs I-Premise
, I-Premise
1 I-Premise
PR I-Premise
, I-Premise
and I-Premise
15 I-Premise
SDs I-Premise
) I-Premise
. I-Premise

Gastrointestinal B-Premise
and I-Premise
GU I-Premise
toxicity I-Premise
persisted I-Premise
5 I-Premise
years I-Premise
after I-Premise
RT I-Premise
and I-Premise
did I-Premise
not I-Premise
differ I-Premise
between I-Premise
the I-Premise
two I-Premise
dose I-Premise
schedules I-Premise
other I-Premise
than I-Premise
in I-Premise
regard I-Premise
to I-Premise
urgency I-Premise
of I-Premise
defecation I-Premise
. I-Premise

Median B-Premise
time I-Premise
to I-Premise
progression I-Premise
of I-Premise
worst I-Premise
pain I-Premise
was I-Premise
also I-Premise
longer I-Premise
with I-Premise
abiraterone I-Premise
plus I-Premise
prednisone I-Premise
( I-Premise
26·7 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
19·4-not I-Premise
estimable I-Premise
] I-Premise
) I-Premise
than I-Premise
with I-Premise
placebo I-Premise
plus I-Premise
prednisone I-Premise
( I-Premise
19·4 I-Premise
months I-Premise
[ I-Premise
16·6-not I-Premise
estimable I-Premise
] I-Premise
) I-Premise
, I-Premise
but I-Premise
the I-Premise
difference I-Premise
was I-Premise
not I-Premise
significant I-Premise
( I-Premise
HR I-Premise
0·85 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0·69-1·04 I-Premise
";" I-Premise
p=0·109 I-Premise
) I-Premise
. I-Premise

At B-Premise
a I-Premise
median I-Premise
follow-up I-Premise
of I-Premise
3.9 I-Premise
years I-Premise
, I-Premise
the I-Premise
estimated I-Premise
4-year I-Premise
recurrence-free I-Premise
survival I-Premise
rate I-Premise
was I-Premise
67.5 I-Premise
% I-Premise
with I-Premise
the I-Premise
16-week I-Premise
regimen I-Premise
versus I-Premise
62.7 I-Premise
% I-Premise
with I-Premise
CAF I-Premise
( I-Premise
P I-Premise
= I-Premise
.19 I-Premise
, I-Premise
two-sided I-Premise
";" I-Premise
P I-Premise
= I-Premise
.095 I-Premise
, I-Premise
one-sided I-Premise
) I-Premise
. I-Premise

Time B-Premise
to I-Premise
pain I-Premise
and I-Premise
time I-Premise
to I-Premise
analgesic I-Premise
use I-Premise
were I-Premise
significantly I-Premise
delayed I-Premise
in I-Premise
patients I-Premise
receiving I-Premise
erlotinib I-Premise
compared I-Premise
with I-Premise
placebo I-Premise
( I-Premise
HR=0.61 I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0.42-0.88 I-Premise
] I-Premise
";" I-Premise
p=0.0080 I-Premise
and I-Premise
HR=0.66 I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0.46-0.94 I-Premise
] I-Premise
";" I-Premise
p=0.0199 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

Difference B-Premise
between I-Premise
groups I-Premise
( I-Premise
p=0.007 I-Premise
) I-Premise
for I-Premise
BMD I-Premise
at I-Premise
femur I-Premise
was I-Premise
significant I-Premise
. I-Premise

The B-Premise
response I-Premise
rate I-Premise
was I-Premise
low I-Premise
in I-Premise
both I-Premise
arms I-Premise
, I-Premise
but I-Premise
superior I-Premise
in I-Premise
the I-Premise
FUP I-Premise
arm I-Premise
: I-Premise
12 I-Premise
% I-Premise
versus I-Premise
0 I-Premise
% I-Premise
( I-Premise
intention-to-treat I-Premise
analysis I-Premise
, I-Premise
P I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
. I-Premise

In B-Premise
the I-Premise
IAD I-Premise
group I-Premise
, I-Premise
a I-Premise
similar I-Premise
trend I-Premise
was I-Premise
seen I-Premise
. I-Premise

The B-Premise
Breast I-Premise
Cancer I-Premise
Subscale I-Premise
scores I-Premise
in I-Premise
group I-Premise
A I-Premise
patients I-Premise
were I-Premise
significantly I-Premise
higher I-Premise
than I-Premise
that I-Premise
of I-Premise
group I-Premise
C I-Premise
patients I-Premise
( I-Premise
p=0.021 I-Premise
) I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
grade I-Premise
3-4 I-Premise
late I-Premise
radiation I-Premise
toxicities I-Premise
. I-Premise

Median B-Premise
survival I-Premise
time I-Premise
was I-Premise
53.6 I-Premise
months I-Premise
for I-Premise
women I-Premise
with I-Premise
decreasing I-Premise
CES-D I-Premise
scores I-Premise
over I-Premise
1 I-Premise
year I-Premise
and I-Premise
25.1 I-Premise
months I-Premise
for I-Premise
women I-Premise
with I-Premise
increasing I-Premise
CES-D I-Premise
scores I-Premise
. I-Premise

The B-Premise
median I-Premise
AUCs I-Premise
( I-Premise
cycle I-Premise
2-6 I-Premise
) I-Premise
received I-Premise
were I-Premise
6.0 I-Premise
( I-Premise
Arm I-Premise
A I-Premise
) I-Premise
and I-Premise
7.2 I-Premise
( I-Premise
Arm I-Premise
B I-Premise
) I-Premise
( I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
. I-Premise

At B-Premise
12 I-Premise
months I-Premise
postradiotherapy I-Premise
, I-Premise
12 I-Premise
( I-Premise
50.0 I-Premise
% I-Premise
) I-Premise
and I-Premise
20 I-Premise
patients I-Premise
( I-Premise
83.3 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
IMRT I-Premise
group I-Premise
had I-Premise
recovered I-Premise
at I-Premise
least I-Premise
25 I-Premise
% I-Premise
of I-Premise
preradiotherapy I-Premise
SWS I-Premise
and I-Premise
SPS I-Premise
flow I-Premise
respectively I-Premise
, I-Premise
compared I-Premise
with I-Premise
1 I-Premise
( I-Premise
4.8 I-Premise
% I-Premise
) I-Premise
and I-Premise
2 I-Premise
patients I-Premise
( I-Premise
9.5 I-Premise
% I-Premise
) I-Premise
, I-Premise
respectively I-Premise
, I-Premise
in I-Premise
the I-Premise
CRT I-Premise
group I-Premise
. I-Premise

Mean B-Premise
use I-Premise
of I-Premise
additional I-Premise
analgesia I-Premise
( I-Premise
intravenous I-Premise
morphine I-Premise
equivalents I-Premise
) I-Premise
was I-Premise
12 I-Premise
mg I-Premise
in I-Premise
the I-Premise
WIC I-Premise
arm I-Premise
and I-Premise
9 I-Premise
mg I-Premise
in I-Premise
the I-Premise
epidural I-Premise
arm I-Premise
. I-Premise

No B-Premise
significant I-Premise
difference I-Premise
in I-Premise
survival I-Premise
among I-Premise
arms I-Premise
A I-Premise
, I-Premise
B I-Premise
, I-Premise
and I-Premise
C I-Premise
was I-Premise
found I-Premise
, I-Premise
with I-Premise
median I-Premise
survival I-Premise
8.2 I-Premise
, I-Premise
7.0 I-Premise
, I-Premise
and I-Premise
6.8 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
substantial I-Premise
differences I-Premise
between I-Premise
the I-Premise
two I-Premise
treatments I-Premise
in I-Premise
Spitzer I-Premise
's I-Premise
quality I-Premise
of I-Premise
life I-Premise
score I-Premise
and I-Premise
for I-Premise
each I-Premise
item I-Premise
. I-Premise

Analysing B-Premise
response I-Premise
to I-Premise
FUFA I-Premise
and I-Premise
FOLFIRI I-Premise
in I-Premise
the I-Premise
per I-Premise
protocol I-Premise
set I-Premise
( I-Premise
n=119 I-Premise
) I-Premise
after I-Premise
un-blinding I-Premise
TS I-Premise
in I-Premise
the I-Premise
data I-Premise
base I-Premise
revealed I-Premise
a I-Premise
trend I-Premise
to I-Premise
better I-Premise
overall I-Premise
response I-Premise
to I-Premise
FOLFIRI I-Premise
( I-Premise
9/19 I-Premise
, I-Premise
47 I-Premise
% I-Premise
) I-Premise
in I-Premise
TS I-Premise
high I-Premise
compared I-Premise
to I-Premise
FUFA I-Premise
( I-Premise
5/23 I-Premise
, I-Premise
22 I-Premise
% I-Premise
, I-Premise
p=0.077 I-Premise
) I-Premise
. I-Premise

No B-Premise
treatment-related I-Premise
deaths I-Premise
occurred I-Premise
. I-Premise

Kaplan-Meier B-Premise
survival I-Premise
analysis I-Premise
did I-Premise
not I-Premise
indicate I-Premise
an I-Premise
overall I-Premise
survival I-Premise
benefit I-Premise
for I-Premise
the I-Premise
IG I-Premise
. I-Premise

Sexual B-Premise
functioning I-Premise
was I-Premise
statistically I-Premise
significantly I-Premise
improved I-Premise
( I-Premise
P I-Premise
=.04 I-Premise
) I-Premise
in I-Premise
the I-Premise
treatment I-Premise
group I-Premise
compared I-Premise
with I-Premise
the I-Premise
usual-care I-Premise
group I-Premise
. I-Premise

The B-Premise
proportions I-Premise
of I-Premise
patients I-Premise
with I-Premise
adverse I-Premise
events I-Premise
were I-Premise
21 I-Premise
% I-Premise
in I-Premise
the I-Premise
low-dose I-Premise
group I-Premise
versus I-Premise
33 I-Premise
% I-Premise
in I-Premise
the I-Premise
high-dose I-Premise
group I-Premise
( I-Premise
P=0.007 I-Premise
) I-Premise
and I-Premise
23 I-Premise
% I-Premise
in I-Premise
the I-Premise
thyrotropin I-Premise
alfa I-Premise
group I-Premise
versus I-Premise
30 I-Premise
% I-Premise
in I-Premise
the I-Premise
group I-Premise
undergoing I-Premise
thyroid I-Premise
hormone I-Premise
withdrawal I-Premise
( I-Premise
P=0.11 I-Premise
) I-Premise
. I-Premise

A B-Premise
significant I-Premise
improvement I-Premise
in I-Premise
symptoms I-Premise
after I-Premise
treatment I-Premise
was I-Premise
found I-Premise
on I-Premise
day I-Premise
5 I-Premise
( I-Premise
p I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
and I-Premise
on I-Premise
day I-Premise
10 I-Premise
( I-Premise
p I-Premise
= I-Premise
0.0002 I-Premise
) I-Premise
. I-Premise

Grade B-Premise
3/4 I-Premise
diarrhea I-Premise
occurred I-Premise
in I-Premise
36 I-Premise
% I-Premise
of I-Premise
patients I-Premise
treated I-Premise
weekly I-Premise
and I-Premise
in I-Premise
19 I-Premise
% I-Premise
of I-Premise
those I-Premise
treated I-Premise
once I-Premise
every I-Premise
3 I-Premise
weeks I-Premise
( I-Premise
P I-Premise
=.002 I-Premise
) I-Premise
. I-Premise

Based B-Premise
on I-Premise
the I-Premise
results I-Premise
of I-Premise
the I-Premise
area I-Premise
under I-Premise
the I-Premise
curve I-Premise
( I-Premise
AUC I-Premise
) I-Premise
analysis I-Premise
, I-Premise
patients I-Premise
receiving I-Premise
HMB/Arg/Gln I-Premise
had I-Premise
a I-Premise
strong I-Premise
trend I-Premise
higher I-Premise
LBM I-Premise
throughout I-Premise
the I-Premise
study I-Premise
as I-Premise
measured I-Premise
by I-Premise
both I-Premise
bioimpedance I-Premise
( I-Premise
p I-Premise
= I-Premise
0.08 I-Premise
) I-Premise
and I-Premise
skin-fold I-Premise
measurements I-Premise
( I-Premise
p I-Premise
= I-Premise
0.08 I-Premise
) I-Premise
. I-Premise

However B-Premise
, I-Premise
the I-Premise
number I-Premise
of I-Premise
enrolled I-Premise
patients I-Premise
was I-Premise
not I-Premise
sufficient I-Premise
to I-Premise
draw I-Premise
definitive I-Premise
conclusions I-Premise
. I-Premise

More B-Premise
major I-Premise
complications I-Premise
( I-Premise
stent I-Premise
: I-Premise
6 I-Premise
in I-Premise
4 I-Premise
patients I-Premise
vs I-Premise
GJJ I-Premise
: I-Premise
0 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.02 I-Premise
) I-Premise
, I-Premise
recurrent I-Premise
obstructive I-Premise
symptoms I-Premise
( I-Premise
stent I-Premise
: I-Premise
8 I-Premise
in I-Premise
5 I-Premise
patients I-Premise
vs I-Premise
GJJ I-Premise
: I-Premise
1 I-Premise
in I-Premise
1 I-Premise
patient I-Premise
";" I-Premise
P I-Premise
= I-Premise
.02 I-Premise
) I-Premise
, I-Premise
and I-Premise
reinterventions I-Premise
( I-Premise
stent I-Premise
: I-Premise
10 I-Premise
in I-Premise
7 I-Premise
patients I-Premise
vs I-Premise
GJJ I-Premise
: I-Premise
2 I-Premise
in I-Premise
2 I-Premise
patients I-Premise
";" I-Premise
P I-Premise
< I-Premise
.01 I-Premise
) I-Premise
were I-Premise
observed I-Premise
after I-Premise
stent I-Premise
placement I-Premise
compared I-Premise
with I-Premise
GJJ I-Premise
. I-Premise

Global B-Premise
QOL I-Premise
, I-Premise
emotional/role I-Premise
functioning I-Premise
, I-Premise
nausea/vomiting I-Premise
, I-Premise
pain I-Premise
, I-Premise
swallowing I-Premise
, I-Premise
speech I-Premise
, I-Premise
social I-Premise
contact/eating I-Premise
, I-Premise
insomnia I-Premise
showed I-Premise
rapid I-Premise
recovery I-Premise
( I-Premise
< I-Premise
6months I-Premise
) I-Premise
while I-Premise
physical/cognitive I-Premise
functioning I-Premise
, I-Premise
dry I-Premise
mouth I-Premise
, I-Premise
sticky I-Premise
saliva I-Premise
, I-Premise
fatigue I-Premise
, I-Premise
senses I-Premise
showed I-Premise
delayed I-Premise
recovery I-Premise
( I-Premise
> I-Premise
6months I-Premise
) I-Premise
. I-Premise

The B-Premise
overall I-Premise
remission I-Premise
rate I-Premise
was I-Premise
87 I-Premise
% I-Premise
with I-Premise
31 I-Premise
% I-Premise
complete I-Premise
remissions I-Premise
. I-Premise

A B-Premise
decrease I-Premise
in I-Premise
transfusion I-Premise
requirement I-Premise
did I-Premise
not I-Premise
reach I-Premise
significance I-Premise
over I-Premise
all I-Premise
3 I-Premise
months I-Premise
, I-Premise
but I-Premise
there I-Premise
was I-Premise
a I-Premise
significant I-Premise
reduction I-Premise
in I-Premise
the I-Premise
percentage I-Premise
of I-Premise
patients I-Premise
transfused I-Premise
in I-Premise
the I-Premise
second I-Premise
and I-Premise
third I-Premise
months I-Premise
( I-Premise
27 I-Premise
% I-Premise
r-HuEPO I-Premise
vs. I-Premise
56 I-Premise
% I-Premise
placebo I-Premise
) I-Premise
and I-Premise
a I-Premise
trend I-Premise
toward I-Premise
reduction I-Premise
in I-Premise
the I-Premise
mean I-Premise
total I-Premise
number I-Premise
of I-Premise
units I-Premise
transfused I-Premise
( I-Premise
1.20 I-Premise
units I-Premise
r-HuEPO I-Premise
vs. I-Premise
2.02 I-Premise
units I-Premise
placebo I-Premise
) I-Premise
, I-Premise
suggesting I-Premise
a I-Premise
lag I-Premise
of I-Premise
1 I-Premise
month I-Premise
before I-Premise
r-HuEPO I-Premise
can I-Premise
affect I-Premise
the I-Premise
transfusion I-Premise
requirement I-Premise
. I-Premise

No B-Premise
significant I-Premise
longitudinal I-Premise
changes I-Premise
were I-Premise
detected I-Premise
in I-Premise
the I-Premise
global I-Premise
health I-Premise
status I-Premise
in I-Premise
both I-Premise
groups I-Premise
upon I-Premise
available I-Premise
follow-up I-Premise
. I-Premise

With B-Premise
median I-Premise
follow-up I-Premise
of I-Premise
15.8 I-Premise
months I-Premise
, I-Premise
there I-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
in I-Premise
1-year I-Premise
survival I-Premise
( I-Premise
46 I-Premise
% I-Premise
v I-Premise
41 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
P I-Premise
=.42 I-Premise
) I-Premise
, I-Premise
median I-Premise
survival I-Premise
( I-Premise
9.9 I-Premise
v I-Premise
9.9 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
P I-Premise
=.43 I-Premise
) I-Premise
, I-Premise
or I-Premise
median I-Premise
time I-Premise
to I-Premise
progression I-Premise
( I-Premise
4.0 I-Premise
v I-Premise
3.0 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
P I-Premise
=.54 I-Premise
) I-Premise
between I-Premise
the I-Premise
two I-Premise
regimens I-Premise
. I-Premise

LV5FU2 B-Premise
plus I-Premise
oxaliplatin I-Premise
gave I-Premise
higher I-Premise
frequencies I-Premise
of I-Premise
National I-Premise
Cancer I-Premise
Institute I-Premise
common I-Premise
toxicity I-Premise
criteria I-Premise
grade I-Premise
3/4 I-Premise
neutropenia I-Premise
( I-Premise
41 I-Premise
. I-Premise
7 I-Premise
% I-Premise
v I-Premise
5.3 I-Premise
% I-Premise
of I-Premise
patients I-Premise
) I-Premise
, I-Premise
grade I-Premise
3/4 I-Premise
diarrhea I-Premise
( I-Premise
11.9 I-Premise
% I-Premise
v I-Premise
5.3 I-Premise
% I-Premise
) I-Premise
, I-Premise
and I-Premise
grade I-Premise
3 I-Premise
neurosensory I-Premise
toxicity I-Premise
( I-Premise
18.2 I-Premise
% I-Premise
v I-Premise
0 I-Premise
% I-Premise
) I-Premise
, I-Premise
but I-Premise
this I-Premise
did I-Premise
not I-Premise
result I-Premise
in I-Premise
impairment I-Premise
of I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
QoL I-Premise
) I-Premise
. I-Premise

Response B-Premise
rates I-Premise
were I-Premise
26.0 I-Premise
% I-Premise
( I-Premise
FU/LV/bevacizumab I-Premise
) I-Premise
and I-Premise
15.2 I-Premise
% I-Premise
( I-Premise
FU/LV/placebo I-Premise
) I-Premise
( I-Premise
P I-Premise
= I-Premise
.055 I-Premise
) I-Premise
";" I-Premise
duration B-Premise
of I-Premise
response I-Premise
was I-Premise
9.2 I-Premise
months I-Premise
( I-Premise
FU/LV/bevacizumab I-Premise
) I-Premise
and I-Premise
6.8 I-Premise
months I-Premise
( I-Premise
FU/LV/placebo I-Premise
) I-Premise
";" I-Premise
hazard B-Premise
ratio I-Premise
was I-Premise
0.42 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.088 I-Premise
. I-Premise

The B-Premise
difference I-Premise
in I-Premise
PFS I-Premise
between I-Premise
three I-Premise
and I-Premise
four I-Premise
cycles I-Premise
is I-Premise
-1.0 I-Premise
% I-Premise
( I-Premise
80 I-Premise
% I-Premise
confidence I-Premise
limit I-Premise
[ I-Premise
CL I-Premise
] I-Premise
, I-Premise
-3.8 I-Premise
% I-Premise
, I-Premise
+1.8 I-Premise
% I-Premise
) I-Premise
. I-Premise

Eighty B-Premise
percent I-Premise
of I-Premise
patients I-Premise
receiving I-Premise
second-line I-Premise
chemotherapy I-Premise
in I-Premise
control I-Premise
arm I-Premise
were I-Premise
treated I-Premise
with I-Premise
continuous I-Premise
infusion I-Premise
5-FU I-Premise
. I-Premise

Patients B-Premise
reported I-Premise
increased I-Premise
leakage I-Premise
with I-Premise
a I-Premise
full I-Premise
bladder I-Premise
( I-Premise
urge I-Premise
incontinence I-Premise
) I-Premise
between I-Premise
the I-Premise
2 I-Premise
and I-Premise
3-year I-Premise
questionnaires I-Premise
( I-Premise
42 I-Premise
% I-Premise
versus I-Premise
50 I-Premise
% I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.03 I-Premise
) I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
significant I-Premise
differences I-Premise
in I-Premise
loco-regional I-Premise
or I-Premise
survival I-Premise
between I-Premise
the I-Premise
two I-Premise
arms I-Premise
. I-Premise

In B-Premise
a I-Premise
quality-of-life I-Premise
analysis I-Premise
, I-Premise
all I-Premise
significant I-Premise
differences I-Premise
, I-Premise
except I-Premise
on I-Premise
diarrhoea I-Premise
score I-Premise
, I-Premise
were I-Premise
in I-Premise
favour I-Premise
of I-Premise
the I-Premise
irinotecan I-Premise
group I-Premise
. I-Premise

Time B-Premise
to I-Premise
5 I-Premise
% I-Premise
deterioration I-Premise
of I-Premise
global I-Premise
health I-Premise
status I-Premise
( I-Premise
primary I-Premise
end I-Premise
point I-Premise
) I-Premise
significantly I-Premise
favored I-Premise
DCF I-Premise
over I-Premise
CF I-Premise
( I-Premise
log-rank I-Premise
test I-Premise
, I-Premise
P I-Premise
= I-Premise
.01 I-Premise
) I-Premise
. I-Premise

Cross-sectional B-Premise
comparisons I-Premise
showed I-Premise
statistically I-Premise
significant I-Premise
differences I-Premise
for I-Premise
some I-Premise
domains/items I-Premise
at I-Premise
specific I-Premise
assessment I-Premise
times I-Premise
with I-Premise
all I-Premise
differences I-Premise
favoring I-Premise
the I-Premise
DOX I-Premise
alone I-Premise
arm I-Premise
. I-Premise

In B-Premise
multivariate I-Premise
analysis I-Premise
, I-Premise
prophylactic I-Premise
alpha-blockers I-Premise
resulted I-Premise
in I-Premise
statistically I-Premise
lower I-Premise
maximum I-Premise
dysuria I-Premise
scores I-Premise
, I-Premise
while B-Premise
the I-Premise
maximum I-Premise
IPSS I-Premise
after I-Premise
implantation I-Premise
and I-Premise
isotope I-Premise
type I-Premise
( I-Premise
but I-Premise
only I-Premise
at I-Premise
6 I-Premise
months I-Premise
) I-Premise
were I-Premise
the I-Premise
best I-Premise
predictors I-Premise
of I-Premise
the I-Premise
resolution I-Premise
of I-Premise
dysuria I-Premise
. I-Premise

In B-Premise
the I-Premise
oxycodone/paracetamol I-Premise
group I-Premise
, I-Premise
67 I-Premise
% I-Premise
rated I-Premise
GI I-Premise
as I-Premise
good I-Premise
, I-Premise
very I-Premise
good I-Premise
, I-Premise
or I-Premise
excellent I-Premise
. I-Premise

There B-Premise
was I-Premise
significantly I-Premise
more I-Premise
grade I-Premise
3-4 I-Premise
neutropenia I-Premise
( I-Premise
P I-Premise
= I-Premise
.001 I-Premise
) I-Premise
and I-Premise
dyspnea I-Premise
( I-Premise
P I-Premise
= I-Premise
.014 I-Premise
) I-Premise
with I-Premise
PB+G I-Premise
. I-Premise

Median B-Premise
survival I-Premise
with I-Premise
GC I-Premise
and I-Premise
PE I-Premise
was I-Premise
8.0 I-Premise
and I-Premise
8.1 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Superior B-Premise
survival I-Premise
was I-Premise
observed I-Premise
with I-Premise
the I-Premise
combined I-Premise
paclitaxel I-Premise
regimens I-Premise
( I-Premise
median I-Premise
survival I-Premise
time I-Premise
, I-Premise
9.9 I-Premise
months I-Premise
";" I-Premise
1-year I-Premise
survival I-Premise
rate I-Premise
, I-Premise
38.9 I-Premise
% I-Premise
) I-Premise
compared I-Premise
with I-Premise
etoposide I-Premise
plus I-Premise
cisplatin I-Premise
( I-Premise
median I-Premise
survival I-Premise
time I-Premise
, I-Premise
7.6 I-Premise
months I-Premise
";" I-Premise
1-year I-Premise
survival I-Premise
rate I-Premise
, I-Premise
31.8 I-Premise
% I-Premise
";" I-Premise
P I-Premise
= I-Premise
. I-Premise
48 I-Premise
) I-Premise
. I-Premise

Breast B-Premise
symptoms I-Premise
increased I-Premise
for I-Premise
both I-Premise
groups I-Premise
during I-Premise
radiotherapy I-Premise
, I-Premise
without I-Premise
loss I-Premise
of I-Premise
strength I-Premise
or I-Premise
range I-Premise
of I-Premise
movement I-Premise
. I-Premise

Significant B-Premise
deterioration I-Premise
was I-Premise
noted I-Premise
after I-Premise
chemotherapy I-Premise
in I-Premise
the I-Premise
placebo I-Premise
group I-Premise
in I-Premise
QoL I-Premise
scores I-Premise
, I-Premise
appetite I-Premise
, I-Premise
nausea I-Premise
and I-Premise
vomiting I-Premise
, I-Premise
and I-Premise
global I-Premise
health I-Premise
status I-Premise
. I-Premise

The B-Premise
rate I-Premise
of I-Premise
QOL I-Premise
drop-out I-Premise
for I-Premise
any I-Premise
reason I-Premise
was I-Premise
higher I-Premise
for I-Premise
C I-Premise
( I-Premise
53 I-Premise
% I-Premise
) I-Premise
compared I-Premise
to I-Premise
CP I-Premise
( I-Premise
38 I-Premise
% I-Premise
) I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

Both B-Premise
groups I-Premise
exhibited I-Premise
significant I-Premise
decreases I-Premise
in I-Premise
hot I-Premise
flashes I-Premise
, I-Premise
depressive I-Premise
symptoms I-Premise
, I-Premise
and I-Premise
other I-Premise
quality-of-life I-Premise
symptoms I-Premise
, I-Premise
including I-Premise
significant I-Premise
improvements I-Premise
in I-Premise
mental I-Premise
health I-Premise
from I-Premise
pre- I-Premise
to I-Premise
post-treatment I-Premise
. I-Premise

PFS B-Premise
was I-Premise
11 I-Premise
months I-Premise
for I-Premise
HDCT I-Premise
and I-Premise
9 I-Premise
months I-Premise
for I-Premise
ST I-Premise
( I-Premise
HR I-Premise
, I-Premise
0.6 I-Premise
in I-Premise
favor I-Premise
of I-Premise
HDCT I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.5 I-Premise
to I-Premise
0.9 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.006 I-Premise
) I-Premise
. I-Premise

Compared B-Premise
with I-Premise
RELP I-Premise
, I-Premise
patients I-Premise
receiving I-Premise
UM I-Premise
had I-Premise
significantly I-Premise
shorter I-Premise
duration I-Premise
of I-Premise
operation I-Premise
and I-Premise
hospital I-Premise
stay I-Premise
, I-Premise
shorter I-Premise
time I-Premise
periods I-Premise
to I-Premise
walk I-Premise
, I-Premise
return I-Premise
to I-Premise
daily I-Premise
activities I-Premise
, I-Premise
or I-Premise
sit I-Premise
without I-Premise
pain I-Premise
and I-Premise
to I-Premise
return I-Premise
to I-Premise
work I-Premise
or I-Premise
school I-Premise
, I-Premise
and I-Premise
fewer I-Premise
complications I-Premise
. I-Premise

Thirty-eight B-Premise
patients I-Premise
in I-Premise
the I-Premise
treatment I-Premise
group I-Premise
, I-Premise
and I-Premise
58 I-Premise
in I-Premise
the I-Premise
placebo I-Premise
group I-Premise
, I-Premise
suffered I-Premise
breakthrough I-Premise
pain I-Premise
on I-Premise
day I-Premise
3 I-Premise
( I-Premise
P I-Premise
< I-Premise
0·001 I-Premise
) I-Premise
. I-Premise

Severe B-Premise
toxicities I-Premise
of I-Premise
TOM I-Premise
+ I-Premise
LFA-5-FU I-Premise
were I-Premise
neutropenia I-Premise
( I-Premise
16 I-Premise
% I-Premise
) I-Premise
and I-Premise
diarrhoea I-Premise
( I-Premise
16 I-Premise
% I-Premise
) I-Premise
, I-Premise
but I-Premise
median I-Premise
relative I-Premise
DI8 I-Premise
was I-Premise
93 I-Premise
% I-Premise
for I-Premise
TOM I-Premise
, I-Premise
and I-Premise
82 I-Premise
% I-Premise
for I-Premise
5-FU I-Premise
. I-Premise

Sexual B-Premise
functioning I-Premise
and I-Premise
symptoms I-Premise
did I-Premise
not I-Premise
differ I-Premise
between I-Premise
the I-Premise
treatment I-Premise
groups I-Premise
. I-Premise

In B-Premise
an I-Premise
intent-to-treat I-Premise
analysis I-Premise
, I-Premise
there I-Premise
were I-Premise
no I-Premise
significant I-Premise
differences I-Premise
between I-Premise
the I-Premise
two I-Premise
treatments I-Premise
in I-Premise
median I-Premise
time I-Premise
to I-Premise
progression I-Premise
( I-Premise
HDCT I-Premise
, I-Premise
11.1 I-Premise
months I-Premise
";" I-Premise
AT I-Premise
, I-Premise
10.6 I-Premise
months I-Premise
";" I-Premise
P I-Premise
= I-Premise
.67 I-Premise
) I-Premise
, I-Premise
duration I-Premise
of I-Premise
response I-Premise
( I-Premise
HDCT I-Premise
, I-Premise
13.9 I-Premise
months I-Premise
";" I-Premise
AT I-Premise
, I-Premise
14.3 I-Premise
months I-Premise
";" I-Premise
P I-Premise
= I-Premise
.98 I-Premise
) I-Premise
, I-Premise
and I-Premise
overall I-Premise
survival I-Premise
( I-Premise
HDCT I-Premise
, I-Premise
26.9 I-Premise
months I-Premise
";" I-Premise
AT I-Premise
, I-Premise
23.4 I-Premise
months I-Premise
";" I-Premise
P I-Premise
= I-Premise
.60 I-Premise
) I-Premise
. I-Premise

Toxicity B-Premise
( I-Premise
WHO I-Premise
grade I-Premise
3-4 I-Premise
) I-Premise
was I-Premise
lower I-Premise
with I-Premise
FU I-Premise
than I-Premise
with I-Premise
FUP I-Premise
( I-Premise
20 I-Premise
% I-Premise
versus I-Premise
48 I-Premise
% I-Premise
, I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
, I-Premise
as I-Premise
was I-Premise
neutropenia I-Premise
( I-Premise
6 I-Premise
% I-Premise
versus I-Premise
23 I-Premise
% I-Premise
) I-Premise
, I-Premise
vomiting I-Premise
( I-Premise
4 I-Premise
% I-Premise
versus I-Premise
17 I-Premise
% I-Premise
) I-Premise
and I-Premise
toxicity-related I-Premise
deaths I-Premise
( I-Premise
one I-Premise
versus I-Premise
four I-Premise
early I-Premise
in I-Premise
the I-Premise
trial I-Premise
) I-Premise
. I-Premise

For B-Premise
the I-Premise
chemotherapy I-Premise
group I-Premise
, I-Premise
the I-Premise
mean I-Premise
Quality I-Premise
Adjusted I-Premise
Life I-Premise
Months I-Premise
over I-Premise
24 I-Premise
months I-Premise
( I-Premise
QALM-24 I-Premise
) I-Premise
was I-Premise
9.6 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
: I-Premise
8.7 I-Premise
, I-Premise
11.2 I-Premise
) I-Premise
months I-Premise
compared I-Premise
with I-Premise
the I-Premise
mean I-Premise
QALM-24 I-Premise
of I-Premise
8.6 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
: I-Premise
7.6 I-Premise
, I-Premise
10.5 I-Premise
) I-Premise
months I-Premise
for I-Premise
the I-Premise
no I-Premise
chemotherapy I-Premise
group I-Premise
. I-Premise

Patients B-Premise
in I-Premise
the I-Premise
observation I-Premise
arm I-Premise
showed I-Premise
considerable I-Premise
improvements I-Premise
in I-Premise
QOL I-Premise
by I-Premise
3 I-Premise
months I-Premise
. I-Premise

The B-Premise
response I-Premise
rates I-Premise
, I-Premise
QOL I-Premise
, I-Premise
and I-Premise
median I-Premise
RD I-Premise
, I-Premise
TTP I-Premise
, I-Premise
and I-Premise
TTF I-Premise
were I-Premise
not I-Premise
significantly I-Premise
different I-Premise
between I-Premise
the I-Premise
arms I-Premise
. I-Premise

The B-Premise
RRs I-Premise
were I-Premise
identical I-Premise
in I-Premise
the I-Premise
2 I-Premise
arms I-Premise
( I-Premise
6.7 I-Premise
% I-Premise
";" I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
] I-Premise
, I-Premise
1.8-16.5 I-Premise
% I-Premise
) I-Premise
. I-Premise

At B-Premise
least I-Premise
one I-Premise
episode I-Premise
of I-Premise
grade I-Premise
3-4 I-Premise
toxicity I-Premise
was I-Premise
observed I-Premise
in I-Premise
27 I-Premise
, I-Premise
25 I-Premise
, I-Premise
38 I-Premise
and I-Premise
47 I-Premise
% I-Premise
of I-Premise
the I-Premise
patients I-Premise
in I-Premise
the I-Premise
LV5FU2 I-Premise
, I-Premise
ldLV5FU2 I-Premise
, I-Premise
HD-FU I-Premise
and I-Premise
Tomudex I-Premise
arms I-Premise
, I-Premise
respectively I-Premise
( I-Premise
p I-Premise
= I-Premise
0.016 I-Premise
) I-Premise
. I-Premise

Patients B-Premise
treated I-Premise
with I-Premise
gemcitabine-carboplatin I-Premise
reported I-Premise
significantly I-Premise
faster I-Premise
palliation I-Premise
of I-Premise
abdominal I-Premise
symptoms I-Premise
and I-Premise
a I-Premise
significantly I-Premise
improved I-Premise
global I-Premise
quality I-Premise
of I-Premise
life I-Premise
. I-Premise

Severe B-Premise
HSRs I-Premise
were I-Premise
rare I-Premise
( I-Premise
1.5 I-Premise
% I-Premise
patients I-Premise
) I-Premise
and I-Premise
were I-Premise
not I-Premise
affected I-Premise
by I-Premise
either I-Premise
dose I-Premise
or I-Premise
schedule I-Premise
. I-Premise

After B-Premise
the I-Premise
exercise I-Premise
program I-Premise
, I-Premise
improvements I-Premise
were I-Premise
observed I-Premise
in I-Premise
Group I-Premise
1 I-Premise
in I-Premise
6-minute I-Premise
walk I-Premise
test I-Premise
, I-Premise
BDI I-Premise
, I-Premise
EORTC I-Premise
QLQ-C30 I-Premise
functional I-Premise
, I-Premise
and I-Premise
EORTC I-Premise
QLQ-C30 I-Premise
BR23 I-Premise
functional I-Premise
scores I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

The B-Premise
median I-Premise
TDD I-Premise
in I-Premise
HRQOL I-Premise
was I-Premise
8.3 I-Premise
months I-Premise
with I-Premise
EVE I-Premise
+ I-Premise
EXE I-Premise
versus I-Premise
5.8 I-Premise
months I-Premise
with I-Premise
PBO I-Premise
+ I-Premise
EXE I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
, I-Premise
0.74 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.0084 I-Premise
) I-Premise
. I-Premise

At B-Premise
4 I-Premise
years I-Premise
, I-Premise
64 I-Premise
( I-Premise
18 I-Premise
% I-Premise
) I-Premise
of I-Premise
353 I-Premise
patients I-Premise
on I-Premise
combined I-Premise
therapy I-Premise
and I-Premise
39 I-Premise
( I-Premise
12 I-Premise
% I-Premise
) I-Premise
of I-Premise
337 I-Premise
on I-Premise
endocrine-alone I-Premise
therapy I-Premise
had I-Premise
moderate I-Premise
to I-Premise
severe I-Premise
urinary I-Premise
bother I-Premise
( I-Premise
p=0.005 I-Premise
) I-Premise
, I-Premise
and I-Premise
16 I-Premise
( I-Premise
4 I-Premise
% I-Premise
) I-Premise
of I-Premise
355 I-Premise
on I-Premise
combined I-Premise
therapy I-Premise
and I-Premise
five I-Premise
( I-Premise
2 I-Premise
% I-Premise
) I-Premise
of I-Premise
338 I-Premise
on I-Premise
endocrine I-Premise
treatment I-Premise
alone I-Premise
had I-Premise
pain I-Premise
while I-Premise
urinating I-Premise
( I-Premise
p=0.024 I-Premise
) I-Premise
. I-Premise

The B-Premise
scores I-Premise
of I-Premise
TCM I-Premise
efficacy I-Premise
( I-Premise
24.52 I-Premise
+/- I-Premise
8.98 I-Premise
vs I-Premise
29.76 I-Premise
+/- I-Premise
7.09 I-Premise
, I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
and I-Premise
the I-Premise
6-min I-Premise
walking I-Premise
distance I-Premise
( I-Premise
233.4 I-Premise
+/- I-Premise
29.2 I-Premise
m I-Premise
vs I-Premise
205.8 I-Premise
+/- I-Premise
31.9 I-Premise
m I-Premise
, I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
were I-Premise
better I-Premise
in I-Premise
the I-Premise
treated I-Premise
group I-Premise
. I-Premise

The B-Premise
median I-Premise
survival I-Premise
was I-Premise
22.7 I-Premise
weeks I-Premise
for I-Premise
regimen I-Premise
1 I-Premise
and I-Premise
28.3 I-Premise
weeks I-Premise
for I-Premise
regimen I-Premise
2 I-Premise
( I-Premise
P I-Premise
= I-Premise
0.197 I-Premise
) I-Premise
. I-Premise

Mean B-Premise
dominant I-Premise
fibroid I-Premise
diameter I-Premise
was I-Premise
7.6 I-Premise
± I-Premise
3.0 I-Premise
, I-Premise
5.8 I-Premise
± I-Premise
2.9 I-Premise
, I-Premise
and I-Premise
5 I-Premise
± I-Premise
2.9 I-Premise
cm I-Premise
at I-Premise
baseline I-Premise
, I-Premise
6 I-Premise
months I-Premise
, I-Premise
and I-Premise
5 I-Premise
years I-Premise
. I-Premise

Patients B-Premise
who I-Premise
experienced I-Premise
more I-Premise
concentration I-Premise
and I-Premise
memory I-Premise
problems I-Premise
at I-Premise
T1 I-Premise
benefited I-Premise
more I-Premise
from I-Premise
CBT I-Premise
for I-Premise
fatigue I-Premise
and I-Premise
are I-Premise
indicators I-Premise
. I-Premise

Patients B-Premise
without I-Premise
pain I-Premise
had I-Premise
a I-Premise
significantly I-Premise
lower I-Premise
2-year I-Premise
risk I-Premise
of I-Premise
progression I-Premise
in I-Premise
both I-Premise
groups I-Premise
. I-Premise

With B-Premise
94 I-Premise
patients I-Premise
still I-Premise
alive I-Premise
, I-Premise
the I-Premise
one-year I-Premise
probability I-Premise
of I-Premise
survival I-Premise
was I-Premise
61 I-Premise
% I-Premise
, I-Premise
54 I-Premise
% I-Premise
, I-Premise
and I-Premise
59 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
. I-Premise

These B-Premise
findings I-Premise
are I-Premise
consistent I-Premise
with I-Premise
evidence I-Premise
that I-Premise
only I-Premise
the I-Premise
combined I-Premise
intervention I-Premise
yielded I-Premise
increases I-Premise
in I-Premise
both I-Premise
exercise I-Premise
and I-Premise
stress I-Premise
management I-Premise
activity I-Premise
. I-Premise

Patients B-Premise
allocated I-Premise
to I-Premise
misoprostol I-Premise
did I-Premise
report I-Premise
slightly I-Premise
increased I-Premise
soreness I-Premise
( I-Premise
7.6 I-Premise
vs I-Premise
6.9 I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.04 I-Premise
) I-Premise
and I-Premise
a I-Premise
greater I-Premise
use I-Premise
of I-Premise
analgesics I-Premise
. I-Premise

Patients B-Premise
with I-Premise
complete I-Premise
or I-Premise
partial I-Premise
response I-Premise
were I-Premise
more I-Premise
likely I-Premise
to I-Premise
have I-Premise
improvement I-Premise
in I-Premise
the I-Premise
QOL I-Premise
response I-Premise
than I-Premise
patients I-Premise
with I-Premise
stable I-Premise
or I-Premise
progressive I-Premise
disease I-Premise
( I-Premise
P I-Premise
< I-Premise
.01 I-Premise
) I-Premise
. I-Premise

Objective B-Premise
response I-Premise
rates I-Premise
were I-Premise
66.7 I-Premise
% I-Premise
for I-Premise
patients I-Premise
in I-Premise
the I-Premise
high-dose I-Premise
group I-Premise
and I-Premise
64.4 I-Premise
% I-Premise
for I-Premise
patients I-Premise
in I-Premise
the I-Premise
AT I-Premise
arm I-Premise
( I-Premise
P I-Premise
= I-Premise
.82 I-Premise
) I-Premise
. I-Premise

A B-Premise
second I-Premise
infusion I-Premise
of I-Premise
pamidronate I-Premise
did I-Premise
not I-Premise
decrease I-Premise
resorption I-Premise
further I-Premise
, I-Premise
but B-Premise
maintained I-Premise
the I-Premise
suppression I-Premise
of I-Premise
resorption I-Premise
at I-Premise
similar I-Premise
levels I-Premise
for I-Premise
a I-Premise
further I-Premise
four I-Premise
weeks I-Premise
. I-Premise

Intrusive B-Premise
thoughts I-Premise
also I-Premise
influenced I-Premise
the I-Premise
trajectory I-Premise
of I-Premise
pain I-Premise
, I-Premise
depressive I-Premise
symptoms I-Premise
, I-Premise
negative I-Premise
affect I-Premise
, I-Premise
and I-Premise
physical I-Premise
functioning I-Premise
over I-Premise
time I-Premise
";" I-Premise
women B-Premise
with I-Premise
higher I-Premise
intrusions I-Premise
at I-Premise
baseline I-Premise
started I-Premise
worse I-Premise
and I-Premise
improved I-Premise
over I-Premise
time I-Premise
, I-Premise
whereas I-Premise
those I-Premise
with I-Premise
lower I-Premise
intrusions I-Premise
remained I-Premise
at I-Premise
a I-Premise
constant I-Premise
, I-Premise
lower I-Premise
level I-Premise
over I-Premise
time I-Premise
. I-Premise

Clinic B-Premise
discussions I-Premise
were I-Premise
associated I-Premise
with I-Premise
severity I-Premise
of I-Premise
patient-reported I-Premise
symptoms I-Premise
but I-Premise
not I-Premise
with I-Premise
patient-reported I-Premise
functional I-Premise
concerns I-Premise
. I-Premise

The B-Premise
median I-Premise
overall I-Premise
survival I-Premise
was I-Premise
10.5 I-Premise
months I-Premise
( I-Premise
placebo I-Premise
) I-Premise
and I-Premise
10.1 I-Premise
months I-Premise
( I-Premise
thalidomide I-Premise
) I-Premise
( I-Premise
HR I-Premise
for I-Premise
death I-Premise
= I-Premise
1.09 I-Premise
, I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
= I-Premise
0.93 I-Premise
to I-Premise
1.27 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.28 I-Premise
) I-Premise
. I-Premise

Outcomes B-Premise
in I-Premise
the I-Premise
nurse I-Premise
group I-Premise
were I-Premise
not I-Premise
inferior I-Premise
to I-Premise
outcomes I-Premise
in I-Premise
the I-Premise
gastroenterologist I-Premise
group I-Premise
( I-Premise
mean I-Premise
difference I-Premise
1·36 I-Premise
, I-Premise
one I-Premise
sided I-Premise
95 I-Premise
% I-Premise
CI I-Premise
-1·48 I-Premise
) I-Premise
. I-Premise

Mucositis B-Premise
occurs I-Premise
in I-Premise
almost I-Premise
all I-Premise
patients I-Premise
treated I-Premise
with I-Premise
radiotherapy I-Premise
for I-Premise
head I-Premise
and I-Premise
neck I-Premise
cancer I-Premise
. I-Premise

Results B-Premise
indicated I-Premise
statistically I-Premise
significant I-Premise
differences I-Premise
for I-Premise
4 I-Premise
of I-Premise
the I-Premise
6 I-Premise
quality I-Premise
of I-Premise
life I-Premise
measures I-Premise
: I-Premise
anxiety I-Premise
( I-Premise
p I-Premise
= I-Premise
.03 I-Premise
) I-Premise
, I-Premise
perception I-Premise
of I-Premise
hospitalization I-Premise
( I-Premise
p I-Premise
= I-Premise
.03 I-Premise
) I-Premise
, I-Premise
relaxation I-Premise
( I-Premise
p I-Premise
= I-Premise
.001 I-Premise
) I-Premise
, I-Premise
and I-Premise
stress I-Premise
( I-Premise
p I-Premise
= I-Premise
.001 I-Premise
) I-Premise
. I-Premise

The B-Premise
improvement I-Premise
in I-Premise
pain-related I-Premise
impairment I-Premise
was I-Premise
not I-Premise
sustained I-Premise
at I-Premise
6 I-Premise
and I-Premise
12 I-Premise
weeks I-Premise
. I-Premise

The B-Premise
nutritional I-Premise
condition I-Premise
in I-Premise
the I-Premise
INT I-Premise
group I-Premise
was I-Premise
nearly I-Premise
the I-Premise
same I-Premise
as I-Premise
that I-Premise
in I-Premise
the I-Premise
RY I-Premise
group I-Premise
. I-Premise

Patients B-Premise
receiving I-Premise
tamoxifen I-Premise
had I-Premise
significantly I-Premise
more I-Premise
vaginal I-Premise
discharge I-Premise
( I-Premise
P I-Premise
< I-Premise
.0001 I-Premise
) I-Premise
. I-Premise

Best B-Premise
response I-Premise
to I-Premise
induction I-Premise
therapy I-Premise
was I-Premise
complete I-Premise
remission I-Premise
for I-Premise
176 I-Premise
patients I-Premise
( I-Premise
33 I-Premise
% I-Premise
) I-Premise
, I-Premise
partial I-Premise
remission I-Premise
for I-Premise
341 I-Premise
( I-Premise
64 I-Premise
% I-Premise
) I-Premise
, I-Premise
and I-Premise
15 I-Premise
patients I-Premise
( I-Premise
3 I-Premise
% I-Premise
) I-Premise
had I-Premise
undergone I-Premise
surgical I-Premise
resection I-Premise
. I-Premise

In B-Premise
patients I-Premise
in I-Premise
group I-Premise
1 I-Premise
who I-Premise
had I-Premise
gynecomastia I-Premise
or I-Premise
breast I-Premise
pain I-Premise
a I-Premise
significant I-Premise
decrease I-Premise
in I-Premise
symptoms I-Premise
was I-Premise
achieved I-Premise
in I-Premise
those I-Premise
receiving I-Premise
tamoxifen I-Premise
( I-Premise
p I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

No B-Premise
statistically I-Premise
significant I-Premise
difference I-Premise
in I-Premise
QOL I-Premise
response I-Premise
between I-Premise
treatment I-Premise
arms I-Premise
was I-Premise
found I-Premise
for I-Premise
any I-Premise
domain I-Premise
or I-Premise
item I-Premise
except I-Premise
nausea I-Premise
and I-Premise
vomiting I-Premise
( I-Premise
P I-Premise
= I-Premise
0.04 I-Premise
) I-Premise
. I-Premise

The B-Premise
rate I-Premise
of I-Premise
endometrial I-Premise
cancer I-Premise
was I-Premise
increased I-Premise
in I-Premise
the I-Premise
tamoxifen I-Premise
group I-Premise
( I-Premise
risk I-Premise
ratio I-Premise
= I-Premise
2.53 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
= I-Premise
1.35-4.97 I-Premise
) I-Premise
";" I-Premise
this I-Premise
increased I-Premise
risk I-Premise
occurred I-Premise
predominantly I-Premise
in I-Premise
women I-Premise
aged I-Premise
50 I-Premise
years I-Premise
or I-Premise
older I-Premise
. I-Premise

The B-Premise
results I-Premise
of I-Premise
both I-Premise
the I-Premise
FLIC I-Premise
and I-Premise
FACT-L I-Premise
demonstrated I-Premise
significantly I-Premise
lower I-Premise
scores I-Premise
corresponding I-Premise
to I-Premise
lower I-Premise
KPS I-Premise
values I-Premise
( I-Premise
P I-Premise
= I-Premise
0.009 I-Premise
and I-Premise
P I-Premise
= I-Premise
0.016 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

The B-Premise
total I-Premise
medical-resource I-Premise
utilization I-Premise
cost I-Premise
per I-Premise
patient I-Premise
was I-Premise
8.9 I-Premise
% I-Premise
higher I-Premise
with I-Premise
the I-Premise
combination I-Premise
: I-Premise
24,475 I-Premise
dollars I-Premise
for I-Premise
combination I-Premise
therapy I-Premise
versus I-Premise
22,477 I-Premise
dollars I-Premise
for I-Premise
single-agent I-Premise
docetaxel I-Premise
. I-Premise

There B-Premise
was I-Premise
a I-Premise
significantly I-Premise
higher I-Premise
risk I-Premise
of I-Premise
death I-Premise
in I-Premise
the I-Premise
TMX120 I-Premise
group I-Premise
compared I-Premise
with I-Premise
the I-Premise
P I-Premise
group I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
, I-Premise
1.39 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
, I-Premise
1.07-1.81 I-Premise
) I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
in I-Premise
QOL I-Premise
as I-Premise
assessed I-Premise
by I-Premise
the I-Premise
FACT-Anemia I-Premise
or I-Premise
ESAS I-Premise
instruments I-Premise
. I-Premise

The B-Premise
15-year I-Premise
actuarial I-Premise
locoregional I-Premise
recurrence I-Premise
rates I-Premise
were I-Premise
5.8 I-Premise
% I-Premise
for I-Premise
EBRT I-Premise
versus I-Premise
15.5 I-Premise
% I-Premise
for I-Premise
NAT I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
, I-Premise
and I-Premise
15-year I-Premise
overall I-Premise
survival I-Premise
was I-Premise
52 I-Premise
% I-Premise
versus I-Premise
60 I-Premise
% I-Premise
( I-Premise
P I-Premise
= I-Premise
.14 I-Premise
) I-Premise
. I-Premise

Among B-Premise
these I-Premise
32 I-Premise
patients I-Premise
, I-Premise
8 I-Premise
had I-Premise
a I-Premise
partial I-Premise
response I-Premise
( I-Premise
intent-to-treat I-Premise
response I-Premise
rate I-Premise
, I-Premise
20 I-Premise
% I-Premise
) I-Premise
, I-Premise
and I-Premise
10 I-Premise
( I-Premise
25 I-Premise
% I-Premise
) I-Premise
had I-Premise
stable I-Premise
disease I-Premise
. I-Premise

The B-Premise
combined I-Premise
anthracycline I-Premise
followed I-Premise
by I-Premise
taxane I-Premise
group I-Premise
had I-Premise
significantly I-Premise
higher I-Premise
utility I-Premise
scores I-Premise
that I-Premise
the I-Premise
taxane-alone I-Premise
group I-Premise
, I-Premise
with I-Premise
no I-Premise
significant I-Premise
difference I-Premise
depending I-Premise
on I-Premise
the I-Premise
type I-Premise
of I-Premise
taxane I-Premise
. I-Premise

The B-Premise
costs I-Premise
during I-Premise
the I-Premise
follow-up I-Premise
period I-Premise
did I-Premise
not I-Premise
differ I-Premise
between I-Premise
the I-Premise
two I-Premise
groups I-Premise
. I-Premise

Consolidation B-Premise
chemotherapy I-Premise
was I-Premise
completed I-Premise
in I-Premise
75 I-Premise
% I-Premise
of I-Premise
the I-Premise
patients I-Premise
. I-Premise

The B-Premise
Sexual/Relationship I-Premise
Satisfaction I-Premise
subscale I-Premise
was I-Premise
associated I-Premise
with I-Premise
all I-Premise
measures I-Premise
of I-Premise
psychological I-Premise
well-being I-Premise
( I-Premise
r=-0.45 I-Premise
to I-Premise
-0.70 I-Premise
, I-Premise
all I-Premise
P I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
. I-Premise

The B-Premise
average I-Premise
increase I-Premise
in I-Premise
arm I-Premise
volume I-Premise
was I-Premise
2.8 I-Premise
% I-Premise
in I-Premise
the I-Premise
SNBM I-Premise
group I-Premise
and I-Premise
4.2 I-Premise
% I-Premise
in I-Premise
the I-Premise
RAC I-Premise
group I-Premise
( I-Premise
P I-Premise
= I-Premise
0.002 I-Premise
) I-Premise
. I-Premise

Three B-Premise
of I-Premise
the I-Premise
quality-of-life I-Premise
domains I-Premise
showed I-Premise
trends I-Premise
toward I-Premise
increases I-Premise
in I-Premise
the I-Premise
exercise I-Premise
group I-Premise
: I-Premise
physical I-Premise
functioning I-Premise
( I-Premise
P I-Premise
=.050 I-Premise
) I-Premise
, I-Premise
general I-Premise
health I-Premise
( I-Premise
P I-Premise
=.048 I-Premise
) I-Premise
, I-Premise
and I-Premise
vitality I-Premise
( I-Premise
P I-Premise
=.023 I-Premise
) I-Premise
. I-Premise

The B-Premise
most I-Premise
common I-Premise
grade I-Premise
3 I-Premise
to I-Premise
4 I-Premise
toxicities I-Premise
were I-Premise
neutropenia I-Premise
( I-Premise
82.9 I-Premise
% I-Premise
for I-Premise
docetaxel I-Premise
";" I-Premise
69.2 I-Premise
% I-Premise
for I-Premise
vinorelbine I-Premise
";" I-Premise
P I-Premise
= I-Premise
.031 I-Premise
) I-Premise
and I-Premise
leukopenia I-Premise
( I-Premise
58.0 I-Premise
% I-Premise
for I-Premise
docetaxel I-Premise
";" I-Premise
51.7 I-Premise
% I-Premise
for I-Premise
vinorelbine I-Premise
) I-Premise
. I-Premise

CRF B-Premise
was I-Premise
significantly I-Premise
reduced I-Premise
in I-Premise
the I-Premise
intervention I-Premise
group I-Premise
, I-Premise
corresponding I-Premise
to I-Premise
a I-Premise
Fatigue I-Premise
score I-Premise
reduction I-Premise
of I-Premise
3.04 I-Premise
( I-Premise
effect I-Premise
size I-Premise
of I-Premise
0.44 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0.17-0.72 I-Premise
) I-Premise
( I-Premise
P I-Premise
= I-Premise
.002 I-Premise
) I-Premise
, I-Premise
the I-Premise
FACT-An I-Premise
score I-Premise
by I-Premise
5.40 I-Premise
( I-Premise
P I-Premise
= I-Premise
.015 I-Premise
) I-Premise
, I-Premise
the I-Premise
FACT-An I-Premise
Toi I-Premise
score I-Premise
by I-Premise
5.22 I-Premise
( I-Premise
P I-Premise
= I-Premise
.009 I-Premise
) I-Premise
and I-Premise
the I-Premise
Anaemia-ANS I-Premise
by I-Premise
3.76 I-Premise
( I-Premise
P I-Premise
= I-Premise
.002 I-Premise
) I-Premise
. I-Premise

At B-Premise
4 I-Premise
months I-Premise
, I-Premise
J-pouch I-Premise
patients I-Premise
had I-Premise
10.3 I-Premise
% I-Premise
less I-Premise
stool I-Premise
fragmentation I-Premise
but I-Premise
poorer I-Premise
stool I-Premise
deferment I-Premise
and I-Premise
more I-Premise
nocturnal I-Premise
leakage I-Premise
. I-Premise

In B-Premise
the I-Premise
IMRT I-Premise
group I-Premise
, I-Premise
there I-Premise
was I-Premise
consistent I-Premise
improvement I-Premise
over I-Premise
time I-Premise
with I-Premise
xerostomia-related I-Premise
symptoms I-Premise
significantly I-Premise
less I-Premise
common I-Premise
than I-Premise
in I-Premise
the I-Premise
CRT I-Premise
group I-Premise
at I-Premise
12 I-Premise
months I-Premise
postradiotherapy I-Premise
. I-Premise

Mitomycin-C B-Premise
had I-Premise
no I-Premise
impact I-Premise
on I-Premise
survival I-Premise
( I-Premise
p I-Premise
= I-Premise
0.75 I-Premise
) I-Premise
. I-Premise

The B-Premise
total I-Premise
efficiencies I-Premise
of I-Premise
non-squamous I-Premise
cell I-Premise
carcinoma I-Premise
were I-Premise
27.62 I-Premise
% I-Premise
and I-Premise
16.00 I-Premise
% I-Premise
. I-Premise

Patients B-Premise
with I-Premise
PSA I-Premise
nadir I-Premise
≤ I-Premise
0.2 I-Premise
ng/ml I-Premise
, I-Premise
though I-Premise
had I-Premise
significantly I-Premise
higher I-Premise
2-year I-Premise
risk I-Premise
of I-Premise
progression I-Premise
compared I-Premise
to I-Premise
CAD I-Premise
( I-Premise
53 I-Premise
% I-Premise
vs. I-Premise
31 I-Premise
% I-Premise
( I-Premise
P I-Premise
= I-Premise
0.03 I-Premise
) I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Patients B-Premise
had I-Premise
significant I-Premise
concerns I-Premise
about I-Premise
the I-Premise
delivery I-Premise
of I-Premise
radiotherapy I-Premise
services I-Premise
, I-Premise
such I-Premise
as I-Premise
transport I-Premise
, I-Premise
accommodation I-Premise
and I-Premise
travel I-Premise
costs I-Premise
associated I-Premise
with I-Premise
receiving I-Premise
radiotherapy I-Premise
. I-Premise

With B-Premise
a I-Premise
median I-Premise
follow-up I-Premise
of I-Premise
17 I-Premise
months I-Premise
, I-Premise
median I-Premise
PFS I-Premise
was I-Premise
8.6 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
7.9 I-Premise
to I-Premise
9.7 I-Premise
months I-Premise
) I-Premise
for I-Premise
gemcitabine I-Premise
plus I-Premise
carboplatin I-Premise
and I-Premise
5.8 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
5.2 I-Premise
to I-Premise
7.1 I-Premise
months I-Premise
) I-Premise
for I-Premise
carboplatin I-Premise
. I-Premise

The B-Premise
overall I-Premise
progression-free I-Premise
survival I-Premise
rate I-Premise
was I-Premise
53 I-Premise
% I-Premise
at I-Premise
1 I-Premise
year I-Premise
and I-Premise
17 I-Premise
% I-Premise
at I-Premise
3 I-Premise
years I-Premise
. I-Premise

After B-Premise
treatment I-Premise
in I-Premise
the I-Premise
treated I-Premise
group I-Premise
, I-Premise
the I-Premise
body I-Premise
weight I-Premise
was I-Premise
increased I-Premise
in I-Premise
11 I-Premise
patients I-Premise
( I-Premise
20.0 I-Premise
% I-Premise
) I-Premise
, I-Premise
stabilized I-Premise
in I-Premise
28 I-Premise
( I-Premise
50.9 I-Premise
% I-Premise
) I-Premise
and I-Premise
decreased I-Premise
in I-Premise
16 I-Premise
( I-Premise
29.1 I-Premise
% I-Premise
) I-Premise
, I-Premise
while I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
it I-Premise
was I-Premise
increased I-Premise
in I-Premise
5 I-Premise
( I-Premise
9.4 I-Premise
% I-Premise
) I-Premise
, I-Premise
stabilized I-Premise
in I-Premise
26 I-Premise
( I-Premise
49.1 I-Premise
% I-Premise
) I-Premise
and I-Premise
decreased I-Premise
in I-Premise
22 I-Premise
( I-Premise
41.5 I-Premise
% I-Premise
) I-Premise
, I-Premise
difference I-Premise
between I-Premise
the I-Premise
two I-Premise
groups I-Premise
was I-Premise
significant I-Premise
, I-Premise
too I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

Systemic B-Premise
recurrence I-Premise
was I-Premise
7/74 I-Premise
( I-Premise
stage I-Premise
III I-Premise
";" I-Premise
9.4 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
IV I-Premise
arm I-Premise
and I-Premise
5/92 I-Premise
( I-Premise
stage I-Premise
III I-Premise
";" I-Premise
5.4 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
oral I-Premise
arm I-Premise
, I-Premise
respectively I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
statistically I-Premise
significant I-Premise
differences I-Premise
in I-Premise
patients I-Premise
' I-Premise
QOL I-Premise
outcomes I-Premise
over I-Premise
the I-Premise
study I-Premise
period I-Premise
. I-Premise

This B-Premise
trend I-Premise
for I-Premise
OS I-Premise
benefit I-Premise
for I-Premise
GEM-CAP I-Premise
was I-Premise
consistent I-Premise
across I-Premise
different I-Premise
prognostic I-Premise
subgroups I-Premise
according I-Premise
to I-Premise
baseline I-Premise
stratification I-Premise
factors I-Premise
( I-Premise
stage I-Premise
and I-Premise
performance I-Premise
status I-Premise
) I-Premise
and I-Premise
remained I-Premise
after I-Premise
adjusting I-Premise
for I-Premise
these I-Premise
stratification I-Premise
factors I-Premise
( I-Premise
P I-Premise
= I-Premise
.077 I-Premise
) I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
differences I-Premise
in I-Premise
the I-Premise
in-hospital I-Premise
mortality I-Premise
or I-Premise
early I-Premise
complication I-Premise
rates I-Premise
, I-Premise
but B-Premise
late I-Premise
complications I-Premise
were I-Premise
more I-Premise
frequent I-Premise
after I-Premise
rigid I-Premise
stenting I-Premise
( I-Premise
risk I-Premise
ratio=2.47 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
1.88-3.04 I-Premise
) I-Premise
. I-Premise

Mean B-Premise
weight I-Premise
changes I-Premise
per I-Premise
4-week I-Premise
period I-Premise
were I-Premise
-1.0 I-Premise
kg I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
= I-Premise
-1.5 I-Premise
to I-Premise
-0.5 I-Premise
) I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
and I-Premise
0.2 I-Premise
kg I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
-0.2 I-Premise
to I-Premise
+0.6 I-Premise
) I-Premise
in I-Premise
the I-Premise
ATP I-Premise
group I-Premise
( I-Premise
P I-Premise
=.002 I-Premise
) I-Premise
. I-Premise

DC/CIK B-Premise
treatment I-Premise
prolongs I-Premise
progression-free I-Premise
survival I-Premise
( I-Premise
3.20 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
2.94-3.50 I-Premise
] I-Premise
vs I-Premise
2.56 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
2.39-2.73 I-Premise
] I-Premise
";" I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

Mean B-Premise
index I-Premise
scores I-Premise
remained I-Premise
stable I-Premise
( I-Premise
0.78 I-Premise
at I-Premise
baseline I-Premise
[ I-Premise
n=267 I-Premise
] I-Premise
, I-Premise
0.79 I-Premise
at I-Premise
eight I-Premise
weeks I-Premise
[ I-Premise
n=186 I-Premise
] I-Premise
, I-Premise
P=0.34 I-Premise
, I-Premise
Wilcoxon I-Premise
signed I-Premise
rank I-Premise
test I-Premise
) I-Premise
, I-Premise
attributable I-Premise
to I-Premise
a I-Premise
modest I-Premise
deterioration I-Premise
of I-Premise
physical I-Premise
function I-Premise
domain I-Premise
scores I-Premise
coincident I-Premise
with I-Premise
small I-Premise
improvements I-Premise
in I-Premise
pain I-Premise
and I-Premise
anxiety/depression I-Premise
scores I-Premise
. I-Premise

Sleep B-Premise
quality I-Premise
differed I-Premise
over I-Premise
1 I-Premise
years I-Premise
time I-Premise
( I-Premise
F I-Premise
[ I-Premise
4,162 I-Premise
] I-Premise
= I-Premise
7.7 I-Premise
, I-Premise
P I-Premise
< I-Premise
.001 I-Premise
";" I-Premise
by I-Premise
group I-Premise
, I-Premise
F I-Premise
[ I-Premise
1,173 I-Premise
] I-Premise
= I-Premise
4.8 I-Premise
, I-Premise
P I-Premise
= I-Premise
.029 I-Premise
";" I-Premise
and I-Premise
over I-Premise
time I-Premise
by I-Premise
group I-Premise
, I-Premise
F I-Premise
[ I-Premise
4,162 I-Premise
] I-Premise
= I-Premise
3.3 I-Premise
, I-Premise
P I-Premise
= I-Premise
.013 I-Premise
) I-Premise
. I-Premise

Toxicity B-Premise
was I-Premise
mild I-Premise
in I-Premise
both I-Premise
arms I-Premise
. I-Premise

At B-Premise
6 I-Premise
months I-Premise
, I-Premise
there I-Premise
was I-Premise
a I-Premise
clinically I-Premise
relevant I-Premise
, I-Premise
but I-Premise
nonsignificant I-Premise
reduction I-Premise
in I-Premise
presentations I-Premise
to I-Premise
emergency I-Premise
departments I-Premise
( I-Premise
21 I-Premise
% I-Premise
vs I-Premise
33 I-Premise
% I-Premise
";" I-Premise
χ1 I-Premise
= I-Premise
1.41 I-Premise
, I-Premise
P I-Premise
= I-Premise
.23 I-Premise
) I-Premise
and I-Premise
readmission I-Premise
to I-Premise
the I-Premise
hospital I-Premise
( I-Premise
37 I-Premise
% I-Premise
vs I-Premise
47 I-Premise
% I-Premise
";" I-Premise
χ1 I-Premise
= I-Premise
0.82 I-Premise
, I-Premise
P I-Premise
= I-Premise
.37 I-Premise
) I-Premise
among I-Premise
intervention I-Premise
compared I-Premise
with I-Premise
control I-Premise
group I-Premise
participants I-Premise
. I-Premise

Seventy-one B-Premise
percent I-Premise
of I-Premise
patients I-Premise
in I-Premise
the I-Premise
EDS I-Premise
group I-Premise
and I-Premise
76 I-Premise
% I-Premise
in I-Premise
the I-Premise
QW I-Premise
group I-Premise
achieved I-Premise
the I-Premise
target I-Premise
hemoglobin I-Premise
of I-Premise
≥11.0 I-Premise
g/dL I-Premise
. I-Premise

Corresponding B-Premise
median I-Premise
failure-free I-Premise
survival I-Premise
times I-Premise
were I-Premise
3.1 I-Premise
and I-Premise
1.7 I-Premise
months I-Premise
( I-Premise
P I-Premise
= I-Premise
0.20 I-Premise
) I-Premise
. I-Premise

In B-Premise
addition I-Premise
, I-Premise
on I-Premise
the I-Premise
physical I-Premise
and I-Premise
psychological I-Premise
subscales I-Premise
, I-Premise
the I-Premise
Etoposide I-Premise
group I-Premise
had I-Premise
a I-Premise
significantly I-Premise
better I-Premise
QOL I-Premise
than I-Premise
the I-Premise
other I-Premise
3 I-Premise
treatment I-Premise
groups I-Premise
( I-Premise
p I-Premise
< I-Premise
0.04 I-Premise
) I-Premise
. I-Premise

Mean B-Premise
numbers I-Premise
of I-Premise
chemotherapy I-Premise
cycles I-Premise
were I-Premise
6.5+/-3.7 I-Premise
( I-Premise
IV I-Premise
arm I-Premise
) I-Premise
vs. I-Premise
7.2+/-4.3 I-Premise
( I-Premise
oral I-Premise
arm I-Premise
) I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Many B-Premise
patients I-Premise
( I-Premise
24 I-Premise
% I-Premise
) I-Premise
failed I-Premise
to I-Premise
complete I-Premise
at I-Premise
least I-Premise
6 I-Premise
weeks I-Premise
of I-Premise
therapy I-Premise
, I-Premise
including I-Premise
five I-Premise
( I-Premise
8 I-Premise
% I-Premise
) I-Premise
treatment-related I-Premise
early I-Premise
deaths I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
group I-Premise
differences I-Premise
with I-Premise
respect I-Premise
to I-Premise
survival I-Premise
. I-Premise

16 B-Premise
( I-Premise
29 I-Premise
% I-Premise
) I-Premise
patients I-Premise
in I-Premise
the I-Premise
open I-Premise
oesophagectomy I-Premise
group I-Premise
had I-Premise
pulmonary I-Premise
infection I-Premise
in I-Premise
the I-Premise
first I-Premise
2 I-Premise
weeks I-Premise
compared I-Premise
with I-Premise
five I-Premise
( I-Premise
9 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
minimally I-Premise
invasive I-Premise
group I-Premise
( I-Premise
relative I-Premise
risk I-Premise
[ I-Premise
RR I-Premise
] I-Premise
0·30 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0·12-0·76 I-Premise
";" I-Premise
p=0·005 I-Premise
) I-Premise
. I-Premise

Patients B-Premise
who I-Premise
preferred I-Premise
RET I-Premise
improved I-Premise
QoL I-Premise
when I-Premise
they I-Premise
were I-Premise
assigned I-Premise
to I-Premise
receive I-Premise
RET I-Premise
compared I-Premise
with I-Premise
UC I-Premise
( I-Premise
mean I-Premise
difference I-Premise
, I-Premise
16.5 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
] I-Premise
, I-Premise
4.3-28.7 I-Premise
";" I-Premise
P= I-Premise
.008 I-Premise
) I-Premise
or I-Premise
AET I-Premise
( I-Premise
mean I-Premise
difference I-Premise
, I-Premise
11 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
-1.1-23.4 I-Premise
";" I-Premise
P= I-Premise
.076 I-Premise
) I-Premise
. I-Premise

The B-Premise
incidence I-Premise
of I-Premise
Grade I-Premise
4 I-Premise
toxicity I-Premise
was I-Premise
56 I-Premise
% I-Premise
in I-Premise
patients I-Premise
receiving I-Premise
mitomycin-C I-Premise
and I-Premise
29 I-Premise
% I-Premise
in I-Premise
those I-Premise
who I-Premise
did I-Premise
not I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
significant I-Premise
effects I-Premise
of I-Premise
the I-Premise
intervention I-Premise
on I-Premise
mood I-Premise
, I-Premise
QOL I-Premise
or I-Premise
healthcare I-Premise
utilisation I-Premise
. I-Premise

The B-Premise
female I-Premise
patients I-Premise
in I-Premise
the I-Premise
ORP I-Premise
group I-Premise
had I-Premise
significantly I-Premise
lower I-Premise
body I-Premise
image I-Premise
scores I-Premise
than I-Premise
the I-Premise
male I-Premise
patients I-Premise
( I-Premise
14.9 I-Premise
vs I-Premise
18.3 I-Premise
) I-Premise
. I-Premise

The B-Premise
median I-Premise
survival I-Premise
time I-Premise
in I-Premise
the I-Premise
two I-Premise
groups I-Premise
was I-Premise
16.9 I-Premise
and I-Premise
17.0 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
, I-Premise
with I-Premise
59.62 I-Premise
% I-Premise
and I-Premise
65.87 I-Premise
% I-Premise
survival I-Premise
rates I-Premise
of I-Premise
1 I-Premise
year I-Premise
and I-Premise
27.28 I-Premise
% I-Premise
and I-Premise
27.93 I-Premise
% I-Premise
survival I-Premise
rates I-Premise
of I-Premise
2 I-Premise
years I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Clinically B-Premise
meaningful I-Premise
improvements I-Premise
in I-Premise
SF-36 I-Premise
, I-Premise
pain I-Premise
, I-Premise
fatigue I-Premise
and I-Premise
sleep I-Premise
problems I-Premise
were I-Premise
also I-Premise
maintained I-Premise
throughout I-Premise
the I-Premise
2 I-Premise
years I-Premise
of I-Premise
abatacept I-Premise
treatment I-Premise
. I-Premise

QOL B-Premise
improvement I-Premise
rates I-Premise
( I-Premise
Functional I-Premise
Assessment I-Premise
of I-Premise
Cancer I-Premise
Therapy-Head I-Premise
& I-Premise
amp I-Premise
";" I-Premise
Neck I-Premise
total I-Premise
score I-Premise
) I-Premise
were I-Premise
13.4 I-Premise
% I-Premise
, I-Premise
18.0 I-Premise
% I-Premise
, I-Premise
and I-Premise
6.0 I-Premise
% I-Premise
for I-Premise
gefitinib I-Premise
250 I-Premise
mg/day I-Premise
, I-Premise
500 I-Premise
mg/day I-Premise
, I-Premise
and I-Premise
methotrexate I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Fat B-Premise
mass I-Premise
had I-Premise
significantly I-Premise
decreased I-Premise
by I-Premise
month I-Premise
12 I-Premise
in I-Premise
the I-Premise
exemestane I-Premise
, I-Premise
but I-Premise
not I-Premise
in I-Premise
the I-Premise
tamoxifen I-Premise
group I-Premise
";" I-Premise
the B-Premise
between-group I-Premise
difference I-Premise
was I-Premise
statistically I-Premise
significant I-Premise
( I-Premise
P I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
. I-Premise

281 B-Premise
( I-Premise
85 I-Premise
% I-Premise
) I-Premise
of I-Premise
332 I-Premise
in I-Premise
the I-Premise
combined-treatment I-Premise
group I-Premise
and I-Premise
227 I-Premise
( I-Premise
72 I-Premise
% I-Premise
) I-Premise
of I-Premise
313 I-Premise
in I-Premise
the I-Premise
endocrine-only I-Premise
group I-Premise
had I-Premise
erectile I-Premise
dysfunction I-Premise
( I-Premise
p=0.0002 I-Premise
) I-Premise
. I-Premise

Intrusive B-Premise
thoughts I-Premise
were I-Premise
associated I-Premise
with I-Premise
higher I-Premise
levels I-Premise
of I-Premise
all I-Premise
symptoms I-Premise
at I-Premise
baseline I-Premise
and I-Premise
at I-Premise
the I-Premise
12-month I-Premise
assessment I-Premise
. I-Premise

The B-Premise
SCNS I-Premise
physical I-Premise
and I-Premise
patient I-Premise
care I-Premise
subscales I-Premise
( I-Premise
-14.2 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
-26.2 I-Premise
to I-Premise
-2.2 I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.02 I-Premise
and I-Premise
-7.4 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
-13.7 I-Premise
to I-Premise
-1.1 I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.02 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
and I-Premise
self-reported I-Premise
health I-Premise
state I-Premise
( I-Premise
12.8 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
3.2 I-Premise
to I-Premise
22.4 I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.01 I-Premise
) I-Premise
also I-Premise
differed I-Premise
significantly I-Premise
. I-Premise

The B-Premise
difference I-Premise
in I-Premise
mean I-Premise
volume I-Premise
change I-Premise
between I-Premise
randomisation I-Premise
groups I-Premise
at I-Premise
12 I-Premise
months I-Premise
was I-Premise
not I-Premise
statistically I-Premise
significant I-Premise
( I-Premise
P I-Premise
= I-Premise
0.6 I-Premise
) I-Premise
, I-Premise
-1.3 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
-6.1 I-Premise
to I-Premise
3.5 I-Premise
) I-Premise
, I-Premise
nor I-Premise
was I-Premise
there I-Premise
a I-Premise
significant I-Premise
difference I-Premise
in I-Premise
response I-Premise
at I-Premise
6 I-Premise
months I-Premise
( I-Premise
P I-Premise
= I-Premise
0.7 I-Premise
) I-Premise
, I-Premise
where I-Premise
mean I-Premise
change I-Premise
in I-Premise
arm I-Premise
volume I-Premise
from I-Premise
baseline I-Premise
in I-Premise
the I-Premise
treatment I-Premise
and I-Premise
placebo I-Premise
groups I-Premise
was I-Premise
-2.3 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
-7.9 I-Premise
to I-Premise
3.4 I-Premise
) I-Premise
and I-Premise
-1.1 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
-3.9 I-Premise
to I-Premise
1.7 I-Premise
) I-Premise
, I-Premise
respectively I-Premise
. I-Premise

No B-Premise
discernible I-Premise
important I-Premise
effect I-Premise
on I-Premise
the I-Premise
patients I-Premise
' I-Premise
3-month I-Premise
postoperative I-Premise
course I-Premise
was I-Premise
identified I-Premise
. I-Premise

Compared B-Premise
with I-Premise
the I-Premise
intervention I-Premise
group I-Premise
, I-Premise
mean I-Premise
difference I-Premise
scores I-Premise
between I-Premise
the I-Premise
baseline I-Premise
( I-Premise
T1 I-Premise
) I-Premise
and I-Premise
immediate I-Premise
after I-Premise
the I-Premise
test I-Premise
( I-Premise
T2 I-Premise
) I-Premise
assessments I-Premise
increased I-Premise
significantly I-Premise
more I-Premise
for I-Premise
the I-Premise
control I-Premise
group I-Premise
for I-Premise
worst I-Premise
and I-Premise
average I-Premise
fatigue I-Premise
, I-Premise
Functional I-Premise
Assessment I-Premise
of I-Premise
Cancer I-Premise
Therapy-Fatigue I-Premise
, I-Premise
and I-Premise
Piper I-Premise
fatigue I-Premise
severity I-Premise
and I-Premise
interference I-Premise
measures I-Premise
. I-Premise

Protein B-Premise
intake I-Premise
also I-Premise
increased I-Premise
in I-Premise
both I-Premise
groups I-Premise
1 I-Premise
and I-Premise
2 I-Premise
( I-Premise
p I-Premise
< I-Premise
or I-Premise
= I-Premise
.006 I-Premise
) I-Premise
. I-Premise

Four B-Premise
toxic I-Premise
deaths I-Premise
occurred I-Premise
in I-Premise
the I-Premise
NP I-Premise
arm I-Premise
and I-Premise
eight I-Premise
in I-Premise
the I-Premise
NIP I-Premise
arm I-Premise
. I-Premise

Patients B-Premise
who I-Premise
received I-Premise
EBRT I-Premise
reported I-Premise
significantly I-Premise
higher I-Premise
levels I-Premise
of I-Premise
diarrhea I-Premise
and I-Premise
bowel I-Premise
symptoms I-Premise
. I-Premise

WHO B-Premise
grade I-Premise
3-4 I-Premise
toxicity I-Premise
occurred I-Premise
in I-Premise
13 I-Premise
% I-Premise
of I-Premise
cycles I-Premise
of I-Premise
experimental I-Premise
arm I-Premise
and I-Premise
in I-Premise
8 I-Premise
% I-Premise
of I-Premise
cycles I-Premise
in I-Premise
control I-Premise
arm I-Premise
. I-Premise

After B-Premise
RT I-Premise
, I-Premise
> I-Premise
90 I-Premise
% I-Premise
of I-Premise
patients I-Premise
experienced I-Premise
RT I-Premise
toxicity I-Premise
";" I-Premise
this B-Premise
was I-Premise
not I-Premise
significantly I-Premise
different I-Premise
between I-Premise
groups I-Premise
, I-Premise
with I-Premise
a I-Premise
trend I-Premise
for I-Premise
reduced I-Premise
symptomatology I-Premise
in I-Premise
group I-Premise
1 I-Premise
versus I-Premise
group I-Premise
2/group I-Premise
3 I-Premise
( I-Premise
p I-Premise
< I-Premise
.07 I-Premise
) I-Premise
. I-Premise

The B-Premise
estimated I-Premise
treatment I-Premise
effects I-Premise
( I-Premise
intervention I-Premise
minus I-Premise
usual I-Premise
care I-Premise
) I-Premise
for I-Premise
all I-Premise
participants I-Premise
were I-Premise
a I-Premise
mean I-Premise
( I-Premise
SE I-Premise
) I-Premise
of I-Premise
4.6 I-Premise
( I-Premise
2 I-Premise
) I-Premise
for I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
P I-Premise
= I-Premise
.02 I-Premise
) I-Premise
, I-Premise
-27.8 I-Premise
( I-Premise
15 I-Premise
) I-Premise
for I-Premise
symptom I-Premise
intensity I-Premise
( I-Premise
P I-Premise
= I-Premise
.06 I-Premise
) I-Premise
, I-Premise
and I-Premise
-1.8 I-Premise
( I-Premise
0.81 I-Premise
) I-Premise
for I-Premise
depressed I-Premise
mood I-Premise
( I-Premise
P I-Premise
= I-Premise
.02 I-Premise
) I-Premise
. I-Premise

In B-Premise
grade I-Premise
IV I-Premise
the I-Premise
corresponding I-Premise
median I-Premise
survival I-Premise
time I-Premise
was I-Premise
12.3 I-Premise
( I-Premise
2.1-89.2 I-Premise
) I-Premise
and I-Premise
10.3 I-Premise
( I-Premise
0.3-91.7+ I-Premise
) I-Premise
months I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Linear B-Premise
mixed I-Premise
models I-Premise
( I-Premise
primary I-Premise
model I-Premise
) I-Premise
demonstrated I-Premise
no I-Premise
statistically I-Premise
significant I-Premise
overall I-Premise
difference I-Premise
between I-Premise
EVE I-Premise
+ I-Premise
EXE I-Premise
and I-Premise
PBO I-Premise
+ I-Premise
EXE I-Premise
for I-Premise
QL2 I-Premise
( I-Premise
LSM I-Premise
difference I-Premise
= I-Premise
-1.91 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
-4.61 I-Premise
, I-Premise
0.78 I-Premise
) I-Premise
, I-Premise
BRBS I-Premise
( I-Premise
LSM I-Premise
difference I-Premise
= I-Premise
-0.18 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
-1.98 I-Premise
, I-Premise
1.62 I-Premise
) I-Premise
, I-Premise
or I-Premise
BRAS I-Premise
( I-Premise
LSM I-Premise
difference I-Premise
= I-Premise
-0.42 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
-2.94 I-Premise
, I-Premise
2.10 I-Premise
) I-Premise
. I-Premise

No B-Premise
significant I-Premise
effect I-Premise
was I-Premise
seen I-Premise
for I-Premise
general I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
FACT-G I-Premise
) I-Premise
, I-Premise
which I-Premise
was I-Premise
the I-Premise
primary I-Premise
outcome I-Premise
. I-Premise

No B-Premise
late I-Premise
arising I-Premise
QOL I-Premise
issues I-Premise
were I-Premise
observed I-Premise
. I-Premise

Numeric B-Premise
rating I-Premise
scale I-Premise
scores I-Premise
for I-Premise
pain I-Premise
intensity I-Premise
in I-Premise
group I-Premise
1 I-Premise
and I-Premise
group I-Premise
2 I-Premise
were I-Premise
significantly I-Premise
lower I-Premise
than I-Premise
those I-Premise
in I-Premise
group I-Premise
3 I-Premise
at I-Premise
T I-Premise
( I-Premise
0-12 I-Premise
) I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
";" I-Premise
T I-Premise
( I-Premise
12-24 I-Premise
) I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
";" I-Premise
and I-Premise
T I-Premise
( I-Premise
24-48 I-Premise
) I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

A B-Premise
multivariate I-Premise
analysis I-Premise
found I-Premise
the I-Premise
use I-Premise
of I-Premise
breast I-Premise
IMRT I-Premise
( I-Premise
P I-Premise
= I-Premise
.003 I-Premise
) I-Premise
and I-Premise
smaller I-Premise
breast I-Premise
size I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
were I-Premise
significantly I-Premise
associated I-Premise
with I-Premise
a I-Premise
decreased I-Premise
risk I-Premise
of I-Premise
moist I-Premise
desquamation I-Premise
. I-Premise

The B-Premise
nutrition I-Premise
intervention I-Premise
group I-Premise
had I-Premise
a I-Premise
higher I-Premise
mean I-Premise
total I-Premise
energy I-Premise
( I-Premise
P=0.029 I-Premise
) I-Premise
and I-Premise
protein I-Premise
intake I-Premise
( I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
compared I-Premise
with I-Premise
the I-Premise
standard I-Premise
practice I-Premise
group I-Premise
. I-Premise

Compared B-Premise
with I-Premise
patients I-Premise
who I-Premise
were I-Premise
treated I-Premise
with I-Premise
standard I-Premise
chemotherapy I-Premise
, I-Premise
patients I-Premise
who I-Premise
were I-Premise
treated I-Premise
with I-Premise
capecitabine I-Premise
had I-Premise
significantly I-Premise
better I-Premise
QoL I-Premise
, I-Premise
role I-Premise
function I-Premise
, I-Premise
and I-Premise
social I-Premise
function I-Premise
, I-Premise
fewer I-Premise
systemic I-Premise
adverse I-Premise
effects I-Premise
, I-Premise
less I-Premise
psychological I-Premise
distress I-Premise
, I-Premise
and I-Premise
less I-Premise
fatigue I-Premise
during I-Premise
and I-Premise
at I-Premise
the I-Premise
completion I-Premise
of I-Premise
treatment I-Premise
( I-Premise
P I-Premise
≤ I-Premise
.005 I-Premise
) I-Premise
. I-Premise

Concerning B-Premise
the I-Premise
eating I-Premise
function I-Premise
, I-Premise
both I-Premise
groups I-Premise
had I-Premise
improvements I-Premise
in I-Premise
dysphagia I-Premise
but I-Premise
there I-Premise
were I-Premise
frequent I-Premise
need I-Premise
for I-Premise
endoscopic I-Premise
intervention I-Premise
. I-Premise

The B-Premise
total I-Premise
clinical I-Premise
effective I-Premise
rates I-Premise
in I-Premise
PP I-Premise
group I-Premise
and I-Premise
GP I-Premise
group I-Premise
were I-Premise
25.20 I-Premise
% I-Premise
and I-Premise
17.74 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Grade B-Premise
4/5 I-Premise
infection I-Premise
was I-Premise
observed I-Premise
in I-Premise
4.6 I-Premise
% I-Premise
of I-Premise
PE I-Premise
patients I-Premise
and I-Premise
1.8 I-Premise
% I-Premise
of I-Premise
topotecan I-Premise
patients I-Premise
. I-Premise

Tumor B-Premise
response I-Premise
rates I-Premise
were I-Premise
comparable I-Premise
between I-Premise
treatment I-Premise
arms I-Premise
( I-Premise
10.2 I-Premise
% I-Premise
v I-Premise
8.2 I-Premise
% I-Premise
) I-Premise
. I-Premise

Intervention B-Premise
patients I-Premise
also I-Premise
experienced I-Premise
greater I-Premise
rates I-Premise
of I-Premise
depression I-Premise
treatment I-Premise
( I-Premise
72.3 I-Premise
% I-Premise
v I-Premise
10.4 I-Premise
% I-Premise
of I-Premise
EUC I-Premise
patients I-Premise
";" I-Premise
P I-Premise
< I-Premise
.0001 I-Premise
) I-Premise
and I-Premise
significantly I-Premise
better I-Premise
quality-of-life I-Premise
outcomes I-Premise
, I-Premise
including I-Premise
social/family I-Premise
( I-Premise
adjusted I-Premise
mean I-Premise
difference I-Premise
between I-Premise
groups I-Premise
, I-Premise
2.7 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
1.22 I-Premise
to I-Premise
4.17 I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
, I-Premise
emotional I-Premise
( I-Premise
adjusted I-Premise
mean I-Premise
difference I-Premise
, I-Premise
1.29 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.26 I-Premise
to I-Premise
2.22 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.01 I-Premise
) I-Premise
, I-Premise
functional I-Premise
( I-Premise
adjusted I-Premise
mean I-Premise
difference I-Premise
, I-Premise
1.34 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.08 I-Premise
to I-Premise
2.59 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.04 I-Premise
) I-Premise
, I-Premise
and I-Premise
physical I-Premise
well-being I-Premise
( I-Premise
adjusted I-Premise
mean I-Premise
difference I-Premise
, I-Premise
2.79 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.49 I-Premise
to I-Premise
5.1 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.02 I-Premise
) I-Premise
. I-Premise

Patients B-Premise
in I-Premise
the I-Premise
NGT I-Premise
group I-Premise
reported I-Premise
significantly I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
better I-Premise
scores I-Premise
of I-Premise
QoL I-Premise
at I-Premise
both I-Premise
6 I-Premise
months I-Premise
and I-Premise
1 I-Premise
year I-Premise
. I-Premise

Survival B-Premise
without I-Premise
performance-status I-Premise
deterioration I-Premise
( I-Premise
p=0.0001 I-Premise
) I-Premise
, I-Premise
without I-Premise
weight I-Premise
loss I-Premise
of I-Premise
more I-Premise
than I-Premise
5 I-Premise
% I-Premise
( I-Premise
p=0.018 I-Premise
) I-Premise
, I-Premise
and I-Premise
pain-free I-Premise
survival I-Premise
( I-Premise
p=0.003 I-Premise
) I-Premise
were I-Premise
significantly I-Premise
better I-Premise
in I-Premise
the I-Premise
patients I-Premise
given I-Premise
irinotecan I-Premise
. I-Premise

Patients B-Premise
on I-Premise
marimastat I-Premise
had I-Premise
significantly I-Premise
poorer I-Premise
quality I-Premise
of I-Premise
life I-Premise
at I-Premise
3 I-Premise
and I-Premise
6 I-Premise
months I-Premise
. I-Premise

Neither B-Premise
group I-Premise
had I-Premise
a I-Premise
survival I-Premise
advantage I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
0.95 I-Premise
, I-Premise
0.73 I-Premise
to I-Premise
1.24 I-Premise
";" I-Premise
P=0.71 I-Premise
) I-Premise
. I-Premise

Quality B-Premise
of I-Premise
life I-Premise
assessed I-Premise
using I-Premise
EQ-5D I-Premise
showed I-Premise
no I-Premise
evidence I-Premise
of I-Premise
a I-Premise
difference I-Premise
. I-Premise

TSS B-Premise
improved I-Premise
in I-Premise
49 I-Premise
patients I-Premise
( I-Premise
77 I-Premise
% I-Premise
) I-Premise
on I-Premise
regimen I-Premise
1 I-Premise
, I-Premise
and I-Premise
in I-Premise
57 I-Premise
( I-Premise
92 I-Premise
% I-Premise
) I-Premise
patients I-Premise
on I-Premise
regimen I-Premise
2 I-Premise
, I-Premise
a I-Premise
difference I-Premise
of I-Premise
15 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
3-28 I-Premise
) I-Premise
in I-Premise
the I-Premise
proportion I-Premise
improving I-Premise
between I-Premise
the I-Premise
two I-Premise
regimens I-Premise
. I-Premise

During B-Premise
the I-Premise
study I-Premise
, I-Premise
31.7 I-Premise
% I-Premise
of I-Premise
placebo-treated I-Premise
patients I-Premise
achieved I-Premise
a I-Premise
> I-Premise
or I-Premise
= I-Premise
2 I-Premise
g/dL I-Premise
HgB I-Premise
increase I-Premise
compared I-Premise
with I-Premise
72.7 I-Premise
% I-Premise
of I-Premise
epoetin-treated I-Premise
patients I-Premise
( I-Premise
P I-Premise
< I-Premise
.0001 I-Premise
) I-Premise
. I-Premise

Median B-Premise
survival I-Premise
was I-Premise
14 I-Premise
months I-Premise
with I-Premise
MMC I-Premise
and I-Premise
15 I-Premise
months I-Premise
in I-Premise
5-FU I-Premise
alone I-Premise
";" I-Premise
one-year I-Premise
survival I-Premise
51.7 I-Premise
% I-Premise
vs. I-Premise
57.2 I-Premise
% I-Premise
. I-Premise

QOL B-Premise
, I-Premise
except I-Premise
for I-Premise
symptoms I-Premise
of I-Premise
sensory I-Premise
neuropathy I-Premise
and I-Premise
hearing I-Premise
loss I-Premise
, I-Premise
in I-Premise
those I-Premise
treated I-Premise
with I-Premise
chemotherapy I-Premise
returned I-Premise
to I-Premise
baseline I-Premise
by I-Premise
9 I-Premise
months I-Premise
. I-Premise

One B-Premise
patient I-Premise
died I-Premise
of I-Premise
febrile I-Premise
neutropenia I-Premise
during I-Premise
treatment I-Premise
. I-Premise

PFS B-Premise
was I-Premise
significantly I-Premise
prolonged I-Premise
in I-Premise
the I-Premise
erlotinib I-Premise
treatment I-Premise
arm I-Premise
, I-Premise
both I-Premise
overall I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
: I-Premise
0.57 I-Premise
";" I-Premise
p=0.0067 I-Premise
) I-Premise
and I-Premise
in I-Premise
patients I-Premise
with I-Premise
EGFR I-Premise
IHC-positive I-Premise
disease I-Premise
( I-Premise
HR=0.50 I-Premise
";" I-Premise
p=0.0057 I-Premise
) I-Premise
. I-Premise

Hospice B-Premise
care I-Premise
was I-Premise
so I-Premise
good I-Premise
during I-Premise
the I-Premise
study I-Premise
that I-Premise
overall I-Premise
quality I-Premise
of I-Premise
life I-Premise
improved I-Premise
as I-Premise
a I-Premise
result I-Premise
of I-Premise
standard I-Premise
care I-Premise
and I-Premise
left I-Premise
little I-Premise
room I-Premise
for I-Premise
improvement I-Premise
in I-Premise
other I-Premise
variables I-Premise
. I-Premise

Similarly B-Premise
, I-Premise
both I-Premise
groups I-Premise
showed I-Premise
a I-Premise
decline I-Premise
in I-Premise
physical I-Premise
and I-Premise
functional I-Premise
well I-Premise
being I-Premise
but I-Premise
recovered I-Premise
in I-Premise
the I-Premise
3 I-Premise
months I-Premise
posttreatment I-Premise
follow-up I-Premise
, I-Premise
with I-Premise
the I-Premise
rhDNase I-Premise
group I-Premise
exhibiting I-Premise
speedier I-Premise
recovery I-Premise
. I-Premise

The B-Premise
-1 I-Premise
and I-Premise
2-year I-Premise
survival I-Premise
rates I-Premise
were I-Premise
31 I-Premise
and I-Premise
36 I-Premise
% I-Premise
, I-Premise
and I-Premise
10 I-Premise
and I-Premise
11 I-Premise
% I-Premise
respectively I-Premise
. I-Premise

After B-Premise
RT I-Premise
, I-Premise
QOL I-Premise
function I-Premise
scores I-Premise
improved I-Premise
( I-Premise
p I-Premise
< I-Premise
.003 I-Premise
) I-Premise
proportionally I-Premise
with I-Premise
improved I-Premise
nutritional I-Premise
intake I-Premise
and I-Premise
status I-Premise
in I-Premise
group I-Premise
1/group I-Premise
2 I-Premise
( I-Premise
p I-Premise
< I-Premise
.05 I-Premise
) I-Premise
and I-Premise
worsened I-Premise
in I-Premise
group I-Premise
3 I-Premise
( I-Premise
p I-Premise
< I-Premise
.05 I-Premise
) I-Premise
";" I-Premise
at B-Premise
3 I-Premise
months I-Premise
, I-Premise
patients I-Premise
in I-Premise
group I-Premise
1 I-Premise
maintained I-Premise
or I-Premise
improved I-Premise
overall I-Premise
QOL I-Premise
, I-Premise
whereas I-Premise
patients I-Premise
in I-Premise
groups I-Premise
2 I-Premise
and I-Premise
3 I-Premise
maintained I-Premise
or I-Premise
worsened I-Premise
overall I-Premise
QOL I-Premise
. I-Premise

Hemoglobin B-Premise
responses I-Premise
defined I-Premise
as I-Premise
mean I-Premise
hemoglobin I-Premise
> I-Premise
or I-Premise
= I-Premise
12 I-Premise
g/dL I-Premise
or I-Premise
a I-Premise
> I-Premise
or I-Premise
= I-Premise
2 I-Premise
g/dL I-Premise
increase I-Premise
compared I-Premise
with I-Premise
baseline I-Premise
were I-Premise
significantly I-Premise
higher I-Premise
in I-Premise
the I-Premise
epoetin I-Premise
alfa I-Premise
group I-Premise
versus I-Premise
SOC I-Premise
: I-Premise
52.0 I-Premise
% I-Premise
v I-Premise
5.1 I-Premise
% I-Premise
and I-Premise
65.7 I-Premise
% I-Premise
v I-Premise
6.3 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
( I-Premise
P I-Premise
< I-Premise
.0001 I-Premise
for I-Premise
both I-Premise
comparisons I-Premise
) I-Premise
. I-Premise

Grade B-Premise
3 I-Premise
to I-Premise
4 I-Premise
treatment-related I-Premise
adverse I-Premise
events I-Premise
occurred I-Premise
in I-Premise
69 I-Premise
% I-Premise
( I-Premise
DCF I-Premise
) I-Premise
v I-Premise
59 I-Premise
% I-Premise
( I-Premise
CF I-Premise
) I-Premise
of I-Premise
patients I-Premise
. I-Premise

Mean B-Premise
scores I-Premise
were I-Premise
generally I-Premise
improved I-Premise
by I-Premise
the I-Premise
end-of-treatment I-Premise
assessment I-Premise
vs. I-Premise
baseline I-Premise
in I-Premise
both I-Premise
arms I-Premise
. I-Premise

No B-Premise
significant I-Premise
main I-Premise
effect I-Premise
of I-Premise
the I-Premise
interventions I-Premise
emerged I-Premise
on I-Premise
cancer-specific I-Premise
distress I-Premise
, I-Premise
but B-Premise
EDU I-Premise
prompted I-Premise
greater I-Premise
reduction I-Premise
in I-Premise
this I-Premise
outcome I-Premise
relative I-Premise
to I-Premise
CTL I-Premise
at I-Premise
6 I-Premise
months I-Premise
for I-Premise
patients I-Premise
who I-Premise
felt I-Premise
more I-Premise
prepared I-Premise
for I-Premise
re-entry I-Premise
. I-Premise

The B-Premise
survival I-Premise
benefit I-Premise
of I-Premise
D3P I-Premise
compared I-Premise
with I-Premise
MP I-Premise
has I-Premise
persisted I-Premise
with I-Premise
extended I-Premise
follow-up I-Premise
( I-Premise
P I-Premise
= I-Premise
.004 I-Premise
) I-Premise
. I-Premise

The B-Premise
median I-Premise
time I-Premise
to I-Premise
development I-Premise
of I-Premise
severe I-Premise
mucositis I-Premise
from I-Premise
the I-Premise
start I-Premise
of I-Premise
radiotherapy I-Premise
was I-Premise
3.61 I-Premise
weeks I-Premise
on I-Premise
BCoG I-Premise
and I-Premise
3.96 I-Premise
weeks I-Premise
on I-Premise
placebo I-Premise
( I-Premise
P I-Premise
=.61 I-Premise
) I-Premise
. I-Premise

The B-Premise
median I-Premise
survival I-Premise
was I-Premise
7.8 I-Premise
months I-Premise
( I-Premise
range I-Premise
, I-Premise
4-11.6 I-Premise
months I-Premise
) I-Premise
. I-Premise

Over B-Premise
the I-Premise
first I-Premise
15 I-Premise
months I-Premise
, I-Premise
radiotherapy I-Premise
for I-Premise
this I-Premise
population I-Premise
is I-Premise
not I-Premise
a I-Premise
cost-effective I-Premise
treatment I-Premise
. I-Premise

HRQOL B-Premise
and I-Premise
symptom I-Premise
relief I-Premise
were I-Premise
equivalent I-Premise
in I-Premise
the I-Premise
treatment I-Premise
arms I-Premise
. I-Premise

The B-Premise
median I-Premise
PFS I-Premise
was I-Premise
12.1 I-Premise
months I-Premise
in I-Premise
Arm I-Premise
A I-Premise
and I-Premise
B I-Premise
[ I-Premise
hazard I-Premise
ratio I-Premise
( I-Premise
HR I-Premise
) I-Premise
0.99 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
( I-Premise
CI I-Premise
) I-Premise
0.85-1.15 I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.93 I-Premise
] I-Premise
. I-Premise

The B-Premise
QLQ-C30 I-Premise
subscales I-Premise
pain I-Premise
( I-Premise
P=0.12 I-Premise
) I-Premise
, I-Premise
insomnia I-Premise
( I-Premise
P=0.068 I-Premise
) I-Premise
, I-Premise
appetite I-Premise
loss I-Premise
( I-Premise
P=0.074 I-Premise
) I-Premise
and I-Premise
the I-Premise
QLQ-MY24 I-Premise
item I-Premise
sick I-Premise
( I-Premise
P=0.086 I-Premise
) I-Premise
scored I-Premise
marginally I-Premise
better I-Premise
during I-Premise
thalidomide I-Premise
maintenance I-Premise
. I-Premise

Compared B-Premise
with I-Premise
the I-Premise
control I-Premise
group I-Premise
, I-Premise
the I-Premise
intervention I-Premise
groups I-Premise
had I-Premise
a I-Premise
significant I-Premise
decrease I-Premise
in I-Premise
levels I-Premise
of I-Premise
endocrine I-Premise
symptoms I-Premise
( I-Premise
Functional I-Premise
Assessment I-Premise
of I-Premise
Cancer I-Premise
Therapy-Endocrine I-Premise
Symptoms I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
";" I-Premise
effect I-Premise
size I-Premise
, I-Premise
0.31-0.52 I-Premise
) I-Premise
and I-Premise
urinary I-Premise
symptoms I-Premise
( I-Premise
Bristol I-Premise
Female I-Premise
Lower I-Premise
Urinary I-Premise
Tract I-Premise
Symptoms I-Premise
Questionnaire I-Premise
";" I-Premise
P=.002 I-Premise
";" I-Premise
effect I-Premise
size I-Premise
, I-Premise
0.29-0.33 I-Premise
) I-Premise
, I-Premise
and I-Premise
they I-Premise
showed I-Premise
an I-Premise
improvement I-Premise
in I-Premise
physical I-Premise
functioning I-Premise
( I-Premise
36-Item I-Premise
Short I-Premise
Form I-Premise
Health I-Premise
Survey I-Premise
physical I-Premise
functioning I-Premise
subscale I-Premise
";" I-Premise
P=.002 I-Premise
";" I-Premise
effect I-Premise
size I-Premise
, I-Premise
0.37-0.46 I-Premise
) I-Premise
. I-Premise

The B-Premise
effects I-Premise
of I-Premise
ATP I-Premise
on I-Premise
body I-Premise
weight I-Premise
, I-Premise
muscle I-Premise
strength I-Premise
, I-Premise
and I-Premise
albumin I-Premise
concentration I-Premise
were I-Premise
especially I-Premise
marked I-Premise
in I-Premise
cachectic I-Premise
patients I-Premise
( I-Premise
P I-Premise
=.0002 I-Premise
, I-Premise
P I-Premise
=.0001 I-Premise
, I-Premise
and I-Premise
P I-Premise
= I-Premise
. I-Premise
1 I-Premise
, I-Premise
respectively I-Premise
, I-Premise
for I-Premise
ATP I-Premise
versus I-Premise
no I-Premise
ATP I-Premise
) I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
serious I-Premise
events I-Premise
with I-Premise
the I-Premise
1 I-Premise
+ I-Premise
2.5 I-Premise
dosage I-Premise
or I-Premise
after I-Premise
ccHRT I-Premise
discontinuation I-Premise
. I-Premise

For B-Premise
6 I-Premise
months I-Premise
post-surgery I-Premise
younger I-Premise
patients I-Premise
reported I-Premise
less I-Premise
favourable I-Premise
QOL I-Premise
scores I-Premise
( I-Premise
p I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
and I-Premise
greater I-Premise
levels I-Premise
of I-Premise
anxiety I-Premise
( I-Premise
p I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
. I-Premise

Nineteen B-Premise
percent I-Premise
of I-Premise
patients I-Premise
treated I-Premise
with I-Premise
IFNalpha2a I-Premise
plus I-Premise
13-CRA I-Premise
were I-Premise
progression-free I-Premise
at I-Premise
24 I-Premise
months I-Premise
, I-Premise
compared I-Premise
with I-Premise
10 I-Premise
% I-Premise
of I-Premise
patients I-Premise
treated I-Premise
with I-Premise
IFNalpha2a I-Premise
alone I-Premise
( I-Premise
P I-Premise
=.05 I-Premise
) I-Premise
. I-Premise

A B-Premise
trend I-Premise
towards I-Premise
increased I-Premise
myelosuppression I-Premise
and I-Premise
infectious I-Premise
complications I-Premise
with I-Premise
TCF I-Premise
versus I-Premise
TC I-Premise
or I-Premise
ECF I-Premise
was I-Premise
observed I-Premise
. I-Premise

While B-Premise
under I-Premise
treatment I-Premise
, I-Premise
responders I-Premise
reported I-Premise
significantly I-Premise
better I-Premise
physical I-Premise
well-being I-Premise
( I-Premise
months I-Premise
3 I-Premise
to I-Premise
11 I-Premise
) I-Premise
, I-Premise
mood I-Premise
( I-Premise
months I-Premise
5 I-Premise
to I-Premise
11 I-Premise
) I-Premise
, I-Premise
coping I-Premise
( I-Premise
months I-Premise
5 I-Premise
to I-Premise
9 I-Premise
) I-Premise
, I-Premise
and I-Premise
appetite I-Premise
( I-Premise
months I-Premise
7 I-Premise
to I-Premise
11 I-Premise
) I-Premise
and I-Premise
less I-Premise
dizziness I-Premise
( I-Premise
month I-Premise
9 I-Premise
) I-Premise
than I-Premise
patients I-Premise
with I-Premise
SD I-Premise
( I-Premise
6m I-Premise
) I-Premise
. I-Premise

55.6 B-Premise
% I-Premise
patients I-Premise
treated I-Premise
over I-Premise
4 I-Premise
days I-Premise
and I-Premise
33.3 I-Premise
% I-Premise
of I-Premise
patients I-Premise
treated I-Premise
over I-Premise
11 I-Premise
days I-Premise
experienced I-Premise
acute I-Premise
grade I-Premise
≥ I-Premise
2 I-Premise
toxicity I-Premise
( I-Premise
p=0.085 I-Premise
) I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
statistically I-Premise
significant I-Premise
differences I-Premise
between I-Premise
the I-Premise
arms I-Premise
in I-Premise
the I-Premise
extent I-Premise
of I-Premise
severe I-Premise
mucositis I-Premise
as I-Premise
measured I-Premise
by I-Premise
physician I-Premise
, I-Premise
in I-Premise
oral I-Premise
toxicities I-Premise
as I-Premise
recorded I-Premise
by I-Premise
patients I-Premise
, I-Premise
or I-Premise
in I-Premise
radiotherapy I-Premise
delays I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
significant I-Premise
survival I-Premise
differences I-Premise
between I-Premise
the I-Premise
244 I-Premise
interferon-alfa-treated I-Premise
patients I-Premise
and I-Premise
248 I-Premise
noninterferon-alfa I-Premise
patients I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
, I-Premise
1.00 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.81-1.24 I-Premise
) I-Premise
or I-Premise
between I-Premise
the I-Premise
247 I-Premise
interleukin-2 I-Premise
and I-Premise
245 I-Premise
noninterleukin-2-treated I-Premise
patients I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
, I-Premise
1.07 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.87-1.33 I-Premise
";" I-Premise
log I-Premise
rank I-Premise
, I-Premise
0.99 I-Premise
and I-Premise
0.52 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

Fatigue B-Premise
was I-Premise
lower I-Premise
at I-Premise
1 I-Premise
year I-Premise
than I-Premise
before I-Premise
CTX I-Premise
";" I-Premise
no B-Premise
group I-Premise
effects I-Premise
were I-Premise
found I-Premise
. I-Premise

Upon B-Premise
the I-Premise
completion I-Premise
of I-Premise
PMP I-Premise
, I-Premise
pain I-Premise
scores I-Premise
were I-Premise
significantly I-Premise
reduced I-Premise
in I-Premise
both I-Premise
groups I-Premise
, I-Premise
yet B-Premise
patients I-Premise
in I-Premise
the I-Premise
experimental I-Premise
group I-Premise
showed I-Premise
a I-Premise
significant I-Premise
increase I-Premise
in I-Premise
the I-Premise
use I-Premise
of I-Premise
PRN I-Premise
analgesics I-Premise
and I-Premise
nonpharmacological I-Premise
strategies I-Premise
to I-Premise
relieve I-Premise
pain I-Premise
( I-Premise
P I-Premise
< I-Premise
.05 I-Premise
) I-Premise
and I-Premise
significantly I-Premise
reduce I-Premise
barriers I-Premise
to I-Premise
managing I-Premise
their I-Premise
cancer I-Premise
pain I-Premise
( I-Premise
P I-Premise
< I-Premise
.05 I-Premise
) I-Premise
compared I-Premise
with I-Premise
the I-Premise
control I-Premise
group I-Premise
. I-Premise

Time B-Premise
to I-Premise
final I-Premise
healing I-Premise
was I-Premise
significantly I-Premise
shorter I-Premise
and I-Premise
quality I-Premise
of I-Premise
life I-Premise
scores I-Premise
on I-Premise
the I-Premise
CWIS I-Premise
were I-Premise
higher I-Premise
in I-Premise
patients I-Premise
receiving I-Premise
RELP I-Premise
than I-Premise
in I-Premise
those I-Premise
receiving I-Premise
UM I-Premise
. I-Premise

Combination B-Premise
treatment I-Premise
in I-Premise
the I-Premise
GemCis I-Premise
arm I-Premise
was I-Premise
associated I-Premise
with I-Premise
a I-Premise
prolonged I-Premise
median I-Premise
progression-free I-Premise
survival I-Premise
( I-Premise
5.3 I-Premise
months I-Premise
v I-Premise
3.1 I-Premise
months I-Premise
";" I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
= I-Premise
0.75 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.053 I-Premise
) I-Premise
. I-Premise

The B-Premise
global I-Premise
QL I-Premise
scores I-Premise
were I-Premise
better I-Premise
for I-Premise
PVI I-Premise
5-FU I-Premise
+ I-Premise
MMC I-Premise
arm I-Premise
at I-Premise
24 I-Premise
weeks I-Premise
, I-Premise
but B-Premise
the I-Premise
remaining I-Premise
QL I-Premise
data I-Premise
showed I-Premise
no I-Premise
differences I-Premise
. I-Premise

The B-Premise
-1 I-Premise
and I-Premise
2-year I-Premise
survival I-Premise
rates I-Premise
were I-Premise
25 I-Premise
% I-Premise
and I-Premise
7 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
median B-Premise
time I-Premise
to I-Premise
progression I-Premise
was I-Premise
4.3 I-Premise
months I-Premise
( I-Premise
range I-Premise
, I-Premise
0.2-13.8 I-Premise
months I-Premise
) I-Premise
. I-Premise

Median B-Premise
time I-Premise
to I-Premise
HRQoL I-Premise
deterioration I-Premise
was I-Premise
longer I-Premise
in I-Premise
patients I-Premise
assigned I-Premise
to I-Premise
abiraterone I-Premise
plus I-Premise
prednisone I-Premise
than I-Premise
in I-Premise
those I-Premise
assigned I-Premise
to I-Premise
placebo I-Premise
plus I-Premise
prednisone I-Premise
as I-Premise
assessed I-Premise
by I-Premise
the I-Premise
FACT-P I-Premise
total I-Premise
score I-Premise
( I-Premise
12·7 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
11·1-14·0 I-Premise
] I-Premise
vs I-Premise
8·3 I-Premise
months I-Premise
[ I-Premise
7·4-10·6 I-Premise
] I-Premise
";" I-Premise
HR I-Premise
0·78 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0·66-0·92 I-Premise
";" I-Premise
p=0·003 I-Premise
) I-Premise
and I-Premise
by I-Premise
the I-Premise
score I-Premise
on I-Premise
its I-Premise
prostate-cancer-specific I-Premise
subscale I-Premise
( I-Premise
11·1 I-Premise
months I-Premise
[ I-Premise
8·6-13·8 I-Premise
] I-Premise
vs I-Premise
5·8 I-Premise
months I-Premise
[ I-Premise
5·5-8·3 I-Premise
] I-Premise
";" I-Premise
HR I-Premise
0·70 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0·60-0·83 I-Premise
";" I-Premise
p I-Premise
< I-Premise
0·0001 I-Premise
) I-Premise
. I-Premise

The B-Premise
FFM/FM I-Premise
ratio I-Premise
had I-Premise
significantly I-Premise
increased I-Premise
in I-Premise
the I-Premise
exemestane I-Premise
group I-Premise
, I-Premise
but I-Premise
not I-Premise
the I-Premise
tamoxifen I-Premise
group I-Premise
";" I-Premise
the B-Premise
between-group I-Premise
difference I-Premise
was I-Premise
statistically I-Premise
significant I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

Anemia B-Premise
was I-Premise
the I-Premise
most I-Premise
common I-Premise
hematological I-Premise
toxicity I-Premise
( I-Premise
88 I-Premise
% I-Premise
of I-Premise
patients I-Premise
) I-Premise
. I-Premise

Median B-Premise
survival I-Premise
time I-Premise
for I-Premise
all I-Premise
patients I-Premise
was I-Premise
15 I-Premise
months I-Premise
, I-Premise
with I-Premise
no I-Premise
difference I-Premise
in I-Premise
survival I-Premise
between I-Premise
the I-Premise
two I-Premise
treatment I-Premise
arms I-Premise
( I-Premise
P I-Premise
=.26 I-Premise
) I-Premise
. I-Premise

Operative B-Premise
time I-Premise
was I-Premise
53 I-Premise
minutes I-Premise
longer I-Premise
in I-Premise
the I-Premise
laparoscopic I-Premise
group I-Premise
( I-Premise
P I-Premise
< I-Premise
0.0001 I-Premise
) I-Premise
. I-Premise

Scores B-Premise
on I-Premise
a I-Premise
scale I-Premise
assessing I-Premise
daily I-Premise
functioning I-Premise
and I-Premise
enjoyment I-Premise
( I-Premise
Q-LES-Q I-Premise
) I-Premise
improved I-Premise
from I-Premise
year I-Premise
7 I-Premise
to I-Premise
year I-Premise
9 I-Premise
. I-Premise

A B-Premise
similar I-Premise
pattern I-Premise
was I-Premise
observed I-Premise
for I-Premise
knee I-Premise
extensor I-Premise
muscles I-Premise
( I-Premise
P I-Premise
=.02 I-Premise
) I-Premise
. I-Premise

Thus B-Premise
far I-Premise
, I-Premise
with I-Premise
a I-Premise
median I-Premise
follow-up I-Premise
of I-Premise
86 I-Premise
weeks I-Premise
, I-Premise
median I-Premise
survival I-Premise
has I-Premise
not I-Premise
been I-Premise
reached I-Premise
in I-Premise
either I-Premise
group I-Premise
. I-Premise

Progression-free B-Premise
survival I-Premise
rates I-Premise
were I-Premise
also I-Premise
similar I-Premise
in I-Premise
the I-Premise
two I-Premise
groups I-Premise
( I-Premise
HR I-Premise
= I-Premise
1.07 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
0.92 I-Premise
to I-Premise
1.24 I-Premise
) I-Premise
. I-Premise

CP B-Premise
resulted I-Premise
in I-Premise
more I-Premise
anastomotic I-Premise
leaks I-Premise
. I-Premise

Longer B-Premise
time I-Premise
to I-Premise
worsening I-Premise
was I-Premise
recorded I-Premise
for I-Premise
pain I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
0·76 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0·59-0·99 I-Premise
";" I-Premise
p=0·041 I-Premise
) I-Premise
and I-Premise
haemoptysis I-Premise
( I-Premise
HR I-Premise
0·58 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0·34-0·97 I-Premise
";" I-Premise
p=0·038 I-Premise
) I-Premise
with I-Premise
pemetrexed I-Premise
than I-Premise
with I-Premise
placebo I-Premise
";" I-Premise
no B-Premise
other I-Premise
significant I-Premise
differences I-Premise
in I-Premise
analyses I-Premise
of I-Premise
time I-Premise
to I-Premise
worsening I-Premise
were I-Premise
noted I-Premise
. I-Premise

Median B-Premise
survival I-Premise
in I-Premise
the I-Premise
C3 I-Premise
group I-Premise
was I-Premise
28 I-Premise
vs I-Premise
32 I-Premise
weeks I-Premise
in I-Premise
the I-Premise
C6 I-Premise
group I-Premise
( I-Premise
P=0.75 I-Premise
, I-Premise
HR I-Premise
1.04 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0.82-1.31 I-Premise
) I-Premise
. I-Premise

No B-Premise
myomectomy I-Premise
cases I-Premise
had I-Premise
further I-Premise
intervention I-Premise
. I-Premise

No B-Premise
differences I-Premise
were I-Premise
observed I-Premise
in I-Premise
global I-Premise
quality I-Premise
of I-Premise
life I-Premise
subdomain I-Premise
( I-Premise
P=0.40 I-Premise
) I-Premise
between I-Premise
the I-Premise
two I-Premise
regimen I-Premise
. I-Premise

In B-Premise
planned I-Premise
subgroup I-Premise
analyses I-Premise
, I-Premise
statistically I-Premise
significant I-Premise
or I-Premise
borderline I-Premise
significant I-Premise
interactions I-Premise
were I-Premise
identified I-Premise
for I-Premise
type I-Premise
of I-Premise
lymphoma I-Premise
( I-Premise
P I-Premise
( I-Premise
interaction I-Premise
) I-Premise
= I-Premise
0.006 I-Premise
) I-Premise
, I-Premise
current I-Premise
treatment I-Premise
status I-Premise
( I-Premise
P I-Premise
( I-Premise
interaction I-Premise
) I-Premise
= I-Premise
0.036 I-Premise
) I-Premise
, I-Premise
time I-Premise
since I-Premise
diagnosis I-Premise
( I-Premise
P I-Premise
( I-Premise
interaction I-Premise
) I-Premise
= I-Premise
0.010 I-Premise
) I-Premise
, I-Premise
body I-Premise
mass I-Premise
index I-Premise
( I-Premise
P I-Premise
( I-Premise
interaction I-Premise
) I-Premise
= I-Premise
0.075 I-Premise
) I-Premise
, I-Premise
and I-Premise
baseline I-Premise
sleep I-Premise
quality I-Premise
( I-Premise
P I-Premise
( I-Premise
interaction I-Premise
) I-Premise
= I-Premise
0.041 I-Premise
) I-Premise
. I-Premise

Hospital B-Premise
stay I-Premise
for I-Premise
patients I-Premise
who I-Premise
received I-Premise
EOF I-Premise
( I-Premise
n=71 I-Premise
) I-Premise
was I-Premise
4.7 I-Premise
vs. I-Premise
5.8 I-Premise
days I-Premise
for I-Premise
the I-Premise
TOF I-Premise
group I-Premise
( I-Premise
n=72 I-Premise
) I-Premise
( I-Premise
P=0.006 I-Premise
) I-Premise
. I-Premise

Trained B-Premise
versus I-Premise
control I-Premise
patients I-Premise
reported I-Premise
reduced I-Premise
barriers I-Premise
to I-Premise
pain I-Premise
relief I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
, I-Premise
lower I-Premise
usual I-Premise
pain I-Premise
( I-Premise
P=.03 I-Premise
) I-Premise
, I-Premise
and I-Premise
greater I-Premise
opioid I-Premise
use I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

Patients B-Premise
in I-Premise
the I-Premise
IG I-Premise
had I-Premise
significantly I-Premise
improved I-Premise
scores I-Premise
on I-Premise
the I-Premise
FACIT-Fatigue I-Premise
Scale I-Premise
at I-Premise
study I-Premise
completion I-Premise
, I-Premise
improved I-Premise
fatigue I-Premise
and I-Premise
pain I-Premise
scores I-Premise
, I-Premise
as I-Premise
well I-Premise
as I-Premise
overall I-Premise
physical I-Premise
functioning I-Premise
and I-Premise
mental I-Premise
health I-Premise
composite I-Premise
scores I-Premise
. I-Premise

Compared B-Premise
with I-Premise
the I-Premise
control I-Premise
group I-Premise
, I-Premise
the I-Premise
death I-Premise
number I-Premise
decreased I-Premise
, I-Premise
the I-Premise
survival I-Premise
rate I-Premise
increased I-Premise
, I-Premise
the I-Premise
life I-Premise
span I-Premise
of I-Premise
dead I-Premise
children I-Premise
was I-Premise
prolonged I-Premise
in I-Premise
the I-Premise
treatment I-Premise
group I-Premise
, I-Premise
showing I-Premise
statistical I-Premise
difference I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

Psychological B-Premise
quality I-Premise
of I-Premise
life I-Premise
also I-Premise
improved I-Premise
more I-Premise
in I-Premise
the I-Premise
intervention I-Premise
group I-Premise
, I-Premise
from I-Premise
49.6 I-Premise
to I-Premise
61.2 I-Premise
vs. I-Premise
50.1 I-Premise
to I-Premise
51.5 I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
[ I-Premise
F I-Premise
( I-Premise
( I-Premise
1,84 I-Premise
) I-Premise
) I-Premise
= I-Premise
10.9 I-Premise
, I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
] I-Premise
. I-Premise

Significantly B-Premise
more I-Premise
neutropenia I-Premise
was I-Premise
seen I-Premise
when I-Premise
Taxol I-Premise
was I-Premise
administered I-Premise
as I-Premise
a I-Premise
24-hour I-Premise
infusion I-Premise
. I-Premise

No B-Premise
unique I-Premise
safety I-Premise
observations I-Premise
were I-Premise
reported I-Premise
during I-Premise
open-label I-Premise
exposure I-Premise
. I-Premise

Regarding B-Premise
the I-Premise
postoperative I-Premise
complication I-Premise
, I-Premise
there I-Premise
were I-Premise
more I-Premise
cases I-Premise
of I-Premise
postoperative I-Premise
reflux I-Premise
oesophagitis I-Premise
and I-Premise
impairment I-Premise
of I-Premise
pulmonary I-Premise
function I-Premise
in I-Premise
the I-Premise
WS I-Premise
group I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

The B-Premise
experimental-to-PC I-Premise
hazard I-Premise
ratios I-Premise
of I-Premise
death I-Premise
were I-Premise
1.15 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.79 I-Premise
to I-Premise
1.67 I-Premise
) I-Premise
for I-Premise
VC I-Premise
, I-Premise
1.32 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.91 I-Premise
to I-Premise
1.92 I-Premise
) I-Premise
for I-Premise
GC I-Premise
, I-Premise
and I-Premise
1.26 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.86 I-Premise
to I-Premise
1.82 I-Premise
) I-Premise
for I-Premise
TC I-Premise
. I-Premise

The B-Premise
proportion I-Premise
of I-Premise
patients I-Premise
without I-Premise
progression I-Premise
at I-Premise
2 I-Premise
years I-Premise
was I-Premise
not I-Premise
statistically I-Premise
significantly I-Premise
different I-Premise
between I-Premise
the I-Premise
two I-Premise
treatment I-Premise
arms I-Premise
( I-Premise
40.0 I-Premise
% I-Premise
for I-Premise
PT I-Premise
versus I-Premise
37.5 I-Premise
% I-Premise
for I-Premise
TC I-Premise
, I-Premise
difference I-Premise
= I-Premise
2.5 I-Premise
% I-Premise
, I-Premise
one-sided I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
= I-Premise
- I-Premise
infinity I-Premise
to I-Premise
8.2 I-Premise
% I-Premise
) I-Premise
. I-Premise

Women B-Premise
with I-Premise
advanced I-Premise
breast I-Premise
cancer I-Premise
randomized I-Premise
to I-Premise
the I-Premise
seated I-Premise
exercise I-Premise
intervention I-Premise
had I-Premise
a I-Premise
slower I-Premise
decline I-Premise
in I-Premise
total I-Premise
and I-Premise
physical I-Premise
well-being I-Premise
and I-Premise
less I-Premise
increase I-Premise
in I-Premise
fatigue I-Premise
scores I-Premise
starting I-Premise
with I-Premise
the I-Premise
third I-Premise
cycle I-Premise
of I-Premise
chemotherapy I-Premise
. I-Premise

At B-Premise
enrollment I-Premise
, I-Premise
mood I-Premise
and I-Premise
emotional I-Premise
functioning I-Premise
were I-Premise
similar I-Premise
among I-Premise
all I-Premise
patients I-Premise
, I-Premise
with I-Premise
no I-Premise
differences I-Premise
by I-Premise
type I-Premise
of I-Premise
treatment I-Premise
received I-Premise
. I-Premise

For B-Premise
the I-Premise
Pemetrexed I-Premise
group I-Premise
, I-Premise
objective I-Premise
response I-Premise
rate I-Premise
( I-Premise
ORR I-Premise
) I-Premise
was I-Premise
13.0 I-Premise
% I-Premise
( I-Premise
3/23 I-Premise
) I-Premise
, I-Premise
disease I-Premise
control I-Premise
rate I-Premise
( I-Premise
DCR I-Premise
) I-Premise
was I-Premise
30.4 I-Premise
% I-Premise
( I-Premise
7/23 I-Premise
) I-Premise
, I-Premise
and I-Premise
median I-Premise
progression-free I-Premise
survival I-Premise
( I-Premise
mPFS I-Premise
) I-Premise
was I-Premise
3.1 I-Premise
months I-Premise
. I-Premise

Median B-Premise
overall I-Premise
survival I-Premise
times I-Premise
were I-Premise
8.3 I-Premise
, I-Premise
11.0 I-Premise
, I-Premise
and I-Premise
10.4 I-Premise
months I-Premise
for I-Premise
ECF I-Premise
, I-Premise
TC I-Premise
, I-Premise
and I-Premise
TCF I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Median B-Premise
time I-Premise
to I-Premise
progress I-Premise
for I-Premise
radiotherapy I-Premise
only I-Premise
and I-Premise
radiotherapy I-Premise
and I-Premise
estramustin I-Premise
group I-Premise
in I-Premise
grade I-Premise
III I-Premise
tumours I-Premise
was I-Premise
6.5 I-Premise
and I-Premise
10.1 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
. I-Premise

According B-Premise
to I-Premise
the I-Premise
Radiation I-Premise
Therapy I-Premise
Oncology I-Premise
Group I-Premise
scale I-Premise
, I-Premise
the I-Premise
Grade I-Premise
2 I-Premise
or I-Premise
greater I-Premise
rectal I-Premise
toxicity I-Premise
rate I-Premise
was I-Premise
14 I-Premise
% I-Premise
and I-Premise
19.5 I-Premise
% I-Premise
for I-Premise
the I-Premise
-70 I-Premise
and I-Premise
80-Gy I-Premise
arms I-Premise
( I-Premise
p I-Premise
= I-Premise
.22 I-Premise
) I-Premise
, I-Premise
respectively I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
differences I-Premise
in I-Premise
functional I-Premise
outcome I-Premise
, I-Premise
morbidity I-Premise
, I-Premise
or I-Premise
QOL I-Premise
between I-Premise
LRP I-Premise
and I-Premise
ORP I-Premise
. I-Premise

In B-Premise
the I-Premise
bevacizumab I-Premise
group I-Premise
, I-Premise
the I-Premise
levels I-Premise
of I-Premise
VEGF I-Premise
in I-Premise
the I-Premise
pleural I-Premise
fluid I-Premise
were I-Premise
significantly I-Premise
lower I-Premise
compared I-Premise
to I-Premise
those I-Premise
of I-Premise
the I-Premise
cisplatin I-Premise
group I-Premise
after I-Premise
treatment I-Premise
, I-Premise
which I-Premise
showed I-Premise
greater I-Premise
efficacy I-Premise
( I-Premise
p I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
. I-Premise

After B-Premise
intervention I-Premise
, I-Premise
EG I-Premise
participants I-Premise
showed I-Premise
improved I-Premise
QOL I-Premise
via I-Premise
decreased I-Premise
fear I-Premise
of I-Premise
recurrence I-Premise
and I-Premise
increased I-Premise
mindfulness I-Premise
attitude I-Premise
. I-Premise

Complete B-Premise
remission I-Premise
was I-Premise
achieved I-Premise
in I-Premise
91 I-Premise
% I-Premise
( I-Premise
170/186 I-Premise
) I-Premise
of I-Premise
all I-Premise
patients I-Premise
. I-Premise

Relative B-Premise
to I-Premise
women I-Premise
continuing I-Premise
tamoxifen I-Premise
, I-Premise
women I-Premise
switching I-Premise
to I-Premise
anastrozole I-Premise
experienced I-Premise
a I-Premise
decrease I-Premise
of I-Premise
53 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
41 I-Premise
% I-Premise
-63 I-Premise
% I-Premise
) I-Premise
in I-Premise
double I-Premise
endometrial I-Premise
thickness I-Premise
and I-Premise
a I-Premise
decrease I-Premise
of I-Premise
51 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
39 I-Premise
% I-Premise
-60 I-Premise
% I-Premise
) I-Premise
in I-Premise
uterine I-Premise
volume I-Premise
. I-Premise

Scores B-Premise
were I-Premise
stable I-Premise
over I-Premise
time I-Premise
and I-Premise
considerably I-Premise
lower I-Premise
than I-Premise
the I-Premise
general I-Premise
population I-Premise
norms I-Premise
. I-Premise

19 B-Premise
( I-Premise
34 I-Premise
% I-Premise
) I-Premise
patients I-Premise
in I-Premise
the I-Premise
open I-Premise
oesophagectomy I-Premise
group I-Premise
had I-Premise
pulmonary I-Premise
infection I-Premise
in-hospital I-Premise
compared I-Premise
with I-Premise
seven I-Premise
( I-Premise
12 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
minimally I-Premise
invasive I-Premise
group I-Premise
( I-Premise
0·35 I-Premise
, I-Premise
0·16-0·78 I-Premise
";" I-Premise
p=0·005 I-Premise
) I-Premise
. I-Premise

Thyroid B-Premise
ablation I-Premise
was I-Premise
complete I-Premise
in I-Premise
631 I-Premise
of I-Premise
the I-Premise
684 I-Premise
patients I-Premise
( I-Premise
92 I-Premise
% I-Premise
) I-Premise
. I-Premise

Dose B-Premise
reductions I-Premise
were I-Premise
required I-Premise
for I-Premise
10 I-Premise
% I-Premise
of I-Premise
patients I-Premise
with I-Premise
rash I-Premise
and I-Premise
4 I-Premise
% I-Premise
of I-Premise
patients I-Premise
with I-Premise
diarrhea I-Premise
. I-Premise

Patients B-Premise
who I-Premise
received I-Premise
the I-Premise
TOF I-Premise
scheme I-Premise
had I-Premise
significantly I-Premise
higher I-Premise
overall I-Premise
postoperative I-Premise
complications I-Premise
( I-Premise
39 I-Premise
vs. I-Premise
17 I-Premise
% I-Premise
in I-Premise
EOF I-Premise
group I-Premise
, I-Premise
P=0.003 I-Premise
) I-Premise
and I-Premise
infective I-Premise
complications I-Premise
( I-Premise
14 I-Premise
% I-Premise
in I-Premise
TOF I-Premise
group I-Premise
vs. I-Premise
3 I-Premise
% I-Premise
in I-Premise
EOF I-Premise
group I-Premise
, I-Premise
P=0.017 I-Premise
) I-Premise
. I-Premise

Compared B-Premise
with I-Premise
urinary I-Premise
markers I-Premise
in I-Premise
patients I-Premise
who I-Premise
received I-Premise
placebo I-Premise
, I-Premise
urinary I-Premise
markers I-Premise
of I-Premise
bone I-Premise
resorption I-Premise
were I-Premise
statistically I-Premise
significantly I-Premise
decreased I-Premise
in I-Premise
patients I-Premise
who I-Premise
received I-Premise
zoledronic I-Premise
acid I-Premise
at I-Premise
either I-Premise
dose I-Premise
( I-Premise
P I-Premise
=.001 I-Premise
) I-Premise
. I-Premise

The B-Premise
acceptance I-Premise
of I-Premise
K-tape I-Premise
was I-Premise
better I-Premise
than I-Premise
the I-Premise
bandage I-Premise
, I-Premise
and I-Premise
benefits I-Premise
included I-Premise
longer I-Premise
wearing I-Premise
time I-Premise
, I-Premise
less I-Premise
difficulty I-Premise
in I-Premise
usage I-Premise
, I-Premise
and I-Premise
increased I-Premise
comfort I-Premise
and I-Premise
convenience I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

Comparing B-Premise
the I-Premise
changes I-Premise
in I-Premise
low-frequency I-Premise
low-intensity I-Premise
electrotherapy I-Premise
with I-Premise
manual I-Premise
lymphatic I-Premise
drainage I-Premise
changes I-Premise
, I-Premise
there I-Premise
were I-Premise
no I-Premise
significant I-Premise
differences I-Premise
. I-Premise

Quality B-Premise
of I-Premise
life I-Premise
was I-Premise
maintained I-Premise
better I-Premise
in I-Premise
patients I-Premise
receiving I-Premise
three I-Premise
cycles I-Premise
";" I-Premise
no B-Premise
differences I-Premise
were I-Premise
detected I-Premise
between I-Premise
3 I-Premise
and I-Premise
5 I-Premise
days I-Premise
of I-Premise
treatment I-Premise
. I-Premise

The B-Premise
mean I-Premise
reduction I-Premise
in I-Premise
AK I-Premise
count I-Premise
was I-Premise
59.2 I-Premise
% I-Premise
for I-Premise
ALA-PDT I-Premise
and I-Premise
41.4 I-Premise
% I-Premise
for I-Premise
imiquimod I-Premise
5 I-Premise
% I-Premise
cream I-Premise
( I-Premise
p I-Premise
= I-Premise
.002 I-Premise
) I-Premise
. I-Premise

In B-Premise
multivariate I-Premise
analysis I-Premise
, I-Premise
baseline I-Premise
neutrophil I-Premise
( I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
, I-Premise
baseline I-Premise
platelet I-Premise
counts I-Premise
( I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
and I-Premise
the I-Premise
difference I-Premise
between I-Premise
white I-Premise
blood I-Premise
cell I-Premise
( I-Premise
WBC I-Premise
) I-Premise
and I-Premise
neutrophil I-Premise
count I-Premise
( I-Premise
P I-Premise
= I-Premise
0.009 I-Premise
) I-Premise
had I-Premise
a I-Premise
significant I-Premise
adverse I-Premise
prognostic I-Premise
value I-Premise
. I-Premise

Progression-free B-Premise
survival I-Premise
( I-Premise
PFS I-Premise
) I-Premise
was I-Premise
significantly I-Premise
longer I-Premise
for I-Premise
FU24h I-Premise
+ I-Premise
LV I-Premise
( I-Premise
median I-Premise
FU I-Premise
+ I-Premise
LV I-Premise
, I-Premise
4.0 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
3.4 I-Premise
to I-Premise
4.9 I-Premise
] I-Premise
";" I-Premise
FU24h I-Premise
, I-Premise
4.1 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
3.4 I-Premise
to I-Premise
5.0 I-Premise
] I-Premise
";" I-Premise
FU24h I-Premise
+ I-Premise
LV I-Premise
5.6 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
4.4 I-Premise
to I-Premise
6.7 I-Premise
] I-Premise
";" I-Premise
P I-Premise
=.029 I-Premise
) I-Premise
. I-Premise

Poor B-Premise
quality I-Premise
of I-Premise
life I-Premise
score I-Premise
between I-Premise
two I-Premise
groups I-Premise
was I-Premise
observed I-Premise
at I-Premise
1 I-Premise
month I-Premise
( I-Premise
23.9 I-Premise
% I-Premise
vs. I-Premise
13 I-Premise
% I-Premise
) I-Premise
and I-Premise
2 I-Premise
months I-Premise
( I-Premise
15.8 I-Premise
% I-Premise
vs. I-Premise
3.7 I-Premise
% I-Premise
) I-Premise
after I-Premise
chemotherapy I-Premise
. I-Premise

18 B-Premise
months I-Premise
post-surgery I-Premise
approximately I-Premise
twice I-Premise
as I-Premise
many I-Premise
patients I-Premise
in I-Premise
the I-Premise
standard I-Premise
group I-Premise
compared I-Premise
with I-Premise
the I-Premise
SNB I-Premise
group I-Premise
reported I-Premise
substantial I-Premise
arm I-Premise
swelling I-Premise
( I-Premise
14 I-Premise
% I-Premise
versus I-Premise
7 I-Premise
% I-Premise
) I-Premise
( I-Premise
p I-Premise
= I-Premise
0.002 I-Premise
) I-Premise
or I-Premise
numbness I-Premise
( I-Premise
19 I-Premise
% I-Premise
versus I-Premise
8.7 I-Premise
% I-Premise
) I-Premise
( I-Premise
p I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
. I-Premise

No B-Premise
evidence I-Premise
of I-Premise
a I-Premise
difference I-Premise
was I-Premise
observed I-Premise
between I-Premise
the I-Premise
two I-Premise
treatment I-Premise
groups I-Premise
in I-Premise
terms I-Premise
of I-Premise
activity I-Premise
level I-Premise
, I-Premise
anxiety I-Premise
, I-Premise
depression I-Premise
, I-Premise
and I-Premise
psychological I-Premise
distress I-Premise
, I-Premise
as I-Premise
recorded I-Premise
by I-Premise
the I-Premise
patients I-Premise
. I-Premise

In B-Premise
secondary I-Premise
outcomes I-Premise
, I-Premise
the I-Premise
intervention I-Premise
group I-Premise
experienced I-Premise
a I-Premise
significantly I-Premise
greater I-Premise
decrease I-Premise
in I-Premise
HADS I-Premise
anxiety I-Premise
score I-Premise
( I-Premise
-0.90 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
-1.51 I-Premise
to I-Premise
-0.29 I-Premise
) I-Premise
as I-Premise
well I-Premise
as I-Premise
global I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
5.22 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.93 I-Premise
to I-Premise
9.50 I-Premise
) I-Premise
and I-Premise
several I-Premise
functioning I-Premise
scores I-Premise
of I-Premise
the I-Premise
EORTC I-Premise
QLQ-C30 I-Premise
. I-Premise

Dyspnea B-Premise
, I-Premise
fatigue I-Premise
and I-Premise
coughing I-Premise
domains I-Premise
were I-Premise
worse I-Premise
in I-Premise
the I-Premise
11 I-Premise
day I-Premise
group I-Premise
at I-Premise
baseline I-Premise
. I-Premise

The B-Premise
operation I-Premise
time I-Premise
was I-Premise
significantly I-Premise
longer I-Premise
, I-Premise
and I-Premise
the I-Premise
leakage I-Premise
rate I-Premise
was I-Premise
higher I-Premise
in I-Premise
the I-Premise
transthoracic I-Premise
group I-Premise
( I-Premise
Student I-Premise
's I-Premise
t-test I-Premise
and I-Premise
Fischer I-Premise
's I-Premise
exact I-Premise
test I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

Response B-Premise
rates I-Premise
were I-Premise
34 I-Premise
% I-Premise
[ I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
( I-Premise
CI I-Premise
) I-Premise
20 I-Premise
% I-Premise
to I-Premise
51 I-Premise
% I-Premise
] I-Premise
in I-Premise
arm I-Premise
A I-Premise
and I-Premise
35 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
: I-Premise
20 I-Premise
% I-Premise
to I-Premise
53 I-Premise
% I-Premise
) I-Premise
in I-Premise
arm I-Premise
B I-Premise
. I-Premise

Marital B-Premise
status I-Premise
also I-Premise
moderated I-Premise
QoL I-Premise
response I-Premise
( I-Premise
P= I-Premise
.026 I-Premise
) I-Premise
, I-Premise
age I-Premise
moderated I-Premise
aerobic I-Premise
fitness I-Premise
response I-Premise
( I-Premise
P= I-Premise
.029 I-Premise
) I-Premise
, I-Premise
chemotherapy I-Premise
regimen I-Premise
moderated I-Premise
strength I-Premise
gain I-Premise
( I-Premise
P= I-Premise
.009 I-Premise
) I-Premise
, I-Premise
and I-Premise
disease I-Premise
stage I-Premise
moderated I-Premise
both I-Premise
lean I-Premise
body I-Premise
mass I-Premise
gain I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
and I-Premise
fat I-Premise
loss I-Premise
( I-Premise
P= I-Premise
.059 I-Premise
) I-Premise
. I-Premise

The B-Premise
TC I-Premise
regimen I-Premise
was I-Premise
associated I-Premise
with I-Premise
a I-Premise
higher I-Premise
frequency I-Premise
of I-Premise
hematologic I-Premise
toxicity I-Premise
, I-Premise
but B-Premise
a I-Premise
lower I-Premise
frequency I-Premise
of I-Premise
gastrointestinal I-Premise
and I-Premise
neurologic I-Premise
toxicity I-Premise
, I-Premise
than I-Premise
the I-Premise
PT I-Premise
regimen I-Premise
. I-Premise

Patients B-Premise
who I-Premise
had I-Premise
no I-Premise
preference I-Premise
had I-Premise
improved I-Premise
QoL I-Premise
when I-Premise
they I-Premise
were I-Premise
assigned I-Premise
to I-Premise
receive I-Premise
AET I-Premise
compared I-Premise
with I-Premise
RET I-Premise
( I-Premise
mean I-Premise
difference I-Premise
, I-Premise
23 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
4.9-41 I-Premise
";" I-Premise
P= I-Premise
.014 I-Premise
) I-Premise
. I-Premise

Physical B-Premise
performance I-Premise
of I-Premise
the I-Premise
training I-Premise
group I-Premise
improved I-Premise
significantly I-Premise
during I-Premise
the I-Premise
programme I-Premise
( I-Premise
9.4+/-20 I-Premise
watts I-Premise
, I-Premise
p=0.01 I-Premise
) I-Premise
but I-Premise
remained I-Premise
unchanged I-Premise
in I-Premise
the I-Premise
relaxation I-Premise
group I-Premise
( I-Premise
1.5+/-14.8 I-Premise
watts I-Premise
, I-Premise
p=0.37 I-Premise
) I-Premise
. I-Premise

Increased B-Premise
symptoms I-Premise
were I-Premise
reflected I-Premise
by I-Premise
the I-Premise
frequent I-Premise
use I-Premise
of I-Premise
incontinence I-Premise
materials I-Premise
after I-Premise
EBRT I-Premise
( I-Premise
day I-Premise
and I-Premise
night I-Premise
use I-Premise
, I-Premise
42.9 I-Premise
% I-Premise
v I-Premise
15.2 I-Premise
% I-Premise
for I-Premise
NAT I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

There B-Premise
was I-Premise
a I-Premise
significant I-Premise
improvement I-Premise
in I-Premise
overall I-Premise
quality I-Premise
of I-Premise
life I-Premise
between I-Premise
the I-Premise
two I-Premise
treatment I-Premise
arms I-Premise
in I-Premise
favor I-Premise
of I-Premise
the I-Premise
r-HuEPO-treated I-Premise
group I-Premise
. I-Premise

Median B-Premise
length I-Premise
of I-Premise
stay I-Premise
was I-Premise
4 I-Premise
( I-Premise
range I-Premise
2-35 I-Premise
, I-Premise
interquartile I-Premise
range I-Premise
3-5 I-Premise
) I-Premise
days I-Premise
. I-Premise

Pairwise B-Premise
comparisons I-Premise
revealed I-Premise
significant I-Premise
differences I-Premise
between I-Premise
groups I-Premise
at I-Premise
90 I-Premise
days I-Premise
( I-Premise
P I-Premise
= I-Premise
.002 I-Premise
) I-Premise
but B-Premise
not I-Premise
at I-Premise
1 I-Premise
year I-Premise
( I-Premise
P I-Premise
= I-Premise
.052 I-Premise
) I-Premise
. I-Premise

Postoperative B-Premise
morbidity I-Premise
rate I-Premise
was I-Premise
28.9 I-Premise
percent I-Premise
in I-Premise
the I-Premise
laparoscopic I-Premise
vs. I-Premise
40 I-Premise
percent I-Premise
in I-Premise
the I-Premise
open I-Premise
group I-Premise
( I-Premise
P I-Premise
= I-Premise
0.18 I-Premise
) I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
opportunistic I-Premise
infections I-Premise
. I-Premise

Liposomal B-Premise
tretinoin I-Premise
is I-Premise
a I-Premise
new I-Premise
therapeutic I-Premise
agent I-Premise
that I-Premise
has I-Premise
been I-Premise
reported I-Premise
to I-Premise
have I-Premise
some I-Premise
clinical I-Premise
activity I-Premise
in I-Premise
patients I-Premise
with I-Premise
AIDS-associated I-Premise
Kaposi I-Premise
sarcoma I-Premise
. I-Premise

Gefitinib B-Premise
did I-Premise
not I-Premise
show I-Premise
better I-Premise
OS I-Premise
compared I-Premise
with I-Premise
GP I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
, I-Premise
0.932 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.716 I-Premise
to I-Premise
1.213 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.604 I-Premise
";" I-Premise
median I-Premise
OS I-Premise
, I-Premise
22.3 I-Premise
v I-Premise
22.9 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

The B-Premise
quality I-Premise
of I-Premise
life I-Premise
improved I-Premise
in I-Premise
control I-Premise
group I-Premise
by I-Premise
13.7 I-Premise
% I-Premise
, I-Premise
while I-Premise
combined I-Premise
treatment I-Premise
group I-Premise
showed I-Premise
improvement I-Premise
of I-Premise
83.5 I-Premise
% I-Premise
( I-Premise
p I-Premise
< I-Premise
0.05 I-Premise
vs. I-Premise
control I-Premise
group I-Premise
) I-Premise
. I-Premise

A B-Premise
mean I-Premise
of I-Premise
10.6 I-Premise
units I-Premise
of I-Premise
PRBCs I-Premise
over I-Premise
5 I-Premise
months I-Premise
were I-Premise
administered I-Premise
to I-Premise
those I-Premise
who I-Premise
received I-Premise
epoetin I-Premise
alpha I-Premise
compared I-Premise
with I-Premise
13 I-Premise
units I-Premise
for I-Premise
those I-Premise
who I-Premise
did I-Premise
not I-Premise
receive I-Premise
epoetin I-Premise
( I-Premise
P I-Premise
= I-Premise
.04 I-Premise
) I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
in I-Premise
grade I-Premise
III/IV I-Premise
adverse I-Premise
events I-Premise
between I-Premise
the I-Premise
two I-Premise
groups I-Premise
. I-Premise

Seventeen B-Premise
of I-Premise
25 I-Premise
HBO-treated I-Premise
patients I-Premise
( I-Premise
68 I-Premise
% I-Premise
) I-Premise
improved I-Premise
versus I-Premise
8 I-Premise
of I-Premise
21 I-Premise
controls I-Premise
( I-Premise
38.1 I-Premise
% I-Premise
";" I-Premise
P I-Premise
= I-Premise
.043 I-Premise
, I-Premise
χ I-Premise
( I-Premise
2 I-Premise
) I-Premise
test I-Premise
) I-Premise
. I-Premise

There B-Premise
were I-Premise
also I-Premise
no I-Premise
differences I-Premise
in I-Premise
the I-Premise
frequency I-Premise
of I-Premise
incompletely I-Premise
infarcted I-Premise
leiomyomas I-Premise
, I-Premise
degree I-Premise
of I-Premise
improvement I-Premise
in I-Premise
symptom I-Premise
score I-Premise
, I-Premise
patient I-Premise
satisfaction I-Premise
, I-Premise
or I-Premise
QOL I-Premise
. I-Premise

Exemestane B-Premise
patients I-Premise
reported I-Premise
more I-Premise
bone/muscle I-Premise
aches I-Premise
( I-Premise
P I-Premise
< I-Premise
.0001 I-Premise
) I-Premise
, I-Premise
vaginal I-Premise
dryness I-Premise
( I-Premise
P I-Premise
= I-Premise
.0004 I-Premise
) I-Premise
, I-Premise
and I-Premise
difficulty I-Premise
sleeping I-Premise
( I-Premise
P I-Premise
= I-Premise
.03 I-Premise
) I-Premise
. I-Premise

Based B-Premise
on I-Premise
serum I-Premise
rhTSH-stimulated I-Premise
Tg I-Premise
alone I-Premise
( I-Premise
Tg I-Premise
< I-Premise
0.8 I-Premise
microg/l I-Premise
, I-Premise
BRAHMS I-Premise
Tg I-Premise
Kryptor I-Premise
) I-Premise
, I-Premise
no I-Premise
difference I-Premise
in I-Premise
ablation I-Premise
success I-Premise
was I-Premise
observed I-Premise
between I-Premise
rhTSH I-Premise
and I-Premise
hypothyroidism I-Premise
groups I-Premise
, I-Premise
91.7 I-Premise
% I-Premise
and I-Premise
97.1 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
. I-Premise

The B-Premise
hazard I-Premise
ratios I-Premise
for I-Premise
progression-free I-Premise
survival I-Premise
( I-Premise
PFS I-Premise
) I-Premise
were I-Premise
1.36 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.97 I-Premise
to I-Premise
1.90 I-Premise
) I-Premise
for I-Premise
VC I-Premise
, I-Premise
1.39 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.99 I-Premise
to I-Premise
1.96 I-Premise
) I-Premise
for I-Premise
GC I-Premise
, I-Premise
and I-Premise
1.27 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.90 I-Premise
to I-Premise
1.78 I-Premise
) I-Premise
for I-Premise
TC I-Premise
. I-Premise

Seventy-eight B-Premise
percent I-Premise
of I-Premise
patients I-Premise
expressed I-Premise
satisfaction I-Premise
with I-Premise
their I-Premise
treatment I-Premise
whatever I-Premise
their I-Premise
location I-Premise
, I-Premise
whereas I-Premise
57 I-Premise
% I-Premise
of I-Premise
patients I-Premise
preferred I-Premise
future I-Premise
treatment I-Premise
to I-Premise
continue I-Premise
at I-Premise
the I-Premise
hospital I-Premise
, I-Premise
81 I-Premise
% I-Premise
at I-Premise
GP I-Premise
surgeries I-Premise
and I-Premise
90 I-Premise
% I-Premise
at I-Premise
home I-Premise
. I-Premise

Without B-Premise
ADT I-Premise
testosterone I-Premise
remained I-Premise
at I-Premise
castrate I-Premise
level I-Premise
for I-Premise
4 I-Premise
months I-Premise
. I-Premise

Dermatology B-Premise
Life I-Premise
Quality I-Premise
Index I-Premise
( I-Premise
DLQI I-Premise
) I-Premise
scores I-Premise
were I-Premise
assessed I-Premise
for I-Premise
each I-Premise
treatment I-Premise
modality I-Premise
at I-Premise
week I-Premise
4 I-Premise
and I-Premise
were I-Premise
1.95 I-Premise
and I-Premise
1.38 I-Premise
, I-Premise
respectively I-Premise
( I-Premise
p I-Premise
= I-Premise
.20 I-Premise
) I-Premise
. I-Premise

For B-Premise
TMZ-5 I-Premise
versus I-Premise
TMZ-21 I-Premise
, I-Premise
12-week I-Premise
PFS I-Premise
rates I-Premise
were I-Premise
similar I-Premise
( I-Premise
63.6 I-Premise
% I-Premise
and I-Premise
65.7 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
P I-Premise
= I-Premise
.745 I-Premise
) I-Premise
, I-Premise
but B-Premise
TMZ-5 I-Premise
improved I-Premise
overall I-Premise
PFS I-Premise
( I-Premise
HR I-Premise
, I-Premise
1.38 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
1.05 I-Premise
to I-Premise
1.82 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.023 I-Premise
) I-Premise
, I-Premise
survival I-Premise
( I-Premise
HR I-Premise
, I-Premise
1.32 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.99 I-Premise
to I-Premise
1.75 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.056 I-Premise
) I-Premise
, I-Premise
and I-Premise
global I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
49 I-Premise
% I-Premise
v I-Premise
19 I-Premise
% I-Premise
improved I-Premise
> I-Premise
10 I-Premise
points I-Premise
at I-Premise
6 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
P I-Premise
= I-Premise
.005 I-Premise
) I-Premise
. I-Premise

Grades B-Premise
3/4 I-Premise
toxicities I-Premise
occurred I-Premise
infrequently I-Premise
in I-Premise
both I-Premise
arms I-Premise
. I-Premise

The B-Premise
incidence I-Premise
of I-Premise
severe I-Premise
ARSR I-Premise
( I-Premise
RTOG/EORTC I-Premise
grade I-Premise
≤2 I-Premise
) I-Premise
at I-Premise
the I-Premise
follow-up I-Premise
visit I-Premise
was I-Premise
23 I-Premise
% I-Premise
( I-Premise
n I-Premise
= I-Premise
45 I-Premise
) I-Premise
in I-Premise
the I-Premise
Calendula I-Premise
group I-Premise
and I-Premise
19 I-Premise
% I-Premise
( I-Premise
n I-Premise
= I-Premise
38 I-Premise
) I-Premise
in I-Premise
the I-Premise
Essex I-Premise
group I-Premise
. I-Premise

Fatigue B-Premise
and I-Premise
global I-Premise
health I-Premise
scores I-Premise
improved I-Premise
in I-Premise
both I-Premise
groups I-Premise
during I-Premise
the I-Premise
intervention I-Premise
( I-Premise
fatigue I-Premise
: I-Premise
training I-Premise
group I-Premise
21 I-Premise
% I-Premise
, I-Premise
relaxation I-Premise
group I-Premise
19 I-Premise
% I-Premise
";" I-Premise
global I-Premise
health I-Premise
of I-Premise
both I-Premise
groups I-Premise
19 I-Premise
% I-Premise
, I-Premise
p I-Premise
for I-Premise
all I-Premise
< I-Premise
or I-Premise
=0.01 I-Premise
) I-Premise
";" I-Premise
however B-Premise
, I-Premise
there I-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
between I-Premise
changes I-Premise
in I-Premise
the I-Premise
scores I-Premise
of I-Premise
both I-Premise
groups I-Premise
( I-Premise
p=0.67 I-Premise
) I-Premise
. I-Premise

The B-Premise
daytime I-Premise
group I-Premise
showed I-Premise
a I-Premise
significant I-Premise
effect I-Premise
on I-Premise
general I-Premise
health I-Premise
, I-Premise
vitality I-Premise
, I-Premise
social I-Premise
functioning I-Premise
, I-Premise
mental I-Premise
health I-Premise
, I-Premise
and I-Premise
role I-Premise
emotional I-Premise
as I-Premise
revealed I-Premise
on I-Premise
the I-Premise
SF-8 I-Premise
. I-Premise

Manual B-Premise
lymphatic I-Premise
drainage I-Premise
showed I-Premise
no I-Premise
significant I-Premise
changes I-Premise
in I-Premise
any I-Premise
of I-Premise
the I-Premise
outcomes I-Premise
. I-Premise

That B-Premise
is I-Premise
, I-Premise
by I-Premise
specifically I-Premise
lowering I-Premise
intervention I-Premise
patients I-Premise
' I-Premise
distress I-Premise
at I-Premise
4 I-Premise
months I-Premise
, I-Premise
their I-Premise
health I-Premise
was I-Premise
improved I-Premise
at I-Premise
12 I-Premise
months I-Premise
( I-Premise
p I-Premise
< I-Premise
.05 I-Premise
) I-Premise
. I-Premise

We B-Premise
found I-Premise
no I-Premise
difference I-Premise
in I-Premise
follow-up I-Premise
costs I-Premise
. I-Premise

This B-Premise
difference I-Premise
was I-Premise
not I-Premise
statistically I-Premise
significant I-Premise
( I-Premise
log-rank I-Premise
test I-Premise
, I-Premise
p=0.818 I-Premise
) I-Premise
. I-Premise

The B-Premise
surviving I-Premise
fraction I-Premise
was I-Premise
significantly I-Premise
higher I-Premise
in I-Premise
the I-Premise
vaccine I-Premise
group I-Premise
based I-Premise
on I-Premise
Kaplan-Meier I-Premise
analysis I-Premise
. I-Premise

At B-Premise
radiotherapy I-Premise
completion I-Premise
, I-Premise
energy I-Premise
intake I-Premise
increased I-Premise
in I-Premise
G1/G2 I-Premise
( I-Premise
P I-Premise
< I-Premise
or I-Premise
= I-Premise
.04 I-Premise
) I-Premise
, I-Premise
G1 I-Premise
more I-Premise
than I-Premise
G2 I-Premise
( I-Premise
P I-Premise
= I-Premise
.001 I-Premise
) I-Premise
, I-Premise
and I-Premise
decreased I-Premise
in I-Premise
G3 I-Premise
( I-Premise
P I-Premise
< I-Premise
.01 I-Premise
) I-Premise
. I-Premise

The B-Premise
sample I-Premise
size I-Premise
was I-Premise
small I-Premise
, I-Premise
and I-Premise
patients I-Premise
applied I-Premise
a I-Premise
small I-Premise
amount I-Premise
of I-Premise
imiquimod I-Premise
5 I-Premise
% I-Premise
cream I-Premise
( I-Premise
half I-Premise
a I-Premise
sachet I-Premise
) I-Premise
to I-Premise
a I-Premise
large I-Premise
surface I-Premise
area I-Premise
. I-Premise

Treatment B-Premise
effects I-Premise
favored I-Premise
castration I-Premise
for I-Premise
both I-Premise
endpoints I-Premise
( I-Premise
P I-Premise
< I-Premise
or I-Premise
= I-Premise
0.002 I-Premise
) I-Premise
, I-Premise
with I-Premise
hazard I-Premise
ratios I-Premise
( I-Premise
bicalutamide I-Premise
: I-Premise
castration I-Premise
) I-Premise
of I-Premise
1.54 I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
, I-Premise
1.18 I-Premise
to I-Premise
2.00 I-Premise
) I-Premise
for I-Premise
time I-Premise
to I-Premise
treatment I-Premise
failure I-Premise
and I-Premise
1.6 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
1.19 I-Premise
to I-Premise
2.15 I-Premise
) I-Premise
for I-Premise
time I-Premise
to I-Premise
disease I-Premise
progression I-Premise
. I-Premise

Eighteen B-Premise
months I-Premise
after I-Premise
surgery I-Premise
, I-Premise
any I-Premise
differences I-Premise
in I-Premise
quality I-Premise
of I-Premise
life I-Premise
between I-Premise
patients I-Premise
randomized I-Premise
to I-Premise
LAC I-Premise
or I-Premise
open I-Premise
colectomy I-Premise
favored I-Premise
LAC I-Premise
. I-Premise

The B-Premise
mean I-Premise
hematocrit I-Premise
increased I-Premise
by I-Premise
6.0 I-Premise
percentage I-Premise
points I-Premise
in I-Premise
the I-Premise
r-HuEPO I-Premise
group I-Premise
versus I-Premise
1.3 I-Premise
in I-Premise
the I-Premise
placebo I-Premise
group I-Premise
. I-Premise

At B-Premise
week I-Premise
12 I-Premise
, I-Premise
changes I-Premise
in I-Premise
TPV I-Premise
for I-Premise
degarelix I-Premise
and I-Premise
goserelin I-Premise
were I-Premise
similar I-Premise
( I-Premise
-37.2 I-Premise
% I-Premise
vs I-Premise
-39.0 I-Premise
% I-Premise
) I-Premise
and I-Premise
met I-Premise
the I-Premise
predefined I-Premise
non-inferiority I-Premise
criterion I-Premise
. I-Premise

Improvement B-Premise
was I-Premise
noted I-Premise
in I-Premise
physical I-Premise
capacity I-Premise
: I-Premise
estimated I-Premise
mean I-Premise
difference I-Premise
between I-Premise
groups I-Premise
for I-Premise
maximum I-Premise
oxygen I-Premise
consumption I-Premise
was I-Premise
0.16 I-Premise
l/min I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0.1 I-Premise
to I-Premise
0.2 I-Premise
, I-Premise
P I-Premise
< I-Premise
0.0001 I-Premise
) I-Premise
and I-Premise
for I-Premise
muscular I-Premise
strength I-Premise
( I-Premise
leg I-Premise
press I-Premise
) I-Premise
was I-Premise
29.7 I-Premise
kg I-Premise
( I-Premise
23.4 I-Premise
to I-Premise
34.9 I-Premise
, I-Premise
P I-Premise
< I-Premise
0.0001 I-Premise
) I-Premise
. I-Premise

Immediate B-Premise
lung I-Premise
expansion I-Premise
did I-Premise
not I-Premise
correlate I-Premise
with I-Premise
radiologic I-Premise
recurrence I-Premise
, I-Premise
clinical I-Premise
recurrence I-Premise
, I-Premise
or I-Premise
complications I-Premise
( I-Premise
p I-Premise
= I-Premise
0.60 I-Premise
, I-Premise
0.15 I-Premise
, I-Premise
and I-Premise
0.20 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

Patients B-Premise
receiving I-Premise
FLOT I-Premise
exhibited I-Premise
higher I-Premise
response I-Premise
rates I-Premise
and I-Premise
had I-Premise
improved I-Premise
disease-free I-Premise
and I-Premise
progression-free I-Premise
survival I-Premise
( I-Premise
PFS I-Premise
) I-Premise
. I-Premise

After B-Premise
4 I-Premise
weeks I-Premise
of I-Premise
NHT I-Premise
, I-Premise
negative I-Premise
changes I-Premise
of I-Premise
FACT-B I-Premise
and I-Premise
FACT-G I-Premise
scores I-Premise
were I-Premise
found I-Premise
in I-Premise
group I-Premise
B I-Premise
and I-Premise
C I-Premise
patients I-Premise
, I-Premise
but B-Premise
there I-Premise
were I-Premise
positive I-Premise
changes I-Premise
in I-Premise
group I-Premise
A I-Premise
patients I-Premise
. I-Premise

The B-Premise
median I-Premise
survival I-Premise
reached I-Premise
8 I-Premise
months I-Premise
in I-Premise
Study I-Premise
A I-Premise
and I-Premise
9 I-Premise
months I-Premise
in I-Premise
Study I-Premise
B I-Premise
. I-Premise

The B-Premise
global I-Premise
HRQOL I-Premise
scale I-Premise
was I-Premise
comparable I-Premise
at I-Premise
baseline I-Premise
on I-Premise
both I-Premise
treatment I-Premise
arms I-Premise
( I-Premise
P I-Premise
= I-Premise
.848 I-Premise
) I-Premise
";" I-Premise
at B-Premise
no I-Premise
point I-Premise
was I-Premise
any I-Premise
significant I-Premise
difference I-Premise
apparent I-Premise
on I-Premise
this I-Premise
end I-Premise
point I-Premise
. I-Premise

A B-Premise
positive I-Premise
longitudinal I-Premise
impact I-Premise
of I-Premise
the I-Premise
intervention I-Premise
on I-Premise
symptom I-Premise
discussion I-Premise
was I-Premise
observed I-Premise
, I-Premise
but B-Premise
not I-Premise
for I-Premise
function I-Premise
discussion I-Premise
, I-Premise
suggesting I-Premise
that I-Premise
potentially I-Premise
serious I-Premise
problems I-Premise
may I-Premise
remain I-Premise
unaddressed I-Premise
. I-Premise

Resorption B-Premise
markers I-Premise
did I-Premise
not I-Premise
decrease I-Premise
after I-Premise
placebo I-Premise
, I-Premise
but B-Premise
NTx I-Premise
and I-Premise
Crosslaps I-Premise
both I-Premise
decreased I-Premise
by I-Premise
70 I-Premise
% I-Premise
after I-Premise
pamidronate I-Premise
( I-Premise
P I-Premise
= I-Premise
0.001 I-Premise
) I-Premise
. I-Premise

Sentinel B-Premise
nodes I-Premise
were I-Premise
found I-Premise
in I-Premise
95 I-Premise
% I-Premise
of I-Premise
the I-Premise
SNBM I-Premise
group I-Premise
( I-Premise
29 I-Premise
% I-Premise
positive I-Premise
) I-Premise
and I-Premise
93 I-Premise
% I-Premise
of I-Premise
the I-Premise
RAC I-Premise
group I-Premise
( I-Premise
25 I-Premise
% I-Premise
positive I-Premise
) I-Premise
. I-Premise

These B-Premise
differences I-Premise
were I-Premise
not I-Premise
significant I-Premise
. I-Premise

Compared B-Premise
to I-Premise
EUC I-Premise
, I-Premise
TEC I-Premise
was I-Premise
associated I-Premise
with I-Premise
increased I-Premise
pain I-Premise
communication I-Premise
self-efficacy I-Premise
after I-Premise
the I-Premise
intervention I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
";" I-Premise
both B-Premise
groups I-Premise
showed I-Premise
significant I-Premise
( I-Premise
P I-Premise
< I-Premise
.0001 I-Premise
) I-Premise
, I-Premise
similar I-Premise
, I-Premise
reductions I-Premise
in I-Premise
pain I-Premise
misconceptions I-Premise
. I-Premise

Patient B-Premise
diaries I-Premise
demonstrated I-Premise
lower I-Premise
swallowing I-Premise
dysfunction I-Premise
AUC I-Premise
with I-Premise
amifostine I-Premise
( I-Premise
z I-Premise
test I-Premise
P I-Premise
= I-Premise
.025 I-Premise
) I-Premise
. I-Premise

Compared B-Premise
with I-Premise
the I-Premise
control I-Premise
group I-Premise
of I-Premise
the I-Premise
same I-Premise
period I-Premise
, I-Premise
the I-Premise
2-and I-Premise
3-year I-Premise
somatic I-Premise
functions I-Premise
, I-Premise
psychological I-Premise
functions I-Premise
, I-Premise
and I-Premise
the I-Premise
general I-Premise
symptoms I-Premise
scores I-Premise
decreased I-Premise
in I-Premise
the I-Premise
treatment I-Premise
group I-Premise
";" I-Premise
the B-Premise
2-year I-Premise
somatic I-Premise
functions I-Premise
and I-Premise
psychological I-Premise
functions I-Premise
decreased I-Premise
in I-Premise
the I-Premise
treatment I-Premise
group I-Premise
";" I-Premise
the B-Premise
3-year I-Premise
psychological I-Premise
functions I-Premise
and I-Premise
the I-Premise
general I-Premise
symptoms I-Premise
scores I-Premise
decreased I-Premise
in I-Premise
the I-Premise
treatment I-Premise
group I-Premise
, I-Premise
all I-Premise
with I-Premise
statistical I-Premise
difference I-Premise
( I-Premise
all I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

Although B-Premise
there I-Premise
was I-Premise
a I-Premise
tendency I-Premise
for I-Premise
improved I-Premise
survival I-Premise
in I-Premise
grade I-Premise
III I-Premise
, I-Premise
no I-Premise
statistical I-Premise
significant I-Premise
differences I-Premise
were I-Premise
found I-Premise
between I-Premise
the I-Premise
treatment I-Premise
groups I-Premise
. I-Premise

Overall B-Premise
rate I-Premise
of I-Premise
adverse I-Premise
events I-Premise
( I-Premise
AEs I-Premise
) I-Premise
was I-Premise
comparable I-Premise
between I-Premise
the I-Premise
ASA404 I-Premise
and I-Premise
placebo I-Premise
arms I-Premise
. I-Premise

Comparing B-Premise
survival I-Premise
for I-Premise
the I-Premise
two I-Premise
dose I-Premise
levels I-Premise
of I-Premise
paclitaxel I-Premise
revealed I-Premise
no I-Premise
significant I-Premise
difference I-Premise
. I-Premise

As B-Premise
hypothesized I-Premise
, I-Premise
Bcl-2 I-Premise
levels I-Premise
decreased I-Premise
with I-Premise
CRA/IFN I-Premise
therapy I-Premise
only I-Premise
in I-Premise
Arm I-Premise
B I-Premise
( I-Premise
p I-Premise
= I-Premise
0.03 I-Premise
) I-Premise
. I-Premise

The B-Premise
pectoral I-Premise
stretching I-Premise
program I-Premise
did I-Premise
not I-Premise
influence I-Premise
the I-Premise
outcomes I-Premise
measured I-Premise
because I-Premise
the I-Premise
symptoms I-Premise
reported I-Premise
by I-Premise
patients I-Premise
were I-Premise
not I-Premise
a I-Premise
consequence I-Premise
of I-Premise
contracture I-Premise
. I-Premise

Median B-Premise
survival I-Premise
was I-Premise
16.6 I-Premise
months I-Premise
for I-Premise
the I-Premise
FU/LV/bevacizumab I-Premise
group I-Premise
and I-Premise
12.9 I-Premise
months I-Premise
for I-Premise
the I-Premise
FU/LV/placebo I-Premise
group I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
, I-Premise
0.79 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.16 I-Premise
) I-Premise
. I-Premise

Significant B-Premise
effects I-Premise
were I-Premise
seen I-Premise
on I-Premise
vitality I-Premise
( I-Premise
effect I-Premise
size I-Premise
0.55 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0.27 I-Premise
to I-Premise
0.82 I-Premise
) I-Premise
, I-Premise
physical I-Premise
functioning I-Premise
( I-Premise
0.37 I-Premise
, I-Premise
0.09 I-Premise
to I-Premise
0.65 I-Premise
) I-Premise
, I-Premise
role I-Premise
physical I-Premise
( I-Premise
0.37 I-Premise
, I-Premise
0.10 I-Premise
to I-Premise
0.64 I-Premise
) I-Premise
, I-Premise
role I-Premise
emotional I-Premise
( I-Premise
0.32 I-Premise
, I-Premise
0.05 I-Premise
to I-Premise
0.59 I-Premise
) I-Premise
, I-Premise
and I-Premise
mental I-Premise
health I-Premise
( I-Premise
0.28 I-Premise
, I-Premise
0.02 I-Premise
to I-Premise
0.56 I-Premise
) I-Premise
scores I-Premise
. I-Premise

The B-Premise
median I-Premise
survival I-Premise
duration I-Premise
for I-Premise
the I-Premise
stage I-Premise
IIIB I-Premise
subgroup I-Premise
was I-Premise
7.9 I-Premise
months I-Premise
for I-Premise
etoposide I-Premise
plus I-Premise
cisplatin I-Premise
patients I-Premise
versus I-Premise
13.1 I-Premise
months I-Premise
for I-Premise
all I-Premise
paclitaxel I-Premise
patients I-Premise
( I-Premise
P I-Premise
=.152 I-Premise
) I-Premise
. I-Premise

The B-Premise
5-year I-Premise
biochemical I-Premise
+/- I-Premise
clinical I-Premise
relapse-free I-Premise
and I-Premise
overall I-Premise
survival I-Premise
was I-Premise
55.9 I-Premise
% I-Premise
and I-Premise
85.3 I-Premise
% I-Premise
respectively I-Premise
for I-Premise
all I-Premise
patients I-Premise
, I-Premise
and I-Premise
did I-Premise
not I-Premise
differ I-Premise
between I-Premise
the I-Premise
two I-Premise
schedules I-Premise
. I-Premise

A B-Premise
model I-Premise
measuring I-Premise
effectiveness I-Premise
of I-Premise
CCSP I-Premise
on I-Premise
QOL I-Premise
( I-Premise
total I-Premise
and I-Premise
subscale I-Premise
) I-Premise
at I-Premise
1-year I-Premise
follow-up I-Premise
showed I-Premise
that I-Premise
the I-Premise
CCSP I-Premise
group I-Premise
( I-Premise
n I-Premise
= I-Premise
38 I-Premise
) I-Premise
had I-Premise
significant I-Premise
improvement I-Premise
in I-Premise
overall I-Premise
QOL I-Premise
( I-Premise
p I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
, I-Premise
health I-Premise
and I-Premise
functioning I-Premise
( I-Premise
p I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
, I-Premise
and I-Premise
socioeconomic I-Premise
( I-Premise
p I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
and I-Premise
psychological/spiritual I-Premise
well-being I-Premise
( I-Premise
p I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
compared I-Premise
with I-Premise
the I-Premise
control I-Premise
group I-Premise
( I-Premise
n I-Premise
= I-Premise
35 I-Premise
) I-Premise
. I-Premise

Rash B-Premise
( I-Premise
75 I-Premise
% I-Premise
versus I-Premise
17 I-Premise
% I-Premise
) I-Premise
and I-Premise
diarrhea I-Premise
( I-Premise
54 I-Premise
% I-Premise
versus I-Premise
18 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
erlotnib I-Premise
and I-Premise
placebo I-Premise
group I-Premise
respectively I-Premise
were I-Premise
the I-Premise
most I-Premise
common I-Premise
adverse I-Premise
events I-Premise
. I-Premise

For B-Premise
the I-Premise
chemoradiation I-Premise
group I-Premise
, I-Premise
the I-Premise
mean I-Premise
QALM-24 I-Premise
was I-Premise
7.1 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
: I-Premise
6.0 I-Premise
, I-Premise
9.0 I-Premise
) I-Premise
months I-Premise
compared I-Premise
with I-Premise
the I-Premise
mean I-Premise
QALM-24 I-Premise
of I-Premise
8.1 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
: I-Premise
7.0 I-Premise
, I-Premise
10.0 I-Premise
) I-Premise
months I-Premise
for I-Premise
the I-Premise
no I-Premise
chemoradiation I-Premise
group I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
significant I-Premise
intervention I-Premise
by I-Premise
subgroup I-Premise
interactions I-Premise
( I-Premise
P I-Premise
> I-Premise
.10 I-Premise
) I-Premise
. I-Premise

No B-Premise
differences I-Premise
were I-Premise
observed I-Premise
in I-Premise
toxicity I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
in I-Premise
the I-Premise
mean I-Premise
area I-Premise
under I-Premise
the I-Premise
mucositis I-Premise
curve I-Premise
( I-Premise
13.2 I-Premise
vs I-Premise
16.6 I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.1 I-Premise
) I-Premise
. I-Premise

Toxicity B-Premise
was I-Premise
found I-Premise
to I-Premise
be I-Premise
relatively I-Premise
negligible I-Premise
in I-Premise
both I-Premise
groups I-Premise
. I-Premise

The B-Premise
median I-Premise
overall I-Premise
survival I-Premise
( I-Premise
OS I-Premise
) I-Premise
was I-Premise
34.1 I-Premise
and I-Premise
30.7 I-Premise
months I-Premise
in I-Premise
Arms I-Premise
A I-Premise
and I-Premise
B I-Premise
, I-Premise
respectively I-Premise
( I-Premise
HR I-Premise
0.98 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0.81-1.18 I-Premise
, I-Premise
P I-Premise
= I-Premise
0.82 I-Premise
) I-Premise
. I-Premise

Clinically B-Premise
relevant I-Premise
improvements I-Premise
in I-Premise
symptoms I-Premise
and I-Premise
mood I-Premise
disturbance I-Premise
were I-Premise
seen I-Premise
for I-Premise
both I-Premise
groups I-Premise
over I-Premise
the I-Premise
study I-Premise
period I-Premise
. I-Premise

The B-Premise
saving I-Premise
in I-Premise
the I-Premise
laparoscopic I-Premise
group I-Premise
was I-Premise
$ I-Premise
1,396 I-Premise
per I-Premise
patient I-Premise
randomized I-Premise
( I-Premise
$ I-Premise
647 I-Premise
the I-Premise
result I-Premise
of I-Premise
shorter I-Premise
length I-Premise
of I-Premise
hospital I-Premise
stay I-Premise
and I-Premise
$ I-Premise
749 I-Premise
the I-Premise
result I-Premise
of I-Premise
the I-Premise
lower I-Premise
cost I-Premise
of I-Premise
postoperative I-Premise
complications I-Premise
) I-Premise
. I-Premise

QOL B-Premise
improved I-Premise
in I-Premise
the I-Premise
study I-Premise
group I-Premise
. I-Premise

Although B-Premise
there I-Premise
are I-Premise
no I-Premise
differences I-Premise
in I-Premise
overall I-Premise
quality I-Premise
of I-Premise
life I-Premise
scores I-Premise
between I-Premise
the I-Premise
patients I-Premise
treated I-Premise
with I-Premise
and I-Premise
without I-Premise
radiotherapy I-Premise
, I-Premise
there I-Premise
are I-Premise
several I-Premise
dimensions I-Premise
that I-Premise
exhibit I-Premise
significant I-Premise
advantage I-Premise
to I-Premise
the I-Premise
omission I-Premise
of I-Premise
irradiation I-Premise
. I-Premise

The B-Premise
KPS I-Premise
score I-Premise
in I-Premise
the I-Premise
treated I-Premise
group I-Premise
after I-Premise
treatment I-Premise
was I-Premise
improved I-Premise
in I-Premise
13 I-Premise
patients I-Premise
( I-Premise
23.6 I-Premise
% I-Premise
) I-Premise
, I-Premise
stabilized I-Premise
in I-Premise
27 I-Premise
( I-Premise
49.6 I-Premise
% I-Premise
) I-Premise
and I-Premise
declined I-Premise
in I-Premise
15 I-Premise
( I-Premise
27.3 I-Premise
% I-Premise
) I-Premise
, I-Premise
while I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
, I-Premise
it I-Premise
was I-Premise
improved I-Premise
in I-Premise
7 I-Premise
( I-Premise
13.2 I-Premise
% I-Premise
) I-Premise
, I-Premise
stabilized I-Premise
in I-Premise
21 I-Premise
( I-Premise
39.6 I-Premise
% I-Premise
) I-Premise
and I-Premise
declined I-Premise
in I-Premise
25 I-Premise
( I-Premise
47.2 I-Premise
% I-Premise
) I-Premise
, I-Premise
the I-Premise
difference I-Premise
between I-Premise
the I-Premise
two I-Premise
groups I-Premise
was I-Premise
significant I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

Small B-Premise
( I-Premise
< I-Premise
0.2 I-Premise
standard I-Premise
deviations I-Premise
) I-Premise
but I-Premise
statistically I-Premise
significant I-Premise
differences I-Premise
in I-Premise
mean I-Premise
change I-Premise
scores I-Premise
from I-Premise
baseline I-Premise
were I-Premise
seen I-Premise
for I-Premise
the I-Premise
SF-36 I-Premise
domains I-Premise
of I-Premise
physical I-Premise
functioning I-Premise
( I-Premise
12 I-Premise
months I-Premise
) I-Premise
, I-Premise
bodily I-Premise
pain I-Premise
( I-Premise
6 I-Premise
months I-Premise
) I-Premise
and I-Premise
vitality I-Premise
( I-Premise
6 I-Premise
and I-Premise
12 I-Premise
months I-Premise
) I-Premise
, I-Premise
and I-Premise
the I-Premise
MENQOL I-Premise
vasomotor I-Premise
( I-Premise
6 I-Premise
, I-Premise
12 I-Premise
, I-Premise
and I-Premise
24 I-Premise
months I-Premise
) I-Premise
and I-Premise
sexual I-Premise
domains I-Premise
( I-Premise
12 I-Premise
and I-Premise
24 I-Premise
months I-Premise
) I-Premise
. I-Premise

Following B-Premise
discontinuation I-Premise
of I-Premise
ccHRT I-Premise
, I-Premise
patient I-Premise
satisfaction I-Premise
was I-Premise
variable I-Premise
, I-Premise
with I-Premise
15 I-Premise
% I-Premise
electing I-Premise
to I-Premise
continue I-Premise
or I-Premise
restart I-Premise
HRT I-Premise
and I-Premise
7 I-Premise
% I-Premise
resuming I-Premise
at I-Premise
follow-up I-Premise
. I-Premise

When B-Premise
stent I-Premise
obstruction I-Premise
was I-Premise
not I-Premise
regarded I-Premise
as I-Premise
a I-Premise
major I-Premise
complication I-Premise
, I-Premise
no I-Premise
differences I-Premise
in I-Premise
complications I-Premise
were I-Premise
found I-Premise
( I-Premise
P I-Premise
= I-Premise
.4 I-Premise
) I-Premise
. I-Premise

Ancillary B-Premise
" I-Premise
on-treatment I-Premise
" I-Premise
analyzes I-Premise
showed I-Premise
that I-Premise
participants I-Premise
who I-Premise
recalled I-Premise
an I-Premise
exercise I-Premise
recommendation I-Premise
reported I-Premise
significantly I-Premise
more I-Premise
total I-Premise
exercise I-Premise
than I-Premise
participants I-Premise
who I-Premise
did I-Premise
not I-Premise
recall I-Premise
an I-Premise
exercise I-Premise
recommendation I-Premise
( I-Premise
mean I-Premise
difference I-Premise
, I-Premise
4.1 I-Premise
MET I-Premise
hr I-Premise
per I-Premise
week I-Premise
: I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
1.9-6.4 I-Premise
MET I-Premise
hr I-Premise
per I-Premise
week I-Premise
";" I-Premise
p I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

They B-Premise
deteriorated I-Premise
during I-Premise
follow-up I-Premise
in I-Premise
women I-Premise
not I-Premise
continuing I-Premise
ccHRT I-Premise
. I-Premise

Other B-Premise
analyzed I-Premise
QOL I-Premise
parameters I-Premise
favored I-Premise
the I-Premise
group I-Premise
receiving I-Premise
placebo I-Premise
but B-Premise
were I-Premise
not I-Premise
statistically I-Premise
significant I-Premise
after I-Premise
adjustment I-Premise
for I-Premise
multiple I-Premise
testing I-Premise
. I-Premise

The B-Premise
use I-Premise
of I-Premise
prophylactic I-Premise
tamsulosin I-Premise
resulted I-Premise
in I-Premise
a I-Premise
statistically I-Premise
lower I-Premise
dysuria I-Premise
severity I-Premise
score I-Premise
( I-Premise
difference I-Premise
of I-Premise
2.7 I-Premise
vs I-Premise
4.2 I-Premise
, I-Premise
P I-Premise
< I-Premise
0.005 I-Premise
) I-Premise
at I-Premise
1 I-Premise
month I-Premise
, I-Premise
with I-Premise
no I-Premise
discernible I-Premise
differences I-Premise
at I-Premise
3 I-Premise
, I-Premise
6 I-Premise
, I-Premise
12 I-Premise
and I-Premise
18 I-Premise
months I-Premise
. I-Premise

The B-Premise
response I-Premise
rate I-Premise
in I-Premise
the I-Premise
5-FU+low-dose I-Premise
CDDP I-Premise
arm I-Premise
( I-Premise
n=75 I-Premise
) I-Premise
was I-Premise
significantly I-Premise
higher I-Premise
than I-Premise
that I-Premise
in I-Premise
the I-Premise
5-FU I-Premise
arm I-Premise
( I-Premise
n=77 I-Premise
) I-Premise
( I-Premise
25.3 I-Premise
% I-Premise
vs. I-Premise
11.7 I-Premise
% I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.037 I-Premise
) I-Premise
. I-Premise

Compared B-Premise
with I-Premise
baseline I-Premise
, I-Premise
the I-Premise
QoL I-Premise
improved I-Premise
in I-Premise
both I-Premise
groups I-Premise
but I-Premise
to I-Premise
different I-Premise
degrees I-Premise
. I-Premise

Overall B-Premise
response I-Premise
rate I-Premise
was I-Premise
higher I-Premise
with I-Premise
DCF I-Premise
( I-Premise
chi2 I-Premise
P I-Premise
= I-Premise
.01 I-Premise
) I-Premise
. I-Premise

Climacteric B-Premise
symptoms I-Premise
remained I-Premise
significantly I-Premise
below I-Premise
baseline I-Premise
values I-Premise
after I-Premise
dosage I-Premise
reduction I-Premise
";" I-Premise
some B-Premise
symptoms I-Premise
recurred I-Premise
after I-Premise
discontinuation I-Premise
of I-Premise
ccHRT I-Premise
. I-Premise

Elbow B-Premise
flexor I-Premise
muscle I-Premise
strength I-Premise
declined I-Premise
by I-Premise
-5.5 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
-9.6 I-Premise
% I-Premise
to I-Premise
-1 I-Premise
. I-Premise
4 I-Premise
% I-Premise
) I-Premise
per I-Premise
4 I-Premise
weeks I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
but I-Premise
remained I-Premise
stable I-Premise
( I-Premise
0.0 I-Premise
% I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI= I-Premise
-1.4 I-Premise
% I-Premise
to I-Premise
+1.4 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
ATP I-Premise
group I-Premise
( I-Premise
P I-Premise
=.01 I-Premise
) I-Premise
. I-Premise

The B-Premise
relative I-Premise
risks I-Premise
of I-Premise
any I-Premise
lymphedema I-Premise
and I-Premise
sensory I-Premise
loss I-Premise
for I-Premise
the I-Premise
sentinel I-Premise
lymph I-Premise
node I-Premise
biopsy I-Premise
group I-Premise
compared I-Premise
with I-Premise
the I-Premise
standard I-Premise
axillary I-Premise
treatment I-Premise
group I-Premise
at I-Premise
12 I-Premise
months I-Premise
were I-Premise
0.37 I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
= I-Premise
0.23 I-Premise
to I-Premise
0.60 I-Premise
";" I-Premise
absolute I-Premise
rates I-Premise
: I-Premise
5 I-Premise
% I-Premise
versus I-Premise
13 I-Premise
% I-Premise
) I-Premise
and I-Premise
0.37 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
0.27 I-Premise
to I-Premise
0.50 I-Premise
";" I-Premise
absolute I-Premise
rates I-Premise
: I-Premise
11 I-Premise
% I-Premise
versus I-Premise
31 I-Premise
% I-Premise
) I-Premise
, I-Premise
respectively I-Premise
. I-Premise

A B-Premise
statistically I-Premise
significant I-Premise
improvement I-Premise
in I-Premise
general I-Premise
health I-Premise
score I-Premise
in I-Premise
both I-Premise
homeopathy I-Premise
groups I-Premise
( I-Premise
p I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
on I-Premise
the I-Premise
SF-36 I-Premise
after I-Premise
1 I-Premise
year I-Premise
was I-Premise
found I-Premise
. I-Premise

Therapy B-Premise
with I-Premise
combined I-Premise
bevacizumab I-Premise
plus I-Premise
cisplatin I-Premise
significantly I-Premise
reduced I-Premise
VEGF I-Premise
levels I-Premise
in I-Premise
the I-Premise
pleural I-Premise
fluid I-Premise
( I-Premise
p I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
. I-Premise

The B-Premise
overall I-Premise
response I-Premise
rate I-Premise
was I-Premise
34.6 I-Premise
% I-Premise
for I-Premise
NP I-Premise
and I-Premise
35.7 I-Premise
% I-Premise
for I-Premise
NIP I-Premise
. I-Premise

Tamoxifen B-Premise
reduced I-Premise
the I-Premise
occurrence I-Premise
of I-Premise
estrogen I-Premise
receptor-positive I-Premise
tumors I-Premise
by I-Premise
69 I-Premise
% I-Premise
, I-Premise
but I-Premise
no I-Premise
difference I-Premise
in I-Premise
the I-Premise
occurrence I-Premise
of I-Premise
estrogen I-Premise
receptor-negative I-Premise
tumors I-Premise
was I-Premise
seen I-Premise
. I-Premise

We B-Premise
recorded I-Premise
the I-Premise
following I-Premise
pair-wise I-Premise
mean I-Premise
difference I-Premise
in I-Premise
change I-Premise
in I-Premise
IBDQ-B I-Premise
score I-Premise
between I-Premise
groups I-Premise
: I-Premise
nurse I-Premise
versus I-Premise
booklet I-Premise
4·12 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0·04-8·19 I-Premise
";" I-Premise
p=0·04 I-Premise
) I-Premise
, I-Premise
gastroenterologist I-Premise
versus I-Premise
booklet I-Premise
5·47 I-Premise
( I-Premise
1·14-9·81 I-Premise
";" I-Premise
p=0·01 I-Premise
) I-Premise
. I-Premise

At B-Premise
1 I-Premise
and I-Premise
4 I-Premise
months I-Premise
, I-Premise
more I-Premise
patients I-Premise
in I-Premise
the I-Premise
4 I-Premise
day I-Premise
group I-Premise
experienced I-Premise
a I-Premise
clinically I-Premise
meaningful I-Premise
worsening I-Premise
in I-Premise
the I-Premise
dyspnea I-Premise
QOL I-Premise
domain I-Premise
compared I-Premise
to I-Premise
the I-Premise
11 I-Premise
day I-Premise
group I-Premise
( I-Premise
44.5 I-Premise
% I-Premise
vs I-Premise
15.4 I-Premise
% I-Premise
, I-Premise
p=0.02 I-Premise
";" I-Premise
38.5 I-Premise
% I-Premise
vs I-Premise
12.0 I-Premise
% I-Premise
, I-Premise
p=0.03 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

We B-Premise
observed I-Premise
a I-Premise
significant I-Premise
reduction I-Premise
in I-Premise
anxiety I-Premise
( I-Premise
STAI I-Premise
, I-Premise
POMS I-Premise
) I-Premise
among I-Premise
group I-Premise
participants I-Premise
, I-Premise
a I-Premise
reduction I-Premise
in I-Premise
anger I-Premise
, I-Premise
depression I-Premise
and I-Premise
fatigue I-Premise
( I-Premise
POMS I-Premise
) I-Premise
, I-Premise
a I-Premise
significant I-Premise
improvement I-Premise
in I-Premise
vigor I-Premise
and I-Premise
interpersonal I-Premise
relationships I-Premise
( I-Premise
POMS I-Premise
) I-Premise
, I-Premise
in I-Premise
emotional I-Premise
and I-Premise
role I-Premise
functioning I-Premise
, I-Premise
in I-Premise
health I-Premise
status I-Premise
and I-Premise
fatigue I-Premise
level I-Premise
( I-Premise
EORTC I-Premise
QLQ-C30 I-Premise
) I-Premise
. I-Premise

More B-Premise
thrombocytopenia I-Premise
occurred I-Premise
with I-Premise
GCa I-Premise
( I-Premise
P I-Premise
= I-Premise
.03 I-Premise
) I-Premise
, I-Premise
but B-Premise
this I-Premise
was I-Premise
not I-Premise
associated I-Premise
with I-Premise
increased I-Premise
hospital I-Premise
admission I-Premise
or I-Premise
fatality I-Premise
. I-Premise

No B-Premise
adverse I-Premise
effects I-Premise
were I-Premise
noted I-Premise
. I-Premise

Within B-Premise
the I-Premise
randomised I-Premise
controlled I-Premise
trial I-Premise
, I-Premise
the I-Premise
Barthel I-Premise
Index I-Premise
demonstrated I-Premise
a I-Premise
small I-Premise
but I-Premise
significant I-Premise
fall I-Premise
in I-Premise
functionality I-Premise
with I-Premise
radiotherapy I-Premise
compared I-Premise
with I-Premise
the I-Premise
no I-Premise
radiotherapy I-Premise
arm I-Premise
of I-Premise
the I-Premise
trial I-Premise
. I-Premise

These B-Premise
changes I-Premise
were I-Premise
similar I-Premise
in I-Premise
both I-Premise
groups I-Premise
, I-Premise
indicating I-Premise
that I-Premise
acupuncture I-Premise
was I-Premise
as I-Premise
effective I-Premise
as I-Premise
venlafaxine I-Premise
. I-Premise

Grade B-Premise
4 I-Premise
neutropenia I-Premise
( I-Premise
27 I-Premise
% I-Premise
v I-Premise
19 I-Premise
% I-Premise
) I-Premise
and I-Premise
infusion I-Premise
site I-Premise
pain I-Premise
( I-Premise
10 I-Premise
% I-Premise
v I-Premise
0.5 I-Premise
% I-Premise
) I-Premise
were I-Premise
reported I-Premise
more I-Premise
frequently I-Premise
in I-Premise
the I-Premise
ASA404 I-Premise
arm I-Premise
. I-Premise

Among B-Premise
responding I-Premise
patients I-Premise
, I-Premise
mean I-Premise
scores I-Premise
generally I-Premise
improved I-Premise
from I-Premise
time I-Premise
of I-Premise
response I-Premise
to I-Premise
end-of-treatment I-Premise
assessment I-Premise
, I-Premise
substantially I-Premise
driven I-Premise
by I-Premise
patients I-Premise
achieving I-Premise
complete I-Premise
response I-Premise
( I-Premise
CR I-Premise
) I-Premise
. I-Premise

There B-Premise
is I-Premise
a I-Premise
further I-Premise
significant I-Premise
reduction I-Premise
in I-Premise
both I-Premise
uterine I-Premise
volume I-Premise
and I-Premise
dominant I-Premise
fibroid I-Premise
diameter I-Premise
between I-Premise
6 I-Premise
months I-Premise
and I-Premise
5 I-Premise
years I-Premise
after I-Premise
UAE I-Premise
. I-Premise

The B-Premise
score I-Premise
on I-Premise
the I-Premise
quality I-Premise
of I-Premise
life I-Premise
of I-Premise
transhiatal I-Premise
patients I-Premise
was I-Premise
significantly I-Premise
higher I-Premise
than I-Premise
that I-Premise
of I-Premise
transthoracic I-Premise
patients I-Premise
in I-Premise
the I-Premise
third I-Premise
, I-Premise
sixth I-Premise
and I-Premise
twelfth I-Premise
month I-Premise
. I-Premise

Good B-Premise
quality I-Premise
of I-Premise
life I-Premise
score I-Premise
was I-Premise
observed I-Premise
at I-Premise
1 I-Premise
month I-Premise
( I-Premise
19.5 I-Premise
% I-Premise
vs. I-Premise
49 I-Premise
% I-Premise
) I-Premise
and I-Premise
2 I-Premise
months I-Premise
( I-Premise
47 I-Premise
% I-Premise
vs. I-Premise
72 I-Premise
% I-Premise
) I-Premise
, I-Premise
respectively I-Premise
( I-Premise
P I-Premise
< I-Premise
.05 I-Premise
) I-Premise
. I-Premise

The B-Premise
average I-Premise
costs I-Premise
of I-Premise
the I-Premise
primary I-Premise
treatment I-Premise
were I-Premise
higher I-Premise
in I-Premise
GM-CSF-treated I-Premise
patients I-Premise
than I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
, I-Premise
i.e I-Premise
. I-Premise
US I-Premise
$ I-Premise
40782 I-Premise
and I-Premise
US I-Premise
$ I-Premise
34465 I-Premise
, I-Premise
respectively I-Premise
( I-Premise
P I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
. I-Premise

The B-Premise
median I-Premise
OS I-Premise
was I-Premise
24 I-Premise
months I-Premise
for I-Premise
the I-Premise
HDCT I-Premise
arm I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
21 I-Premise
to I-Premise
35 I-Premise
months I-Premise
) I-Premise
and I-Premise
28 I-Premise
months I-Premise
for I-Premise
ST I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
22 I-Premise
to I-Premise
33 I-Premise
months I-Premise
";" I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
, I-Premise
0.9 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.6 I-Premise
to I-Premise
1.2 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.43 I-Premise
) I-Premise
. I-Premise

Adjusted B-Premise
linear I-Premise
mixed-model I-Premise
analyses I-Premise
showed I-Premise
that I-Premise
, I-Premise
at I-Premise
6-month I-Premise
follow-up I-Premise
, I-Premise
the I-Premise
RET I-Premise
group I-Premise
reported I-Premise
higher I-Premise
self-esteem I-Premise
[ I-Premise
adjusted I-Premise
mean I-Premise
difference I-Premise
, I-Premise
1.6 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
) I-Premise
, I-Premise
0.1-3.2 I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.032 I-Premise
] I-Premise
and I-Premise
the I-Premise
AET I-Premise
group I-Premise
reported I-Premise
lower I-Premise
anxiety I-Premise
( I-Premise
adjusted I-Premise
mean I-Premise
difference I-Premise
, I-Premise
-4.7 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
-0.0 I-Premise
to I-Premise
-9.3 I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.049 I-Premise
) I-Premise
compared I-Premise
with I-Premise
the I-Premise
usual I-Premise
care I-Premise
group I-Premise
. I-Premise

The B-Premise
median I-Premise
survival I-Premise
of I-Premise
all I-Premise
406 I-Premise
eligible I-Premise
patients I-Premise
was I-Premise
346 I-Premise
days I-Premise
with I-Premise
15 I-Premise
% I-Premise
of I-Premise
the I-Premise
patients I-Premise
alive I-Premise
at I-Premise
two I-Premise
years I-Premise
. I-Premise

The B-Premise
main I-Premise
cost I-Premise
drivers I-Premise
distinguishing I-Premise
epoetin-alfa I-Premise
from I-Premise
placebo I-Premise
were I-Premise
the I-Premise
costs I-Premise
of I-Premise
drug I-Premise
and I-Premise
patient I-Premise
care I-Premise
due I-Premise
to I-Premise
increased I-Premise
survival I-Premise
. I-Premise

Compliance B-Premise
with I-Premise
QOL I-Premise
was I-Premise
87 I-Premise
% I-Premise
at I-Premise
baseline I-Premise
and I-Premise
more I-Premise
than I-Premise
70 I-Premise
% I-Premise
during I-Premise
treatment I-Premise
. I-Premise

During B-Premise
treatment I-Premise
, I-Premise
quality I-Premise
of I-Premise
life I-Premise
declined I-Premise
significantly I-Premise
more I-Premise
with I-Premise
the I-Premise
16-week I-Premise
regimen I-Premise
than I-Premise
CAF I-Premise
, I-Premise
but B-Premise
by I-Premise
4 I-Premise
months I-Premise
posttreatment I-Premise
, I-Premise
there I-Premise
was I-Premise
no I-Premise
difference I-Premise
. I-Premise

Adjusted B-Premise
for I-Premise
baseline I-Premise
score I-Premise
, I-Premise
disease I-Premise
, I-Premise
and I-Premise
demographic I-Premise
covariates I-Premise
, I-Premise
the I-Premise
intervention I-Premise
group I-Premise
showed I-Premise
an I-Premise
estimated I-Premise
improvement I-Premise
at I-Premise
six I-Premise
weeks I-Premise
for I-Premise
the I-Premise
primary I-Premise
outcome I-Premise
, I-Premise
fatigue I-Premise
, I-Premise
of I-Premise
-6.6 I-Premise
points I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
-12.3 I-Premise
to I-Premise
-0.9 I-Premise
, I-Premise
P=0.02 I-Premise
";" I-Premise
effect I-Premise
size=0.33 I-Premise
, I-Premise
0.04 I-Premise
to I-Premise
0.61 I-Premise
) I-Premise
. I-Premise

In B-Premise
planned I-Premise
subgroup I-Premise
analyses I-Premise
, I-Premise
a I-Premise
significant I-Premise
interaction I-Premise
was I-Premise
noted I-Premise
( I-Premise
P I-Premise
= I-Premise
.01 I-Premise
) I-Premise
: I-Premise
limited-stage I-Premise
vandetanib I-Premise
patients I-Premise
had I-Premise
longer I-Premise
overall I-Premise
survival I-Premise
( I-Premise
HR I-Premise
, I-Premise
0.45 I-Premise
";" I-Premise
one-sided I-Premise
P I-Premise
= I-Premise
.07 I-Premise
) I-Premise
and I-Premise
extensive-stage I-Premise
vandetanib I-Premise
patients I-Premise
shorter I-Premise
survival I-Premise
compared I-Premise
with I-Premise
placebo I-Premise
( I-Premise
HR I-Premise
, I-Premise
2.27 I-Premise
";" I-Premise
one-sided I-Premise
P I-Premise
= I-Premise
.996 I-Premise
) I-Premise
. I-Premise

At B-Premise
T3 I-Premise
, I-Premise
no I-Premise
significant I-Premise
difference I-Premise
on I-Premise
fatigue I-Premise
was I-Premise
found I-Premise
between I-Premise
CBT I-Premise
and I-Premise
usual I-Premise
care I-Premise
. I-Premise

Grade B-Premise
4 I-Premise
neutropenia I-Premise
and I-Premise
thrombocytopenia I-Premise
occurred I-Premise
in I-Premise
50 I-Premise
% I-Premise
and I-Premise
3 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
, I-Premise
of I-Premise
PE I-Premise
patients I-Premise
in I-Premise
step I-Premise
1 I-Premise
and I-Premise
60 I-Premise
% I-Premise
and I-Premise
13 I-Premise
% I-Premise
of I-Premise
topotecan I-Premise
patients I-Premise
in I-Premise
step I-Premise
2 I-Premise
. I-Premise

The B-Premise
75 I-Premise
% I-Premise
AK I-Premise
clearance I-Premise
rate I-Premise
was I-Premise
34.6 I-Premise
% I-Premise
for I-Premise
ALA-PDT I-Premise
and I-Premise
25 I-Premise
% I-Premise
for I-Premise
imiquimod I-Premise
5 I-Premise
% I-Premise
cream I-Premise
( I-Premise
p I-Premise
= I-Premise
.30 I-Premise
) I-Premise
. I-Premise

In B-Premise
both I-Premise
the I-Premise
patients I-Premise
' I-Premise
subjective I-Premise
assessment I-Premise
of I-Premise
their I-Premise
QL I-Premise
and I-Premise
the I-Premise
physicians I-Premise
' I-Premise
perception I-Premise
of I-Premise
the I-Premise
patients I-Premise
' I-Premise
QL I-Premise
, I-Premise
the I-Premise
largest I-Premise
adverse I-Premise
QL I-Premise
effects I-Premise
of I-Premise
Ax I-Premise
were I-Premise
observed I-Premise
from I-Premise
baseline I-Premise
to I-Premise
the I-Premise
first I-Premise
postoperative I-Premise
assessment I-Premise
, I-Premise
but B-Premise
the I-Premise
differences I-Premise
tended I-Premise
to I-Premise
disappear I-Premise
in I-Premise
6 I-Premise
to I-Premise
12 I-Premise
months I-Premise
. I-Premise

Among B-Premise
the I-Premise
17 I-Premise
participants I-Premise
with I-Premise
depressive I-Premise
symptoms I-Premise
at I-Premise
baseline I-Premise
, I-Premise
both I-Premise
the I-Premise
Onward I-Premise
and I-Premise
the I-Premise
III-only I-Premise
condition I-Premise
showed I-Premise
large I-Premise
reductions I-Premise
in I-Premise
the I-Premise
depression I-Premise
scale I-Premise
of I-Premise
HADS I-Premise
( I-Premise
d I-Premise
= I-Premise
1.27 I-Premise
and I-Premise
0.89 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

No B-Premise
differences I-Premise
in I-Premise
QOL I-Premise
between I-Premise
groups I-Premise
2 I-Premise
and I-Premise
3 I-Premise
were I-Premise
found I-Premise
. I-Premise

We B-Premise
observed I-Premise
no I-Premise
significant I-Premise
changes I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
. I-Premise

Compared B-Premise
with I-Premise
patients I-Premise
in I-Premise
the I-Premise
TC I-Premise
arm I-Premise
, I-Premise
patients I-Premise
in I-Premise
the I-Premise
TC-Top I-Premise
arm I-Premise
had I-Premise
more I-Premise
grade I-Premise
3-4 I-Premise
hematologic I-Premise
toxic I-Premise
effects I-Premise
( I-Premise
requiring I-Premise
more I-Premise
supportive I-Premise
care I-Premise
) I-Premise
and I-Premise
more I-Premise
grade I-Premise
3-4 I-Premise
infections I-Premise
( I-Premise
5.1 I-Premise
% I-Premise
versus I-Premise
2.7 I-Premise
% I-Premise
";" I-Premise
P I-Premise
= I-Premise
.034 I-Premise
) I-Premise
but I-Premise
did I-Premise
not I-Premise
have I-Premise
a I-Premise
statistically I-Premise
significant I-Premise
increase I-Premise
in I-Premise
febrile I-Premise
neutropenia I-Premise
( I-Premise
3.3 I-Premise
% I-Premise
versus I-Premise
3.1 I-Premise
% I-Premise
";" I-Premise
P I-Premise
= I-Premise
.80 I-Premise
) I-Premise
. I-Premise

Excess B-Premise
limb I-Premise
size I-Premise
( I-Premise
circumference I-Premise
and I-Premise
water I-Premise
displacement I-Premise
) I-Premise
and I-Premise
excess I-Premise
water I-Premise
composition I-Premise
were I-Premise
reduced I-Premise
significantly I-Premise
in I-Premise
the I-Premise
bandage I-Premise
group I-Premise
";" I-Premise
excess B-Premise
circumference I-Premise
and I-Premise
excess I-Premise
water I-Premise
composition I-Premise
were I-Premise
reduced I-Premise
significantly I-Premise
in I-Premise
the I-Premise
tape I-Premise
group I-Premise
. I-Premise

The B-Premise
3-year I-Premise
overall I-Premise
survival I-Premise
for I-Premise
neoadjuvant I-Premise
versus I-Premise
control I-Premise
arm I-Premise
was I-Premise
94.1 I-Premise
% I-Premise
and I-Premise
67.7 I-Premise
% I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
= I-Premise
0.24 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.078 I-Premise
to I-Premise
0.73 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.012 I-Premise
) I-Premise
. I-Premise

More B-Premise
patients I-Premise
survived I-Premise
> I-Premise
/= I-Premise
3 I-Premise
years I-Premise
in I-Premise
the I-Premise
D3P I-Premise
and I-Premise
D1P I-Premise
arms I-Premise
( I-Premise
18.6 I-Premise
% I-Premise
and I-Premise
16.6 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
) I-Premise
compared I-Premise
with I-Premise
the I-Premise
MP I-Premise
arm I-Premise
( I-Premise
13.5 I-Premise
% I-Premise
) I-Premise
. I-Premise

Concomitant B-Premise
or I-Premise
prior I-Premise
use I-Premise
of I-Premise
protease I-Premise
inhibitors I-Premise
did I-Premise
not I-Premise
appear I-Premise
to I-Premise
affect I-Premise
the I-Premise
patient I-Premise
's I-Premise
response I-Premise
to I-Premise
treatment I-Premise
( I-Premise
P I-Premise
= I-Premise
0.183 I-Premise
) I-Premise
. I-Premise

The B-Premise
combined I-Premise
treatment I-Premise
group I-Premise
demonstrated I-Premise
13 I-Premise
cases I-Premise
of I-Premise
complete I-Premise
remission I-Premise
and I-Premise
22 I-Premise
cases I-Premise
of I-Premise
partial I-Premise
remission I-Premise
. I-Premise

The B-Premise
postoperative I-Premise
QOL I-Premise
and I-Premise
complication I-Premise
scores I-Premise
at I-Premise
60 I-Premise
months I-Premise
after I-Premise
surgery I-Premise
were I-Premise
significantly I-Premise
better I-Premise
than I-Premise
those I-Premise
at I-Premise
3 I-Premise
months I-Premise
after I-Premise
surgery I-Premise
in I-Premise
each I-Premise
group I-Premise
( I-Premise
P I-Premise
< I-Premise
.01 I-Premise
) I-Premise
. I-Premise

cryoablation B-Premise
was I-Premise
associated I-Premise
with I-Premise
more I-Premise
acute I-Premise
urinary I-Premise
dysfunction I-Premise
( I-Premise
mean I-Premise
PCI I-Premise
urinary I-Premise
function I-Premise
cryoablation=69.4 I-Premise
";" I-Premise
mean I-Premise
EBRT=90.7 I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
, I-Premise
which I-Premise
resolved I-Premise
over I-Premise
time I-Premise
. I-Premise

However B-Premise
, I-Premise
raw I-Premise
QOL I-Premise
scores I-Premise
were I-Premise
not I-Premise
different I-Premise
at I-Premise
these I-Premise
time-points I-Premise
between I-Premise
treatment I-Premise
groups I-Premise
. I-Premise

Sertraline B-Premise
had I-Premise
no I-Premise
significant I-Premise
effect I-Premise
( I-Premise
scale I-Premise
, I-Premise
benefit I-Premise
over I-Premise
placebo I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
] I-Premise
) I-Premise
on I-Premise
depression I-Premise
( I-Premise
CES-D I-Premise
0.4 I-Premise
[ I-Premise
-2.6 I-Premise
to I-Premise
3.4 I-Premise
] I-Premise
) I-Premise
, I-Premise
anxiety I-Premise
( I-Premise
HADS-A I-Premise
2.0 I-Premise
[ I-Premise
-1.5 I-Premise
to I-Premise
5.5 I-Premise
] I-Premise
) I-Premise
, I-Premise
fatigue I-Premise
( I-Premise
FACT-F I-Premise
0.3 I-Premise
[ I-Premise
-4.3 I-Premise
to I-Premise
4.9 I-Premise
] I-Premise
) I-Premise
, I-Premise
overall I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
FACT-G I-Premise
1.7 I-Premise
[ I-Premise
-1.3 I-Premise
to I-Premise
4.7 I-Premise
] I-Premise
) I-Premise
, I-Premise
or I-Premise
clinicians I-Premise
' I-Premise
ratings I-Premise
( I-Premise
SQLI I-Premise
2.0 I-Premise
[ I-Premise
-2.5 I-Premise
to I-Premise
6.5 I-Premise
] I-Premise
) I-Premise
, I-Premise
and I-Premise
the I-Premise
95 I-Premise
% I-Premise
CI I-Premise
ruled I-Premise
out I-Premise
a I-Premise
clinically I-Premise
significant I-Premise
benefit I-Premise
for I-Premise
all I-Premise
main I-Premise
outcomes I-Premise
. I-Premise

No B-Premise
significant I-Premise
between-group I-Premise
differences I-Premise
were I-Premise
observed I-Premise
for I-Premise
fatigue I-Premise
, I-Premise
quality I-Premise
of I-Premise
life I-Premise
or I-Premise
psychological I-Premise
distress I-Premise
. I-Premise

No B-Premise
pain I-Premise
training I-Premise
patients I-Premise
reported I-Premise
severe I-Premise
pain I-Premise
( I-Premise
> I-Premise
6 I-Premise
on I-Premise
a I-Premise
0-10 I-Premise
scale I-Premise
) I-Premise
at I-Premise
1-month I-Premise
outcomes I-Premise
( I-Premise
P=.03 I-Premise
) I-Premise
. I-Premise

Protein B-Premise
intake I-Premise
increased I-Premise
in I-Premise
G1/G2 I-Premise
( I-Premise
P I-Premise
< I-Premise
or I-Premise
= I-Premise
.007 I-Premise
) I-Premise
, I-Premise
G1 I-Premise
less I-Premise
than I-Premise
G2 I-Premise
( I-Premise
not I-Premise
significant I-Premise
) I-Premise
, I-Premise
and I-Premise
decreased I-Premise
in I-Premise
G3 I-Premise
( I-Premise
P I-Premise
< I-Premise
.01 I-Premise
) I-Premise
. I-Premise

By B-Premise
the I-Premise
end I-Premise
of I-Premise
the I-Premise
treatment I-Premise
period I-Premise
, I-Premise
hot I-Premise
flash I-Premise
scores I-Premise
( I-Premise
frequency I-Premise
x I-Premise
average I-Premise
severity I-Premise
) I-Premise
decreased I-Premise
68 I-Premise
% I-Premise
from I-Premise
baseline I-Premise
to I-Premise
end I-Premise
point I-Premise
in I-Premise
the I-Premise
hypnosis I-Premise
arm I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

Depression B-Premise
scores I-Premise
yielded I-Premise
a I-Premise
linear I-Premise
interaction I-Premise
comparing I-Premise
UCO I-Premise
and I-Premise
SMEX I-Premise
( I-Premise
p I-Premise
= I-Premise
0.019 I-Premise
) I-Premise
, I-Premise
with I-Premise
decreases I-Premise
in I-Premise
SMEX I-Premise
but I-Premise
not I-Premise
UCO I-Premise
. I-Premise

Treatment-related B-Premise
toxicity I-Premise
was I-Premise
less I-Premise
in I-Premise
the I-Premise
single-agent I-Premise
arm I-Premise
and I-Premise
quality-of-life I-Premise
( I-Premise
QOL I-Premise
) I-Premise
analysis I-Premise
favored I-Premise
the I-Premise
single-agent I-Premise
arm I-Premise
. I-Premise

The B-Premise
quality-of-life I-Premise
questionnaire I-Premise
results I-Premise
before I-Premise
and I-Premise
5 I-Premise
years I-Premise
after I-Premise
treatment I-Premise
were I-Premise
available I-Premise
for I-Premise
103 I-Premise
patients I-Premise
with I-Premise
no I-Premise
differences I-Premise
found I-Premise
between I-Premise
the I-Premise
-70 I-Premise
and I-Premise
80-Gy I-Premise
arms I-Premise
. I-Premise

Both B-Premise
energy I-Premise
and I-Premise
protein I-Premise
intake I-Premise
decreased I-Premise
significantly I-Premise
in I-Premise
group I-Premise
3 I-Premise
( I-Premise
p I-Premise
< I-Premise
.01 I-Premise
) I-Premise
. I-Premise

For B-Premise
sexually I-Premise
active I-Premise
female I-Premise
rectal I-Premise
and I-Premise
anal I-Premise
cancer I-Premise
survivors I-Premise
enrolled I-Premise
in I-Premise
a I-Premise
sexual I-Premise
health I-Premise
intervention I-Premise
, I-Premise
sexual I-Premise
dysfunction I-Premise
was I-Premise
significantly I-Premise
and I-Premise
consistently I-Premise
associated I-Premise
with I-Premise
specific I-Premise
measures I-Premise
of I-Premise
psychological I-Premise
well-being I-Premise
, I-Premise
most I-Premise
notably I-Premise
Sexual/Relationship I-Premise
Satisfaction I-Premise
. I-Premise

Cox B-Premise
regression I-Premise
models I-Premise
that I-Premise
took I-Premise
TNM I-Premise
staging I-Premise
or I-Premise
the I-Premise
residual I-Premise
tumor I-Premise
classification I-Premise
and I-Premise
tumor I-Premise
site I-Premise
into I-Premise
account I-Premise
also I-Premise
found I-Premise
significant I-Premise
differences I-Premise
at I-Premise
10 I-Premise
years I-Premise
. I-Premise

Absolute B-Premise
change I-Premise
in I-Premise
arm I-Premise
volume I-Premise
at I-Premise
12 I-Premise
months I-Premise
was I-Premise
2.5 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
-0.40 I-Premise
to I-Premise
5.3 I-Premise
) I-Premise
in I-Premise
the I-Premise
treatment I-Premise
group I-Premise
compared I-Premise
to I-Premise
1.2 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
-2.8 I-Premise
to I-Premise
5.1 I-Premise
) I-Premise
in I-Premise
the I-Premise
placebo I-Premise
group I-Premise
. I-Premise

Occurrence B-Premise
of I-Premise
grade I-Premise
3 I-Premise
and I-Premise
4 I-Premise
diarrhea I-Premise
was I-Premise
higher I-Premise
in I-Premise
the I-Premise
FU24h I-Premise
+ I-Premise
LV I-Premise
arm I-Premise
( I-Premise
22 I-Premise
% I-Premise
) I-Premise
compared I-Premise
with I-Premise
the I-Premise
FU24h I-Premise
( I-Premise
6 I-Premise
% I-Premise
) I-Premise
or I-Premise
FU I-Premise
+ I-Premise
LV I-Premise
( I-Premise
9 I-Premise
% I-Premise
) I-Premise
arms I-Premise
";" I-Premise
however B-Premise
, I-Premise
stomatitis I-Premise
( I-Premise
11 I-Premise
% I-Premise
in I-Premise
FU I-Premise
+ I-Premise
LV I-Premise
v I-Premise
3 I-Premise
% I-Premise
in I-Premise
FU24h I-Premise
v I-Premise
5 I-Premise
% I-Premise
in I-Premise
FU24h I-Premise
+ I-Premise
LV I-Premise
arms I-Premise
) I-Premise
and I-Premise
hematologic I-Premise
toxicity I-Premise
were I-Premise
higher I-Premise
in I-Premise
the I-Premise
bolus I-Premise
FU I-Premise
+ I-Premise
LV I-Premise
arm I-Premise
. I-Premise

The B-Premise
mean I-Premise
liver I-Premise
volume I-Premise
decreased I-Premise
2.9 I-Premise
% I-Premise
, I-Premise
from I-Premise
4606 I-Premise
mL I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
( I-Premise
CI I-Premise
) I-Premise
: I-Premise
547-8665 I-Premise
) I-Premise
to I-Premise
4471 I-Premise
mL I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
: I-Premise
542-8401 I-Premise
mL I-Premise
) I-Premise
, I-Premise
in I-Premise
patients I-Premise
given I-Premise
lanreotide I-Premise
. I-Premise

Improvement B-Premise
over I-Premise
time I-Premise
and I-Premise
time I-Premise
x I-Premise
treatment I-Premise
effects I-Premise
only I-Premise
reached I-Premise
trend I-Premise
significance I-Premise
levels I-Premise
( I-Premise
ps I-Premise
= I-Premise
0.07 I-Premise
& I-Premise
amp I-Premise
";" I-Premise
0.12 I-Premise
) I-Premise
as I-Premise
this I-Premise
pilot I-Premise
was I-Premise
not I-Premise
powered I-Premise
to I-Premise
detect I-Premise
these I-Premise
differences I-Premise
. I-Premise

Of B-Premise
the I-Premise
41 I-Premise
patients I-Premise
who I-Premise
reported I-Premise
swelling I-Premise
at I-Premise
baseline I-Premise
, I-Premise
38 I-Premise
( I-Premise
93 I-Premise
% I-Premise
) I-Premise
improved I-Premise
. I-Premise

CE B-Premise
at I-Premise
the I-Premise
oral I-Premise
dose I-Premise
administered I-Premise
was I-Premise
well I-Premise
tolerated I-Premise
by I-Premise
these I-Premise
patients I-Premise
with I-Premise
CACS I-Premise
. I-Premise

A B-Premise
7 I-Premise
% I-Premise
response I-Premise
rate I-Premise
was I-Premise
observed I-Premise
with I-Premise
topotecan I-Premise
( I-Premise
complete I-Premise
response I-Premise
, I-Premise
2 I-Premise
% I-Premise
";" I-Premise
partial I-Premise
response I-Premise
, I-Premise
5 I-Premise
% I-Premise
) I-Premise
. I-Premise

The B-Premise
final I-Premise
multivariate I-Premise
model I-Premise
predicted I-Premise
poor I-Premise
survival I-Premise
with I-Premise
multiple I-Premise
sites I-Premise
of I-Premise
visceral I-Premise
disease I-Premise
( I-Premise
P=0.003 I-Premise
) I-Premise
, I-Premise
DFI I-Premise
< I-Premise
/=2 I-Premise
years I-Premise
( I-Premise
P=0.026 I-Premise
) I-Premise
and I-Premise
pain I-Premise
( I-Premise
P=0.003 I-Premise
) I-Premise
. I-Premise

Among B-Premise
patients I-Premise
who I-Premise
had I-Premise
measurable I-Premise
disease I-Premise
( I-Premise
TC I-Premise
, I-Premise
n I-Premise
= I-Premise
147 I-Premise
";" I-Premise
TC-Top I-Premise
, I-Premise
n I-Premise
= I-Premise
145 I-Premise
) I-Premise
, I-Premise
overall I-Premise
( I-Premise
i.e. I-Premise
, I-Premise
complete I-Premise
or I-Premise
partial I-Premise
) I-Premise
response I-Premise
was I-Premise
69.0 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
61.4 I-Premise
% I-Premise
to I-Premise
76.5 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
TC-Top I-Premise
arm I-Premise
and I-Premise
76.2 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
69.3 I-Premise
% I-Premise
to I-Premise
83.1 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
TC I-Premise
arm I-Premise
( I-Premise
P I-Premise
= I-Premise
.166 I-Premise
) I-Premise
. I-Premise

The B-Premise
mean I-Premise
changes I-Premise
in I-Premise
the I-Premise
endpoints I-Premise
from I-Premise
baseline I-Premise
in I-Premise
the I-Premise
trial I-Premise
group I-Premise
were I-Premise
significantly I-Premise
greater I-Premise
compared I-Premise
with I-Premise
the I-Premise
control I-Premise
group I-Premise
: I-Premise
in I-Premise
the I-Premise
primary I-Premise
endpoints I-Premise
, I-Premise
body I-Premise
weight I-Premise
( I-Premise
p I-Premise
= I-Premise
0.05 I-Premise
) I-Premise
, I-Premise
fatigue I-Premise
( I-Premise
p I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
and I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
p I-Premise
= I-Premise
0.01 I-Premise
) I-Premise
, I-Premise
and I-Premise
in I-Premise
the I-Premise
secondary I-Premise
endpoints I-Premise
, I-Premise
grip I-Premise
strength I-Premise
( I-Premise
p I-Premise
= I-Premise
0.05 I-Premise
) I-Premise
, I-Premise
Glasgow I-Premise
Prognostic I-Premise
Score I-Premise
( I-Premise
p I-Premise
= I-Premise
0.02 I-Premise
) I-Premise
, I-Premise
Eastern I-Premise
Cooperative I-Premise
Oncology I-Premise
Group I-Premise
performance I-Premise
status I-Premise
( I-Premise
p I-Premise
= I-Premise
0.02 I-Premise
) I-Premise
, I-Premise
IL-6 I-Premise
( I-Premise
p I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
and I-Premise
tumor I-Premise
necrosis I-Premise
factor-α I-Premise
( I-Premise
p I-Premise
= I-Premise
0.01 I-Premise
) I-Premise
. I-Premise

The B-Premise
carboplatin I-Premise
containing I-Premise
regimen I-Premise
( I-Premise
MVC I-Premise
) I-Premise
has I-Premise
a I-Premise
significant I-Premise
better I-Premise
toxicity I-Premise
profile I-Premise
than I-Premise
the I-Premise
cisplatin I-Premise
containing I-Premise
( I-Premise
MVP I-Premise
) I-Premise
regimen I-Premise
as I-Premise
proven I-Premise
both I-Premise
by I-Premise
the I-Premise
EORTC I-Premise
questionnaires I-Premise
and I-Premise
by I-Premise
the I-Premise
WHO I-Premise
toxicity I-Premise
data I-Premise
reported I-Premise
by I-Premise
physicians I-Premise
. I-Premise

Patients B-Premise
randomly I-Premise
assigned I-Premise
to I-Premise
the I-Premise
intervention I-Premise
arm I-Premise
showed I-Premise
significant I-Premise
improvements I-Premise
on I-Premise
symptoms I-Premise
of I-Premise
depression I-Premise
( I-Premise
p I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
and I-Premise
anxiety I-Premise
( I-Premise
p I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
, I-Premise
health-related I-Premise
QOL I-Premise
( I-Premise
p I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
( I-Premise
i.e I-Premise
. I-Premise
better I-Premise
global I-Premise
health I-Premise
status I-Premise
, I-Premise
and I-Premise
physical I-Premise
and I-Premise
emotional I-Premise
functioning I-Premise
, I-Premise
and I-Premise
less I-Premise
insomnia I-Premise
) I-Premise
when I-Premise
compared I-Premise
with I-Premise
controls I-Premise
. I-Premise

In B-Premise
patients I-Premise
who I-Premise
had I-Premise
tumors I-Premise
with I-Premise
wild-type I-Premise
KRAS I-Premise
status I-Premise
, I-Premise
cetuximab I-Premise
resulted I-Premise
in I-Premise
less I-Premise
PF I-Premise
deterioration I-Premise
at I-Premise
8 I-Premise
weeks I-Premise
( I-Premise
-0.7 I-Premise
v I-Premise
-7.2 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.11 I-Premise
) I-Premise
and I-Premise
16 I-Premise
weeks I-Premise
( I-Premise
-3.4 I-Premise
v I-Premise
-13.8 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.008 I-Premise
) I-Premise
compared I-Premise
with I-Premise
BSC I-Premise
. I-Premise

Grade B-Premise
3 I-Premise
hypertension I-Premise
was I-Premise
more I-Premise
common I-Premise
with I-Premise
bevacizumab I-Premise
treatment I-Premise
( I-Premise
16 I-Premise
% I-Premise
v I-Premise
3 I-Premise
% I-Premise
) I-Premise
but B-Premise
was I-Premise
controlled I-Premise
with I-Premise
oral I-Premise
medication I-Premise
and I-Premise
did I-Premise
not I-Premise
cause I-Premise
study I-Premise
drug I-Premise
discontinuation I-Premise
. I-Premise

No B-Premise
significant I-Premise
differences I-Premise
were I-Premise
seen I-Premise
in I-Premise
favour I-Premise
of I-Premise
the I-Premise
supportive I-Premise
care I-Premise
group I-Premise
, I-Premise
except B-Premise
for I-Premise
hair I-Premise
loss I-Premise
. I-Premise

The B-Premise
addition I-Premise
of I-Premise
mitoxantrone I-Premise
to I-Premise
prednisone I-Premise
after I-Premise
failure I-Premise
of I-Premise
prednisone I-Premise
alone I-Premise
was I-Premise
associated I-Premise
with I-Premise
improvements I-Premise
in I-Premise
pain I-Premise
, I-Premise
pain I-Premise
impact I-Premise
, I-Premise
pain I-Premise
relief I-Premise
, I-Premise
insomnia I-Premise
, I-Premise
and I-Premise
global I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
.001 I-Premise
< I-Premise
P I-Premise
< I-Premise
.003 I-Premise
) I-Premise
. I-Premise

No B-Premise
acute I-Premise
Grade I-Premise
4 I-Premise
radiation I-Premise
toxicity I-Premise
developed I-Premise
. I-Premise

Furthermore B-Premise
, I-Premise
letrozole I-Premise
significantly I-Premise
improved I-Premise
distant I-Premise
DFS I-Premise
( I-Premise
HR=0.60 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0.43 I-Premise
, I-Premise
0.84 I-Premise
";" I-Premise
P=0.002 I-Premise
) I-Premise
and I-Premise
, I-Premise
in I-Premise
women I-Premise
with I-Premise
node-positive I-Premise
tumors I-Premise
, I-Premise
overall I-Premise
survival I-Premise
( I-Premise
HR=0.61 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0.38 I-Premise
, I-Premise
0.98 I-Premise
";" I-Premise
P=0.04 I-Premise
) I-Premise
. I-Premise

Although B-Premise
the I-Premise
change I-Premise
in I-Premise
fiber I-Premise
intake I-Premise
between I-Premise
the I-Premise
groups I-Premise
was I-Premise
not I-Premise
significant I-Premise
, I-Premise
there B-Premise
was I-Premise
a I-Premise
trend I-Premise
in I-Premise
the I-Premise
anticipated I-Premise
direction I-Premise
( I-Premise
P=0.083 I-Premise
) I-Premise
. I-Premise

A B-Premise
significant I-Premise
difference I-Premise
was I-Premise
evidenced I-Premise
for I-Premise
the I-Premise
worst I-Premise
pain I-Premise
( I-Premise
P I-Premise
< I-Premise
0.035 I-Premise
) I-Premise
. I-Premise

In B-Premise
the I-Premise
latter I-Premise
patients I-Premise
the I-Premise
received I-Premise
dose I-Premise
intensities I-Premise
( I-Premise
RDI I-Premise
) I-Premise
of I-Premise
cisplatin I-Premise
, I-Premise
adriamycin I-Premise
and I-Premise
etoposide I-Premise
were I-Premise
significantly I-Premise
higher I-Premise
in I-Premise
the I-Premise
late-alternation I-Premise
arm I-Premise
. I-Premise

Time B-Premise
to I-Premise
response I-Premise
and I-Premise
ORR I-Premise
favor I-Premise
TCF I-Premise
over I-Premise
TC I-Premise
for I-Premise
further I-Premise
evaluation I-Premise
, I-Premise
particularly I-Premise
in I-Premise
the I-Premise
neoadjuvant I-Premise
setting I-Premise
. I-Premise

This B-Premise
revealed I-Premise
a I-Premise
significant I-Premise
difference I-Premise
in I-Premise
the I-Premise
median I-Premise
survival I-Premise
in I-Premise
favor I-Premise
of I-Premise
the I-Premise
patients I-Premise
on I-Premise
the I-Premise
placebo I-Premise
arm I-Premise
of I-Premise
the I-Premise
trial I-Premise
( I-Premise
63 I-Premise
v I-Premise
129 I-Premise
days I-Premise
";" I-Premise
hazard I-Premise
ratio I-Premise
, I-Premise
1.84 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.04 I-Premise
) I-Premise
. I-Premise

The B-Premise
estimated I-Premise
cost I-Premise
of I-Premise
radiotherapy I-Premise
, I-Premise
including I-Premise
retreatments I-Premise
and I-Premise
nonmedical I-Premise
costs I-Premise
, I-Premise
was I-Premise
statistically I-Premise
significantly I-Premise
lower I-Premise
for I-Premise
the I-Premise
single-fraction I-Premise
schedule I-Premise
than I-Premise
for I-Premise
the I-Premise
multiple-fraction I-Premise
schedule I-Premise
( I-Premise
$ I-Premise
2438 I-Premise
versus I-Premise
$ I-Premise
3311 I-Premise
, I-Premise
difference I-Premise
= I-Premise
$ I-Premise
873 I-Premise
, I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
on I-Premise
the I-Premise
difference I-Premise
= I-Premise
$ I-Premise
449 I-Premise
to I-Premise
$ I-Premise
1297 I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

The B-Premise
hazard I-Premise
ratio I-Premise
was I-Premise
0.63 I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
, I-Premise
0.52-0.75 I-Premise
";" I-Premise
log-rank I-Premise
, I-Premise
P I-Premise
< I-Premise
0.0001 I-Premise
) I-Premise
. I-Premise

Symptomatic B-Premise
response I-Premise
during I-Premise
the I-Premise
first I-Premise
four I-Premise
weeks I-Premise
was I-Premise
seen I-Premise
after I-Premise
pamidronate I-Premise
, I-Premise
but I-Premise
not I-Premise
with I-Premise
placebo I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

However B-Premise
, I-Premise
complete I-Premise
gingival I-Premise
healing I-Premise
occurred I-Premise
in I-Premise
only I-Premise
14 I-Premise
of I-Premise
25 I-Premise
HBO-treated I-Premise
patients I-Premise
( I-Premise
52 I-Premise
% I-Premise
) I-Premise
versus I-Premise
7 I-Premise
of I-Premise
21 I-Premise
controls I-Premise
( I-Premise
33.3 I-Premise
% I-Premise
";" I-Premise
P I-Premise
= I-Premise
.203 I-Premise
, I-Premise
χ I-Premise
( I-Premise
2 I-Premise
) I-Premise
test I-Premise
) I-Premise
, I-Premise
and I-Premise
time I-Premise
to I-Premise
healing I-Premise
was I-Premise
59 I-Premise
weeks I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
42.8 I-Premise
% I-Premise
to I-Premise
75.8 I-Premise
% I-Premise
) I-Premise
for I-Premise
HBO-treated I-Premise
patients I-Premise
versus I-Premise
70 I-Premise
weeks I-Premise
( I-Premise
95 I-Premise
CI I-Premise
, I-Premise
52.2 I-Premise
% I-Premise
to I-Premise
88.36 I-Premise
% I-Premise
) I-Premise
for I-Premise
controls I-Premise
( I-Premise
P I-Premise
= I-Premise
.32 I-Premise
, I-Premise
log-rank I-Premise
test I-Premise
) I-Premise
. I-Premise

The B-Premise
overall I-Premise
response I-Premise
rate I-Premise
was I-Premise
16 I-Premise
% I-Premise
in I-Premise
the I-Premise
PLD I-Premise
arm I-Premise
compared I-Premise
with I-Premise
29 I-Premise
% I-Premise
in I-Premise
the I-Premise
GEM I-Premise
arm I-Premise
( I-Premise
P I-Premise
= I-Premise
.056 I-Premise
) I-Premise
. I-Premise

Peripheral B-Premise
neuropathy I-Premise
and I-Premise
alopecia I-Premise
were I-Premise
more I-Premise
common I-Premise
with I-Premise
CVP I-Premise
. I-Premise

Body B-Premise
cell I-Premise
mass I-Premise
was I-Premise
maintained I-Premise
throughout I-Premise
the I-Premise
study I-Premise
in I-Premise
group I-Premise
B I-Premise
, I-Premise
but I-Premise
declined I-Premise
significantly I-Premise
up I-Premise
to I-Premise
weeks I-Premise
4 I-Premise
and I-Premise
8 I-Premise
in I-Premise
group I-Premise
A I-Premise
( I-Premise
intergroup I-Premise
difference I-Premise
: I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
and I-Premise
0.01 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

In B-Premise
analyses I-Premise
controlling I-Premise
for I-Premise
study I-Premise
site I-Premise
and I-Premise
baseline I-Premise
depressive I-Premise
symptoms I-Premise
, I-Premise
VID I-Premise
produced I-Premise
significant I-Premise
improvement I-Premise
in I-Premise
energy/fatigue I-Premise
at I-Premise
6 I-Premise
months I-Premise
relative I-Premise
to I-Premise
CTL I-Premise
, I-Premise
particularly I-Premise
among I-Premise
women I-Premise
who I-Premise
felt I-Premise
less I-Premise
prepared I-Premise
for I-Premise
re-entry I-Premise
at I-Premise
baseline I-Premise
. I-Premise

Scores B-Premise
on I-Premise
the I-Premise
physical I-Premise
function I-Premise
, I-Premise
role-physical I-Premise
, I-Premise
and I-Premise
general I-Premise
health I-Premise
subscales I-Premise
of I-Premise
the I-Premise
SF-36 I-Premise
were I-Premise
significantly I-Premise
lower I-Premise
than I-Premise
Canadian I-Premise
normative I-Premise
data I-Premise
at I-Premise
all I-Premise
time I-Premise
points I-Premise
. I-Premise

Complicated B-Premise
neutropenia I-Premise
was I-Premise
more I-Premise
frequent I-Premise
with I-Premise
DCF I-Premise
than I-Premise
CF I-Premise
( I-Premise
29 I-Premise
% I-Premise
v I-Premise
12 I-Premise
% I-Premise
) I-Premise
. I-Premise

Response B-Premise
rates I-Premise
were I-Premise
also I-Premise
significantly I-Premise
improved I-Premise
with I-Premise
docetaxel I-Premise
versus I-Premise
vinorelbine I-Premise
( I-Premise
22.7 I-Premise
% I-Premise
v I-Premise
9.9 I-Premise
% I-Premise
";" I-Premise
P I-Premise
= I-Premise
.019 I-Premise
) I-Premise
. I-Premise

The B-Premise
scapula-oriented I-Premise
exercise I-Premise
group I-Premise
showed I-Premise
improvements I-Premise
in I-Premise
pain I-Premise
, I-Premise
physical I-Premise
function I-Premise
, I-Premise
social I-Premise
function I-Premise
, I-Premise
and I-Premise
global I-Premise
quality I-Premise
of I-Premise
life I-Premise
compared I-Premise
with I-Premise
baseline I-Premise
, I-Premise
whereas I-Premise
the I-Premise
general I-Premise
exercise I-Premise
group I-Premise
showed I-Premise
improved I-Premise
fatigue I-Premise
and I-Premise
range I-Premise
of I-Premise
motion I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
statistically I-Premise
significant I-Premise
effect I-Premise
on I-Premise
the I-Premise
General I-Premise
Quality I-Premise
of I-Premise
Life I-Premise
score I-Premise
( I-Premise
FACT-G I-Premise
) I-Premise
or I-Premise
on I-Premise
any I-Premise
of I-Premise
the I-Premise
individual I-Premise
wellbeing I-Premise
scores I-Premise
";" I-Premise
Physical I-Premise
( I-Premise
P I-Premise
= I-Premise
.13 I-Premise
) I-Premise
, I-Premise
Emotional I-Premise
( I-Premise
P I-Premise
= I-Premise
.87 I-Premise
) I-Premise
, I-Premise
Social I-Premise
( I-Premise
P I-Premise
= I-Premise
.83 I-Premise
) I-Premise
and I-Premise
Functional I-Premise
( I-Premise
P I-Premise
= I-Premise
.26 I-Premise
) I-Premise
. I-Premise

While B-Premise
emotional I-Premise
functioning I-Premise
, I-Premise
fatigue I-Premise
, I-Premise
and I-Premise
pain I-Premise
scores I-Premise
were I-Premise
significantly I-Premise
improved I-Premise
in I-Premise
both I-Premise
groups I-Premise
, I-Premise
global I-Premise
health I-Premise
status I-Premise
, I-Premise
functional I-Premise
and I-Premise
cognitive I-Premise
functioning I-Premise
scores I-Premise
appeared I-Premise
to I-Premise
be I-Premise
improved I-Premise
only I-Premise
in I-Premise
patients I-Premise
of I-Premise
group I-Premise
I I-Premise
. I-Premise

Three B-Premise
patients I-Premise
receiving I-Premise
fludarabine I-Premise
died I-Premise
of I-Premise
treatment-related I-Premise
toxicity I-Premise
compared I-Premise
with I-Premise
none I-Premise
of I-Premise
the I-Premise
patients I-Premise
receiving I-Premise
CVP I-Premise
. I-Premise

The B-Premise
Grade I-Premise
2 I-Premise
or I-Premise
greater I-Premise
urinary I-Premise
toxicity I-Premise
was I-Premise
10 I-Premise
% I-Premise
at I-Premise
70 I-Premise
Gy I-Premise
and I-Premise
17.5 I-Premise
% I-Premise
at I-Premise
80 I-Premise
Gy I-Premise
( I-Premise
p I-Premise
= I-Premise
.046 I-Premise
) I-Premise
. I-Premise

An B-Premise
objective I-Premise
response I-Premise
( I-Premise
complete I-Premise
[ I-Premise
CR I-Premise
] I-Premise
or I-Premise
partial I-Premise
[ I-Premise
PR I-Premise
] I-Premise
) I-Premise
was I-Premise
obtained I-Premise
in I-Premise
55 I-Premise
% I-Premise
, I-Premise
48 I-Premise
% I-Premise
, I-Premise
16 I-Premise
% I-Premise
, I-Premise
and I-Premise
7 I-Premise
% I-Premise
of I-Premise
patients I-Premise
treated I-Premise
with I-Premise
CEF I-Premise
, I-Premise
E I-Premise
, I-Premise
M I-Premise
, I-Premise
and I-Premise
MV I-Premise
, I-Premise
respectively I-Premise
. I-Premise

If B-Premise
offered I-Premise
a I-Premise
choice I-Premise
, I-Premise
80 I-Premise
% I-Premise
of I-Premise
the I-Premise
patients I-Premise
prior I-Premise
to I-Premise
start I-Premise
and I-Premise
58 I-Premise
% I-Premise
of I-Premise
the I-Premise
patients I-Premise
after I-Premise
completion I-Premise
of I-Premise
the I-Premise
program I-Premise
indicated I-Premise
that I-Premise
they I-Premise
preferred I-Premise
the I-Premise
entire I-Premise
multidimensional I-Premise
program I-Premise
. I-Premise

No B-Premise
significant I-Premise
difference I-Premise
in I-Premise
time I-Premise
to I-Premise
progression I-Premise
or I-Premise
survival I-Premise
was I-Premise
found I-Premise
between I-Premise
the I-Premise
two I-Premise
arms I-Premise
. I-Premise

However B-Premise
, I-Premise
there I-Premise
was I-Premise
no I-Premise
QoL I-Premise
difference I-Premise
at I-Premise
the I-Premise
time I-Premise
of I-Premise
ablation I-Premise
between I-Premise
T4-WD I-Premise
and I-Premise
T3-WD I-Premise
Groups I-Premise
. I-Premise

No B-Premise
group-related I-Premise
negative I-Premise
effects I-Premise
were I-Premise
observed I-Premise
and I-Premise
the I-Premise
global I-Premise
satisfaction I-Premise
levels I-Premise
were I-Premise
very I-Premise
high I-Premise
. I-Premise

However B-Premise
, I-Premise
this I-Premise
difference I-Premise
did I-Premise
not I-Premise
translate I-Premise
into I-Premise
a I-Premise
worse I-Premise
feeling I-Premise
of I-Premise
general I-Premise
well-being I-Premise
as I-Premise
measured I-Premise
by I-Premise
a I-Premise
simple I-Premise
visual I-Premise
analogue I-Premise
scale I-Premise
( I-Premise
5.8 I-Premise
vs I-Premise
5.2 I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.3 I-Premise
) I-Premise
. I-Premise

In B-Premise
response I-Premise
to I-Premise
training I-Premise
, I-Premise
QOL I-Premise
, I-Premise
VO2peak I-Premise
( I-Premise
mean I-Premise
3.9 I-Premise
ml/kg/min I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.93 I-Premise
, I-Premise
6.90 I-Premise
) I-Premise
performance I-Premise
in I-Premise
leg I-Premise
press I-Premise
( I-Premise
17.9 I-Premise
kg I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
12.8 I-Premise
, I-Premise
22.4 I-Premise
) I-Premise
and I-Premise
sit-stand I-Premise
test I-Premise
( I-Premise
- I-Premise
0.67 I-Premise
s I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
- I-Premise
0.52 I-Premise
, I-Premise
- I-Premise
1.2 I-Premise
) I-Premise
improved I-Premise
( I-Premise
p I-Premise
< I-Premise
or I-Premise
= I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

Only B-Premise
1 I-Premise
patient I-Premise
in I-Premise
each I-Premise
group I-Premise
had I-Premise
acute I-Premise
nonhematologic I-Premise
toxicity I-Premise
greater I-Premise
than I-Premise
Grade I-Premise
3 I-Premise
( I-Premise
nausea I-Premise
and I-Premise
vomiting I-Premise
) I-Premise
. I-Premise

DPPE B-Premise
plus I-Premise
DOX I-Premise
was I-Premise
associated I-Premise
with I-Premise
more I-Premise
gastrointestinal I-Premise
and I-Premise
CNS I-Premise
toxicity I-Premise
. I-Premise

No B-Premise
statistically I-Premise
significant I-Premise
difference I-Premise
was I-Premise
noted I-Premise
in I-Premise
the I-Premise
time I-Premise
to I-Premise
local I-Premise
failure I-Premise
between I-Premise
the I-Premise
surgical I-Premise
and I-Premise
RT I-Premise
arms I-Premise
. I-Premise

Other B-Premise
grade I-Premise
3/4 I-Premise
toxic I-Premise
effects I-Premise
were I-Premise
rare I-Premise
( I-Premise
< I-Premise
5 I-Premise
% I-Premise
) I-Premise
. I-Premise

The B-Premise
mean I-Premise
BAP I-Premise
increased I-Premise
from I-Premise
baseline I-Premise
in I-Premise
group I-Premise
B I-Premise
patients I-Premise
but I-Premise
decreased I-Premise
from I-Premise
baseline I-Premise
in I-Premise
group I-Premise
C I-Premise
patients I-Premise
at I-Premise
3 I-Premise
months I-Premise
and I-Premise
15 I-Premise
months I-Premise
. I-Premise

At B-Premise
four I-Premise
weeks I-Premise
, I-Premise
patients I-Premise
who I-Premise
received I-Premise
thalidomide I-Premise
had I-Premise
gained I-Premise
on I-Premise
average I-Premise
0.37 I-Premise
kg I-Premise
in I-Premise
weight I-Premise
and I-Premise
1.0 I-Premise
cm I-Premise
( I-Premise
3 I-Premise
) I-Premise
in I-Premise
arm I-Premise
muscle I-Premise
mass I-Premise
( I-Premise
AMA I-Premise
) I-Premise
compared I-Premise
with I-Premise
a I-Premise
loss I-Premise
of I-Premise
2.21 I-Premise
kg I-Premise
( I-Premise
absolute I-Premise
difference I-Premise
-2.59 I-Premise
kg I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
( I-Premise
CI I-Premise
) I-Premise
-4.3 I-Premise
to I-Premise
-0.8 I-Premise
) I-Premise
";" I-Premise
p I-Premise
= I-Premise
0.005 I-Premise
) I-Premise
and I-Premise
4.46 I-Premise
cm I-Premise
( I-Premise
3 I-Premise
) I-Premise
( I-Premise
absolute I-Premise
difference I-Premise
-5.6 I-Premise
cm I-Premise
( I-Premise
3 I-Premise
) I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
-8.9 I-Premise
to I-Premise
-2.2 I-Premise
) I-Premise
";" I-Premise
p I-Premise
= I-Premise
0.002 I-Premise
) I-Premise
in I-Premise
the I-Premise
placebo I-Premise
group I-Premise
. I-Premise

When B-Premise
participants I-Premise
in I-Premise
the I-Premise
sham I-Premise
acupuncture I-Premise
group I-Premise
were I-Premise
crossed I-Premise
over I-Premise
to I-Premise
TRUE I-Premise
acupuncture I-Premise
, I-Premise
a I-Premise
further I-Premise
reduction I-Premise
in I-Premise
the I-Premise
frequency I-Premise
of I-Premise
hot I-Premise
flashes I-Premise
was I-Premise
seen I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
difference I-Premise
between I-Premise
groups I-Premise
in I-Premise
mean I-Premise
change I-Premise
in I-Premise
EXIT25 I-Premise
score I-Premise
from I-Premise
baseline I-Premise
to I-Premise
6-month I-Premise
follow-up I-Premise
assessment I-Premise
. I-Premise

Dizziness B-Premise
( I-Premise
3.1 I-Premise
% I-Premise
vs. I-Premise
5.4 I-Premise
% I-Premise
) I-Premise
and I-Premise
vaginal I-Premise
discharge I-Premise
( I-Premise
1.2 I-Premise
% I-Premise
vs. I-Premise
5.2 I-Premise
% I-Premise
) I-Premise
were I-Premise
significantly I-Premise
less I-Premise
frequent I-Premise
with I-Premise
anastrozole I-Premise
compared I-Premise
to I-Premise
tamoxifen I-Premise
. I-Premise

Visual B-Premise
analogue I-Premise
scale I-Premise
scores I-Premise
trended I-Premise
downward I-Premise
over I-Premise
time I-Premise
irrespective I-Premise
of I-Premise
chemotherapy I-Premise
response I-Premise
status I-Premise
, I-Premise
with I-Premise
a I-Premise
statistically I-Premise
meaningful I-Premise
deterioration I-Premise
in I-Premise
patients I-Premise
who I-Premise
progressed I-Premise
( I-Premise
68.9 I-Premise
vs. I-Premise
64.4 I-Premise
, I-Premise
P=0.029 I-Premise
) I-Premise
. I-Premise

Self-reported B-Premise
time I-Premise
spent I-Premise
on I-Premise
hair I-Premise
removal I-Premise
declined I-Premise
from I-Premise
112 I-Premise
to I-Premise
21 I-Premise
min I-Premise
per I-Premise
week I-Premise
in I-Premise
the I-Premise
intervention I-Premise
group I-Premise
and I-Premise
from I-Premise
92 I-Premise
to I-Premise
56 I-Premise
min I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
[ I-Premise
F I-Premise
( I-Premise
( I-Premise
1,80 I-Premise
) I-Premise
) I-Premise
= I-Premise
10.2 I-Premise
, I-Premise
P I-Premise
< I-Premise
/= I-Premise
0.05 I-Premise
] I-Premise
. I-Premise

The B-Premise
estimated I-Premise
median I-Premise
overall I-Premise
survival I-Premise
times I-Premise
for I-Premise
RS I-Premise
+ I-Premise
WBRT I-Premise
and I-Premise
S I-Premise
+ I-Premise
WBRT I-Premise
patients I-Premise
were I-Premise
6.2 I-Premise
and I-Premise
2.8 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
0.53 I-Premise
, I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
0.20-1.43 I-Premise
, I-Premise
P I-Premise
= I-Premise
0.20 I-Premise
) I-Premise
. I-Premise

Global B-Premise
quality I-Premise
of I-Premise
life I-Premise
was I-Premise
not I-Premise
statistically I-Premise
different I-Premise
between I-Premise
treatment I-Premise
groups I-Premise
. I-Premise

FACT-B B-Premise
scores I-Premise
were I-Premise
similar I-Premise
in I-Premise
the I-Premise
exemestane I-Premise
group I-Premise
and I-Premise
anastrozole I-Premise
group I-Premise
. I-Premise

Although B-Premise
improvements I-Premise
in I-Premise
the I-Premise
UC I-Premise
group I-Premise
occurred I-Premise
by I-Premise
12-months I-Premise
post-surgery I-Premise
, I-Premise
the B-Premise
change I-Premise
did I-Premise
not I-Premise
meet I-Premise
the I-Premise
clinically I-Premise
relevant I-Premise
threshold I-Premise
. I-Premise

In B-Premise
contrast I-Premise
, I-Premise
the I-Premise
UC I-Premise
group I-Premise
experienced I-Premise
no I-Premise
change I-Premise
, I-Premise
or I-Premise
worsening I-Premise
QoL I-Premise
, I-Premise
fitness I-Premise
and I-Premise
fatigue I-Premise
, I-Premise
mid-intervention I-Premise
. I-Premise

There B-Premise
was I-Premise
a I-Premise
significant I-Premise
effect I-Premise
of I-Premise
group I-Premise
on I-Premise
women I-Premise
's I-Premise
perceptions I-Premise
of I-Premise
social I-Premise
support I-Premise
with I-Premise
those I-Premise
in I-Premise
the I-Premise
intervention I-Premise
group I-Premise
being I-Premise
more I-Premise
satisfied I-Premise
with I-Premise
the I-Premise
emotional I-Premise
support I-Premise
they I-Premise
received I-Premise
( I-Premise
p I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

SGN-15 B-Premise
was I-Premise
active I-Premise
against I-Premise
Le I-Premise
( I-Premise
y I-Premise
) I-Premise
-positive I-Premise
tumors I-Premise
in I-Premise
early I-Premise
phase I-Premise
clinical I-Premise
trials I-Premise
and I-Premise
was I-Premise
synergistic I-Premise
with I-Premise
docetaxel I-Premise
in I-Premise
preclinical I-Premise
experiments I-Premise
. I-Premise

Risk B-Premise
for I-Premise
distress I-Premise
accounted I-Premise
for I-Premise
very I-Premise
few I-Premise
moderation I-Premise
effects I-Premise
. I-Premise

This B-Premise
translated I-Premise
into I-Premise
a I-Premise
lower I-Premise
proportion I-Premise
of I-Premise
patients I-Premise
experiencing I-Premise
moist I-Premise
desquamation I-Premise
during I-Premise
or I-Premise
up I-Premise
to I-Premise
6 I-Premise
weeks I-Premise
after I-Premise
their I-Premise
radiation I-Premise
treatment I-Premise
";" I-Premise
31.2 I-Premise
% I-Premise
with I-Premise
IMRT I-Premise
compared I-Premise
with I-Premise
47.8 I-Premise
% I-Premise
with I-Premise
standard I-Premise
treatment I-Premise
( I-Premise
P I-Premise
= I-Premise
.002 I-Premise
) I-Premise
. I-Premise

Toxicity B-Premise
was I-Premise
generally I-Premise
limited I-Premise
to I-Premise
musculoskeletal I-Premise
symptoms I-Premise
( I-Premise
18 I-Premise
% I-Premise
grade I-Premise
3/4 I-Premise
for I-Premise
marimastat I-Premise
) I-Premise
. I-Premise

At B-Premise
a I-Premise
median I-Premise
follow-up I-Premise
of I-Premise
30 I-Premise
months I-Premise
, I-Premise
letrozole I-Premise
significantly I-Premise
improved I-Premise
disease-free I-Premise
survival I-Premise
( I-Premise
DFS I-Premise
";" I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
, I-Premise
the I-Premise
primary I-Premise
end I-Premise
point I-Premise
, I-Premise
compared I-Premise
with I-Premise
placebo I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
for I-Premise
recurrence I-Premise
or I-Premise
contralateral I-Premise
breast I-Premise
cancer I-Premise
0.58 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
0.45 I-Premise
, I-Premise
0.76 I-Premise
] I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
. I-Premise

At B-Premise
3 I-Premise
years I-Premise
, I-Premise
overall I-Premise
survival I-Premise
in I-Premise
both I-Premise
arms I-Premise
was I-Premise
57 I-Premise
% I-Premise
( I-Premise
58.5 I-Premise
% I-Premise
in I-Premise
the I-Premise
TC I-Premise
arm I-Premise
and I-Premise
55.7 I-Premise
% I-Premise
in I-Premise
the I-Premise
TC-Top I-Premise
arm I-Premise
) I-Premise
. I-Premise

The B-Premise
SF-6D I-Premise
score I-Premise
decreased I-Premise
to I-Premise
21·2 I-Premise
± I-Premise
2·5 I-Premise
in I-Premise
the I-Premise
oxycodone/paracetamol I-Premise
group I-Premise
at I-Premise
the I-Premise
end I-Premise
of I-Premise
the I-Premise
phase I-Premise
( I-Premise
P I-Premise
= I-Premise
0·001 I-Premise
) I-Premise
. I-Premise

The B-Premise
rate I-Premise
of I-Premise
vomiting I-Premise
in I-Premise
the I-Premise
GE I-Premise
and I-Premise
GP I-Premise
arms I-Premise
was I-Premise
20.0 I-Premise
and I-Premise
20.5 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
( I-Premise
p I-Premise
= I-Premise
0.96 I-Premise
) I-Premise
. I-Premise

At B-Premise
12 I-Premise
months I-Premise
, I-Premise
patients I-Premise
receiving I-Premise
tamoxifen I-Premise
had I-Premise
a I-Premise
significantly I-Premise
higher I-Premise
mean I-Premise
hot I-Premise
flash I-Premise
score I-Premise
( I-Premise
P I-Premise
= I-Premise
.03 I-Premise
) I-Premise
, I-Premise
with I-Premise
daily I-Premise
hot I-Premise
flashes I-Premise
increasing I-Premise
from I-Premise
baseline I-Premise
by I-Premise
33 I-Premise
% I-Premise
compared I-Premise
with I-Premise
a I-Premise
7 I-Premise
% I-Premise
increase I-Premise
from I-Premise
baseline I-Premise
with I-Premise
exemestane I-Premise
. I-Premise

Patients B-Premise
receiving I-Premise
erlotinib I-Premise
had I-Premise
significantly I-Premise
longer I-Premise
median I-Premise
time I-Premise
to I-Premise
deterioration I-Premise
for I-Premise
all I-Premise
three I-Premise
symptoms I-Premise
( I-Premise
4.9 I-Premise
v I-Premise
3.7 I-Premise
months I-Premise
for I-Premise
cough I-Premise
[ I-Premise
P I-Premise
= I-Premise
.04 I-Premise
] I-Premise
";" I-Premise
4.7 I-Premise
v I-Premise
2.9 I-Premise
months I-Premise
for I-Premise
dyspnea I-Premise
[ I-Premise
P I-Premise
= I-Premise
.04 I-Premise
] I-Premise
, I-Premise
and I-Premise
2.8 I-Premise
v I-Premise
1.9 I-Premise
months I-Premise
for I-Premise
pain I-Premise
[ I-Premise
P I-Premise
= I-Premise
.03 I-Premise
] I-Premise
) I-Premise
. I-Premise

Complete B-Premise
resection I-Premise
was I-Premise
performed I-Premise
in I-Premise
73 I-Premise
% I-Premise
of I-Premise
26 I-Premise
patients I-Premise
undergoing I-Premise
thoracotomy I-Premise
. I-Premise

This B-Premise
difference I-Premise
, I-Premise
however I-Premise
, I-Premise
was I-Premise
not I-Premise
observed I-Premise
when I-Premise
the I-Premise
global I-Premise
quality I-Premise
of I-Premise
life I-Premise
was I-Premise
evaluated I-Premise
with I-Premise
the I-Premise
EORTC I-Premise
patients I-Premise
compiled I-Premise
questionnaires I-Premise
. I-Premise

QOL B-Premise
was I-Premise
poorer I-Premise
for I-Premise
patients I-Premise
receiving I-Premise
AC→T I-Premise
at I-Premise
6 I-Premise
months I-Premise
but I-Premise
similar I-Premise
to I-Premise
others I-Premise
by I-Premise
12 I-Premise
months I-Premise
. I-Premise

The B-Premise
PSA I-Premise
response I-Premise
rates I-Premise
were I-Premise
50 I-Premise
% I-Premise
and I-Premise
23 I-Premise
% I-Premise
, I-Premise
measurable I-Premise
disease I-Premise
response I-Premise
rates I-Premise
( I-Premise
CR+PR I-Premise
) I-Premise
14 I-Premise
% I-Premise
and I-Premise
15 I-Premise
% I-Premise
, I-Premise
and I-Premise
median I-Premise
overall I-Premise
survival I-Premise
19.4 I-Premise
months I-Premise
and I-Premise
13.9 I-Premise
months I-Premise
on I-Premise
Arm I-Premise
A I-Premise
and I-Premise
Arm I-Premise
B I-Premise
respectively I-Premise
. I-Premise

As B-Premise
of I-Premise
October I-Premise
15 I-Premise
, I-Premise
2005 I-Premise
, I-Premise
eight I-Premise
of I-Premise
26 I-Premise
patients I-Premise
in I-Premise
the I-Premise
CONT I-Premise
group I-Premise
and I-Premise
26 I-Premise
of I-Premise
32 I-Premise
patients I-Premise
in I-Premise
the I-Premise
INT I-Premise
group I-Premise
had I-Premise
documented I-Premise
disease I-Premise
progression I-Premise
( I-Premise
P I-Premise
< I-Premise
.0001 I-Premise
) I-Premise
. I-Premise

The B-Premise
results I-Premise
were I-Premise
statistically I-Premise
significant I-Premise
. I-Premise

By B-Premise
the I-Premise
end I-Premise
of I-Premise
follow-up I-Premise
, I-Premise
patients I-Premise
receiving I-Premise
radiotherapy I-Premise
were I-Premise
expressing I-Premise
less I-Premise
anxiety I-Premise
about I-Premise
recurrence I-Premise
than I-Premise
those I-Premise
who I-Premise
had I-Premise
not I-Premise
received I-Premise
radiotherapy I-Premise
. I-Premise

Compared B-Premise
only I-Premise
with I-Premise
patients I-Premise
with I-Premise
SD I-Premise
( I-Premise
6m I-Premise
) I-Premise
, I-Premise
responders I-Premise
showed I-Premise
no I-Premise
significant I-Premise
difference I-Premise
in I-Premise
baseline I-Premise
QL I-Premise
and I-Premise
time I-Premise
to I-Premise
treatment I-Premise
failure I-Premise
( I-Premise
328.5 I-Premise
v I-Premise
340 I-Premise
days I-Premise
) I-Premise
. I-Premise

Pain B-Premise
decreased I-Premise
faster I-Premise
for I-Premise
HBO-treated I-Premise
subjects I-Premise
( I-Premise
P I-Premise
< I-Premise
.01 I-Premise
, I-Premise
linear I-Premise
regression I-Premise
) I-Premise
. I-Premise

For B-Premise
astrocytoma I-Premise
grade I-Premise
III I-Premise
the I-Premise
median I-Premise
survival I-Premise
time I-Premise
was I-Premise
10.6 I-Premise
( I-Premise
1.3-92.7 I-Premise
) I-Premise
months I-Premise
for I-Premise
the I-Premise
radiotherapy I-Premise
only I-Premise
group I-Premise
and I-Premise
17.3 I-Premise
( I-Premise
0.4-96.9+ I-Premise
) I-Premise
months I-Premise
for I-Premise
the I-Premise
estramustine I-Premise
+ I-Premise
radiotherapy I-Premise
group I-Premise
. I-Premise

HRQOL B-Premise
ratings I-Premise
improved I-Premise
with I-Premise
ccHRT I-Premise
, I-Premise
irrespective I-Premise
of I-Premise
dosage I-Premise
, I-Premise
including I-Premise
depressed I-Premise
mood I-Premise
, I-Premise
anxiety I-Premise
, I-Premise
health I-Premise
perception I-Premise
and I-Premise
sexual I-Premise
interest I-Premise
. I-Premise

Patients B-Premise
overwhelmingly I-Premise
reported I-Premise
that I-Premise
CCSP I-Premise
was I-Premise
beneficial I-Premise
. I-Premise

QOL B-Premise
score I-Premise
changes I-Premise
per I-Premise
4-week I-Premise
period I-Premise
in I-Premise
the I-Premise
ATP I-Premise
group I-Premise
showed I-Premise
overall I-Premise
less I-Premise
deterioration I-Premise
than I-Premise
in I-Premise
the I-Premise
control I-Premise
group-physical I-Premise
scores I-Premise
( I-Premise
-0.2 I-Premise
% I-Premise
versus I-Premise
-2.4 I-Premise
% I-Premise
";" I-Premise
P I-Premise
= I-Premise
. I-Premise
2 I-Premise
) I-Premise
";" I-Premise
functional I-Premise
scores I-Premise
( I-Premise
+0.4 I-Premise
% I-Premise
versus I-Premise
-5.5 I-Premise
% I-Premise
";" I-Premise
P I-Premise
=.02 I-Premise
) I-Premise
";" I-Premise
psychologic I-Premise
scores I-Premise
( I-Premise
-0.7 I-Premise
% I-Premise
versus I-Premise
-2.4 I-Premise
% I-Premise
";" I-Premise
P I-Premise
=.11 I-Premise
) I-Premise
";" I-Premise
overall I-Premise
QOL I-Premise
score I-Premise
( I-Premise
+0.1 I-Premise
% I-Premise
versus I-Premise
-3.5 I-Premise
% I-Premise
";" I-Premise
P I-Premise
=.0001 I-Premise
) I-Premise
. I-Premise

Arthralgia B-Premise
and I-Premise
fatigue I-Premise
were I-Premise
less I-Premise
frequent I-Premise
, I-Premise
but I-Premise
vaginal I-Premise
discharge I-Premise
was I-Premise
more I-Premise
frequent I-Premise
in I-Premise
the I-Premise
tamoxifen I-Premise
group I-Premise
than I-Premise
in I-Premise
the I-Premise
exemestane I-Premise
group I-Premise
or I-Premise
anastrozole I-Premise
group I-Premise
. I-Premise

No B-Premise
significant I-Premise
differences I-Premise
were I-Premise
noted I-Premise
in I-Premise
the I-Premise
distress I-Premise
levels I-Premise
before I-Premise
and I-Premise
after I-Premise
completion I-Premise
of I-Premise
the I-Premise
study I-Premise
in I-Premise
the I-Premise
three I-Premise
groups I-Premise
. I-Premise

Beyond B-Premise
tumor I-Premise
and I-Premise
nodal I-Premise
stage I-Premise
, I-Premise
Karnofsky I-Premise
performance I-Premise
status I-Premise
, I-Premise
primary I-Premise
site I-Premise
, I-Premise
cigarette I-Premise
use I-Premise
, I-Premise
use I-Premise
of I-Premise
concurrent I-Premise
chemotherapy I-Premise
, I-Premise
and I-Premise
altered I-Premise
fractionation I-Premise
schedules I-Premise
, I-Premise
the I-Premise
FACT-H I-Premise
& I-Premise
amp I-Premise
";" I-Premise
N I-Premise
score I-Premise
was I-Premise
independently I-Premise
predictive I-Premise
of I-Premise
LRC I-Premise
( I-Premise
but I-Premise
not I-Premise
OS I-Premise
) I-Premise
, I-Premise
with I-Premise
p I-Premise
= I-Premise
0.0038 I-Premise
. I-Premise

QOL B-Premise
was I-Premise
not I-Premise
significantly I-Premise
different I-Premise
between I-Premise
the I-Premise
two I-Premise
arms I-Premise
, I-Premise
except I-Premise
for I-Premise
pain I-Premise
, I-Premise
which I-Premise
showed I-Premise
more I-Premise
clinically I-Premise
meaningful I-Premise
improvement I-Premise
and I-Premise
less I-Premise
deterioration I-Premise
at I-Premise
6 I-Premise
weeks I-Premise
follow-up I-Premise
( I-Premise
v I-Premise
pretreatment I-Premise
) I-Premise
in I-Premise
the I-Premise
AM I-Premise
arm I-Premise
( I-Premise
P I-Premise
= I-Premise
.003 I-Premise
) I-Premise
. I-Premise

This B-Premise
negative I-Premise
impact I-Premise
tended I-Premise
to I-Premise
last I-Premise
longer I-Premise
in I-Premise
the I-Premise
HDC I-Premise
group I-Premise
, I-Premise
as I-Premise
for I-Premise
most I-Premise
of I-Premise
the I-Premise
QLQ-C30 I-Premise
scales I-Premise
, I-Premise
the I-Premise
QOL I-Premise
scores I-Premise
of I-Premise
HDC I-Premise
patients I-Premise
tend I-Premise
to I-Premise
improve I-Premise
at I-Premise
a I-Premise
slower I-Premise
rate I-Premise
than I-Premise
that I-Premise
of I-Premise
patients I-Premise
receiving I-Premise
standard I-Premise
chemotherapy I-Premise
. I-Premise

The B-Premise
median I-Premise
time I-Premise
to I-Premise
progression I-Premise
for I-Premise
marimastat I-Premise
patients I-Premise
was I-Premise
4.3 I-Premise
months I-Premise
compared I-Premise
with I-Premise
4.4 I-Premise
months I-Premise
for I-Premise
placebo I-Premise
patients I-Premise
( I-Premise
P I-Premise
=.81 I-Premise
) I-Premise
. I-Premise

However B-Premise
, I-Premise
1-month I-Premise
GI I-Premise
toxicity I-Premise
was I-Premise
not I-Premise
only I-Premise
worse I-Premise
in I-Premise
patients I-Premise
with I-Premise
the I-Premise
hypofractionated I-Premise
RT I-Premise
schedule I-Premise
but I-Premise
also I-Premise
adversely I-Premise
affected I-Premise
daily I-Premise
activities I-Premise
. I-Premise

Mean B-Premise
( I-Premise
+/- I-Premise
SD I-Premise
) I-Premise
increase I-Premise
in I-Premise
Hb I-Premise
from I-Premise
baseline I-Premise
to I-Premise
week I-Premise
12 I-Premise
was I-Premise
1.75 I-Premise
+/- I-Premise
2.15 I-Premise
g/dL I-Premise
in I-Premise
the I-Premise
30,000 I-Premise
IU I-Premise
group I-Premise
( I-Premise
P I-Premise
= I-Premise
0.008 I-Premise
vs. I-Premise
baseline I-Premise
) I-Premise
and I-Premise
1.04 I-Premise
+/- I-Premise
1.75 I-Premise
g/dL I-Premise
in I-Premise
the I-Premise
20,000 I-Premise
IU I-Premise
group I-Premise
( I-Premise
non-significant I-Premise
) I-Premise
. I-Premise

Sensitivity B-Premise
analyses I-Premise
showed I-Premise
that I-Premise
varying I-Premise
the I-Premise
mean I-Premise
hospital I-Premise
cost I-Premise
per I-Premise
day I-Premise
from I-Premise
the I-Premise
5th I-Premise
to I-Premise
the I-Premise
95th I-Premise
percentile I-Premise
resulted I-Premise
in I-Premise
cost-utility I-Premise
ratios I-Premise
ranging I-Premise
from I-Premise
20,326 I-Premise
dollars I-Premise
to I-Premise
as I-Premise
low I-Premise
as I-Premise
6360 I-Premise
dollars I-Premise
. I-Premise

Mild B-Premise
or I-Premise
moderate I-Premise
nausea I-Premise
was I-Premise
the I-Premise
most I-Premise
common I-Premise
side I-Premise
effect I-Premise
of I-Premise
estramustine I-Premise
. I-Premise

From B-Premise
the I-Premise
1-year I-Premise
survival I-Premise
analysis I-Premise
, I-Premise
the I-Premise
hazard I-Premise
ratio I-Premise
for I-Premise
probability I-Premise
of I-Premise
death I-Premise
was I-Premise
1.29 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.96 I-Premise
to I-Premise
1.72 I-Premise
) I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
in I-Premise
any I-Premise
of I-Premise
the I-Premise
subjects I-Premise
revealed I-Premise
by I-Premise
the I-Premise
questionnaire I-Premise
regarding I-Premise
subjective I-Premise
or I-Premise
objective I-Premise
symptoms I-Premise
, I-Premise
or I-Premise
by I-Premise
the I-Premise
SF-8 I-Premise
between I-Premise
the I-Premise
daytime I-Premise
group I-Premise
and I-Premise
the I-Premise
nocturnal I-Premise
group I-Premise
after I-Premise
3 I-Premise
months I-Premise
of I-Premise
treatment I-Premise
. I-Premise

Other B-Premise
toxicities I-Premise
were I-Premise
mild I-Premise
and I-Premise
generally I-Premise
well I-Premise
tolerated I-Premise
. I-Premise

For B-Premise
those I-Premise
patients I-Premise
who I-Premise
have I-Premise
recurrence I-Premise
of I-Premise
disease I-Premise
at I-Premise
least I-Premise
6 I-Premise
months I-Premise
after I-Premise
initial I-Premise
therapy I-Premise
, I-Premise
the I-Premise
paclitaxel-platinum I-Premise
combination I-Premise
has I-Premise
been I-Premise
shown I-Premise
to I-Premise
be I-Premise
a I-Premise
superior I-Premise
treatment I-Premise
to I-Premise
platinum I-Premise
monotherapy I-Premise
. I-Premise

Food B-Premise
intake I-Premise
and I-Premise
appetite I-Premise
VAS I-Premise
scores I-Premise
were I-Premise
significantly I-Premise
higher I-Premise
in I-Premise
the I-Premise
ghrelin I-Premise
group I-Premise
than I-Premise
in I-Premise
the I-Premise
placebo I-Premise
group I-Premise
( I-Premise
18.2 I-Premise
± I-Premise
5.2 I-Premise
kcal/kg/day I-Premise
vs I-Premise
12.7 I-Premise
± I-Premise
3.4 I-Premise
kcal/kg/day I-Premise
[ I-Premise
P I-Premise
= I-Premise
.001 I-Premise
] I-Premise
and I-Premise
6.2 I-Premise
± I-Premise
0.9 I-Premise
vs I-Premise
4.1 I-Premise
± I-Premise
0.9 I-Premise
[ I-Premise
P I-Premise
< I-Premise
.0001 I-Premise
] I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

Acupuncture B-Premise
had I-Premise
the I-Premise
additional I-Premise
benefit I-Premise
of I-Premise
increased I-Premise
sex I-Premise
drive I-Premise
in I-Premise
some I-Premise
women I-Premise
, I-Premise
and I-Premise
most I-Premise
reported I-Premise
an I-Premise
improvement I-Premise
in I-Premise
their I-Premise
energy I-Premise
, I-Premise
clarity I-Premise
of I-Premise
thought I-Premise
, I-Premise
and I-Premise
sense I-Premise
of I-Premise
well-being I-Premise
. I-Premise

Induction B-Premise
chemotherapy I-Premise
was I-Premise
completed I-Premise
in I-Premise
78 I-Premise
% I-Premise
of I-Premise
the I-Premise
patients I-Premise
. I-Premise

The B-Premise
1-year I-Premise
PFS I-Premise
rates I-Premise
were I-Premise
16.7 I-Premise
% I-Premise
with I-Premise
gefitinib I-Premise
and I-Premise
2.8 I-Premise
% I-Premise
with I-Premise
GP I-Premise
( I-Premise
HR I-Premise
, I-Premise
1.198 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.944 I-Premise
to I-Premise
1.520 I-Premise
) I-Premise
. I-Premise

At B-Premise
postintervention I-Premise
, I-Premise
AET I-Premise
was I-Premise
superior I-Premise
to I-Premise
UC I-Premise
for I-Premise
patient-rated I-Premise
physical I-Premise
functioning I-Premise
( I-Premise
mean I-Premise
group I-Premise
difference I-Premise
, I-Premise
+9.0 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
2.0 I-Premise
to I-Premise
16.0 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.012 I-Premise
) I-Premise
, I-Premise
overall I-Premise
QoL I-Premise
( I-Premise
P I-Premise
= I-Premise
.021 I-Premise
) I-Premise
, I-Premise
fatigue I-Premise
( I-Premise
P I-Premise
= I-Premise
.013 I-Premise
) I-Premise
, I-Premise
happiness I-Premise
( I-Premise
P I-Premise
= I-Premise
.004 I-Premise
) I-Premise
, I-Premise
depression I-Premise
( I-Premise
P I-Premise
= I-Premise
.005 I-Premise
) I-Premise
, I-Premise
general I-Premise
health I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
, I-Premise
cardiovascular I-Premise
fitness I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
, I-Premise
and I-Premise
lean I-Premise
body I-Premise
mass I-Premise
( I-Premise
P I-Premise
= I-Premise
.008 I-Premise
) I-Premise
. I-Premise

QOL B-Premise
scores I-Premise
were I-Premise
increased I-Premise
and I-Premise
complication I-Premise
scores I-Premise
were I-Premise
improved I-Premise
in I-Premise
the I-Premise
postoperative I-Premise
periods I-Premise
( I-Premise
P I-Premise
< I-Premise
.01 I-Premise
) I-Premise
. I-Premise

At B-Premise
a I-Premise
median I-Premise
follow-up I-Premise
of I-Premise
6.6 I-Premise
years I-Premise
, I-Premise
results I-Premise
for I-Premise
Sx I-Premise
+ I-Premise
Ax I-Premise
and I-Premise
Sx I-Premise
yielded I-Premise
similar I-Premise
DFS I-Premise
( I-Premise
6-year I-Premise
DFS I-Premise
, I-Premise
67 I-Premise
% I-Premise
v I-Premise
66 I-Premise
% I-Premise
";" I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
Sx I-Premise
+ I-Premise
Ax/Sx I-Premise
, I-Premise
1.06 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.79 I-Premise
to I-Premise
1.42 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.69 I-Premise
) I-Premise
and I-Premise
OS I-Premise
( I-Premise
6-year I-Premise
OS I-Premise
, I-Premise
75 I-Premise
% I-Premise
v I-Premise
73 I-Premise
% I-Premise
";" I-Premise
HR I-Premise
Sx I-Premise
+ I-Premise
Ax/Sx I-Premise
, I-Premise
1.05 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.76 I-Premise
to I-Premise
1.46 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.77 I-Premise
) I-Premise
. I-Premise

Objective B-Premise
response I-Premise
rates I-Premise
were I-Premise
22.8 I-Premise
% I-Premise
( I-Premise
13 I-Premise
of I-Premise
57 I-Premise
) I-Premise
in I-Premise
E I-Premise
and I-Premise
8.9 I-Premise
% I-Premise
( I-Premise
5 I-Premise
of I-Premise
56 I-Premise
) I-Premise
in I-Premise
V I-Premise
( I-Premise
p I-Premise
= I-Premise
0.0388 I-Premise
) I-Premise
. I-Premise

At B-Premise
6-month I-Premise
follow-up I-Premise
, I-Premise
AET I-Premise
was I-Premise
still I-Premise
borderline I-Premise
or I-Premise
significantly I-Premise
superior I-Premise
to I-Premise
UC I-Premise
for I-Premise
overall I-Premise
QoL I-Premise
( I-Premise
P I-Premise
= I-Premise
.054 I-Premise
) I-Premise
, I-Premise
happiness I-Premise
( I-Premise
P I-Premise
= I-Premise
.034 I-Premise
) I-Premise
, I-Premise
and I-Premise
depression I-Premise
( I-Premise
P I-Premise
= I-Premise
.009 I-Premise
) I-Premise
without I-Premise
an I-Premise
increased I-Premise
risk I-Premise
of I-Premise
disease I-Premise
recurrence/progression I-Premise
. I-Premise

The B-Premise
HR I-Premise
for I-Premise
overall I-Premise
survival I-Premise
was I-Premise
0.96 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0.75-1.23 I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.7349 I-Premise
) I-Premise
. I-Premise

The B-Premise
intervention I-Premise
also I-Premise
improved I-Premise
all I-Premise
other I-Premise
fatigue I-Premise
aspects I-Premise
measured I-Premise
by I-Premise
MFI I-Premise
, I-Premise
including I-Premise
Physical I-Premise
Fatigue I-Premise
and I-Premise
Mental I-Premise
Fatigue I-Premise
( I-Premise
acupuncture I-Premise
effect I-Premise
, I-Premise
-2.36 I-Premise
and I-Premise
-1.94 I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
both I-Premise
at I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
, I-Premise
anxiety I-Premise
and I-Premise
depression I-Premise
( I-Premise
acupuncture I-Premise
effect I-Premise
, I-Premise
-1.83 I-Premise
and I-Premise
-2.13 I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
both I-Premise
at I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
, I-Premise
and I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
Physical I-Premise
Well-Being I-Premise
effect I-Premise
, I-Premise
3.30 I-Premise
";" I-Premise
Functional I-Premise
Well-Being I-Premise
effect I-Premise
, I-Premise
3.57 I-Premise
";" I-Premise
both I-Premise
at I-Premise
P I-Premise
< I-Premise
.001 I-Premise
";" I-Premise
Emotional I-Premise
Well-Being I-Premise
effect I-Premise
, I-Premise
1.93 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.001 I-Premise
";" I-Premise
and I-Premise
Social I-Premise
Functioning I-Premise
Well-Being I-Premise
effect I-Premise
, I-Premise
1.05 I-Premise
";" I-Premise
P I-Premise
< I-Premise
.05 I-Premise
) I-Premise
. I-Premise

Of B-Premise
the I-Premise
25 I-Premise
patients I-Premise
in I-Premise
whom I-Premise
3-month I-Premise
MR I-Premise
imaging I-Premise
follow-up I-Premise
was I-Premise
completed I-Premise
, I-Premise
those I-Premise
treated I-Premise
with I-Premise
TAGM I-Premise
were I-Premise
significantly I-Premise
more I-Premise
likely I-Premise
to I-Premise
have I-Premise
complete I-Premise
infarction I-Premise
of I-Premise
all I-Premise
leiomyomas I-Premise
( I-Premise
six I-Premise
patients I-Premise
vs I-Premise
one I-Premise
patient I-Premise
";" I-Premise
P I-Premise
= I-Premise
.02 I-Premise
) I-Premise
, I-Premise
were I-Premise
more I-Premise
likely I-Premise
to I-Premise
have I-Premise
at I-Premise
least I-Premise
90 I-Premise
% I-Premise
tumor I-Premise
infarction I-Premise
( I-Premise
eight I-Premise
patients I-Premise
vs I-Premise
four I-Premise
patients I-Premise
";" I-Premise
P I-Premise
= I-Premise
.03 I-Premise
) I-Premise
, I-Premise
and I-Premise
had I-Premise
a I-Premise
lower I-Premise
mean I-Premise
percent I-Premise
of I-Premise
residual I-Premise
perfused I-Premise
fibroid I-Premise
tumor I-Premise
tissue I-Premise
( I-Premise
9.6 I-Premise
% I-Premise
vs I-Premise
44.3 I-Premise
% I-Premise
";" I-Premise
P I-Premise
= I-Premise
.004 I-Premise
) I-Premise
compared I-Premise
with I-Premise
patients I-Premise
treated I-Premise
with I-Premise
PVA I-Premise
. I-Premise

Mean B-Premise
depression I-Premise
scores I-Premise
fell I-Premise
from I-Premise
6.7 I-Premise
to I-Premise
3.6 I-Premise
in I-Premise
the I-Premise
intervention I-Premise
group I-Premise
, I-Premise
compared I-Premise
with I-Premise
6.1 I-Premise
to I-Premise
5.4 I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
[ I-Premise
F I-Premise
( I-Premise
( I-Premise
1,83 I-Premise
) I-Premise
) I-Premise
= I-Premise
14.7 I-Premise
, I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
] I-Premise
. I-Premise

Among B-Premise
the I-Premise
54 I-Premise
patients I-Premise
who I-Premise
exhibited I-Premise
isolated I-Premise
local I-Premise
relapse I-Premise
, I-Premise
35 I-Premise
% I-Premise
( I-Premise
19/54 I-Premise
) I-Premise
survived I-Premise
in I-Premise
further I-Premise
remission I-Premise
longer I-Premise
than I-Premise
2 I-Premise
years I-Premise
after I-Premise
retreatment I-Premise
, I-Premise
including I-Premise
local I-Premise
therapy I-Premise
( I-Premise
surgery I-Premise
+/- I-Premise
radiotherapy I-Premise
) I-Premise
. I-Premise

However B-Premise
, I-Premise
subjective I-Premise
changes I-Premise
in I-Premise
QOL I-Premise
scores I-Premise
on I-Premise
nausea I-Premise
and I-Premise
vomiting I-Premise
were I-Premise
significantly I-Premise
higher I-Premise
in I-Premise
the I-Premise
GP I-Premise
arm I-Premise
( I-Premise
p I-Premise
= I-Premise
0.001 I-Premise
) I-Premise
. I-Premise

Liver B-Premise
and I-Premise
kidney I-Premise
function I-Premise
and I-Premise
blood I-Premise
tests I-Premise
of I-Premise
the I-Premise
treatment I-Premise
group I-Premise
were I-Premise
within I-Premise
the I-Premise
normal I-Premise
range I-Premise
before I-Premise
and I-Premise
after I-Premise
treatment I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
unexpected I-Premise
serious I-Premise
adverse I-Premise
events I-Premise
. I-Premise

Patients B-Premise
in I-Premise
the I-Premise
PCDE I-Premise
arm I-Premise
had I-Premise
a I-Premise
statistically I-Premise
significant I-Premise
higher I-Premise
frequency I-Premise
of I-Premise
combined I-Premise
complete I-Premise
plus I-Premise
partial I-Premise
responses I-Premise
compared I-Premise
with I-Premise
those I-Premise
in I-Premise
the I-Premise
EP I-Premise
arm I-Premise
( I-Premise
21 I-Premise
% I-Premise
plus I-Premise
55 I-Premise
% I-Premise
versus I-Premise
13 I-Premise
% I-Premise
plus I-Premise
48 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
P I-Premise
=.02 I-Premise
for I-Premise
difference I-Premise
in I-Premise
combined I-Premise
objective I-Premise
responses I-Premise
) I-Premise
. I-Premise

The B-Premise
difference I-Premise
in I-Premise
the I-Premise
mean I-Premise
General I-Premise
Fatigue I-Premise
score I-Premise
, I-Premise
between I-Premise
those I-Premise
who I-Premise
received I-Premise
the I-Premise
intervention I-Premise
and I-Premise
those I-Premise
who I-Premise
did I-Premise
not I-Premise
, I-Premise
was I-Premise
-3.11 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
-3.97 I-Premise
to I-Premise
-2.25 I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

One-year B-Premise
progression-free I-Premise
survival I-Premise
was I-Premise
0 I-Premise
% I-Premise
with I-Premise
FU I-Premise
versus I-Premise
10 I-Premise
% I-Premise
with I-Premise
FUP I-Premise
( I-Premise
log-rank I-Premise
test I-Premise
, I-Premise
P I-Premise
= I-Premise
0.0001 I-Premise
) I-Premise
. I-Premise

The B-Premise
final I-Premise
multivariate I-Premise
model I-Premise
for I-Premise
response I-Premise
selected I-Premise
DFI I-Premise
( I-Premise
P=0.009 I-Premise
) I-Premise
, I-Premise
multiple I-Premise
sites I-Premise
of I-Premise
visceral I-Premise
disease I-Premise
( I-Premise
P=0.037 I-Premise
) I-Premise
and I-Premise
dyspnoea I-Premise
( I-Premise
P= I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
using I-Premise
forward I-Premise
selection I-Premise
, I-Premise
but B-Premise
model I-Premise
instability I-Premise
was I-Premise
indicated I-Premise
by I-Premise
the I-Premise
inclusion I-Premise
of I-Premise
fatigue I-Premise
and I-Premise
emotional I-Premise
function I-Premise
in I-Premise
the I-Premise
final I-Premise
model I-Premise
when I-Premise
backward I-Premise
selection I-Premise
was I-Premise
used I-Premise
. I-Premise

In B-Premise
the I-Premise
gefitinib I-Premise
250 I-Premise
mg/day I-Premise
, I-Premise
500 I-Premise
mg/day I-Premise
, I-Premise
and I-Premise
methotrexate I-Premise
groups I-Premise
, I-Premise
respectively I-Premise
, I-Premise
median I-Premise
overall I-Premise
survival I-Premise
was I-Premise
5.6 I-Premise
, I-Premise
6.0 I-Premise
, I-Premise
and I-Premise
6.7 I-Premise
months I-Premise
";" I-Premise
ORRs I-Premise
( I-Premise
Response I-Premise
Evaluation I-Premise
Criteria I-Premise
in I-Premise
Solid I-Premise
Tumors I-Premise
) I-Premise
were I-Premise
2.7 I-Premise
% I-Premise
, I-Premise
7.6 I-Premise
% I-Premise
and I-Premise
3.9 I-Premise
% I-Premise
, I-Premise
with I-Premise
no I-Premise
statistically I-Premise
significant I-Premise
difference I-Premise
between I-Premise
either I-Premise
gefitinib I-Premise
arm I-Premise
and I-Premise
methotrexate I-Premise
. I-Premise

The B-Premise
rate I-Premise
of I-Premise
> I-Premise
/= I-Premise
grade I-Premise
3 I-Premise
esophagitis I-Premise
was I-Premise
30 I-Premise
% I-Premise
with I-Premise
AM I-Premise
versus I-Premise
34 I-Premise
% I-Premise
without I-Premise
AM I-Premise
( I-Premise
P I-Premise
= I-Premise
.9 I-Premise
) I-Premise
. I-Premise

The B-Premise
dose-intensified I-Premise
arm I-Premise
was I-Premise
slightly I-Premise
more I-Premise
emetogenic I-Premise
and I-Premise
generated I-Premise
more I-Premise
grade I-Premise
3 I-Premise
to I-Premise
4 I-Premise
anemia I-Premise
but I-Premise
less I-Premise
febrile I-Premise
neutropenia I-Premise
episodes I-Premise
. I-Premise

Subdomain B-Premise
analysis I-Premise
revealed I-Premise
a I-Premise
clinically I-Premise
moderate I-Premise
improvement I-Premise
from I-Premise
baseline I-Premise
for I-Premise
LAC I-Premise
in I-Premise
total I-Premise
QOL I-Premise
index I-Premise
at I-Premise
18 I-Premise
months I-Premise
( I-Premise
P I-Premise
= I-Premise
0.02 I-Premise
) I-Premise
as I-Premise
well I-Premise
as I-Premise
other I-Premise
small I-Premise
symptomatic I-Premise
improvements I-Premise
. I-Premise

By B-Premise
2 I-Premise
weeks I-Premise
post-treatment I-Premise
, I-Premise
the I-Premise
venlafaxine I-Premise
group I-Premise
experienced I-Premise
significant I-Premise
increases I-Premise
in I-Premise
hot I-Premise
flashes I-Premise
, I-Premise
whereas I-Premise
hot I-Premise
flashes I-Premise
in I-Premise
the I-Premise
acupuncture I-Premise
group I-Premise
remained I-Premise
at I-Premise
low I-Premise
levels I-Premise
. I-Premise

Lower B-Premise
scores I-Premise
were I-Premise
associated I-Premise
with I-Premise
the I-Premise
combination I-Premise
therapy I-Premise
. I-Premise

GHS B-Premise
change I-Premise
scores I-Premise
were I-Premise
-0.5 I-Premise
and I-Premise
-7.1 I-Premise
( I-Premise
P I-Premise
= I-Premise
.008 I-Premise
) I-Premise
at I-Premise
8 I-Premise
weeks I-Premise
and I-Premise
were I-Premise
-3.6 I-Premise
and I-Premise
-15.2 I-Premise
( I-Premise
P I-Premise
= I-Premise
.008 I-Premise
) I-Premise
at I-Premise
16 I-Premise
weeks I-Premise
for I-Premise
cetuximab I-Premise
and I-Premise
BSC I-Premise
, I-Premise
respectively I-Premise
. I-Premise

At B-Premise
3 I-Premise
months I-Premise
, I-Premise
G1 I-Premise
patients I-Premise
maintained/improved I-Premise
function I-Premise
, I-Premise
symptoms I-Premise
, I-Premise
and I-Premise
single-item I-Premise
scores I-Premise
( I-Premise
P I-Premise
< I-Premise
.02 I-Premise
) I-Premise
";" I-Premise
in I-Premise
G2 I-Premise
, I-Premise
only I-Premise
few I-Premise
function I-Premise
and I-Premise
symptom I-Premise
scales I-Premise
improved I-Premise
( I-Premise
P I-Premise
< I-Premise
.05 I-Premise
) I-Premise
";" I-Premise
in I-Premise
G3 I-Premise
, I-Premise
QoL I-Premise
remained I-Premise
as I-Premise
poor I-Premise
as I-Premise
after I-Premise
radiotherapy I-Premise
. I-Premise

The B-Premise
intervention I-Premise
demonstrated I-Premise
a I-Premise
trend I-Premise
toward I-Premise
improved I-Premise
CRF I-Premise
, I-Premise
although B-Premise
this I-Premise
effect I-Premise
was I-Premise
reduced I-Premise
once I-Premise
confounders I-Premise
had I-Premise
been I-Premise
controlled I-Premise
statistically I-Premise
. I-Premise

Median B-Premise
survival I-Premise
was I-Premise
14.6 I-Premise
months I-Premise
( I-Premise
temozolomide I-Premise
+ I-Premise
radiotherapy I-Premise
) I-Premise
versus I-Premise
12.1 I-Premise
months I-Premise
( I-Premise
radiotherapy I-Premise
alone I-Premise
) I-Premise
. I-Premise

Fatigue B-Premise
scores I-Premise
indicated I-Premise
less I-Premise
increase I-Premise
and I-Premise
physical I-Premise
well-being I-Premise
subscale I-Premise
scores I-Premise
showed I-Premise
less I-Premise
decline I-Premise
for I-Premise
the I-Premise
experimental I-Premise
group I-Premise
( I-Premise
p I-Premise
= I-Premise
0.008 I-Premise
and I-Premise
p I-Premise
= I-Premise
0.02 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

There B-Premise
was I-Premise
a I-Premise
trend I-Premise
towards I-Premise
improved I-Premise
global I-Premise
HRQOL I-Premise
during I-Premise
the I-Premise
treatment I-Premise
period I-Premise
. I-Premise

The B-Premise
nutrition I-Premise
intervention I-Premise
group I-Premise
had I-Premise
a I-Premise
higher I-Premise
mean I-Premise
protein I-Premise
intake I-Premise
( I-Premise
1.1 I-Premise
to I-Premise
1.3 I-Premise
g/kg/day I-Premise
) I-Premise
compared I-Premise
with I-Premise
the I-Premise
standard I-Premise
practice I-Premise
group I-Premise
( I-Premise
1.0 I-Premise
to I-Premise
1.1 I-Premise
g/kg/day I-Premise
) I-Premise
( I-Premise
P=0.001 I-Premise
) I-Premise
. I-Premise

Response B-Premise
was I-Premise
slightly I-Premise
higher I-Premise
at I-Premise
the I-Premise
175-mg/m2 I-Premise
dose I-Premise
( I-Premise
20 I-Premise
% I-Premise
) I-Premise
than I-Premise
at I-Premise
135 I-Premise
mg/m2 I-Premise
( I-Premise
15 I-Premise
% I-Premise
) I-Premise
, I-Premise
but B-Premise
this I-Premise
was I-Premise
not I-Premise
statistically I-Premise
significant I-Premise
( I-Premise
P I-Premise
= I-Premise
.2 I-Premise
) I-Premise
. I-Premise

Median B-Premise
TTP I-Premise
was I-Premise
4.5 I-Premise
and I-Premise
4.6 I-Premise
months I-Premise
respectively I-Premise
for I-Premise
weekly I-Premise
VNR/CDDP I-Premise
arm I-Premise
and I-Premise
the I-Premise
day I-Premise
1-8 I-Premise
VNR/CDDP I-Premise
one I-Premise
. I-Premise

The B-Premise
median I-Premise
PFS I-Premise
was I-Premise
8.8 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
8.1-10.4 I-Premise
months I-Premise
) I-Premise
and I-Premise
11.3 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
9.7-12.7 I-Premise
months I-Premise
";" I-Premise
P I-Premise
= I-Premise
.247 I-Premise
";" I-Premise
hazard I-Premise
ratio I-Premise
, I-Premise
0.82 I-Premise
) I-Premise
";" I-Premise
the I-Premise
median I-Premise
OS I-Premise
was I-Premise
25.0 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
18.8-not I-Premise
assessable I-Premise
[ I-Premise
N/A I-Premise
] I-Premise
months I-Premise
) I-Premise
and I-Premise
24.3 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
20.3-N/A I-Premise
months I-Premise
";" I-Premise
P I-Premise
= I-Premise
.475 I-Premise
";" I-Premise
hazard I-Premise
ratio I-Premise
, I-Premise
0.84 I-Premise
) I-Premise
, I-Premise
with I-Premise
PB I-Premise
and I-Premise
PB+G I-Premise
, I-Premise
respectively I-Premise
. I-Premise

After B-Premise
2 I-Premise
and I-Premise
3 I-Premise
years I-Premise
, I-Premise
this I-Premise
had I-Premise
decreased I-Premise
to I-Premise
49 I-Premise
% I-Premise
and I-Premise
41 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
( I-Premise
P I-Premise
< I-Premise
0.02 I-Premise
) I-Premise
. I-Premise

Cost B-Premise
savings I-Premise
due I-Premise
to I-Premise
reduced I-Premise
docetaxel I-Premise
dose I-Premise
and I-Premise
hospital I-Premise
use I-Premise
were I-Premise
the I-Premise
major I-Premise
cost I-Premise
offsets I-Premise
with I-Premise
the I-Premise
combination I-Premise
. I-Premise

No B-Premise
statistical I-Premise
significance I-Premise
was I-Premise
found I-Premise
in I-Premise
the I-Premise
FACT-G I-Premise
scores I-Premise
and I-Premise
FACT-B I-Premise
scores I-Premise
among I-Premise
different I-Premise
groups I-Premise
at I-Premise
baseline I-Premise
, I-Premise
week I-Premise
4 I-Premise
, I-Premise
week I-Premise
8 I-Premise
and I-Premise
week I-Premise
12 I-Premise
after I-Premise
NHT I-Premise
. I-Premise

As B-Premise
with I-Premise
previously I-Premise
published I-Premise
results I-Premise
at I-Premise
2 I-Premise
years I-Premise
, I-Premise
there I-Premise
was I-Premise
no I-Premise
statistically I-Premise
significant I-Premise
difference I-Premise
in I-Premise
the I-Premise
Trial I-Premise
Outcome I-Premise
Index I-Premise
of I-Premise
the I-Premise
FACT-B I-Premise
, I-Premise
the I-Premise
primary I-Premise
endpoint I-Premise
of I-Premise
the I-Premise
study I-Premise
, I-Premise
between I-Premise
treatments I-Premise
at I-Premise
5 I-Premise
years I-Premise
. I-Premise

ALT B-Premise
had I-Premise
a I-Premise
positive I-Premise
, I-Premise
statistically I-Premise
and I-Premise
clinically I-Premise
significant I-Premise
immediate I-Premise
effect I-Premise
on I-Premise
limb I-Premise
volume I-Premise
but B-Premise
no I-Premise
long-term I-Premise
effect I-Premise
was I-Premise
noted I-Premise
. I-Premise

Older B-Premise
adult I-Premise
patients I-Premise
reported I-Premise
better I-Premise
overall I-Premise
QOL I-Premise
( I-Premise
LASA I-Premise
74.4 I-Premise
vs. I-Premise
62.9 I-Premise
, I-Premise
p I-Premise
= I-Premise
0.040 I-Premise
) I-Premise
, I-Premise
higher I-Premise
social I-Premise
well-being I-Premise
( I-Premise
FACT-G I-Premise
91.1 I-Premise
vs. I-Premise
83.3 I-Premise
, I-Premise
p I-Premise
= I-Premise
0.045 I-Premise
) I-Premise
, I-Premise
and I-Premise
fewer I-Premise
problems I-Premise
with I-Premise
anger I-Premise
( I-Premise
POMS I-Premise
anger-hostility I-Premise
95.0 I-Premise
vs. I-Premise
86.4 I-Premise
, I-Premise
p I-Premise
= I-Premise
0.028 I-Premise
) I-Premise
. I-Premise

Treatments B-Premise
were I-Premise
well I-Premise
tolerated I-Premise
in I-Premise
the I-Premise
3 I-Premise
groups I-Premise
. I-Premise

These B-Premise
findings I-Premise
were I-Premise
associated I-Premise
with I-Premise
higher I-Premise
post-procedure I-Premise
pain I-Premise
scores I-Premise
in I-Premise
the I-Premise
SEMS I-Premise
patient I-Premise
group I-Premise
( I-Premise
mean I-Premise
difference I-Premise
of I-Premise
the I-Premise
European I-Premise
Organisation I-Premise
for I-Premise
Research I-Premise
and I-Premise
Treatment I-Premise
of I-Premise
Cancer I-Premise
QLQ I-Premise
C-30 I-Premise
pain I-Premise
symptom I-Premise
score I-Premise
at I-Premise
week I-Premise
1=11.13 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
: I-Premise
2.89-19.4 I-Premise
";" I-Premise
P=0.01 I-Premise
) I-Premise
. I-Premise

The B-Premise
main I-Premise
nonhematologic I-Premise
adverse I-Premise
effect I-Premise
was I-Premise
fatigue I-Premise
( I-Premise
grade I-Premise
3/4 I-Premise
in I-Premise
18 I-Premise
% I-Premise
of I-Premise
patients I-Premise
) I-Premise
. I-Premise

Grade B-Premise
2-3 I-Premise
alopecia I-Premise
( I-Premise
68 I-Premise
% I-Premise
PE I-Premise
vs I-Premise
17 I-Premise
% I-Premise
GC I-Premise
) I-Premise
and I-Premise
nausea I-Premise
( I-Premise
43 I-Premise
% I-Premise
PE I-Premise
vs I-Premise
26 I-Premise
% I-Premise
GC I-Premise
) I-Premise
were I-Premise
more I-Premise
frequent I-Premise
with I-Premise
PE I-Premise
. I-Premise

Progression-free B-Premise
survival I-Premise
( I-Premise
PFS I-Premise
) I-Premise
from I-Premise
date I-Premise
of I-Premise
randomization I-Premise
on I-Premise
step I-Premise
2 I-Premise
was I-Premise
significantly I-Premise
better I-Premise
with I-Premise
topotecan I-Premise
compared I-Premise
with I-Premise
observation I-Premise
( I-Premise
3.6 I-Premise
months I-Premise
v I-Premise
2.3 I-Premise
months I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

Intention-to-treat B-Premise
analyses I-Premise
indicated I-Premise
that I-Premise
AET I-Premise
resulted I-Premise
in I-Premise
a I-Premise
nonsignificant I-Premise
( I-Premise
P I-Premise
= I-Premise
0.16 I-Premise
) I-Premise
improvement I-Premise
in I-Premise
global I-Premise
sleep I-Premise
quality I-Premise
compared I-Premise
with I-Premise
usual I-Premise
care I-Premise
[ I-Premise
mean I-Premise
group I-Premise
difference I-Premise
= I-Premise
-0.64 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
( I-Premise
CI I-Premise
) I-Premise
, I-Premise
-1.56 I-Premise
to I-Premise
+0.27 I-Premise
] I-Premise
. I-Premise

Tamoxifen B-Premise
reduced I-Premise
the I-Premise
risk I-Premise
of I-Premise
invasive I-Premise
breast I-Premise
cancer I-Premise
by I-Premise
49 I-Premise
% I-Premise
( I-Premise
two-sided I-Premise
P I-Premise
< I-Premise
.00001 I-Premise
) I-Premise
, I-Premise
with I-Premise
cumulative I-Premise
incidence I-Premise
through I-Premise
69 I-Premise
months I-Premise
of I-Premise
follow-up I-Premise
of I-Premise
43.4 I-Premise
versus I-Premise
22.0 I-Premise
per I-Premise
1000 I-Premise
women I-Premise
in I-Premise
the I-Premise
placebo I-Premise
and I-Premise
tamoxifen I-Premise
groups I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Median B-Premise
time I-Premise
to I-Premise
progression I-Premise
of I-Premise
mean I-Premise
pain I-Premise
intensity I-Premise
was I-Premise
longer I-Premise
in I-Premise
patients I-Premise
assigned I-Premise
to I-Premise
abiraterone I-Premise
plus I-Premise
prednisone I-Premise
( I-Premise
26·7 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
19·3-not I-Premise
estimable I-Premise
] I-Premise
) I-Premise
than I-Premise
in I-Premise
those I-Premise
assigned I-Premise
to I-Premise
placebo I-Premise
plus I-Premise
prednisone I-Premise
( I-Premise
18·4 I-Premise
months I-Premise
[ I-Premise
14·9-not I-Premise
estimable I-Premise
] I-Premise
";" I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
0·82 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0·67-1·00 I-Premise
";" I-Premise
p=0·0490 I-Premise
) I-Premise
, I-Premise
as I-Premise
was I-Premise
median I-Premise
time I-Premise
to I-Premise
progression I-Premise
of I-Premise
pain I-Premise
interference I-Premise
with I-Premise
daily I-Premise
activities I-Premise
( I-Premise
10·3 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
9·3-13·0 I-Premise
] I-Premise
vs I-Premise
7·4 I-Premise
months I-Premise
[ I-Premise
6·4-8·6 I-Premise
] I-Premise
";" I-Premise
HR I-Premise
0·79 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0·67-0·93 I-Premise
";" I-Premise
p=0·005 I-Premise
) I-Premise
. I-Premise

Quality B-Premise
of I-Premise
life I-Premise
was I-Premise
well I-Premise
preserved I-Premise
in I-Premise
the I-Premise
euthyroid I-Premise
group I-Premise
, I-Premise
compared I-Premise
with I-Premise
the I-Premise
hypothyroid I-Premise
group I-Premise
, I-Premise
as I-Premise
demonstrated I-Premise
by I-Premise
their I-Premise
lower I-Premise
pretreatment I-Premise
scores I-Premise
on I-Premise
the I-Premise
Billewicz I-Premise
scale I-Premise
for I-Premise
hypothyroid I-Premise
signs I-Premise
and I-Premise
symptoms I-Premise
, I-Premise
27 I-Premise
+/- I-Premise
7 I-Premise
vs. I-Premise
18 I-Premise
+/- I-Premise
4 I-Premise
( I-Premise
P I-Premise
< I-Premise
0.0001 I-Premise
) I-Premise
and I-Premise
their I-Premise
significantly I-Premise
higher I-Premise
Short I-Premise
Form-36 I-Premise
Health I-Premise
Assessment I-Premise
Scale I-Premise
scores I-Premise
in I-Premise
five I-Premise
of I-Premise
eight I-Premise
categories I-Premise
. I-Premise

Dose B-Premise
intensities I-Premise
of I-Premise
concurrent I-Premise
cisplatin I-Premise
, I-Premise
late I-Premise
RT I-Premise
toxicities I-Premise
and I-Premise
quality I-Premise
of I-Premise
life I-Premise
scores I-Premise
were I-Premise
comparable I-Premise
in I-Premise
both I-Premise
arms I-Premise
. I-Premise

QOL B-Premise
response I-Premise
analyses I-Premise
showed I-Premise
that I-Premise
44 I-Premise
% I-Premise
, I-Premise
34 I-Premise
% I-Premise
, I-Premise
and I-Premise
42 I-Premise
% I-Premise
of I-Premise
patients I-Premise
receiving I-Premise
erlotinib I-Premise
had I-Premise
improvement I-Premise
in I-Premise
these I-Premise
three I-Premise
symptoms I-Premise
, I-Premise
respectively I-Premise
. I-Premise

At B-Premise
6 I-Premise
months I-Premise
after I-Premise
the I-Premise
end I-Premise
of I-Premise
RT I-Premise
, I-Premise
global I-Premise
HRQOL I-Premise
was I-Premise
higher I-Premise
in I-Premise
the I-Premise
TPF I-Premise
arm I-Premise
than I-Premise
in I-Premise
the I-Premise
PF I-Premise
arm I-Premise
, I-Premise
but B-Premise
the I-Premise
low I-Premise
compliance I-Premise
does I-Premise
not I-Premise
allow I-Premise
to I-Premise
draw I-Premise
definitive I-Premise
conclusions I-Premise
. I-Premise

Trends B-Premise
observed I-Premise
for I-Premise
the I-Premise
treatment I-Premise
groups I-Premise
were I-Premise
similar I-Premise
. I-Premise

ES B-Premise
scores I-Premise
and I-Premise
CES-D I-Premise
scores I-Premise
were I-Premise
similar I-Premise
in I-Premise
all I-Premise
treatment I-Premise
groups I-Premise
. I-Premise

Results B-Premise
showed I-Premise
improved I-Premise
patient I-Premise
depression I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
as I-Premise
a I-Premise
result I-Premise
of I-Premise
the I-Premise
intervention I-Premise
and I-Premise
improvement I-Premise
in I-Premise
both I-Premise
groups I-Premise
in I-Premise
patients I-Premise
' I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

At B-Premise
the I-Premise
10-point I-Premise
minimal I-Premise
important I-Premise
difference I-Premise
, I-Premise
the I-Premise
median I-Premise
TDD I-Premise
with I-Premise
EVE I-Premise
+ I-Premise
EXE I-Premise
was I-Premise
11.7 I-Premise
months I-Premise
versus I-Premise
8.4 I-Premise
months I-Premise
with I-Premise
PBO I-Premise
+ I-Premise
EXE I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
, I-Premise
0.80 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.1017 I-Premise
) I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
found I-Premise
in I-Premise
the I-Premise
primary I-Premise
outcome I-Premise
measure I-Premise
, I-Premise
the I-Premise
hot I-Premise
flash I-Premise
severity I-Premise
score I-Premise
, I-Premise
although B-Premise
there I-Premise
was I-Premise
a I-Premise
positive I-Premise
trend I-Premise
in I-Premise
the I-Premise
single I-Premise
remedy I-Premise
group I-Premise
during I-Premise
the I-Premise
first I-Premise
3 I-Premise
months I-Premise
of I-Premise
the I-Premise
study I-Premise
( I-Premise
p I-Premise
= I-Premise
0.1 I-Premise
) I-Premise
. I-Premise

By B-Premise
contrast I-Premise
, I-Premise
for I-Premise
patients I-Premise
with I-Premise
ER-positive I-Premise
tumors I-Premise
, I-Premise
addition I-Premise
of I-Premise
CMF I-Premise
provided I-Premise
no I-Premise
benefit I-Premise
in I-Premise
terms I-Premise
of I-Premise
DFS I-Premise
( I-Premise
5-year I-Premise
DFS I-Premise
= I-Premise
84 I-Premise
% I-Premise
for I-Premise
CMF I-Premise
-- I-Premise
> I-Premise
tamoxifen I-Premise
versus I-Premise
85 I-Premise
% I-Premise
for I-Premise
tamoxifen I-Premise
alone I-Premise
";" I-Premise
difference I-Premise
= I-Premise
-1 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
-6 I-Premise
% I-Premise
to I-Premise
4 I-Premise
% I-Premise
";" I-Premise
RR I-Premise
= I-Premise
0.99 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
0.75 I-Premise
to I-Premise
1.30 I-Premise
";" I-Premise
P I-Premise
=.92 I-Premise
) I-Premise
or I-Premise
OS I-Premise
( I-Premise
5-year I-Premise
OS I-Premise
= I-Premise
95 I-Premise
% I-Premise
for I-Premise
CMF I-Premise
-- I-Premise
> I-Premise
tamoxifen I-Premise
versus I-Premise
93 I-Premise
% I-Premise
for I-Premise
tamoxifen I-Premise
alone I-Premise
";" I-Premise
difference I-Premise
= I-Premise
2 I-Premise
% I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
-1 I-Premise
% I-Premise
to I-Premise
5 I-Premise
% I-Premise
";" I-Premise
RR I-Premise
= I-Premise
0.95 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
0.64 I-Premise
to I-Premise
1.40 I-Premise
";" I-Premise
P I-Premise
=.80 I-Premise
) I-Premise
. I-Premise

Patients B-Premise
with I-Premise
UM I-Premise
had I-Premise
lower I-Premise
levels I-Premise
of I-Premise
pain I-Premise
one I-Premise
week I-Premise
after I-Premise
surgery I-Premise
. I-Premise

Median B-Premise
progression-free I-Premise
survival I-Premise
was I-Premise
18.2 I-Premise
months I-Premise
in I-Premise
the I-Premise
TC-Top I-Premise
arm I-Premise
versus I-Premise
18.5 I-Premise
months I-Premise
in I-Premise
the I-Premise
TC I-Premise
arm I-Premise
( I-Premise
stratum-adjusted I-Premise
HR I-Premise
= I-Premise
0.97 I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
0.85 I-Premise
to I-Premise
1.10 I-Premise
] I-Premise
";" I-Premise
P I-Premise
= I-Premise
.688 I-Premise
) I-Premise
. I-Premise

At B-Premise
the I-Premise
post-treatment I-Premise
assessment I-Premise
, I-Premise
IMCP I-Premise
participants I-Premise
demonstrated I-Premise
significantly I-Premise
greater I-Premise
improvement I-Premise
than I-Premise
the I-Premise
control I-Premise
condition I-Premise
for I-Premise
the I-Premise
primary I-Premise
outcomes I-Premise
of I-Premise
spiritual I-Premise
well-being I-Premise
( I-Premise
b I-Premise
= I-Premise
0.39 I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
, I-Premise
including I-Premise
both I-Premise
components I-Premise
of I-Premise
spiritual I-Premise
well-being I-Premise
( I-Premise
sense I-Premise
of I-Premise
meaning I-Premise
: I-Premise
b I-Premise
= I-Premise
0.34 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.003 I-Premise
and I-Premise
faith I-Premise
: I-Premise
b I-Premise
= I-Premise
0.42 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.03 I-Premise
) I-Premise
, I-Premise
and I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
b I-Premise
= I-Premise
0.76 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.013 I-Premise
) I-Premise
. I-Premise

A B-Premise
complete I-Premise
resolution I-Premise
of I-Premise
all I-Premise
symptoms I-Premise
was I-Premise
achieved I-Premise
in I-Premise
three I-Premise
( I-Premise
5 I-Premise
% I-Premise
) I-Premise
on I-Premise
regimen I-Premise
1 I-Premise
, I-Premise
and I-Premise
in I-Premise
14 I-Premise
( I-Premise
23 I-Premise
% I-Premise
) I-Premise
patients I-Premise
on I-Premise
regimen I-Premise
2 I-Premise
( I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
, I-Premise
a I-Premise
difference I-Premise
in I-Premise
the I-Premise
proportion I-Premise
between I-Premise
the I-Premise
two I-Premise
regimens I-Premise
of I-Premise
21 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
10-33 I-Premise
) I-Premise
. I-Premise

Patients B-Premise
in I-Premise
the I-Premise
rhDNase I-Premise
group I-Premise
exhibited I-Premise
significant I-Premise
clinical I-Premise
improvement I-Premise
in I-Premise
OPS I-Premise
, I-Premise
blindly I-Premise
assessed I-Premise
by I-Premise
a I-Premise
physician I-Premise
, I-Premise
compared I-Premise
with I-Premise
the I-Premise
placebo I-Premise
group I-Premise
( I-Premise
67 I-Premise
% I-Premise
vs I-Premise
27 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
P=.046 I-Premise
) I-Premise
. I-Premise

An B-Premise
objective I-Premise
response I-Premise
was I-Premise
observed I-Premise
in I-Premise
28 I-Premise
, I-Premise
21 I-Premise
, I-Premise
22 I-Premise
and I-Premise
10 I-Premise
% I-Premise
of I-Premise
the I-Premise
patients I-Premise
in I-Premise
the I-Premise
LV5FU2 I-Premise
, I-Premise
ldLV5FU2 I-Premise
, I-Premise
HD-FU I-Premise
and I-Premise
Tomudex I-Premise
arms I-Premise
, I-Premise
respectively I-Premise
( I-Premise
p I-Premise
= I-Premise
0.04 I-Premise
) I-Premise
. I-Premise

At B-Premise
a I-Premise
median I-Premise
followup I-Premise
of I-Premise
26 I-Premise
months I-Premise
we I-Premise
observed I-Premise
12 I-Premise
biochemical I-Premise
relapses I-Premise
. I-Premise

Frequent B-Premise
grade I-Premise
3 I-Premise
to I-Premise
4 I-Premise
toxicities I-Premise
for I-Premise
DCF I-Premise
v I-Premise
CF I-Premise
were I-Premise
: I-Premise
neutropenia I-Premise
( I-Premise
82 I-Premise
% I-Premise
v I-Premise
57 I-Premise
% I-Premise
) I-Premise
, I-Premise
stomatitis I-Premise
( I-Premise
21 I-Premise
% I-Premise
v I-Premise
27 I-Premise
% I-Premise
) I-Premise
, I-Premise
diarrhea I-Premise
( I-Premise
19 I-Premise
% I-Premise
v I-Premise
8 I-Premise
% I-Premise
) I-Premise
, I-Premise
lethargy I-Premise
( I-Premise
19 I-Premise
% I-Premise
v I-Premise
14 I-Premise
% I-Premise
) I-Premise
. I-Premise

Median B-Premise
OS I-Premise
was I-Premise
13.8 I-Premise
months I-Premise
for I-Premise
arm I-Premise
1 I-Premise
versus I-Premise
14.4 I-Premise
months I-Premise
for I-Premise
arm I-Premise
2 I-Premise
( I-Premise
P I-Premise
=.4 I-Premise
) I-Premise
. I-Premise

Significant B-Premise
KPS-by-gender I-Premise
interactions I-Premise
were I-Premise
noted I-Premise
for I-Premise
FACT-L I-Premise
in I-Premise
the I-Premise
physical I-Premise
well-being I-Premise
and I-Premise
additional I-Premise
concerns-lung I-Premise
subscales I-Premise
( I-Premise
P I-Premise
= I-Premise
0.012 I-Premise
and I-Premise
P I-Premise
= I-Premise
0.0003 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

There B-Premise
was I-Premise
a I-Premise
significant I-Premise
decrease I-Premise
in I-Premise
QoL I-Premise
from I-Premise
baseline I-Premise
( I-Premise
t0 I-Premise
) I-Premise
to I-Premise
t1 I-Premise
( I-Premise
RRA I-Premise
period I-Premise
) I-Premise
in I-Premise
the I-Premise
hypothyroid I-Premise
group I-Premise
with I-Premise
significant I-Premise
differences I-Premise
in I-Premise
FACIT-F I-Premise
TOI I-Premise
( I-Premise
P I-Premise
< I-Premise
10 I-Premise
( I-Premise
-3 I-Premise
) I-Premise
) I-Premise
, I-Premise
FACT-G I-Premise
total I-Premise
score I-Premise
( I-Premise
P I-Premise
= I-Premise
0.005 I-Premise
) I-Premise
and I-Premise
FACIT-F I-Premise
total I-Premise
score I-Premise
( I-Premise
P I-Premise
= I-Premise
0.003 I-Premise
) I-Premise
. I-Premise

Progression-free B-Premise
survival I-Premise
( I-Premise
PFS I-Premise
) I-Premise
of I-Premise
the I-Premise
patients I-Premise
in I-Premise
the I-Premise
Tomudex I-Premise
arm I-Premise
was I-Premise
statistically I-Premise
lower I-Premise
compared I-Premise
to I-Premise
that I-Premise
of I-Premise
patients I-Premise
treated I-Premise
with I-Premise
LV5FU2 I-Premise
or I-Premise
ldLV5FU2 I-Premise
( I-Premise
combined I-Premise
group I-Premise
";" I-Premise
p I-Premise
= I-Premise
0.013 I-Premise
, I-Premise
log I-Premise
rank I-Premise
test I-Premise
) I-Premise
. I-Premise

The B-Premise
net I-Premise
balance I-Premise
resulted I-Premise
in I-Premise
$ I-Premise
351 I-Premise
extra I-Premise
cost I-Premise
per I-Premise
patient I-Premise
randomly I-Premise
allocated I-Premise
to I-Premise
the I-Premise
laparoscopic I-Premise
group I-Premise
. I-Premise

The B-Premise
median I-Premise
survival I-Premise
time I-Premise
was I-Premise
4.7 I-Premise
months I-Premise
in I-Premise
the I-Premise
octreotide I-Premise
group I-Premise
compared I-Premise
with I-Premise
5.3 I-Premise
months I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
. I-Premise

Global B-Premise
quality I-Premise
of I-Premise
life I-Premise
was I-Premise
similar I-Premise
in I-Premise
both I-Premise
arms I-Premise
, I-Premise
but B-Premise
substantive I-Premise
differences I-Premise
in I-Premise
many I-Premise
symptom I-Premise
scores I-Premise
favored I-Premise
docetaxel I-Premise
. I-Premise

However B-Premise
, I-Premise
at I-Premise
the I-Premise
final I-Premise
analysis I-Premise
in I-Premise
July I-Premise
2006 I-Premise
of I-Premise
all I-Premise
patients I-Premise
( I-Premise
n=189 I-Premise
) I-Premise
and I-Premise
with I-Premise
longer I-Premise
follow-up I-Premise
, I-Premise
survival I-Premise
did I-Premise
not I-Premise
differ I-Premise
significantly I-Premise
between I-Premise
the I-Premise
treatment I-Premise
groups I-Premise
( I-Premise
unadjusted I-Premise
hazard I-Premise
ratio I-Premise
1.35 I-Premise
[ I-Premise
0.95-1.91 I-Premise
] I-Premise
, I-Premise
log-rank I-Premise
p=0.09 I-Premise
";" I-Premise
adjusted I-Premise
hazard I-Premise
ratio I-Premise
1.27 I-Premise
[ I-Premise
0.87-1.84 I-Premise
] I-Premise
, I-Premise
Cox I-Premise
model I-Premise
p=0.20 I-Premise
) I-Premise
. I-Premise

No B-Premise
differences I-Premise
were I-Premise
found I-Premise
between I-Premise
groups I-Premise
regarding I-Premise
quality I-Premise
of I-Premise
life I-Premise
, I-Premise
complications I-Premise
, I-Premise
drainage I-Premise
time I-Premise
, I-Premise
hospital I-Premise
stay I-Premise
, I-Premise
and I-Premise
survival I-Premise
. I-Premise

At B-Premise
3 I-Premise
months I-Premise
, I-Premise
the I-Premise
reduction I-Premise
of I-Premise
incidence/severity I-Premise
of I-Premise
grade I-Premise
1+2 I-Premise
anorexia I-Premise
, I-Premise
nausea/vomiting I-Premise
, I-Premise
xerostomia I-Premise
, I-Premise
and I-Premise
dysgeusia I-Premise
was I-Premise
different I-Premise
: I-Premise
90 I-Premise
% I-Premise
of I-Premise
the I-Premise
patients I-Premise
improved I-Premise
in I-Premise
group I-Premise
1 I-Premise
versus I-Premise
67 I-Premise
% I-Premise
in I-Premise
group I-Premise
2 I-Premise
versus I-Premise
51 I-Premise
% I-Premise
in I-Premise
group I-Premise
3 I-Premise
( I-Premise
p I-Premise
< I-Premise
.0001 I-Premise
) I-Premise
. I-Premise

No B-Premise
study I-Premise
arm I-Premise
effect I-Premise
was I-Premise
observed I-Premise
for I-Premise
function I-Premise
discussions I-Premise
. I-Premise

Compared B-Premise
with I-Premise
the I-Premise
control I-Premise
group I-Premise
, I-Premise
the I-Premise
intervention I-Premise
group I-Premise
had I-Premise
an I-Premise
improvement I-Premise
in I-Premise
fatigue I-Premise
as I-Premise
shown I-Premise
by I-Premise
a I-Premise
significantly I-Premise
greater I-Premise
decrease I-Premise
in I-Premise
BFI I-Premise
global I-Premise
score I-Premise
( I-Premise
-0.66 I-Premise
points I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
-1.04 I-Premise
to I-Premise
-0.27 I-Premise
) I-Premise
and I-Premise
FSS I-Premise
total I-Premise
score I-Premise
( I-Premise
-0.49 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
-0.78 I-Premise
to I-Premise
-0.21 I-Premise
) I-Premise
. I-Premise

Mean B-Premise
total I-Premise
costs I-Premise
of I-Premise
GJJ I-Premise
were I-Premise
higher I-Premise
compared I-Premise
with I-Premise
stent I-Premise
placement I-Premise
( I-Premise
$ I-Premise
16,535 I-Premise
vs I-Premise
$ I-Premise
11,720 I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
P I-Premise
= I-Premise
.049 I-Premise
[ I-Premise
comparing I-Premise
medians I-Premise
] I-Premise
) I-Premise
. I-Premise

At B-Premise
eight I-Premise
weeks I-Premise
, I-Premise
patients I-Premise
in I-Premise
the I-Premise
thalidomide I-Premise
group I-Premise
had I-Premise
lost I-Premise
0.06 I-Premise
kg I-Premise
in I-Premise
weight I-Premise
and I-Premise
0.5 I-Premise
cm I-Premise
( I-Premise
3 I-Premise
) I-Premise
in I-Premise
AMA I-Premise
compared I-Premise
with I-Premise
a I-Premise
loss I-Premise
of I-Premise
3.62 I-Premise
kg I-Premise
( I-Premise
absolute I-Premise
difference I-Premise
-3.57 I-Premise
kg I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
-6.8 I-Premise
to I-Premise
-0.3 I-Premise
) I-Premise
";" I-Premise
p I-Premise
= I-Premise
0.034 I-Premise
) I-Premise
and I-Premise
8.4 I-Premise
cm I-Premise
( I-Premise
3 I-Premise
) I-Premise
( I-Premise
absolute I-Premise
difference I-Premise
-7.9 I-Premise
cm I-Premise
( I-Premise
3 I-Premise
) I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
-14.0 I-Premise
to I-Premise
-1.8 I-Premise
) I-Premise
";" I-Premise
p I-Premise
= I-Premise
0.014 I-Premise
) I-Premise
in I-Premise
the I-Premise
placebo I-Premise
group I-Premise
. I-Premise

Eight B-Premise
of I-Premise
the I-Premise
17 I-Premise
quality-of-life I-Premise
( I-Premise
QOL I-Premise
) I-Premise
variables I-Premise
assessed I-Premise
showed I-Premise
an I-Premise
improvement I-Premise
of I-Premise
more I-Premise
than I-Premise
10 I-Premise
% I-Premise
between I-Premise
baseline I-Premise
and I-Premise
the I-Premise
start I-Premise
of I-Premise
the I-Premise
third I-Premise
cycle I-Premise
of I-Premise
treatment I-Premise
. I-Premise

Patients B-Premise
in I-Premise
the I-Premise
78-Gy I-Premise
arm I-Premise
reported I-Premise
more I-Premise
frequent I-Premise
bowel I-Premise
movements I-Premise
at I-Premise
3 I-Premise
years I-Premise
and I-Premise
less I-Premise
change I-Premise
in I-Premise
bowel I-Premise
function I-Premise
at I-Premise
2 I-Premise
years I-Premise
than I-Premise
patients I-Premise
in I-Premise
the I-Premise
70-Gy I-Premise
arm I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
difference I-Premise
between I-Premise
the I-Premise
two I-Premise
groups I-Premise
in I-Premise
disease-free I-Premise
survival I-Premise
( I-Premise
DFS I-Premise
) I-Premise
( I-Premise
2-year I-Premise
DFS I-Premise
79.8 I-Premise
% I-Premise
in I-Premise
the I-Premise
intervention I-Premise
arm I-Premise
and I-Premise
76.4 I-Premise
% I-Premise
in I-Premise
the I-Premise
control I-Premise
arm I-Premise
";" I-Premise
p I-Premise
= I-Premise
0.527 I-Premise
) I-Premise
and I-Premise
overall I-Premise
survival I-Premise
( I-Premise
OS I-Premise
) I-Premise
( I-Premise
2-year I-Premise
OS I-Premise
83.1 I-Premise
% I-Premise
in I-Premise
the I-Premise
intervention I-Premise
arm I-Premise
and I-Premise
84.3 I-Premise
% I-Premise
in I-Premise
the I-Premise
control I-Premise
arm I-Premise
";" I-Premise
p I-Premise
= I-Premise
0.925 I-Premise
) I-Premise
. I-Premise

The B-Premise
corresponding I-Premise
mean I-Premise
amounts I-Premise
of I-Premise
residual I-Premise
contrast-enhancing I-Premise
tumor I-Premise
tissue I-Premise
were I-Premise
29.2 I-Premise
and I-Premise
24.4 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Median B-Premise
survival I-Premise
times I-Premise
were I-Premise
29 I-Premise
weeks I-Premise
in I-Premise
the I-Premise
chemotherapy I-Premise
group I-Premise
versus I-Premise
11 I-Premise
weeks I-Premise
in I-Premise
the I-Premise
supportive I-Premise
care I-Premise
group I-Premise
, I-Premise
and I-Premise
1-year I-Premise
survival I-Premise
rates I-Premise
were I-Premise
28 I-Premise
% I-Premise
versus I-Premise
8 I-Premise
% I-Premise
. I-Premise

Fatigue B-Premise
at I-Premise
T2 I-Premise
was I-Premise
predicted I-Premise
by I-Premise
a I-Premise
significant I-Premise
interaction I-Premise
between I-Premise
self-reported I-Premise
cognitive I-Premise
functioning I-Premise
and I-Premise
CBT I-Premise
. I-Premise

For B-Premise
in-hospital I-Premise
mortality I-Premise
, I-Premise
one I-Premise
patient I-Premise
in I-Premise
the I-Premise
open I-Premise
oesophagectomy I-Premise
group I-Premise
died I-Premise
from I-Premise
anastomotic I-Premise
leakage I-Premise
and I-Premise
two I-Premise
in I-Premise
the I-Premise
minimally I-Premise
invasive I-Premise
group I-Premise
from I-Premise
aspiration I-Premise
and I-Premise
mediastinitis I-Premise
after I-Premise
anastomotic I-Premise
leakage I-Premise
. I-Premise

The B-Premise
projected I-Premise
2-year I-Premise
PFS I-Premise
is I-Premise
90.4 I-Premise
% I-Premise
on I-Premise
three I-Premise
cycles I-Premise
and I-Premise
89.4 I-Premise
% I-Premise
on I-Premise
four I-Premise
cycles I-Premise
. I-Premise

Cox B-Premise
multivariate I-Premise
analysis I-Premise
showed I-Premise
paclitaxel I-Premise
plus I-Premise
supportive I-Premise
care I-Premise
to I-Premise
be I-Premise
statistically I-Premise
significantly I-Premise
associated I-Premise
with I-Premise
improved I-Premise
survival I-Premise
( I-Premise
two-sided I-Premise
P I-Premise
=.048 I-Premise
) I-Premise
. I-Premise

The B-Premise
body I-Premise
image I-Premise
and I-Premise
cosmesis I-Premise
scores I-Premise
of I-Premise
female I-Premise
patients I-Premise
were I-Premise
significantly I-Premise
higher I-Premise
in I-Premise
the I-Premise
LRP I-Premise
group I-Premise
than I-Premise
in I-Premise
the I-Premise
ORP I-Premise
group I-Premise
( I-Premise
body I-Premise
image I-Premise
, I-Premise
17.4 I-Premise
vs I-Premise
14.9 I-Premise
";" I-Premise
cosmesis I-Premise
, I-Premise
19.1 I-Premise
vs I-Premise
13.0 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

Significant B-Premise
improvements I-Premise
in I-Premise
self-reported I-Premise
anxiety I-Premise
, I-Premise
depression I-Premise
, I-Premise
interference I-Premise
of I-Premise
hot I-Premise
flashes I-Premise
on I-Premise
daily I-Premise
activities I-Premise
, I-Premise
and I-Premise
sleep I-Premise
were I-Premise
observed I-Premise
for I-Premise
patients I-Premise
who I-Premise
received I-Premise
the I-Premise
hypnosis I-Premise
intervention I-Premise
( I-Premise
P I-Premise
< I-Premise
.005 I-Premise
) I-Premise
in I-Premise
comparison I-Premise
to I-Premise
the I-Premise
no I-Premise
treatment I-Premise
control I-Premise
group I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
difference I-Premise
in I-Premise
response I-Premise
rates I-Premise
, I-Premise
with I-Premise
64 I-Premise
% I-Premise
( I-Premise
complete I-Premise
response I-Premise
[ I-Premise
CR I-Premise
] I-Premise
, I-Premise
9 I-Premise
% I-Premise
) I-Premise
for I-Premise
fludarabine I-Premise
versus I-Premise
52 I-Premise
% I-Premise
( I-Premise
CR I-Premise
, I-Premise
7 I-Premise
% I-Premise
) I-Premise
for I-Premise
CVP I-Premise
( I-Premise
P I-Premise
=.72 I-Premise
) I-Premise
. I-Premise

The B-Premise
groups I-Premise
that I-Premise
included I-Premise
CBT I-Premise
also I-Premise
showed I-Premise
a I-Premise
significant I-Premise
decrease I-Premise
in I-Premise
the I-Premise
perceived I-Premise
burden I-Premise
of I-Premise
hot I-Premise
flashes I-Premise
and I-Premise
night I-Premise
sweats I-Premise
( I-Premise
problem I-Premise
rating I-Premise
scale I-Premise
of I-Premise
the I-Premise
Hot I-Premise
Flush I-Premise
Rating I-Premise
Scale I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
";" I-Premise
effect I-Premise
size I-Premise
, I-Premise
0.39-0.56 I-Premise
) I-Premise
and I-Premise
an I-Premise
increase I-Premise
in I-Premise
sexual I-Premise
activity I-Premise
( I-Premise
Sexual I-Premise
Activity I-Premise
Questionnaire I-Premise
habit I-Premise
subscale I-Premise
";" I-Premise
P=.027 I-Premise
";" I-Premise
effect I-Premise
size I-Premise
, I-Premise
0.65 I-Premise
) I-Premise
. I-Premise

AET B-Premise
did I-Premise
not I-Premise
interfere I-Premise
with I-Premise
chemotherapy I-Premise
completion I-Premise
rate I-Premise
or I-Premise
treatment I-Premise
response I-Premise
. I-Premise

A B-Premise
slight I-Premise
increase I-Premise
in I-Premise
transfusions I-Premise
was I-Premise
reported I-Premise
in I-Premise
the I-Premise
QW I-Premise
group I-Premise
. I-Premise

Conversely B-Premise
, I-Premise
the I-Premise
nocturnal I-Premise
group I-Premise
exhibited I-Premise
a I-Premise
significant I-Premise
decrease I-Premise
in I-Premise
the I-Premise
occurrence I-Premise
of I-Premise
muscle I-Premise
cramps I-Premise
in I-Premise
the I-Premise
legs I-Premise
( I-Premise
P I-Premise
= I-Premise
0.014 I-Premise
) I-Premise
and I-Premise
significantly I-Premise
improved I-Premise
Fisher I-Premise
's I-Premise
ratio I-Premise
after I-Premise
3 I-Premise
months I-Premise
( I-Premise
P I-Premise
= I-Premise
0.04 I-Premise
) I-Premise
. I-Premise

Comparison B-Premise
of I-Premise
combined I-Premise
hormone I-Premise
therapy I-Premise
( I-Premise
n=815 I-Premise
) I-Premise
versus I-Premise
oestrogen I-Premise
therapy I-Premise
( I-Premise
n=826 I-Premise
) I-Premise
outcomes I-Premise
revealed I-Premise
no I-Premise
significant I-Premise
differences I-Premise
. I-Premise

The B-Premise
treatment I-Premise
groups I-Premise
reported I-Premise
improved I-Premise
QoL I-Premise
, I-Premise
fitness I-Premise
and I-Premise
fatigue I-Premise
over I-Premise
time I-Premise
and I-Premise
changes I-Premise
observed I-Premise
between I-Premise
baseline I-Premise
and I-Premise
post-intervention I-Premise
were I-Premise
clinically I-Premise
relevant I-Premise
. I-Premise

Median B-Premise
PFS I-Premise
was I-Premise
5.5 I-Premise
months I-Premise
in I-Premise
both I-Premise
arms I-Premise
( I-Premise
HR I-Premise
, I-Premise
1.04 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.727 I-Premise
) I-Premise
, I-Premise
while I-Premise
ORR I-Premise
was I-Premise
25 I-Premise
% I-Premise
in I-Premise
both I-Premise
arms I-Premise
( I-Premise
P I-Premise
= I-Premise
1.0 I-Premise
) I-Premise
. I-Premise

The B-Premise
3-drug I-Premise
combination I-Premise
, I-Premise
supportive I-Premise
care I-Premise
and I-Premise
radiotherapy I-Premise
groups I-Premise
did I-Premise
not I-Premise
differ I-Premise
significantly I-Premise
from I-Premise
each I-Premise
other I-Premise
with I-Premise
respect I-Premise
to I-Premise
the I-Premise
total I-Premise
FLI-C I-Premise
score I-Premise
or I-Premise
its I-Premise
subscales I-Premise
. I-Premise

By B-Premise
contrast I-Premise
, I-Premise
QoL I-Premise
was I-Premise
preserved I-Premise
in I-Premise
the I-Premise
rhTSH I-Premise
group I-Premise
. I-Premise

A B-Premise
statistically I-Premise
significant I-Premise
improvement I-Premise
in I-Premise
resilience I-Premise
, I-Premise
perceived I-Premise
stress I-Premise
, I-Premise
anxiety I-Premise
, I-Premise
and I-Premise
overall I-Premise
quality I-Premise
of I-Premise
life I-Premise
at I-Premise
12 I-Premise
weeks I-Premise
, I-Premise
compared I-Premise
with I-Premise
baseline I-Premise
was I-Premise
observed I-Premise
in I-Premise
the I-Premise
study I-Premise
arm I-Premise
. I-Premise

Mean B-Premise
hemoglobin I-Premise
levels I-Premise
were I-Premise
higher I-Premise
in I-Premise
the I-Premise
epoetin I-Premise
alfa I-Premise
group I-Premise
compared I-Premise
with I-Premise
the I-Premise
placebo I-Premise
group I-Premise
after I-Premise
4 I-Premise
cycles I-Premise
of I-Premise
chemotherapy I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
other I-Premise
significant I-Premise
associations I-Premise
between I-Premise
attrition I-Premise
and I-Premise
any I-Premise
demographic I-Premise
, I-Premise
medical I-Premise
, I-Premise
psychiatric I-Premise
, I-Premise
or I-Premise
study-related I-Premise
variables I-Premise
. I-Premise

The B-Premise
change I-Premise
in I-Premise
global I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
P I-Premise
= I-Premise
0.067 I-Premise
";" I-Premise
effect I-Premise
size I-Premise
, I-Premise
0.33 I-Premise
) I-Premise
and I-Premise
strength I-Premise
of I-Premise
external I-Premise
rotation I-Premise
( I-Premise
P I-Premise
= I-Premise
0.001 I-Premise
";" I-Premise
effect I-Premise
size I-Premise
, I-Premise
0.55 I-Premise
) I-Premise
were I-Premise
significantly I-Premise
greater I-Premise
in I-Premise
the I-Premise
scapula-oriented I-Premise
exercise I-Premise
group I-Premise
than I-Premise
in I-Premise
the I-Premise
general I-Premise
exercise I-Premise
and I-Premise
control I-Premise
group I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
significant I-Premise
differences I-Premise
between I-Premise
the I-Premise
narrow I-Premise
gastric I-Premise
tube I-Premise
group I-Premise
( I-Premise
NGT I-Premise
group I-Premise
, I-Premise
n=52 I-Premise
) I-Premise
and I-Premise
the I-Premise
whole-stomach I-Premise
group I-Premise
( I-Premise
WS I-Premise
group I-Premise
, I-Premise
n=52 I-Premise
) I-Premise
with I-Premise
regard I-Premise
to I-Premise
patient I-Premise
and I-Premise
cancer I-Premise
characteristics I-Premise
, I-Premise
operative I-Premise
procedure I-Premise
, I-Premise
postoperative I-Premise
intensive I-Premise
care I-Premise
unit I-Premise
( I-Premise
ICU I-Premise
) I-Premise
hospitalisation I-Premise
, I-Premise
and I-Premise
overall I-Premise
survival I-Premise
at I-Premise
1 I-Premise
year I-Premise
. I-Premise

Opioid B-Premise
escalation I-Premise
index I-Premise
was I-Premise
significantly I-Premise
lower I-Premise
in I-Premise
patients I-Premise
receiving I-Premise
methadone I-Premise
( I-Premise
p I-Premise
< I-Premise
0.0001 I-Premise
) I-Premise
, I-Premise
although I-Premise
requiring I-Premise
up I-Premise
and I-Premise
down I-Premise
changes I-Premise
in I-Premise
doses I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
significant I-Premise
differences I-Premise
in I-Premise
failure-free I-Premise
survival I-Premise
, I-Premise
time I-Premise
to I-Premise
locoregional I-Premise
failure I-Premise
, I-Premise
or I-Premise
quality I-Premise
of I-Premise
life I-Premise
as I-Premise
measured I-Premise
by I-Premise
Functional I-Premise
Assessment I-Premise
of I-Premise
Cancer I-Premise
Therapy-Head I-Premise
and I-Premise
Neck I-Premise
. I-Premise

The B-Premise
successful I-Premise
ablation I-Premise
rate I-Premise
was I-Premise
91.0 I-Premise
% I-Premise
in I-Premise
T4-WD I-Premise
Group I-Premise
, I-Premise
91.7 I-Premise
% I-Premise
in I-Premise
T3-WD I-Premise
Group I-Premise
, I-Premise
and I-Premise
91.3 I-Premise
% I-Premise
in I-Premise
rhTSH I-Premise
Group I-Premise
, I-Premise
without I-Premise
significant I-Premise
between-preparation I-Premise
differences I-Premise
( I-Premise
p I-Premise
= I-Premise
0.2061 I-Premise
) I-Premise
. I-Premise

Complete B-Premise
and I-Premise
partial I-Premise
response I-Premise
rates I-Premise
to I-Premise
induction I-Premise
PE I-Premise
were I-Premise
3 I-Premise
% I-Premise
and I-Premise
32 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
. I-Premise

The B-Premise
primary I-Premise
outcome I-Premise
was I-Premise
significantly I-Premise
lower I-Premise
in I-Premise
the I-Premise
intervention I-Premise
arm I-Premise
( I-Premise
adjusted I-Premise
difference I-Premise
-16.8 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
-28.34 I-Premise
to I-Premise
-5.3 I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.006 I-Premise
) I-Premise
. I-Premise

Anxiety B-Premise
scores I-Premise
yielded I-Premise
a I-Premise
quadratic I-Premise
interaction I-Premise
comparing I-Premise
UCO I-Premise
and I-Premise
SMEX I-Premise
( I-Premise
p I-Premise
= I-Premise
0.049 I-Premise
) I-Premise
, I-Premise
with I-Premise
trends I-Premise
for I-Premise
changes I-Premise
in I-Premise
SMEX I-Premise
but I-Premise
not I-Premise
UCO I-Premise
. I-Premise

During B-Premise
thalidomide I-Premise
maintenance I-Premise
, I-Premise
the I-Premise
scores I-Premise
for I-Premise
the I-Premise
QLQ-MY24 I-Premise
paraesthesia I-Premise
became I-Premise
significantly I-Premise
higher I-Premise
in I-Premise
the I-Premise
MPT I-Premise
arm I-Premise
( I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
. I-Premise

Significant B-Premise
differences I-Premise
of I-Premise
FACT-B I-Premise
score I-Premise
( I-Premise
p=0.008 I-Premise
) I-Premise
and I-Premise
FACT-G I-Premise
score I-Premise
( I-Premise
p=0.019 I-Premise
) I-Premise
were I-Premise
observed I-Premise
at I-Premise
that I-Premise
time I-Premise
point I-Premise
. I-Premise

There B-Premise
was I-Premise
a I-Premise
significant I-Premise
decrease I-Premise
in I-Premise
pad I-Premise
use I-Premise
in I-Premise
group I-Premise
A I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
differences I-Premise
at I-Premise
3 I-Premise
years I-Premise
after I-Premise
random I-Premise
assignment I-Premise
according I-Premise
to I-Premise
treatment I-Premise
except I-Premise
for I-Premise
hot I-Premise
flashes I-Premise
. I-Premise

Toxicity B-Premise
profile I-Premise
was I-Premise
as I-Premise
follows I-Premise
: I-Premise
leukopenia I-Premise
( I-Premise
30/74 I-Premise
vs. I-Premise
17/92 I-Premise
) I-Premise
and I-Premise
alopecia I-Premise
( I-Premise
21/74 I-Premise
vs. I-Premise
13/92 I-Premise
) I-Premise
were I-Premise
statistically I-Premise
more I-Premise
common I-Premise
in I-Premise
the I-Premise
IV I-Premise
arm I-Premise
. I-Premise

CPT-11 B-Premise
+ I-Premise
LFA-5-FU I-Premise
compares I-Premise
favorably I-Premise
in I-Premise
term I-Premise
of I-Premise
activity I-Premise
and I-Premise
toxicity I-Premise
with I-Premise
other I-Premise
combination I-Premise
regimens I-Premise
including I-Premise
CPT-11 I-Premise
and I-Premise
continuous I-Premise
infusional I-Premise
5-FU I-Premise
. I-Premise

As B-Premise
for I-Premise
the I-Premise
secondary I-Premise
efficacy I-Premise
endpoints I-Premise
, I-Premise
patient I-Premise
appetite I-Premise
increased I-Premise
, I-Premise
and I-Premise
ECOG I-Premise
PS I-Premise
decreased I-Premise
significantly I-Premise
in I-Premise
both I-Premise
arms I-Premise
. I-Premise

ORR B-Premise
was I-Premise
25.0 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
13 I-Premise
% I-Premise
to I-Premise
41 I-Premise
% I-Premise
) I-Premise
for I-Premise
ECF I-Premise
, I-Premise
18.5 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
9 I-Premise
% I-Premise
to I-Premise
34 I-Premise
% I-Premise
) I-Premise
for I-Premise
TC I-Premise
, I-Premise
and I-Premise
36.6 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
23 I-Premise
% I-Premise
to I-Premise
53 I-Premise
% I-Premise
) I-Premise
for I-Premise
TCF I-Premise
( I-Premise
n I-Premise
= I-Premise
119 I-Premise
) I-Premise
. I-Premise

Haemoglobin B-Premise
response I-Premise
( I-Premise
increase I-Premise
in I-Premise
Hb I-Premise
> I-Premise
or=2 I-Premise
g/dL I-Premise
from I-Premise
baseline I-Premise
) I-Premise
was I-Premise
observed I-Premise
in I-Premise
78.3 I-Premise
% I-Premise
of I-Premise
patients I-Premise
receiving I-Premise
epoetin I-Premise
beta I-Premise
30,000 I-Premise
IU I-Premise
and I-Premise
66.7 I-Premise
% I-Premise
receiving I-Premise
epoetin I-Premise
beta I-Premise
20,000 I-Premise
IU I-Premise
. I-Premise

Similar B-Premise
results I-Premise
were I-Premise
found I-Premise
for I-Premise
low-dose I-Premise
radioiodine I-Premise
plus I-Premise
thyrotropin I-Premise
alfa I-Premise
( I-Premise
84.3 I-Premise
% I-Premise
) I-Premise
versus I-Premise
high-dose I-Premise
radioiodine I-Premise
plus I-Premise
thyroid I-Premise
hormone I-Premise
withdrawal I-Premise
( I-Premise
87.6 I-Premise
% I-Premise
) I-Premise
or I-Premise
high-dose I-Premise
radioiodine I-Premise
plus I-Premise
thyrotropin I-Premise
alfa I-Premise
( I-Premise
90.2 I-Premise
% I-Premise
) I-Premise
. I-Premise

The B-Premise
two I-Premise
groups I-Premise
were I-Premise
comparable I-Premise
, I-Premise
with I-Premise
low I-Premise
global I-Premise
QOL I-Premise
scores I-Premise
and I-Premise
significant I-Premise
symptom I-Premise
burden I-Premise
, I-Premise
especially I-Premise
pain I-Premise
and I-Premise
fatigue I-Premise
, I-Premise
after I-Premise
thoracotomy I-Premise
. I-Premise

After B-Premise
a I-Premise
median I-Premise
follow-up I-Premise
of I-Premise
23 I-Premise
months I-Premise
, I-Premise
both I-Premise
groups I-Premise
had I-Premise
similar I-Premise
progression-free I-Premise
survival I-Premise
( I-Premise
medians I-Premise
of I-Premise
15.0 I-Premise
months I-Premise
for I-Premise
docetaxel-carboplatin I-Premise
and I-Premise
14.8 I-Premise
months I-Premise
for I-Premise
paclitaxel-carboplatin I-Premise
";" I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
docetaxel-paclitaxel I-Premise
= I-Premise
0.97 I-Premise
, I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
= I-Premise
0.83 I-Premise
to I-Premise
1.13 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.707 I-Premise
) I-Premise
, I-Premise
overall I-Premise
survival I-Premise
rates I-Premise
at I-Premise
2 I-Premise
years I-Premise
( I-Premise
64.2 I-Premise
% I-Premise
and I-Premise
68.9 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
HR I-Premise
= I-Premise
1.13 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
0.92 I-Premise
to I-Premise
1.39 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.238 I-Premise
) I-Premise
, I-Premise
and I-Premise
objective I-Premise
tumor I-Premise
( I-Premise
58.7 I-Premise
% I-Premise
and I-Premise
59.5 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
difference I-Premise
between I-Premise
docetaxel I-Premise
and I-Premise
paclitaxel I-Premise
= I-Premise
-0.8 I-Premise
% I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
-8.6 I-Premise
% I-Premise
to I-Premise
7.1 I-Premise
% I-Premise
";" I-Premise
P I-Premise
= I-Premise
.868 I-Premise
) I-Premise
and I-Premise
CA-125 I-Premise
( I-Premise
75.8 I-Premise
% I-Premise
and I-Premise
76.8 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
difference I-Premise
docetaxel-paclitaxel I-Premise
= I-Premise
-1.0 I-Premise
% I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
-7.2 I-Premise
% I-Premise
to I-Premise
5.1 I-Premise
% I-Premise
";" I-Premise
P I-Premise
= I-Premise
.794 I-Premise
) I-Premise
response I-Premise
rates I-Premise
. I-Premise

In B-Premise
both I-Premise
groups I-Premise
, I-Premise
the I-Premise
hot I-Premise
flash I-Premise
score I-Premise
peaked I-Premise
at I-Premise
3 I-Premise
months I-Premise
and I-Premise
decreased I-Premise
thereafter I-Premise
. I-Premise

The B-Premise
relative I-Premise
hazard I-Premise
of I-Premise
death I-Premise
for I-Premise
vinorelbine-treated I-Premise
patients I-Premise
was I-Premise
0.65 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
0.45-0.93 I-Premise
) I-Premise
. I-Premise

Regarding B-Premise
the I-Premise
QoL I-Premise
investigation I-Premise
, I-Premise
the I-Premise
scores I-Premise
of I-Premise
QoL I-Premise
dropped I-Premise
for I-Premise
all I-Premise
patients I-Premise
at I-Premise
3 I-Premise
weeks I-Premise
after I-Premise
surgery I-Premise
. I-Premise

Men B-Premise
with I-Premise
prostate I-Premise
cancer I-Premise
and I-Premise
their I-Premise
spouses I-Premise
reported I-Premise
positive I-Premise
outcomes I-Premise
from I-Premise
a I-Premise
family I-Premise
intervention I-Premise
that I-Premise
offered I-Premise
them I-Premise
information I-Premise
and I-Premise
support I-Premise
. I-Premise

The B-Premise
median I-Premise
progression-free I-Premise
survival I-Premise
( I-Premise
PFS I-Premise
) I-Premise
for I-Premise
the I-Premise
vaccine I-Premise
group I-Premise
was I-Premise
8.5 I-Premise
months I-Premise
, I-Premise
and I-Premise
8.0 I-Premise
months I-Premise
for I-Premise
the I-Premise
control I-Premise
group I-Premise
( I-Premise
P I-Premise
= I-Premise
0.075 I-Premise
) I-Premise
. I-Premise

Patients B-Premise
carrying I-Premise
the I-Premise
GPX1-CC I-Premise
genotype I-Premise
had I-Premise
a I-Premise
clinically I-Premise
significant I-Premise
decline I-Premise
in I-Premise
the I-Premise
UNISCALE I-Premise
( I-Premise
odds I-Premise
ratio I-Premise
( I-Premise
OR I-Premise
) I-Premise
: I-Premise
7.5 I-Premise
";" I-Premise
p I-Premise
= I-Premise
0.04 I-Premise
) I-Premise
, I-Premise
total I-Premise
Functional I-Premise
Assessment I-Premise
of I-Premise
Cancer I-Premise
Therapy-Lung I-Premise
score I-Premise
( I-Premise
OR I-Premise
: I-Premise
11.0 I-Premise
";" I-Premise
p I-Premise
= I-Premise
0.04 I-Premise
) I-Premise
, I-Premise
physical I-Premise
( I-Premise
OR I-Premise
: I-Premise
7.1 I-Premise
";" I-Premise
p I-Premise
= I-Premise
0.03 I-Premise
) I-Premise
, I-Premise
functional I-Premise
( I-Premise
OR I-Premise
: I-Premise
5.2 I-Premise
";" I-Premise
p I-Premise
= I-Premise
0.04 I-Premise
) I-Premise
, I-Premise
and I-Premise
emotional I-Premise
well-being I-Premise
constructs I-Premise
( I-Premise
OR I-Premise
: I-Premise
23.8 I-Premise
";" I-Premise
p I-Premise
= I-Premise
0.01 I-Premise
) I-Premise
. I-Premise

A B-Premise
small I-Premise
decline I-Premise
in I-Premise
visual I-Premise
analogue I-Premise
scale I-Premise
scores I-Premise
was I-Premise
observed I-Premise
( I-Premise
70.7 I-Premise
vs. I-Premise
68.2 I-Premise
, I-Premise
P=0.026 I-Premise
) I-Premise
. I-Premise

The B-Premise
adherence I-Premise
rate I-Premise
to I-Premise
ALT I-Premise
was I-Premise
significantly I-Premise
higher I-Premise
than I-Premise
the I-Premise
adherence I-Premise
to I-Premise
self-management I-Premise
therapy I-Premise
. I-Premise

Median B-Premise
OS I-Premise
was I-Premise
9.45 I-Premise
and I-Premise
10 I-Premise
months I-Premise
respectively I-Premise
for I-Premise
weekly I-Premise
VNR/CDDP I-Premise
arm I-Premise
and I-Premise
the I-Premise
day I-Premise
1-8 I-Premise
VNR/CDDP I-Premise
one I-Premise
without I-Premise
statistically I-Premise
a I-Premise
significant I-Premise
difference I-Premise
( I-Premise
log-rank I-Premise
test I-Premise
, I-Premise
p=0.259 I-Premise
) I-Premise
. I-Premise

After B-Premise
radiotherapy I-Premise
and I-Premise
at I-Premise
3 I-Premise
months I-Premise
, I-Premise
rates I-Premise
of I-Premise
anorexia I-Premise
, I-Premise
nausea I-Premise
, I-Premise
vomiting I-Premise
, I-Premise
and I-Premise
diarrhea I-Premise
were I-Premise
higher I-Premise
in I-Premise
G3 I-Premise
( I-Premise
P I-Premise
< I-Premise
.05 I-Premise
) I-Premise
. I-Premise

No B-Premise
QOL I-Premise
difference I-Premise
was I-Premise
found I-Premise
, I-Premise
although I-Premise
more I-Premise
side I-Premise
effects I-Premise
occurred I-Premise
in I-Premise
CAD I-Premise
. I-Premise

Quality B-Premise
of I-Premise
life I-Premise
evaluated I-Premise
6 I-Premise
months I-Premise
after I-Premise
random I-Premise
assignment I-Premise
using I-Premise
the I-Premise
30-item I-Premise
Quality I-Premise
of I-Premise
Life I-Premise
Questionnaire I-Premise
was I-Premise
not I-Premise
significantly I-Premise
different I-Premise
between I-Premise
the I-Premise
two I-Premise
groups I-Premise
of I-Premise
randomly I-Premise
assigned I-Premise
patients I-Premise
. I-Premise

Transient B-Premise
grade I-Premise
4 I-Premise
neutropenia I-Premise
occurred I-Premise
in I-Premise
18 I-Premise
and I-Premise
2 I-Premise
patients I-Premise
, I-Premise
and I-Premise
grade I-Premise
3 I-Premise
to I-Premise
4 I-Premise
thrombosis I-Premise
in I-Premise
7 I-Premise
patients I-Premise
and I-Premise
1 I-Premise
patient I-Premise
in I-Premise
Arm I-Premise
A I-Premise
and I-Premise
Arm I-Premise
B I-Premise
respectively I-Premise
. I-Premise

Considering B-Premise
the I-Premise
short-term I-Premise
quality I-Premise
of I-Premise
life I-Premise
, I-Premise
the I-Premise
administration I-Premise
of I-Premise
GM-CSF I-Premise
resulted I-Premise
in I-Premise
more I-Premise
problems I-Premise
with I-Premise
regard I-Premise
to I-Premise
depressed I-Premise
mood I-Premise
, I-Premise
diarrhoea I-Premise
and I-Premise
rash/eczema I-Premise
. I-Premise

Tamoxifen B-Premise
administration I-Premise
did I-Premise
not I-Premise
alter I-Premise
the I-Premise
average I-Premise
annual I-Premise
rate I-Premise
of I-Premise
ischemic I-Premise
heart I-Premise
disease I-Premise
";" I-Premise
however I-Premise
, I-Premise
a I-Premise
reduction I-Premise
in I-Premise
hip I-Premise
, I-Premise
radius I-Premise
( I-Premise
Colles I-Premise
' I-Premise
) I-Premise
, I-Premise
and I-Premise
spine I-Premise
fractures I-Premise
was I-Premise
observed I-Premise
. I-Premise

At B-Premise
6 I-Premise
weeks I-Premise
, I-Premise
initial I-Premise
effects I-Premise
were I-Premise
retained I-Premise
. I-Premise

Of O
558 O
women O
randomly O
assigned O
to O
treatment O
, O
418 O
completed O
the O
6-month O
assessment O
and O
399 O
completed O
the O
12-month O
assessment O
. O

To O
compare O
protracted O
venous O
infusion O
( O
PVI O
) O
5-fluorouracil O
( O
5-FU O
) O
with O
and O
without O
mitomycin O
C O
( O
MMC O
) O
in O
a O
prospectively O
randomised O
study O
and O
analyse O
for O
tumour O
response O
, O
survival O
, O
toxicity O
and O
quality O
of O
life O
( O
QL O
) O
. O

Premenopausal O
women O
with O
breast O
cancer O
receiving O
adjuvant O
chemotherapy O
are O
at O
risk O
for O
amenorrhea O
. O

Patients O
with O
platinum-sensitive O
recurrent O
ovarian O
cancer O
were O
randomly O
assigned O
to O
receive O
either O
gemcitabine O
plus O
carboplatin O
or O
carboplatin O
alone O
, O
every O
21 O
days O
. O

Opioid O
consumption O
, O
pain O
intensity O
, O
symptoms O
and O
adverse O
effects O
, O
mood O
, O
sleep O
, O
patient O
's O
preference O
, O
quality O
of O
life O
before O
starting O
the O
study O
, O
the O
first O
week O
after O
and O
the O
second O
week O
after O
were O
recorded O
. O

Of O
the O
186 O
total O
patients O
, O
113 O
had O
initial O
treatment O
with O
platinum O
therapy O
and O
DNA O
samples O
of O
whom O
46 O
also O
had O
QOL O
data O
. O

No O
significant O
differences O
were O
noted O
at O
baseline O
between O
the O
two O
treatment O
groups O
. O

Tumor O
response O
was O
evaluated O
at O
Week O
12 O
and O
Month O
6 O
";" O
progression-free O
patients O
received O
further O
identical O
treatment O
for O
a O
maximum O
of O
3 O
additional O
months O
. O

This O
double-blind O
randomized O
phase O
II O
trial O
examined O
whether O
vandetanib O
, O
an O
inhibitor O
of O
vascular O
endothelial O
and O
epidermal O
growth O
factor O
receptors O
, O
could O
prolong O
progression-free O
survival O
in O
responding O
patients O
with O
small-cell O
lung O
cancer O
. O

From O
May O
1999 O
to O
December O
2004 O
, O
patients O
with O
breast O
cancer O
< O
or O
3 O
cm O
were O
randomly O
assigned O
to O
receive O
SLN O
biopsy O
associated O
with O
ALND O
( O
ALND O
arm O
) O
or O
SLN O
biopsy O
followed O
by O
ALND O
only O
if O
the O
SLN O
was O
metastatic O
( O
SLN O
arm O
) O
. O

This O
randomised O
multicentre O
trial O
was O
conducted O
to O
establish O
the O
optimal O
duration O
of O
palliative O
chemotherapy O
in O
advanced O
non-small-cell O
lung O
cancer O
( O
NSCLC O
) O
. O

The O
changes O
in O
the O
BMD O
, O
bone O
turnover O
proteins O
and O
quality-of-life O
( O
QoL O
) O
were O
analyzed O
and O
presented O
here O
. O

This O
study O
examined O
( O
i O
) O
whether O
patient-caregiver O
dyads O
( O
i.e. O
, O
pairs O
) O
randomly O
assigned O
to O
a O
brief O
or O
extensive O
dyadic O
intervention O
( O
the O
FOCUS O
Program O
) O
had O
better O
outcomes O
than O
dyads O
randomly O
assigned O
to O
usual O
care O
and O
( O
ii O
) O
whether O
patients O
' O
risk O
for O
distress O
and O
other O
factors O
moderated O
the O
effect O
of O
the O
brief O
or O
extensive O
program O
on O
outcomes O
. O

Outpatient O
clinic O
of O
a O
comprehensive O
cancer O
center O
. O

A O
subset O
of O
166 O
patients O
also O
answered O
additional O
questionnaires O
to O
estimate O
nonradiotherapy O
and O
nonmedical O
costs O
. O

Analyses O
of O
covariance O
were O
used O
to O
study O
the O
long-term O
effectiveness O
of O
CBT O
. O

Tumour O
tissue O
was O
obtained O
from O
168 O
patients O
with O
mCRC O
for O
relative O
thymidylate O
synthase O
( O
TS O
) O
mRNA O
quantitation O
. O

ORR O
was O
20 O
% O
with O
a O
7.2-month O
median O
response O
duration O
. O

Symptoms O
were O
analyzed O
by O
repeated-measures O
analysis O
of O
variance O
. O

One O
hundred O
and O
two O
candidates O
with O
CACS O
were O
randomly O
assigned O
to O
two O
treatment O
groups O
( O
trial O
group O
and O
control O
group O
) O
: O
the O
trial O
group O
received O
MA O
( O
160 O
mg O
po O
, O
bid O
) O
plus O
thalidomide O
( O
50 O
mg O
po O
, O
bid O
) O
, O
while O
the O
control O
group O
received O
MA O
( O
160 O
mg O
po O
, O
bid O
) O
alone O
. O

on O
day O
1 O
, O
followed O
on O
day O
2 O
by O
LFA O
, O
250 O
mg/m2 O
i.v O
. O

Patients O
with O
previously O
untreated O
stage O
III O
or O
IV O
( O
excluding O
T1-2N1 O
and O
M1 O
) O
squamous O
cell O
carcinoma O
of O
the O
oral O
cavity O
, O
oropharynx O
, O
hypopharynx O
, O
or O
larynx O
were O
randomly O
assigned O
to O
receive O
definitive O
radiotherapy O
( O
70 O
Gy O
in O
7 O
weeks O
) O
concurrently O
with O
either O
CIS O
( O
100 O
mg/m O
( O
2 O
) O
) O
on O
day O
1 O
of O
weeks O
1 O
, O
4 O
, O
and O
7 O
or O
CIS O
( O
75 O
mg/m O
( O
2 O
) O
) O
plus O
TPZ O
( O
290 O
mg/m O
( O
2 O
) O
/d O
) O
on O
day O
1 O
of O
weeks O
1 O
, O
4 O
, O
and O
7 O
and O
TPZ O
alone O
( O
160 O
mg/m O
( O
2 O
) O
/d O
) O
on O
days O
1 O
, O
3 O
, O
and O
5 O
of O
weeks O
2 O
and O
3 O
( O
TPZ/CIS O
) O
. O

Psychosocial O
symptoms O
were O
assessed O
with O
the O
use O
of O
a O
self-report O
screening O
instrument O
, O
and O
distressed O
women O
were O
referred O
for O
counseling O
if O
needed O
. O

The O
aim O
of O
this O
multicenter O
, O
double-blind O
, O
prospective O
, O
randomized O
trial O
was O
to O
evaluate O
the O
clinical O
efficacy O
of O
an O
economically O
viable O
antimicrobial O
lozenge O
( O
bacitracin O
, O
clotrimazole O
, O
and O
gentamicin O
[ O
BcoG O
] O
) O
in O
the O
alleviation O
of O
radiation-induced O
mucositis O
in O
patients O
with O
head O
and O
neck O
cancer O
. O

Primary O
outcome O
measures O
assessed O
spiritual O
well-being O
and O
quality O
of O
life O
";" O
secondary O
outcomes O
included O
anxiety O
, O
depression O
, O
hopelessness O
, O
symptom O
burden O
, O
and O
symptom-related O
distress O
. O

All O
statistical O
tests O
were O
two-sided O
. O

To O
compare O
the O
effectiveness O
and O
tolerability O
of O
gemcitabine O
plus O
cisplatin O
with O
single-agent O
gemcitabine O
as O
first-line O
chemotherapy O
for O
locally O
advanced O
or O
metastatic O
pancreatic O
cancer O
. O

Patients O
( O
n O
= O
110 O
) O
with O
stage O
II O
, O
III O
, O
or O
IV O
breast O
cancer O
scheduled O
to O
receive O
high O
dose O
chemotherapy O
and O
autologous O
hematopoietic O
stem O
cell O
transplantation O
were O
randomized O
to O
either O
CCSP O
treatment O
or O
control O
group O
. O

Clinical O
, O
treatment O
and O
dosimetric O
variables O
evaluated O
included O
alpha-blocker O
, O
age O
, O
IPSS O
before O
and O
the O
maximum O
after O
treatment O
, O
prostate O
volume O
on O
ultrasonography O
, O
hormonal O
status O
, O
supplemental O
radiotherapy O
, O
isotope O
, O
urethral O
dose O
, O
V O
( O
100/200 O
) O
, O
D90 O
, O
and O
time O
to O
obtaining O
a O
normal O
IPSS O
. O

The O
final O
sample O
was O
302 O
dyads O
. O

573 O
patients O
with O
newly O
diagnosed O
glioblastoma O
were O
randomly O
allocated O
either O
radiotherapy O
alone O
or O
radiotherapy O
and O
temozolomide O
. O

The O
general O
linear O
model O
was O
used O
for O
continuous O
outcome O
while O
analysis O
of O
associates O
between O
categorical O
outcomes O
was O
performed O
as O
analysis O
of O
marginal O
homogeneity O
in O
contingency O
tables O
. O

Exercise O
, O
fatigue O
, O
and O
QOL O
. O

This O
randomised O
non-inferiority O
trial O
was O
designed O
to O
assess O
whether O
radiosurgery O
plus O
adjuvant O
whole O
brain O
radiotherapy O
( O
RS O
+ O
WBRT O
) O
is O
as O
effective O
as O
surgery O
plus O
whole O
brain O
radiotherapy O
( O
S O
+ O
WBRT O
) O
for O
cancer O
patients O
with O
a O
solitary O
brain O
metastasis O
, O
with O
respect O
to O
overall O
survival O
and O
quality O
of O
life O
. O

The O
study O
was O
closed O
to O
additional O
accrual O
and O
all O
DPPE O
was O
discontinued O
. O

Of O
the O
analyzable O
patients O
, O
90 O
% O
had O
a O
Karnofsky O
performance O
score O
of O
90-100 O
, O
18 O
% O
had O
weight O
loss O
> O
5 O
% O
, O
37 O
% O
had O
squamous O
cell O
histologic O
features O
, O
and O
54 O
% O
had O
bulky O
N2 O
disease O
. O

Most O
effects O
were O
found O
at O
3 O
months O
only O
. O

However O
, O
few O
studies O
have O
investigated O
their O
effectiveness O
in O
patients O
who O
are O
receiving O
chemotherapy O
. O

Over O
the O
next O
24 O
months O
, O
oral O
lesion O
size O
and O
number O
, O
pain O
, O
and O
quality O
of O
life O
were O
assessed O
. O

The O
study O
was O
conducted O
in O
the O
palliative O
care O
and O
hospice O
ward O
of O
a O
public O
hospital O
in O
Hong O
Kong O
. O

Changes O
in O
mean O
scores O
from O
baseline O
to O
eight O
weeks O
and O
the O
prognostic O
value O
of O
the O
EQ-5D O
were O
evaluated O
. O

Serum O
CA125 O
concentration O
often O
rises O
several O
months O
before O
clinical O
or O
symptomatic O
relapse O
in O
women O
with O
ovarian O
cancer O
. O

Data O
come O
from O
the O
Moving O
Beyond O
Cancer O
psychoeducational O
intervention O
trial O
, O
aimed O
at O
easing O
the O
transition O
from O
patient O
to O
survivor O
. O

In O
this O
project O
, O
the O
QOL O
differences O
between O
older O
adult O
( O
age O
65 O
) O
and O
younger O
adult O
( O
age O
18-64 O
) O
advanced O
cancer O
patients O
in O
response O
to O
a O
multidisciplinary O
intervention O
designed O
to O
improve O
QOL O
were O
examined O
. O

The O
present O
study O
extends O
this O
work O
by O
evaluating O
separate O
and O
combined O
effects O
of O
stress O
management O
training O
and O
home-based O
exercise O
. O

Ten O
years O
of O
treatment O
planned O
. O

Sensitivity O
analyses O
were O
also O
performed O
for O
selected O
QOL O
domains O
and O
items O
, O
using O
other O
types O
of O
summary O
measures O
and O
statistics O
. O

To O
compare O
the O
efficacy O
of O
low-frequency O
low-intensity O
electrotherapy O
and O
manual O
lymphatic O
drainage O
in O
the O
treatment O
of O
chronic O
upper O
limb O
breast O
cancer-related O
lymphoedema O
. O

Data O
collection O
occurred O
at O
baseline O
before O
randomization O
and O
at O
4 O
months O
, O
8 O
months O
, O
and O
12 O
months O
. O

Intervention O
group O
patients O
received O
5 O
calls O
from O
a O
specialist O
colorectal O
nurse O
in O
the O
6 O
months O
after O
hospital O
discharge O
. O

Assessments O
were O
performed O
before O
TRT O
and O
until O
week O
54 O
. O

Eighty-one O
pamidronate O
patients O
and O
80 O
control O
patients O
were O
monitored O
for O
a O
median O
of O
18 O
and O
21 O
months O
, O
respectively O
, O
for O
events O
of O
skeletal O
morbidity O
and O
the O
radiologic O
course O
of O
metastatic O
bone O
disease O
. O

Two-hundred O
seventeen O
of O
425 O
therapeutic O
trial O
patients O
were O
eligible O
and O
registered O
to O
the O
HRQL O
study O
. O

Patients O
with O
prior O
cytotoxic O
therapy O
for O
MBC O
were O
ineligible O
. O

To O
assess O
whether O
the O
administration O
of O
recombinant O
human O
erythropoietin O
( O
r-HuEPO O
) O
would O
increase O
the O
hematocrit O
, O
reduce O
the O
requirement O
for O
transfusion O
, O
and O
improve O
the O
quality O
of O
life O
in O
anemic O
cancer O
patients O
receiving O
myelosuppressive O
, O
cisplatin-based O
chemotherapy O
. O

All O
subjects O
completed O
the O
Functional O
Assessment O
of O
Chronic O
Illness O
Therapy O
Fatigue O
Version O
IV O
( O
FACIT O
F O
) O
at O
baseline O
and O
at O
the O
time O
of O
the O
next O
three O
cycles O
. O

We O
used O
these O
data O
in O
a O
Cox O
proportional O
hazards O
analysis O
to O
examine O
whether O
decreasing O
depression O
symptoms O
over O
the O
first O
year O
of O
the O
study O
( O
the O
length O
of O
the O
intervention O
) O
would O
be O
associated O
with O
longer O
survival O
. O

To O
compare O
the O
toxicities O
, O
tumor O
control O
, O
survival O
, O
and O
quality O
of O
life O
of O
nasopharyngeal O
cancer O
( O
NPC O
) O
patients O
treated O
with O
sequential O
neoadjuvant O
chemotherapy O
followed O
by O
concurrent O
cisplatin-radiotherapy O
( O
CRT O
) O
or O
CRT O
alone O
. O

Advanced O
gastric O
cancer O
patients O
were O
randomly O
assigned O
to O
docetaxel O
75 O
mg/m2 O
and O
cisplatin O
75 O
mg/m2 O
( O
day O
1 O
) O
plus O
fluorouracil O
750 O
mg/m2/d O
( O
days O
1 O
to O
5 O
) O
every O
3 O
weeks O
or O
cisplatin O
100 O
mg/m2 O
( O
day O
1 O
) O
plus O
fluorouracil O
1,000 O
mg/m2/d O
( O
days O
1 O
to O
5 O
) O
every O
4 O
weeks O
. O

In O
one O
of O
these O
trials O
, O
HOVON49 O
, O
a O
prospective O
health-related O
quality-of-life O
( O
HRQoL O
) O
study O
was O
initiated O
in O
order O
to O
assess O
the O
impact O
of O
thalidomide O
on O
QoL O
. O

Patients O
were O
then O
followed O
for O
6 O
months O
and O
evaluated O
for O
quality O
of O
life O
, O
completion O
of O
adjuvant O
treatment O
, O
and O
depressive O
symptoms O
. O

In O
the O
SUSTENT O
study O
, O
patients O
were O
randomized O
to O
GJJ O
( O
n O
= O
18 O
) O
or O
stent O
placement O
( O
n O
= O
21 O
) O
. O

Results O
Baseline O
prognostic O
data O
were O
equally O
distributed O
in O
the O
treatment O
groups O
. O

Also O
, O
we O
evaluated O
their O
effects O
on O
patient O
hormonal O
status O
, O
quality O
of O
life O
( O
QOL O
) O
, O
sexual O
function O
and O
prostate O
specific O
antigen O
relapse-free O
survival O
. O

The O
primary O
endpoint O
was O
change O
in O
Inflammatory O
Bowel O
Disease O
Questionnaire-Bowel O
subset O
score O
( O
IBDQ-B O
) O
at O
6 O
months O
, O
analysed O
by O
intention O
to O
treat O
. O

The O
trial O
is O
registered O
, O
ISRCTN13771934 O
, O
and O
was O
closed O
March O
15 O
, O
2011 O
. O

The O
primary O
endpoint O
was O
survival O
, O
and O
HRQOL O
was O
a O
secondary O
endpoint O
. O

Clinicians O
working O
with O
patients O
who O
have O
advanced O
cancer O
should O
consider O
IMCP O
as O
an O
approach O
to O
enhance O
quality O
of O
life O
and O
spiritual O
well-being O
. O

Sixty O
consecutive O
radiation O
oncology O
outpatients O
( O
51 O
men O
and O
nine O
women O
";" O
age O
61.9+/-14 O
years O
[ O
mean+/-standard O
deviation O
] O
) O
. O

Fatigue O
is O
a O
frequent O
problem O
after O
surgical O
treatment O
of O
solid O
tumours O
. O

Transfusion O
data O
were O
available O
for O
79 O
of O
81 O
evaluable O
patients O
( O
98 O
% O
) O
who O
completed O
the O
treatment/observation O
period O
. O

All O
had O
chemotherapy O
. O

Tumor O
response O
, O
duration O
of O
tumor O
control O
, O
tumor-related O
signs O
and O
symptoms O
( O
TRSS O
) O
, O
quality O
of O
life O
( O
QOL O
) O
, O
survival O
, O
and O
tolerability O
were O
evaluated O
. O

If O
CA125 O
concentration O
exceeded O
twice O
the O
upper O
limit O
of O
normal O
, O
patients O
were O
randomly O
assigned O
( O
1:1 O
) O
by O
minimisation O
to O
early O
or O
delayed O
chemotherapy O
. O

A O
lack O
of O
preliminary O
randomised O
data O
supporting O
the O
trial O
's O
hypotheses O
was O
thought O
to O
underlie O
the O
poor O
accrual O
, O
so O
, O
with O
no O
knowledge O
of O
the O
data O
, O
the O
independent O
trial O
steering O
committee O
agreed O
to O
the O
unusual O
step O
of O
releasing O
interim O
data O
. O

In O
a O
controlled O
multicentre O
trial O
, O
patients O
were O
randomised O
to O
receive O
supportive O
care O
only O
or O
supportive O
care O
plus O
chemotherapy O
. O

Chemotherapy O
was O
first-line O
or O
second-line O
for O
MBC O
. O

Those O
in O
the O
intervention O
group O
received O
six O
multidisciplinary O
90-minute O
sessions O
designed O
to O
address O
the O
five O
major O
domains O
of O
QOL O
. O

A O
phase O
III O
randomized O
multicenter O
trial O
was O
planned O
to O
compare O
GEM O
( O
1,000 O
mg/m O
( O
2 O
) O
on O
days O
1 O
, O
8 O
, O
and O
15 O
every O
28 O
days O
) O
with O
PLD O
( O
40 O
mg/m O
( O
2 O
) O
every O
28 O
days O
) O
in O
ovarian O
cancer O
patients O
who O
experienced O
treatment O
failure O
with O
only O
one O
platinum/paclitaxel O
regimen O
and O
who O
experienced O
recurrence O
or O
progression O
within O
12 O
months O
after O
completion O
of O
primary O
treatment O
. O

Patients O
were O
randomised O
to O
receive O
either O
5-FU/folinic O
acid O
( O
FA O
, O
FUFA O
) O
alone O
or O
in O
combination O
with O
irinotecan O
5-fluorouracil/folinic O
acid O
and O
irinotecan O
( O
FOLFIRI O
) O
stratified O
by O
TS O
( O
low O
versus O
high O
) O
. O

In O
the O
MRC O
OV05/EORTC O
55955 O
collaborative O
trial O
, O
we O
aimed O
to O
establish O
the O
benefits O
of O
early O
treatment O
on O
the O
basis O
of O
increased O
CA125 O
concentrations O
compared O
with O
delayed O
treatment O
on O
the O
basis O
of O
clinical O
recurrence O
. O

Future O
research O
should O
investigate O
ways O
to O
augment O
this O
intervention O
to O
enhance O
its O
benefits O
. O

Patients O
with O
advanced O
HIV-associated O
KS O
were O
randomly O
assigned O
to O
receive O
paclitaxel O
at O
a O
dose O
of O
100 O
mg/m2 O
intravenously O
( O
iv O
) O
every O
2 O
weeks O
or O
PLD O
at O
a O
dose O
of O
20 O
mg/m2 O
iv O
every O
3 O
weeks O
. O

Compared O
with O
placebo O
, O
prophylactic O
treatment O
with O
bisphosphonates O
reduces O
risk O
of O
skeletal O
events O
in O
patients O
with O
multiple O
myeloma O
. O

Overall O
response O
rate O
was O
34 O
% O
( O
95 O
% O
CL O
26-42 O
% O
) O
in O
the O
weekly O
VNR/CDDP O
arm O
, O
and O
32 O
% O
( O
95 O
% O
CL O
24-40 O
% O
) O
in O
patients O
treated O
with O
day O
1-8 O
VNR/CDDP O
without O
any O
statistically O
significant O
difference O
. O

Caloric O
intake O
, O
body O
composition O
( O
dual-energy O
x-ray O
absorptiometry O
) O
, O
and O
respiratory O
gas O
exchanges O
at O
rest O
and O
during O
exercise O
were O
measured O
including O
health-related O
quality O
of O
life O
. O

108 O
, O
111 O
, O
and O
107 O
patients O
, O
respectively O
, O
were O
analysed O
. O

To O
analyze O
and O
compare O
radiologic O
lung O
expansion O
after O
talc O
pleurodesis O
performed O
either O
by O
videothoracoscopy O
or O
chest O
tube O
and O
correlate O
it O
with O
clinical O
outcome O
. O

Treatment-induced O
arm O
lymphoedema O
is O
a O
common O
and O
distressing O
complication O
of O
curative O
surgery O
and O
radiotherapy O
for O
early O
breast O
cancer O
. O

Eligible O
patients O
had O
to O
have O
a O
history O
of O
primary O
breast O
cancer O
without O
evidence O
of O
detectable O
disease O
and O
14 O
or O
more O
weekly O
hot O
flashes O
for O
at O
least O
1 O
month O
. O

on O
day O
1 O
, O
followed O
on O
day O
2 O
by O
LFA O
, O
250 O
mg/m2 O
i.v O
. O

The O
primary O
end-point O
of O
the O
study O
was O
the O
incidence O
of O
Radiation O
Therapy O
Oncology O
Group O
grade O
3 O
mucositis O
. O

They O
recorded O
frequency O
, O
duration O
, O
and O
distress O
of O
nausea O
, O
vomiting O
, O
and O
retching O
daily O
, O
beginning O
the O
evening O
of O
chemotherapy O
administration O
and O
continuing O
for O
seven O
days O
. O

Adult O
patients O
with O
anaemia O
( O
Hb O
< O
11 O
g/dL O
) O
were O
randomized O
to O
receive O
epoetin O
beta O
30,000 O
IU O
or O
20,000 O
IU O
once O
weekly O
for O
12 O
weeks O
. O

Data O
were O
extracted O
from O
the O
database O
of O
a O
prospective O
randomized O
controlled O
trial O
that O
included O
patients O
with O
resectable O
mid O
or O
lower O
thoracic O
esophageal O
cancers O
. O

Participants O
, O
identified O
within O
1 O
month O
after O
surgery O
( O
registration O
) O
, O
provided O
demographic O
information O
and O
limited O
measures O
of O
quality O
of O
life O
. O

Significance O
testing O
of O
group-by-time O
interactions O
in O
286 O
patients O
who O
completed O
all O
assessments O
was O
used O
to O
evaluate O
intervention O
efficacy O
. O

Baseline O
scores O
from O
both O
EQ-5D O
scales O
were O
significant O
predictors O
of O
OS O
in O
Cox O
proportional O
hazard O
models O
. O

Using O
KPS O
scores O
, O
changes O
in O
quality O
of O
life O
were O
compared O
before O
and O
after O
the O
treatment O
. O

This O
study O
sought O
to O
evaluate O
effectiveness O
of O
autologous O
dendritic O
cell O
vaccine O
( O
immunotherapy O
) O
for O
glioblastoma O
multiforme O
( O
GBM O
) O
. O

Eligible O
patients O
were O
randomized O
to O
receive O
: O
( O
a O
) O
VNR O
25mg/m O
( O
2 O
) O
on O
day O
1 O
, O
8 O
and O
15 O
plus O
CDDP O
100mg/m O
( O
2 O
) O
on O
day O
1 O
every O
4 O
weeks O
or O
( O
b O
) O
VNR O
30 O
mg/m O
( O
2 O
) O
on O
day O
1 O
and O
8 O
plus O
CDDP O
80 O
mg/m O
( O
2 O
) O
on O
day O
1 O
every O
3 O
weeks O
. O

By O
March O
2007 O
, O
data O
on O
310 O
additional O
deaths O
were O
obtained O
( O
total O
= O
867 O
deaths O
) O
. O

We O
aimed O
to O
test O
, O
in O
a O
randomized O
controlled O
trial O
, O
the O
clinical O
and O
cost O
effectiveness O
of O
a O
rehabilitation O
intervention O
for O
patients O
with O
advanced O
, O
recurrent O
cancer O
. O

QoL O
was O
evaluated O
with O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
questionnaires O
QLQ-C30 O
and O
QLQ-LC13 O
, O
and O
the O
QoL O
data O
were O
analyzed O
by O
fitting O
a O
linear O
mixed O
model O
for O
each O
QoL O
scale O
. O

Physician O
and O
nurse O
ratings O
were O
closer O
to O
patients O
' O
ratings O
of O
pain O
for O
trained O
versus O
nutrition O
groups O
( O
P=.04 O
and O
< O
.001 O
, O
respectively O
) O
. O

There O
were O
532 O
eligible O
patients O
( O
266 O
marimastat O
and O
266 O
placebo O
) O
. O

Sixteen O
subjects O
were O
randomly O
assigned O
to O
either O
a O
training O
( O
n O
= O
8 O
";" O
age O
: O
50 O
+/- O
5 O
yrs O
) O
or O
control O
non-exercising O
group O
( O
n O
= O
8 O
";" O
age O
: O
51 O
+/- O
10 O
yrs O
) O
. O

Participants O
had O
significant O
disease O
load O
with O
65 O
% O
of O
participants O
presenting O
with O
two O
or O
more O
regions O
affected O
by O
bone O
metastases O
and O
an O
average O
Gleason O
score O
of O
8.2±0.9 O
. O

Group O
1 O
received O
20 O
mg O
of O
CRO O
, O
group O
2 O
received O
10 O
mg O
of O
CRO O
, O
and O
group O
3 O
received O
a O
placebo O
at O
1 O
hour O
before O
transarterial O
chemoembolization O
( O
T O
( O
0 O
) O
) O
and O
12 O
( O
T O
( O
12 O
) O
) O
and O
24 O
( O
T O
( O
24 O
) O
) O
hours O
after O
T O
( O
0 O
) O
. O

Patients O
in O
the O
three O
groups O
did O
not O
differ O
significantly O
in O
baseline O
characteristics O
or O
tumor O
, O
node O
and O
metastasis O
( O
TNM O
) O
staging O
. O

Three O
hundred O
and O
sixteen O
patients O
completed O
1,201 O
questionnaires O
. O

All O
patients O
received O
oral O
iron O
supplementation O
. O

This O
randomized O
phase O
II O
trial O
evaluated O
two O
docetaxel-based O
regimens O
to O
see O
which O
would O
be O
most O
promising O
according O
to O
overall O
response O
rate O
( O
ORR O
) O
for O
comparison O
in O
a O
phase O
III O
trial O
with O
epirubicin-cisplatin-fluorouracil O
( O
ECF O
) O
as O
first-line O
advanced O
gastric O
cancer O
therapy O
. O

Stratification O
factors O
included O
chemotherapy O
cycle O
length O
, O
screening O
hemoglobin O
( O
< O
10 O
g/dL O
vs. O
≥10 O
g/dL O
) O
, O
and O
tumor O
type O
( O
lung/gynecological O
vs. O
other O
nonmyeloid O
malignancies O
) O
. O

This O
includes O
cross-sectional O
comparisons O
, O
together O
with O
a O
global O
test O
for O
the O
QOL O
response O
rate O
. O

Three O
patients O
were O
excluded O
from O
the O
trial O
. O

The O
patients O
were O
observed O
for O
a O
minimum O
of O
3 O
years O
. O

Forty-eight O
women O
( O
56 O
+/- O
10 O
years O
) O
, O
with O
a O
12.8 O
% O
lymphedema O
relative O
volume O
, O
participated O
in O
the O
study O
. O

Due O
to O
the O
various O
inter-individual O
differences O
in O
the O
biological O
characteristics O
of O
tumor O
cells O
, O
as O
well O
as O
issues O
on O
the O
efficacy O
, O
adverse O
reactions O
, O
and O
defects O
of O
existing O
drugs O
, O
we O
compared O
the O
clinical O
efficacy O
and O
toxicity O
of O
pemetrexed O
and O
gemcitabine O
combined O
with O
cisplatin O
for O
the O
treatment O
of O
previously O
untreated O
advanced O
non-small O
cell O
lung O
cancer O
( O
NSCLC O
) O
. O

Patients O
were O
stratified O
by O
menopausal O
and O
hormone-receptor O
status O
. O

Secondary O
end O
points O
included O
progression-free O
survival O
( O
PFS O
) O
, O
overall O
survival O
( O
OS O
) O
, O
adverse O
events O
( O
AEs O
) O
, O
and O
quality-of-life O
measures O
. O

Survival O
curves O
were O
plotted O
and O
were O
compared O
with O
the O
Mantel-Haenszel O
test O
. O

We O
conducted O
a O
prospective O
, O
randomized O
, O
multicentre O
clinical O
trial O
comparing O
the O
effects O
and O
costs O
of O
GM-CSF O
as O
an O
adjunct O
to O
intensive O
chemotherapy O
in O
elderly O
patients O
with O
acute O
myeloid O
leukaemia O
( O
AML O
) O
. O

Assessments O
at O
baseline O
, O
one O
, O
three O
, O
and O
6 O
months O
included O
barriers O
, O
the O
Brief O
Pain O
Inventory O
, O
opioid O
use O
, O
and O
physician O
and O
nurse O
ratings O
of O
their O
patients O
' O
pain O
. O

The O
primary O
endpoint O
was O
the O
difference O
in O
proportion O
of O
patients O
with O
ARSR O
, O
assessed O
with O
the O
Radiation O
Therapy O
Oncology O
Group/The O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
Acute O
Radiation O
Morbidity O
Scoring O
Criteria O
( O
RTOG/EORTC O
scale O
) O
at O
follow-up O
. O

Intrapatient O
dose-escalation O
of O
SGN-15 O
to O
350 O
mg/m2 O
was O
permitted O
in O
the O
second O
half O
of O
the O
study O
. O

A O
brief O
training O
in O
the O
SMART O
program O
can O
enhance O
resilience O
and O
quality O
of O
life O
and O
decrease O
stress O
and O
anxiety O
. O

Analysis O
was O
by O
intention O
to O
treat O
. O

Other O
functional O
assessments O
included O
pulmonary O
and O
eating O
functions O
. O

A O
total O
of O
420 O
patients O
were O
randomised O
and O
411 O
were O
analysed O
. O

Time O
to O
disease O
progression O
, O
response O
rate O
, O
adverse O
events O
, O
and O
QOL O
were O
secondary O
end O
points O
. O

All O
patients O
were O
randomly O
assigned O
to O
two O
groups O
, O
the O
55 O
patients O
in O
the O
treated O
group O
were O
treated O
with O
radiotherapy O
combined O
with O
the O
TCM O
therapy O
, O
and O
the O
53 O
in O
the O
control O
group O
were O
given O
radiotherapy O
alone O
. O

Investigators O
, O
blinded O
to O
the O
results O
, O
stopped O
the O
trial O
early O
because O
of O
a O
low O
enrollment O
rate O
. O

bolus O
( O
arm O
A O
) O
";" O
TOM O
, O
3 O
mg/m2 O
i.v O
. O

Their O
anthropometric O
data O
, O
body O
composition O
, O
including O
fat O
mass O
( O
FM O
) O
and O
fat-free O
mass O
( O
FFM O
) O
, O
and O
lipid O
profiles O
, O
caloric O
intake O
and O
physical O
activity O
were O
assessed O
1 O
week O
before O
randomisation O
, O
and O
6 O
and O
12 O
months O
later O
. O

The O
primary O
outcome O
measures O
were O
dysphagia O
, O
quality O
of O
life O
( O
QL O
) O
6 O
weeks O
following O
treatment O
, O
and O
total O
cost O
of O
treatment O
. O

A O
phase O
III O
trial O
( O
Cancer O
and O
Leukemia O
Group O
B O
CALGB-49907 O
) O
was O
conducted O
to O
test O
whether O
older O
patients O
with O
early-stage O
breast O
cancer O
would O
have O
equivalent O
relapse-free O
and O
overall O
survival O
with O
capecitabine O
compared O
with O
standard O
chemotherapy O
. O

According O
to O
the O
1997-American O
Society O
for O
Therapeutic O
Radiology O
and O
Oncology O
definition O
, O
the O
5-year O
biochemical O
relapse O
rate O
was O
39 O
% O
and O
28 O
% O
in O
the O
-70 O
and O
80-Gy O
arms O
, O
respectively O
( O
p O
= O
.036 O
) O
. O

Patients O
receiving O
DPPE O
were O
aggressively O
premedicated O
to O
ameliorate O
toxicity O
. O

Patients O
( O
age O
range O
, O
16 O
to O
80 O
years O
) O
had O
tumor O
stage O
T1 O
to O
T3 O
, O
with O
possible O
spread O
to O
nearby O
lymph O
nodes O
but O
without O
metastasis O
. O

The O
main O
outcome O
measures O
are O
quality O
of O
life O
( O
QOL O
) O
( O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
Core O
Quality O
of O
Life O
Questionnaire O
[ O
EORTC-QLQ-C30 O
] O
and O
Colorectal O
Cancer-Specific O
Module O
[ O
QLQ-CR38 O
] O
) O
, O
sexual O
functioning O
( O
Female O
Sexual O
Functioning O
Index O
) O
, O
and O
psychological O
well-being O
( O
Brief O
Symptom O
Inventory O
Depression/Anxiety O
, O
Impact O
of O
Events O
Scale-Revised O
, O
CR-38 O
Body O
Image O
) O
. O

A O
randomized O
controlled O
trial O
previously O
conducted O
in O
radiation O
oncology O
patients O
demonstrated O
that O
nutrition O
intervention O
had O
a O
beneficial O
impact O
on O
body O
weight O
, O
nutritional O
status O
, O
and O
quality O
of O
life O
compared O
with O
standard O
practice O
, O
but O
it O
did O
not O
report O
on O
dietary O
intake O
data O
. O

Fifty O
four O
patients O
were O
enrolled O
. O

The O
impact O
of O
the O
side O
effects O
of O
megestrol O
acetate O
on O
the O
quality O
of O
life O
of O
noncachectic O
women O
with O
advanced O
breast O
cancer O
was O
studied O
in O
a O
dose-response O
clinical O
trial O
of O
the O
Cancer O
and O
Leukemia O
Group O
B O
( O
CALGB O
8741 O
) O
. O

Degarelix O
treatment O
evokes O
, O
however O
, O
significantly O
better O
relief O
of O
lower O
urinary O
tract O
symptoms O
in O
patients O
having O
moderate O
and O
severe O
voiding O
problems O
. O

Exclusion O
criteria O
included O
age O
greater O
than O
70 O
years O
, O
World O
Health O
Organization O
( O
WHO O
) O
performance O
status O
greater O
than O
2 O
, O
prior O
chemotherapy O
for O
metastatic O
disease O
, O
and O
presence O
of O
liver O
metastases O
in O
patients O
younger O
than O
50 O
. O

The O
distribution O
of O
bulky O
N2 O
disease O
was O
uniform O
among O
the O
treatment O
arms O
. O

Thus O
, O
an O
alternative O
regimen O
without O
significant O
neurotoxicity O
was O
evaluated O
by O
comparing O
gemcitabine O
plus O
carboplatin O
with O
single-agent O
carboplatin O
in O
platinum-sensitive O
recurrent O
ovarian O
cancer O
patients O
. O

Patients O
completed O
the O
EORTC O
QLQ O
C30 O
and O
the O
Prostate O
Cancer O
Index O
( O
PCI O
) O
before O
treatment O
and O
at O
1.5 O
, O
3 O
, O
6 O
, O
12 O
, O
18 O
, O
24 O
, O
and O
36 O
months O
post-treatment O
. O

V325 O
represents O
the O
largest O
trial O
with O
the O
longest O
prospectively O
controlled O
evaluations O
of O
QOL O
during O
protocol O
chemotherapy O
and O
follow-up O
in O
patients O
with O
advanced O
gastric O
or O
gastroesophageal O
junction O
cancer O
. O

The O
aim O
of O
this O
study O
was O
to O
compare O
the O
toxicity O
and O
efficacy O
of O
radiation O
therapy O
( O
RT O
) O
for O
localized O
carcinoma O
of O
the O
prostate O
, O
using O
a O
hypofractionated O
( O
55 O
Gy/20 O
fractions/4 O
weeks O
) O
vs. O
a O
conventionally O
fractionated O
( O
64 O
Gy/32 O
fractions/6.5 O
weeks O
) O
dose O
schedule O
. O

At O
the O
fourth O
time O
point O
, O
60 O
% O
of O
living O
patients O
in O
both O
arms O
completed O
a O
QOL O
assessment O
. O

Patients O
with O
stage O
IIIb O
and O
IV O
NSCLC O
and O
KP O
< O
/= O
70 O
were O
randomly O
assigned O
to O
receive O
gemcitabine O
1,000 O
mg/m O
( O
2 O
) O
on O
days O
1 O
, O
8 O
, O
and O
15 O
of O
each O
28-day O
cycle O
( O
3w4 O
) O
or O
gemcitabine O
1,500 O
mg/m O
( O
2 O
) O
on O
days O
1 O
and O
8 O
of O
each O
21-day O
cycle O
( O
2w3 O
) O
, O
both O
for O
up O
to O
six O
cycles O
. O

However O
, O
whether O
intrapleural O
delivery O
of O
bevacizumab O
can O
be O
used O
to O
treat O
MPE O
remains O
unknown O
. O

The O
purpose O
of O
this O
study O
was O
to O
assess O
the O
effects O
of O
a O
novel O
mindfulness O
intervention O
called O
mindfulness-based O
art O
therapy O
( O
MBAT O
) O
versus O
standard O
educational O
support O
, O
on O
indices O
of O
stress O
and O
quality O
of O
life O
in O
breast O
cancer O
patients O
with O
high O
stress O
levels O
. O

Results O
for O
functional O
outcome O
and O
quality O
of O
life O
are O
rarely O
reported O
beyond O
10 O
years O
and O
are O
lacking O
from O
randomised O
settings O
. O

The O
feasibility O
of O
measuring O
Bcl-2 O
protein O
in O
a O
cooperative O
group O
setting O
is O
hypothesis O
generating O
and O
supports O
further O
study O
as O
a O
marker O
for O
Bcl-2 O
targeted O
therapy O
. O

Overall O
urinary O
morbidity O
was O
worst O
at O
1 O
month O
after O
the O
implant O
. O

Fatigue O
dimensions O
, O
fatigue O
NRS O
score O
, O
interference O
of O
fatigue O
with O
daily O
life O
, O
symptom O
burden O
, O
quality O
of O
life O
, O
anxiety O
, O
and O
depression O
were O
measured O
at O
baseline O
and O
after O
1 O
, O
2 O
, O
and O
3 O
months O
. O

Assessments O
were O
done O
at O
baseline O
, O
9 O
weeks O
, O
and O
26 O
weeks O
after O
randomisation O
. O

There O
were O
38 O
hospitalized O
patients O
, O
with O
20 O
( O
13 O
males O
and O
7 O
females O
) O
in O
the O
experimental O
group O
and O
18 O
( O
11 O
males O
and O
7 O
females O
) O
in O
the O
control O
group O
";" O
mean O
age O
was O
61.95 O
years O
( O
experimental O
group O
) O
to O
63.94 O
years O
( O
control O
group O
) O
. O

Patients O
' O
subjective O
perspective O
should O
be O
taken O
into O
account O
in O
this O
mainly O
palliative O
setting O
. O

Patients O
with O
breast O
cancer O
reporting O
treatment-induced O
menopausal O
symptoms O
( O
N=422 O
) O
were O
randomly O
assigned O
to O
CBT O
( O
n=109 O
) O
, O
PE O
( O
n=104 O
) O
, O
CBT/PE O
( O
n=106 O
) O
, O
or O
to O
a O
waiting O
list O
control O
group O
( O
n=103 O
) O
. O

Adjusted O
linear O
mixed-model O
analyses O
demonstrated O
that O
patient O
preference O
moderated O
QoL O
response O
( O
P= O
.005 O
) O
. O

Rehabilitation O
aims O
to O
address O
these O
needs O
, O
maximize O
psychological O
and O
physical O
function O
, O
and O
enable O
minimum O
dependency O
regardless O
of O
life O
expectancy O
. O

Secondary O
end O
points O
included O
severity O
and O
duration O
of O
mucositis O
, O
pain O
measurement O
, O
radiation O
therapy O
interruption O
, O
and O
quality O
of O
life O
. O

A O
dramatic O
rise O
in O
incidence O
, O
an O
aging O
population O
, O
and O
expensive O
palliative O
treatments O
have O
led O
to O
an O
escalating O
burden O
on O
clinicians O
managing O
inoperable O
esophageal O
cancer O
with O
only O
limited O
evidence O
of O
effectiveness O
. O

HEC O
participants O
received O
nutritional O
information O
and O
equal O
attention O
. O

After O
documentation O
of O
N2 O
disease O
by O
mediastinoscopy O
or O
anterior O
mediastinotomy O
, O
patients O
received O
induction O
chemotherapy O
with O
cisplatin O
, O
vinblastine O
, O
and O
mitomycin-C. O
Mitomycin-C O
was O
later O
dropped O
from O
the O
induction O
regimen O
. O

General O
practices O
in O
UK O
( O
384 O
) O
, O
Australia O
( O
91 O
) O
, O
and O
New O
Zealand O
( O
24 O
) O
. O

We O
compared O
the O
effect O
on O
QoL O
of O
two O
docetaxel-platinum O
regimens O
with O
vinorelbine-cisplatin O
. O

Treatment O
arms O
were O
compared O
using O
the O
stratified O
log-rank O
test O
and O
Cox O
proportional O
hazards O
model O
adjusted O
for O
trial O
stratum O
( O
visceral O
metastases O
, O
previous O
hormone O
sensitivity O
) O
, O
age O
, O
sex O
, O
race O
, O
baseline O
global O
health O
status O
score O
and O
Eastern O
Cooperative O
Oncology O
Group O
performance O
status O
, O
prognostic O
risk O
factors O
, O
and O
treatment O
history O
. O

251 O
patients O
were O
randomly O
divided O
into O
pemetrexed O
combined O
with O
cisplatin O
group O
( O
PP O
group O
) O
with O
127 O
cases O
and O
gemcitabine O
combined O
with O
cisplatin O
group O
( O
GP O
group O
) O
with O
124 O
cases O
. O

Prospective O
studies O
comparing O
the O
two O
methods O
in O
Asian O
people O
are O
few O
. O

The O
purpose O
of O
this O
analysis O
was O
to O
assess O
the O
impact O
of O
pretreatment O
factors O
on O
quality O
of O
life O
( O
QOL O
) O
in O
patients O
with O
locally O
advanced O
nonsmall O
cell O
lung O
cancer O
( O
NSCLC O
) O
. O

The O
first O
group O
received O
intrapleural O
bevacizumab O
( O
300 O
mg O
) O
with O
cisplatin O
( O
30 O
mg O
) O
therapy O
and O
the O
second O
group O
received O
intrapleural O
cisplatin O
( O
30 O
mg O
) O
therapy O
alone O
. O

QoL O
was O
determined O
at O
the O
time O
of O
ablation O
. O

The O
30 O
items O
in O
15 O
subscales O
of O
the O
QLQ-C30 O
include O
global O
health O
status O
wherein O
higher O
scores O
( O
range O
, O
0-100 O
) O
indicate O
better O
HRQOL O
. O

The O
benefit O
of O
epoetin O
alfa O
in O
maintaining O
hemoglobin O
levels O
in O
cancer O
patients O
with O
hemoglobin O
less O
than O
12 O
g/dL O
has O
not O
been O
evaluated O
. O

Clinical O
follow-up O
was O
obtained O
in O
35 O
patients O
. O

There O
were O
no O
significant O
differences O
in O
preprocedure O
clinical O
and O
pathologic O
variables O
between O
groups O
. O

A O
total O
of O
402 O
eligible O
patients O
were O
registered O
to O
step O
1 O
, O
and O
223 O
eligible O
patients O
were O
registered O
to O
step O
2 O
( O
observation O
, O
n O
= O
111 O
";" O
topotecan O
, O
n O
= O
112 O
) O
. O

Satisfaction O
was O
assessed O
with O
a O
seven-point O
Likert O
scale O
. O

Epoetin O
beta O
rapidly O
increases O
haemoglobin O
( O
Hb O
) O
levels O
and O
improves O
QoL O
in O
anaemic O
patients O
with O
a O
variety O
of O
tumours O
. O

Assessments O
were O
conducted O
at O
baseline O
, O
immediately O
before O
every O
treatment O
cycle O
, O
at O
the O
end O
of O
treatment O
, O
and O
every O
six O
weeks O
for O
12 O
months O
. O

Patients O
were O
randomized O
to O
receive O
epoetin O
alfa O
40,000 O
U O
subcutaneously O
once O
weekly O
or O
placebo O
at O
the O
beginning O
of O
4 O
cycles O
of O
chemotherapy O
administered O
over O
12 O
weeks O
. O

We O
analysed O
data O
with O
prespecified O
criteria O
for O
clinically O
meaningful O
pain O
progression O
and O
deterioration O
in O
HRQoL O
. O

Baseline O
characteristics O
in O
the O
HRQoL O
sub-protocol O
were O
well O
balanced O
between O
the O
anastrozole O
( O
n O
= O
335 O
) O
and O
tamoxifen O
( O
n O
= O
347 O
) O
groups O
in O
the O
primary O
analysis O
population O
. O

Patients O
with O
incompletely O
resected O
tumour O
received O
six O
to O
10 O
courses O
of O
IVA O
according O
to O
stage O
. O

Skin O
care O
, O
30-min O
manual O
lymphatic O
drainage O
, O
1-h O
pneumatic O
compression O
therapy O
, O
application O
of O
a O
short-stretch O
bandage O
or O
K-tape O
for O
each O
group O
, O
and O
a O
20-min O
physical O
therapy O
exercise O
were O
given O
during O
every O
treatment O
session O
. O

A O
randomized O
trial O
comparing O
the O
efficacy O
and O
toxicity O
of O
paclitaxel O
and O
PLD O
was O
performed O
, O
and O
the O
effects O
of O
therapy O
on O
symptom O
palliation O
and O
quality O
of O
life O
were O
determined O
. O

Design O
of O
the O
study O
was O
single-blind O
randomized O
clinical O
trial O
. O

QoL O
was O
assessed O
using O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
QLQ-C30 O
questionnaire O
. O

Sixty-four O
women O
were O
recruited O
prior O
to O
commencement O
of O
radiotherapy O
following O
breast O
cancer O
surgery O
. O

This O
may O
cause O
cisplatin-induced O
gastrointestinal O
disorders O
and O
hinders O
the O
continuation O
of O
chemotherapy O
. O

We O
report O
a O
phase O
III O
trial O
comparing O
DOX O
with O
DPPE O
plus O
DOX O
in O
metastatic O
or O
recurrent O
breast O
cancer O
. O

This O
, O
performance O
status O
, O
Hospital O
Anxiety O
and O
Depression O
( O
HAD O
) O
score O
and O
Spitzer O
's O
quality-of-life O
index O
were O
noted O
before O
treatment O
, O
at O
1 O
month O
after O
treatment O
and O
every O
2 O
months O
thereafter O
. O

After O
four O
cycles O
of O
platinum-based O
induction O
therapy O
, O
663 O
patients O
with O
stage O
IIIB O
or O
stage O
IV O
NSCLC O
and O
Eastern O
Cooperative O
Oncology O
Group O
performance O
status O
of O
0 O
or O
1 O
were O
randomly O
assigned O
( O
in O
a O
2:1 O
ratio O
) O
from O
March O
15 O
, O
2005 O
, O
to O
July O
20 O
, O
2007 O
, O
using O
the O
Pocock O
and O
Simon O
minimisation O
method O
to O
receive O
pemetrexed O
( O
500 O
mg/m O
( O
2 O
) O
every O
21 O
days O
";" O
n=441 O
) O
or O
placebo O
( O
n=222 O
) O
plus O
best O
supportive O
care O
until O
disease O
progression O
. O

Safe O
resistance O
exercise O
prescription O
may O
counteract O
this O
effect O
. O

Assessment O
of O
depression O
added O
to O
usual O
care O
probably O
had O
an O
effect O
because O
it O
is O
not O
normally O
a O
focus O
of O
hospice O
staff O
. O

One O
hundred O
ninety O
patients O
with O
extremity O
STS O
were O
randomized O
after O
stratification O
by O
tumor O
size O
dichotomized O
at O
10 O
cm O
. O

Two O
hundred O
fifteen O
cancer O
patients O
were O
identified O
from O
the O
1,801 O
participants O
in O
the O
parent O
study O
. O

Outcome O
parameters O
were O
: O
postoperative O
morbidity O
, O
length O
of O
hospital O
stay O
, O
quality O
of O
life O
, O
long-term O
survival O
, O
and O
local O
recurrences O
. O

There O
were O
no O
differences O
in O
the O
intraoperative O
time O
and O
hospital O
stay O
. O

Questionnaire O
compliance O
was O
94 O
% O
at O
baseline O
, O
but O
it O
declined O
differentially O
( O
67 O
% O
v O
47 O
% O
for O
cetuximab O
v O
BSC O
at O
16 O
weeks O
) O
. O

In O
addition O
, O
our O
study O
was O
to O
determine O
whether O
a O
disease-specific O
module O
has O
greater O
sensitivity O
to O
group O
differences O
than O
a O
generic O
QOL O
questionnaire O
and O
to O
determine O
the O
most O
pragmatic O
approach O
to O
treating O
epidemic O
Kaposi O
's O
sarcoma O
( O
EKS O
) O
in O
Zimbabwe O
. O

Private O
medical O
clinic O
, O
Seattle O
, O
WA O
. O

Patients O
( O
n O
= O
829 O
) O
completed O
the O
Functional O
Assessment O
of O
Cancer O
Therapy O
- O
Breast O
( O
FACT-B+4 O
) O
and O
the O
Spielberger O
State/Trait O
Anxiety O
Inventory O
( O
STAI O
) O
at O
baseline O
( O
pre-surgery O
) O
and O
at O
1 O
, O
3 O
, O
6 O
, O
12 O
, O
and O
18 O
months O
post-surgery O
. O

The O
incremental O
cost-effectiveness O
ratio O
was O
calculated O
as O
the O
cost O
per O
quality-adjusted O
life O
year O
( O
QALY O
) O
gained O
. O

To O
test O
the O
hypothesis O
that O
modulation O
of O
Bcl-2 O
with O
13-cis O
retinoic O
acid O
( O
CRA O
) O
/interferon-alpha2b O
( O
IFN O
) O
with O
paclitaxel O
( O
TAX O
) O
, O
or O
mitoxantrone O
, O
estramustine O
and O
vinorelbine O
( O
MEV O
) O
will O
have O
clinical O
activity O
in O
men O
with O
metastatic O
castrate-resistant O
prostate O
cancer O
( O
CRPC O
) O
. O

In O
a O
secondary O
analysis O
of O
a O
randomized O
trial O
of O
supportive-expressive O
group O
therapy O
, O
125 O
women O
with O
metastatic O
breast O
cancer O
( O
MBC O
) O
completed O
a O
depression O
symptom O
measure O
( O
Center O
for O
Epidemiologic O
Studies-Depression O
Scale O
[ O
CES-D O
] O
) O
at O
baseline O
and O
were O
randomly O
assigned O
to O
a O
treatment O
group O
or O
to O
a O
control O
group O
that O
received O
educational O
materials O
. O

Surgery O
and O
radiotherapy O
commonly O
cause O
adverse O
musculoskeletal O
problems O
, O
particularly O
loss O
of O
strength O
and O
range O
of O
motion O
, O
in O
the O
upper O
quadrant O
of O
breast O
cancer O
patients O
. O

At O
the O
beginning O
and O
the O
end O
of O
the O
study O
, O
we O
evaluated O
physical O
, O
cognitive O
and O
emotional O
status O
and O
somatic O
complaints O
with O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
Questionnaire O
Core O
Module O
( O
EORTC-QLQ-30 O
) O
questionnaire O
, O
and O
maximal O
physical O
performance O
with O
an O
ergometric O
stress O
test O
. O

Baseline O
global O
health O
status O
scores O
were O
found O
to O
be O
similar O
between O
treatment O
groups O
( O
64.7 O
vs O
65.3 O
) O
. O

The O
primary O
end O
point O
of O
the O
study O
was O
survival O
. O

SCLC O
patients O
in O
complete O
or O
partial O
remission O
were O
eligible O
. O

Other O
measurements O
included O
the O
Hospital O
Anxiety O
and O
Depression O
Scale O
, O
Functional O
Assessment O
of O
Cancer O
Therapy-General O
quality-of-life O
scale O
, O
and O
expectation O
of O
acupuncture O
effect O
. O

Concurrent O
validity O
of O
the O
mood O
linear O
analogue O
self-assessment O
was O
consistently O
confirmed O
across O
four O
language O
groups O
. O

After O
16 O
of O
the O
first O
65 O
randomized O
patients O
experienced O
febrile O
neutropenia O
( O
FN O
) O
, O
the O
doses O
were O
reduced O
to O
DOX O
40 O
mg/m O
( O
2 O
) O
on O
day O
1 O
and O
VNB O
20 O
mg/m O
( O
2 O
) O
on O
days O
1 O
and O
8 O
versus O
DOX O
60 O
mg/m O
( O
2 O
) O
on O
day O
1 O
. O

The O
aim O
of O
the O
present O
trial O
was O
to O
evaluate O
the O
effects O
of O
chemotherapy O
on O
the O
quality O
of O
life O
and O
survival O
of O
patients O
with O
advanced O
non-small O
cell O
lung O
cancer O
( O
NSCLC O
) O
( O
stage O
IIIB O
or O
IV O
) O
. O

This O
study O
compares O
the O
clinical O
effectiveness O
and O
cost-effectiveness O
of O
self-expanding O
metal O
stents O
( O
SEMSs O
) O
with O
other O
palliative O
therapies O
to O
aid O
clinicians O
in O
making O
an O
evidence-based O
treatment O
choice O
. O

Patients O
with O
cytologically O
proven O
, O
symptomatic O
lung O
cancer O
not O
amenable O
to O
curative O
therapy O
, O
with O
performance O
status O
0-3 O
, O
were O
randomised O
to O
receive O
either O
30 O
Gy O
in O
10 O
fractions O
or O
a O
10 O
Gy O
single O
fraction O
. O

The O
primary O
endpoints O
were O
overall O
survival O
( O
OS O
) O
and O
analysis O
of O
toxicity O
, O
while O
secondary O
endpoints O
included O
response O
rates O
, O
time-to-progression O
( O
TTP O
) O
and O
quality O
of O
life O
( O
QoL O
) O
. O

They O
were O
stratified O
by O
radiotherapy O
( O
early O
, O
late O
, O
or O
none O
) O
, O
stage O
( O
extensive O
or O
limited O
) O
, O
response O
( O
complete O
or O
partial O
) O
, O
and O
cooperative O
group O
( O
National O
Cancer O
Institute O
of O
Canada-Clinical O
Trials O
Group O
or O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
) O
. O

To O
investigate O
whether O
frequent O
hospital O
follow-up O
in O
the O
first O
year O
after O
breast O
cancer O
treatment O
might O
partly O
be O
replaced O
by O
nurse-led O
telephone O
follow-up O
without O
deteriorating O
health-related O
quality O
of O
life O
( O
HRQoL O
) O
, O
and O
whether O
a O
short O
educational O
group O
programme O
( O
EGP O
) O
would O
enhance O
HRQoL O
. O

Participants O
were O
enrolled O
in O
a O
randomized O
intervention O
trial O
to O
treat O
sexual O
dysfunction O
and O
completed O
outcome O
measures O
prior O
to O
randomization O
. O

No O
significant O
difference O
in O
outcome O
was O
found O
between O
the O
patients O
with O
and O
without O
baseline O
FACT-H O
& O
amp O
";" O
N O
data O
( O
p O
= O
0.58 O
) O
. O

This O
randomized O
controlled O
trial O
tested O
whether O
acupuncture O
reduces O
vasomotor O
symptoms O
and O
produces O
fewer O
adverse O
effects O
than O
venlafaxine O
. O

Secondary O
endpoints O
included O
toxicity O
, O
response O
to O
treatment O
, O
quality O
of O
life O
, O
and O
overall O
and O
progression-free O
survival O
time O
. O

Quality O
of O
life O
was O
assessed O
in O
131 O
patients O
at O
trial O
entry O
and O
at O
1 O
and O
3 O
months O
while O
on O
treatment O
, O
by O
telephone O
interview O
, O
using O
the O
following O
measures O
: O
the O
Functional O
Living O
Index-Cancer O
( O
FLIC O
) O
, O
Rand O
Functional O
Limitations O
Scale O
, O
Rand O
Mental O
Health O
Inventory O
( O
MHI O
) O
, O
the O
Body O
Image O
Subscale O
, O
and O
linear O
analog O
scales O
of O
drug O
side O
effects O
. O

A O
total O
of O
1113 O
men O
were O
registered O
, O
of O
whom O
970 O
were O
randomly O
assigned O
, O
483 O
to O
short-term O
suppression O
and O
487 O
to O
long-term O
suppression O
. O

HRQoL O
was O
assessed O
with O
the O
EORTC O
Core O
QoL O
Questionnaire O
( O
QLQ-C30 O
) O
and O
the O
myeloma-specific O
module O
( O
QLQ-MY24 O
) O
at O
baseline O
and O
at O
predetermined O
intervals O
during O
treatment O
. O

A O
recent O
randomized O
trial O
to O
compare O
external O
beam O
radiation O
therapy O
( O
EBRT O
) O
to O
cryoablation O
for O
localized O
disease O
showed O
cryoablation O
to O
be O
noninferior O
to O
external O
beam O
EBRT O
in O
disease O
progression O
and O
overall O
and O
disease-specific O
survival O
. O

Thirty-six O
patients O
with O
local-regional O
advanced O
H O
& O
amp O
";" O
N O
cancer O
receiving O
chemoradiationtherapy O
( O
CRT O
) O
were O
randomized O
to O
receive O
either O
placebo O
or O
rhDNase O
. O

Ninety-nine O
patients O
who O
had O
UAE O
and O
eight O
patients O
who O
had O
myomectomy O
were O
analyzed O
. O

Three O
main O
quality O
of O
life O
scales O
( O
general O
health O
status O
, O
functional O
, O
and O
symptom O
scales O
) O
were O
assessed O
and O
compared O
between O
two O
treatment O
groups O
. O

During O
2000-2005 O
, O
two O
concomitant O
chemoradiation O
treatment O
methods O
( O
radiotherapy O
with O
5-fluorouracil O
and O
radiotherapy O
with O
gemcitabine O
) O
were O
analyzed O
in O
the O
study O
. O

We O
randomly O
assigned O
75 O
patients O
to O
usual O
care O
and O
227 O
patients O
to O
acupuncture O
plus O
usual O
care O
( O
random O
assignment O
of O
1:3 O
respectively O
) O
with O
minimization O
controlling O
for O
baseline O
general O
fatigue O
and O
maintenance O
treatment O
. O

HRQOL O
was O
assessed O
with O
the O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
Core O
Quality O
of O
Life O
Questionnaire O
C30 O
( O
EORTC O
QLQ-C30 O
) O
and O
EORTC O
Lung O
Cancer O
Module O
( O
QLQ-LC13 O
) O
tools O
. O

Seventy-six O
patients O
were O
randomly O
assigned O
to O
each O
study O
arm O
. O

Participants O
were O
randomised O
to O
either O
a O
control O
or O
stretch O
group O
. O

Participants O
were O
randomised O
to O
follow-up O
care O
as O
usual O
( O
3-monthly O
outpatient O
clinic O
visits O
) O
, O
nurse-led O
telephone O
follow-up O
, O
or O
the O
former O
strategies O
combined O
with O
an O
educational O
group O
programme O
. O

This O
study O
was O
designed O
to O
determine O
whether O
epoetin O
alpha O
would O
decrease O
the O
number O
of O
transfusion O
events O
and O
units O
of O
packed O
erythrocytes O
( O
PRBCs O
) O
transfused O
, O
and O
the O
secondary O
objective O
was O
to O
study O
the O
effects O
of O
epoetin O
alpha O
on O
quality O
of O
life O
( O
QOL O
) O
and O
complete O
remission O
( O
CR O
) O
rates O
. O

Importantly O
, O
none O
of O
the O
QOL O
domains O
were O
worse O
with O
IMRT O
at O
any O
time O
point O
. O

Subjects O
were O
asked O
to O
document O
the O
frequency O
, O
duration O
, O
and O
intensity O
of O
all O
exercise O
participation O
on O
monthly O
calendars O
. O

To O
examine O
health-related O
quality O
of O
life O
, O
we O
investigated O
the O
effect O
of O
adjuvant O
chemotherapy O
regimens O
on O
utility O
scores O
assessed O
by O
the O
EuroQoL-5D O
( O
EQ-5D O
) O
instrument O
in O
a O
randomized O
, O
controlled O
trial O
for O
breast O
cancer O
patients O
after O
surgery O
. O

Although O
CP O
has O
recently O
been O
shown O
to O
be O
feasible O
in O
patients O
, O
there O
is O
no O
randomized O
controlled O
trial O
comparing O
bowel O
function O
with O
the O
J-pouch O
. O

The O
aim O
of O
this O
study O
was O
to O
assess O
efficacy O
and O
safety O
of O
association O
of O
duloxetine O
and O
rehabilitation O
compared O
with O
rehabilitation O
alone O
in O
men O
with O
SUI O
after O
radical O
retropubic O
prostatectomy O
( O
RRP O
) O
, O
and O
to O
compare O
continence O
rate O
even O
after O
planned O
duloxetine O
suspension O
. O

The O
majority O
of O
patients O
received O
the O
intended O
four O
cycles O
( O
GCa O
, O
64 O
% O
";" O
MIC O
, O
61 O
% O
) O
. O

Secondary O
endpoints O
were O
cases O
of O
breakthrough O
pain O
and O
rescue O
morphine O
consumption O
. O

Follow-up O
time O
ranged O
from O
14 O
to O
56 O
months O
( O
median O
, O
33 O
months O
) O
. O

Treatment-related O
quality O
of O
life O
was O
assessed O
by O
the O
Breast O
Chemotherapy O
Questionnaire O
( O
BCQ O
) O
before O
, O
during O
, O
and O
4 O
months O
after O
treatment O
in O
163 O
patients O
. O

The O
two O
purposes O
of O
the O
study O
were O
to O
describe O
the O
effectiveness O
of O
the O
program O
and O
to O
obtain O
information O
about O
patient O
preferences O
for O
multi O
or O
mono O
dimensional O
rehabilitation O
programs O
. O

Health-related O
quality O
of O
life O
( O
HRQoL O
";" O
exploratory O
endpoint O
) O
was O
evaluated O
using O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
( O
EORTC O
) O
Quality O
of O
Life O
Questionnaire O
( O
QLQ-C30 O
) O
. O

Before O
and O
after O
the O
intervention O
period O
, O
all O
of O
the O
subjects O
performed O
a O
cardiorespiratory O
test O
to O
measure O
peak O
oxygen O
uptake O
( O
VO2peak O
) O
, O
a O
dynamic O
strength O
endurance O
test O
( O
maximum O
number O
of O
repetitions O
for O
chest O
and O
leg O
press O
exercise O
at O
30 O
- O
35 O
% O
and O
100 O
- O
110 O
% O
of O
body O
mass O
, O
respectively O
) O
and O
a O
sit-stand O
test O
. O

Multivariate O
analyses O
were O
used O
to O
evaluate O
the O
association O
of O
the O
genotypes O
on O
the O
four O
endpoints O
. O

After O
the O
administration O
of O
the O
131-I O
dose O
, O
the O
rate O
of O
radiation O
clearance O
from O
blood O
, O
thyroid O
remnant O
, O
and O
whole O
body O
was O
measured O
. O

A O
measure O
of O
3.7 O
GBq O
of O
radioiodine O
was O
given O
to O
both O
groups O
. O

Radiotherapy O
was O
delivered O
on O
weekdays O
2 O
Gy O
daily O
up O
to O
56 O
Gy O
. O

Data O
were O
analyzed O
using O
repeated O
measure O
ANOVA O
through O
general O
linear O
model O
. O

Sunitinib O
has O
demonstrated O
antitumor O
activity O
in O
metastatic O
renal O
cell O
carcinoma O
( O
mRCC O
) O
when O
given O
at O
50 O
mg/d O
on O
a O
4-weeks-on O
2-weeks-off O
regimen O
. O

Wilcoxon O
test O
was O
used O
to O
analyse O
changes O
in O
IEF O
and O
in O
I-QoL O
score O
";" O
Fisher O
exact O
test O
was O
used O
to O
compare O
continent O
patients O
between O
the O
groups O
. O

To O
compare O
the O
outcome O
of O
treatment O
of O
mediastinoscopy-verified O
N2 O
non-small-cell O
lung O
cancer O
treated O
with O
induction O
chemotherapy O
followed O
by O
either O
surgery O
or O
radiotherapy O
( O
RT O
) O
, O
with O
both O
options O
followed O
by O
consolidation O
chemotherapy O
. O

The O
EORTC O
24971/TAX O
323 O
, O
a O
phase O
III O
study O
of O
358 O
patients O
with O
unresectable O
locoregionally O
advanced O
squamous O
cell O
carcinoma O
of O
the O
head O
and O
neck O
, O
showed O
an O
improved O
progression-free O
and O
overall O
survival O
( O
OS O
) O
with O
less O
toxicity O
when O
docetaxel O
( O
T O
) O
was O
added O
to O
cisplatin O
and O
5-fluorouracil O
( O
PF O
) O
for O
induction O
and O
given O
before O
radiotherapy O
( O
RT O
) O
. O

The O
primary O
outcome O
was O
depression O
as O
assessed O
by O
the O
Centre O
for O
Epidemiologic O
Studies O
Depression O
scale O
( O
CES-D O
) O
";" O
the O
main O
secondary O
outcomes O
were O
: O
anxiety O
as O
assessed O
by O
Hospital O
Anxiety O
and O
Depression O
Scales O
( O
HADS-A O
) O
";" O
overall O
quality O
of O
life O
and O
fatigue O
as O
assessed O
by O
Functional O
Assessment O
of O
Cancer O
Therapy O
General O
and O
Fatigue O
scales O
( O
FACT-G O
and O
FACT-F O
, O
respectively O
) O
";" O
and O
clinicians O
' O
ratings O
of O
quality O
of O
life O
by O
use O
of O
Spizter O
's O
Quality O
of O
Life O
Index O
( O
SQLI O
) O
. O

We O
obtained O
quality-of-life O
information O
from O
872 O
( O
99 O
% O
) O
of O
875 O
eligible O
men O
with O
locally O
advanced O
prostate O
cancer O
( O
T3 O
";" O
78 O
% O
) O
who O
were O
randomly O
assigned O
, O
between O
1996 O
and O
2002 O
, O
to O
3 O
months O
of O
total O
androgen O
blockade O
followed O
by O
continuous O
endocrine O
treatment O
( O
439 O
patients O
) O
or O
the O
same O
hormonal O
treatment O
with O
radiotherapy O
3 O
months O
after O
randomisation O
( O
436 O
patients O
) O
. O

Gefitinib O
and O
Pemetrexed O
are O
drugs O
used O
as O
second-line O
therapy O
for O
advanced O
non-small O
cell O
lung O
cancer O
( O
NSCLC O
) O
, O
although O
studies O
comparing O
the O
two O
drugs O
are O
limited O
. O

The O
day O
before O
the O
nutritional O
interventions O
, O
and O
again O
after O
four O
and O
eight O
weeks O
, O
body O
compartments O
were O
determined O
using O
bioelectrical O
impedance O
analysis O
, O
lymphocyte O
subpopulations O
were O
quantified O
using O
flow O
cytometry O
, O
and O
some O
aspects O
of O
the O
quality O
of O
life O
were O
rated O
using O
four O
linear O
analog O
self-assessment O
( O
LASA O
) O
scales O
. O

Possible O
contributing O
factors O
beyond O
the O
efficacy O
of O
the O
intervention O
were O
the O
inability O
of O
patients O
to O
complete O
an O
8-week O
course O
of O
treatment O
and O
return O
in O
a O
timely O
fashion O
for O
follow-up O
assessment O
, O
and O
because O
the O
patients O
may O
have O
only O
had O
weight O
loss O
possible O
not O
related O
to O
cachexia O
, O
but O
other O
causes O
of O
weight O
loss O
, O
such O
as O
decreased O
appetite O
. O

With O
the O
exception O
of O
previous O
chemotherapy O
, O
the O
treatment O
groups O
were O
well O
balanced O
, O
both O
regarding O
treatment- O
and O
patient-related O
factors O
. O

Patients O
were O
randomly O
assigned O
to O
the O
8-week O
MBSR O
program O
or O
standard O
care O
. O

182 O
( O
88 O
% O
) O
of O
208 O
men O
in O
the O
radical O
prostatectomy O
group O
, O
167 O
( O
87 O
% O
) O
of O
192 O
men O
in O
the O
watchful-waiting O
group O
, O
and O
214 O
( O
76 O
% O
) O
of O
281 O
men O
in O
the O
population-based O
control O
group O
answered O
the O
questionnaire O
. O

Hot O
flash O
frequency O
was O
evaluated O
at O
baseline O
, O
at O
6 O
weeks O
, O
and O
at O
6 O
months O
after O
initiation O
of O
treatment O
. O

Ten O
common O
symptoms O
were O
assessed O
by O
self-report O
questionnaire O
administered O
to O
1,614 O
consecutive O
patients O
at O
baseline O
and O
every O
3 O
months O
during O
the O
first O
year O
of O
a O
double-blind O
, O
randomized O
trial O
of O
postmenopausal O
women O
with O
early O
hormone O
receptor-positive O
breast O
cancer O
. O

The O
sample O
size O
was O
defined O
to O
have O
an O
80 O
% O
power O
to O
detect O
a O
35 O
% O
RR O
for O
each O
experimental O
treatment O
, O
and O
to O
show O
a O
difference O
of O
at O
least O
4 O
% O
in O
RR O
with O
the O
standard O
treatment O
if O
the O
TRUE O
difference O
is O
15 O
% O
or O
more O
. O

Thyroid O
ablation O
was O
assessed O
8 O
months O
after O
radioiodine O
administration O
by O
neck O
ultrasonography O
and O
measurement O
of O
recombinant O
human O
thyrotropin-stimulated O
thyroglobulin O
. O

In O
all O
, O
263 O
men O
attended O
47 O
sessions O
. O

The O
primary O
endpoint O
was O
volume O
of O
the O
ipsilateral O
limb O
measured O
opto-electronically O
using O
a O
perometer O
and O
expressed O
as O
a O
percentage O
of O
the O
contralateral O
limb O
volume O
. O

Women O
with O
a O
history O
of O
breast O
cancer O
who O
had O
completed O
all O
surgery O
, O
chemotherapy O
, O
and O
radiation O
treatment O
and O
who O
had O
an O
average O
of O
at O
least O
three O
hot O
flashes O
per O
day O
for O
the O
previous O
month O
. O

The O
Pain O
Education O
Program O
was O
tailored O
to O
the O
needs O
of O
the O
individual O
patient O
and O
consisted O
of O
three O
elements O
: O
( O
1 O
) O
educating O
patients O
about O
the O
basic O
principles O
regarding O
pain O
and O
pain O
management O
";" O
( O
2 O
) O
instructing O
patients O
how O
to O
report O
their O
pain O
in O
a O
pain O
diary O
";" O
and O
( O
3 O
) O
instructing O
patients O
how O
to O
communicate O
about O
pain O
and O
how O
to O
contact O
health O
care O
providers O
. O

Researchers O
and O
outcome O
assessors O
were O
blinded O
for O
assigned O
treatment O
. O

The O
primary O
endpoint O
was O
biochemical O
relapse O
according O
to O
the O
modified O
1997-American O
Society O
for O
Therapeutic O
Radiology O
and O
Oncology O
and O
Phoenix O
definitions O
. O

It O
is O
equieffective O
as O
oral O
( O
p.o O
. O
) O

From O
November O
2002 O
to O
November O
2004 O
, O
65 O
eligible O
patients O
were O
randomly O
assigned O
to O
neoadjuvant O
chemotherapy O
followed O
by O
CRT O
( O
n O
= O
34 O
) O
or O
CRT O
alone O
( O
n O
= O
31 O
) O
. O

Patients O
were O
randomly O
assigned O
to O
receive O
either O
nutrition O
intervention O
( O
n=29 O
) O
( O
nutrition O
counseling O
following O
the O
American O
Dietetic O
Association O
[ O
ADA O
] O
medical O
nutrition O
therapy O
[ O
MNT O
] O
protocol O
for O
radiation O
oncology O
) O
or O
standard O
practice O
( O
n=31 O
) O
( O
general O
nutrition O
talk O
and O
booklet O
) O
. O

The O
CMA O
intervention O
, O
delivered O
by O
a O
nurse O
practitioner O
, O
focused O
on O
symptom O
assessment O
, O
education O
, O
counseling O
and O
, O
as O
appropriate O
, O
specific O
pharmacologic O
and O
behavioral O
interventions O
for O
each O
of O
the O
three O
target O
symptoms O
. O

Two O
university O
hospitals O
in O
Copenhagen O
, O
Denmark O
. O

The O
trial O
was O
closed O
early O
due O
to O
slow O
accrual O
. O

Two O
hundred O
seventy O
one O
patients O
( O
89 O
% O
of O
randomized O
) O
submitted O
the O
baseline O
QOL O
questionnaires O
and O
were O
included O
in O
the O
QOL O
analysis O
. O

Fifty-two O
patients O
with O
breast O
cancer O
were O
divided O
into O
either O
pilates O
exercise O
( O
group O
1 O
) O
and O
control O
group O
( O
group O
2 O
) O
. O

The O
standard O
treatment O
of O
postoperative O
breast O
irradiation O
or O
the O
omission O
of O
radiotherapy O
. O

Few O
reports O
have O
examined O
the O
use O
of O
recombinant O
human O
thyroid-stimulating O
hormone O
( O
rhTSH O
) O
for O
ablation O
of O
postsurgical O
thyroid O
remnants O
after O
low-dose O
radioactive O
iodine O
( O
RI O
) O
therapy O
, O
compared O
with O
conventional O
thyroid O
hormone O
withdrawal O
. O

Randomized O
, O
double-blinded O
, O
placebo-controlled O
. O

An O
intention-to-treat O
analysis O
was O
carried O
out O
. O

To O
study O
the O
effects O
of O
Fuzheng O
Jianpi O
Decoction O
( O
FJD O
) O
combined O
chemotherapy O
on O
the O
quality O
of O
life O
( O
QOL O
) O
and O
the O
survival O
time O
of O
children O
with O
solid O
tumor O
. O

Endpoints O
included O
MD O
Anderson O
Symptom O
Inventory-Head O
and O
Neck O
( O
MDASI-HN O
) O
and O
Functional O
Assessment O
of O
Cancer O
Therapy-Head O
and O
Neck O
( O
FACT-NH O
) O
scores O
, O
along O
with O
clinical O
assessment O
and O
DNA O
concentration O
of O
OPS O
. O

This O
study O
was O
designed O
to O
evaluate O
efficacy O
, O
toxicity O
, O
and O
adverse O
effects O
of O
combination O
of O
chemotherapy O
drugs O
and O
intraperitoneal O
perfusion O
of O
verapamil O
in O
the O
treatment O
of O
malignant O
ascites O
. O

Secondary O
end O
points O
included O
overall O
survival O
, O
response O
rate O
after O
reinitiation O
of O
imatinib O
, O
and O
quality O
of O
life O
. O

To O
explore O
the O
role O
of O
monochemotherapy O
, O
the O
authors O
evaluated O
5-fluorouracil O
( O
5-FU O
) O
, O
modulated O
by O
6S-leucovorin O
( O
6S-LV O
) O
and O
a O
cisplatin-containing O
regimen O
, O
which O
was O
comprised O
of O
epirubicin O
, O
etoposide O
, O
and O
cisplatin O
with O
the O
addition O
of O
the O
reversal O
agent O
lonidamine O
( O
EEP-L O
) O
. O

An O
independent O
data O
review O
board O
recommended O
termination O
of O
recruitment O
because O
of O
insufficient O
differences O
between O
study O
arms O
. O

Secondary O
endpoints O
were O
the O
PSQI O
component O
scores O
. O

This O
randomized O
, O
phase O
II O
trial O
compared O
bevacizumab O
plus O
fluorouracil O
and O
leucovorin O
( O
FU/LV O
) O
versus O
placebo O
plus O
FU/LV O
as O
first-line O
therapy O
in O
patients O
considered O
nonoptimal O
candidates O
for O
first-line O
irinotecan O
. O

The O
median O
number O
of O
cycles O
administered O
was O
two O
in O
both O
arms O
( O
range O
0-14 O
) O
. O

Patient O
compliance O
with O
respect O
to O
the O
HRQOL O
investigation O
was O
minimum O
74 O
% O
. O

At O
the O
last O
follow-up O
date O
, O
26 O
patients O
had O
died O
, O
10 O
of O
their O
disease O
and O
none O
of O
toxicity O
, O
with O
no O
differences O
between O
the O
two O
arms O
. O

Four O
hundred O
forty-five O
patients O
randomly O
received O
either O
docetaxel O
75 O
mg/m O
( O
2 O
) O
and O
cisplatin O
75 O
mg/m O
( O
2 O
) O
each O
on O
day O
1 O
plus O
fluorouracil O
750 O
mg/m O
( O
2 O
) O
/d O
continuous O
infusion O
on O
days O
1 O
to O
5 O
every O
3 O
weeks O
( O
DCF O
) O
or O
cisplatin O
100 O
mg/m O
( O
2 O
) O
on O
day O
1 O
plus O
fluorouracil O
1,000 O
mg/m O
( O
2 O
) O
/d O
continuous O
infusion O
on O
days O
1 O
to O
5 O
every O
4 O
weeks O
( O
CF O
) O
. O

The O
Short O
Form-36 O
Health O
Survey O
and O
the O
Gastrointestinal O
Quality O
of O
Life O
Inventory O
were O
used O
to O
assess O
QOL O
. O

Five O
years O
later O
, O
these O
190 O
men O
underwent O
HRQOL O
evaluation O
by O
using O
the O
cancer-specific O
50-item O
Expanded O
Prostate O
Cancer O
Index O
Composite O
, O
the O
Short O
Form O
12 O
Physical O
Component O
Score O
, O
and O
Short O
Form O
12 O
Mental O
Component O
Score O
. O

Compare O
GJJ O
and O
stent O
placement O
. O

Lymphoma O
patients O
commonly O
experience O
declines O
in O
physical O
functioning O
and O
quality O
of O
life O
( O
QoL O
) O
that O
may O
be O
reversed O
with O
exercise O
training O
. O

104/115 O
of O
the O
patients O
in O
the O
immediate O
treatment O
group O
received O
thoracic O
radiotherapy O
( O
90 O
received O
one O
of O
the O
recommended O
regimens O
) O
. O

The O
management O
of O
cancer-related O
anorexia/cachexia O
syndrome O
( O
CACS O
) O
is O
a O
great O
challenge O
in O
clinical O
practice O
. O

Advanced O
cancer O
patients O
and O
their O
caregivers O
( O
N O
= O
484 O
dyads O
) O
were O
stratified O
by O
patients O
' O
baseline O
risk O
for O
distress O
( O
high O
versus O
low O
) O
, O
cancer O
type O
( O
lung O
, O
colorectal O
, O
breast O
, O
or O
prostate O
) O
, O
and O
research O
site O
and O
then O
randomly O
assigned O
to O
a O
brief O
( O
three-session O
) O
or O
extensive O
( O
six-session O
) O
intervention O
or O
control O
. O

All O
volunteers O
were O
given O
dl-alpha O
tocopheryl O
acetate O
500 O
mg O
twice O
a O
day O
orally O
plus O
pentoxifylline O
400 O
mg O
twice O
a O
day O
orally O
, O
or O
corresponding O
placebos O
, O
for O
6 O
months O
. O

Because O
of O
the O
small O
study O
population O
, O
only O
initial O
hospital O
costs O
would O
have O
been O
statistically O
significant O
if O
the O
Bonferroni O
correction O
for O
multiple O
testing O
had O
been O
applied O
. O

Enzastaurin O
( O
E O
) O
inhibits O
PKCβ O
and O
PI3K/AKT O
signaling O
pathways O
with O
a O
dose-dependent O
effect O
on O
growth O
of O
pancreatic O
carcinoma O
xenografts O
. O

Randomisation O
was O
stratified O
by O
centre O
. O

Patients O
were O
randomly O
assigned O
to O
receive O
: O
docetaxel O
75 O
mg/m2 O
plus O
cisplatin O
75 O
mg/m2 O
, O
every O
3 O
weeks O
( O
DC O
) O
";" O
docetaxel O
75 O
mg/m2 O
and O
carboplatin O
6 O
mg/ml O
min O
, O
every O
3 O
weeks O
( O
DCb O
) O
";" O
or O
vinorelbine O
25 O
mg/m2/week O
plus O
cisplatin O
100 O
mg/m2 O
, O
every O
4 O
weeks O
( O
VC O
) O
. O

Studies O
on O
quality O
of O
life O
( O
QOL O
) O
among O
women O
with O
endometrial O
cancer O
have O
shown O
that O
patients O
who O
undergo O
pelvic O
radiotherapy O
report O
lower O
role O
functioning O
and O
more O
diarrhea O
and O
fatigue O
. O

The O
oral O
pamidronate O
dose O
was O
600 O
mg/d O
( O
high O
dose O
[ O
HD O
] O
) O
during O
the O
earliest O
study O
years O
, O
then O
changed O
to O
300 O
mg/d O
( O
low O
dose O
[ O
LD O
] O
) O
because O
of O
gastrointestinal O
toxicity O
. O

One O
hundred O
thirty-six O
patients O
( O
two O
were O
ineligible O
) O
were O
enrolled O
onto O
the O
randomized O
multicenter O
phase O
II O
trial O
. O

Recombinant O
human O
TSH O
( O
rhTSH O
) O
has O
become O
the O
modality O
of O
choice O
for O
radioiodine O
remnant O
ablation O
( O
RRA O
) O
in O
low-risk O
thyroid O
cancer O
patients O
. O

As O
patients O
with O
pancreas O
and O
periampullary O
cancer O
( O
PPC O
) O
experience O
improved O
survival O
rates O
and O
longevity O
, O
the O
focus O
shifts O
toward O
living O
life O
while O
surviving O
cancer O
. O

This O
article O
reports O
the O
health-related O
quality-of-life O
( O
HRQL O
) O
outcomes O
from O
CO.17 O
. O

The O
median O
follow-up O
was O
71 O
months O
. O

Participants O
( O
n O
= O
49 O
) O
ranged O
in O
age O
from O
50 O
to O
90 O
years O
( O
average O
, O
65.6 O
years O
) O
and O
were O
at O
9.8 O
years O
since O
diagnosis O
( O
range O
, O
1-32 O
years O
) O
, O
and O
the O
majority O
were O
white O
, O
unpartnered O
, O
and O
retired O
. O

For O
patients O
undergoing O
oncologic O
surgery O
, O
the O
quality O
of O
life O
( O
QoL O
) O
is O
generally O
accepted O
as O
an O
important O
outcome O
parameter O
in O
addition O
to O
long-term O
survival O
, O
mortality O
and O
complication O
rates O
. O

Patient O
data O
regarding O
transfusions O
, O
epoetin-alfa O
usage O
, O
chemotherapy O
treatment O
cycles O
, O
and O
adverse O
events O
were O
recorded O
, O
with O
survival O
follow-up O
for O
12-36 O
months O
post-study O
. O

The O
efficacy O
and O
safety O
of O
letrozole O
therapy O
beyond O
5 O
years O
is O
being O
assessed O
in O
a O
re-randomization O
study O
, O
following O
the O
emergence O
of O
new O
data O
suggesting O
that O
clinical O
benefit O
correlates O
with O
the O
duration O
of O
letrozole O
. O

Secondary O
end O
points O
were O
progression-free O
survival O
, O
response O
rate O
, O
response O
duration O
, O
and O
quality O
of O
life O
. O

The O
aim O
of O
this O
study O
was O
to O
evaluate O
pamidronate O
for O
bone O
pain O
in O
a O
randomised O
double-blind O
trial O
and O
to O
evaluate O
the O
contribution O
of O
new O
markers O
of O
bone O
resorption O
in O
patients O
with O
bone O
metastases O
. O

HRQOL O
was O
assessed O
at O
baseline O
, O
at O
end O
of O
cycle O
2 O
, O
and O
4 O
, O
6 O
, O
and O
9 O
months O
after O
completion O
of O
RT O
using O
the O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
( O
EORTC O
) O
Quality O
of O
Life O
Questionnaire O
C30 O
( O
QLQ-C30 O
) O
and O
the O
EORTC O
QLQ O
Head O
and O
Neck O
Cancer-Specific O
Module O
( O
EORTC O
QLQ-H O
& O
amp O
";" O
N35 O
) O
. O

The O
authors O
report O
additional O
sensitivity O
analyses O
using O
10-point O
minimal O
important O
difference O
decreases O
in O
the O
global O
health O
status O
score O
versus O
baseline O
. O

Exploratory O
analysis O
was O
based O
on O
time O
to O
analgesia O
and O
appearance O
of O
key O
symptoms O
( O
pain O
, O
cough O
and O
dyspnoea O
) O
. O

A O
total O
of O
74 O
patients O
were O
enrolled O
for O
the O
study O
. O

Data O
were O
analyzed O
with O
generalized O
estimating O
equations O
methodology O
to O
model O
differences O
between O
groups O
over O
time O
. O

Treatment O
arms O
were O
well O
balanced O
for O
clinicopathologic O
characteristics O
. O

The O
differences O
of O
gender O
, O
age O
, O
primary O
GI O
malignancies O
, O
and O
hematological O
and O
biochemical O
data O
between O
the O
two O
compared O
groups O
were O
not O
statistically O
significant O
( O
all O
P O
> O
0.05 O
) O
. O

Eighty O
percent O
of O
patients O
had O
stage O
IV O
NSCLC O
, O
with O
squamous O
cell O
( O
n=21 O
) O
, O
adenocarcinoma O
( O
n=12 O
) O
, O
and O
undifferentiated O
( O
n=7 O
) O
histologies O
. O

Planned O
subgroup O
analyses O
were O
also O
conducted O
. O

A O
multi-site O
randomized O
study O
was O
conducted O
to O
evaluate O
the O
effects O
of O
a O
psycho-educational O
group O
intervention O
in O
this O
population O
. O

This O
was O
followed O
, O
4 O
weeks O
later O
, O
by O
six O
cycles O
of O
temozolomide O
, O
150 O
or O
200 O
mg/m2 O
daily O
for O
5 O
days O
, O
every O
4 O
weeks O
. O

After O
a O
week O
, O
a O
crossover O
took O
place O
for O
the O
second O
week O
, O
with O
the O
other O
treatment O
at O
an O
inverse O
sequence O
. O

Twenty-nine O
of O
81 O
pamidronate O
( O
HD/LD O
) O
patients O
first O
received O
600 O
mg/d O
and O
were O
then O
changed O
to O
300 O
mg/d O
";" O
52 O
of O
81 O
pamidronate O
LD O
patients O
received O
300 O
mg/d O
throughout O
the O
study O
. O

Of O
289 O
patients O
screened O
, O
243 O
were O
randomly O
assigned O
and O
164 O
( O
CE O
, O
66 O
of O
95 O
patients O
";" O
THC O
, O
65 O
of O
100 O
patients O
";" O
and O
PL O
, O
33 O
of O
48 O
patients O
) O
completed O
treatment O
. O

In O
the O
ALND O
group O
, O
positive O
non-SLNs O
were O
found O
in O
18 O
patients O
with O
negative O
SLN O
, O
giving O
a O
FALSE O
negative O
rate O
of O
16.7 O
% O
( O
18 O
of O
108 O
) O
. O

For O
this O
clinical O
trial O
, O
263 O
patient-spouse O
dyads O
were O
stratified O
by O
research O
site O
, O
phase O
of O
illness O
, O
and O
treatment O
";" O
then O
, O
they O
were O
randomized O
to O
the O
control O
group O
( O
standard O
care O
) O
or O
the O
experimental O
group O
( O
standard O
care O
plus O
a O
5-session O
family O
intervention O
) O
. O

GE O
responses O
: O
1 O
complete O
response O
( O
CR O
, O
1.2 O
% O
) O
, O
6 O
partial O
response O
( O
PR O
, O
7.4 O
% O
) O
, O
and O
33 O
stable O
disease O
( O
SD O
, O
40.7 O
% O
) O
";" O
disease O
control O
rate O
( O
DCR=CR+PR+SD O
, O
49.4 O
% O
) O
. O

There O
were O
no O
statistically O
significant O
differences O
in O
the O
distribution O
of O
variables O
used O
to O
assess O
randomization O
success O
between O
the O
HBO O
and O
standard O
treatment O
groups O
. O

Weight O
, O
the O
Schwartz O
Fatigue O
Scale O
, O
and O
the O
Spitzer O
Quality O
of O
Life O
Scale O
were O
also O
measured O
. O

Four O
hundred O
forty-seven O
patients O
were O
randomly O
assigned O
to O
PCV O
( O
224 O
patients O
) O
or O
TMZ O
( O
sub-random O
assignment O
: O
TMZ-5 O
[ O
200 O
mg/m O
( O
2 O
) O
for O
5 O
days O
, O
112 O
patients O
] O
or O
TMZ-21 O
[ O
100 O
mg/m O
( O
2 O
) O
for O
21 O
days O
, O
111 O
patients O
] O
) O
for O
up O
to O
9 O
months O
or O
until O
progression O
. O

We O
report O
, O
to O
our O
knowledge O
, O
the O
first O
randomized O
trial O
of O
procarbazine O
, O
lomustine O
, O
and O
vincristine O
( O
PCV O
) O
versus O
TMZ O
in O
chemotherapy-naive O
patients O
with O
recurrent O
HGG O
. O

An O
understanding O
of O
the O
patterns O
of O
side-effects O
and O
time O
dimension O
of O
their O
occurrence O
for O
each O
treatment O
is O
important O
for O
full O
patient O
information O
. O

Patients O
with O
advanced O
NSCLC O
with O
no O
evidence O
of O
progression O
after O
four O
cycles O
of O
chemotherapy O
were O
randomized O
to O
receive O
erlotinib O
150 O
mg/day O
or O
placebo O
, O
until O
progressive O
disease O
or O
limiting O
toxicity O
. O

Thirty-six O
patients O
were O
treated O
. O

From O
February O
2006 O
to O
March O
2007 O
, O
291 O
patients O
were O
enrolled O
and O
randomized O
, O
after O
total O
thyroidectomy O
: O
( O
1 O
) O
withdrawal O
of O
levothyroxine O
( O
LT4 O
) O
for O
4 O
weeks O
( O
T4-WD O
Group O
, O
n O
= O
89 O
) O
, O
( O
2 O
) O
withdrawal O
of O
LT4 O
for O
4 O
weeks O
plus O
2 O
weeks O
on O
and O
then O
2 O
weeks O
off O
liothyronine O
( O
LT3 O
) O
( O
T3-WD O
Group O
, O
n O
= O
133 O
) O
, O
and O
( O
3 O
) O
rhTSH O
administration O
( O
rhTSH O
Group O
, O
n O
= O
69 O
) O
. O

The O
starting O
dosage O
was O
60 O
mg/m O
( O
2 O
) O
, O
which O
was O
escalated O
to O
90 O
mg/m O
( O
2 O
) O
and O
then O
120 O
mg/m O
( O
2 O
) O
if O
the O
drug O
was O
well O
tolerated O
( O
< O
or= O
Grade O
2 O
toxicities O
[ O
according O
to O
the O
Southwest O
Oncology O
Group O
toxicity O
scale O
] O
) O
. O

The O
control O
group O
received O
no O
advice O
about O
exercise O
. O

We O
conducted O
a O
multicenter O
randomized O
trial O
to O
compare O
quality-of-life O
outcomes O
between O
patients O
with O
clinically O
node-negative O
invasive O
breast O
cancer O
who O
received O
sentinel O
lymph O
node O
biopsy O
and O
patients O
who O
received O
standard O
axillary O
treatment O
. O

In O
total O
, O
126 O
patients O
from O
East O
and O
South-East O
Asian O
centers O
were O
randomized O
( O
14 O
% O
of O
the O
intent-to-treat O
population O
) O
: O
88 O
from O
Korea O
, O
28 O
from O
China O
and O
10 O
from O
Malaysia O
";" O
one O
patient O
was O
excluded O
from O
this O
analysis O
due O
to O
Indian O
ethnicity O
. O

Health-Related O
Quality O
of O
Life O
[ O
RAND-36 O
and O
Rotterdam O
Symptom O
Check O
List O
( O
RSCL O
) O
] O
, O
exercise O
capacity O
( O
symptom O
limited O
bicycle O
ergometry O
) O
, O
muscle O
force O
( O
hand-held O
dynamometry O
) O
, O
and O
patient O
preferences O
. O

These O
patients O
experience O
significant O
functional O
impairment O
and O
muscle O
atrophy O
, O
which O
may O
lead O
to O
an O
increased O
likelihood O
of O
skeletal O
complicaTIOns O
( O
i.e. O
, O
pathological O
fracture O
, O
bone O
pain O
) O
and/or O
falls O
. O

The O
primary O
end O
points O
for O
QOL O
analysis O
were O
time O
to O
deterioration O
of O
three O
common O
lung O
cancer O
symptoms O
: O
cough O
, O
dyspnea O
, O
and O
pain O
. O

Analysis O
was O
by O
intention-to-treat O
. O

To O
determine O
the O
incremental O
cost O
utility O
of O
epoetin-alfa O
versus O
placebo O
in O
anaemic O
patients O
with O
stage O
IV O
breast O
cancer O
from O
a O
UK O
National O
Health O
Service O
perspective O
. O

Secondary O
end O
points O
were O
depressive O
symptoms O
and O
post-traumatic O
growth O
. O

Randomisation O
was O
by O
use O
of O
a O
computer-generated O
table O
of O
random O
numbers O
in O
blocks O
of O
30 O
. O

Quality O
of O
life O
was O
the O
primary O
outcome O
measure O
, O
together O
with O
anxiety O
and O
depression O
and O
cost-effectiveness O
. O

Patients O
with O
GOO O
. O

Baseline O
FACT-H O
& O
amp O
";" O
N O
data O
were O
available O
for O
1,093 O
patients O
and O
missing O
for O
417 O
patients O
. O

Two O
hundred O
thirty-three O
lung O
cancer O
patients O
and O
their O
caregivers O
were O
randomly O
assigned O
to O
receive O
14 O
telephone-based O
sessions O
of O
either O
caregiver-assisted O
CST O
or O
education/support O
involving O
the O
caregiver O
. O

However O
, O
evidence O
for O
this O
recommendation O
from O
randomized O
clinical O
trials O
is O
lacking O
. O

On O
November O
18 O
, O
2004 O
, O
the O
FDA O
granted O
erlotinib O
regular O
approval O
for O
treatment O
of O
patients O
with O
locally O
advanced O
or O
metastatic O
NSCLC O
after O
failure O
of O
at O
least O
one O
prior O
chemotherapy O
regimen O
. O

HRQOL O
was O
assessed O
using O
EORTC O
QLQ-C30 O
and O
QLQ-BR23 O
questionnaires O
at O
baseline O
and O
every O
6 O
weeks O
thereafter O
until O
treatment O
discontinuation O
because O
of O
disease O
progression O
, O
toxicity O
, O
or O
consent O
withdrawal O
. O

Factors O
from O
the O
EORTC O
QLQ-C30 O
were O
all O
function O
scales O
, O
fatigue O
, O
nausea/vomiting O
, O
pain O
, O
dyspnoea O
, O
insomnia O
, O
loss O
of O
appetite O
and O
global O
QL O
. O

Patients O
were O
assigned O
to O
12 O
weekly O
injections O
of O
subcutaneous O
epoetin O
alpha O
or O
placebo O
, O
targeting O
Hgb O
levels O
between O
120 O
and O
140 O
g/L O
. O

Final O
planned O
overall O
survival O
( O
OS O
) O
analysis O
from O
EGF104900 O
is O
reported O
here O
. O

All O
patients O
were O
treated O
with O
the O
same O
CTF O
regimen O
of O
chemotherapy O
for O
21 O
days O
as O
one O
therapeutic O
cycle O
, O
while O
those O
in O
the O
treatment O
group O
were O
given O
SFI O
additionally O
in O
the O
meanwhite O
. O

Questionnaires O
were O
administered O
by O
a O
clinician O
blinded O
to O
treatment O
. O

The O
patients O
' O
quality O
of O
life O
was O
scored O
using O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
Questionnaire O
30-item O
cancer-specific O
and O
25-item O
prostate-specific O
modules O
. O

A O
secondary O
criterion O
for O
ablation O
, O
an O
rhTSH-stimulated O
serum O
thyroglobulin O
concentration O
less O
than O
2 O
ng/ml O
, O
was O
fulfilled O
by O
23 O
of O
24 O
( O
96 O
% O
) O
euthyroid O
patients O
and O
18 O
of O
21 O
( O
86 O
% O
) O
hypothyroid O
patients O
( O
P O
= O
0.2341 O
) O
. O

Eighty-three O
patients O
discontinued O
, O
65 O
due O
to O
disease O
progression O
and O
16 O
because O
of O
AEs O
";" O
two O
patients O
withdrew O
consent O
. O

Poor O
preoperative O
QOL O
as O
indicated O
by O
a O
rating O
scale O
of O
≤ O
50 O
was O
an O
independent O
predictor O
of O
poor O
QOL O
at O
2 O
months O
postoperatively O
. O

Low O
testosterone O
after O
ADT O
and O
incomplete O
testosterone O
recovery O
may O
explain O
similar O
QOL O
. O

The O
relationship O
between O
change O
in O
self-efficacy O
and O
long-term O
physical O
activity O
( O
PA O
) O
also O
was O
examined O
. O

The O
secondary O
end O
points O
were O
morbidity O
, O
QOL O
, O
and O
functional O
outcome O
. O

Fifty O
patients O
were O
randomly O
assigned O
to O
receive O
12 O
weeks O
of O
acupuncture O
( O
n O
= O
25 O
) O
or O
venlafaxine O
( O
n O
= O
25 O
) O
treatment O
. O

All O
patients O
who O
returned O
questionnaires O
at O
12 O
months O
and O
were O
still O
on O
study O
treatment O
were O
included O
in O
the O
analysis O
of O
the O
primary O
endpoint O
. O

After O
randomization O
, O
L-T4 O
was O
discontinued O
in O
hypothyroid O
( O
hypo O
) O
group O
and O
continued O
in O
rhTSH O
group O
. O

This O
study O
is O
registered O
as O
an O
international O
standard O
randomised O
controlled O
trial O
, O
number O
ISRCTN01534787 O
. O

Primary O
analyses O
were O
done O
by O
intention O
to O
treat O
and O
were O
based O
on O
scale O
scores O
at O
4 O
weeks O
and O
8 O
weeks O
. O

We O
report O
a O
retrospective O
subanalysis O
of O
Asian O
patients O
enrolled O
in O
SATURN O
. O

The O
trial O
was O
designed O
to O
use O
one-sided O
tests O
of O
significance O
for O
power O
calculations O
, O
but O
is O
now O
reported O
with O
both O
one-sided O
and O
the O
traditional O
two-sided O
tests O
of O
significance O
. O

Eighteen O
patients O
were O
excluded O
due O
to O
misclassification O
, O
leaving O
122 O
patients O
eligible O
for O
evaluation O
. O

The O
impact O
of O
psychotherapeutic O
support O
on O
survival O
for O
patients O
with O
gastrointestinal O
cancer O
undergoing O
surgery O
was O
studied O
. O

Measures O
included O
psychological O
( O
distress O
) O
, O
biological O
( O
immune O
) O
, O
and O
health O
outcomes O
( O
performance O
status O
and O
evaluations O
of O
patient O
's O
symptomatology O
, O
including O
toxicity O
from O
cancer O
treatment O
, O
lab O
values O
) O
collected O
at O
baseline O
, O
4 O
months O
, O
and O
12 O
months O
. O

PSA O
and O
testosterone O
data O
were O
used O
from O
a O
phase O
III O
trial O
randomizing O
patients O
without O
progression O
and O
PSA O
< O
4 O
ng/ml O
( O
n O
= O
193 O
) O
, O
after O
6 O
months O
induction O
course O
, O
between O
continuous O
( O
CAD O
) O
( O
n O
= O
96 O
) O
and O
intermittent O
( O
IAD O
) O
( O
n O
= O
97 O
) O
ADT O
. O

The O
main O
objective O
of O
the O
study O
was O
to O
determine O
the O
benefits O
of O
psychosocial O
interventions O
for O
cancer O
patients O
who O
received O
RT O
. O

( O
7,000 O
mg/m O
( O
2 O
) O
day O
1 O
of O
a O
28-day O
cycle O
) O
or O
p.o O
. O

241 O
patients O
( O
121 O
GC O
, O
120 O
PE O
) O
were O
recruited O
, O
of O
which O
216 O
( O
90 O
% O
) O
had O
died O
. O

30 O
patients O
received O
exemestane O
( O
EXE O
) O
25 O
mg O
daily O
and O
celecoxib O
( O
CXB O
) O
400 O
mg O
twice O
daily O
( O
group O
A O
) O
, O
24 O
patients O
received O
EXE O
25 O
mg O
daily O
( O
group O
B O
) O
and O
28 O
patients O
received O
letrozole O
( O
LET O
) O
2.5 O
mg O
daily O
( O
group O
C O
) O
. O

The O
usual O
care O
group O
received O
a O
booklet O
with O
information O
about O
fatigue O
and O
its O
management O
. O

QOL O
was O
assessed O
with O
the O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
Questionnaire O
C30 O
and O
a O
trial-specific O
checklist O
at O
baseline O
and O
at O
weeks O
5 O
and O
9 O
for O
those O
who O
received O
chemotherapy O
and O
at O
follow-up O
months O
3 O
, O
6 O
, O
9 O
, O
12 O
, O
18 O
, O
24 O
, O
30 O
and O
36 O
. O

Toxicity O
was O
evaluated O
by O
the O
Common O
Toxicity O
Criteria O
( O
CTC O
) O
. O

After O
2 O
weeks O
of O
baseline O
assessment O
, O
all O
participants O
received O
a O
consultation O
plus O
either O
oral O
homeopathic O
medicine O
or O
placebo O
, O
assessed O
every O
4 O
weeks O
for O
16 O
weeks O
. O

A O
randomized O
controlled O
trial O
of O
five O
high-fluence O
treatments O
( O
intervention O
) O
vs. O
five O
low-fluence O
treatments O
( O
control O
) O
was O
performed O
over O
6 O
months O
in O
a O
National O
Health O
Service O
teaching O
hospital O
. O

The O
randomization O
procedure O
allowed O
some O
investigators O
to O
participate O
only O
in O
the O
comparison O
of O
three O
versus O
four O
cycles O
. O

Oral O
morphine O
was O
used O
as O
breakthrough O
pain O
medication O
during O
opioid O
titration O
. O

The O
primary O
end O
point O
was O
time-to-progression O
( O
TTP O
) O
. O

However O
, O
there O
is O
a O
wide O
heterogeneity O
in O
the O
clinical O
impact O
of O
hypothyroidism O
. O

The O
objective O
of O
this O
study O
is O
to O
evaluate O
whether O
a O
six-week O
supervised O
multimodal O
exercise O
intervention O
, O
adjunct O
to O
chemotherapy O
and O
standard O
care O
, O
can O
reduce O
the O
patient O
's O
CRF O
level O
. O

Paclitaxel O
was O
administered O
as O
a O
3-hour O
intravenous O
infusion O
every O
3 O
weeks O
. O

Planned O
accrual O
was O
30 O
patients O
per O
arm O
to O
detect O
20 O
% O
difference O
of O
toxicities O
based O
on O
95 O
% O
CIs O
. O

HRQL O
primary O
end O
points O
assessed O
by O
the O
EORTC O
QLQ-C30 O
were O
physical O
function O
( O
PF O
) O
and O
global O
health O
status O
( O
GHS O
) O
";" O
mean O
changes O
from O
baseline O
to O
8 O
and O
16 O
weeks O
were O
assessed O
. O

Patients O
( O
n O
= O
739 O
) O
with O
stage O
M1 O
( O
bone O
or O
soft O
tissue O
metastasis O
) O
prostate O
cancer O
were O
enrolled O
in O
a O
QOL O
protocol O
that O
was O
a O
companion O
to O
Southwest O
Oncology O
Group O
INT-0105 O
, O
a O
randomized O
double-blind O
trial O
comparing O
treatment O
with O
bilateral O
orchiectomy O
( O
surgical O
castration O
) O
plus O
either O
flutamide O
or O
placebo O
. O

on O
day O
1 O
, O
followed O
on O
day O
2 O
by O
LFA O
, O
250 O
mg/m2 O
i.v O
. O

The O
online O
program O
, O
Sleep O
Healthy O
Using O
The O
Internet O
, O
delivers O
the O
primary O
components O
of O
CBT-I O
( O
sleep O
restriction O
, O
stimulus O
control O
, O
cognitive O
restructuring O
, O
sleep O
hygiene O
, O
and O
relapse O
prevention O
) O
. O

We O
prospectively O
compared O
the O
efficacy O
and O
tolerability O
of O
two O
irinotecan O
regimens O
( O
once O
a O
week O
for O
4 O
weeks O
followed O
by O
a O
2-week O
rest O
period O
[ O
weekly O
] O
v O
once O
every O
3 O
weeks O
) O
in O
such O
patients O
. O

Gastrointestinal O
( O
GI O
) O
and O
genitourinary O
( O
GU O
) O
toxicity O
was O
evaluated O
before O
RT O
and O
after O
its O
completion O
using O
modified O
late O
effects O
of O
normal O
tissue-subjective O
, O
objective O
, O
management O
, O
analytic O
( O
LENT-SOMA O
) O
scales O
and O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
sexual O
function O
questionnaire O
. O

The O
treatment O
cycle O
was O
once O
every O
three O
weeks O
. O

We O
therefore O
studied O
the O
effects O
of O
a O
high-fat O
diet O
, O
particularly O
on O
body O
composition O
. O

A O
total O
of O
243 O
patients O
with O
stage O
II O
to O
IIIA/B O
non-small-cell O
lung O
cancer O
received O
induction O
paclitaxel O
225 O
mg/m O
( O
2 O
) O
intravenously O
( O
IV O
) O
days O
1 O
and O
22 O
and O
carboplatin O
area O
under O
the O
curve O
( O
AUC O
) O
days O
1 O
and O
22 O
, O
followed O
by O
concurrent O
weekly O
paclitaxel O
( O
50 O
mg/m O
( O
2 O
) O
IV O
) O
and O
carboplatin O
( O
AUC O
2 O
) O
, O
and O
hyperfractionated O
radiation O
therapy O
( O
69.6 O
Gy O
at O
1.2 O
Gy O
bid O
) O
. O

The O
recommended O
regimens O
were O
17 O
Gy O
in O
two O
fractions O
one O
week O
apart O
or O
10 O
Gy O
as O
a O
single O
dose O
. O

Improvements O
in O
FACT-F O
subscale O
score O
were O
significantly O
( O
P O
< O
0.001 O
) O
correlated O
with O
increases O
in O
Hb O
level O
. O

406 O
eligible O
patients O
were O
entered O
into O
the O
trial O
. O

Seventy-two O
patients O
with O
malignant O
ascites O
were O
divided O
into O
two O
study O
groups O
. O

A O
randomized O
Phase O
III O
trial O
for O
Stage O
IIIA O
( O
T1-T3N2M0 O
) O
non-small O
cell O
lung O
cancer O
was O
conducted O
by O
the O
Radiation O
Therapy O
Oncology O
Group O
( O
RTOG O
) O
and O
Eastern O
Cooperative O
Oncology O
Group O
between O
April O
1990 O
and O
April O
1994 O
. O

The O
aim O
of O
this O
study O
was O
to O
determine O
if O
topical O
misoprostol O
was O
effective O
in O
reducing O
the O
severity O
of O
radiation-induced O
mucositis O
in O
patients O
receiving O
radical O
dose O
radiotherapy O
. O

Seventy-eight O
and O
54 O
% O
of O
C3 O
and O
C6 O
patients O
, O
respectively O
, O
completed O
all O
scheduled O
chemotherapy O
courses O
. O

Histologically O
confirmed O
HIV-positive O
patients O
with O
Kaposi O
's O
sarcoma O
were O
randomized O
to O
receive O
supportive O
care O
only O
or O
supportive O
care O
plus O
either O
radiotherapy O
, O
oral O
Etoposide O
or O
a O
3-drug O
combination O
consisting O
of O
actinomycin-D O
, O
vincristine O
and O
bleomycin O
. O

We O
report O
QOL O
data O
collected O
during O
3 O
years O
after O
random O
assignment O
in O
patients O
without O
disease O
recurrence O
. O

The O
results O
were O
analyzed O
using O
a O
linear O
mixed-effects O
model O
. O

The O
regimens O
were O
compared O
with O
regard O
to O
effects O
on O
survival O
, O
response O
rates O
, O
toxicity O
, O
and O
quality O
of O
life O
. O

To O
pilot O
an O
investigation O
of O
individualized O
homeopathy O
for O
symptoms O
of O
estrogen O
withdrawal O
in O
breast O
cancer O
survivors O
. O

The O
aim O
of O
this O
trial O
was O
to O
determine O
the O
value O
of O
thymidylate O
synthase O
( O
TS O
) O
, O
a O
key O
enzyme O
of O
DNA O
synthesis O
and O
target O
of O
5-FU O
, O
to O
predict O
response O
to O
chemotherapy O
of O
mCRC O
. O

A O
hot O
flash O
score O
was O
calculated O
at O
each O
time O
point O
. O

Observational O
studies O
demonstrate O
an O
association O
between O
physical O
activity O
and O
improved O
outcomes O
in O
breast O
and O
colon O
cancer O
survivors O
. O

The O
benefits O
of O
the O
intervention O
were O
evaluated O
using O
the O
Zung O
Self-rating O
Depression O
Scale O
( O
SDS O
) O
to O
measure O
depression O
, O
the O
Self-rating O
Anxiety O
Scale O
( O
SAS O
) O
to O
assess O
anxiety O
, O
and O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
Questionnaire-Core O
30 O
( O
EORTC O
QLQ-C30 O
) O
to O
survey O
health-related O
QOL O
. O

SATURN O
( O
Sequential O
Tarceva O
in O
Unresectable O
NSCLC O
) O
was O
a O
randomised O
, O
double-blind O
, O
placebo-controlled O
, O
multicentre O
study O
investigating O
the O
impact O
of O
erlotinib O
maintenance O
therapy O
on O
HRQoL O
in O
patients O
with O
locally O
advanced O
or O
recurrent O
NSCLC O
. O

What O
's O
known O
on O
the O
subject O
? O

To O
examine O
the O
effect O
of O
a O
progressive O
upper-body O
exercise O
program O
on O
lymphedema O
secondary O
to O
breast O
cancer O
treatment O
. O

The O
secondary O
endpoints O
included O
patient O
reported O
outcome O
measures O
";" O
Quality O
of O
Life O
Questionnaire O
( O
QLQ-C30 O
) O
, O
Sleep O
disturbances O
( O
MOS-sleep O
questionnaire O
) O
and O
symptoms O
from O
the O
irradiated O
area O
( O
visual O
analogue O
scale O
) O
. O

The O
primary O
outcomes O
were O
survival O
( O
PCV O
v O
TMZ O
) O
and O
12-week O
progression-free O
survival O
( O
PFS O
";" O
TMZ-5 O
v O
TMZ-21 O
) O
. O

Of O
87 O
eligible O
patients O
, O
75 O
consented O
( O
86 O
% O
consent O
rate O
) O
. O

Hormone O
replacement O
therapy O
is O
contraindicated O
in O
patients O
with O
breast O
cancer O
. O

The O
median O
duration O
of O
therapy O
was O
39 O
weeks O
for O
bicalutamide-treated O
patients O
and O
42 O
weeks O
for O
castrated O
patients O
";" O
treatment O
failure O
occurred O
in O
53 O
% O
and O
42 O
% O
and O
disease O
progression O
in O
43 O
% O
and O
33 O
% O
, O
respectively O
. O

The O
primary O
endpoint O
was O
survival O
. O

Challenges O
with O
capturing O
pain O
data O
were O
identified O
and O
resolved O
. O

After O
removing O
patients O
who O
did O
not O
complete O
the O
follow-up O
survey O
or O
censured O
cases O
, O
24 O
patients O
in O
the O
RY O
group O
and O
18 O
patients O
in O
the O
INT O
group O
were O
clinically O
available O
and O
their O
postoperative O
status O
was O
assessed O
. O

All O
patients O
completed O
incontinence O
quality O
of O
life O
( O
I-QoL O
) O
questionnaire O
and O
bladder O
diary O
. O

The O
primary O
outcome O
was O
the O
difference O
in O
the O
change O
in O
Functional O
Assessment O
of O
Cancer O
Therapy-Anemia O
scores O
between O
baseline O
and O
12 O
weeks O
. O

We O
examined O
intrusive O
thoughts O
about O
cancer O
at O
the O
baseline O
assessment O
as O
a O
predictor O
of O
fatigue O
, O
sleep O
problems O
, O
pain O
, O
breast O
cancer-specific O
symptoms O
, O
depressive O
symptoms O
, O
negative O
affect O
, O
and O
quality O
of O
life O
using O
growth O
curve O
modeling O
, O
controlling O
for O
study O
condition O
and O
other O
covariates O
. O

The O
primary O
end O
point O
was O
QL O
reported O
by O
the O
patient O
and O
by O
physician O
assessment O
. O

Four O
hundred O
seventy-two O
advanced O
cancer O
patients O
with O
between O
2 O
% O
and O
10 O
% O
weight O
loss O
were O
randomized O
to O
a O
mixture O
of O
beta-hydroxyl O
beta-methyl O
butyrate O
, O
glutamine O
, O
and O
arginine O
or O
an O
isonitrogenous O
, O
isocaloric O
control O
mixture O
taken O
twice O
a O
day O
for O
8 O
weeks O
. O

MA.17 O
was O
conducted O
to O
determine O
whether O
letrozole O
improves O
outcome O
after O
discontinuation O
of O
tamoxifen O
. O

Cancer O
related O
fatigue O
( O
CRF O
) O
is O
a O
common O
problem O
for O
cancer O
patients O
across O
diagnoses O
during O
chemotherapy O
and O
is O
associated O
with O
physical O
inactivity O
, O
lower O
functional O
level O
and O
lack O
of O
energy O
. O

Patients O
in O
Group O
1 O
performed O
pilates O
and O
home O
exercises O
and O
patients O
in O
group O
2 O
performed O
only O
home O
exercises O
. O

Hospital O
anxiety O
and O
depression O
scale O
scores O
were O
consistent O
with O
the O
primary O
outcome O
measure O
. O

Between O
February O
2003 O
and O
April O
2009 O
, O
40 O
patients O
were O
considered O
eligible O
, O
22 O
consented O
to O
randomisation O
and O
21 O
were O
analysed O
( O
11 O
RS O
+ O
WBRT O
, O
10 O
S O
+ O
WBRT O
) O
. O

Thirty-six O
women O
with O
chronic O
upper O
limb O
breast O
cancer-related O
lymphoedema O
. O

Patients O
were O
randomly O
assigned O
to O
sequential O
doxorubicin O
( O
A O
) O
and O
cyclophosphamide O
( O
C O
) O
followed O
by O
docetaxel O
( O
T O
";" O
AC→T O
) O
, O
concurrent O
TAC O
, O
or O
AT O
, O
which O
varied O
in O
duration O
( O
24 O
, O
12 O
, O
12 O
weeks O
, O
respectively O
) O
, O
and O
use O
of O
C. O
Endocrine O
therapy O
was O
prescribed O
for O
women O
with O
hormone O
receptor-positive O
tumors O
. O

Twenty-four O
mentors O
at O
Mayo O
Clinic O
in O
Rochester O
, O
Minnesota O
, O
were O
randomized O
in O
a O
single-blind O
, O
wait-list O
controlled O
clinical O
trial O
to O
either O
the O
SMART O
intervention O
or O
a O
control O
group O
for O
12 O
weeks O
. O

We O
did O
a O
multicentre O
, O
open-label O
, O
randomised O
controlled O
trial O
at O
five O
study O
centres O
in O
three O
countries O
between O
June O
1 O
, O
2009 O
, O
and O
March O
31 O
, O
2011 O
. O

Swallowing O
function O
was O
assessed O
with O
the O
Functional O
Oral O
Intake O
Scale O
( O
FOIS O
) O
and O
the O
Performance O
Status O
Scale O
for O
Head O
and O
Neck O
Cancer O
Patients O
( O
PSS-H O
& O
N O
) O
at O
baseline O
, O
immediately O
after O
CRT O
, O
and O
at O
3 O
, O
6 O
, O
9 O
, O
and O
12 O
months O
after O
CRT O
. O

Evaluated O
outcomes O
included O
pain O
intensity O
, O
need O
for O
change O
in O
therapy O
, O
quality O
of O
life O
, O
Karnofsky O
Performance O
Status O
, O
general O
condition O
of O
the O
patient O
, O
and O
adverse O
events O
. O

Normally O
distributed O
data O
were O
analyzed O
using O
t O
tests O
and O
random-slope/random-intercept O
mixed O
models O
. O

QOL O
evaluations O
were O
available O
for O
199 O
patients O
. O

Outcome O
parameters O
were O
assessed O
every O
4 O
weeks O
until O
28 O
weeks O
. O

bolus O
( O
arm O
B O
) O
";" O
or O
MTX O
, O
750 O
mg/m2 O
i.v O
. O

A O
randomized O
phase O
III O
trial O
was O
conducted O
to O
determine O
whether O
combination O
therapy O
with O
13-cis-retinoic O
acid O
( O
13-CRA O
) O
plus O
interferon O
alfa-2a O
( O
IFNalpha2a O
) O
is O
superior O
to O
IFNalpha2a O
alone O
in O
patients O
with O
advanced O
renal O
cell O
carcinoma O
( O
RCC O
) O
. O

Finally O
, O
change O
in O
self-efficacy O
for O
PA O
predicted O
PA O
at O
2-year O
follow-up O
. O

This O
reduction O
in O
hot O
flash O
frequency O
persisted O
for O
up O
to O
6 O
months O
after O
the O
completion O
of O
treatment O
. O

Exploratory O
end O
points O
included O
association O
of O
efficacy O
with O
epidermal O
growth O
factor O
receptor O
gene O
copy O
number O
and O
other O
biomarkers O
. O

To O
assess O
concurrent O
validity O
, O
Pearson O
's O
correlation O
between O
the O
linear O
analogue O
self-assessment O
scale O
and O
the O
adjective O
checklist O
were O
calculated O
for O
each O
time-point O
within O
each O
treatment O
group O
and O
for O
the O
two O
assessments O
after O
recurrence O
. O

An O
open O
, O
randomized O
study O
was O
performed O
to O
assess O
the O
effects O
of O
supportive O
pamidronate O
treatment O
on O
morbidity O
from O
bone O
metastases O
in O
breast O
cancer O
patients O
. O

To O
assess O
the O
effectiveness O
of O
mindfulness-based O
stress O
reduction O
( O
MBSR O
) O
for O
mood O
, O
breast- O
and O
endocrine-specific O
quality O
of O
life O
, O
and O
well-being O
after O
hospital O
treatment O
in O
women O
with O
stage O
0 O
to O
III O
breast O
cancer O
. O

Health O
outcomes O
were O
measured O
for O
up O
to O
1 O
year O
post-treatment O
. O

Vinorelbine O
was O
given O
intravenously O
on O
days O
1 O
and O
8 O
of O
a O
21-day O
treatment O
cycle O
, O
for O
a O
total O
of O
six O
cycles O
. O

Exercise O
training O
improves O
supportive O
care O
outcomes O
in O
patients O
with O
breast O
cancer O
who O
are O
receiving O
adjuvant O
therapy O
, O
but O
the O
responses O
are O
heterogeneous O
. O

To O
assess O
the O
efficacy O
of O
prophylactic O
swallowing O
exercises O
on O
swallowing O
function O
in O
patients O
undergoing O
chemoradiation O
therapy O
( O
CRT O
) O
for O
head O
and O
neck O
cancer O
. O

Here O
, O
we O
report O
an O
updated O
analysis O
of O
survival O
. O

Overall O
disease-related O
symptom O
improvement O
was O
assessed O
using O
an O
eight-item O
questionnaire O
. O

Endpoints O
included O
the O
QLQ-C30 O
Global O
Health O
Status O
( O
QL2 O
) O
scale O
, O
the O
QLQ-BR23 O
breast O
symptom O
( O
BRBS O
) O
, O
and O
arm O
symptom O
( O
BRAS O
) O
scales O
. O

Patients O
were O
randomly O
assigned O
to O
three O
arms O
: O
A O
, O
17 O
Gy O
per O
two O
fractions O
( O
n O
= O
146 O
) O
";" O
B O
, O
42 O
Gy O
per O
15 O
fractions O
( O
n O
= O
145 O
) O
";" O
and O
C O
, O
50 O
Gy O
per O
25 O
fractions O
( O
n O
= O
130 O
) O
. O

A O
prospective O
randomized O
, O
controlled O
pilot O
trial O
with O
historical O
control O
. O

The O
aim O
of O
this O
multicenter O
randomized O
trial O
was O
to O
assess O
the O
efficacy O
and O
safety O
of O
sentinel O
lymph O
node O
( O
SLN O
) O
biopsy O
compared O
with O
axillary O
lymph O
node O
dissection O
( O
ALND O
) O
. O

Cannabinoid-related O
toxicity O
was O
assessed O
every O
2 O
weeks O
. O

A O
total O
of O
646 O
node-positive O
, O
receptor-negative O
patients O
were O
randomly O
assigned O
to O
receive O
either O
the O
1 O
6-week O
regimen O
or O
six O
cycles O
of O
CAF O
. O

Convenience O
sample O
of O
38 O
women O
who O
were O
beginning O
outpatient O
chemotherapy O
. O

Patients O
assigned O
to O
delayed O
treatment O
continued O
masked O
CA125 O
measurements O
, O
with O
treatment O
commencing O
at O
clinical O
or O
symptomatic O
relapse O
. O

This O
double-blind O
, O
randomised O
, O
phase O
3 O
trial O
was O
undertaken O
at O
37 O
clinics O
in O
Denmark O
, O
Norway O
, O
and O
Sweden O
. O

Repeated O
measures O
MANCOVA O
was O
used O
to O
evaluate O
outcomes O
. O

In O
all O
, O
55 O
patients O
( O
27 O
on O
tamoxifen O
and O
28 O
on O
exemestane O
) O
completed O
the O
1-year O
study O
period O
. O

From O
February O
1998 O
to O
June O
1999 O
, O
259 O
chemonaïve O
patients O
entered O
the O
study O
and O
were O
randomised O
to O
receive O
either O
vinorelbine-cisplatin O
( O
NP O
";" O
vinorelbine O
30 O
mg/m O
( O
2 O
) O
on O
days O
1 O
, O
8 O
and O
15 O
with O
cisplatin O
80 O
mg/m O
( O
2 O
) O
on O
day O
1 O
) O
or O
vinorelbine-ifosfamide-cisplatin O
( O
NIP O
";" O
vinorelbine O
25 O
mg/m O
( O
2 O
) O
on O
days O
1 O
and O
8 O
, O
ifosfamide O
3 O
g/m O
( O
2 O
) O
on O
day O
1 O
and O
cisplatin O
75 O
mg/m O
( O
2 O
) O
on O
day O
1 O
) O
, O
with O
both O
regimens O
being O
repeated O
every O
3 O
weeks O
. O

Beyond O
standard O
toxicity O
end O
points O
, O
physician O
dysphagia O
logs O
( O
PDLs O
) O
, O
daily O
patient O
swallowing O
diaries O
, O
and O
QOL O
( O
EORTC O
QLQ-C30/LC-13 O
) O
were O
also O
collected O
. O

Kruskall-Wallis O
methodology O
was O
used O
to O
compare O
scores O
between O
older O
and O
younger O
adult O
patients O
randomized O
to O
the O
intervention O
. O

QOL O
was O
evaluated O
by O
using O
the O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
Questionnaire O
C30 O
and O
subscales O
from O
the O
prostate O
cancer O
module O
, O
PR-25 O
, O
and O
the O
ovarian O
cancer O
module O
, O
OV-28 O
. O

This O
study O
addressed O
two O
questions O
: O
the O
dose-response O
relationship O
of O
Taxol O
in O
relapsed O
ovarian O
cancer O
and O
the O
safety O
of O
a O
short O
infusion O
given O
with O
premedication O
. O

A O
total O
of O
217 O
patients O
were O
randomized O
to O
either O
the O
hypofractionated O
( O
108 O
patients O
) O
or O
the O
conventional O
( O
109 O
patients O
) O
dose O
schedule O
, O
with O
planning O
with O
two-dimensional O
( O
2D O
) O
CT O
scan O
planning O
methodology O
in O
the O
majority O
of O
cases O
. O

We O
designed O
a O
trial O
to O
investigate O
the O
effects O
of O
epoetin O
alfa O
therapy O
on O
the O
QOL O
of O
anemic O
patients O
with O
advanced O
non-small-cell O
carcinoma O
of O
the O
lung O
( O
NSCLC O
) O
. O

They O
may O
have O
unmet O
needs O
after O
active O
treatment O
. O

To O
determine O
whether O
drug O
intensification O
improves O
survival O
of O
patients O
with O
extensive O
SCLC O
, O
we O
compared O
this O
treatment O
with O
a O
four-drug O
regimen O
containing O
EP O
plus O
cyclophosphamide O
and O
4'-epidoxorubicin O
( O
PCDE O
) O
. O

These O
patients O
were O
enrolled O
in O
two O
International O
Breast O
Cancer O
Study O
Group O
randomized O
clinical O
trials O
in O
operable O
breast O
cancer O
conducted O
from O
1986 O
to O
1993 O
. O

Assess O
toxicity O
and O
efficacy O
of O
cisplatin O
( O
Cis O
) O
doublet O
combinations O
in O
advanced O
and O
recurrent O
cervical O
carcinoma O
. O

The O
primary O
endpoint O
was O
change O
in O
hemoglobin O
from O
baseline O
to O
Week O
13 O
. O

The O
potential O
long-term O
advantages O
of O
LRP O
over O
ORP O
remain O
to O
be O
determined O
. O

Women O
( O
n O
= O
177 O
) O
with O
uterine O
fibroids O
and O
heavy O
menstrual O
bleeding O
who O
were O
scheduled O
to O
undergo O
hysterectomy O
were O
randomly O
assigned O
to O
undergo O
UAE O
( O
n O
= O
88 O
) O
or O
hysterectomy O
( O
n O
= O
89 O
) O
. O

At O
the O
time O
of O
the O
second O
prespecified O
interim O
analysis O
, O
median O
follow-up O
was O
22·2 O
months O
( O
IQR O
20·2-24·8 O
) O
. O

We O
also O
evaluated O
the O
correlation O
between O
these O
scores O
and O
FACT-G O
, O
-B O
, O
and O
-Taxane O
scores O
at O
each O
time O
point O
. O

Stepwise O
regression O
models O
were O
used O
to O
determine O
predictors O
of O
QOL O
. O

Forty O
patients O
were O
assessable O
for O
toxicity O
and O
32 O
for O
treatment O
response O
. O

We O
investigated O
whether O
cognitive O
behavioural O
therapy O
( O
CBT O
) O
can O
help O
breast O
cancer O
survivors O
to O
effectively O
manage O
HFNS O
. O

In O
the O
randomized O
, O
multinational O
phase O
II/III O
trial O
( O
V325 O
) O
of O
untreated O
advanced O
gastric O
cancer O
patients O
, O
the O
phase O
II O
part O
selected O
docetaxel O
, O
cisplatin O
, O
and O
fluorouracil O
( O
DCF O
) O
over O
docetaxel O
and O
cisplatin O
for O
comparison O
against O
cisplatin O
and O
fluorouracil O
( O
CF O
";" O
reference O
regimen O
) O
in O
the O
phase O
III O
part O
. O

To O
compare O
directly O
the O
effect O
of O
intensity-modulated O
radiotherapy O
( O
IMRT O
) O
vs. O
conventional O
radiotherapy O
( O
CRT O
) O
on O
salivary O
flow O
and O
quality O
of O
life O
( O
QoL O
) O
in O
patients O
with O
early-stage O
nasopharyngeal O
carcinoma O
( O
NPC O
) O
. O

Sentinel O
nodes O
were O
located O
using O
blue O
dye O
, O
alone O
or O
with O
technetium-labeled O
antimony O
sulfide O
colloid O
. O

Forty O
patients O
on O
Arm O
A O
and O
19 O
on O
Arm O
B O
received O
at O
least O
one O
treatment O
. O

A O
total O
of O
93 O
patients O
were O
enrolled O
onto O
the O
trial O
. O

Patients O
( O
aged O
≥18 O
years O
) O
with O
a O
terminal O
prognosis O
( O
life O
expectancy O
≤6 O
months O
) O
who O
were O
receiving O
palliative O
care O
in O
a O
hospital O
or O
community O
setting O
( O
hospice O
or O
home O
) O
in O
Canada O
, O
USA O
, O
and O
Australia O
were O
randomly O
assigned O
to O
dignity O
therapy O
, O
client-centred O
care O
, O
or O
standard O
palliative O
care O
in O
a O
1:1:1 O
ratio O
. O

Treatment O
with O
somatostatin O
analogues O
slowed O
kidney O
growth O
in O
patients O
with O
polycystic O
kidney O
disease O
( O
PKD O
) O
and O
reduced O
liver O
and O
kidney O
volume O
in O
a O
PKD O
rodent O
model O
. O

A O
proof O
of O
principle O
study O
was O
performed O
to O
investigate O
the O
efficacy O
of O
combing O
anti-aromatase O
therapy O
( O
exemestane O
) O
and O
COX-2 O
inhibitors O
neoadjuvantly O
. O

It O
is O
well O
documented O
that O
stress O
is O
associated O
with O
negative O
health O
outcomes O
in O
cancer O
patients O
. O

A O
prospective O
randomized O
study O
was O
conducted O
from O
January O
2003 O
. O

The O
purpose O
of O
this O
study O
was O
to O
assess O
the O
effect O
of O
a O
SMART O
( O
Stress O
Management O
and O
Resiliency O
Training O
) O
program O
for O
increasing O
resiliency O
and O
for O
decreasing O
stress O
and O
anxiety O
among O
mentors O
who O
themselves O
were O
previously O
diagnosed O
with O
breast O
cancer O
. O

These O
samples O
were O
analyzed O
using O
six O
polymorphic O
DNA O
markers O
that O
encode O
five O
important O
enzymes O
in O
the O
glutathione O
metabolic O
pathway O
. O

A O
total O
of O
322 O
participants O
with O
cancer O
of O
the O
gastrointestinal O
tract O
( O
41 O
% O
";" O
67 O
in O
the O
usual O
care O
group O
vs O
66 O
in O
the O
intervention O
group O
) O
, O
lung O
( O
36 O
% O
";" O
58 O
vs O
59 O
) O
, O
genitourinary O
tract O
( O
12 O
% O
";" O
20 O
vs O
19 O
) O
, O
and O
breast O
( O
10 O
% O
";" O
16 O
vs O
17 O
) O
were O
randomized O
. O

Secondary O
end O
points O
included O
objective O
response O
rate O
, O
clinical O
benefit O
rate O
( O
CBR O
) O
, O
duration O
of O
clinical O
benefit O
( O
DoCB O
) O
, O
overall O
survival O
( O
OS O
) O
, O
and O
quality O
of O
life O
( O
QOL O
) O
. O

Proinflammatory O
cytokines O
, O
especially O
tumour O
necrosis O
factor O
alpha O
( O
TNF-alpha O
) O
, O
play O
a O
prominent O
role O
in O
the O
pathogenesis O
of O
cancer O
cachexia O
. O

Therapy O
for O
polycystic O
liver O
is O
invasive O
, O
expensive O
, O
and O
has O
disappointing O
long-term O
results O
. O

Treatment O
was O
delivered O
by O
acupuncturists O
once O
a O
week O
for O
6 O
weeks O
through O
needling O
three O
pairs O
of O
acupoints O
. O

G O
responses O
: O
2 O
PR O
( O
5.3 O
% O
) O
and O
16 O
SD O
( O
42.1 O
% O
) O
";" O
DCR O
( O
47.4 O
% O
) O
. O

Demographic O
and O
clinical O
factors O
studied O
were O
age O
, O
performance O
status O
, O
dominant O
site O
of O
disease O
and O
preceding O
disease-free O
interval O
( O
DFI O
) O
. O

Mean O
change O
scores O
from O
baseline O
were O
compared O
between O
groups O
for O
summary O
measures O
and O
domains O
. O

Previously O
untreated O
stage O
III O
to O
IVB O
NPC O
were O
randomly O
assigned O
to O
( O
1 O
) O
neoadjuvant O
docetaxel O
75 O
mg/m O
( O
2 O
) O
and O
cisplatin O
75 O
mg/m O
( O
2 O
) O
every O
3 O
weeks O
for O
two O
cycles O
, O
followed O
by O
cisplatin O
40 O
mg/m O
( O
2 O
) O
/wk O
concurrent O
with O
radiotherapy O
, O
or O
( O
2 O
) O
CRT O
alone O
. O

We O
investigated O
the O
role O
of O
DC/CIK O
( O
dendritic O
cell/cytokine-induced O
killer O
cells O
) O
immunobiological O
cancer O
therapy O
in O
maintenance O
therapy O
of O
advanced O
non-small O
cell O
lung O
cancer O
. O

Patients O
with O
hormone-refractory O
prostate O
cancer O
and O
a O
history O
of O
bone O
metastases O
were O
randomly O
assigned O
to O
a O
double-blind O
treatment O
regimen O
of O
intravenous O
zoledronic O
acid O
at O
4 O
mg O
( O
N O
= O
214 O
) O
, O
zoledronic O
acid O
at O
8 O
mg O
( O
subsequently O
reduced O
to O
4 O
mg O
";" O
8/4 O
) O
( O
N O
= O
221 O
) O
, O
or O
placebo O
( O
N O
= O
208 O
) O
every O
3 O
weeks O
for O
15 O
months O
. O

Randomized O
controlled O
trial O
. O

Maintenance O
therapy O
, O
commenced O
immediately O
after O
the O
completion O
of O
first-line O
chemotherapy O
, O
is O
a O
promising O
strategy O
for O
improving O
treatment O
outcomes O
in O
patients O
with O
non-small-cell O
lung O
cancer O
( O
NSCLC O
) O
. O

Forty-five O
patients O
were O
eligible O
, O
of O
whom O
34 O
were O
randomized O
( O
mean O
( O
s.d O
. O
) O
age O
70 O
( O
11·8 O
) O
years O
) O
. O

They O
received O
either O
intravenous O
infusions O
of O
synthetic O
human O
ghrelin O
( O
3 O
μg/kg O
) O
or O
saline O
twice O
daily O
for O
1 O
week O
with O
cisplatin O
administration O
. O

Surgical O
resection O
is O
regarded O
as O
the O
only O
curative O
option O
for O
resectable O
oesophageal O
cancer O
, O
but O
pulmonary O
complications O
occurring O
in O
more O
than O
half O
of O
patients O
after O
open O
oesophagectomy O
are O
a O
great O
concern O
. O

Using O
validated O
instruments O
, O
we O
prospectively O
assessed O
QOL O
within O
the O
randomized O
FLOT65+ O
phase O
II O
trial O
. O

CD-DP O
was O
given O
intravenously O
at O
a O
dose O
of O
3 O
mg/m O
( O
2 O
) O
on O
days O
1-5 O
and O
days O
8-12 O
, O
and O
then O
at O
a O
dose O
of O
7 O
mg/m O
( O
2 O
) O
twice O
a O
week O
. O

For O
flare O
protection O
, O
goserelin-treated O
patients O
also O
received O
daily O
bicalutamide O
( O
50 O
mg O
) O
during O
the O
initial O
28 O
days O
. O

A O
randomised O
controlled O
clinical O
trial O
, O
using O
a O
method O
of O
minimisation O
balanced O
by O
centre O
, O
grade O
of O
cancer O
, O
age O
, O
lymphatic/vascular O
invasion O
and O
preoperative O
endocrine O
therapy O
, O
was O
performed O
. O

Two O
hundred O
and O
three O
patients O
, O
recruited O
after O
primary O
treatment O
, O
were O
randomly O
assigned O
either O
to O
a O
treatment O
group O
( O
psycho-educational O
intervention O
) O
or O
to O
a O
waiting-list O
control O
group O
. O

The O
study O
included O
73 O
analyzable O
patients O
enrolled O
between O
1998 O
and O
2002 O
, O
including O
36 O
in O
the O
paclitaxel O
arm O
and O
37 O
in O
the O
PLD O
arm O
";" O
73 O
% O
of O
patients O
received O
highly O
active O
antiretroviral O
therapy O
( O
HAART O
) O
and O
32 O
% O
had O
an O
undetectable O
viral O
load O
( O
< O
400 O
copies/mL O
) O
. O

This O
study O
aimed O
to O
identify O
which O
patient O
characteristics O
predict O
fatigue O
improvement O
after O
CBT O
. O

Survival O
curves O
were O
calculated O
by O
the O
Kaplan-Meier O
method O
, O
and O
hazard O
ratios O
were O
estimated O
with O
the O
Cox O
proportional O
hazards O
model O
. O

In O
the O
absence O
of O
an O
overall O
survival O
benefit O
of O
using O
HDC O
for O
high-risk O
breast O
cancer O
patients O
, O
QOL O
studies O
with O
a O
longer O
follow-up O
play O
an O
important O
role O
in O
informing O
the O
complex O
trade-off O
implied O
by O
HDC O
between O
higher O
toxicity O
, O
reduced O
risk O
of O
relapse O
, O
and O
QOL O
decrease O
after O
the O
active O
phase O
of O
treatment O
. O

The O
EG O
participants O
kept O
home O
practice O
diaries O
. O

Efficacy O
was O
assessed O
after O
the O
completion O
of O
3 O
treatment O
cycles O
";" O
28.9 O
% O
of O
patients O
( O
22 O
of O
76 O
patients O
) O
responded O
( O
no O
CRs O
, O
1 O
PR O
, O
and O
21 O
SDs O
) O
. O

We O
assessed O
HRQOL O
at O
baseline O
and O
at O
every O
3 O
months O
during O
treatment O
until O
progression O
using O
the O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
( O
EORTC O
) O
quality O
of O
life O
questionnaire O
core-30 O
( O
QLQ-C30 O
) O
and O
the O
EORTC O
brain O
cancer O
module O
( O
EORTC O
BN-20 O
) O
. O

We O
conducted O
a O
pragmatic O
, O
randomized O
controlled O
trial O
comparing O
acupuncture O
with O
enhanced O
usual O
care O
. O

Patients O
completed O
the O
Lung O
Cancer O
Symptom O
Scale O
( O
LCSS O
) O
at O
baseline O
, O
after O
each O
cycle O
, O
and O
post-discontinuation O
. O

Training O
efficacy O
was O
not O
modified O
by O
patient O
characteristics O
. O

Seventeen O
participants O
met O
the O
Hospital O
Anxiety O
and O
Depression O
Scale O
( O
HADS O
) O
criteria O
for O
depressive O
symptoms O
( O
HADS O
≥ O
8 O
) O
. O

This O
study O
focussed O
on O
the O
QoL O
in O
patients O
after O
oesophagectomy O
for O
cancer O
, O
comparing O
the O
method O
of O
reconstruction O
( O
narrow O
gastric O
tube O
vs O
whole O
stomach O
) O
. O

For O
each O
outcome O
measure O
, O
a O
repeated-measures O
analysis O
of O
variance O
model O
, O
which O
incorporated O
week O
0 O
measurements O
as O
a O
covariate O
, O
was O
used O
to O
compare O
treatment O
groups O
at O
8 O
and O
12 O
weeks O
. O

This O
Phase O
II O
, O
open-label O
study O
was O
conducted O
to O
confirm O
the O
activity O
of O
SGN-15 O
plus O
docetaxel O
in O
previously O
treated O
NSCLC O
patients O
. O

patients O
were O
randomized O
to O
receive O
either O
ABABAB O
( O
early O
alternating O
chemotherapy O
) O
or O
AAABBB O
( O
late O
alternating O
chemotherapy O
) O
. O

PP O
group O
received O
pemetrexed O
500 O
mg/m² O
iv O
infusion O
d1 O
and O
cisplatin O
75 O
mg/m² O
iv O
infusion O
d1 O
, O
whereas O
GP O
group O
received O
gemcitabine O
1,000 O
mg/m² O
iv O
infusion O
d1,8 O
and O
cisplatin O
75 O
mg/m² O
iv O
infusion O
d1 O
. O

In O
addition O
, O
folic O
acid O
, O
vitamin O
B12 O
, O
and O
dexamethasone O
were O
administered O
in O
both O
groups O
. O

We O
enrolled O
1669 O
eligible O
patients O
, O
382 O
( O
23 O
% O
) O
with O
ER-negative O
tumors O
, O
1217 O
( O
73 O
% O
) O
with O
ER-positive O
tumors O
, O
and O
70 O
( O
4 O
% O
) O
with O
unknown O
ER O
status O
. O

The O
immune O
system O
can O
not O
identify O
and O
remove O
malignant O
and O
mutant O
cells O
, O
which O
cause O
tumor O
cells O
to O
escape O
from O
surveillance O
and O
clearance O
of O
the O
immune O
system O
. O

Men O
who O
wish O
to O
increase O
their O
odds O
of O
retaining O
sexual O
function O
might O
be O
counseled O
to O
choose O
EBRT O
over O
cryoablation O
. O

( O
From O
April O
1996 O
to O
November O
1997 O
, O
191 O
of O
the O
350 O
targeted O
patients O
were O
randomly O
assigned O
. O
) O

All O
statistical O
tests O
were O
two-sided O
. O

However O
, O
because O
of O
toxicity O
associated O
with O
long-term O
bisphosphonate O
treatment O
, O
establishing O
the O
lowest O
effective O
dose O
is O
important O
. O

Two O
hundred O
fifty O
patients O
were O
randomly O
assigned O
, O
80 O
% O
were O
male O
with O
a O
median O
age O
of O
58 O
years O
, O
WHO O
performance O
status O
0 O
, O
1 O
, O
and O
2 O
, O
in O
25 O
% O
, O
62 O
% O
, O
and O
13 O
% O
of O
cases O
. O

This O
article O
compares O
the O
impact O
on O
HRQOL O
of O
first-line O
treatment O
with O
cisplatin O
versus O
raltitrexed O
and O
cisplatin O
. O

Outcomes O
were O
reassessed O
6 O
and O
12 O
weeks O
after O
chemotherapy O
started O
. O

Pancreatic O
cancer O
was O
the O
most O
common O
cause O
of O
GOO O
. O

Outcomes O
were O
assessed O
by O
research O
staff O
with O
whom O
the O
participant O
had O
no O
previous O
contact O
to O
avoid O
any O
possible O
response O
bias O
or O
contamination O
. O

This O
phase O
III O
trial O
was O
conducted O
to O
test O
whether O
the O
novel O
vascular O
disrupting O
agent O
ASA404 O
( O
vadimezan O
) O
, O
when O
combined O
with O
first-line O
platinum-based O
chemotherapy O
, O
improves O
survival O
in O
patients O
with O
advanced O
non-small-cell O
lung O
cancer O
( O
NSCLC O
) O
versus O
chemotherapy O
alone O
. O

Thirty O
days O
after O
the O
treatment O
, O
efficacy O
, O
toxicity O
, O
and O
adverse O
effects O
were O
assessed O
in O
both O
study O
groups O
. O

and O
intravenous O
( O
i.v O
. O
) O

Primary O
objective O
was O
overall O
survival O
( O
OS O
) O
";" O
secondary O
objectives O
assessed O
progression-free O
survival O
( O
PFS O
) O
, O
response O
rate O
( O
RR O
) O
, O
quality O
of O
life O
( O
QOL O
) O
, O
toxicity O
, O
and O
relationships O
between O
biomarker O
expression O
and O
clinical O
outcomes O
. O

All O
parties O
, O
except O
for O
the O
randomisation O
centre O
, O
were O
blinded O
for O
TS O
status O
. O

After O
the O
first O
and O
second O
IAD O
cycle O
92 O
% O
and O
46 O
% O
, O
respectively O
, O
had O
a O
normalized O
testosterone O
. O

The O
primary O
purpose O
of O
this O
study O
was O
to O
compare O
melatonin O
with O
placebo O
for O
appetite O
improvement O
in O
patients O
with O
cancer O
cachexia O
. O

The O
study O
included O
the O
assessment O
of O
patient O
quality O
of O
life O
. O

Manual O
lymphatic O
drainage O
( O
MLD O
) O
and O
compression O
bandage O
combination O
( O
complex O
decongestive O
therapy O
) O
have O
been O
compared O
with O
intermittent O
pneumatic O
compression O
( O
IPC O
) O
plus O
self-lymphatic O
drainage O
( O
SLD O
) O
. O

Locally O
advanced O
breast O
cancer O
patients O
were O
randomly O
assigned O
onto O
a O
study O
comparing O
cyclophosphamide O
( O
C O
";" O
75 O
mg/m O
( O
2 O
) O
orally O
days O
1 O
to O
14 O
) O
, O
epirubicin O
( O
E O
";" O
60 O
mg/m O
( O
2 O
) O
intravenously O
[ O
IV O
] O
days O
1 O
, O
8 O
) O
, O
and O
fluorouracil O
( O
F O
";" O
500 O
mg/m O
( O
2 O
) O
IV O
days O
1 O
, O
8 O
) O
six O
cycles O
every O
28 O
days O
versus O
E O
( O
120 O
mg/m O
( O
2 O
) O
IV O
day O
1 O
) O
, O
C O
( O
830 O
mg/m O
( O
2 O
) O
IV O
day O
1 O
) O
, O
and O
granulocyte O
colony-stimulating O
factor O
( O
filgrastim O
";" O
5 O
micro O
g/kg/d O
subcutaneously O
days O
2 O
to O
13 O
) O
six O
cycles O
every O
14 O
days O
. O

Interventions O
were O
given O
twice O
weekly O
for O
4 O
consecutive O
weeks O
. O

A O
total O
of O
219 O
participants O
from O
12 O
oncology O
clinics O
were O
randomly O
assigned O
in O
a O
clinical O
trial O
. O

Patients O
completed O
questionnaires O
before O
and O
after O
the O
visit O
and O
were O
interviewed O
by O
telephone O
at O
2 O
, O
6 O
, O
and O
12 O
weeks O
. O

The O
aim O
of O
this O
study O
was O
to O
compare O
the O
analgesic O
and O
adverse O
effects O
, O
doses O
, O
as O
well O
as O
cost O
of O
opioid O
drugs O
, O
supportive O
drug O
therapy O
and O
other O
analgesic O
drugs O
in O
patients O
treated O
with O
oral O
sustained-release O
morphine O
, O
transdermal O
fentanyl O
, O
and O
oral O
methadone O
. O

Pain O
and O
physical O
disabilities O
related O
to O
upper O
limb O
dysfunction O
, O
quality O
of O
life O
and O
depression O
were O
used O
as O
subjective O
outcomes O
. O

We O
performed O
a O
4-arm O
randomised O
trial O
to O
compare O
( O
1 O
) O
a O
low-dose O
intravenous O
bolus O
of O
LV O
( O
20 O
mg/m2 O
) O
, O
followed O
by O
an O
intravenous O
bolus O
of O
5FU O
( O
400 O
mg/m2 O
) O
, O
followed O
by O
a O
22-hour O
continuous O
infusion O
of O
5FU O
( O
600 O
mg/m2 O
) O
on O
day O
1 O
and O
day O
2/2 O
weeks O
( O
ldLV5FU2 O
arm O
) O
, O
( O
2 O
) O
a O
weekly O
continuous O
infusion O
of O
high-dose O
5FU O
( O
2.6 O
g/m2/week O
) O
for O
6 O
weeks O
followed O
by O
a O
rest O
week O
( O
HD-FU O
arm O
) O
and O
( O
3 O
) O
raltitrexed O
( O
Tomudex O
arm O
";" O
3 O
mg/m2/3 O
weeks O
) O
to O
standard O
LV5FU2 O
. O

All O
structures O
including O
the O
IUS O
and O
EUS O
were O
contoured O
on O
T2-weighted O
MRI O
at O
day O
30 O
, O
and O
doses O
received O
were O
calculated O
from O
identification O
of O
seeds O
on O
CT. O
Spearman O
's O
( O
nonparametric O
) O
rank O
correlation O
coefficient O
( O
ρ O
) O
was O
used O
for O
statistical O
analyses O
. O

Men O
with O
metastatic O
prostate O
cancer O
( O
n O
= O
161 O
) O
were O
randomized O
to O
receive O
either O
daily O
prednisone O
alone O
or O
mitoxantrone O
( O
every O
3 O
weeks O
) O
plus O
prednisone O
. O

Costs O
were O
in O
British O
pounds O
and O
year O
2000 O
values O
. O

The O
primary O
outcomes O
-- O
reductions O
in O
various O
dimensions O
of O
distress O
before O
and O
after O
completion O
of O
the O
study O
-- O
were O
measured O
with O
the O
Functional O
Assessment O
of O
Chronic O
Illness O
Therapy O
Spiritual O
Well-Being O
Scale O
, O
Patient O
Dignity O
Inventory O
, O
Hospital O
Anxiety O
and O
Depression O
Scale O
, O
items O
from O
the O
Structured O
Interview O
for O
Symptoms O
and O
Concerns O
, O
Quality O
of O
Life O
Scale O
, O
and O
modified O
Edmonton O
Symptom O
Assessment O
Scale O
. O

A O
response O
analysis O
compared O
the O
proportion O
of O
patients O
who O
demonstrated O
an O
important O
change O
in O
QOL O
. O

Exploratory O
analyses O
were O
performed O
on O
a O
data O
set O
from O
a O
previous O
study O
. O

To O
determine O
the O
efficacy O
, O
impact O
on O
quality-of-life O
( O
QoL O
) O
and O
tolerability O
of O
two O
different O
irinotecan O
administration O
schedules O
in O
combination O
with O
capecitabine O
as O
first-line O
treatment O
of O
metastatic O
colorectal O
cancer O
. O

Secondary O
endpoints O
included O
response O
rate O
( O
RR O
) O
, O
overall O
survival O
( O
OS O
) O
, O
toxicity O
, O
and O
quality O
of O
life O
( O
QOL O
) O
. O

To O
determine O
the O
immediate O
and O
long-term O
effects O
of O
TRUE O
acupuncture O
versus O
sham O
acupuncture O
on O
hot O
flash O
frequency O
in O
women O
with O
breast O
cancer O
. O

Standard O
National O
Cancer O
Institute O
of O
Canada O
Clinical O
Trials O
Group O
( O
NCIC O
CTG O
) O
approaches O
were O
applied O
as O
the O
primary O
method O
to O
analyze O
the O
QOL O
data O
from O
this O
trial O
. O

In O
both O
groups O
, O
partners O
completed O
behavioral O
homework O
. O

For O
this O
randomized O
controlled O
trial O
, O
60 O
patients O
with O
cancer O
were O
recruited O
and O
received O
either O
usual O
care O
or O
the O
intervention O
. O

The O
trial O
was O
stopped O
for O
futility O
at O
interim O
analysis O
. O

Eighty O
participants O
completed O
all O
follow-ups O
. O

The O
global O
phase O
III O
SequentiAl O
Tarceva O
in O
UnResectable O
NSCLC O
( O
SATURN O
) O
study O
evaluated O
the O
efficacy O
and O
safety O
of O
the O
epidermal O
growth O
factor O
receptor O
( O
EGFR O
) O
tyrosine-kinase O
inhibitor O
erlotinib O
as O
maintenance O
treatment O
in O
NSCLC O
patients O
without O
progression O
after O
first-line O
chemotherapy O
. O

Future O
studies O
can O
provide O
further O
insight O
on O
how O
to O
tailor O
QOL O
interventions O
for O
these O
age O
groups O
. O

These O
differences O
all O
resolved O
by O
12 O
months O
. O

Grade O
3 O
or O
4 O
neutropenia O
was O
more O
frequent O
in O
GEM-treated O
patients O
versus O
PLD-treated O
patients O
( O
P O
= O
.007 O
) O
. O

The O
primary O
outcome O
was O
the O
feasibility O
of O
a O
large O
RCT O
, O
and O
all O
outcomes O
for O
a O
definitive O
trial O
were O
tested O
. O

The O
primary O
objective O
was O
to O
compare O
complete O
response O
( O
CR O
) O
rates O
. O

Patients O
receiving O
adjuvant O
RT O
reported O
worse O
bowel O
function O
( O
through O
approximately O
2 O
years O
) O
and O
worse O
urinary O
function O
. O

The O
Medical O
Outcomes O
Trust O
Short-Form O
36 O
Survey O
was O
used O
to O
measure O
quality O
of O
life O
before O
and O
after O
the O
intervention O
. O

Instruments O
administered O
at O
baseline O
included O
the O
following O
: O
Quality O
of O
Life O
Index-Cancer O
Version O
( O
QOLI-CV O
) O
, O
State-Trait O
Anxiety O
Inventory O
, O
Beck O
Depression O
Inventory O
, O
and O
Coping O
Strategies O
Questionnaire O
. O

Two O
years O
after O
completing O
radiotherapy O
, O
a O
questionnaire O
that O
assessed O
bladder O
, O
rectal O
, O
and O
sexual O
function O
was O
sent O
to O
301 O
patients O
in O
the O
study O
. O

Major O
end O
points O
were O
the O
frequency O
of O
significant O
HSRs O
and O
objective O
response O
rate O
. O

Patients O
with O
progressive O
, O
androgen-independent O
prostate O
cancer O
were O
randomly O
assigned O
to O
one O
of O
two O
treatments O
: O
either O
ketoconazole/doxorubicin O
alternating O
with O
vinblastine/estramustine O
( O
KA/VE O
) O
or O
paclitaxel O
, O
estramustine O
, O
and O
oral O
etoposide O
( O
TEE O
) O
. O

The O
Programme O
Etude O
Rein O
Cytokines O
( O
PERCY O
) O
Quattro O
trial O
was O
designed O
to O
evaluate O
both O
cytokines O
for O
their O
survival O
benefit O
to O
intermediate O
prognosis O
patients O
, O
who O
represent O
the O
majority O
of O
candidates O
for O
these O
treatments O
. O

Forty-five O
patients O
were O
randomized O
to O
postinduction O
RT O
or O
surgery O
. O

Nocturnal O
administration O
of O
branched-chain O
amino O
acid O
( O
BCAA O
) O
granules O
improves O
serum O
albumin O
levels O
in O
patients O
with O
cirrhosis O
. O

Patients O
were O
followed O
up O
per-protocol O
";" O
there O
were O
no O
deaths O
, O
and O
five O
patients O
had O
a O
total O
of O
six O
complications O
. O

The O
intervention O
targeted O
couples O
' O
communication O
, O
hope O
, O
coping O
, O
uncertainty O
, O
and O
symptom O
management O
. O

Therefore O
a O
phase O
III O
trial O
was O
implemented O
to O
confirm O
this O
activity O
. O

A O
total O
of O
166 O
patients O
were O
randomized O
to O
receive O
intravenous O
5-FU O
( O
450 O
mg/m2/day O
) O
or O
oral O
doxifluridine O
( O
900 O
mg/m2/day O
) O
in O
combination O
with O
leucovorin O
( O
20 O
mg/m2/day O
) O
for O
depth O
of O
invasion O
, O
nodal O
status O
, O
metastasis O
( O
TNM O
) O
stage O
II O
and O
III O
patients O
between O
October O
1997 O
and O
February O
1999 O
. O

Function O
and O
quality O
of O
life O
were O
measured O
by O
the O
Musculoskeletal O
Tumor O
Society O
Rating O
Scale O
( O
MSTS O
) O
, O
the O
Toronto O
Extremity O
Salvage O
Score O
( O
TESS O
) O
, O
and O
the O
Short O
Form-36 O
( O
SF-36 O
) O
at O
randomization O
, O
6 O
weeks O
, O
and O
3 O
, O
6 O
, O
12 O
, O
and O
24 O
months O
after O
surgery O
. O

Methodology O
was O
similar O
to O
our O
recently O
published O
study O
( O
Gautam O
et O
al O
. O

Percentages O
of O
patients O
completing O
9 O
months O
of O
treatment O
in O
the O
PCV O
, O
TMZ-5 O
, O
and O
TMZ-21 O
arms O
were O
17 O
% O
, O
26 O
% O
, O
and O
13 O
% O
, O
respectively O
. O

Preplanning O
constraints O
included O
prostate O
V100 O
higher O
than O
95 O
% O
, O
V150 O
lower O
than O
60 O
% O
, O
and O
V200 O
lower O
than O
20 O
% O
and O
rectal O
R100 O
less O
than O
1cm O
( O
3 O
) O
. O

Three O
hundred O
two O
outpatients O
with O
breast O
cancer O
participated O
. O

Fifty-seven O
( O
57 O
) O
women O
met O
inclusion O
criteria O
and O
53 O
were O
randomized O
to O
the O
study O
. O

There O
were O
70 O
female O
posttreatment O
anal O
or O
rectal O
cancer O
survivors O
assessed O
as O
part O
of O
the O
current O
study O
. O

A O
total O
of O
419 O
women O
were O
randomized O
to O
one O
of O
four O
treatments O
: O
once-daily O
1 O
mg O
E2V/2.5 O
mg O
MPA O
( O
1 O
+ O
2.5 O
group O
) O
";" O
1 O
mg O
E2V/5 O
mg O
MPA O
daily O
( O
1 O
+ O
5 O
group O
) O
";" O
2 O
mg O
E2V/2.5 O
mg O
MPA O
daily O
( O
2 O
+ O
2.5 O
group O
) O
";" O
2 O
mg O
E2V/5 O
mg O
MPA O
daily O
( O
2 O
+ O
5 O
group O
) O
( O
Indivina O
, O
Orion O
Pharma O
) O
. O

317 O
patients O
( O
218 O
from O
the O
abatacept O
and O
99 O
from O
the O
placebo O
group O
) O
entered O
and O
222 O
( O
70 O
% O
) O
completed O
18 O
months O
of O
long-term O
extension O
treatment O
. O

157 O
patients O
in O
the O
90 O
mg O
group O
and O
156 O
in O
the O
30 O
mg O
group O
were O
included O
in O
the O
primary O
analysis O
. O

Uterine O
and O
quality-of-life O
data O
were O
analyzed O
using O
regression O
methods O
, O
and O
missing O
values O
were O
handled O
using O
multiple O
imputation O
. O

To O
investigate O
the O
impact O
of O
dietary O
counseling O
or O
nutritional O
supplements O
on O
outcomes O
in O
cancer O
patients O
: O
nutritional O
, O
morbidity O
, O
and O
quality O
of O
life O
( O
QoL O
) O
during O
and O
3 O
months O
after O
radiotherapy O
. O

Annualized O
percentage O
rates O
for O
cardiovascular O
events O
[ O
corrected O
] O
and O
endometrial O
cancers O
[ O
corrected O
] O
were O
below O
national O
rates O
for O
Finland O
and O
those O
reported O
for O
the O
Women O
's O
Health O
Initiative O
. O

These O
patients O
were O
assigned O
to O
the O
two O
arms O
to O
assess O
the O
value O
of O
low-dose O
CDDP O
when O
added O
to O
a O
continuous O
intravenous O
infusion O
of O
5-FU O
at O
a O
dose O
of O
300 O
mg/m O
( O
2 O
) O
/24 O
hrs O
in O
a O
one-week O
cycle O
consisting O
of O
5 O
days O
of O
treatment O
and O
2 O
days O
of O
rest O
for O
at O
least O
12 O
weeks O
. O

The O
WBC O
, O
Hb O
, O
and O
PLT O
were O
detected O
in O
all O
patients O
before O
treatment O
, O
6 O
months O
after O
treatment O
, O
and O
1 O
year O
after O
treatment O
. O

The O
purpose O
of O
this O
study O
was O
to O
test O
the O
efficacy O
of O
a O
comprehensive O
menopausal O
assessment O
( O
CMA O
) O
intervention O
program O
in O
achieving O
relief O
of O
symptoms O
, O
the O
improvement O
in O
quality O
of O
life O
( O
QOL O
) O
, O
and O
sexual O
functioning O
in O
breast O
cancer O
survivors O
. O

Following O
assessment O
of O
mental O
and O
physical O
well-being O
, O
depression O
, O
anxiety O
, O
exercise O
, O
and O
stress O
reduction O
activity O
before O
chemotherapy O
started O
, O
patients O
were O
randomized O
to O
stress O
management O
training O
( O
SM O
) O
, O
exercise O
( O
EX O
) O
, O
combined O
stress O
management O
and O
exercise O
( O
SMEX O
) O
, O
or O
usual O
care O
only O
( O
UCO O
) O
. O

Before O
CTX O
, O
research O
nurses O
coached O
intervention O
participants O
to O
develop O
a O
BT O
plan O
including O
stimulus O
control O
, O
modified O
sleep O
restriction O
, O
relaxation O
therapy O
, O
and O
sleep O
hygiene O
. O

Subjects O
were O
assessed O
before O
and O
after O
rehabilitation O
program O
, O
with O
respect O
to O
, O
6-min O
walk O
test O
( O
6MWT O
) O
, O
modified O
sit O
and O
reach O
test O
, O
Brief O
Fatigue O
Inventory O
( O
BFI O
) O
, O
Beck O
Depression O
Index O
( O
BDI O
) O
and O
the O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
C30 O
( O
EORTC O
QLQ-C30 O
) O
and O
EORTC O
QLQ O
BR23 O
. O

Study O
follow-up O
was O
completed O
July O
2012 O
. O

A O
median O
of O
four O
cycles O
was O
administered O
in O
each O
arm O
. O

Patients O
completed O
measures O
assessing O
pain O
, O
psychological O
distress O
, O
quality O
of O
life O
( O
QOL O
) O
, O
and O
self-efficacy O
for O
symptom O
management O
";" O
caregivers O
completed O
measures O
assessing O
psychological O
distress O
, O
caregiver O
strain O
, O
and O
self-efficacy O
for O
helping O
the O
patient O
manage O
symptoms O
. O

In O
an O
open O
, O
randomized O
, O
multicenter O
trial O
, O
patients O
were O
randomized O
to O
treatment O
with O
50 O
mg O
bicalutamide O
( O
n O
= O
243 O
) O
once O
daily O
or O
to O
castration O
( O
n O
= O
243 O
) O
, O
either O
orchiectomy O
or O
depot O
injection O
of O
goserelin O
acetate O
every O
28 O
days O
. O

There O
is O
a O
modest O
dose O
effect O
with O
longer O
time O
to O
progression O
at O
175 O
mg/m2 O
. O

This O
multicenter O
, O
open-label O
, O
phase O
III O
study O
randomly O
assigned O
patients O
in O
a O
1:2 O
ratio O
to O
irinotecan O
given O
either O
weekly O
( O
125 O
mg/m O
( O
2 O
) O
) O
or O
once O
every O
3 O
weeks O
( O
350 O
mg/m O
( O
2 O
) O
, O
or O
300 O
mg/m O
( O
2 O
) O
in O
patients O
who O
were O
> O
/= O
70 O
years O
of O
age O
, O
who O
had O
Eastern O
Cooperative O
Oncology O
Group O
performance O
status O
equal O
to O
2 O
, O
or O
who O
had O
prior O
pelvic O
irradiation O
) O
. O

One O
group O
was O
treated O
with O
DC/CIK O
immunobiological O
cancer O
therapy O
, O
and O
the O
other O
was O
taken O
as O
a O
control O
group O
. O

Misoprostol O
is O
a O
synthetic O
prostaglandin O
E1 O
analogue O
, O
with O
properties O
of O
a O
mucosal O
cytoprotectant O
. O

230 O
patients O
with O
previously O
untreated O
, O
non-small O
cell O
lung O
cancer O
that O
is O
locally O
too O
advanced O
for O
resection O
or O
radical O
radiotherapy O
with O
curative O
intent O
, O
with O
minimal O
thoracic O
symptoms O
, O
and O
with O
no O
indication O
for O
immediate O
thoracic O
radiotherapy O
. O

The O
final O
sample O
consisted O
of O
235 O
couples O
: O
123 O
couples O
in O
the O
control O
group O
and O
112 O
couples O
in O
the O
experimental O
group O
. O

The O
primary O
outcome O
was O
QOL O
measured O
by O
the O
functional O
living O
index-cancer O
( O
FLI-C O
) O
and O
supplemented O
by O
the O
Kaposi O
's O
sarcoma O
module O
( O
KSM O
) O
. O

Women O
( O
n O
= O
558 O
) O
completed O
psychosocial O
questionnaires O
within O
4 O
weeks O
posttreatment O
and O
again O
2 O
, O
6 O
, O
and O
12 O
months O
later O
. O

Records O
of O
nutritional O
assessments O
, O
inflammatory O
status O
, O
and O
postoperative O
complications O
were O
compared O
between O
the O
two O
groups O
. O

We O
also O
investigated O
the O
relationship O
between O
Functional O
Assessment O
of O
Cancer O
Therapy O
( O
FACT O
) O
scale O
scores O
and O
EQ-5D O
utilities O
. O

An O
alpha-blocker O
was O
initiated O
either O
prophylactically O
2 O
weeks O
before O
implantation O
and O
continued O
at O
least O
until O
the O
International O
Prostate O
Symptom O
Score O
( O
IPSS O
) O
returned O
to O
normal O
, O
or O
withheld O
until O
the O
onset O
of O
significant O
brachytherapy-related O
urinary O
morbidity O
. O

Local O
symptoms O
were O
scored O
on O
a O
physician-assessed O
, O
five-point O
categorical O
scale O
and O
summed O
to O
produce O
a O
total O
symptom O
score O
( O
TSS O
) O
. O

There O
were O
no O
differences O
at O
later O
time O
points O
. O

After O
anterior O
resection O
for O
cancer O
, O
patients O
were O
allocated O
to O
either O
J-pouch O
or O
CP-anal O
anastomoses O
. O

Forty-two O
patients O
were O
randomized O
to O
receive O
misoprostol O
and O
41 O
to O
receive O
a O
placebo O
. O

A O
randomized O
controlled O
trial O
was O
performed O
to O
assess O
the O
outcome O
of O
early O
oral O
postoperative O
feeding O
( O
EOF O
) O
compared O
with O
traditional O
oral O
feeding O
( O
TOF O
) O
in O
gynecologic O
oncology O
patients O
undergoing O
a O
complex O
laparotomy O
, O
including O
upper O
abdominal O
surgery O
. O

From O
June O
2003 O
to O
December O
2003 O
, O
the O
10-year O
follow-up O
was O
conducted O
. O

One O
hundred O
seven O
patients O
were O
randomly O
assigned O
to O
AM O
( O
n O
= O
54 O
) O
or O
PM O
( O
n O
= O
53 O
) O
dosing O
and O
on O
study O
for O
a O
median O
8.3 O
months O
. O

Eligible O
patients O
were O
vinca O
alkaloid O
and O
anthracycline O
naive O
. O

The O
sample O
size O
required O
in O
a O
larger O
definitive O
study O
is O
32 O
subjects O
per O
group O
. O

Breast O
intensity-modulated O
radiation O
therapy O
( O
IMRT O
) O
is O
a O
technique O
that O
ensures O
a O
more O
homogeneous O
dose O
distribution O
. O

Between O
May O
2002 O
and O
January O
2005 O
, O
533 O
patients O
were O
randomly O
assigned O
to O
GEM O
( O
n O
= O
266 O
) O
and O
GEM-CAP O
( O
n O
= O
267 O
) O
arms O
. O

Data O
were O
collected O
from O
both O
groups O
of O
dyads O
using O
standardized O
assessments O
on O
admission O
and O
1 O
week O
after O
each O
of O
the O
first O
2 O
IDT O
meetings O
in O
which O
these O
dyads O
were O
discussed O
. O

In O
this O
randomised O
controlled O
trial O
, O
we O
recruited O
women O
from O
breast O
clinics O
in O
London O
, O
UK O
, O
who O
had O
problematic O
HFNS O
( O
minimum O
ten O
problematic O
episodes O
a O
week O
) O
after O
breast-cancer O
treatment O
. O

All O
statistical O
tests O
were O
two-sided O
. O

The O
aim O
of O
the O
present O
study O
was O
to O
evaluate O
the O
efficacy O
and O
safety O
of O
combined O
intrapleural O
therapy O
with O
bevacizumab O
and O
cisplatin O
, O
an O
antineoplastic O
agent O
, O
in O
controlling O
MPE O
. O

Patients O
were O
interviewed O
by O
telephone O
before O
treatment O
( O
baseline O
) O
, O
midtreatment O
, O
within O
1 O
month O
post-treatment O
, O
and O
at O
12 O
, O
18 O
, O
and O
24 O
months O
postbaseline O
by O
using O
questionnaires O
from O
the O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
Questionnaire O
C30 O
( O
EORTC O
QLQ-C30 O
) O
, O
a O
breast O
systemic O
adverse O
effects O
scale O
( O
EORTC O
BR23 O
) O
, O
and O
the O
Hospital O
Anxiety O
and O
Depression O
Scale O
( O
HADS O
) O
. O

This O
randomized O
controlled O
trial O
involved O
109 O
women O
commencing O
adjuvant O
chemotherapy O
for O
stage O
I O
or O
II O
breast O
cancer O
in O
five O
chemotherapy O
treatment O
centers O
. O

A O
total O
of O
329 O
patients O
from O
10 O
centers O
in O
9 O
countries O
in O
the O
Asia-Pacific O
region O
enrolled O
in O
a O
double-blind O
randomized O
controlled O
trial O
of O
TMX O
120 O
mg/d O
( O
TMX120 O
) O
against O
P O
as O
a O
control O
arm O
with O
an O
intermediate O
dosage O
of O
TMX O
60 O
mg/d O
( O
TMX60 O
) O
to O
assess O
possible O
dose O
response O
. O

32 O
subjects O
, O
16 O
per O
group O
, O
completed O
the O
study O
follow-up O
. O

The O
impact O
of O
the O
addition O
of O
docetaxel O
on O
patients O
' O
health-related O
quality O
of O
life O
( O
HRQOL O
) O
and O
symptoms O
was O
investigated O
. O

The O
4 O
arms O
were O
well O
balanced O
for O
sex O
ratio O
, O
age O
, O
WHO O
performance O
status O
, O
the O
primary O
tumour O
site O
and O
prior O
adjuvant O
chemotherapy O
. O

A O
total O
of O
166 O
eligible O
patients O
were O
randomly O
assigned O
to O
receive O
adjuvant O
tamoxifen O
, O
exemestane O
, O
or O
anastrozole O
. O

and O
What O
does O
the O
study O
add O
? O

The O
setting O
was O
breast O
cancer O
clinics O
in O
cancer O
centres O
in O
the O
UK O
. O

Forty O
were O
not O
eligible O
for O
randomization O
, O
and O
58 O
patients O
were O
randomly O
assigned O
, O
32 O
and O
26 O
patients O
in O
the O
INT O
and O
CONT O
arms O
, O
respectively O
. O

We O
evaluated O
HRQOL O
with O
the O
EuroQol O
( O
EQ-5D™ O
) O
in O
patients O
with O
APC O
participating O
in O
Cancer O
and O
Leukemia O
Group O
B O
80303 O
, O
a O
multicenter O
, O
double-blind O
, O
randomized O
trial O
comparing O
overall O
survival O
( O
OS O
) O
between O
two O
treatment O
arms O
: O
gemcitabine O
with O
bevacizumab O
or O
gemcitabine O
with O
placebo O
. O

Chemotherapy-naïve O
patients O
age O
70 O
years O
or O
older O
with O
stage O
IIIB/IV O
NSCLC O
and O
performance O
status O
2 O
or O
lower O
were O
eligible O
. O

Patients O
were O
randomly O
assigned O
to O
GEM O
or O
GEM-CAP O
. O

These O
studies O
were O
limited O
by O
a O
lack O
of O
blinding O
and O
absence O
of O
placebo O
controls O
. O

Progression-free O
survival O
, O
survival O
, O
response O
rate O
, O
safety O
, O
and O
HRQOL O
. O

This O
randomized O
, O
double-blind O
, O
placebo-controlled O
pilot O
trial O
assessed O
the O
feasibility O
of O
quantifying O
the O
effects O
of O
epoetin O
alfa O
on O
cognitive O
function O
and O
mood O
, O
and O
evaluated O
its O
effects O
on O
fatigue O
and O
QOL O
in O
patients O
with O
breast O
cancer O
treated O
with O
anthracycline-based O
adjuvant O
or O
neoadjuvant O
chemotherapy O
. O

To O
evaluate O
the O
impact O
of O
letrozole O
compared O
with O
placebo O
after O
adjuvant O
tamoxifen O
on O
quality O
of O
life O
( O
QOL O
) O
in O
the O
MA.17 O
trial O
. O

From O
March O
1995 O
until O
April O
1998 O
, O
812 O
patients O
were O
randomly O
assigned O
to O
receive O
three O
or O
four O
cycles O
: O
of O
these O
, O
681 O
were O
also O
randomly O
assigned O
to O
the O
5-day O
or O
the O
3-day O
schedule O
. O

The O
primary O
outcome O
for O
these O
quality-of-life O
analyses O
was O
time O
to O
worsening O
of O
symptoms O
, O
analysed O
for O
all O
randomised O
patients O
. O

We O
report O
health-related O
quality O
of O
life O
( O
HRQOL O
) O
at O
a O
mean O
of O
5.3 O
years O
for O
168 O
trial-eligible O
men O
who O
either O
chose O
or O
were O
randomly O
assigned O
to O
RP O
or O
BT O
following O
a O
multidisciplinary O
educational O
session O
. O

The O
co-primary O
endpoints O
of O
SATURN O
were O
progression-free O
survival O
( O
PFS O
) O
in O
all O
patients O
and O
in O
those O
with O
positive O
EGFR O
immunohistochemistry O
( O
IHC O
) O
status O
. O

A O
randomised O
controlled O
trial O
of O
radiotherapy O
alone O
versus O
radiotherapy O
with O
concomitant O
and O
adjuvant O
temozolomide O
for O
patients O
with O
glioblastoma O
showed O
that O
survival O
was O
higher O
for O
patients O
assigned O
combination O
treatment O
compared O
with O
those O
assigned O
standard O
radiotherapy O
alone O
. O

Fifty-five O
patients O
were O
randomized O
to O
receive O
epoetin O
alpha O
, O
and O
54 O
patients O
received O
no O
epoetin O
. O

After O
medical O
treatment O
, O
they O
completed O
baseline O
measures O
and O
were O
randomly O
assigned O
to O
standard O
National O
Cancer O
Institute O
print O
material O
( O
CTL O
) O
";" O
standard O
print O
material O
and O
peer-modeling O
videotape O
( O
VID O
) O
";" O
or O
standard O
print O
material O
, O
videotape O
, O
two O
sessions O
with O
a O
trained O
cancer O
educator O
, O
and O
informational O
workbook O
( O
EDU O
) O
. O

Patients O
with O
multiple O
myeloma O
who O
were O
starting O
antimyeloma O
treatment O
were O
randomly O
assigned O
in O
a O
1:1 O
ratio O
to O
receive O
one O
of O
two O
doses O
of O
pamidronate O
( O
30 O
mg O
or O
90 O
mg O
) O
given O
by O
intravenous O
infusion O
once O
a O
month O
for O
at O
least O
3 O
years O
. O

Outcomes O
were O
compared O
between O
groups O
using O
analysis O
of O
covariance O
adjusted O
for O
baseline O
values O
. O

The O
primary O
outcome O
was O
self-reported O
total O
exercise O
( O
in O
metabolic O
equivalent O
[ O
MET O
] O
hours O
per O
week O
) O
at O
5 O
weeks O
postconsultation O
. O

To O
compare O
the O
outcomes O
of O
uterine O
artery O
embolization O
( O
UAE O
) O
for O
leiomyomas O
with O
use O
of O
tris-acryl O
gelatin O
microspheres O
( O
TAGM O
) O
versus O
spherical O
polyvinyl O
alcohol O
( O
PVA O
) O
particles O
. O

Of O
168 O
survey O
responders O
, O
60.7 O
% O
had O
BT O
( O
9.5 O
% O
randomly O
assigned O
) O
and O
39.3 O
% O
had O
RP O
( O
9.5 O
% O
randomly O
assigned O
) O
. O

Patients O
were O
randomly O
assigned O
to O
the O
following O
four O
chemotherapy O
regimens O
: O
four O
cycles O
of O
anthracycline O
followed O
by O
paclitaxel O
( O
ACP O
) O
, O
four O
cycles O
of O
anthracycline-containing O
regimens O
followed O
by O
docetaxel O
( O
ACD O
) O
, O
eight O
cycles O
of O
paclitaxel O
( O
PTX O
) O
, O
and O
eight O
cycles O
of O
docetaxel O
( O
DTX O
) O
. O

Cost-benefit O
analysis O
was O
based O
on O
hospital O
costs O
. O

PSA O
decline O
showed O
no O
predictive O
value O
. O

We O
investigated O
whether O
monitoring O
and O
protocolized O
treatment O
of O
physical O
symptoms O
alleviates O
fatigue O
. O

The O
primary O
outcome O
was O
patient-perceived O
benefits O
, O
using O
the O
emotional O
function O
domain O
of O
the O
EORTC O
quality O
of O
life O
( O
QOL O
) O
QLQC30 O
questionnaire O
evaluated O
after O
12 O
weeks O
. O

Patients O
completed O
a O
comprehensive O
battery O
of O
QOL O
questionnaires O
at O
random O
assignment O
to O
treatment O
and O
at O
1 O
, O
3 O
, O
and O
6 O
months O
later O
. O

Between-group O
differences O
were O
tested O
for O
statistical O
significance O
by O
use O
of O
repeated-measures O
analysis O
, O
and O
reported O
P O
values O
are O
two-sided O
. O

Several O
guidelines O
on O
the O
treatment O
of O
cancer-related O
fatigue O
recommend O
optimizing O
treatment O
of O
accompanying O
symptoms O
. O

Relative O
hazards O
of O
death O
and O
95 O
% O
confidence O
intervals O
( O
CIs O
) O
were O
estimated O
by O
the O
Cox O
model O
. O

Clinical O
examination O
and O
CA125 O
measurement O
were O
done O
every O
3 O
months O
. O

Esophagogastric O
adenocarcinoma O
mainly O
occurs O
in O
elderly O
patients O
, O
but O
they O
are O
underrepresented O
in O
most O
clinical O
trials O
and O
often O
do O
not O
receive O
effective O
combination O
chemotherapy O
, O
most O
probably O
for O
fear O
of O
intolerance O
. O

The O
follow-up O
assessment O
rate O
was O
73 O
% O
( O
329 O
of O
450 O
) O
. O

Prospective O
randomized O
study O
that O
included O
60 O
patients O
( O
45 O
women O
, O
15 O
men O
";" O
mean O
age O
, O
55.2 O
years O
) O
with O
recurrent O
malignant O
pleural O
effusion O
between O
January O
2005 O
and O
January O
2008 O
. O

Intervention O
group O
patients O
received O
the O
Pain O
Education O
Program O
in O
the O
hospital O
, O
and O
3 O
and O
7 O
days O
postdischarge O
by O
telephone O
";" O
this O
was O
done O
by O
nurses O
who O
were O
specially O
trained O
as O
pain O
counselors O
. O

Patients O
were O
randomized O
to O
undergo O
10 O
sessions O
of O
manual O
lymphatic O
drainage O
followed O
by O
10 O
sessions O
of O
low-frequency O
low-intensity O
electrotherapy O
or O
to O
undergo O
first O
low-frequency O
low-intensity O
electrotherapy O
followed O
by O
manual O
lymphatic O
drainage O
. O

Three O
hundred O
three O
patients O
were O
randomized O
to O
DOX O
50 O
mg/m O
( O
2 O
) O
intravenously O
( O
IV O
) O
on O
day O
1 O
and O
VNB O
25 O
mg/m O
( O
2 O
) O
IV O
on O
days O
1 O
and O
8 O
( O
arm O
1 O
) O
or O
DOX O
70 O
mg/m O
( O
2 O
) O
IV O
on O
day O
1 O
( O
arm O
2 O
) O
. O

Subgroup O
analyses O
were O
conducted O
to O
identify O
characteristics O
of O
patients O
deriving O
the O
greatest O
clinical O
benefit O
. O

A O
total O
of O
157 O
patients O
with O
stage O
IIIB O
or O
IV O
NSCLC O
who O
had O
received O
no O
prior O
chemotherapy O
were O
randomly O
assigned O
to O
receive O
either O
best O
supportive O
care O
alone O
( O
78 O
patients O
) O
or O
paclitaxel O
plus O
supportive O
care O
( O
79 O
patients O
) O
. O

186 O
previously O
untreated O
eligible O
patients O
entered O
the O
study O
. O

Twenty-three O
moderately O
malnourished O
patients O
with O
gastrointestinal O
carcinomas O
were O
randomized O
to O
receive O
either O
a O
conventional O
diet O
supplying O
35 O
nonprotein O
kcal O
and O
1.1 O
g O
of O
protein/kg O
per O
day O
( O
group O
A O
, O
n O
= O
11 O
) O
or O
a O
fat-enriched O
artificial O
liquid O
diet O
( O
20 O
nonprotein O
kcal/kg O
per O
day O
) O
plus O
normal O
meals O
( O
group O
B O
, O
n O
= O
12 O
) O
for O
a O
period O
of O
eight O
weeks O
, O
i.e. O
, O
from O
the O
first O
to O
the O
third O
chemotherapy O
cycle O
. O

Future O
exercise O
trials O
targeting O
these O
responsive O
subgroups O
are O
needed O
to O
confirm O
these O
findings O
. O

Treatment O
arms O
were O
compared O
using O
differences O
of O
least O
squares O
mean O
( O
LSM O
) O
changes O
from O
baseline O
and O
95 O
% O
confidence O
intervals O
( O
CIs O
) O
at O
each O
timepoint O
and O
overall O
. O

We O
performed O
a O
prospective O
randomized O
phase O
III O
study O
to O
examine O
whether O
sequential O
administration O
of O
topotecan O
can O
improve O
the O
efficacy O
of O
carboplatin O
and O
paclitaxel O
in O
first-line O
treatment O
of O
advanced O
epithelial O
ovarian O
cancer O
. O

EORTC O
QLQ-C30 O
was O
administered O
at O
screening O
, O
on O
day O
1 O
of O
each O
cycle O
, O
at O
the O
end-of-treatment O
visit O
, O
and O
every O
8 O
wk O
until O
progression O
. O

A O
total O
of O
72 O
NSCLC O
study O
subjects O
with O
MPE O
were O
randomly O
assigned O
to O
one O
of O
two O
groups O
. O

Histology O
, O
marker O
values O
, O
and O
disease O
extent O
are O
well O
balanced O
in O
the O
treatment O
arms O
of O
the O
two O
comparisons O
. O

EORTC-QLQ O
and O
ASES-tests O
were O
performed O
to O
assess O
the O
quality O
of O
life O
before O
and O
after O
6 O
week-treatment O
. O

This O
trial O
is O
registered O
with O
the O
Netherlands O
Trial O
Register O
, O
NTR O
TC O
2452 O
. O

Median O
follow-up O
was O
5.2 O
years O
( O
range O
, O
3.2 O
to O
6.5 O
years O
) O
. O

Estramustine O
was O
given O
orally O
, O
280 O
mg O
twice O
daily O
, O
as O
soon O
as O
the O
diagnosis O
was O
established O
, O
during O
and O
after O
the O
radiotherapy O
for O
a O
period O
of O
in O
total O
3 O
months O
. O

Between O
May O
2003 O
and O
March O
2006 O
, O
107 O
patients O
were O
accrued O
";" O
46 O
had O
limited O
disease O
and O
61 O
extensive O
disease O
. O

We O
aimed O
at O
investigating O
the O
efficacy O
, O
tolerability O
, O
and O
quality O
of O
life O
( O
QOL O
) O
of O
gemcitabine O
( O
GEM O
) O
compared O
with O
pegylated O
liposomal O
doxorubicin O
( O
PLD O
) O
in O
the O
salvage O
treatment O
of O
recurrent O
ovarian O
cancer O
. O

Shoulder O
range O
of O
motion O
, O
strength O
, O
arm O
circumference O
, O
and O
quality O
of O
life O
measurements O
were O
taken O
prior O
to O
, O
and O
at O
completion O
of O
radiotherapy O
, O
and O
at O
7 O
months O
after O
radiotherapy O
. O

The O
aim O
was O
to O
rule O
out O
a O
5 O
% O
decrease O
in O
the O
2-year O
progression-free O
survival O
( O
PFS O
) O
rate O
. O

N O
, O
N-diethyl-2- O
[ O
-4 O
( O
phenylmethyl O
) O
phenoxy O
] O
ethanamine O
( O
DPPE O
";" O
tesmilifene O
) O
is O
a O
novel O
agent O
that O
augments O
chemotherapy O
cytotoxicity O
in O
vitro O
and O
in O
vivo O
. O

Few O
intervention O
studies O
have O
been O
conducted O
to O
help O
couples O
manage O
the O
effects O
of O
prostate O
cancer O
and O
maintain O
their O
quality O
of O
life O
. O

A O
total O
of O
103 O
patients O
with O
gastric O
cancer O
were O
prospectively O
randomly O
divided O
into O
groups O
for O
RY O
( O
n O
= O
51 O
) O
or O
INT O
reconstruction O
( O
n O
= O
52 O
) O
after O
total O
gastrectomy O
. O

The O
primary O
outcome O
was O
overall O
survival O
. O

All O
patients O
were O
followed O
for O
a O
median O
of O
48 O
( O
6-108 O
) O
months O
. O

Multicentre O
, O
randomised O
, O
placebo O
controlled O
, O
double O
blind O
trial O
. O

Fifty-one O
of O
84 O
couples O
randomized O
to O
treatment O
completed O
the O
intervention O
( O
61 O
% O
) O
. O

This O
randomized O
phase O
II O
study O
compared O
two O
treatment O
schedules O
of O
gemcitabine O
in O
patients O
with O
non-small-cell O
lung O
cancer O
( O
NSCLC O
) O
and O
impaired O
Karnofsky O
performance O
status O
( O
KP O
) O
. O

Participants O
in O
both O
groups O
were O
reviewed O
by O
the O
physical O
therapist O
on O
a O
weekly O
basis O
for O
approximately O
6 O
weeks O
, O
and O
were O
given O
general O
information O
about O
skin O
care O
and O
lymphedema O
. O

PORTEC-2 O
accrued O
427 O
patients O
between O
2002 O
and O
2006 O
, O
of O
whom O
214 O
were O
randomly O
assigned O
to O
EBRT O
, O
and O
213 O
were O
randomly O
assigned O
to O
VBT O
. O

Symptoms O
were O
categorized O
as O
none O
, O
mild O
, O
moderate O
, O
or O
severe O
. O

Cognitive O
and O
behavioural O
techniques O
are O
not O
yet O
well O
established O
in O
France O
. O

Three O
years O
after O
treatment O
, O
a O
second O
questionnaire O
was O
sent O
to O
the O
175 O
patients O
with O
adequate O
follow-up O
. O

Vasomotor O
symptoms O
are O
common O
adverse O
effects O
of O
antiestrogen O
hormone O
treatment O
in O
conventional O
breast O
cancer O
care O
. O

We O
report O
on O
the O
quality O
of O
life O
( O
QOL O
) O
outcomes O
for O
this O
trial O
. O

The O
purpose O
of O
this O
article O
is O
to O
compare O
quality O
of O
life O
( O
QOL O
) O
and O
menopausal O
symptoms O
among O
premenopausal O
patients O
with O
lymph O
node-negative O
breast O
cancer O
receiving O
chemotherapy O
, O
goserelin O
, O
or O
their O
sequential O
combination O
, O
and O
to O
investigate O
differential O
effects O
by O
age O
. O

Primary O
endpoint O
was O
overall O
survival O
";" O
secondary O
endpoints O
were O
disease-free O
survival O
, O
response O
rate O
, O
toxicity O
, O
and O
quality O
of O
life O
. O

Of O
those O
, O
34 O
consented O
to O
random O
assignment O
, O
62 O
chose O
RP O
, O
and O
94 O
chose O
BT O
. O

Our O
objective O
was O
to O
examine O
the O
effects O
of O
an O
oncologist O
's O
recommendation O
to O
exercise O
on O
self-reported O
exercise O
behavior O
in O
newly O
diagnosed O
breast O
cancer O
survivors O
attending O
their O
first O
adjuvant O
therapy O
consultation O
. O

Only O
patients O
over O
5 O
years O
of O
age O
with O
parameningeal O
disease O
and O
patients O
over O
12 O
years O
with O
tumours O
at O
any O
site O
were O
given O
systematic O
irradiation O
. O

The O
Intergroup O
conducted O
this O
breast O
cancer O
adjuvant O
trial O
to O
compare O
an O
investigational O
16-week O
regimen O
with O
cyclophosphamide O
, O
doxorubicin O
, O
and O
fluorouracil O
( O
5-FU O
";" O
CAF O
) O
. O

Fifty O
GI O
cancer O
patients O
received O
postoperative O
7 O
days O
of O
isocaloric O
and O
isonitrogenous O
TPN O
after O
operation O
. O

Fifty-one O
patients O
with O
T2 O
, O
N0/N1 O
, O
M0 O
NPC O
took O
part O
in O
a O
randomized O
controlled O
clinical O
study O
and O
received O
IMRT O
or O
CRT O
. O

The O
authors O
conducted O
a O
prospective O
randomized O
study O
in O
which O
45 O
patients O
, O
each O
harboring O
a O
solitary O
contrast-enhancing O
intracerebral O
tumor O
, O
were O
randomized O
for O
surgery O
with O
or O
without O
neuronavigation O
. O

Survival O
was O
the O
major O
study O
end O
point O
. O

The O
primary O
HRQOL O
scale O
was O
global O
HRQOL O
per O
protocol O
. O

To O
compare O
in O
a O
phase O
III O
study O
the O
safety O
and O
efficacy O
of O
fludarabine O
to O
that O
of O
cyclophosphamide O
, O
vincristine O
, O
and O
prednisone O
( O
CVP O
) O
in O
recurrent O
, O
low-grade O
, O
non-Hodgkin O
's O
lymphoma O
after O
previous O
response O
to O
systemic O
treatment O
. O

Analysis O
was O
completed O
with O
use O
of O
chi O
( O
2 O
) O
analysis O
, O
Fisher O
exact O
tests O
, O
Student O
t O
tests O
, O
and O
analysis O
of O
variance O
as O
appropriate O
. O

Palliation O
was O
defined O
as O
an O
improvement O
of O
one O
point O
or O
more O
in O
the O
categorical O
scale O
. O

Baseline O
characteristics O
, O
including O
LCSS O
scores O
, O
were O
well O
balanced O
between O
groups O
. O

A O
follow-up O
phone O
call O
after O
72 O
h O
addressed O
individualized O
treatment O
content O
and O
pain O
communication O
. O

Compliance O
with O
QoL O
questionnaires O
was O
88 O
% O
. O

Secondary O
end O
points O
were O
progression-free O
and O
overall O
survival O
. O

The O
purpose O
of O
this O
study O
is O
to O
compare O
the O
treatment O
and O
retention O
effects O
between O
standard O
decongestive O
lymphatic O
therapy O
( O
DLT O
) O
combined O
with O
pneumatic O
compression O
( O
PC O
) O
and O
modified O
DLT O
, O
in O
which O
the O
use O
of O
a O
short-stretch O
bandage O
is O
replaced O
with O
the O
use O
of O
Kinesio O
tape O
( O
K-tape O
) O
combined O
with O
PC O
. O

Participants O
' O
baseline O
demographics O
included O
median O
age O
67 O
years O
( O
interquartile O
range O
62-73 O
) O
, O
60 O
% O
male O
, O
50 O
% O
with O
a O
Karnofsky O
performance O
status O
< O
70 O
";" O
steroid O
usage O
was O
similar O
in O
the O
two O
groups O
";" O
64/75 O
( O
85 O
% O
) O
received O
WBRT O
( O
20 O
Gy O
in O
five O
fractions O
) O
. O

The O
effects O
, O
safety O
, O
and O
QoL O
were O
determined O
and O
analyzed O
. O

Reports O
of O
thrombotic O
events O
in O
other O
epoetin O
trials O
prompted O
an O
unplanned O
safety O
analysis O
after O
70 O
patients O
had O
been O
randomly O
assigned O
( O
33 O
to O
the O
active O
arm O
and O
37 O
to O
the O
placebo O
arm O
) O
. O

The O
aim O
of O
the O
study O
was O
to O
compare O
clinical O
outcomes O
and O
quality O
of O
life O
in O
patients O
undergoing O
surgery O
for O
pilonidal O
disease O
with O
unroofing O
and O
marsupialization O
( O
UM O
) O
or O
rhomboid O
excision O
and O
Limberg O
flap O
( O
RELP O
) O
procedures O
. O

Notably O
, O
ablation O
preparation O
using O
withdrawal O
of O
LT3 O
for O
2 O
weeks O
did O
not O
prevent O
development O
of O
profound O
hypothyroidism O
, O
as O
also O
occurred O
when O
LT4 O
alone O
was O
withdrawn O
for O
4 O
weeks O
. O

Despite O
premature O
trial O
closure O
, O
our O
data O
provided O
valuable O
insights O
. O

or O
12 O
months O
( O
p.o O
. O
) O
. O

Patients O
with O
breast O
cancer O
experience O
stress O
and O
anxiety O
related O
to O
their O
diagnosis O
, O
with O
resulting O
lower O
quality O
of O
life O
. O

The O
TAX O
327 O
study O
compared O
docetaxel O
administered O
every O
3 O
weeks O
( O
D3 O
) O
, O
weekly O
docetaxel O
( O
D1 O
) O
, O
and O
mitoxantrone O
( O
M O
) O
, O
each O
with O
prednisone O
( O
P O
) O
, O
in O
1,006 O
men O
with O
metastatic O
hormone-resistant O
prostate O
cancer O
( O
HRPC O
) O
. O

Intervention O
patients O
had O
access O
for O
up O
to O
12 O
months O
to O
a O
depression O
care O
manager O
who O
was O
supervised O
by O
a O
psychiatrist O
and O
a O
primary O
care O
provider O
and O
who O
offered O
education O
, O
care O
management O
, O
support O
of O
antidepressant O
management O
, O
and O
brief O
, O
structured O
psychosocial O
interventions O
including O
behavioral O
activation O
and O
problem-solving O
treatment O
. O

A O
total O
of O
798 O
patients O
with O
International O
Federation O
of O
Gynecology O
and O
Obstetrics O
stage O
IIB-IV O
were O
randomly O
assigned O
to O
receive O
six O
courses O
of O
either O
PT O
or O
TC O
at O
3-week O
intervals O
. O

Seven O
hundred O
fifty-two O
patients O
( O
374 O
QW O
patients O
";" O
378 O
EDS O
patients O
) O
received O
≥1 O
dose O
of O
darbepoetin O
alfa O
and O
were O
included O
in O
the O
analysis O
. O

The O
primary O
end O
point O
was O
overall O
survival O
. O

We O
investigated O
whether O
patient O
preparation O
using O
rhTSH O
was O
comparable O
to O
conventional O
thyroid O
hormone O
withdrawal O
with O
respect O
to O
efficacy O
of O
postsurgical O
remnant O
ablation O
in O
low-risk O
patients O
receiving O
a O
30 O
mCi O
RI O
. O

Between O
April O
28 O
, O
2009 O
, O
and O
June O
23 O
, O
2010 O
, O
patients O
with O
progressive O
, O
metastatic O
castration-resistant O
prostate O
cancer O
were O
enrolled O
into O
a O
multinational O
, O
double-blind O
, O
placebo-controlled O
trial O
. O

Finally O
, O
cancer O
progression O
time O
and O
toxicity O
reaction O
of O
the O
two O
groups O
were O
evaluated O
. O

This O
study O
aimed O
to O
compare O
quality O
of O
life O
( O
QOL O
) O
, O
functional O
outcome O
, O
body O
image O
, O
and O
cosmesis O
after O
hand-assisted O
laparoscopic O
( O
LRP O
) O
versus O
open O
restorative O
proctocolectomy O
( O
ORP O
) O
. O

Administration O
of O
the O
vaccine O
was O
begun O
within O
1 O
to O
2 O
months O
postoperatively O
, O
with O
10 O
inoculations O
given O
over O
6 O
months O
. O

The O
primary O
end O
point O
was O
overall O
survival O
. O

The O
intervention O
was O
delivered O
through O
the O
University O
of O
California O
at O
San O
Diego O
";" O
participants O
received O
ten O
phone O
calls O
over O
the O
course O
of O
the O
16-week O
intervention O
. O

Secondary O
outcomes O
included O
additional O
QOL O
measures O
, O
patient O
satisfaction O
, O
safety O
and O
health O
economics O
. O

Multivariate O
analyses O
were O
performed O
for O
both O
OS O
and O
LRC O
. O

Couples O
were O
randomized O
to O
attend O
four O
sessions O
of O
counseling O
together O
or O
to O
have O
the O
man O
attend O
alone O
. O

Numerous O
studies O
have O
examined O
the O
comorbidity O
of O
depression O
with O
cancer O
, O
and O
some O
have O
indicated O
that O
depression O
may O
be O
associated O
with O
cancer O
progression O
or O
survival O
. O

To O
examine O
the O
effects O
of O
a O
scapula-oriented O
exercise O
on O
upper O
limb O
dysfunction O
in O
breast O
cancer O
survivors O
. O

213 O
cancer O
patients O
with O
different O
diagnoses O
were O
randomised O
into O
an O
intervention O
group O
or O
wait-list O
control O
group O
. O

QUARTZ O
is O
a O
randomised O
, O
non-inferiority O
, O
phase O
III O
trial O
comparing O
OSC O
+ O
WBRT O
versus O
OSC O
in O
patients O
with O
inoperable O
brain O
metastases O
from O
NSCLC O
. O

The O
objective O
of O
the O
study O
was O
to O
determine O
the O
efficacy O
of O
systematic O
feedback O
from O
standardized O
assessment O
tools O
for O
hospice O
patient-caregiver O
dyads O
in O
improving O
hospice O
outcomes O
compared O
with O
the O
usual O
clinical O
practice O
. O

Attrition O
was O
assessed O
in O
terms O
of O
the O
percent O
of O
participants O
who O
failed O
to O
complete O
these O
assessments O
, O
and O
demographic O
, O
psychiatric O
, O
medical O
, O
and O
study-related O
correlates O
of O
attrition O
were O
examined O
for O
the O
participants O
in O
each O
of O
these O
categories O
. O

They O
were O
questioned O
on O
the O
topics O
of O
( O
i O
) O
severity O
of O
pain O
, O
( O
ii O
) O
ease O
of O
swallowing O
, O
( O
iii O
) O
satisfaction O
of O
daily O
activities O
, O
( O
iv O
) O
dependence O
on O
medications O
, O
( O
v O
) O
working O
ability O
, O
( O
vi O
) O
fatigue O
, O
( O
vii O
) O
appetite O
, O
( O
viii O
) O
sociality O
, O
( O
ix O
) O
happiness O
and O
( O
x O
) O
self O
respect O
, O
in O
the O
third O
, O
sixth O
and O
twelfth O
month O
. O

Outcomes O
measured O
at O
baseline O
and O
weeks O
4 O
, O
27 O
, O
and O
52 O
included O
QOL O
( O
Linear O
Analogue O
Self-Assessment O
( O
LASA O
) O
, O
Functional O
Assessment O
of O
Cancer O
Therapy-General O
( O
FACT-G O
) O
) O
and O
mood O
( O
Profile O
of O
Mood O
States O
( O
POMS O
) O
) O
. O

Patients O
were O
randomly O
assigned O
at O
registration O
to O
amifostine O
( O
AM O
) O
500 O
mg O
IV O
four O
times O
per O
week O
or O
no O
AM O
during O
chemoradiotherapy O
. O

Secondary O
endpoints O
were O
quality O
of O
life O
and O
toxicity O
. O

Pain O
severity O
was O
assessed O
using O
the O
Brief O
Pain O
Inventory-Short O
Form O
" O
average O
pain O
" O
item O
with O
0 O
representing O
no O
pain O
and O
10 O
representing O
as O
bad O
as O
can O
be O
imagined O
. O

We O
sought O
the O
extent O
to O
which O
arm O
morbidity O
could O
be O
reduced O
by O
using O
sentinel-lymph-node-based O
management O
in O
women O
with O
clinically O
node-negative O
early O
breast O
cancer O
. O

A O
total O
of O
118 O
patients O
( O
59 O
per O
arm O
) O
were O
randomly O
assigned O
to O
receive O
IFN O
at O
a O
dose O
of O
0.5 O
million O
units O
( O
MU O
) O
given O
subcutaneously O
twice O
daily O
( O
IFN1 O
) O
or O
IFN O
at O
a O
dose O
of O
5 O
MU O
given O
subcutaneously O
daily O
( O
IFN5 O
) O
. O

Molecular O
markers O
to O
predict O
response O
to O
5-fluorouracil O
( O
FU O
) O
-based O
treatment O
of O
recurrent O
or O
metastasised O
colorectal O
cancer O
( O
mCRC O
) O
are O
not O
established O
. O

Isotretinoin O
at O
a O
dose O
of O
20 O
mg O
for O
patients O
< O
or O
= O
73 O
kg O
, O
30 O
mg O
for O
patients O
greater O
than O
73 O
kg O
, O
or O
placebo O
daily O
for O
24 O
months O
. O

It O
is O
, O
however O
, O
unclear O
whether O
the O
size O
and O
location O
of O
incisions O
affect O
body O
image O
and O
QOL O
. O

It O
is O
not O
known O
whether O
low-dose O
radioiodine O
( O
1.1 O
GBq O
[ O
30 O
mCi O
] O
) O
is O
as O
effective O
as O
high-dose O
radioiodine O
( O
3.7 O
GBq O
[ O
100 O
mCi O
] O
) O
for O
treating O
patients O
with O
differentiated O
thyroid O
cancer O
or O
whether O
the O
effects O
of O
radioiodine O
( O
especially O
at O
a O
low O
dose O
) O
are O
influenced O
by O
using O
either O
recombinant O
human O
thyrotropin O
( O
thyrotropin O
alfa O
) O
or O
thyroid O
hormone O
withdrawal O
. O

Adjuvant O
chemotherapy O
for O
early O
stage O
non-small-cell O
lung O
cancer O
( O
NSCLC O
) O
is O
now O
the O
standard O
of O
care O
, O
but O
there O
is O
little O
information O
regarding O
its O
impact O
on O
quality O
of O
life O
( O
QOL O
) O
. O

Three O
hundred O
nine O
patients O
were O
analyzed O
per O
protocol O
( O
gefitinib O
arm O
, O
n O
= O
159 O
";" O
GP O
arm O
, O
n O
= O
150 O
) O
. O

Twenty O
patients O
completed O
the O
study O
. O

Outcomes O
were O
medical O
effects O
, O
quality O
of O
life O
, O
and O
costs O
. O

There O
was O
a O
month O
of O
washout O
time O
between O
treatments O
. O

No O
differences O
between O
groups O
were O
observed O
, O
with O
the O
exception O
of O
PCS O
scores O
at O
6-week O
follow-up O
: O
Patients O
in O
the O
UAE O
group O
had O
significantly O
better O
scores O
than O
did O
patients O
in O
the O
hysterectomy O
group O
( O
P O
< O
.001 O
) O
. O

Intensity O
of O
service O
did O
not O
differ O
between O
the O
2 O
groups O
. O

Patients O
received O
six O
cycles O
of O
either O
gemcitabine-carboplatin O
or O
carboplatin O
. O

To O
compare O
short- O
and O
long-term O
effects O
of O
adjuvant O
treatment O
versus O
observation O
after O
surgery O
on O
health-related O
quality O
of O
life O
( O
HRQL O
) O
of O
prostate O
cancer O
patients O
. O

Analysis O
was O
by O
intent O
to O
treat O
. O

Attendance O
by O
the O
partner O
did O
not O
affect O
outcomes O
. O

Those O
in O
the O
treatment O
group O
additionally O
took O
FJD O
, O
50 O
-100 O
mL O
each O
time O
, O
twice O
daily O
. O

Chemonaive O
Taiwanese O
patients O
aged O
70 O
years O
or O
older O
who O
had O
advanced O
NSCLC O
were O
randomized O
to O
receive O
either O
oral O
erlotinib O
150 O
mg O
( O
E O
) O
daily O
or O
oral O
vinorelbine O
60 O
mg/m O
( O
V O
) O
on O
days O
1 O
and O
8 O
every O
3 O
weeks O
. O

At O
disease O
progression O
, O
temozolomide O
salvage O
treatment O
was O
given O
to O
161 O
of O
282 O
patients O
( O
57 O
% O
) O
in O
the O
radiotherapy O
alone O
arm O
, O
and O
to O
62 O
of O
277 O
patients O
( O
22 O
% O
) O
in O
the O
temozolomide O
+ O
radiotherapy O
arm O
. O

Effects O
varied O
by O
intervention O
dose O
. O

The O
immediate O
total O
( O
ie O
, O
> O
90 O
% O
) O
lung O
expansion O
was O
observed O
in O
27 O
patients O
( O
45 O
% O
) O
and O
was O
more O
frequent O
in O
the O
VATS O
group O
( O
60 O
% O
vs O
30 O
% O
, O
respectively O
";" O
p O
= O
0.027 O
) O
. O

To O
evaluate O
the O
analgesic O
effect O
, O
safety O
, O
and O
cost-effectiveness O
of O
controlled-release O
oxycodone O
( O
CRO O
) O
to O
control O
postoperative O
pain O
in O
patients O
with O
liver O
cancer O
who O
are O
undergoing O
transarterial O
chemoembolization O
. O

Differences O
between O
the O
groups O
over O
time O
were O
assessed O
by O
using O
mixed O
modeling O
. O

The O
World O
Health O
Organization O
( O
WHO O
) O
guidelines O
for O
the O
treatment O
of O
cancer O
pain O
recommend O
nonopioid O
analgesics O
as O
first-line O
therapy O
, O
so-called O
" O
weak O
" O
analgesics O
combined O
with O
nonopioid O
analgesics O
as O
second-line O
therapy O
, O
and O
so-called O
" O
strong O
" O
opioids O
( O
with O
nonopioid O
analgesics O
) O
only O
as O
third-line O
therapy O
. O

Previously O
untreated O
patients O
with O
SCLC O
with O
extensive O
disease O
or O
limited O
stage O
with O
poor O
prognostic O
factors O
were O
randomly O
assigned O
to O
six O
3-weekly O
cycles O
of O
GC O
or O
PE O
. O

Women O
with O
ovarian O
cancer O
in O
complete O
remission O
after O
first-line O
platinum-based O
chemotherapy O
and O
a O
normal O
CA125 O
concentration O
were O
registered O
for O
this O
randomised O
controlled O
trial O
. O

Patients O
were O
randomized O
to O
fludarabine O
( O
25 O
mg/m O
( O
2 O
) O
intravenously O
on O
days O
1 O
to O
5 O
, O
every O
28 O
days O
) O
or O
CVP O
( O
cyclophosphamide O
750 O
mg/m O
( O
2 O
) O
and O
vincristine O
1.2 O
mg/m O
( O
2 O
) O
both O
intravenously O
on O
day O
1 O
and O
prednisone O
40 O
mg/m O
( O
2 O
) O
orally O
on O
days O
1 O
to O
5 O
, O
every O
21 O
days O
) O
. O

Differences O
between O
groups O
from O
baseline O
to O
day O
28 O
were O
analyzed O
using O
one-sided O
, O
two-sample O
t O
tests O
or O
Wilcoxon O
two-sample O
tests O
. O

Recruited O
were O
167 O
solid O
tumor O
children O
patients O
at O
Department O
of O
Tumor O
, O
Beijing O
Children O
's O
Hospital O
. O

Thirty O
two O
percent O
of O
women O
randomly O
assigned O
had O
estrogen O
and O
progesterone O
receptor-negative O
breast O
cancer O
, O
42 O
% O
had O
visceral O
metastases O
, O
and O
58 O
% O
had O
bone O
metastases O
. O

We O
performed O
a O
multicenter O
, O
randomized O
controlled O
trial O
examining O
the O
comparative O
effects O
of O
BCAA O
granules O
given O
orally O
for O
3 O
months O
with O
daytime O
or O
nocturnal O
administration O
in O
patients O
with O
compensated O
cirrhosis O
. O

Patients O
without O
prior O
chemotherapy O
for O
metastatic O
disease O
were O
randomly O
assigned O
to O
standard O
combination O
therapy O
with O
doxorubicin O
and O
paclitaxel O
( O
AT O
) O
or O
double O
HDCT O
with O
cyclophosphamide O
, O
mitoxantrone O
, O
and O
etoposide O
followed O
by O
peripheral-blood O
stem-cell O
transplantation O
. O

Three O
hundred O
fifty-six O
patients O
( O
178 O
gemcitabine O
plus O
carboplatin O
";" O
178 O
carboplatin O
) O
were O
randomly O
assigned O
. O

The O
statistical O
calculations O
were O
done O
as O
an O
exploratory O
data O
analysis O
. O

They O
were O
randomly O
assigned O
to O
the O
treatment O
group O
( O
83 O
cases O
) O
and O
the O
control O
group O
( O
84 O
cases O
) O
according O
to O
the O
random O
digit O
table O
. O

Between O
May O
2002 O
and O
April O
2004 O
, O
182 O
patients O
with O
advanced O
GIST O
were O
enrolled O
. O

They O
were O
all O
reconstructed O
with O
stomach O
interposition O
through O
the O
retrosternal O
route O
. O

In O
addition O
, O
the O
impact O
of O
the O
treatment O
arms O
on O
the O
main O
metabolic O
and O
inflammatory O
parameters O
, O
including O
C-reactive O
protein O
( O
CRP O
) O
, O
interleukin O
( O
IL O
) O
-6 O
, O
tumor O
necrosis O
factor O
( O
TNF O
) O
-α O
, O
leptin O
, O
reactive O
oxygen O
species O
( O
ROS O
) O
, O
and O
glutathione O
peroxidase O
, O
was O
evaluated O
. O

Cancer O
patients O
with O
baseline O
" O
worst O
pain O
" O
of O
≥4 O
on O
a O
0-10 O
scale O
or O
at O
least O
moderate O
functional O
impairment O
due O
to O
pain O
were O
randomly O
assigned O
to O
TEC O
or O
enhanced O
usual O
care O
( O
EUC O
) O
during O
a O
telephone O
interview O
conducted O
in O
advance O
of O
a O
planned O
oncology O
office O
visit O
( O
265 O
patients O
randomized O
to O
TEC O
or O
EUC O
";" O
258 O
completed O
at O
least O
one O
follow-up O
) O
. O

A O
further O
aim O
was O
to O
investigate O
the O
role O
of O
high-dose O
chemotherapy O
in O
young O
patients O
with O
parameningeal O
primary O
tumours O
. O

Breast O
and O
prostate O
cancer O
survivors O
( O
N O
= O
543 O
) O
from O
39 O
US O
states O
and O
two O
Canadian O
provinces O
participated O
in O
the O
FRESH O
START O
intervention O
trial O
. O

The O
initial O
treatment O
consisted O
of O
taking O
1 O
capsule O
daily O
of O
either O
30 O
mg O
of O
duloxetine O
or O
placebo O
for O
the O
first O
week O
and O
2 O
capsules O
of O
either O
30 O
mg O
of O
duloxetine O
or O
placebo O
daily O
for O
4 O
additional O
weeks O
. O

At O
a O
median O
follow-up O
of O
56 O
months O
, O
there O
were O
more O
locoregional O
recurrences O
in O
the O
SLN O
arm O
, O
and O
the O
5-year O
disease-free O
survival O
was O
89.9 O
% O
in O
the O
ALND O
arm O
and O
87.6 O
% O
in O
the O
SLN O
arm O
, O
with O
a O
difference O
of O
2.3 O
% O
( O
95 O
% O
confidence O
interval O
: O
-3.1 O
% O
to O
7.6 O
% O
) O
. O

Women O
with O
platinum-pretreated O
epithelial O
ovarian O
cancer O
and O
measurable O
recurrent O
disease O
were O
randomized O
in O
a O
bifactorial O
design O
to O
receive O
either O
175 O
or O
135 O
mg/m2 O
of O
Taxol O
over O
either O
24 O
or O
3 O
hours O
. O

The O
combination O
of O
radiotherapy O
plus O
long-term O
medical O
suppression O
of O
androgens O
( O
> O
or O
= O
2 O
years O
) O
improves O
overall O
survival O
in O
patients O
with O
locally O
advanced O
prostate O
cancer O
. O

QOL O
outcomes O
were O
assessed O
using O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
( O
EORTC O
) O
QOL O
questionnaire O
( O
QLQ-C30 O
) O
and O
Head-Neck O
module O
( O
HN-35 O
) O
at O
baseline O
( O
pre-treatment O
) O
and O
subsequently O
periodically O
on O
follow-up O
. O

Patients O
with O
measurable/evaluable O
HER2-positive O
LR/MBC O
who O
had O
not O
received O
trastuzumab O
or O
chemotherapy O
for O
LR/MBC O
were O
stratified O
by O
prior O
adjuvant O
trastuzumab O
, O
prior O
( O
neo O
) O
adjuvant O
taxane O
, O
hormone O
receptor O
status O
, O
and O
measurable O
disease O
and O
were O
randomly O
assigned O
to O
receive O
docetaxel O
100 O
mg/m O
( O
2 O
) O
plus O
trastuzumab O
8 O
mg/kg O
loading O
dose O
followed O
by O
6 O
mg/kg O
either O
with O
bevacizumab O
15 O
mg/kg O
or O
without O
bevacizumab O
, O
all O
administered O
every O
3 O
weeks O
. O

Opioid O
doses O
, O
pain O
intensity O
, O
adverse O
effects O
, O
symptomatic O
drugs O
, O
were O
recorded O
at O
week O
intervals O
for O
4 O
weeks O
. O

This O
randomized O
phase O
III O
trial O
evaluated O
the O
efficacy O
and O
safety O
of O
docetaxel O
versus O
vinorelbine O
( O
the O
current O
standard O
treatment O
) O
in O
elderly O
patients O
. O

Two O
hundred O
eighty-four O
patients O
were O
included O
in O
this O
side O
study O
( O
MP O
, O
n=149 O
";" O
MPT O
n=135 O
) O
. O

This O
study O
included O
three O
groups O
of O
patients O
, O
enrolled O
consecutively O
. O

Endpoints O
were O
survival O
, O
safety O
, O
efficacy O
, O
and O
quality O
of O
life O
. O

Between O
May O
2003 O
and O
April O
2004 O
, O
98 O
patients O
in O
response O
or O
stable O
disease O
under O
imatinib O
reached O
more O
than O
1 O
year O
of O
follow-up O
. O

A O
total O
of O
769 O
patients O
were O
randomized O
to O
EXE O
25 O
mg/d O
( O
n O
= O
366 O
) O
or O
MA O
( O
n O
= O
403 O
) O
40 O
mg O
four O
times O
daily O
. O

The O
finding O
of O
a O
decrease O
in O
contralateral O
breast O
cancer O
incidence O
following O
tamoxifen O
administration O
for O
adjuvant O
therapy O
led O
to O
the O
concept O
that O
the O
drug O
might O
play O
a O
role O
in O
breast O
cancer O
prevention O
. O

Patients O
randomized O
to O
oral O
nutrition O
only O
served O
as O
control O
subjects O
. O

We O
have O
recently O
suggested O
that O
bolus O
5-fluorouracil O
( O
5-FU O
) O
may O
work O
via O
a O
RNA O
directed O
mechanism O
while O
continuous O
infusion O
5-FU O
may O
kill O
cells O
via O
a O
thymidylate O
synthase O
related O
pathway O
. O

In O
this O
study O
, O
the O
authors O
examined O
personal O
and O
clinical O
factors O
that O
may O
predict O
exercise O
training O
responses O
. O

Patients O
with O
depressive O
symptoms O
were O
randomized O
to O
a O
daily O
oral O
fluoxetine O
or O
a O
placebo O
. O

Patients O
with O
completely O
resected O
primary O
tumour O
received O
three O
courses O
of O
IVA O
( O
ifosfamide O
, O
vincristine O
and O
actinomycin O
D O
) O
. O

This O
study O
provides O
prospective O
data O
on O
how O
multiple O
dosing O
regimens O
available O
with O
darbepoetin O
alfa O
can O
be O
synchronized O
with O
chemotherapy O
administered O
across O
a O
range O
of O
dosing O
schedules O
. O

Cancer O
cells O
rely O
on O
angiogenesis O
for O
growth O
and O
dissemination O
, O
and O
small O
cell O
lung O
cancer O
( O
SCLC O
) O
is O
a O
highly O
angiogenic O
tumor O
. O

At O
baseline O
, O
groups O
were O
comparable O
for O
age O
( O
mean O
, O
61 O
years O
) O
, O
sex O
( O
54 O
% O
men O
) O
, O
weight O
loss O
( O
32 O
% O
> O
or O
= O
10 O
% O
) O
, O
PS O
( O
13 O
% O
ECOG O
= O
2 O
) O
, O
antineoplastic O
treatment O
( O
50 O
% O
) O
, O
appetite O
( O
mean O
VAS O
score O
, O
31/100 O
mm O
) O
, O
and O
QOL O
( O
mean O
score O
, O
30/100 O
) O
. O

Doses O
for O
patients O
aged O
more O
than O
65 O
years O
were O
15 O
mg O
( O
first O
3 O
days O
) O
and O
30 O
mg O
( O
3 O
days O
after O
) O
. O

Twenty-six O
patients O
with O
head O
and O
neck O
cancer O
receiving O
CRT O
. O

5 O
significance O
level O
. O

The O
control O
group O
was O
instructed O
to O
perform O
the O
self-management O
treatment O
. O

To O
describe O
the O
Food O
and O
Drug O
Administration O
( O
FDA O
) O
review O
and O
approval O
of O
erlotinib O
( O
Tarceva O
, O
OSI O
Pharmaceuticals O
, O
Melville O
, O
NY O
) O
for O
treatment O
of O
patients O
with O
locally O
advanced O
or O
metastatic O
non-small O
cell O
lung O
cancer O
( O
NSCLC O
) O
after O
failure O
of O
at O
least O
one O
prior O
chemotherapy O
regimen O
. O

The O
primary O
end O
point O
of O
the O
study O
was O
the O
time O
to O
development O
of O
severe O
mucositis O
from O
the O
start O
of O
radiotherapy O
. O

Women O
in O
the O
writing O
group O
wrote O
for O
20 O
min O
on O
four O
consecutive O
days O
. O

Eighteen O
patients O
underwent O
conventional O
treatment O
( O
surgery O
, O
radiotherapy O
, O
and O
chemotherapy O
) O
and O
received O
adjuvant O
autologous O
dendritic O
cell O
vaccine O
, O
and O
16 O
patients O
( O
control O
group O
) O
underwent O
conventional O
treatment O
only O
. O

This O
study O
tested O
hyperbaric O
oxygen O
( O
HBO O
) O
as O
an O
adjunct O
to O
surgery O
and O
antibiotics O
in O
the O
treatment O
of O
bisphosphonate-related O
osteonecrosis O
of O
the O
jaw O
( O
ONJ O
) O
and O
evaluated O
its O
effects O
on O
gingival O
healing O
, O
pain O
, O
and O
quality O
of O
life O
. O

An O
additional O
281 O
men O
were O
included O
in O
a O
population-based O
control O
group O
matched O
for O
region O
and O
age O
. O

Key O
trial O
variables O
monitored O
monthly O
were O
TPV O
( O
primary O
endpoint O
) O
, O
serum O
testosterone O
, O
prostate-specific O
antigen O
( O
PSA O
) O
, O
the O
International O
Prostate O
Symptom O
Score O
( O
IPSS O
) O
and O
the O
Benign O
Prostate O
Hyperplasia O
Impact O
Index O
. O

Five O
, O
five O
, O
and O
four O
patients O
, O
treated O
with O
oral O
morphine O
, O
transdermal O
fentanyl O
, O
and O
oral O
methadone O
, O
respectively O
, O
required O
opioid O
switching O
. O

GE/G O
median O
OS O
was O
5.6/5.1 O
months O
";" O
median O
PFS O
was O
3.4/3.0 O
months O
. O

194 O
women O
representative O
of O
the O
breast O
cancer O
population O
were O
randomised O
to O
the O
FtF O
( O
n O
= O
67 O
) O
, O
Tel O
( O
n O
= O
67 O
) O
and O
UC O
( O
n O
= O
60 O
) O
groups O
. O

The O
minimum O
follow-up O
time O
was O
5.2 O
years O
for O
the O
surviving O
patients O
. O

The O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
Questionnaire O
C30 O
( O
EORTC O
QLQ-C30 O
) O
and O
the O
gastric O
module O
STO22 O
were O
administered O
every O
8 O
weeks O
until O
progression O
. O

A O
specifically O
designed O
questionnaire O
was O
administered O
at O
three O
months O
to O
assess O
time O
from O
the O
operation O
until O
the O
patient O
was O
able O
to O
walk O
, O
return O
to O
daily O
activities O
, O
or O
sit O
without O
pain O
, O
time O
to O
return O
to O
work O
or O
school O
, O
and O
time O
to O
healing O
. O

Hazard O
ratios O
( O
HRs O
) O
with O
95 O
% O
confidence O
intervals O
( O
CIs O
) O
were O
estimated O
using O
a O
Cox O
proportional O
hazards O
model O
. O

Bootstrap O
simulations O
( O
10,000 O
iterations O
) O
were O
conducted O
to O
account O
for O
uncertainty O
, O
and O
sensitivity O
analyses O
were O
conducted O
to O
establish O
robustness O
. O

Baseline O
HRQOL O
scores O
did O
not O
differ O
between O
groups O
. O

Patients O
with O
acute O
lymphoblastic O
leukemia O
( O
ALL O
) O
, O
lymphoblastic O
lymphoma O
( O
LL O
) O
, O
or O
Burkitt O
lymphoma O
( O
BL O
) O
who O
were O
receiving O
frontline O
myelosuppressive O
chemotherapy O
were O
randomized O
to O
receive O
epoetin O
alpha O
or O
no O
epoetin O
during O
the O
first O
6 O
cycles O
of O
their O
planned O
chemotherapy O
. O

Randomized O
controlled O
trial O
conducted O
from O
November O
2003 O
through O
May O
2008 O
of O
322 O
patients O
with O
advanced O
cancer O
in O
a O
rural O
, O
National O
Cancer O
Institute-designated O
comprehensive O
cancer O
center O
in O
New O
Hampshire O
and O
affiliated O
outreach O
clinics O
and O
a O
VA O
medical O
center O
in O
Vermont O
. O

A O
societal O
cost-utility O
analysis O
was O
performed O
on O
a O
Dutch O
randomized O
, O
controlled O
trial O
of O
1157 O
patients O
with O
painful O
bone O
metastases O
that O
compared O
pain O
responses O
and O
quality O
of O
life O
from O
a O
single-fraction O
treatment O
schedule O
of O
8 O
Gy O
with O
a O
treatment O
schedule O
of O
six O
fractions O
of O
4 O
Gy O
each O
. O

To O
test O
this O
hypothesis O
, O
the O
National O
Surgical O
Adjuvant O
Breast O
and O
Bowel O
Project O
initiated O
the O
Breast O
Cancer O
Prevention O
Trial O
( O
P-1 O
) O
in O
1992 O
. O

All O
statistical O
tests O
were O
two-sided O
. O

Lymphedema O
was O
assessed O
by O
arm O
circumference O
and O
measurement O
of O
arm O
volume O
by O
water O
displacement O
. O

Continence O
scoring O
, O
anorectal O
manometry O
, O
and O
endoanal O
ultrasound O
assessments O
were O
made O
before O
surgery O
. O

Two O
promising O
approaches O
to O
address O
this O
include O
dance/movement O
therapy O
and O
mindfulness O
. O

The O
program O
consisted O
of O
two O
90-minute O
group O
training O
sessions O
, O
a O
brief O
individual O
session O
, O
and O
3 O
follow-up O
telephone O
calls O
. O

QoL O
was O
the O
first O
endpoint O
and O
the O
statistical O
power O
was O
inadequate O
to O
assess O
other O
parameters O
. O

Only O
34 O
% O
( O
39/116 O
) O
received O
intensive O
local O
therapy O
defined O
as O
radical O
wide O
field O
radiotherapy O
or O
radical O
surgery O
or O
both O
. O

Gemcitabine O
( O
G O
) O
is O
standard O
therapy O
for O
pancreatic O
cancer O
. O

Resilience O
, O
perceived O
stress O
, O
anxiety O
, O
and O
quality O
of O
life O
improved O
at O
12 O
weeks O
in O
the O
active O
but O
not O
the O
control O
arm O
. O

They O
completed O
assessments O
of O
psychosocial O
, O
spiritual O
, O
and O
physical O
well-being O
pretreatment O
, O
midtreatment O
, O
and O
2 O
months O
post-treatment O
. O

In O
a O
prospective O
randomised O
single-centre O
study O
from O
2007 O
to O
2008 O
, O
104 O
patients O
underwent O
oesophagectomy O
for O
cancer O
. O

Psychosocial O
stress O
was O
measured O
using O
the O
Symptoms O
Checklist-90-Revised O
, O
and O
quality O
of O
life O
was O
measured O
using O
the O
Medical O
Outcomes O
Study O
Short-Form O
Health O
Survey O
at O
baseline O
, O
immediately O
post-intervention O
, O
and O
at O
6 O
months O
. O

77 O
adult O
patients O
with O
cancer O
receiving O
moderately O
or O
highly O
emetogenic O
chemotherapy O
agents O
. O

The O
primary O
endpoint O
is O
toxicity O
, O
and O
secondary O
endpoints O
include O
response O
rate O
, O
survival O
outcome O
and O
quality O
of O
life O
( O
QOL O
) O
. O

Patients O
had O
metastatic O
CRC O
and O
one O
of O
the O
following O
characteristics O
: O
age O
> O
or O
= O
65 O
years O
, O
Eastern O
Cooperative O
Oncology O
Group O
performance O
status O
1 O
or O
2 O
, O
serum O
albumin O
< O
or O
= O
3.5 O
g/dL O
, O
or O
prior O
abdominal/pelvic O
radiotherapy O
. O

Further O
investigation O
in O
larger O
numbers O
of O
patients O
is O
warranted O
. O

Topical O
photodynamic O
therapy O
( O
PDT O
) O
with O
aminolevulinic O
acid O
( O
ALA O
) O
and O
5 O
% O
imiquimod O
cream O
are O
effective O
therapies O
for O
the O
treatment O
of O
actinic O
keratoses O
( O
AKs O
) O
, O
but O
no O
split-face O
studies O
directly O
comparing O
these O
treatment O
options O
are O
available O
in O
the O
literature O
. O

We O
explored O
the O
quality O
of O
life O
( O
QoL O
) O
of O
such O
patients O
in O
a O
multicenter O
randomized O
trial O
that O
compared O
vinorelbine O
treatment O
with O
supportive O
care O
alone O
. O

Chemotherapy O
consisted O
of O
intravenous O
( O
i.v O
. O
) O

Stage O
was O
limited O
for O
279 O
patients O
( O
52 O
% O
) O
and O
extensive O
for O
253 O
( O
48 O
% O
) O
. O

The O
effect O
of O
treatment O
was O
measured O
using O
a O
" O
Well-Being O
scale O
" O
, O
with O
the O
difference O
of O
the O
average O
score O
of O
the O
" O
Well-Being O
scale O
" O
on O
day O
10 O
being O
defined O
as O
primary O
and O
that O
on O
day O
5 O
as O
secondary O
endpoint O
. O

To O
prospectively O
evaluate O
and O
compare O
health-related O
quality-of-life O
( O
QOL O
) O
outcomes O
in O
patients O
with O
head-neck O
squamous O
cell O
carcinoma O
randomized O
to O
either O
intensity-modulated O
radiation O
therapy O
( O
IMRT O
) O
or O
three-dimensional O
conformal O
radiotherapy O
( O
3D-CRT O
) O
and O
assess O
serial O
longitudinal O
change O
in O
QOL O
over O
time O
. O

Hot O
flash O
frequency O
and O
severity O
, O
Kupperman O
Menopausal O
Index O
( O
KMI O
) O
, O
Short O
Form O
36 O
( O
SF-36 O
) O
. O

This O
was O
a O
randomized O
, O
double-blind O
, O
parallel-group O
, O
dose-finding O
study O
assessing O
the O
efficacy O
and O
safety O
of O
once-weekly O
epoetin O
beta O
in O
patients O
with O
solid O
tumours O
receiving O
chemotherapy O
. O

Conducted O
in O
small O
groups O
, O
intervention O
sessions O
were O
offered O
weekly O
for O
4 O
months O
and O
followed O
by O
monthly O
sessions O
for O
8 O
months O
. O

This O
double-blind O
, O
placebo-controlled O
study O
randomly O
assigned O
patients O
to O
placebo O
or O
epoetin O
alfa O
( O
Ortho O
Biotech O
, O
Bridgewater O
, O
NJ O
) O
40,000 O
U O
subcutaneous O
weekly O
for O
16 O
weeks O
. O

23 O
centres O
in O
the O
United O
Kingdom O
, O
Ireland O
, O
and O
South O
Africa O
. O

Mixed-effects O
models O
and O
multivariate O
regressions O
were O
used O
to O
examine O
the O
longitudinal O
impact O
of O
the O
intervention O
on O
patient-physician O
communication O
, O
dynamics O
of O
patient-physician O
interaction O
, O
and O
the O
association O
between O
PROs O
and O
the O
content O
of O
clinic O
discussion O
. O

Most O
had O
a O
baseline O
IBDQ-B O
score O
indicating O
moderate-to-severe O
symptoms O
. O

Third-generation O
aromatase O
inhibitors O
, O
such O
as O
letrozole O
, O
provide O
a O
new O
option O
for O
extended O
adjuvant O
hormonal O
therapy O
after O
5 O
years O
of O
tamoxifen O
. O

Symptom O
intensity O
was O
measured O
by O
the O
Edmonton O
Symptom O
Assessment O
Scale O
( O
score O
range O
, O
0-900 O
) O
. O

A O
significant O
barrier O
to O
positive O
pain O
management O
is O
patients O
' O
misconceptions O
regarding O
analgesics O
and O
inadequate O
use O
of O
nonpharmacological O
strategies O
as O
pain O
relief O
. O

Pneumocystis O
carinii O
pneumonia O
prophylaxis O
was O
required O
during O
temozolomide O
+ O
radiotherapy O
treatment O
and O
was O
continued O
until O
recovery O
of O
lymphocytopenia O
( O
Common O
Toxicity O
Criteria O
grade O
< O
1 O
) O
. O

The O
baseline O
characteristics O
( O
with O
the O
exception O
of O
site O
of O
metastases O
) O
were O
balanced O
among O
patients O
with O
CR/PR O
, O
SD O
( O
6m O
) O
, O
and O
progressive O
disease O
( O
PD O
) O
. O

Thirty-one O
posttreatment O
cancer O
survivors O
were O
randomized O
in O
groups O
of O
seven O
to O
nine O
to O
either O
the O
8-week O
III O
+ O
ISG O
intervention O
or O
the O
8-week O
III O
condition O
. O

Lung O
expansion O
was O
evaluated O
through O
chest O
CT O
scans O
obtained O
0 O
, O
1 O
, O
3 O
and O
6 O
months O
after O
pleurodesis O
. O

To O
analyze O
the O
prospectively O
collected O
health-related O
quality-of-life O
( O
HRQOL O
) O
data O
from O
patients O
enrolled O
in O
two O
Radiation O
Therapy O
Oncology O
Group O
randomized O
Phase O
III O
head O
and O
neck O
cancer O
trials O
( O
90-03 O
and O
91-11 O
) O
to O
assess O
their O
value O
as O
an O
independent O
prognostic O
factor O
for O
locoregional O
control O
( O
LRC O
) O
and/or O
overall O
survival O
( O
OS O
) O
. O

Exercise O
for O
Health O
was O
a O
randomized O
, O
controlled O
trial O
designed O
to O
evaluate O
two O
modes O
of O
delivering O
( O
face-to-face O
[ O
FtF O
] O
and O
over-the-telephone O
[ O
Tel O
] O
) O
an O
8-month O
translational O
exercise O
intervention O
, O
commencing O
6-weeks O
post-breast O
cancer O
surgery O
( O
PS O
) O
. O

This O
phase O
III O
study O
was O
performed O
to O
determine O
the O
superiority O
of O
doxorubicin O
( O
DOX O
) O
and O
vinorelbine O
( O
VNB O
) O
( O
arm O
1 O
) O
versus O
DOX O
alone O
( O
arm O
2 O
) O
in O
metastatic O
breast O
cancer O
( O
MBC O
) O
for O
overall O
survival O
( O
OS O
) O
, O
time O
to O
treatment O
failure O
( O
TTF O
) O
, O
toxicity O
, O
and O
quality O
of O
life O
( O
QOL O
) O
. O

In O
both O
arms O
, O
radiotherapy O
was O
delivered O
as O
60 O
Gy/30 O
fractions O
to O
the O
tumor O
site O
with O
a O
2 O
to O
3 O
cm O
margin O
. O

Outpatient O
department O
of O
a O
National O
Health O
Service O
( O
NHS O
) O
homeopathic O
hospital O
. O

Participants O
were O
randomly O
allocated O
to O
receive O
either O
usual O
care O
or O
usual O
care O
plus O
group O
CBT O
( O
1:1 O
) O
. O

We O
evaluated O
the O
effects O
of O
lanreotide O
, O
a O
somatostatin O
analogue O
, O
in O
patients O
with O
polycystic O
liver O
because O
of O
autosomal-dominant O
( O
AD O
) O
PKD O
or O
autosomal-dominant O
polycystic O
liver O
disease O
( O
PCLD O
) O
. O

A O
total O
of O
724 O
patients O
( O
51 O
% O
with O
limited O
and O
49 O
% O
with O
extensive O
disease O
) O
were O
randomly O
assigned O
to O
receive O
placebo O
or O
thalidomide O
capsules O
, O
100-200 O
mg O
daily O
for O
up O
to O
2 O
years O
. O

Patients O
( O
N O
= O
572 O
) O
with O
pretreated O
EGFR-detectable O
advanced O
CRC O
were O
randomly O
assigned O
to O
cetuximab O
and O
best O
supportive O
care O
( O
BSC O
) O
or O
to O
BSC O
alone O
. O

Mood O
was O
measured O
by O
the O
Center O
for O
Epidemiological O
Studies O
Depression O
Scale O
( O
range O
, O
0-60 O
) O
. O

Over O
30 O
% O
of O
patients O
with O
non-small O
cell O
lung O
cancer O
( O
NSCLC O
) O
develop O
brain O
metastases O
. O

In O
this O
part O
of O
our O
study O
, O
a O
blinded O
assessor O
collected O
subjective O
outcomes O
of O
the O
patient O
's O
reported O
measures O
of O
OM O
using O
Oral O
Mucositis O
Weekly O
Questionnaire-Head O
and O
Neck O
( O
OMWQ-HN O
) O
and O
QOL O
using O
Functional O
Assessment O
of O
Cancer O
Treatment-Head O
and O
Neck O
( O
FACT-HN O
) O
Questionnaire O
. O

Drug O
toxicity O
and O
quality O
of O
life O
were O
observed O
. O

Because O
neither O
clinical O
nor O
HRQOL O
outcomes O
differed O
based O
on O
the O
study O
arm O
, O
analyses O
were O
pooled O
. O

Patients O
with O
bone O
metastasis-related O
pain O
at O
Numeric O
Rating O
Scale O
≥4 O
were O
enrolled O
to O
this O
randomized O
placebo-controlled O
trial O
. O

In O
this O
international O
, O
6-month O
, O
open-label O
trial O
, O
patients O
had O
active O
RA O
, O
an O
inadequate O
response O
to O
anti-TNF O
therapy O
for O
3 O
months O
or O
longer O
and O
a O
disease O
activity O
score O
in O
28 O
joints O
( O
DAS28 O
( O
C-reactive O
protein O
";" O
CRP O
) O
of O
5.1 O
or O
greater O
. O

Seven O
days O
of O
diary O
and O
actigraphy O
data O
did O
not O
corroborate O
with O
monthly O
reflections O
( O
PSQI O
) O
. O

Discharged O
patients O
were O
followed-up O
in O
the O
outpatient O
clinic O
. O

infusion O
and O
5-FU O
, O
850 O
mg/m2 O
s O
i.v O
. O

The O
main O
outcome O
measures O
were O
the O
unmet O
supportive O
care O
needs O
, O
health O
service O
utilization O
, O
and O
quality O
of O
life O
at O
1 O
, O
3 O
, O
and O
6 O
months O
postdischarge O
. O

Multicentre O
randomised O
controlled O
trial O
. O

Significance O
was O
set O
at O
alpha O
< O
or O
= O
0.01 O
. O

It O
can O
have O
debilitating O
and O
dose-limiting O
consequences O
. O

Patients O
with O
untreated O
cytologically O
or O
histologically O
proven O
metastatic O
or O
locally O
advanced O
adenocarcinoma O
of O
the O
pancreas O
were O
deemed O
measurable O
or O
evaluable O
. O

Endpoints O
were O
quality O
of O
life O
( O
QoL O
) O
, O
aerobic O
fitness O
, O
muscular O
strength O
, O
lean O
body O
mass O
, O
and O
body O
fat O
. O

The O
treatments O
were O
repeated O
every O
3 O
weeks O
for O
six O
cycles O
";" O
in O
responding O
patients O
, O
an O
additional O
three O
cycles O
of O
single-agent O
carboplatin O
was O
permitted O
. O

Supervised O
12 O
week O
group O
exercise O
programme O
in O
addition O
to O
usual O
care O
, O
compared O
with O
usual O
care O
. O

Data O
of O
299 O
patients O
were O
available O
for O
evaluation O
. O

From O
1984 O
to O
1989 O
, O
the O
Swiss O
Group O
for O
Clinical O
Cancer O
Research O
( O
SAKK O
) O
performed O
a O
randomized O
phase O
III O
trial O
comparing O
early O
versus O
late O
alternating O
chemotherapy O
in O
patients O
with O
small-cell O
lung O
cancer O
. O

Using O
a O
computer-generated O
randomisation O
sequence O
, O
we O
randomly O
allocated O
patients O
to O
one O
of O
three O
groups O
( O
1:1:1 O
";" O
stratified O
by O
tumour O
site O
[ O
urological O
, O
gynaecological O
, O
or O
gastrointestinal O
] O
, O
and O
degree O
of O
bowel O
dysfunction O
[ O
IBDQ-B O
score O
< O
60 O
vs O
60-70 O
] O
) O
: O
usual O
care O
( O
a O
detailed O
self-help O
booklet O
) O
, O
gastroenterologist-led O
algorithm-based O
treatment O
, O
or O
nurse-led O
algorithm-based O
treatment O
. O

In O
445 O
randomly O
assigned O
and O
treated O
patients O
( O
DCF O
= O
221 O
";" O
CF O
= O
224 O
) O
, O
TTP O
was O
longer O
with O
DCF O
versus O
CF O
( O
32 O
% O
risk O
reduction O
";" O
log-rank O
P O
< O
.001 O
) O
. O

A O
body O
image O
questionnaire O
was O
used O
to O
evaluate O
body O
image O
and O
cosmesis O
. O

One O
hundred O
and O
eight O
cancer O
patients O
, O
no O
longer O
responsive O
to O
opioids O
for O
moderate O
pain O
, O
were O
selected O
to O
randomly O
receive O
initial O
daily O
doses O
of O
60 O
mg O
of O
oral O
sustained-release O
morphine O
, O
15 O
mg O
of O
oral O
methadone O
, O
or O
0.6 O
mg O
( O
25 O
microg/h O
) O
of O
transdermal O
fentanyl O
. O

Treosulfan O
, O
an O
alkylating O
agent O
, O
has O
demonstrated O
activity O
in O
recurrent O
ovarian O
carcinoma O
. O

Anxiety O
, O
mood O
, O
pain O
, O
perception O
of O
hospitalization O
or O
procedure O
, O
relaxation O
, O
and O
stress O
were O
measured O
using O
a O
self-report O
Visual O
Analog O
Scale O
( O
VAS O
) O
for O
each O
of O
the O
variables O
. O

Categorical O
data O
were O
compared O
using O
a O
stratified O
Cochran-Mantel-Haenszel O
test O
. O

Sexual O
dysfunction O
represents O
a O
complex O
and O
multifactorial O
construct O
that O
can O
affect O
both O
men O
and O
women O
and O
has O
been O
noted O
to O
often O
deteriorate O
significantly O
after O
treatment O
for O
rectal O
and O
anal O
cancer O
. O

Haemoglobin O
levels O
, O
transfusion O
need O
and O
QoL O
[ O
Functional O
Assessment O
of O
Cancer O
Therapy-fatigue O
( O
FACT-F O
) O
subscale O
score O
] O
were O
assessed O
at O
regular O
intervals O
. O

The O
median O
follow-up O
time O
was O
27.2 O
months O
for O
all O
patients O
and O
49 O
months O
for O
surviving O
patients O
. O

Primary O
objectives O
were O
to O
record O
changes O
from O
baseline O
KP O
and O
to O
assess O
symptom O
palliation O
. O

Follow-up O
examinations O
were O
performed O
12 O
months O
after O
ablation O
to O
assess O
ablation O
outcome O
in O
each O
group O
by O
131 O
whole O
body O
scans O
( O
WBSs O
) O
, O
serum O
thyroglobulin O
measurement O
after O
TSH O
stimulation O
, O
and O
neck O
ultrasonography O
. O

Median O
survival O
time O
was O
19.2 O
months O
( O
95 O
% O
CI O
, O
17.5 O
to O
21.3 O
months O
) O
in O
the O
D3P O
arm O
, O
17.8 O
months O
( O
95 O
% O
CI O
, O
16.2 O
to O
19.2 O
months O
) O
in O
the O
D1P O
arm O
, O
and O
16.3 O
months O
( O
95 O
% O
CI O
, O
14.3 O
to O
17.9 O
months O
) O
in O
the O
MP O
arm O
. O

For O
cost-effectiveness O
, O
the O
incremental O
cost-effectiveness O
ratio O
was O
calculated O
. O

Studies O
have O
shown O
that O
there O
is O
a O
high O
prevalence O
of O
depression O
in O
cancer O
patients O
. O

Between O
April O
1990 O
and O
April O
1994 O
, O
70 O
eligible O
patients O
participated O
in O
a O
phase O
III O
trial O
comparing O
a O
regimen O
containing O
sequential O
chemotherapy O
and O
radiation O
therapy O
versus O
sequential O
chemotherapy O
plus O
surgery O
. O

Costs O
and O
benefits O
were O
jointly O
determined O
for O
the O
stage O
IV O
breast O
cancer O
subgroup O
( O
n O
= O
55 O
) O
. O

Those O
who O
received O
prednisone O
alone O
could O
have O
mitoxantrone O
added O
after O
6 O
weeks O
if O
there O
was O
no O
improvement O
in O
pain O
. O

On O
March O
15 O
, O
2005 O
, O
the O
US O
Food O
and O
Drug O
Administration O
approved O
temozolomide O
( O
Temodar O
capsules O
, O
Schering-Plough O
Research O
Institute O
) O
for O
the O
treatment O
of O
adult O
patients O
with O
newly O
diagnosed O
glioblastoma O
multiforme O
concomitantly O
with O
radiotherapy O
and O
then O
as O
maintenance O
treatment O
. O

Breast O
cancer O
patients O
initiating O
adjuvant O
chemotherapy O
( O
n O
= O
242 O
) O
were O
randomly O
assigned O
to O
usual O
care O
( O
n O
= O
82 O
) O
, O
resistance O
exercise O
training O
( O
RET O
";" O
n O
= O
82 O
) O
, O
or O
aerobic O
exercise O
training O
( O
AET O
";" O
n O
= O
78 O
) O
for O
the O
duration O
of O
their O
chemotherapy O
. O

Post-surgery O
, O
227 O
breast O
cancer O
patients O
were O
randomized O
to O
intervention O
or O
assessment O
only O
Study O
Arms O
. O

Postmenopausal O
women O
aged O
50-69 O
years O
at O
randomisation O
. O

These O
results O
were O
robust O
to O
sensitivity O
analysis O
. O

All O
patients O
were O
given O
supportive O
treatment O
and O
were O
randomised O
to O
receive O
palliative O
thoracic O
radiotherapy O
either O
immediately O
or O
delayed O
until O
needed O
to O
treat O
symptoms O
. O

HRQOL O
data O
were O
not O
collected O
after O
disease O
progression O
. O

Care O
closer O
to O
home O
is O
being O
explored O
as O
a O
means O
of O
improving O
patient O
experience O
as O
well O
as O
efficiency O
in O
terms O
of O
cost O
savings O
. O

Patients O
were O
randomized O
to O
receive O
MVP O
regimen O
( O
Mitomycin-C O
8 O
mg/m2 O
d1 O
, O
Vinblastine O
4 O
mg/m2 O
d O
1-8 O
, O
Cisplatin O
100 O
mg/m2 O
d1 O
) O
or O
MVC O
regimen O
( O
Mitomycin-C O
8 O
mg/m2 O
d1 O
, O
Vinblastine O
4 O
mg/m2 O
d O
1-8 O
, O
Carboplatin O
300 O
mg/m2 O
d1 O
) O
every O
3 O
weeks O
. O

To O
test O
these O
observations O
with O
a O
large O
, O
randomized O
clinical O
trial O
, O
an O
intervention O
that O
significantly O
impacts O
physical O
activity O
in O
these O
patients O
is O
needed O
. O

We O
conducted O
a O
randomized O
pilot O
study O
in O
patients O
treated O
with O
four O
fractions O
of O
lung O
SBRT O
delivered O
over O
4 O
or O
over O
11 O
days O
. O

An O
EGP O
does O
not O
unequivocally O
affect O
positive O
HRQoL O
outcomes O
. O

Thirty-six O
patients O
in O
Study O
A O
received O
bolus O
6S-LV O
, O
100 O
mg/m2 O
, O
followed O
by O
bolus O
5-FU O
, O
370 O
mg/m2 O
, O
on O
Days O
1-5 O
and O
36 O
others O
in O
Study O
B O
received O
epirubicin O
, O
30 O
mg/m2 O
, O
on O
Days O
1 O
and O
5 O
";" O
etoposide O
, O
100 O
mg/m2 O
, O
on O
Days O
1 O
, O
3 O
, O
and O
5 O
";" O
cisplatin O
, O
30 O
mg/m2 O
, O
on O
Days O
2 O
and O
4 O
";" O
and O
lonidamine O
, O
150 O
mg/day O
. O

This O
study O
examined O
how O
PRO O
feedback O
had O
an O
impact O
on O
patient-physician O
communication O
over O
time O
to O
gain O
a O
better O
understanding O
of O
how O
it O
may O
influence O
patient O
care O
. O

postprostatectomy O
SUI O
with O
daily O
incontinent O
episodes O
frequency O
( O
IEF O
) O
of O
four O
or O
greater O
. O

cancer O
survivors O
with O
different O
diagnoses O
, O
and O
cancer-related O
physical O
and O
psychosocial O
problems O
. O

A O
counseling O
intervention O
aimed O
at O
improving O
levels O
of O
sexual O
satisfaction O
and O
increasing O
successful O
utilization O
of O
medical O
treatment O
for O
erectile O
dysfunction O
( O
ED O
) O
was O
developed O
and O
pilot-tested O
for O
both O
the O
survivor O
of O
prostate O
carcinoma O
and O
his O
partner O
. O

The O
most O
likely O
advantage O
of O
LRP O
is O
the O
superior O
cosmetic O
result O
. O

Forty O
patients O
( O
31 O
men O
and O
9 O
women O
) O
were O
enrolled O
and O
received O
3-5 O
courses O
of O
treatment O
. O

Gefitinib O
has O
shown O
high O
response O
rate O
and O
improved O
progression-free O
survival O
( O
PFS O
) O
in O
never-smokers O
with O
lung O
adenocarcinoma O
( O
NSLAs O
) O
. O

Two O
hundred O
eighty-nine O
patients O
were O
assessable O
for O
response O
, O
and O
99 O
responders O
were O
assessable O
for O
response O
duration O
( O
RD O
) O
. O

After O
stratification O
by O
estrogen O
receptor O
( O
ER O
) O
status O
, O
patients O
were O
randomly O
assigned O
to O
receive O
three O
28-day O
courses O
of O
" O
classical O
" O
adjuvant O
CMF O
chemotherapy O
( O
cyclophosphamide O
at O
100 O
mg/m O
( O
2 O
) O
on O
days O
1-14 O
, O
orally O
";" O
methotrexate O
at O
40 O
mg/m O
( O
2 O
) O
on O
days O
1 O
and O
8 O
, O
intravenously O
";" O
and O
5-fluorouracil O
at O
600 O
mg/m O
( O
2 O
) O
on O
days O
1 O
and O
8 O
, O
intravenously O
) O
followed O
by O
tamoxifen O
( O
20 O
mg/day O
, O
orally O
for O
57 O
months O
) O
( O
CMF O
-- O
> O
tamoxifen O
) O
or O
to O
receive O
tamoxifen O
alone O
( O
20 O
mg/day O
, O
orally O
for O
60 O
months O
) O
. O

Secondary O
outcome O
measures O
were O
self-reports O
of O
interference O
of O
hot O
flashes O
on O
daily O
activities O
. O

This O
study O
tested O
the O
efficacy O
of O
a O
caregiver-assisted O
CST O
protocol O
in O
a O
sample O
of O
patients O
with O
lung O
cancer O
. O

To O
test O
the O
equivalence O
of O
three O
versus O
four O
cycles O
of O
bleomycin O
, O
etoposide O
, O
and O
cisplatin O
( O
BEP O
) O
and O
of O
the O
5-day O
schedule O
versus O
3 O
days O
per O
cycle O
in O
good-prognosis O
germ O
cell O
cancer O
. O

Also O
the O
demographic O
data O
, O
operative O
results O
and O
survival O
were O
recorded O
. O

Carry-over O
, O
period O
and O
treatment O
effects O
were O
analysed O
. O

Eligible O
patients O
were O
required O
to O
have O
NSCLC O
unsuitable O
for O
curative O
therapy O
and O
baseline O
hemoglobin O
( O
Hgb O
) O
levels O
less O
than O
121 O
g/L O
. O

All O
patients O
had O
stage O
IV O
or O
relapsed O
disease O
and O
a O
performance O
score O
of O
0 O
or O
1 O
. O

of O
grape O
juice O
or O
placebo O
prior O
to O
meals O
for O
one O
week O
following O
each O
of O
four O
chemotherapy O
treatment O
cycles O
. O

Quality O
of O
life O
was O
assessed O
using O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
Core O
30 O
( O
EORTC O
QLQ-C30 O
) O
questionnaire O
. O

Results O
for O
quality O
of O
life O
, O
symptom O
palliation O
, O
and O
tolerability O
are O
presented O
here O
. O

48 O
patients O
were O
randomised O
( O
supportive O
care O
26 O
, O
chemotherapy O
22 O
) O
, O
being O
eligible O
for O
comparative O
analyses O
. O

Between O
1993 O
and O
2002 O
, O
women O
> O
or O
= O
60 O
years O
old O
with O
clinically O
node-negative O
operable O
breast O
cancer O
in O
whom O
adjuvant O
tamoxifen O
was O
considered O
indicated O
regardless O
of O
pathologic O
nodal O
status O
were O
randomly O
assigned O
to O
primary O
surgery O
plus O
axillary O
clearance O
( O
Sx O
+ O
Ax O
) O
followed O
by O
tamoxifen O
( O
Tam O
) O
versus O
Sx O
without O
Ax O
followed O
by O
Tam O
for O
5 O
consecutive O
years O
. O

The O
primary O
outcome O
for O
both O
interventions O
was O
HRQoL O
, O
measured O
by O
EORTC O
QLQ-C30 O
. O

Gynecological O
neoplastic O
disease O
progression O
is O
characterized O
by O
specific O
energy O
metabolism O
alterations O
and O
by O
symptoms O
including O
fatigue O
, O
anorexia O
, O
nausea O
, O
anemia O
, O
and O
immunodepression O
, O
which O
result O
in O
a O
cachexia O
syndrome O
and O
a O
marked O
decrease O
in O
patient O
quality O
of O
life O
( O
QoL O
) O
. O

The O
applicant O
has O
committed O
to O
conduct O
post-marketing O
clinical O
trials O
to O
assess O
further O
the O
effect O
of O
epidermal O
growth O
factor O
receptor O
expression O
, O
measured O
with O
immunohistochemical O
staining O
, O
on O
erlotinib O
treatment O
effect O
. O

Of O
the O
246 O
patients O
in O
the O
intent-to-treat O
set O
, O
89·4 O
% O
completed O
the O
3-day O
efficacy O
phase O
. O

Between-group O
differences O
in O
change O
from O
baseline O
were O
assessed O
using O
linear O
mixed O
models O
with O
selected O
covariates O
. O

Patients O
in O
the O
IG O
and O
UCG O
were O
comparable O
with O
regard O
to O
demographics O
, O
comorbidities O
, O
cancer O
type O
and O
staging O
, O
type O
of O
resection O
, O
preoperative O
fatigue O
and O
pain O
levels O
, O
adjuvant O
therapy O
, O
and O
baseline O
walking O
distance O
. O

This O
study O
was O
a O
pilot O
randomized O
controlled O
trial O
. O

The O
primary O
end O
point O
was O
progression-free O
survival O
( O
PFS O
) O
. O

Repeated-measures O
analysis O
of O
variance O
done O
on O
an O
intention O
to O
treat O
basis O
. O

Inclusion O
criteria O
were O
an O
age O
of O
18 O
years O
or O
older O
";" O
total O
thyroidectomy O
for O
differentiated O
thyroid O
carcinoma O
";" O
tumor-node-metastasis O
( O
TNM O
) O
stage O
, O
ascertained O
on O
pathological O
examination O
( O
p O
) O
of O
a O
surgical O
specimen O
, O
of O
pT1 O
( O
with O
tumor O
diameter O
≤1 O
cm O
) O
and O
N1 O
or O
Nx O
, O
pT1 O
( O
with O
tumor O
diameter O
> O
1 O
to O
2 O
cm O
) O
and O
any O
N O
stage O
, O
or O
pT2N0 O
";" O
absence O
of O
distant O
metastasis O
";" O
and O
no O
iodine O
contamination O
. O

We O
compared O
fulvestrant O
500 O
mg O
regimen O
with O
the O
approved O
dose O
of O
fulvestrant O
250 O
mg O
per O
month O
for O
treatment O
of O
postmenopausal O
women O
with O
estrogen O
receptor-positive O
advanced O
breast O
cancer O
who O
experienced O
progression O
after O
prior O
endocrine O
therapy O
. O

A O
multicenter O
randomized O
controlled O
trial O
was O
performed O
to O
assess O
the O
role O
of O
high-dose O
TMX O
versus O
placebo O
( O
P O
) O
in O
the O
treatment O
of O
patients O
with O
inoperable O
HCC O
with O
respect O
to O
survival O
and O
quality O
of O
life O
( O
QoL O
) O
. O

The O
study O
group O
joined O
a O
weekly O
session O
of O
ALT O
for O
3 O
months O
in O
addition O
to O
the O
self-management O
therapy O
. O

The O
main O
outcomes O
were O
self-reported O
severity O
of O
facial O
hair O
( O
measured O
on O
a O
scale O
of O
1-10 O
) O
, O
depression O
, O
anxiety O
( O
measured O
on O
the O
Hospital O
Anxiety O
and O
Depression O
Scale O
) O
and O
quality O
of O
life O
( O
measured O
on O
the O
WHOQOL-BREF O
) O
. O

The O
primary O
end O
points O
were O
body O
image O
and O
cosmesis O
. O

One O
hundred O
thirty-two O
anemic O
cancer O
patients O
receiving O
cyclic O
, O
cisplatin-containing O
, O
myelosuppressive O
chemotherapy O
were O
evaluated O
. O

Although O
numerous O
treatment O
modalities O
have O
been O
explored O
in O
patients O
with O
advanced O
HCC O
, O
the O
therapeutic O
options O
are O
still O
limited O
. O

Paclitaxel O
and O
pegylated O
liposomal O
doxorubicin O
( O
PLD O
) O
are O
active O
cytotoxic O
agents O
for O
the O
treatment O
of O
human O
immunodeficiency O
virus O
( O
HIV O
) O
-associated O
Kaposi O
sarcoma O
( O
KS O
) O
. O

Each O
patient O
was O
examined O
just O
before O
and O
after O
each O
treatment O
. O

Intravenous O
5-FU O
and O
oral O
doxifluridine O
were O
compared O
with O
respect O
to O
therapeutic O
efficacy O
, O
drug O
toxicity O
, O
and O
quality O
of O
life O
. O

Arm O
circumferences O
were O
measured O
before O
and O
the O
1st O
, O
3rd O
, O
and O
6th O
weeks O
of O
the O
treatment O
. O

Demographics O
and O
disease O
state O
were O
similar O
between O
groups O
. O

Thirty-two O
women O
with O
breast O
cancer O
were O
randomly O
assigned O
to O
scapula-oriented O
exercise O
group O
( O
n O
= O
16 O
) O
and O
general O
exercise O
group O
( O
n O
= O
16 O
) O
. O

Newly O
diagnosed O
advanced O
cancer O
patients O
undergoing O
radiation O
therapy O
were O
randomized O
to O
active O
QOL O
intervention O
or O
control O
groups O
. O

The O
authors O
conducted O
a O
randomized O
study O
to O
confirm O
the O
effectiveness O
and O
safety O
of O
treatment O
of O
CACS O
utilizing O
megestrol O
acetate O
( O
MA O
) O
plus O
thalidomide O
. O

A O
non-randomised O
cohort O
was O
also O
recruited O
, O
in O
order O
to O
complete O
a O
comprehensive O
cohort O
study O
. O

BMD O
of O
48 O
patients O
were O
analyzed O
";" O
23 O
belongs O
to O
group O
A O
, O
10 O
to O
group O
B O
and O
15 O
to O
group O
C. O
The O
serum O
bone O
turnover O
proteins O
bone-specific O
alkaline O
phosphatase O
( O
BAP O
) O
and O
carboxyterminal O
crosslinked O
telopeptide O
of O
type O
I O
collagen O
( O
ICTP O
) O
, O
were O
measured O
with O
commercially O
available O
test O
kits O
before O
treatment O
, O
3 O
months O
and O
15 O
months O
after O
treatment O
. O

A O
total O
of O
168 O
patients O
with O
rectal O
cancer O
were O
randomly O
assigned O
to O
laparoscopic O
( O
n O
= O
83 O
) O
or O
open O
( O
n O
= O
85 O
) O
resection O
. O

The O
primary O
outcome O
was O
quality O
of O
life O
at O
1 O
year O
of O
follow-up O
, O
as O
measured O
by O
the O
Medical O
Outcomes O
Study O
36-Item O
Short-Form O
General O
Health O
Survey O
( O
SF-36 O
) O
. O

There O
was O
no O
difference O
of O
sex O
between O
two O
groups O
( O
IV O
arm O
: O
male/female O
= O
45/29 O
, O
oral O
arm O
: O
male/female O
= O
59/33 O
) O
. O

Dose O
escalation O
was O
achieved O
in O
77 O
% O
of O
patients O
who O
had O
≥1 O
cycle O
. O

Tumour-related O
symptoms O
were O
present O
in O
134 O
( O
71 O
% O
) O
patients O
and O
weight O
loss O
of O
more O
than O
5 O
% O
was O
seen O
in O
15 O
( O
8 O
% O
) O
patients O
. O

infusion O
and O
5-FU O
, O
1050 O
mg/m2 O
i.v O
. O

Three-hundred O
forty-eight O
patients O
( O
81 O
% O
) O
were O
evaluable O
for O
QOL O
. O

A O
10-point O
change O
in O
QOL O
scores O
from O
baseline O
was O
considered O
clinically O
significant O
. O

We O
have O
compared O
an O
alternating O
regimen O
of O
bolus O
and O
continuous O
infusion O
5-FU O
, O
selectively O
modulated O
for O
the O
schedule O
of O
administration O
, O
with O
modulated O
bolus O
5-FU O
in O
advanced O
colorectal O
cancer O
patients O
. O

QOL O
variables O
related O
to O
survival O
were O
baseline O
support O
( O
P O
= O
0.001 O
) O
and O
baseline O
outlook O
( O
P O
= O
0.01 O
) O
. O

Peri- O
and O
postoperative O
parameters O
under O
investigation O
included O
the O
following O
: O
duration O
of O
the O
procedure O
";" O
surgeon O
's O
estimate O
of O
the O
usefulness O
of O
neuronavigation O
";" O
quantification O
of O
the O
extent O
of O
resection O
, O
determined O
using O
magnetic O
resonance O
imaging O
";" O
and O
the O
postoperative O
course O
, O
as O
evaluated O
by O
neurological O
examinations O
, O
the O
patient O
's O
quality-of-life O
self-assessment O
, O
application O
of O
the O
Barthel O
index O
and O
the O
Karnofsky O
Performance O
Scale O
score O
, O
and O
the O
patient O
's O
time O
of O
death O
. O

Based O
on O
an O
intention O
to O
treat O
analysis O
, O
there O
was O
no O
statistically O
significant O
difference O
in O
the O
8-week O
lean O
body O
mass O
between O
the O
two O
arms O
. O

The O
aim O
of O
this O
study O
was O
to O
compare O
the O
quality O
of O
life O
( O
QOL O
) O
of O
high-risk O
breast O
cancer O
patients O
included O
in O
a O
randomized O
clinical O
trial O
( O
PEGASE O
1 O
) O
comparing O
conventional O
chemotherapy O
versus O
adding O
an O
additional O
high-dose O
chemotherapy O
( O
HDC O
) O
cycle O
with O
blood O
stem O
cell O
support O
. O

A O
total O
of O
157 O
patients O
were O
randomized O
to O
UAE O
or O
surgery O
( O
hysterectomy O
or O
myomectomy O
) O
. O

Interviews O
were O
conducted O
to O
explore O
women O
's O
experience O
of O
writing O
. O

On O
the O
basis O
of O
previous O
case O
studies O
, O
this O
study O
was O
developed O
to O
evaluate O
the O
effect O
of O
a O
hypnosis O
intervention O
for O
hot O
flashes O
. O

Treatment O
arms O
were O
balanced O
with O
respect O
to O
performance O
status O
grade O
0-1 O
( O
83 O
% O
versus O
86 O
% O
, O
respectively O
) O
and O
the O
presence O
of O
metastases O
( O
92 O
% O
versus O
89 O
% O
, O
respectively O
) O
. O

Survival O
curves O
were O
calculated O
using O
the O
Kaplan-Meier O
method O
, O
and O
hazard O
ratios O
were O
estimated O
using O
the O
Cox O
proportional O
hazards O
model O
. O

It O
may O
thus O
be O
possible O
to O
selectively O
modulate O
each O
schedule O
biochemically O
. O

Participants O
were O
randomly O
assigned O
to O
receive O
a O
10-month O
program O
of O
mailed O
print O
materials O
on O
diet O
and O
PA O
available O
in O
the O
public O
domain O
or O
a O
10-month O
program O
of O
tailored O
materials O
designed O
to O
increase O
fruit O
and O
vegetable O
( O
F O
& O
V O
) O
intake O
, O
decrease O
fat O
intake O
, O
and/or O
increase O
PA. O
Changes O
in O
self-efficacy O
for O
F O
& O
V O
intake O
and O
fat O
restriction O
were O
analyzed O
as O
potential O
mediators O
of O
the O
intervention O
's O
effects O
on O
diet O
at O
2-year O
follow-up O
. O

This O
study O
was O
designed O
to O
evaluate O
the O
impact O
of O
laparoscopic O
rectal O
resection O
on O
short-term O
postoperative O
morbidity O
and O
costs O
. O

235 O
patients O
completed O
follow-up O
. O

The O
mean O
age O
of O
randomised O
women O
was O
62.8 O
( O
SD O
4.8 O
) O
years O
. O

The O
objective O
of O
this O
study O
is O
to O
explore O
the O
inflammatory O
modulation O
effect O
of O
glutamine-enriched O
total O
parenteral O
nutrition O
( O
TPN O
) O
by O
investigating O
the O
alterations O
of O
inflammation-related O
cytokines O
in O
gastrointestinal O
( O
GI O
) O
cancer O
patients O
postoperatively O
. O

The O
majority O
of O
the O
patient O
loss O
was O
because O
of O
patient O
preference O
( O
45 O
% O
of O
enrolled O
patients O
) O
. O

Consecutive O
daily O
intravenous O
infusion O
for O
5 O
days O
per O
every O
month O
for O
a O
total O
of O
12 O
cycles O
( O
IV O
arm O
, O
n O
= O
74 O
) O
and O
oral O
doxifluridine O
daily O
for O
3 O
weeks O
and O
1 O
week O
rest O
for O
a O
total O
of O
12 O
cycles O
( O
oral O
arm O
, O
n O
= O
92 O
) O
. O

Sixty O
patients O
were O
randomly O
assigned O
to O
two O
groups O
by O
digital O
table O
, O
the O
control O
group O
and O
the O
treatment O
group O
, O
30 O
in O
each O
group O
. O

One O
hundred O
twenty-six O
patients O
referred O
for O
resection O
of O
the O
esophagus O
( O
n O
= O
48 O
) O
, O
stomach O
( O
n O
= O
28 O
) O
, O
or O
pancreas O
( O
n O
= O
50 O
) O
were O
considered O
to O
be O
included O
before O
operation O
. O

In O
a O
recent O
randomized O
trial O
, O
stent O
placement O
was O
preferred O
in O
patients O
with O
a O
relatively O
short O
survival O
and O
GJJ O
in O
patients O
with O
a O
longer O
survival O
. O

Analysis O
was O
by O
intention O
to O
treat O
. O

After O
surgery O
for O
differentiated O
thyroid O
carcinoma O
, O
many O
patients O
are O
treated O
with O
radioiodine O
to O
ablate O
remnant O
thyroid O
tissue O
. O

Adverse O
events O
for O
duloxetine O
was O
15.2 O
% O
. O

Chemotherapy O
regimens O
consisted O
of O
a O
control O
FU O
arm O
( O
5-FU O
500 O
mg/m O
( O
2 O
) O
/day O
for O
5 O
days O
) O
and O
the O
investigational O
FUP O
arm O
( O
continuous O
5-FU O
1000 O
mg/m O
( O
2 O
) O
/day O
for O
5 O
days O
plus O
cisplatin O
100 O
mg/m O
( O
2 O
) O
on O
day O
1 O
or O
day O
2 O
) O
. O

The O
aim O
of O
this O
study O
was O
to O
examine O
whether O
ALT O
is O
a O
safe O
method O
and O
whether O
there O
are O
differences O
in O
adherence O
, O
limb O
volume O
, O
and O
quality O
of O
life O
between O
women O
who O
perform O
only O
self-management O
treatment O
and O
women O
who O
participate O
as O
well O
in O
ALT O
. O

The O
16-week O
regimen O
features O
greater O
doxorubicin O
and O
5-FU O
dose-intensity O
than O
CAF O
and O
improved O
scheduling O
of O
antimetabolites O
with O
sequential O
methotrexate O
and O
5-FU O
, O
as O
well O
as O
infusion O
5-FU O
. O

Health O
outcomes O
were O
examined O
according O
to O
treatment O
received O
: O
mastectomy O
with O
and O
without O
chemotherapy O
, O
and O
lumpectomy O
with O
and O
without O
chemotherapy O
. O

All O
living O
Swedish O
and O
Finnish O
men O
( O
400 O
of O
695 O
) O
randomly O
assigned O
to O
radical O
prostatectomy O
or O
watchful O
waiting O
in O
SPCG-4 O
from O
1989 O
to O
1999 O
were O
included O
in O
our O
analysis O
. O

Evaluation O
at O
baseline O
, O
after O
8 O
sessions O
, O
and O
1 O
month O
after O
programme O
completion O
, O
included O
evaluations O
using O
the O
STAI O
, O
POMS O
, O
MAC O
, O
EORTC O
QLQ-C30 O
and O
EORTC O
QLQ-BR23 O
breast O
module O
scales O
. O

Primary O
end O
point O
was O
overall O
survival O
, O
secondary O
end O
points O
were O
objective O
response O
rate O
( O
ORR O
) O
, O
safety O
, O
symptom O
improvement O
, O
and O
quality O
of O
life O
( O
QOL O
) O
. O

Two O
hundred O
and O
ninety-seven O
patients O
were O
randomised O
( O
C3 O
150 O
, O
C6 O
147 O
) O
. O

Objective O
outcome O
measures O
included O
shoulder O
range O
of O
motion O
and O
strength O
. O

Fifty O
patients O
with O
advanced O
pancreatic O
cancer O
who O
had O
lost O
at O
least O
10 O
% O
of O
their O
body O
weight O
were O
randomised O
to O
receive O
thalidomide O
200 O
mg O
daily O
or O
placebo O
for O
24 O
weeks O
in O
a O
single O
centre O
, O
double O
blind O
, O
randomised O
controlled O
trial O
. O

At O
baseline O
, O
no O
significant O
difference O
was O
observed O
among O
the O
three O
groups O
. O

Patients O
with O
stage O
IIIB O
or O
IV O
NSCLC O
and O
WHO O
performance O
status O
( O
PS O
) O
0-2 O
were O
randomised O
to O
receive O
three O
( O
C3 O
) O
or O
six O
( O
C6 O
) O
courses O
of O
carboplatin O
( O
area O
under O
the O
curve O
( O
AUC O
) O
4 O
, O
Chatelut O
's O
formula O
, O
equivalent O
to O
Calvert O
's O
AUC O
5 O
) O
on O
day O
1 O
and O
vinorelbine O
25 O
mg O
m O
( O
-2 O
) O
on O
days O
1 O
and O
8 O
of O
a O
3-week O
cycle O
. O

Responsiveness O
to O
treatment O
and O
recurrence O
were O
analyzed O
using O
paired O
t O
tests O
and O
the O
squared O
ratio O
of O
these O
t O
tests O
, O
an O
estimate O
of O
relative O
efficiency O
. O

Between O
April O
2010 O
and O
May O
2011 O
, O
patients O
undergoing O
elective O
LCR O
in O
two O
centres O
were O
randomized O
to O
analgesia O
via O
epidural O
or O
WIC O
. O

The O
administration O
of O
the O
smallest O
possible O
amount O
of O
radioiodine O
would O
improve O
care O
. O

QOL O
variables O
were O
analyzed O
in O
449 O
randomized O
patients O
from O
the O
COST O
trial O
93-46-53 O
( O
INT O
146 O
) O
. O

A O
median O
number O
of O
4 O
cycles O
( O
range O
, O
1-12 O
) O
were O
administered O
per O
patient O
. O

Most O
of O
these O
effects O
were O
observed O
at O
both O
the O
12-week O
and O
6-month O
follow-ups O
. O

A O
total O
of O
438 O
patients O
underwent O
randomization O
";" O
data O
could O
be O
analyzed O
for O
421 O
. O

infusion O
and O
5-FU O
, O
800 O
mg/m2 O
i.v O
. O

Thalidomide O
with O
melphalan/prednisone O
( O
MPT O
) O
was O
defined O
as O
standard O
treatment O
in O
elderly O
patients O
with O
multiple O
myeloma O
( O
MM O
) O
based O
on O
five O
randomized O
trials O
. O

The O
psychiatrist O
prescribed O
antidepressant O
medications O
for O
patients O
preferring O
or O
assessed O
to O
require O
medication O
. O

This O
phase O
III O
study O
investigated O
the O
effect O
of O
combining O
oxaliplatin O
with O
LV5FU2 O
, O
with O
progression-free O
survival O
as O
the O
primary O
end O
point O
. O

The O
primary O
end O
point O
was O
overall O
survival O
( O
OS O
) O
. O

All O
patients O
were O
randomized O
to O
receive O
half O
of O
a O
sachet O
of O
imiquimod O
5 O
% O
cream O
twice O
weekly O
on O
half O
of O
their O
face O
and O
two O
sessions O
of O
PDT O
with O
20 O
% O
solution O
of O
ALA O
applied O
for O
1 O
hour O
to O
the O
other O
side O
of O
the O
face O
. O

Androgen O
deprivation O
therapy O
( O
ADT O
) O
is O
commonly O
used O
as O
a O
primary O
treatment O
for O
patients O
with O
prostate O
cancer O
( O
PCa O
) O
who O
are O
not O
eligible O
for O
radical O
treatment O
options O
. O

The O
European O
Study O
Group O
for O
Pancreatic O
Cancer O
( O
ESPAC-1 O
) O
study O
is O
the O
largest O
study O
of O
adjuvant O
treatment O
for O
pancreatic O
ductal O
adenocarcinoma O
to O
date O
and O
confirmed O
a O
survival O
advantage O
for O
adjuvant O
chemotherapy O
but O
not O
for O
chemoradiation O
. O

This O
paper O
reports O
the O
health-related O
quality O
of O
life O
( O
HRQOL O
) O
of O
the O
patients O
in O
this O
trial O
. O

Twenty-one O
patients O
received O
BCAA O
granules O
three O
times O
a O
day O
( O
one O
sachet O
after O
each O
meal O
: O
the O
daytime O
group O
) O
, O
and O
16 O
patients O
received O
the O
granules O
twice O
a O
day O
( O
one O
sachet O
after O
breakfast O
, O
and O
two O
sachets O
before O
bedtime O
: O
the O
nocturnal O
group O
) O
. O

The O
functional O
assessment O
of O
chronic O
illness O
therapy-fatigue O
( O
FACIT-F O
) O
was O
administered O
from O
the O
early O
postoperative O
period O
to O
9 O
months O
. O

Subjects O
were O
42 O
consecutive O
men O
from O
a O
prospective O
study O
of O
brachytherapy O
as O
monotherapy O
with O
( O
125 O
) O
I O
for O
intermediate-risk O
localized O
prostate O
cancer O
. O

Improvements O
can O
be O
made O
in O
the O
quality O
of O
cancer O
care O
if O
supportive O
care O
needs O
are O
addressed O
";" O
however O
, O
there O
are O
few O
trials O
of O
supportive O
care O
interventions O
to O
guide O
policy O
and O
practice O
. O

Main O
exclusion O
criteria O
were O
brain O
or O
bone O
metastases O
. O

Equivalence O
was O
defined O
as O
less O
than O
20 O
% O
difference O
in O
the O
number O
achieving O
an O
improvement O
in O
the O
TSS O
. O

A O
longitudinal O
QoL O
study O
on O
a O
subset O
of O
ESPAC-1 O
patients O
who O
prospectively O
completed O
the O
EORTC O
QLQ O
C-30 O
questionnaire O
during O
treatment O
and O
follow-up O
. O

SLNs O
were O
identified O
in O
662 O
of O
697 O
patients O
( O
95 O
% O
) O
and O
positive O
SLNs O
were O
found O
in O
189 O
of O
662 O
patients O
( O
28.5 O
% O
) O
. O

The O
majority O
of O
prostate O
carcinoma O
survivors O
experience O
enduring O
sexual O
difficulties O
and O
associated O
distress O
in O
the O
years O
after O
definitive O
treatment O
. O

Patients O
( O
n O
= O
429 O
) O
were O
randomly O
assigned O
to O
receive O
doxorubicin O
50 O
mg/m O
( O
2 O
) O
plus O
docetaxel O
75 O
mg/m O
( O
2 O
) O
( O
n O
= O
214 O
) O
or O
doxorubicin O
60 O
mg/m O
( O
2 O
) O
plus O
cyclophosphamide O
600 O
mg/m O
( O
2 O
) O
( O
n O
= O
215 O
) O
on O
day O
1 O
, O
every O
3 O
weeks O
for O
up O
to O
eight O
cycles O
. O

Randomized O
controlled O
trial O
. O

Patients O
aged O
18-75 O
years O
, O
undergoing O
an O
elective O
laparotomy O
and O
with O
a O
preoperative O
suspicion O
of O
gynecologic O
malignancy O
, O
were O
eligible O
. O

Baseline O
questionnaires O
were O
available O
for O
490 O
( O
86 O
% O
) O
patients O
. O

Here O
, O
we O
report O
a O
6-month O
follow-up O
of O
exercise O
behavior O
and O
patient-rated O
outcomes O
from O
an O
exercise O
trial O
in O
breast O
cancer O
patients O
. O

The O
AVEREL O
trial O
[ O
A O
Study O
of O
Avastin O
( O
Bevacizumab O
) O
in O
Combination O
With O
Herceptin O
( O
Trastuzumab O
) O
/Docetaxel O
in O
Patients O
With O
HER2-Positive O
Metastatic O
Breast O
Cancer O
] O
evaluated O
first-line O
bevacizumab-containing O
therapy O
for O
human O
epidermal O
growth O
factor O
receptor O
2 O
( O
HER2 O
) O
-positive O
locally O
recurrent/metastatic O
breast O
cancer O
( O
LR/MBC O
) O
. O

Survival O
status O
for O
all O
patients O
was O
determined O
from O
our O
own O
records O
and O
from O
three O
external O
sources O
: O
the O
Hamburg O
cancer O
registry O
, O
family O
doctors O
, O
and O
the O
general O
citizen O
registration O
offices O
. O

To O
facilitate O
the O
transition O
to O
recovery O
, O
we O
conducted O
the O
Moving O
Beyond O
Cancer O
( O
MBC O
) O
trial O
, O
a O
multisite O
, O
randomized O
, O
controlled O
trial O
of O
psychoeducational O
interventions O
for O
breast O
cancer O
patients O
. O

A O
total O
of O
358 O
patients O
were O
randomly O
assigned O
between O
July O
2003 O
and O
March O
2005 O
in O
two O
Canadian O
centers O
, O
and O
331 O
were O
included O
in O
the O
analysis O
. O

For O
progression O
analysis O
, O
173 O
patients O
' O
data O
were O
available O
. O

We O
report O
the O
QOL O
results O
of O
JBR.10 O
, O
a O
North O
American O
, O
intergroup O
, O
randomized O
trial O
of O
adjuvant O
cisplatin O
and O
vinorelbine O
compared O
with O
observation O
in O
patients O
who O
have O
completely O
resected O
, O
stages O
IB O
to O
II O
NSCLC O
. O

However O
, O
it O
is O
rarely O
implemented O
given O
its O
limited O
availability O
. O

We O
developed O
Individual O
Meaning-Centered O
Psychotherapy O
( O
IMCP O
) O
to O
address O
the O
need O
for O
brief O
interventions O
targeting O
spiritual O
well-being O
and O
meaning O
for O
patients O
with O
advanced O
cancer O
. O

This O
study O
was O
initiated O
to O
compare O
up-front O
tandem O
HDCT O
and O
standard O
combination O
therapy O
in O
patients O
with O
metastatic O
breast O
cancer O
. O

A O
phase O
III O
randomized O
study O
was O
performed O
to O
establish O
the O
most O
effective O
and O
safest O
treatment O
to O
improve O
the O
key O
symptoms O
in O
advanced O
gynecological O
cancer O
patients O
, O
i.e. O
, O
lean O
body O
mass O
( O
LBM O
) O
, O
resting O
energy O
expenditure O
( O
REE O
) O
, O
fatigue O
, O
and O
QoL O
. O

Randomized O
, O
controlled O
, O
longitudinal O
trial O
. O

A O
total O
of O
53 O
patients O
completed O
the O
QOL O
and O
functional O
outcome O
questionnaires O
. O

Primary O
-- O
patients O
alive O
and O
without O
moderate O
or O
severe O
cough O
, O
chest O
pain O
, O
haemoptysis O
, O
or O
dyspnoea O
six O
months O
from O
randomisation O
, O
as O
recorded O
by O
clinicians O
. O

Patients O
completed O
the O
Functional O
Assessment O
of O
Cancer O
Therapy-Breast O
( O
FACT-B O
) O
questionnaire O
plus O
endocrine O
subscale O
( O
ES O
) O
at O
baseline O
, O
3 O
and O
6 O
months O
, O
and O
every O
6 O
months O
thereafter O
. O

We O
conducted O
a O
two-arm O
, O
wait-list O
control O
, O
randomized O
trial O
of O
a O
complex O
rehabilitation O
intervention O
delivered O
by O
a O
hospice-based O
multidisciplinary O
team O
vs. O
usual O
care O
for O
active O
, O
progressive O
, O
recurrent O
hematological O
and O
breast O
malignancies O
, O
with O
a O
follow-up O
at O
three O
months O
. O

The O
general O
exercise O
group O
performed O
body O
conditioning O
exercise O
. O

Patients O
with O
previously O
untreated O
histologically O
or O
cytologically O
proven O
locally O
advanced O
or O
metastatic O
carcinoma O
of O
the O
pancreas O
with O
a O
performance O
status O
< O
or= O
2 O
were O
recruited O
. O

102 O
men O
completed O
the O
study O
. O

A O
multicenter O
, O
randomized O
, O
double-blind O
, O
placebo-controlled O
trial O
was O
conducted O
. O

Based O
on O
pattern-mixture O
models O
, O
patients O
who O
dropped O
out O
early O
had O
worse O
QL2 O
decline O
on O
both O
treatments O
. O

Twenty-one O
centers O
in O
The O
Netherlands O
. O

MH O
and O
QOL O
were O
assessed O
with O
standardized O
questionnaires O
at O
baseline O
";" O
cycle O
4 O
, O
day O
1 O
";" O
and O
every O
6 O
months O
through O
24 O
months O
. O

Of O
1060 O
registered O
, O
the O
first O
300 O
consecutive O
patients O
were O
included O
in O
the O
current O
utility O
study O
. O

Although O
initial O
pre-trial O
interviews O
revealed O
concerns O
among O
health-care O
professionals O
and O
some O
patients O
regarding O
community O
treatment O
, O
opinions O
were O
largely O
more O
favourable O
in O
post-trial O
interviews O
. O

After O
written O
informed O
consent O
was O
obtained O
, O
210 O
patients O
with O
liver O
cancer O
were O
randomized O
into O
three O
groups O
of O
70 O
patients O
. O

We O
compared O
the O
effectiveness O
and O
toxicity O
of O
the O
combination O
of O
vinorelbine O
plus O
gemcitabine O
with O
those O
of O
each O
drug O
given O
alone O
in O
an O
open-label O
, O
randomized O
phase O
III O
trial O
in O
elderly O
patients O
with O
advanced O
NSCLC O
. O

Several O
multicomponent O
regimens O
have O
been O
reported O
to O
be O
useful O
in O
advanced O
androgen-independent O
prostate O
cancer O
. O

Paclitaxel O
was O
administered O
at O
two O
different O
dose O
levels O
( O
135 O
mg/m O
( O
2 O
) O
and O
250 O
mg/m O
( O
2 O
) O
) O
, O
and O
etoposide O
was O
given O
at O
a O
dose O
of O
100 O
mg/m O
( O
2 O
) O
daily O
on O
days O
1 O
to O
3 O
. O

HRQOL O
questionnaires O
, O
using O
a O
validated O
instrument O
, O
the O
Functional O
Assessment O
of O
Cancer O
Therapy-Head O
and O
Neck O
( O
FACT-H O
& O
amp O
";" O
N O
) O
, O
version O
2 O
, O
were O
completed O
by O
patients O
before O
the O
start O
of O
treatment O
. O

A O
single-item O
linear O
analogue O
self-assessment O
scale O
for O
mood O
was O
compared O
with O
a O
28-item O
adjective O
checklist O
for O
emotional O
well-being O
. O

An O
outcome O
of O
noninferiority O
of O
short-term O
androgen O
suppression O
as O
compared O
with O
long-term O
suppression O
required O
a O
hazard O
ratio O
of O
more O
than O
1.35 O
for O
overall O
survival O
, O
with O
a O
one-sided O
alpha O
level O
of O
0.05 O
. O

Caregivers O
and O
patients O
are O
adversely O
affected O
. O

The O
majority O
of O
pain O
topics O
had O
to O
be O
discussed O
. O

Five O
hundred O
seventy-three O
glioblastoma O
multiforme O
patients O
were O
randomized O
to O
receive O
either O
temozolomide O
+ O
radiotherapy O
( O
n O
= O
287 O
) O
or O
radiotherapy O
alone O
( O
n O
= O
286 O
) O
. O

In O
all O
, O
152 O
fatigued O
patients O
with O
advanced O
cancer O
were O
randomly O
assigned O
to O
protocolized O
patient-tailored O
treatment O
( O
PPT O
) O
of O
symptoms O
or O
care O
as O
usual O
. O

The O
KS O
Functional O
Assessment O
of O
HIV O
( O
FAHI O
) O
quality O
of O
life O
instrument O
was O
used O
before O
and O
after O
every O
other O
treatment O
cycle O
. O

To O
report O
5-year O
contrast-enhanced O
magnetic O
resonance O
imaging O
findings O
of O
the O
REST O
trial O
recruits O
who O
underwent O
either O
uterine O
artery O
embolization O
( O
UAE O
) O
or O
myomectomy O
. O

We O
therefore O
sought O
to O
assess O
the O
effect O
of O
LAC O
on O
QOL O
in O
the O
short O
and O
long O
term O
, O
using O
individual O
item O
analysis O
of O
multi-item O
QOL O
assessments O
. O

We O
aimed O
to O
assess O
quality O
of O
life O
in O
men O
with O
locally O
advanced O
prostate O
cancer O
in O
an O
open-label O
phase O
III O
randomised O
comparison O
between O
lifelong O
endocrine O
treatment O
with O
and O
without O
radiotherapy O
. O

We O
examined O
the O
efficacy O
and O
safety O
of O
adding O
gemcitabine O
to O
paclitaxel/bevacizumab O
( O
PB O
) O
. O

Patients O
were O
evaluated O
on O
five O
occasions O
over O
the O
experimental O
period O
. O

Outcomes O
were O
lymphoedema O
volume O
, O
pain O
, O
heaviness O
and O
tightness O
, O
and O
health-related O
quality O
of O
life O
measured O
with O
the O
Functional O
Assessment O
of O
Cancer O
Therapy O
Questionnaire O
for O
Breast O
Cancer O
version O
4 O
( O
FACT-B+4 O
) O
. O

The O
Active O
After O
Cancer O
Trial O
( O
AACT O
) O
was O
a O
multicenter O
pilot O
study O
evaluating O
the O
feasibility O
of O
a O
telephone-based O
exercise O
intervention O
in O
a O
cooperative O
group O
setting O
. O

We O
recruited O
273 O
participants O
and O
randomly O
assigned O
136 O
to O
the O
intervention O
group O
. O

Patients O
were O
randomly O
assigned O
to O
intervention O
( O
n O
= O
242 O
) O
or O
enhanced O
usual O
care O
( O
EUC O
";" O
n O
= O
230 O
) O
. O

To O
evaluate O
the O
impact O
of O
laser O
treatment O
on O
the O
severity O
of O
facial O
hirsutism O
and O
on O
psychological O
morbidity O
in O
women O
with O
PCOS O
. O

Results O
Baseline O
characteristics O
of O
the O
424 O
patients O
were O
balanced O
between O
treatment O
arms O
. O

Longitudinal O
data O
were O
available O
for O
166 O
Swedish O
men O
who O
had O
answered O
quality-of-life O
questionnaires O
at O
an O
earlier O
timepoint O
. O

To O
determine O
1-year O
outcomes O
of O
a O
four-component O
behavioral O
therapy O
( O
BT O
) O
sleep O
intervention O
( O
Individualized O
Sleep O
Promotion O
Plan O
[ O
ISPP O
] O
) O
versus O
a O
healthy O
eating O
control O
( O
HEC O
) O
on O
cancer-related O
fatigue O
in O
women O
receiving O
breast O
cancer O
adjuvant O
chemotherapy O
treatment O
( O
CTX O
) O
. O

In O
Lithuania O
, O
about O
400 O
cases O
of O
pancreatic O
cancer O
are O
diagnosed O
each O
year O
, O
and O
more O
than O
50 O
% O
of O
patients O
are O
diagnosed O
with O
stage O
IV O
disease O
. O

Three O
patients O
were O
ineligible O
. O

Patients O
completed O
the O
Short O
Form O
36-item O
Health O
Survey O
( O
SF-36 O
) O
and O
the O
Menopause O
Specific O
Quality O
of O
Life O
Questionnaire O
( O
MENQOL O
) O
at O
baseline O
, O
6 O
months O
, O
and O
annually O
. O

Therefore O
, O
a O
randomized O
double-blind O
placebo-controlled O
multicenter O
trial O
was O
performed O
to O
assess O
the O
efficacy O
of O
long-acting O
octreotide O
for O
the O
treatment O
of O
advanced O
HCC O
. O

We O
evaluated O
thalidomide O
, O
an O
anti-angiogenic O
agent O
, O
when O
combined O
with O
chemotherapy O
and O
as O
maintenance O
treatment O
. O

Outcomes O
measured O
were O
scores O
on O
a O
composite O
menopausal O
symptom O
scale O
, O
the O
RAND O
Short O
Form O
Health O
Survey O
Vitality O
Scale O
, O
and O
the O
Cancer O
Rehabilitation O
Evaluation O
System O
( O
CARES O
) O
Sexual O
Functioning O
Scale O
at O
baseline O
and O
at O
4-month O
follow-up O
. O

Patients O
were O
randomized O
in O
a O
2-by-2 O
factorial O
design O
to O
medroxyprogesterone O
acetate O
200 O
mg O
daily O
, O
interferon-alfa O
9 O
million O
IU O
3 O
times O
a O
week O
, O
subcutaneous O
interleukin-2 O
9 O
million O
IU O
daily O
, O
or O
a O
combination O
of O
both O
cytokines O
. O

At O
baseline O
and O
three O
follow-up O
points O
, O
101 O
of O
125 O
women O
completed O
a O
depression O
symptom O
measure O
. O

The O
primary O
hypothesis O
was O
that O
duloxetine O
would O
be O
more O
effective O
than O
placebo O
in O
decreasing O
chemotherapy-induced O
peripheral O
neuropathic O
pain O
. O

This O
pilot O
trial O
assessed O
the O
feasibility O
of O
a O
randomized O
controlled O
trial O
( O
RCT O
) O
comparing O
epidural O
analgesia O
and O
use O
of O
a O
local O
anaesthetic O
wound O
infusion O
catheter O
( O
WIC O
) O
following O
LCR O
. O

We O
investigated O
the O
role O
of O
tamoxifen O
and O
radiotherapy O
( O
RT O
) O
for O
the O
prevention O
and O
treatment O
of O
gynecomastia O
and O
breast O
pain O
during O
adjuvant O
bicalutamide O
monotherapy O
after O
radical O
prostatectomy O
( O
RP O
) O
in O
patients O
with O
prostate O
cancer O
. O

The O
functional O
outcomes O
and O
quality O
of O
life O
in O
patients O
receiving O
esophagectomy O
or O
definitive O
CRT O
is O
uncertain O
. O

The O
primary O
end O
points O
were O
response O
and O
overall O
survival O
time O
. O

To O
assess O
the O
efficacy O
of O
monthly O
degarelix O
treatment O
for O
reduction O
of O
total O
prostate O
volume O
( O
TPV O
) O
, O
relief O
of O
lower O
urinary O
tract O
symptoms O
( O
LUTS O
) O
and O
improvement O
of O
quality O
of O
life O
( O
QoL O
) O
in O
patients O
with O
prostate O
cancer O
( O
PCa O
) O
using O
monthly O
goserelin O
as O
active O
control O
. O

Days O
1 O
, O
8 O
, O
and O
15 O
in O
28-day O
cycles O
";" O
G O
arm O
: O
G O
as O
in O
GE O
. O

Expression B-Premise
of I-Premise
somatostatin I-Premise
receptors I-Premise
is I-Premise
found I-Premise
in I-Premise
HCCs I-Premise
, I-Premise
but O
the B-Claim
efficacy I-Claim
of I-Claim
the I-Claim
somatostatin I-Claim
analogue I-Claim
octreotide I-Claim
remains I-Claim
controversial I-Claim
. I-Claim

Chemotherapy B-Claim
seems I-Claim
to I-Claim
improve I-Claim
symptoms I-Claim
control I-Claim
, I-Claim
even O
if O
randomised O
studies O
with O
quality O
of O
life O
as O
first O
endpoint O
are O
lacking O
and O
often O
chemotherapy O
toxicity O
compromises O
the O
frail O
cost/benefit O
ratio O
. O

Particularly O
, O
there B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
regarding I-Premise
time I-Premise
to I-Premise
definitive I-Premise
deterioration I-Premise
of I-Premise
global I-Premise
health I-Premise
status/quality I-Premise
of I-Premise
life I-Premise
from I-Premise
baseline I-Premise
( I-Premise
primary I-Premise
endpoint I-Premise
) I-Premise
. I-Premise

Fulvestrant B-Claim
500 I-Claim
mg I-Claim
was I-Claim
associated I-Claim
with I-Claim
a I-Claim
statistically I-Claim
significant I-Claim
increase I-Claim
in I-Claim
PFS I-Claim
and I-Claim
not I-Claim
associated I-Claim
with I-Claim
increased I-Claim
toxicity I-Claim
, I-Claim
corresponding O
to O
a O
clinically O
meaningful O
improvement O
in O
benefit O
versus O
risk O
compared O
with O
fulvestrant O
250 O
mg O
. O

Median B-Claim
overall I-Claim
survival I-Claim
and I-Claim
progression-free I-Claim
survival I-Claim
were I-Claim
more I-Claim
favorable I-Claim
in I-Claim
the I-Claim
combination I-Claim
arm I-Claim
as I-Claim
compared I-Claim
with I-Claim
gemcitabine I-Claim
alone I-Claim
, I-Claim
although B-Premise
the I-Premise
difference I-Premise
did I-Premise
not I-Premise
attain I-Premise
statistical I-Premise
significance I-Premise
. I-Premise

Moreover O
, O
a B-Premise
significant I-Premise
lower I-Premise
serum I-Premise
C-reactive I-Premise
protein I-Premise
level I-Premise
was I-Premise
detected I-Premise
in I-Premise
glutamine-enriched I-Premise
TPN I-Premise
compared I-Premise
with I-Premise
standard I-Premise
TPN I-Premise
( I-Premise
P I-Premise
= I-Premise
0.013 I-Premise
) I-Premise
. I-Premise

However O
, O
overall B-Premise
survival I-Premise
from I-Premise
date I-Premise
of I-Premise
randomization I-Premise
on I-Premise
step I-Premise
2 I-Premise
was I-Premise
not I-Premise
significantly I-Premise
different I-Premise
between I-Premise
the I-Premise
observation I-Premise
and I-Premise
topotecan I-Premise
arms I-Premise
( I-Premise
8.9 I-Premise
months I-Premise
v I-Premise
9.3 I-Premise
months I-Premise
";" I-Premise
P I-Premise
=.43 I-Premise
) I-Premise
. I-Premise

Also O
, O
the B-Premise
Kaplan-Meier I-Premise
survival I-Premise
curves I-Premise
of I-Premise
these I-Premise
two I-Premise
groups I-Premise
were I-Premise
not I-Premise
significantly I-Premise
different I-Premise
by I-Premise
log-rank I-Premise
test I-Premise
( I-Premise
p=0.286 I-Premise
) I-Premise
. I-Premise

No B-Premise
between-treatment I-Premise
differences I-Premise
were I-Premise
observed I-Premise
for I-Premise
changes I-Premise
in I-Premise
quality I-Premise
of I-Premise
life I-Premise
or I-Premise
performance I-Premise
status I-Premise
, I-Premise
but O
patients B-Premise
started I-Premise
on I-Premise
strong I-Premise
opioids I-Premise
had I-Premise
significantly I-Premise
better I-Premise
pain I-Premise
relief I-Premise
than I-Premise
patients I-Premise
treated I-Premise
according I-Premise
to I-Premise
WHO I-Premise
guidelines I-Premise
( I-Premise
P=0.041 I-Premise
) I-Premise
. I-Premise

Although B-Premise
a I-Premise
dosage I-Premise
of I-Premise
50 I-Premise
mg I-Premise
of I-Premise
bicalutamide I-Premise
once I-Premise
daily I-Premise
was I-Premise
not I-Premise
as I-Premise
effective I-Premise
as I-Premise
castration I-Premise
, I-Premise
the B-Claim
favorable I-Claim
quality I-Claim
of I-Claim
life I-Claim
outcomes I-Claim
and I-Claim
the I-Claim
low I-Claim
incidence I-Claim
of I-Claim
nonhormonal I-Claim
adverse I-Claim
events I-Claim
provide I-Claim
reasons I-Claim
to I-Claim
evaluate I-Claim
bicalutamide I-Claim
, I-Claim
as I-Claim
a I-Claim
single I-Claim
therapeutic I-Claim
agent I-Claim
, I-Claim
at I-Claim
higher I-Claim
doses I-Claim
. I-Claim

Consistent O
with O
the O
2-year O
analysis O
, O
there B-Claim
were I-Claim
differences I-Claim
between I-Claim
treatment I-Claim
groups I-Claim
in I-Claim
patient-reported I-Claim
side I-Claim
effects I-Claim
: I-Claim
diarrhea B-Premise
( I-Premise
anastrozole I-Premise
3.1 I-Premise
% I-Premise
vs. I-Premise
tamoxifen I-Premise
1.3 I-Premise
% I-Premise
) I-Premise
, I-Premise
vaginal I-Premise
dryness I-Premise
( I-Premise
18.5 I-Premise
% I-Premise
vs. I-Premise
9.1 I-Premise
% I-Premise
) I-Premise
, I-Premise
diminished I-Premise
libido I-Premise
( I-Premise
34.0 I-Premise
% I-Premise
vs. I-Premise
26.1 I-Premise
% I-Premise
) I-Premise
, I-Premise
and I-Premise
dyspareunia I-Premise
( I-Premise
17.3 I-Premise
% I-Premise
vs. I-Premise
8.1 I-Premise
% I-Premise
) I-Premise
were I-Premise
significantly I-Premise
more I-Premise
frequent I-Premise
with I-Premise
anastrozole I-Premise
compared I-Premise
to I-Premise
tamoxifen I-Premise
. I-Premise

Slowly O
, O
recovery B-Premise
was I-Premise
found I-Premise
at I-Premise
both I-Premise
6 I-Premise
months I-Premise
and I-Premise
1 I-Premise
year I-Premise
in I-Premise
both I-Premise
groups I-Premise
. I-Premise

Adverse B-Premise
drug I-Premise
reactions I-Premise
were I-Premise
reported I-Premise
in I-Premise
3 I-Premise
% I-Premise
( I-Premise
9 I-Premise
patients I-Premise
) I-Premise
, I-Premise
and O
8 B-Premise
patients I-Premise
were I-Premise
lost I-Premise
to I-Premise
follow-up I-Premise
. I-Premise

The B-Premise
disease-related I-Premise
symptoms I-Premise
improved I-Premise
with I-Premise
time I-Premise
, I-Premise
and O
the B-Premise
benefits I-Premise
lasted I-Premise
for I-Premise
the I-Premise
entire I-Premise
treatment I-Premise
period I-Premise
. I-Premise

Each B-Claim
of I-Claim
these I-Claim
regimens I-Claim
produced I-Claim
clinically I-Claim
significant I-Claim
responses I-Claim
, I-Claim
and O
the B-Claim
observed I-Claim
median I-Claim
survival I-Claim
( I-Claim
18.9 I-Claim
months I-Claim
for I-Claim
all I-Claim
71 I-Claim
patients I-Claim
) I-Claim
compares I-Claim
favorably I-Claim
with I-Claim
previously I-Claim
published I-Claim
results I-Claim
, I-Claim
especially I-Claim
in I-Claim
the I-Claim
community I-Claim
setting I-Claim
. I-Claim

Whereas O
patients B-Claim
with I-Claim
early I-Claim
alternating I-Claim
chemotherapy I-Claim
achieve I-Claim
a I-Claim
better I-Claim
subjective I-Claim
adjustment I-Claim
, I-Claim
late B-Claim
alternating I-Claim
chemotherapy I-Claim
allows I-Claim
for I-Claim
a I-Claim
higher I-Claim
RDI I-Claim
of I-Claim
cisplatin I-Claim
, I-Claim
adriamycin I-Claim
and I-Claim
etoposide I-Claim
, I-Claim
which I-Claim
results I-Claim
in I-Claim
a I-Claim
significantly I-Claim
longer I-Claim
median I-Claim
survival I-Claim
of I-Claim
patients I-Claim
with I-Claim
extensive I-Claim
disease I-Claim
. I-Claim

Although O
many O
drug O
combination O
therapies O
have O
been O
proposed O
, O
there B-Claim
is I-Claim
no I-Claim
standard I-Claim
therapy I-Claim
for I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
gastric I-Claim
carcinoma I-Claim
. I-Claim

Hematologic B-Premise
toxicity I-Premise
was I-Premise
higher I-Premise
in I-Premise
the I-Premise
PCDE I-Premise
arm I-Premise
( I-Premise
22 I-Premise
% I-Premise
with I-Premise
documented I-Premise
infections I-Premise
compared I-Premise
with I-Premise
8 I-Premise
% I-Premise
in I-Premise
the I-Premise
EP I-Premise
arm I-Premise
";" I-Premise
P I-Premise
=.0038 I-Premise
) I-Premise
, I-Premise
and O
the B-Premise
toxicity-related I-Premise
death I-Premise
rate I-Premise
was I-Premise
9 I-Premise
% I-Premise
in I-Premise
the I-Premise
PCDE I-Premise
arm I-Premise
versus I-Premise
5.5 I-Premise
% I-Premise
in I-Premise
the I-Premise
EP I-Premise
arm I-Premise
( I-Premise
P I-Premise
=.22 I-Premise
) I-Premise
. I-Premise

However O
, O
the O
early B-Claim
postoperative I-Claim
outcome I-Claim
does I-Claim
not I-Claim
give I-Claim
a I-Claim
complete I-Claim
answer I-Claim
and O
the B-Claim
eventual I-Claim
cost-effectiveness I-Claim
will I-Claim
only I-Claim
become I-Claim
clear I-Claim
after I-Claim
long-term I-Claim
follow-up I-Claim
. I-Claim

Likewise O
, O
emotional B-Premise
, I-Premise
functional I-Premise
well-being I-Premise
, I-Premise
and I-Premise
QoL I-Premise
aspects I-Premise
specifically I-Premise
related I-Premise
to I-Premise
lung I-Premise
cancer I-Premise
were I-Premise
better I-Premise
improved I-Premise
in I-Premise
the I-Premise
Gefitinib I-Premise
group I-Premise
than I-Premise
in I-Premise
the I-Premise
Pemetrexed I-Premise
group I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

Local B-Premise
recurrence I-Premise
rate I-Premise
and I-Premise
five-year I-Premise
survival I-Premise
were I-Premise
similar I-Premise
in I-Premise
both I-Premise
groups I-Premise
";" I-Premise
however B-Claim
, I-Claim
the I-Claim
limited I-Claim
number I-Claim
of I-Claim
patients I-Claim
does I-Claim
not I-Claim
allow I-Claim
firm I-Claim
conclusions I-Claim
. I-Claim

However O
, O
QOL B-Claim
scores I-Claim
were I-Claim
not I-Claim
significantly I-Claim
different I-Claim
among I-Claim
the I-Claim
regimens I-Claim
. I-Claim

Gastrointestinal B-Premise
toxicity I-Premise
of I-Premise
pamidronate I-Premise
caused I-Premise
a I-Premise
23 I-Premise
% I-Premise
drop-out I-Premise
rate I-Premise
, I-Premise
but B-Claim
other I-Claim
cancer-associated I-Claim
factors I-Claim
seemed I-Claim
to I-Claim
contribute I-Claim
to I-Claim
this I-Claim
toxicity I-Claim
. I-Claim

Overall O
, O
QoL B-Claim
scores I-Claim
were I-Claim
similar I-Claim
in I-Claim
the I-Claim
two I-Claim
treatment I-Claim
groups I-Claim
, I-Claim
but B-Claim
thalidomide I-Claim
was I-Claim
associated I-Claim
with I-Claim
less I-Claim
insomnia I-Claim
and I-Claim
diarrhea I-Claim
and I-Claim
more I-Claim
constipation I-Claim
and I-Claim
peripheral I-Claim
neuropathy I-Claim
. I-Claim

Both B-Premise
groups I-Premise
showed I-Premise
an I-Premise
increase I-Premise
in I-Premise
symptom I-Premise
and I-Premise
interference I-Premise
scores I-Premise
, I-Premise
although O
patients B-Premise
in I-Premise
the I-Premise
rhDNase I-Premise
group I-Premise
showed I-Premise
a I-Premise
greater I-Premise
decline I-Premise
in I-Premise
both I-Premise
scores I-Premise
during I-Premise
the I-Premise
3 I-Premise
months I-Premise
posttreatment I-Premise
. I-Premise

This B-Claim
toxicity I-Claim
profile I-Claim
of I-Claim
GE I-Claim
is I-Claim
similar I-Claim
to I-Claim
GP I-Claim
, I-Claim
but B-Claim
the I-Claim
apparent I-Claim
inferior I-Claim
efficacy I-Claim
may I-Claim
discourage I-Claim
further I-Claim
investigation I-Claim
. O

Therefore O
, O
IAD B-Claim
is I-Claim
not I-Claim
a I-Claim
good I-Claim
treatment I-Claim
option I-Claim
for I-Claim
many I-Claim
metastatic I-Claim
prostate I-Claim
cancer I-Claim
patients I-Claim
. I-Claim

These B-Claim
results I-Claim
suggest I-Claim
that I-Claim
sexual I-Claim
functioning I-Claim
may I-Claim
require I-Claim
focused I-Claim
assessment I-Claim
by I-Claim
providers I-Claim
, I-Claim
beyond I-Claim
broad I-Claim
QOL I-Claim
assessments I-Claim
, I-Claim
and O
that O
attention B-Claim
to I-Claim
Sexual/Relationship I-Claim
Satisfaction I-Claim
may I-Claim
be I-Claim
critical I-Claim
in I-Claim
the I-Claim
development I-Claim
and I-Claim
implementation I-Claim
of I-Claim
interventions I-Claim
for I-Claim
this I-Claim
cohort I-Claim
of I-Claim
patients I-Claim
. I-Claim

However O
, O
we B-Premise
reported I-Premise
a I-Premise
response I-Premise
rate I-Premise
of I-Premise
43.1 I-Premise
and I-Premise
38.6 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
, I-Premise
in I-Premise
MVP I-Premise
and I-Premise
MVC I-Premise
arm I-Premise
( I-Premise
P=0.59 I-Premise
) I-Premise
and I-Premise
a I-Premise
median I-Premise
survival I-Premise
of I-Premise
10.2 I-Premise
and I-Premise
7.2 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
, I-Premise
for I-Premise
cisplatin I-Premise
and I-Premise
carboplatin I-Premise
arm I-Premise
( I-Premise
P=0.39 I-Premise
) I-Premise
. I-Premise

The B-Claim
findings I-Claim
support I-Claim
the I-Claim
case I-Claim
for I-Claim
assessment I-Claim
of I-Claim
health-related I-Claim
QoL I-Claim
in I-Claim
relation I-Claim
to I-Claim
head-and-neck I-Claim
cancer I-Claim
using I-Claim
a I-Claim
site-specific I-Claim
approach I-Claim
. O

TRUE B-Premise
acupuncture I-Premise
was I-Premise
associated I-Premise
with I-Premise
0.8 I-Premise
fewer I-Premise
hot I-Premise
flashes I-Premise
per I-Premise
day I-Premise
than I-Premise
sham I-Premise
at I-Premise
6 I-Premise
weeks I-Premise
, O
but B-Premise
the I-Premise
difference I-Premise
did I-Premise
not I-Premise
reach I-Premise
statistical I-Premise
significance I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
-0.7 I-Premise
to I-Premise
2.4 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.3 I-Premise
) I-Premise
. I-Premise

Improvements B-Premise
in I-Premise
self-esteem I-Premise
observed I-Premise
with I-Premise
RET I-Premise
during I-Premise
breast I-Premise
cancer I-Premise
chemotherapy I-Premise
were I-Premise
maintained I-Premise
at I-Premise
6-month I-Premise
follow-up I-Premise
whereas O
reductions B-Premise
in I-Premise
anxiety I-Premise
not I-Premise
observed I-Premise
with I-Premise
AET I-Premise
during I-Premise
breast I-Premise
cancer I-Premise
chemotherapy I-Premise
emerged I-Premise
at I-Premise
6-month I-Premise
follow-up I-Premise
. I-Premise

Results B-Premise
of I-Premise
exploratory I-Premise
analyses I-Premise
suggested I-Premise
that I-Premise
the I-Premise
CST I-Premise
intervention I-Premise
was I-Premise
more I-Premise
beneficial I-Premise
to I-Premise
patients/caregivers I-Premise
with I-Premise
Stage I-Premise
II I-Premise
and I-Premise
III I-Premise
cancers I-Premise
, I-Premise
whereas O
the B-Premise
education/support I-Premise
intervention I-Premise
was I-Premise
more I-Premise
beneficial I-Premise
to I-Premise
patients/caregivers I-Premise
with I-Premise
Stage I-Premise
I I-Premise
cancer I-Premise
. I-Premise

Hence O
, O
nurse-led B-Claim
telephone I-Claim
follow-up I-Claim
seems I-Claim
an I-Claim
appropriate I-Claim
way I-Claim
to I-Claim
reduce I-Claim
clinic I-Claim
visits I-Claim
and I-Claim
represents I-Claim
an I-Claim
accepted I-Claim
alternative I-Claim
strategy I-Claim
. I-Claim

At O
final O
analysis O
, O
there B-Premise
was I-Premise
no I-Premise
difference I-Premise
in I-Premise
OS I-Premise
seen I-Premise
between I-Premise
ASA404 I-Premise
( I-Premise
n I-Premise
= I-Premise
649 I-Premise
) I-Premise
and I-Premise
placebo I-Premise
( I-Premise
n I-Premise
= I-Premise
650 I-Premise
) I-Premise
arms I-Premise
: I-Premise
median I-Premise
OS I-Premise
was I-Premise
13.4 I-Premise
and I-Premise
12.7 I-Premise
months I-Premise
respectively I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
, I-Premise
1.01 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.85 I-Premise
to I-Premise
1.19 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.535 I-Premise
) I-Premise
. I-Premise

Moreover O
, O
the B-Premise
meta-analysis I-Premise
of I-Premise
two I-Premise
additional I-Premise
studies I-Premise
involving I-Premise
935 I-Premise
patients I-Premise
showed I-Premise
a I-Premise
significant I-Premise
survival I-Premise
benefit I-Premise
in I-Premise
favor I-Premise
of I-Premise
GEM-CAP I-Premise
( I-Premise
HR I-Premise
, I-Premise
0.86 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.75 I-Premise
to I-Premise
0.98 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.02 I-Premise
) I-Premise
with I-Premise
no I-Premise
intertrial I-Premise
heterogeneity I-Premise
. I-Premise

In O
this O
setting O
, O
local B-Claim
control I-Claim
and I-Claim
survival I-Claim
were I-Claim
essentially I-Claim
equal I-Claim
between I-Claim
the I-Claim
surgical I-Claim
and I-Claim
RT I-Claim
arms I-Claim
. I-Claim

Thus O
, O
elderly B-Claim
patients I-Claim
in I-Claim
need I-Claim
of I-Claim
intensified I-Claim
chemotherapy I-Claim
may I-Claim
receive I-Claim
FLOT I-Claim
without I-Claim
compromising I-Claim
patient-reported I-Claim
outcome I-Claim
parameters I-Claim
. I-Claim

However O
, O
CRT B-Claim
was I-Claim
associated I-Claim
with I-Claim
progressive I-Claim
deteriorations I-Claim
in I-Claim
pulmonary I-Claim
function I-Claim
in I-Claim
the I-Claim
longer I-Claim
term I-Claim
. I-Claim

Furthermore O
, O
if B-Claim
offered I-Claim
the I-Claim
choice I-Claim
, I-Claim
the I-Claim
majority I-Claim
of I-Claim
cancer I-Claim
survivors I-Claim
seem I-Claim
to I-Claim
prefer I-Claim
multidimensional I-Claim
programs I-Claim
to I-Claim
programs I-Claim
with I-Claim
only I-Claim
one I-Claim
component I-Claim
. I-Claim

All O
endometrial O
cancers O
in O
the O
tamoxifen O
group O
were O
stage O
I O
( O
localized O
disease O
) O
";" O
no B-Premise
endometrial I-Premise
cancer I-Premise
deaths I-Premise
have I-Premise
occurred I-Premise
in I-Premise
this I-Premise
group I-Premise
. I-Premise

Whereas B-Premise
, I-Premise
after I-Premise
24 I-Premise
wk I-Premise
, I-Premise
31 I-Premise
in I-Premise
group I-Premise
A I-Premise
versus I-Premise
41 I-Premise
in I-Premise
group I-Premise
B I-Premise
were I-Premise
dry I-Premise
( I-Premise
p=0.08 I-Premise
) I-Premise
. O

Nonetheless O
, O
no B-Claim
correlation I-Claim
between I-Claim
immediate I-Claim
lung I-Claim
expansion I-Claim
and I-Claim
clinical I-Claim
outcome I-Claim
was I-Claim
found I-Claim
in I-Claim
this I-Claim
study I-Claim
. I-Claim

The B-Claim
Pain I-Claim
Education I-Claim
Program I-Claim
proved I-Claim
to I-Claim
be I-Claim
feasible I-Claim
: I-Claim
75.0 B-Premise
% I-Premise
of I-Premise
the I-Premise
patients I-Premise
had I-Premise
read I-Premise
the I-Premise
entire I-Premise
pain I-Premise
brochure I-Premise
, I-Premise
55.7 I-Premise
% I-Premise
had I-Premise
listened I-Premise
to I-Premise
the I-Premise
audio I-Premise
cassette I-Premise
, I-Premise
and I-Premise
85.6 I-Premise
% I-Premise
of I-Premise
pain I-Premise
scores I-Premise
were I-Premise
completed I-Premise
in I-Premise
the I-Premise
pain I-Premise
diary I-Premise
. I-Premise

For B-Premise
BT I-Premise
versus I-Premise
RP I-Premise
, I-Premise
there I-Premise
was I-Premise
no I-Premise
difference I-Premise
in I-Premise
bowel I-Premise
or I-Premise
hormonal I-Premise
domains I-Premise
, I-Premise
but O
men B-Premise
treated I-Premise
with I-Premise
BT I-Premise
scored I-Premise
better I-Premise
in I-Premise
urinary I-Premise
( I-Premise
91.8 I-Premise
v I-Premise
88.1 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.02 I-Premise
) I-Premise
and I-Premise
sexual I-Premise
( I-Premise
52.5 I-Premise
v I-Premise
39.2 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.001 I-Premise
) I-Premise
domains I-Premise
, I-Premise
and I-Premise
in I-Premise
patient I-Premise
satisfaction I-Premise
( I-Premise
93.6 I-Premise
v I-Premise
76.9 I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

As O
well O
, O
Etoposide B-Claim
resulted I-Claim
in I-Claim
better I-Claim
physical I-Claim
and I-Claim
psychological I-Claim
subscale I-Claim
scores I-Claim
than I-Claim
radiotherapy I-Claim
, I-Claim
3-drugs I-Claim
and I-Claim
supportive I-Claim
care I-Claim
. I-Claim

Myelosuppression B-Premise
, I-Premise
renal I-Premise
insufficiency I-Premise
, I-Premise
and I-Premise
fatigue I-Premise
were I-Premise
more I-Premise
common I-Premise
in I-Premise
the I-Premise
GP I-Premise
arm I-Premise
, I-Premise
but O
skin B-Premise
toxicities I-Premise
and I-Premise
liver I-Premise
dysfunction I-Premise
were I-Premise
more I-Premise
common I-Premise
in I-Premise
the I-Premise
gefitinib I-Premise
arm I-Premise
. I-Premise

Given O
the O
substantial O
survival O
benefit O
of O
combined O
treatment O
, O
the B-Claim
increase I-Claim
of I-Claim
symptoms I-Claim
seems I-Claim
acceptable I-Claim
and I-Claim
has I-Claim
little I-Claim
extra I-Claim
effect I-Claim
on I-Claim
quality I-Claim
of I-Claim
life I-Claim
after I-Claim
4 I-Claim
years I-Claim
compared I-Claim
with I-Claim
endocrine I-Claim
treatment I-Claim
alone I-Claim
. I-Claim

However O
, O
there B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
of I-Premise
QOL I-Premise
scores I-Premise
and I-Premise
postoperative I-Premise
complication I-Premise
scores I-Premise
between I-Premise
the I-Premise
2 I-Premise
reconstruction I-Premise
groups I-Premise
. I-Premise

Taken B-Premise
together I-Premise
with I-Premise
the I-Premise
broader I-Premise
literature I-Premise
in I-Premise
this I-Premise
area I-Premise
, I-Premise
results B-Claim
from I-Claim
this I-Claim
study I-Claim
suggest I-Claim
that I-Claim
psychosocial I-Claim
interventions I-Claim
can I-Claim
lead I-Claim
to I-Claim
improvements I-Claim
in I-Claim
a I-Claim
range I-Claim
of I-Claim
outcomes I-Claim
for I-Claim
cancer I-Claim
patients I-Claim
. I-Claim

This O
randomized O
trial O
demonstrates O
that O
ATP B-Claim
has I-Claim
beneficial I-Claim
effects I-Claim
on I-Claim
weight I-Claim
, I-Claim
muscle I-Claim
strength I-Claim
, I-Claim
and I-Claim
QOL I-Claim
in I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
NSCLC I-Claim
. I-Claim

Future B-Claim
trial I-Claim
design I-Claim
must I-Claim
ensure I-Claim
adequate I-Claim
power I-Claim
to I-Claim
account I-Claim
for I-Claim
the I-Claim
nonspecific I-Claim
impact I-Claim
of I-Claim
such I-Claim
complex I-Claim
individualized I-Claim
interventions I-Claim
while I-Claim
pragmatic I-Claim
designs I-Claim
may I-Claim
more I-Claim
readily I-Claim
answer I-Claim
questions I-Claim
of I-Claim
clinical I-Claim
and I-Claim
cost I-Claim
effectiveness I-Claim
. O

Moreover O
, O
these B-Claim
two I-Claim
treatment I-Claim
protocols I-Claim
are I-Claim
inefficient I-Claim
and I-Claim
cost I-Claim
time I-Claim
in I-Claim
application I-Claim
. I-Claim

However O
, O
there B-Premise
were I-Premise
no I-Premise
differences I-Premise
in I-Premise
the I-Premise
bowel I-Premise
function I-Premise
, I-Premise
continence I-Premise
score I-Premise
, I-Premise
and I-Premise
quality I-Premise
of I-Premise
life I-Premise
at I-Premise
1 I-Premise
year I-Premise
. I-Premise

Specifically O
, O
AET B-Premise
improved I-Premise
global I-Premise
sleep I-Premise
quality I-Premise
in I-Premise
patients I-Premise
with I-Premise
lymphoma I-Premise
who I-Premise
had I-Premise
indolent I-Premise
non-Hodgkin I-Premise
lymphoma I-Premise
( I-Premise
P I-Premise
= I-Premise
0.001 I-Premise
) I-Premise
, I-Premise
were I-Premise
receiving I-Premise
chemotherapy I-Premise
( I-Premise
P I-Premise
= I-Premise
0.013 I-Premise
) I-Premise
, I-Premise
were I-Premise
< I-Premise
2 I-Premise
years I-Premise
post-diagnosis I-Premise
( I-Premise
P I-Premise
= I-Premise
0.005 I-Premise
) I-Premise
, I-Premise
were I-Premise
obese I-Premise
( I-Premise
P I-Premise
= I-Premise
0.025 I-Premise
) I-Premise
, I-Premise
and I-Premise
were I-Premise
poor I-Premise
sleepers I-Premise
at I-Premise
baseline I-Premise
( I-Premise
P I-Premise
= I-Premise
0.007 I-Premise
) I-Premise
. I-Premise

In O
addition O
to O
known O
clinical O
factors O
, O
patient-assessed B-Claim
QL I-Claim
variables I-Claim
appear I-Claim
to I-Claim
be I-Claim
prognostic I-Claim
for I-Claim
survival I-Claim
and I-Claim
response I-Claim
to I-Claim
chemotherapy I-Claim
in I-Claim
women I-Claim
with I-Claim
advanced I-Claim
breast I-Claim
cancer I-Claim
. I-Claim

In O
addition O
, O
tumor B-Claim
response I-Claim
was I-Claim
shown I-Claim
to I-Claim
have I-Claim
a I-Claim
beneficial I-Claim
effect I-Claim
on I-Claim
QoL I-Claim
indicators I-Claim
. I-Claim

QOL B-Premise
analyses I-Premise
favored I-Premise
Arm I-Premise
A. I-Premise
SGN-15 B-Claim
plus I-Claim
docetaxel I-Claim
is I-Claim
a I-Claim
well-tolerated I-Claim
and I-Claim
active I-Claim
second I-Claim
and I-Claim
third I-Claim
line I-Claim
treatment I-Claim
for I-Claim
NSCLC I-Claim
patients I-Claim
. O

Thus O
, O
the B-Premise
rate I-Premise
of I-Premise
efficacy I-Premise
was I-Premise
significantly I-Premise
higher I-Premise
in I-Premise
the I-Premise
combined I-Premise
treatment I-Premise
group I-Premise
( I-Premise
85.36 I-Premise
% I-Premise
";" I-Premise
p I-Premise
< I-Premise
0.05 I-Premise
vs. I-Premise
control I-Premise
group I-Premise
) I-Premise
. I-Premise

However O
, O
there B-Claim
was I-Claim
a I-Claim
significant I-Claim
improvement I-Claim
in I-Claim
secondary I-Claim
endpoints I-Claim
of I-Claim
clinically I-Claim
assessed I-Claim
OPS I-Claim
and I-Claim
DNA I-Claim
concentration I-Claim
compared I-Claim
with I-Claim
placebo I-Claim
in I-Claim
H I-Claim
& I-Claim
N I-Claim
cancer I-Claim
patients I-Claim
treated I-Claim
with I-Claim
CRT I-Claim
. I-Claim

Moreover O
, O
adopting B-Premise
a I-Premise
combined I-Premise
aerobic I-Premise
and I-Premise
resistance I-Premise
exercise I-Premise
program I-Premise
after I-Premise
breast I-Premise
cancer I-Premise
chemotherapy I-Premise
was I-Premise
associated I-Premise
with I-Premise
further I-Premise
improvements I-Premise
in I-Premise
patient-rated I-Premise
outcomes I-Premise
. I-Premise

Overall B-Premise
the I-Premise
treatment I-Premise
was I-Premise
well I-Premise
tolerated I-Premise
. O

Parenteral B-Claim
feeding I-Claim
was I-Claim
associated I-Claim
with I-Claim
the I-Claim
highest I-Claim
rate I-Claim
of I-Claim
nutrition-related I-Claim
complications I-Claim
, I-Claim
whereas O
enteral B-Claim
feeding I-Claim
reduced I-Claim
quality I-Claim
of I-Claim
life I-Claim
most I-Claim
extensively I-Claim
. I-Claim

However O
, O
when B-Premise
compared I-Premise
with I-Premise
sham I-Premise
acupuncture I-Premise
, I-Premise
the I-Premise
reduction I-Premise
by I-Premise
the I-Premise
acupuncture I-Premise
regimen I-Premise
as I-Premise
provided I-Premise
in I-Premise
the I-Premise
current I-Premise
study I-Premise
did I-Premise
not I-Premise
reach I-Premise
statistical I-Premise
significance I-Premise
. I-Premise

QOL B-Claim
and I-Claim
sexual I-Claim
function I-Claim
are I-Claim
not I-Claim
negatively I-Claim
influenced I-Claim
by I-Claim
these I-Claim
2 I-Claim
treatment I-Claim
options I-Claim
. O

Although O
capecitabine B-Claim
was I-Claim
associated I-Claim
with I-Claim
better I-Claim
QoL I-Claim
during I-Claim
treatment I-Claim
, O
QoL B-Premise
was I-Premise
similar I-Premise
for I-Premise
both I-Premise
groups I-Premise
at I-Premise
1 I-Premise
year I-Premise
. I-Premise

In O
particular O
, O
physical B-Premise
functioning I-Premise
remains I-Premise
deteriorated I-Premise
1 I-Premise
year I-Premise
after I-Premise
inclusion I-Premise
for I-Premise
HDC I-Premise
patients I-Premise
comparatively I-Premise
to I-Premise
conventional I-Premise
chemotherapy I-Premise
patients I-Premise
( I-Premise
85.99 I-Premise
vs. I-Premise
76.65 I-Premise
, I-Premise
P I-Premise
= I-Premise
0.021 I-Premise
) I-Premise
, O
and B-Premise
the I-Premise
pain I-Premise
score I-Premise
was I-Premise
still I-Premise
higher I-Premise
in I-Premise
the I-Premise
HDC I-Premise
group I-Premise
at I-Premise
that I-Premise
time I-Premise
( I-Premise
28.32 I-Premise
vs. I-Premise
15.97 I-Premise
, I-Premise
P I-Premise
= I-Premise
0.004 I-Premise
) I-Premise
. I-Premise

Medical B-Claim
effects I-Claim
were I-Claim
better I-Claim
after I-Claim
GJJ I-Claim
, O
although B-Claim
GJJ I-Claim
had I-Claim
higher I-Claim
total I-Claim
costs I-Claim
. I-Claim

In O
light O
of O
the O
results O
obtained O
in O
the O
study O
, O
the B-Claim
extensive I-Claim
use I-Claim
of I-Claim
the I-Claim
drug I-Claim
for I-Claim
cancer I-Claim
pain I-Claim
should I-Claim
be I-Claim
questioned I-Claim
. I-Claim

In O
conclusion O
, O
TMX B-Claim
does I-Claim
not I-Claim
prolong I-Claim
survival I-Claim
in I-Claim
patients I-Claim
with I-Claim
inoperable I-Claim
HCC I-Claim
and I-Claim
has I-Claim
an I-Claim
increasingly I-Claim
negative I-Claim
impact I-Claim
with I-Claim
increasing I-Claim
dose I-Claim
. I-Claim

The B-Premise
addition I-Premise
of I-Premise
RT I-Premise
to I-Premise
surgery I-Premise
resulted I-Premise
in I-Premise
more I-Premise
frequent I-Premise
urination I-Premise
, I-Premise
as I-Premise
well I-Premise
as I-Premise
early I-Premise
report I-Premise
of I-Premise
more I-Premise
bowel I-Premise
dysfunction I-Premise
, O
although B-Premise
bowel I-Premise
function I-Premise
differences I-Premise
disappeared I-Premise
over I-Premise
the I-Premise
5-year I-Premise
period I-Premise
. I-Premise

Notably O
, O
patients B-Premise
receiving I-Premise
FLO I-Premise
or I-Premise
FLOT I-Premise
as I-Premise
palliative I-Premise
treatment I-Premise
( I-Premise
n I-Premise
= I-Premise
98 I-Premise
) I-Premise
achieved I-Premise
comparable I-Premise
QOL I-Premise
results I-Premise
. I-Premise

Anti-aromatase B-Claim
therapy I-Claim
is I-Claim
important I-Claim
in I-Claim
the I-Claim
treatment I-Claim
of I-Claim
breast I-Claim
cancer I-Claim
in I-Claim
postmenopausal I-Claim
women I-Claim
but O
they O
have O
effects O
on O
the O
bone O
mineral O
density O
( O
BMD O
) O
and O
osteoporosis O
. O

Given O
the O
existing O
evidence O
supporting O
the O
importance O
of O
social O
support O
in O
adjustment O
to O
breast O
cancer O
, O
it B-Claim
seems I-Claim
feasible I-Claim
to I-Claim
suggest I-Claim
that I-Claim
EW I-Claim
may I-Claim
be I-Claim
a I-Claim
cost I-Claim
effective I-Claim
accessible I-Claim
treatment I-Claim
that I-Claim
could I-Claim
be I-Claim
incorporated I-Claim
into I-Claim
the I-Claim
ongoing I-Claim
care I-Claim
of I-Claim
women I-Claim
. I-Claim

CAF B-Premise
produced I-Premise
significantly I-Premise
higher I-Premise
grades I-Premise
of I-Premise
leukopenia I-Premise
, I-Premise
granulocytopenia I-Premise
, I-Premise
and I-Premise
thrombocytopenia I-Premise
, I-Premise
as I-Premise
well I-Premise
as I-Premise
liver I-Premise
and I-Premise
cardiac I-Premise
toxicity I-Premise
, I-Premise
whereas O
the B-Premise
16-week I-Premise
regimen I-Premise
produced I-Premise
significantly I-Premise
higher I-Premise
grades I-Premise
of I-Premise
anemia I-Premise
, I-Premise
nausea I-Premise
, I-Premise
stomatitis I-Premise
, I-Premise
and I-Premise
weight I-Premise
loss I-Premise
, I-Premise
as I-Premise
well I-Premise
as I-Premise
skin I-Premise
and I-Premise
neurotoxicity I-Premise
. I-Premise

Pain B-Premise
and I-Premise
analgesic I-Premise
scores I-Premise
increased I-Premise
more I-Premise
in I-Premise
patients I-Premise
who I-Premise
received I-Premise
placebo I-Premise
than I-Premise
in I-Premise
patients I-Premise
who I-Premise
received I-Premise
zoledronic I-Premise
acid I-Premise
, I-Premise
but O
there B-Premise
were I-Premise
no I-Premise
differences I-Premise
in I-Premise
disease I-Premise
progression I-Premise
, I-Premise
performance I-Premise
status I-Premise
, I-Premise
or I-Premise
quality-of-life I-Premise
scores I-Premise
among I-Premise
the I-Premise
groups I-Premise
. I-Premise

This B-Claim
randomised I-Claim
trial I-Claim
encountered I-Claim
the I-Claim
accrual I-Claim
difficulties I-Claim
and I-Claim
consequent I-Claim
low I-Claim
statistical I-Claim
power I-Claim
commonly I-Claim
associated I-Claim
with I-Claim
interdisciplinary I-Claim
studies I-Claim
drawing I-Claim
from I-Claim
a I-Claim
small I-Claim
eligible I-Claim
population I-Claim
, I-Claim
but O
can O
contribute O
to O
future O
overviews O
on O
the O
management O
of O
solitary O
brain O
metastases O
. O

In O
this O
trial O
, O
histologic B-Claim
confirmation I-Claim
of I-Claim
N2 I-Claim
disease I-Claim
in I-Claim
the I-Claim
surgical I-Claim
and I-Claim
nonsurgical I-Claim
arms I-Claim
eliminated I-Claim
the I-Claim
usual I-Claim
biases I-Claim
from I-Claim
clinical I-Claim
staging I-Claim
. I-Claim

